<SEC-DOCUMENT>0001213900-14-007643.txt : 20141031
<SEC-HEADER>0001213900-14-007643.hdr.sgml : 20141031
<ACCEPTANCE-DATETIME>20141031154540
ACCESSION NUMBER:		0001213900-14-007643
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20140930
FILED AS OF DATE:		20141031
DATE AS OF CHANGE:		20141031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		141186552

	BUSINESS ADDRESS:	
		STREET 1:		546 5TH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212-300-2131

	MAIL ADDRESS:	
		STREET 1:		546 5TH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0914_actiniumpharma.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>FORM
10-Q</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Mark One)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#9746; <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
the quarterly period ended<B> September 30, 2014</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#9744;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
the transition period from _______________________ to ___________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Commission
File Number: &nbsp;<B>000-52446</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ACTINIUM
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>88-0378336</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State
    or Other Jurisdiction of<BR>
Incorporation or Organization)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(I.R.S.
    Employer<BR>
Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>546
                                         Fifth Avenue, 14<SUP>th</SUP> Floor</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>New
        York, NY</B></FONT></P></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>1003610036</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Address
    of Principal Executive Offices)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Zip
    Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(732)
243-9495</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Registrant&rsquo;s
Telephone Number, Including Area Code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Former
Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#9746;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#9746;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. &nbsp;See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller
reporting company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 75%; text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.625in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Large
    accelerated filer&nbsp;&#9744;</FONT></TD>
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accelerated
filer&nbsp;&#9744;</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.625in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non-accelerated
    filer&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;(Do not check if a smaller reporting company)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Smaller
reporting company&nbsp;&#9746;</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9744;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9746;&nbsp;No</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">APPLICABLE
ONLY TO ISSUERS INVOLVED IN BANKRUPTCY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PROCEEDINGS
DURING THE PRECEDING FIVE YEARS:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the
Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9744;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;No</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">APPLICABLE
ONLY TO CORPORATE ISSUERS:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">Indicate the number
of shares outstanding of each of the issuer&rsquo;s classes of common stock, as of October 30, 2014: 30,005,507</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Actinium
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>FORM
10-Q</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>For
period ended September 30, 2014</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
I-- FINANCIAL INFORMATION</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item
    1.</FONT></TD>
    <TD STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Financial
    Statements</FONT></TD>
    <TD STYLE="width: 10%; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Management&rsquo;s
    Discussion and Analysis of Financial Condition and Results of Operations</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quantitative and
    Qualitative Disclosures About Market Risk</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Controls and Procedures</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
    II-- OTHER INFORMATION</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal Proceedings</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">28</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 1A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Risk Factors</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">28</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unregistered Sales
    of Equity Securities and Use of Proceeds</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">28</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Defaults Upon
    Senior Securities</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">28</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mine Safety Disclosures</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">28</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other Information</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">28</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibits</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">28</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">29</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
I - FINANCIAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
1. &nbsp;FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
accompanying consolidated financial statements have been prepared by the Company and are unaudited. &nbsp;In the opinion of management,
all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results
of operations and cash flows at September 30, 2014 and December 31, 2013 and for the nine months ended September 30, 2014 and
2013 have been made. &nbsp;Certain information and footnote disclosures normally included in financial statements prepared in
accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. &nbsp;It
is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in
the Company&rsquo;s audited financial statements for the year ended December 31, 2013. &nbsp;The results of operations for the
nine months ended September 30, 2014 are not necessarily indicative of the operating results for the full year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Actinium
    Pharmaceuticals, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Consolidated
    Balance Sheets</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Unaudited)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&nbsp;30,<BR>
2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR>
2013</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Current Assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0.125in">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">11,750,675</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,533,366</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">671,903</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">218,389</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.25in">Total Current Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,422,578</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,751,755</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Property and equipment, net of accumulated depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">141,011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,920</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Security deposit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34,733</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,598,322</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,765,675</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">Liabilities and Stockholders' Equity&nbsp;(Deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,731,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">378,955</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Accounts payable and accrued expenses - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">278,291</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,185</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">157,825</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Derivative liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,216,935</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,707,255</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total Current Liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,226,433</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,325,220</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,226,433</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,325,220</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders' Equity (Deficit):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in; text-indent: -0.25in">Preferred stock, $0.01 par value; 50,000,000 authorized, none issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in">Common stock, $0.001 par value; 200,000,000 shares authorized; 29,619,495
    and 24,565,447 shares issued and outstanding, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,620</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,565</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">88,120,950</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,933,145</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(85,778,681</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(66,517,255</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total Stockholders' Equity (Deficit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,371,889</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,559,545</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total Liabilities and Stockholders' Equity (Deficit)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,598,322</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,765,675</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">See
accompanying notes to consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Actinium
    Pharmaceuticals, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Consolidated
                                         Statements of Operations</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Unaudited)</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months ended<BR>
September&nbsp;30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended<BR>
September&nbsp;30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: left; padding-left: 0.125in">Research and development, net of reimbursements</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,773,438</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">778,232</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,236,343</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,373,200</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,257,147</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">830,730</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,347,827</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,730,233</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Depreciation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,326</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,783</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Loss on disposition of equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,122</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,044,911</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,608,962</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,607,953</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,107,555</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss from operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,044,911</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,608,962</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(15,607,953</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,107,555</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,299</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,508</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Gain (loss) on change in fair value of derivative liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">967,887</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">189,348</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,653,473</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">216,112</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Total other income (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">967,887</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">188,049</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,653,473</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">213,604</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(6,077,024</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,420,913</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(19,261,426</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(4,893,951</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss per common share&nbsp;&nbsp;- basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.21</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.06</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.73</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.22</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Weighted average common shares outstanding&nbsp;&nbsp;- basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">28,496,902</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">23,601,895</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">26,540,368</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">22,401,711</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">See
accompanying notes to consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Actinium
    Pharmaceuticals, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Consolidated
    Statements of Cash Flows</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Unaudited)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">For the Nine</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">For the Nine</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">September&nbsp;30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">September&nbsp;30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Cash Flows From Operating Activities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(19,261,426</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(4,893,951</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,221,673</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">284,371</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Depreciation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,783</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Loss on disposition of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,122</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Loss (gain) on change in fair value of derivative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,653,473</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(216,112</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0in">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Increase) decrease in:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(453,514</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114,143</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Security deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(34,733</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Increase (decrease) in:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,352,252</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(585,043</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Accounts payable and accrued expenses - related party</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">197,106</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">344,501</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used In Operating Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,301,386</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,947,969</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Investing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Purchase of property and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(150,874</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(8,030</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used In Investing Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(150,874</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(8,030</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Payments on note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(157,825</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(140,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Sales of common stock, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,435,305</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Proceeds from the exercise of options and warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">392,089</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,467,393</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Provided By Financing Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,669,569</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,327,393</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net change&nbsp;in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,217,309</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,628,606</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash and cash equivalents at beginning of period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,533,366</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,618,669</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Cash and cash equivalents at end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,750,675</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,990,063</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental disclosures of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Cash paid for interest</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">561</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Cash paid for income taxes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental disclosure of non-cash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Transfer warrant derivatives from liability to equity classification</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,143,793</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">600,880</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">See
accompanying notes to consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Actinium
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note
1 &ndash; Description of Business and Summary of Significant Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Nature
of Business &ndash;</B> Actinium Pharmaceuticals, Inc. (the &ldquo;Company&rdquo; or &ldquo;Actinium&rdquo;) is a biotechnology
company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT)
platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI),
(hereinafter referred to collectively as &ldquo;Actinium&rdquo;) initiated collaborative efforts with large institutions to establish
the proof of concept of APIT and has supported one Phase 1/2 clinical trial and one Phase 1 clinical trial at Memorial Sloan-Kettering
Cancer Center (&ldquo;MSKCC&rdquo;) under an MSKCC Physician IND Application. In 2012, Actinium launched a multi-center corporate
sponsored trial in acute myeloid leukemia (AML) patients. &nbsp;Actinium&rsquo;s objective, through research and development,
is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other
appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&rsquo;s compounds have
been with patients having acute myeloid leukemia and it is believed that Actinium&rsquo;s APIT platform will have wider applicability
for different types of cancer where suitable monoclonal antibodies can be found.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
December 28, 2012, the Company entered into a transaction (the &ldquo;Share Exchange&rdquo;), pursuant to which the Company acquired
100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&ldquo;API&rdquo;), in exchange for the
issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. As a result
of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each
API shareholder received 0.333 shares (the &ldquo;Exchange Ratio&rdquo;) of Actinium common stock for each API share exchanged.
At the closing, all of the API shareholders&rsquo; options and warrants to purchase API common stock was exchanged at the Exchange
Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&nbsp;&nbsp;The Share Exchange was accounted
for as a reverse takeover/recapitalization effected by a share exchange, wherein API was considered the acquirer for accounting
and financial reporting purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
a result of the Share Exchange, the Company was then considered a holding company operating through API, a clinical-stage biopharmaceutical
company developing certain cancer treatments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
March 20, 2013, the Company&rsquo;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&nbsp;&nbsp;On
April&nbsp;11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from
Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals,
Inc. (filed in Delaware, the Company merged (the &ldquo;Merger&rdquo;) into itself Actinium Corporation (a 93.7% owned subsidiary),
and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company was cancelled
and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company&rsquo;s common stock.&nbsp;&nbsp;A
total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Basis
of Presentation - Unaudited Interim Financial Information &ndash;</B> The accompanying unaudited interim consolidated financial
statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States
of America (&ldquo;U.S. GAAP&rdquo;) for interim financial information, and in accordance with the rules and regulations of the
United States Securities and Exchange Commission (the &ldquo;SEC&rdquo;) with respect to Form 10-Q and Article 8 of Regulation
S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.
The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments)
which are, in the opinion of management, necessary&nbsp;for a fair statement of the results for the interim periods presented.
Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial
statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended
December 31, 2013 and notes thereto contained in the Company&rsquo;s annual report on Form 10-K for the year ended December 31,
2013, as filed with the SEC on February 28, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Principles
of Consolidation &ndash;</B> The consolidated financial statements include the Company&rsquo;s accounts and those of the Company&rsquo;s
wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Use
of Estimates in Financial Statement Presentation &ndash;</B> The preparation of these consolidated financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported
amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Reclassification
&ndash;</B> Certain prior period amounts have been reclassified to conform to current period presentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Cash
and Cash Equivalents &ndash;</B> The Company considers all highly liquid accounts with original maturities of three months or
less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At September 30, 2014 and December 31,
2013, all of the Company&rsquo;s cash was deposited in one bank.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Property
and Equipment &ndash;</B> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated
useful lives of three years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated
useful lives of three to seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed
from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Impairment
of Long-Lived Assets &ndash;&nbsp;</B>Management reviews long-lived assets for impairment whenever events or changes in circumstances
indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an
evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&rsquo;s
carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the
difference between the fair value of such asset and its carrying value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Derivatives
&ndash;</B>&nbsp;All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open
market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined
using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Fair
Value of Financial Instruments &ndash;</B>&nbsp;Fair value is defined as the price that would be received to sell an asset, or
paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established
for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and
the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.55in; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level
1 Inputs &ndash; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has
the ability to access at the measurement date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.55in; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.55in; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level
2 Inputs &ndash; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly
or indirectly. These might include quoted prices for similar assets or liabilities&nbsp;in&nbsp;active markets, quoted prices
for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable
for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived
principally from or corroborated by market data by correlation or other means.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.55in; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.55in; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level
3 Inputs &ndash; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions
about the assumptions that market participants would use in pricing the assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within
the fair value hierarchy as of September 30, 2014 and December 31, 2013. As required by ASC 820 &ldquo;<I>Fair Value Measurements
and Disclosures&rdquo;</I>, financial assets and liabilities are classified in their entirety based on the lowest level of input
that is significant to the fair value measurement. The Company&rsquo;s assessment of the significance of a particular input to
the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement
within the fair value hierarchy levels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Level 1</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Level 2</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Level 3</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Derivative liabilities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; padding-left: 0.125in">At September 30, 2014</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">8,216,935</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">8,216,935</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">At December 31, 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,707,255</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,707,255</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Income
Taxes &ndash;</B> The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred
tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of
assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that
the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based
upon management&rsquo;s assessment as to their realization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Research
and Development Costs &ndash;</B> Research and development costs are expensed as incurred. Research and development reimbursements
and grants are recorded by the Company as a reduction of research and development costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><B>Share-Based Payments
&ndash;</B> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option
pricing model. The fair value determined represents the cost for the award and is recognized over the vesting period during which
an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based
on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture
rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at
the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Earnings
(Loss) Per Common Share &ndash;</B> The Company calculates net loss per common share in accordance with ASC 260 &ldquo;Earnings
Per Share&rdquo; (&ldquo;ASC 260&rdquo;). Basic and diluted net loss per common share was determined by dividing net loss applicable
to common stockholders by the weighted average number of shares of common stock outstanding during the period. The Company&rsquo;s
potentially dilutive shares, which include outstanding common stock options and warrants have not been included in the computation
of diluted net loss per share for all periods as the result would be anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">September&nbsp;30,<BR>
2013</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">September&nbsp;30,<BR>
2014</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Options</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,280,184</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,998,084</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">9,441,942</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">7,933,747</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">11,722,126</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,931,831</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Recent
Accounting Pronouncements &ndash; </B>In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update
2014-09, Revenue from Contracts with Customers. Amendments in this Update create Topic 606, Revenue from Contracts with Customers,
and supersede the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue
recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments supersede the cost guidance
in Subtopic 605-35, Revenue Recognition&mdash;Construction-Type and Production-Type Contracts, and create new Subtopic 340-40,
Other Assets and Deferred Costs&mdash;Contracts with Customers. In summary, the core principle of Topic 606 is that an entity
recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services. The amendments in this Update are effective
for the Company for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting
period. The Company is currently evaluating the effects of ASU 2014-09 on the consolidated financial statements<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-10, Development Stage Entities. The
amendments in this Update remove the definition of a development stage entity from Topic 915, thereby removing the distinction
between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements
for development stage entities to (1) present inception-to-date information on the statements of income, cash flows, and shareholder&rsquo;s
equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development
stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development
stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic
275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.&nbsp; Finally, the
amendments also remove paragraph 810-10-15-16, which states that a development stage entity does not meet the condition in paragraph
810-10-15-14(a) to be a variable interest entity (VIE) if (1) the entity can demonstrate that the equity invested in the legal
entity is sufficient to permit it to finance the activities it is currently engaged in and (2) the entity&rsquo;s governing documents
and contractual arrangements allow additional equity investments. Under the amendments, all entities within the scope of the Variable
Interest Entities Subsections of Subtopic 810-10, Consolidation&mdash;Overall, would be required to evaluate whether the total
equity investment at risk is sufficient using the guidance provided in paragraphs 810-10-25-45 through 25-47, which requires both
qualitative and quantitative evaluations. The amendments in this Update are effective for annual reporting periods beginning after
December 15, 2014, and interim periods therein, and early adoption is required. The Company evaluated and adopted ASU 2014-10
at June 30, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-12, Compensation- Stock Compensation.
The amendments in this update apply to reporting entities that grant their employees share-based payments in which the terms of
the award provide that a performance target can be achieved after the requisite service period. The amendments in this
Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, and
early adoption is permitted. The Company is currently evaluating the effects of ASU 2014-12 on the consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
August 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-15, Presentation of Financial Statements-
Going Concern. The Update provides U.S. GAAP guidance on management&rsquo;s responsibility in evaluating whether there is substantial
doubt about a company&rsquo;s ability to continue as a going concern and about related footnote disclosures. For each reporting
period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company&rsquo;s
ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in this
Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.
The Company is currently evaluating the effects of ASU 2014-15 on the consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Subsequent
Events &ndash;</B> The Company&rsquo;s management reviewed all material events through the date of the consolidated financial
statements were issued for subsequent event disclosure consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note
2 &ndash; Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>MSKCC:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">In 2010, General
Atlantic Group Limited donated all of the equity shares of its wholly owned subsidiary, Actinium Holdings Ltd. (formerly named
General Atlantic Investments Limited) to Memorial Sloan Kettering Cancer Center (MSKCC).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">On February 11,
2002, the Company entered into a License, Development and Commercialization Agreement with Sloan-Kettering Institute of Cancer
Research (SKI),&nbsp;an entity related to MSKCC (&ldquo;License Agreement&rdquo;).&nbsp;&nbsp;The agreement was amended in August
2006.&nbsp;&nbsp;Pursuant to the agreement, the Company licensed certain intellectual property from SKI, including critical patents
with respect to the Company&rsquo;s core technology, and also supports ongoing research and clinical development of related drug
candidates.&nbsp;&nbsp;MSKCC agreed, subject to certain conditions, to utilize the funds paid for certain clinical and preclinical
programs and activities related to the Company&rsquo;s drug development and clinical study programs, including the payment of certain
costs and expenses that would otherwise have been borne by the Company.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company is obligated to make the following milestone payments:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">Milestones</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Payments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">(1) filing of an New Drug Application (&ldquo;NDA&rdquo;) or regulatory approval&nbsp;for each licensed product</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">750,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(2) upon the receipt of regulatory approval from the U.S. FDA for each&nbsp;licensed product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,750,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Under
the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products
until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certain
amounts due under the License Agreement were deferred and then forgiven under a forbearance-related arrangement.&nbsp;&nbsp;On
June 19, 2011, the Company nonetheless agreed to pay SKI (a) $50,000 in 2011, (b) $200,000 in 2012 and (c) $250,000 in 2013 under
this agreement, in respect of the $50,000 annual maintenance fees and research payments.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">On September 4,
2013, the Company entered into a letter agreement with SKI to set forth the amount that the Company owes SKI for the period from
2011 to 2014 under the License Agreement.&nbsp;&nbsp;The total amount that the Company owes SKI for the period from 2011 to 2014
is $815,100 plus all relevant licensed intellectual property related pass through costs to be determined.&nbsp;&nbsp;The amount
owed does not include amounts the Company may owe for patent expenses under the License Agreement.&nbsp;&nbsp;During 2014, the
annual maintenance fee is $189,000 plus pass through costs.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">On March 27, 2012, the
Company entered into an additional clinical trial agreement with MSKCC Cancer Center with respect to conducting a Phase 1/2 trial
of combination therapy of low dose cytarabine and fractionated dose of Lintuzumab-Ac225.&nbsp;&nbsp;The Company will pay $31,185
for each patient that has completed the clinical trial.&nbsp;&nbsp;Upon execution of the agreement, the Company paid a start-up
fee of $79,623 in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">For the three months
ended September 30, 2014 and 2013, the Company incurred approximately $26,000 and $0, respectively, for maintenance fees and research
conducted by MSKCC For the nine months ended September 30, 2014 and 2013, the Company incurred $197,106 and $218,604, respectively,
for maintenance fees and research conducted by MSKCC.&nbsp;&nbsp;As of September 30, 2014 and December 31, 2013, the Company has
a payable to MSKCC covering the annual maintenance costs, clinical trials expense and patent costs totaling $278,291 and $81,185,
respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Placement
Agent:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
August 7, 2012, the Company entered into an engagement agreement with a Healthcare Investment Bank as its placement agent for
the 2012 Common Stock Offering whereby a director of the Company, is the Head of its Healthcare Investment Banking team.&nbsp;&nbsp;&nbsp;Pursuant
to the agreement, the placement agent was engaged as the exclusive agent for the 2012 Common Stock Offering. &nbsp;&nbsp;In consideration
for its services, the placement agent received (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock
Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering,
and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.&nbsp;&nbsp;The placement agent or its designees
also received warrants to purchase shares of the Company&rsquo;s Common Stock in an amount equal to 10% of the shares of common
stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise
of the B warrants included in such units.&nbsp;&nbsp;The placement agent also received the same fee and expense schedule for any
cash exercise of warrants within 6 months of the final closing of the 2012 Common Stock Offering and a 5% solicitation fee for
any warrants exercised as a result of being called for redemption by the Company.&nbsp;&nbsp;Upon the final closing of the 2012
Common Stock Offering of the units, the placement agent was engaged by the Company to provide certain financial advisory services
to the Company for a period of at least 6 months for a monthly fee of $25,000.&nbsp;&nbsp;The agreement also provides that (i)
if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange)
with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate
consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described
above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the
Company&rsquo;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth
in the August 7, 2012 engagement agreement.&nbsp;&nbsp;For a period ending one year after the expiration of all lock-up agreements
entered into in connection with the Share Exchange, any change in the size of the Company board of directors must be approved
by the placement agent.&nbsp;&nbsp;The placement agent also was engaged by the Company as placement agent for its Stock Offering
and Convertible Notes financing in 2011 and, as a part of the fee for that engagement, designees of the placement agent also hold
warrants to purchase 1,251,015 shares of the Company&rsquo;s Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">On December 9, 2013,
the Company entered into another engagement agreement with its placement agent for the 2013 Common Stock Offering, (&ldquo;the
Offering&rdquo;). The Offering was completed in two tranches, December 9, 2013 and January 10, 2014. The agreement entered in on
December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable
expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company&rsquo;s Common Stock
in an amount equal to 10% of the shares of common stock issued or issuable. Subsequent to the closing of the 2013 offering, the
placement agent continued to provide certain financial advisory services to the Company until three months after the Company had
up-listed its securities for trading on a U.S. National Exchange for a monthly fee of $25,000.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">On December 27, 2013,&nbsp;the
Company completed the first sale of the Offering pursuant to a Unit Purchase Agreement, with certain accredited investors (the
&ldquo;Investors&rdquo;)&nbsp;pursuant to which the Investors agreed to purchase (i) an aggregate of 554,310 shares (the &ldquo;Shares&rdquo;)
of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 138,577 shares of common stock at an
exercise price of $9.00 per share. The Company received $3,325,860&nbsp;in gross proceeds from the sale of securities.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">On January 10, 2014,&nbsp;
the Company conducted the final closing (the &ldquo;Final Closing&rdquo;) of the Offering pursuant to a Unit Purchase Agreement,
dated as of January 10, 2014 (the &ldquo;Purchase Agreement&rdquo;) and Subscription Agreement, dated as of January 10, 2014 (the
&ldquo;Subscription Agreement&rdquo;), with certain accredited investors (the &ldquo;Investors&rdquo;)&nbsp;&nbsp;pursuant to
which the Investors at the Final Closing agreed to purchase (i) an aggregate of 551,810 shares ( the &ldquo;Shares&rdquo;) of
common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 137,952 shares of common stock at an exercise
price of $9.00 per share. The Company received $3,310,860&nbsp;in gross proceeds from the sale of securities under the Purchase
Agreement at the Final Closing, bringing the total gross proceeds received by the Company in the Offering to $6,636,720. &nbsp;The
aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2014, the placement agent received a cash fee of approximately $0.4 million from the sale
of securities and was issued warrants to purchase 68,976 shares of the Company&rsquo;s Common Stock at $9.00 per share for a period
of 5 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
May 28, 2014, the Company and the placement agent agreed to terminate the December 9, 2013 engagement agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">On July 10, 2014
the Company completed a public offering that totaled 1,827,123 common shares, representing gross proceeds of approximately $13.7
million and a net amount of approximately $12.6 million after deducting the underwriting discount and the other offering expenses.
The Placement Agent acted as sole book-running manager for the offering, the Placement Agent acted as lead manager and MLV &amp;
Co. acted as co-manager. The offering was made pursuant to a shelf registration statement previously filed with and declared effective
by the U.S. Securities and Exchange Commission.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note
3 &ndash; Property and Equipment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Property
and equipment consisted of the following at September 30, 2014 and December 31, 2013:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">September&nbsp;30,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December&nbsp;31,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Lives</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 9%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 9%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 9%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Office equipment</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3-5 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">166,354</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15,480</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(25,343</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,560</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">141,011</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">13,920</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Depreciation
expense for the three months ended September 30, 2014 and 2013 was $14,326 and $0, respectively. Depreciation expense for the
nine months ended September 30, 2014 and 2013 was $23,783 and $0, respectively. The Company wrote off certain undepreciated property
and equipment during the nine months ended September 30, 2013 and recorded a loss of $4,122 on the disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note
4 &ndash; Note Payable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
December 28, 2013, the Company entered into a premium finance agreement to pay a premium of $157,825 for its director and officer
liability insurance policy. Pursuant to the agreement, the Company paid a down payment of $15,995 in January 2014 and&nbsp;was
required&nbsp;to pay $15,995 in monthly installment for nine months. During the nine months ended September 30, 2014, the Company
paid $157,825. As of September 30, 2014 and December 31, 2013, the outstanding balance related to the premium finance agreement
was $0 and $157,825, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note
5 &ndash; Derivatives</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">The Company has determined
that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&rsquo;s
common stock at prices below such warrants&rsquo; respective exercise prices and these provisions could result in modification
of the warrants&rsquo; exercise price based on a variable that is not an input to the fair value of a &ldquo;fixed-for-fixed&rdquo;
option as defined under FASB ASC Topic No. 815 &ndash; 40. The warrants granted in connection with the issuance of the 2012 Common
Stock Offering, and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise
price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock)
is issued (or becomes contractually issuable) at a price per share (a &ldquo;Lower Price&rdquo;) that is less than the exercise
price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant
agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to
which the Lower Price is less than the exercise price of the warrant at the time.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Activities
for derivative warrant instruments during the nine months ended September 30, 2014 were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Units</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Fair Value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Balance, December 31, 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,968,623</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,707,255</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Transfer from liability classification to equity classification</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(306,900</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,143,793</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Change in fair value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,653,473</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Balance, September 30, 2014</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,661,723</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,216,935</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2014, 2,117,304 warrants were exercised, of which 306,900 were derivative warrants. The fair
value of these warrants totaling $2,143,793 were measured on the various exercise dates and reclassified to additional paid-in
capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions
at each balance sheet date.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">September&nbsp;30,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December&nbsp;31,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Market value of common stock on measurement date (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6.70</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5.89</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Adjusted exercise price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.48</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Risk free interest rate (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.07</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.27</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Warrant lives in years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.5 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected volatility (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected dividend yield (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Probability of stock offering in any period over 5 years (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Range of percentage of existing shares offered (6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Offering price range (7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    market value of common stock at the above measurement dates is based on the Company&rsquo;s trading price quoted on the OTC
    Markets for December 31, 2013 and on the NYSE MKT for September 30, 2014.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Because
    the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was
    estimated by management using the historical volatilities of comparable companies in the same industry and region.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%; padding: 0; text-indent: 0"></TD>
    <TD STYLE="width: 3%; text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(4)</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Management
    determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(5)</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Management
    determines the probability of future stock offering at each evaluation date.</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%; padding: 0; text-indent: 0"></TD>
    <TD STYLE="width: 3%; text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(6)</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Management
    estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares
    outstanding at September 30, 2014 and December 31, 2013, respectively.</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(7)</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Represents
    the estimated offering price range in future offerings as determined by management.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note
6 &ndash; Commitments and Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>License
and Research Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company has entered into license and research and development agreements with third parties under which the Company is obligated
to make upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a.</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AbbView
    Biotherapeutics Corp <FONT STYLE="line-height: 115%">(<FONT STYLE="color: Black">formerly Abbott Biotherapeutics Corp)</FONT>
    &ndash; </FONT> The Company entered into a Product Development and Patent License Agreement with AbbVie Biotherapeutics Corp.
    (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when
    conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">Milestones</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Payments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">(1) when Company initiates a Phase I Clinical Trial of a licensed product</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">750,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(2) when Company initiates a Phase II Clinical Trial of a licensed product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">(3) when Company initiates a Phase III Clinical Trial of a licensed product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(4) Biological License Application filing with U.S. FDA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,750,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">(5) First commercial sale</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(6) after the first $10,000,000 in net sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">Under the agreement,
the Company shall pay to AbbVie Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed
products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company met its first milestone in 2012 and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone
payment of $750,000 on July 24, 2012.&nbsp;&nbsp;The milestone payment for the Phase 1 Clinical Trial was recorded as research
and development expense. The Company has not initiated a Phase 2 Clinical Trial and no payment has been made to Abbott Biotherapeutics
Corp. since the July 24, 2012 payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left; text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b.&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Memorial
    Sloan Kettering Cancer Center (MSKCC) &ndash; see related party disclosure.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c.&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Oak
    Ridge National Laboratory (ORNL) &ndash; The Company is contracted to purchase radioactive material to be used for research
    and development, with a renewal option at the contract end.&nbsp;&nbsp;For 2013, the Company was obligated and paid approximately
    $0.3 million to purchase of radioactive material with ORNL.&nbsp;&nbsp;During 2014, the Company signed a contract with ORNL
    to purchase $0.4 million of radioactive material.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d.&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AptivSolutions
    provides project management services for the study of the drug Ac-225-HuM195 (Actimab-A) used in the Company&rsquo;s Phase
    1 and Phase 2 clinical trials.&nbsp;&nbsp;The total project is estimated to cost approximately $1.9 million and requires a
    12.5% down payment of the total estimated project cost.&nbsp;&nbsp;The down payment totaling $239,000 was paid in 2007 and
    2012.&nbsp;&nbsp;On August 6, 2012, October 22, 2012 and May 16, 2013, the agreement was amended to provide for additional
    services.&nbsp;&nbsp;The total project is now estimated at approximately $2.2 million. As of September 30, 2014, approximately
    $1.2 million has been expensed to date. &nbsp;AptivSolutions bills the Company when services are rendered and the Company
    records the related expense to research and development costs.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;e.&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
                                         June 15, 2012, the Company entered into a license and sponsored research agreement with
                                         Fred Hutchinson Cancer Research Center (FHCRC) to build upon previous and ongoing clinical
                                         trials, with BC8 (licensed antibody).&nbsp;&nbsp;FHCRC has currently completed Phase
                                         1 and Phase 2 of the clinical trial and the Company intends to start preparation for
                                         a pivotal trial leading to an FDA approval.&nbsp;&nbsp;The Company has been granted exclusive
                                         rights to the BC8 antibody and related master cell bank developed by FHCRC.&nbsp;&nbsp;The
                                         cost to develop the trial will range from $13.2 million to $23.5 million, depending on
                                         the trial design as required by the FDA.&nbsp;&nbsp;Under the terms of the sponsored
                                         research agreement, the Company will fund the FHCRC lab with $150,000 per year for the
                                         first two years and $250,000 thereafter.&nbsp;&nbsp;Payments made toward funding the
                                         lab will be credited toward royalty payments owed to FHCRC in the given year.&nbsp;&nbsp;A
                                         milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug.&nbsp;&nbsp;Upon
                                         commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
        the nine months ended September 30, 2014 and 2013, the Company recorded fees of approximately $0.1 million and $75,000,
        respectively, related to this agreement.</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">f.&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
    July 19, 2012, the Company entered into a clinical trial agreement with FHCRC.&nbsp;&nbsp;The Company will pay $31,366 for
    each patient that has completed the clinical trial. The Company paid a start-up fee of $19,749 in 2013.&nbsp;&nbsp;During
    the clinical trial additional fees apply and will be invoiced when applicable. For the nine months ended September&nbsp;30,
    2014, the Company paid approximately $16,000 for patient enrollment.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">g.&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
    August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center.&nbsp;&nbsp;The
    total estimated cost of conducting the clinical trial is approximately $500,000, which includes a non- refundable institutional
    fee of $14,500.&nbsp;&nbsp;The estimated cost is based on treating 24 patients through 2013.&nbsp;&nbsp;Upon execution of
    the agreement, the Company paid $33,946. During 2013, there was one patient treated and the Company paid $34,383 in July 2013.
    During the nine months ended September 30, 2014, the Company recorded an expense of approximately $0.1 million.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">h.&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
    September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University.&nbsp;&nbsp;The Phase
    1/2 clinical trial will be conducted with Actinium 225.&nbsp;&nbsp;The clinical trial will be conducted under the protocols
    established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&nbsp;&nbsp;The
    Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee
    of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable. The Company paid the
    start-up fee in February 2013. There were no payments made during the nine months ended September 30, 2014 for this agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">i.&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
    November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania.&nbsp;&nbsp;The
    Phase 1/2 clinical trial will be conducted with Actinium 225.&nbsp;&nbsp;The clinical trial will be conducted under the protocols
    established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&nbsp;&nbsp;The
    Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up
    fee of $16,000 and additional administrative fees, when applicable.&nbsp;&nbsp;The Company accrued the $16,000 fee at December
    31, 2013 and paid the fee in January 2014. During the nine months ended September 30, 2014, the Company recorded an expense
    of approximately $16,000.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">j.&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
    January 27, 2014, the Company entered into a manufacturing agreement with Goodwin Biotechnology Inc.&nbsp;&nbsp;(&ldquo;Goodwin&rdquo;).
    Goodwin will oversee the current Good Manufacturing Practices (cGMP) production of a monoclonal antibody anticipated to be
    used in an upcoming phase 3 clinical trial of Iomab-B. Total cost of the agreement is $3.3 million. The Company paid a non-refundable
    payment of $562,790 upon execution of the agreement. Periodic payments will be made upon reaching certain milestones. As of
    September 30, 2014, the remaining cost of the agreement is approximately $2.3 million. Goodwin bills the Company when services
    are rendered and the Company records the related expense to research and development costs.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">k.&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 94%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
                                         June 20, 2014, the Company entered into a CRO agreement with Act Oncology. Act Oncology
                                         provides project management services for the study of Iomab-B used for the intended Phase
                                         3 clinical trial.&nbsp;&nbsp;The total project is estimated to cost approximately $0.8
                                         million. The Company paid approximately $0.3 million during the nine months ended September
                                         30, 2014. Act Oncology bills the Company when services are rendered and the Company records
                                         the related expense to research and development costs.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">l.&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On
September 30, 2014, the Company entered into a research agreement with the Albert Einstein College of Medicine of Yeshiva University
(&ldquo;Einstein&rdquo;). According to the agreement, Einstein will use certain materials provided by the Company to complete
a research project. The research project will explore the feasibility of using Actinium 225 to prepare patients with blood borne
cancers to receive a hematopoietic stem cell transplant. Einstein will periodically provide the Company with reports showing project
data or research. The total fixed price of the project is $183,391 which is payable to Einstein in three payments. A payment of
approximately $92,000 was made subsequent to September&nbsp;30, 2014.&nbsp;&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Lease
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue,&nbsp;New York, NY. The agreement
was terminated on May 31, 2013. On June 4, 2013 and amended on October&nbsp;4, 2013, the Company entered into two rental agreements
for office space at 546 Fifth Avenue,&nbsp;New York, NY. One of the agreements was terminated on July 6, 2014. The Company plans
to maintain office space at 546 Fifth Avenue, New York, NY at least until December 31, 2014. The Company paid a one month refundable
deposit on the space that it maintains in New York, NY. &nbsp;On April 22, 2014, the Company entered into a sublease agreement
for office space located at 379 Thornall Street, Edison, NJ. This agreement expires on September 30, 2016. The Company issued
a security deposit of $34,733 to the existing tenant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note
7 &ndash; Equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">On December 9, 2013,
the Company entered into another engagement agreement with its placement agent for the 2013 Common Stock Offering, &lsquo;the
Offering&rdquo;) The Offering was completed in two tranches, on December 9, 2013 and January 10, 2014. The agreement entered on
December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable
expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company&rsquo;s Common Stock
in an amount equal to 10% of the shares of common stock issued or issuable. Subsequent to the closing of the 2013 offering, the
placement agent continued to provide certain financial advisory services to the Company until three months after the Company had
up-listed its securities for trading on a U.S. National Exchange for a monthly fee of $25,000.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">On December 27, 2013,&nbsp;the
Company completed the first sale of the Offering pursuant to a Unit Purchase Agreement, with certain accredited investors (the
&ldquo;Investors&rdquo;)&nbsp;pursuant to which: the Investors agreed to purchase (i) an aggregate of 554,310 shares (the &ldquo;Shares&rdquo;)
of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 138,577 shares of common stock at an
exercise price of $9.00 per share. The Company received $3,325,860&nbsp;in gross proceeds from the sale of securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">In January 2014, the
Company completed the final tranche of a private placement of the Company&rsquo;s common stock and warrants and received approximately
$3.3 million total gross proceeds from accredited investors (&ldquo;2014 Closing&rdquo;). The Company paid its placement agent
total cash fees of approximately $395,000 and paid attorney fees of $40,000 for their services resulting in net proceeds of $2,873,557.
In the 2014 Closing, the Company sold 551,810 shares of common stock at $6.00 per share and granted 137,952 units of five-year
warrants with an exercise price of $9.00 per share. The warrants are exercisable for a period of five years from the date of issuance.
The transaction date fair value of the warrants of $0.6 million was determined utilizing the Black-Scholes option pricing model
utilizing the following assumptions: risk free interest rate - 1.64%, expected volatility - 88%, expected dividend yield - 0%,
and a contractual life of 5 years. During the nine months ended September 30, 2014, 83,332 warrants were exercised.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
March 24, 2014, the Company filed a shelf registration statement on Form S-3 (the &ldquo;Registration Statement&rdquo;) which
was effective on April 17, 2014. This Registration Statement contained two prospectuses: (i) a base prospectus which covers the
offering, issuance and sale by the Company of up to $200,000,000 of its common stock, preferred stock, warrants and/or units;
and (ii) a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price
of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the &ldquo; Sales Agreement &rdquo; )
with MLV &amp; Co. LLC ( &ldquo; MLV &rdquo; ) dated March 24, 2014. The Company will pay MLV in cash, upon the sale of common
stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. On April 28,
2014, the Company issued 500 shares and received net proceeds of $6,000 under the Sales Agreement with MLV.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Placement
Agent &ndash;&nbsp;</B>During January 2014, in connection with the Common Stock Offering, the Company issued the Placement Agent
warrants to purchase an aggregate of 68,976 shares of common stock with an exercise price of $9.00 per share. The transaction
date fair value of the warrants of $0.2 million was determined utilizing the Black-Scholes option pricing model utilizing the
following assumptions: risk free interest rate &ndash; 1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual
life of 5 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><B>Public Offering</B><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">
- On June 30, 2014, the Company received gross proceeds of $12,525,000 from the public offering of 1,670,000 shares of the Company&rsquo;s
common stock, $0.001 par value per share at a price to the public of $7.50 per share less underwriting discounts. The Company
paid an underwriting discount of $876,750, paid the other offering expenses of $125,000, and paid attorney and auditor fees of
$72,000 resulting in net proceeds of $11,451,250. Under the terms of the underwriting agreement, the Company also granted the
underwriters a 30-day option to purchase up to an additional 250,000 shares of common stock to cover over-allotments, if any,
at the offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
July 10, 2014, the underwriter exercised their over-allotment option to purchase an additional 157,123 shares from the Company
for $7.50 per share. Including the exercise of the over-allotment option of $1.2 million, in gross proceeds, Actinium&rsquo;s
offering totaled 1,827,123 shares, representing gross proceeds of approximately $13.7 million and approximately $12.6 million
net after deducting the underwriting discount and the other offering expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Approval
of the Equity Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2013, the Company granted employees, consultants and board members 180,000 shares of restricted
stock. During the nine months ended September 30, 2014, the Company granted 602,907 shares of restricted stock and cancelled 50,000
shares of restricted stock. Of the total shares of restricted stock granted, 20,000 shares vest 3 months from the grant date,
30,240 shares vest 1 year from the grant date, 202,667 shares have a vesting period of 4 years and 350,000 shares vest at the
date of grant. The remaining restricted shares granted are performance based and upon the achievement of certain milestones.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stock
Option Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Following
is a summary of option activities for the nine months ended September 30, 2014:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Number of Units</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Term (in years)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Outstanding, December 31, 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,985,384</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3.23</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8.34</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,908,696</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,323,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.89</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 1.5pt">Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(310,400</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.96</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Outstanding, September 30, 2014</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,998,084</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.98</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.60</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,731,296</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Exercisable, September 30, 2014</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">643,206</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.04</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.27</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,734,610</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2014, the Company granted employees and its board members 1,323,100 options to purchase the
Company&rsquo;s common stock with exercise prices ranging from $5.55 to $11.95 and a term of 10 years with vesting over a 4-year
period.&nbsp;&nbsp;The options have an aggregated fair value of $8.6 million that was calculated using the Black-Scholes option-pricing
model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.84% - 2.07% (2) expected life
of 6 years, (3) expected volatility of 86.56% to 87.76%, and (4) zero expected dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2014, the Company received gross proceeds of $275,153 for exercise of options for 310,400
shares of the Company&rsquo;s common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense
at September 30, 2014 was $10,953,856. During the three months ended September 30, 2014 and 2013, the Company recorded option
expense of $734,799 and $95,971, respectively. During the nine months ended September 30, 2014 and 2013, the Company recorded
option expense of $1,623,994 and $284,371, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Following
is a summary of warrant activities for the nine months ended September 30, 2014:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Number of Units</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Term (in years)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Outstanding, December 31, 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9,673,290</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.06</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4.89</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">47,396,307</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">406,928</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.81</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,117,304</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.125in">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(29,167</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.70</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Outstanding, September 30, 2014</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,933,747</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.47</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.15</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,641,772</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Exercisable, September 30, 2014</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,733,747</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.28</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.01</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">42,641,772</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2014, the Company granted warrants to purchase 137,952 shares of the Company&rsquo;s common
stock to investors and warrants to purchase 68,976 shares of the Company&rsquo;s common stock to its placement agent in connection
with the January 2014 closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2014, the Company also granted two consultants warrants to purchase 200,000 shares of the
Company&rsquo;s common stock with exercise prices ranging from $5.55 to $11.66 per share and a term of 10 years. These warrants
vest when certain milestones are met. The fair value of the February 2014 and June 2014 were $0.6 million and $1.2 million, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2014, 2,117,304 warrants were exercised by the warrant holders. The Company issued 1,984,524
shares of common stock and received gross proceeds of $116,936.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the three months ended September 30, 2014 and 2013, the Company did not record any stock-based compensation related to the warrants.
During the nine months ended September 30, 2014 and 2013, the Company recorded stock-based compensation related to the warrants
of $98,224 and $0, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B>Note
8 &ndash; Subsequent Events&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During October 2014,
the Company issued approximately 386,000 shares of common stock for the conversion of approximately 485,000 warrants and approximately
$18,000.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: yellow"><B></B></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
2. &nbsp;MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>FORWARD-LOOKING
STATEMENT NOTICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
&nbsp;For this purpose, any statements contained in this Form 10-Q that are not statements of historical fact may be deemed to
be forward-looking statements. &nbsp;Without limiting the foregoing, words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo;
&ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate&rdquo; or &ldquo;continue&rdquo; or comparable terminology are
intended to identify forward-looking statements. &nbsp;These statements by their nature involve substantial risks and uncertainties,
and actual results may differ materially depending on a variety of factors, many of which are not within our control. &nbsp;These
factors include but are not limited to economic conditions generally and in the industries in which we may participate; competition
within our chosen industry, including competition from much larger competitors; technological advances and failure to successfully
develop business relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description
of Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Actinium
is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle
immunotherapy (APIT) platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary,
MedActinium, Inc. (MAI), (hereinafter referred to collectively as &ldquo;Actinium&rdquo;) has initiated collaborative efforts
with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase 1/2 clinical
trial and one Phase 1 clinical trial at Memorial Sloan-Kettering Cancer Center (&ldquo;MSKCC&rdquo;) under an MSKCC Physician
IND Application. In 2012, Actinium launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients.
Actinium&rsquo;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal
antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial
clinical trials of Actinium&rsquo;s compounds have been with patients having acute myeloid leukemia and it is believed that Actinium&rsquo;s
APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
were incorporated under the laws of the State of Nevada on October 6, 1997. We were a shell entity that was in the market for
a merger with an appropriate operating company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
December 28, 2012, we entered into a transaction (the &ldquo;Share Exchange&rdquo;), pursuant to which the Company acquired 21%
of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&ldquo;Actinium&rdquo;), in exchange for the
issuance of 4,309,015 shares of common stock, par value $0.001 per share, of the Company (the &ldquo;Common Stock&rdquo;), which
were issued to the shareholders of Actinium. As a result of the Share Exchange, the former shareholders of Actinium became the
controlling shareholders of the Company. The Share Exchange was accounted for as a reverse takeover/recapitalization effected
by a share exchange, wherein Actinium is considered the acquirer for accounting and financial reporting purposes. As a result
of the Share Exchange, the Company assumed the business and operations of Actinium.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
March 11, 2013, Actinium Corporation&nbsp;continued its Share Exchange with us, whereby we acquired an additional 36% of the issued
and outstanding capital stock of Actinium Corporation from the Actinium Corporation Shareholders in exchange for the issuance
of 7,344,390 shares of Common Stock of us to the Actinium Shareholders.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
April 11, 2013, the change of domicile from the State of Nevada to the State of Delaware and the change of Cactus Ventures, Inc.&rsquo;s
name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc. became effective in accordance with Articles of Merger filed
with the State of Nevada and a Certificate of Merger filed with the State of Delaware.&nbsp;&nbsp;In connection with the name
change we also changed (i) the name of our subsidiary Actinium Pharmaceuticals, Inc. to Actinium Corporation, (ii) our par value
to $0.001 per share, and (iii) the number of authorized shares of preferred stock to 10 million shares.&nbsp;Effective April 18,
2013 our new trading symbol became ATNM. On September 25, 2013, we merged with our subsidiary, Actinium Corporation, and we were
the surviving entity of the merger.&nbsp;&nbsp;In January 2014 we increased our authorized shares of common stock to 200 million
shares and authorized shares of preferred stock to 50 million shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
August 22, 2013, Actinium Corporation&nbsp;continued its Share Exchange with us, whereby we acquired an additional 38.2% of the
issued and outstanding capital stock of Actinium Corporation from the Actinium Corporation Shareholders in exchange for the issuance
of 8,009,550 shares of Common Stock of us to the Actinium Shareholders.&nbsp;&nbsp;On September 25, 2013 in accordance with a
Certificate of Ownership Merging Actinium Corporation into us, we merged with Actinium Corporation, and Actinium Corporation ceased
to exist. As a result of the merger, Actinium Corporation stock owned by us has been cancelled and each share of Actinium Corporation
not owned by us was exchanged for 0.333 shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
March 26, 2014, we began trading our common stock on the NYSE MKT market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Plan
of Operation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We develop drugs for the treatment of cancer
with the intent to cure or significantly improve survival of the affected patients. As of now none of our drugs have been approved
for sale in the United States or elsewhere. We have no commercial operations in sales or marketing of our products. All our product
candidates are under development. In order to market and sell our products we must conduct clinical trials on patients and obtain
regulatory approvals from appropriate regulatory agencies like the Food and Drug Administration (FDA) in the United States and
similar agencies elsewhere in the world.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
products under development are monoclonal antibodies labeled with radioisotopes. We have one program with an antibody labeled
with a beta emitter and several programs based on a proprietary patent protected platform technology called APIT. Our APIT technology
is based on attaching actinium 225 (Ac-225) or bismuth 213 (Bi-213) alpha emitting radioisotopes to monoclonal antibodies. Alpha
emitting radioisotopes are unstable chemical elements that decay by releasing alpha particles. Alpha particles can kill any cell
in the immediate proximity of where they are released. Monoclonal antibodies are genetically engineered proteins that specifically
target certain cells, including cancer cells. It is crucial for the success of our drug candidates to contain monoclonal antibodies
that can successfully seek cancer cells and can kill them with the attached isotope while not harming nearby normal cells. We
do not have technology and operational capabilities to develop and manufacture such monoclonal antibodies and we therefore rely
on collaboration with third parties to gain access to such monoclonal antibodies. We have secured rights to two monoclonal antibodies,
HuM195 (Lintuzumab), in 2003 through a collaborative licensing agreement with Abbivie Biotherapeutics Corp and BC8 in 2012 with
the Fred Hutchinson Cancer Research Center (&ldquo;FHCRC&rdquo;). We expect to negotiate collaborative agreements with other potential
partners that would provide us with access to additional monoclonal antibodies. Establishing and maintaining such collaborative
agreements is a key to our success as a company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Under
our own sponsorship as well as activity at FHCRC, we have four product candidates in active clinical trials: Actimab-A (HuM195-Ac-225),
Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. At this time, the Company is actively pursuing development of Actimab-A and Iomab-B
while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase 1 trials at the FHCRC. Actimab-A is a combination of the monoclonal
antibody we have in-licensed, Lintuzumab (HuM195), and the alpha emitting isotope actinium 225. Actimab-A has shown promising
results throughout preclinical development and an ongoing clinical trial started in 2006 in AML in the elderly. We have expanded
the number of patients and number of clinical centers by commencing a new AML clinical trial which we have launched in 2012. This
trial targets newly diagnosed AML patients over the age of 60. In order to conduct the trial we are engaged in funding, monitoring
and quality assurance and control of the Lintuzumab antibody; procurement of actinium 225 isotope; funding, monitoring and quality
assurance and control of the drug candidate Actimab-A manufacturing and organizing and monitoring clinical trials. We estimate
that the direct costs to completion of both parts of the ongoing Phase 1/2 trial will be approximately $7 million. Iomab-B is
a combination of the in-licensed monoclonal antibody BC8 and the beta emitting radioisotope iodine 131. This construct has been
extensively tested in Phase I and Phase 2 clinical trials in approximately 250 patients with different blood cancer indications
who were in need of a hematopoietic stem cell transplantation (HSCT). Iomab-B is used to condition the bone marrow of these patients
by destroying blood cancer cells in their bone marrow and elsewhere thus allowing for a subsequent transplant containing healthy
donor bone marrow stem cells. We have decided to develop this drug candidate by initially focusing on the patients over 50 with
active acute myeloid leukemia in relapse and/or refractory to existing treatments. Our intention is to request the FDA in 2014
to allow us to enter into a pivotal trial with Iomab-B. We estimate the direct costs of such a trial to completion anticipated
in 2016 will be approximately $25-30 million.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have primarily management position employees and consultants who direct, organize and monitor the activities described above through
contractors. Much of the<I> in vivo</I> laboratory and clinical work contracted for by the Company was conducted at MSKCC in New
York. We also made clinical trial arrangements with other well-known cancer centers. Our Actimab-A drug candidate and its components
are contract manufactured and maintained under our supervision by specialized contract manufacturers and suppliers in the United
States, including IsoTex Diagnostics, Oak Ridge National Laboratory, Pacific GMP, Fischer Bioservices, BioReliance and others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have never generated revenue. Currently
we do not have a recurring source of revenues to cover our operating costs. As of September 30, 2014, we had an accumulated deficit
of approximately $85.8 million. We incurred a net loss for the three months ended September 30, 2014 of approximately $6.1 million
compared to a net loss of $1.4 million for the three months ended September 30, 2013. We incurred net losses of $19.3 million
and $4.9 million for the nine months ended September 30, 2014 and 2013, respectively. We believe that we have enough cash on hand
to fund our operations through the next 12 months.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Opportunities,
Challenges and Risks</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
market for drugs for cancer treatment is a large market in need of novel products, in which successful products can command multibillion
dollars in annual sales. A number of large pharmaceutical and biotechnology company regularly acquire products in development,
with preference given to products in Phase 2 or later clinical trials. These deals are typically structured to include an upfront
payment that ranges from several million dollars to tens of million dollars or more and additional milestone payments tied to
regulatory submissions and approvals and sales milestones. Our goal is to develop our product candidates through Phase 2 clinical
trials and enter into partnership agreements with one or more large pharmaceutical and/or biotechnology companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
believe our future success will be heavily dependent upon our ability to successfully conduct clinical trials and preclinical
development of our drug candidates. This will in turn depend on our ability to continue our collaboration with MSKCC and our Clinical
Advisory Board members. In addition, we plan to continue and expand other research and clinical trial collaborations. Moreover,
we will have to maintain sufficient supply of actinium 225 and successfully maintain and if and when needed replenish or obtain
our reserves of monoclonal antibodies. We will have to maintain and improve manufacturing procedures we have developed for production
of our drug candidates from the components that include the iodine 131 and actinium 225 isotopes, monoclonal antibodies and other
materials. It is possible that despite our best efforts our clinical trials results may not meet regulatory requirements for approval.
If our efforts are successful, we will be able to partner our development stage products on commercially favorable terms only
if they enjoy appropriate patent coverage and/or considerable know-how and other protection that ensures market exclusivity. For
that reason we intend to continue our efforts to maintain existing and generate new intellectual property. Intellectual property
is a key factor in the success of our business as well as market exclusivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
achieve the goals discussed above we intend to continue to invest in research and development at high and constantly increasing
rates thus incurring further losses until one or more of our products are sufficiently developed to partner them to large pharmaceutical
and biotechnology companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Results
of Operations &ndash; Three Months Ended September 30, 2014 Compared to the Three Months Ended September 30, 2013</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table sets forth, for the periods indicated, data derived from our statements of operations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months ended <BR>&nbsp;September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0.25in">Research and development, net of reimbursements</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,773,438</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">778,232</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,257,147</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">830,730</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Depreciation expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,326</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,044,911</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,608,962</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0in">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,299</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Gain on change in fair value of derivative liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">967,887</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">189,348</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total other income (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">967,887</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">188,049</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(6,077,024</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,420,913</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Revenues</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
recorded no commercial revenues for the three months ended September 30, 2014 and 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Research
and Development Expense</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Research
and development expenses increased by approximately $3.0 million to approximately $3.8 million for the three months ended September
30, 2014 compared to approximately $0.8 million for the three months ended September 30, 2013. The increase is primarily attributable
to the manufacturing of BC8 of approximately $2.4 million, the antibody that is the key component of Iomab-B and approximately
$0.6 million of costs related to continuing the multi-center clinical trial for Actimab&trade;-A which commenced in the third
quarter of 2012. The increased expenses also reflect development work on significantly improving the efficacy and cost structure
of the Actimab&trade;-A manufacturing and costs related to Iomab-B&rsquo;s clinical development and regulatory submissions. We
expect to incur increased research and development costs in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>General
and Administrative Expenses</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Overall,
total general and administrative expenses increased by approximately $2.5 million to $3.3 million for the three months ended September
30, 2014 compared to approximately $0.8 million for the three months ended September 30, 2013. The increase was largely attributable
to increases in stock-based compensation costs and payroll related expenses of approximately $1.7 million and $0.6 million, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Also,
the increase to a lesser extent can be attributed to additional professional fees associated with the Company listing its common
stock on the NYSE MKT. In addition to the professional fees incurred, we increased our personnel. As such, payroll-related expenses
for the three months ended September 30, 2014 increased compared to the same period in 2013. We expect to incur increased general
and administrative costs in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Other
Income</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other
income was approximately $1.0 million for the three months ended September 30, 2014 compared to other income of $0.2 million for
the three months ended September 30, 2013. The Company recorded a gain on the change in fair value of the Company&rsquo;s embedded
derivative liability in the approximate amount $1.0 million during the three months ended September 30, 2014 as compared to a
gain of approximately $0.2 million during the comparable three-month period ended September 30, 2013. The change is mainly attributable
to the fluctuation of the Company&rsquo;s stock price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Net
Loss</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
loss increased by approximately $4.7 million to approximately $6.1 million for the three months ended September 30, 2014 compared
to a net loss of approximately $1.4 million for the three months ended September 30, 2013. The increase was primarily due to additional
costs incurred by the Company in research and development expenses, non-cash stock-based compensation costs and professional fees
as discussed above, offset by an increase in the gain from change in fair value of the derivative liability.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Results
of Operations &ndash; Nine Months Ended September 30, 2014 Compared to the Nine Months Ended September 30 2013</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table sets forth, for the periods indicated, data derived from our statements of operations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended <BR>&nbsp;September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0.25in">Research and development, net of reimbursements</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,236,343</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,373,200</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,347,827</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,730,233</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,783</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Loss on disposition of equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,122</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,607,953</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,107,555</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,508</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">(Loss) gain on change in fair value of derivative liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,653,473</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">216,112</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total other income (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,653,473</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">213,604</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(19,261,426</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,893,951</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Revenues</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
recorded no commercial revenues for the nine months ended September 30, 2014 and 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Research
and Development Expense</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Research
and development expenses increased by approximately $5.8 million to approximately $8.2 million for the nine months ended September
30, 2014 compared to approximately $2.4 million for the nine months ended September 30, 2013. For the nine months ended September
30, 2014 we incurred an increase of approximately $3.5 million of manufacturing costs of BC8, the antibody that is the key component
of Iomab-B. and the costs related to continuing the multi-center clinical trial for Actimab&trade;-A which commenced in the third
quarter of 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>General
and Administrative Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Overall,
total general and administrative expenses increased by approximately $4.6 million to $7.3 million for the nine months ended September
30, 2014 compared to approximately $2.7 million for the nine months ended September 30, 2013. The increase was largely attributable
to increases in stock-based compensation costs and salaries and benefits of approximately $3.3 million and $1.0 million, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
expect to incur increased general and administrative costs in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Other
Income (Expense)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other
expense was $3.7 million for the nine months ended September 30, 2014 compared to other income of $0.2 million for the nine months
ended September 30, 2013. The Company recorded a loss on the change in fair value of the Company&rsquo;s embedded derivative liability
of approximately $3.7 million during the nine months ended September 30, 2014 as compared to a gain of approximately $0.2 million
during the comparable nine month period ended September 30, 2013. The change is mainly attributable to the fluctuation of the
Company&rsquo;s stock price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Net
Loss</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
loss increased by approximately $14.4 million to approximately $19.3 million for the nine months ended September 30, 2014 compared
to approximately $4.9 million for the nine months ended September 30, 2013. The increase was primarily due to an increase in the
loss from change in fair value of the derivative liability, in conjunction with additional costs incurred by the Company in research
and development expenses, non-cash stock-based compensation costs and professional fees as discussed above.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have financed our operations primarily through sales of the Company&rsquo;s stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
did not have any cash or cash equivalents held in financial institutions located outside of the United States as of September
30, 2014 and December 31, 2013. We do not anticipate this practice will change in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following tables sets forth selected cash flow information for the periods indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended <BR>September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Cash used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(9,301,386</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(4,947,969</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(150,874</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,030</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,669,569</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,327,393</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net&nbsp;change in cash</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,217,309</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,628,606</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
cash used in operating activities was approximately $9.3 million for the nine months ended September 30, 2014 compared to approximately
$4.9 million used in operations for the same period in 2013. Cash used in operations increased due to the increase in spending
related to preparations and eventual launch and conduct of a multicenter clinical trial and an increase in spending related to
professional fees combined with an increase in payroll-related expenses.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
cash provided by financing activities were approximately $15.7 million and approximately $3.3 million for the nine months ended
September 30, 2014 and 2013, respectively. During the nine months ended September 30, 2014, the Company issued common stock and
received net proceeds of approximately $15.4 million and approximately $0.4 million from the exercise of warrants and options
compared to approximately $3.5 million received during the nine months ended September 30, 2013 from the exercise of warrants.
These increases were offset by payments on notes payable of $157,825 and $140,000 for the nine months ended September 30, 2014
and 2013, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have experienced cumulative losses of approximately $85.8 million from inception (June 13, 2000) through September 30, 2014, and
have stockholders' equity of $2.4 million at September 30, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Recent
Equity Offerings</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2013, we completed the sale of
units pursuant the Unit Purchase Agreement, dated December 27, 2013 (the &ldquo;December Purchase Agreement&rdquo;), and Subscription
Agreement, dated December 27, 2013 (the &ldquo;December Subscription Agreement&rdquo;), among the Company and certain accredited
investors. The securities sold in the offering consisted of an aggregate of (i) 554,310 shares of our common stock, and (ii) warrants
to purchase 138,577 shares of our Common Stock at an exercise price of $9.00 per share, subject to adjustment (&ldquo;2013 Common
Stock Offering&rdquo;). The warrants are exercisable for a period of five years from the date of issuance. The Company received
gross proceeds of approximately $3.3 million from the sale of securities under the Purchase Agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 10, 2014,&nbsp;we conducted the
final closing (the &ldquo;Final Closing&rdquo;) of our private placement of securities (the &ldquo;Offering&rdquo;) pursuant to
a Unit Purchase Agreement, dated as of January 10, 2014 (the &ldquo;January Purchase Agreement&rdquo;) and Subscription Agreement,
dated as of January 10, 2014 (the &ldquo;January Subscription Agreement&rdquo;), with certain accredited investors (the &ldquo;Investors&rdquo;)&nbsp;&nbsp;pursuant
to which the Investors at the Final Closing agreed to purchase (i) an aggregate of 551,810 shares ( the &ldquo;Shares&rdquo;)
of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 137,952 shares of common stock at an
exercise price of $6.00 per share (the &ldquo;Warrants&rdquo;).&nbsp;&nbsp;We received $3,310,860&nbsp;in gross proceeds from
the sale of securities under the January Purchase Agreement at the Final Closing, bringing the total gross proceeds received by
the Company in the Offering to $6,636,720. &nbsp;The aggregate offering amount of securities sold to investors was increased from
$6.0 million to $6.6 million in order to cover over-allotments.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
March&nbsp;24, 2014, we filed a shelf registration statement on Form S-3 (the &ldquo;Registration Statement&rdquo;) that was deemed
effective on April 17, 2014.&nbsp;&nbsp;This Registration Statement contained two prospectuses: (i) a base prospectus which covers
the offering, issuance and sale by the Company of up to $200,000,000 of its common stock, preferred stock, warrants and/or units;
and (ii) a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price
of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the &ldquo;Sales Agreement&rdquo;) with
MLV &amp; Co. LLC (&ldquo;MLV&rdquo;). For the nine months ended September 30, 2014, the Company issued 500 shares under this
agreement totaling approximately $6,200.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sales
of the our common stock through MLV, if any, will be made on the NYSE MKT LLC, on any other existing trading market for the common
stock or to or through a market maker. Subject to the terms and conditions of the Sales Agreement, MLV will use commercially reasonable
efforts to sell our common stock from time to time, based upon our instructions (including any price, time or size limits or other
customary parameters or conditions we may impose). We will pay to MLV in cash, upon the sale of common stock pursuant to the Sales
Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock.&nbsp;&nbsp;We have also provided MLV with
customary indemnification rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 30, 2014, the Company received gross
proceeds of approximately $12.5 million from the public offering of 1,670,000 shares of the Company&rsquo;s common stock, $0.001
par value per share at a price to the public of $7.50 per share less underwriting discounts. The Company paid an underwriting
discount of $0.9 million, paid the other offering expenses of $125,000, and paid attorney and auditor fees of $72,000 resulting
in net proceeds of approximately $11.9 million. Under the terms of the underwriting agreement, the Company granted the underwriters
a 30-day option to purchase up to an additional 250,000 shares of common stock to cover over-allotments, if any, at the offering
price. On July 10, 2014, the underwriters exercised their over-allotment and purchased an additional 157,123 shares of the Company&rsquo;s
common stock for gross proceeds of approximately $1.2 million.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that is material to investors.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Seasonality</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
do not have a seasonal business cycle. Our revenues and operating results are generally derived evenly throughout the calendar
year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Critical
Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
financial statements have been prepared in accordance with accounting principles generally accepted in the United States. To prepare
these consolidated&nbsp;financial statements, we must make estimates and assumptions that affect the reported amounts of assets
and liabilities. These estimates also affect our expenses. Judgments must also be made about the disclosure of contingent liabilities.
Actual results could be significantly different from these estimates. We believe that the following discussion addresses the accounting
policies that are necessary to understand and evaluate our reported financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Derivatives</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
derivatives are recorded at fair value and recorded on the balance sheet. Fair values for securities traded in the open market
and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using
market based pricing models incorporating readily observable market data and requiring judgment and estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Fair
Value of Financial Instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fair
value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority
to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair
value hierarchy is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.35in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Level 1 Inputs &ndash; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity
has the ability to access at the measurement date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.35in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Level 2 Inputs &ndash; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either
directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for
identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable
for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived
principally from or corroborated by market data by correlation or other means.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.35in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Level 3 Inputs &ndash; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own
assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Income
Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities
are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and
are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company
reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset
will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&rsquo;s
assessment as to their realization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Research
and Development Costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company
as a reduction of research and development costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Share-Based
Payments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model.
&nbsp; The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately
expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized
compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period.
Excess tax benefits, if any, are recognized as an addition to paid-in capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Recent
Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers.
Amendments in this Update create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition requirements
in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics
of the Codification. In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition-Construction-Type
and Production-Type Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs-Contracts with Customers. In summary,
the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.
This Accounting Standards Update is the final version of Proposed Accounting Standards Update 2011-230-Revenue Recognition (Topic
605) and Proposed Accounting Standards Update 2011-250-Revenue Recognition (Topic 605): Codification Amendments, both of which
have been deleted. Accounting Standards Update 2014-09. The amendments in this Update are effective for the Company for annual
reporting periods beginning after December 15, 2016, including interim periods within that reporting period. We are currently
evaluating the effects of ASU 2014-09 on the consolidated financial statements<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-10, Development Stage Entities. The
amendments in this Update remove the definition of a development stage entity from Topic 915, thereby removing the distinction
between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements
for development stage entities to (1) present inception-to-date information on the statements of income, cash flows, and shareholder&rsquo;s
equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development
stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development
stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic
275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.&nbsp; Finally, the
amendments also remove paragraph 810-10-15-16, which states that a development stage entity does not meet the condition in paragraph
810-10-15-14(a) to be a variable interest entity (VIE) if (1) the entity can demonstrate that the equity invested in the legal
entity is sufficient to permit it to finance the activities it is currently engaged in and (2) the entity&rsquo;s governing documents
and contractual arrangements allow additional equity investments. Under the amendments, all entities within the scope of the Variable
Interest Entities Subsections of Subtopic 810-10, Consolidation-Overall, would be required to evaluate whether the total equity
investment at risk is sufficient using the guidance provided in paragraphs 810-10-25-45 through 25-47, which requires both qualitative
and quantitative evaluations. The amendments in this Update are effective for annual reporting periods beginning after December
15, 2014, and interim periods therein, and early adoption is required. We evaluated and adopted ASU 2014-10 at June 30, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-12, Compensation- Stock Compensation.
The amendments in this update apply to reporting entities that grant their employees share-based payments in which the terms of
the award provide that a performance target can be achieved after the requisite service period. achieved The amendments in this
Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, and
early adoption is permitted. We are currently evaluating the effects of ASU 2014-12 on the consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
August 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-15, Presentation of Financial Statements-
Going Concern. The Update provides U.S. GAAP guidance on management&rsquo;s responsibility in evaluating whether there is substantial
doubt about a company&rsquo;s ability to continue as a going concern and about related footnote disclosures. For each reporting
period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company&rsquo;s
ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in this
Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.
We are currently evaluating the effects of ASU 2014-15 on the consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations,
financial position, or cash flows of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
3. &nbsp;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not
required by smaller reporting companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
4. &nbsp;CONTROLS AND PROCEDURES.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Evaluation
of Disclosure Controls and Procedures.</I> &nbsp;We carried out an evaluation, under the supervision and with the participation
of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design
and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange
Act of 1934, as amended (the &lsquo;&lsquo;Exchange Act&rsquo;&rsquo;). Disclosure controls and procedures include, without limitation,
controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files
or submits under the Exchange Act is accumulated and communicated to the issuer&rsquo;s management, including its principal executive
and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding
required disclosure. During the <U>second</U> quarter of 2014, we hired outside consultants to draft and test our internal control
policies. Based upon our evaluation, our principal executive officer and principal financial officer concluded that our disclosure
controls and procedures are effective as of September 30, 2014, in ensuring that material information that we are required to
disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the Securities and Exchange Commission rules and forms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Changes
in Internal Control over Financial Reporting</I>. There were no changes in our system of internal controls over financial reporting
during the period covered by this report that has materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
II &ndash; OTHER INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
1A. &nbsp;RISK FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not
Applicable to a smaller reporting company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On July
25, 2014, the Company issued 150,000 shares of common stock having a fair value of $1,048,500 ($6.99/share) in exchange for consulting
services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On September
18, 2014, the Company issued 7,874 shares of common stock having a fair value of $50,000($6.35/share) in exchange for consulting
services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Company
determined that the securities described above were issued in transactions that were exempt from the registration under the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), pursuant to Section 4(a)(2) thereunder. This determination was based
on the non-public manner in which we offered the securities and on the representations of the recipients of the securities, which
included, in pertinent part, that they were &ldquo;accredited investors&rdquo; within the meaning of Rule 501 of Regulation D
promulgated under the Securities Act, that they were acquiring such securities for investment purposes for their own account and
not with a view toward resale or distribution, and that they understood such securities may not be sold or otherwise disposed
of without registration under the Securities Act or an applicable exemption therefrom.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
3. DEFAULTS UPON SENIOR SECURITIES.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">None</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
4. MINE SAFETY DISCLOSURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
5. OTHER INFORMATION.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Item 8.01. Other Events.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><U>Rule 10b5-1 Trading Plans </U></P>

</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt">On October 31, 2014, the board of the Company approved
for adoption by its employees, officers, directors, consultants, and their affiliates, and other entities or individuals approved
by the board (collectively, &ldquo;Plan Participants&rdquo;), the entering into of stock trading plans in accordance with the guidelines
established by the Securities and Exchange Commission under Rule 10b5-1 (&quot;Rule 10b5-1&quot;) of the Securities Exchange Act
of 1934. Rule 10b5-1 trading plans allow these individuals to gradually diversify their holdings while minimizing the market effects
of trades and eliminating any market concern that trades were made while these individuals were in possession of material, nonpublic
information. Plan Participant&rsquo;s may implement Rule 10b5-1 trading plans provided that, among other things, these individuals
are not in possession of any material, nonpublic information at the time they adopt their plan. There is a cooling off period of
the earlier of (i) the next open window (non-blackout period) or (ii) 30 days before the first trade under the plan. As of the
date hereof, none of the Company&rsquo;s Plan Participant&rsquo;s have entered into a trading plan.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
6. EXHIBITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Copies
of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 8%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 81%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Title
    of Document</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Location</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification
    of the Principal Executive Officer and Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification
    of the Principal Executive Officer and Principal Financial and Accounting Officer pursuant to U.S.C. Section 1350 as adopted
    pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.INS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Instance Document</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.SCH</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0">XBRL Taxonomy Extension Schema Document</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.CAL</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0">XBRL Taxonomy Calculation Linkbase Document</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.DEF</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0">XBRL Taxonomy Extension Definition Linkbase
Document</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.LAB</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0">XBRL Taxonomy Label Linkbase Document</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.PRE</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0">XBRL Taxonomy Presentation Linkbase Document</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attached</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*
The Exhibit attached to this Form 10-Q shall not be deemed &quot;filed&quot; for purposes of Section 18 of the Securities Exchange
Act of 1934 (the &quot;Exchange Act&quot;) or otherwise subject to liability under that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by
specific reference in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ACTINIUM
    PHARMACEUTICALS, INC.</B></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 26%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: October
    31, 2014</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/&nbsp;Kaushik
    J. Dave</I></FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Kaushik
    J. Dave</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President
                                         and Chief Executive Officer, and Interim Chief Financial Officer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Duly
        Authorized Officer, Principal</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Executive
        Officer and Principal Financial and Accounting Officer)</FONT></P></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">29</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<HR NOSHADE STYLE="color: Black; width: 100%; height: 1.5pt; margin-top: 0; margin-bottom: 0">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>f10q0914ex31i_actiniumpharma.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
AND PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Kaushik J. Dave, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; width: 2%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%; width: 98%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I have reviewed this Form 10-Q of Actinium Pharmaceuticals, Inc.;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; width: 2%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; width: 2%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%; width: 96%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this report any change in the registrant&rsquo;s internal control over financing reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; width: 2%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%; width: 98%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; width: 2%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; width: 2%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%; width: 96%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Actinium Pharmaceutical, Inc.</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 115%; width: 2%; vertical-align: top; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 98%; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Kaushik J. Dave&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Kaushik J. Dave</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">President,&nbsp;Chief Executive Officer and Interim Chief Financial
        Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Principal Executive Officer and Principal Financial and Accounting
        Officer)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">October 31, 2014&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR SIZE="2" NOSHADE STYLE="margin-top: 3pt; width: 100%; margin-bottom: 3pt; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#8232;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>3
<FILENAME>f10q0914ex32i_actiniumpharma.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Exhibit 32.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER AND PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Quarterly Report
of Actinium Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended&nbsp;September 30, 2014&nbsp;as filed
with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Kaushik J. Dave, President,&nbsp;Chief
Executive Officer&nbsp;and Interim Chief Financial Officer&nbsp;of the Company, certify, pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="width: 98%; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Actinium Pharmaceuticals, Inc.</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="line-height: 115%; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 5%; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 95%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">/s/ Kaushik J. Dave</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Kaushik J. Dave</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">President,&nbsp;Chief Executive Officer and Interim Chief
        Financial Officer&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">(Principal Executive Officer and Principal Financial and
        Accounting Officer)</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">October 31, 2014 &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR SIZE="2" NOSHADE STYLE="margin-top: 3pt; width: 100%; margin-bottom: 3pt; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>4
<FILENAME>atnm-20140930.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated using Ez-XBRL version 7.1.0.0 [10/31/2014 12:34:30 AM] -->
<!-- Based on XBRL 2.1 -->

<xbrli:xbrl xmlns:atnm="http://actiniumpharmaceuticals.com/20140930"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
 xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact"
 xmlns:ref="http://www.xbrl.org/2006/ref"
 xmlns:net="http://www.xbrl.org/2009/role/net"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
 xmlns:exch="http://xbrl.sec.gov/exch/2012-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
 xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31"
 xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes"
 xmlns:us-types="http://fasb.org/us-types/2014-01-31"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:utr="http://www.xbrl.org/2009/utr"
>
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="atnm-20140930.xsd" />
<!-- Context Section  -->
<xbrli:context id="Context_Custom_01_Dec_2007T00_00_00_TO_31_Dec_2007T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-12-01
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_20_May_2011T00_00_00_TO_19_Jun_2011T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:SloanKetteringInstituteOfCancerResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-05-20
</xbrli:startDate>
<xbrli:endDate>
2011-06-19
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_27_Mar_2012T00_00_00_TO_27_Mar_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-27
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_15_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_15_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_15_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-06-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-15
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_19_Jul_2012T00_00_00_TO_19_Jul_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-07-19
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_07_Jul_2012T00_00_00_TO_06_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-07
</xbrli:startDate>
<xbrli:endDate>
2012-08-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_08_Jul_2012T00_00_00_TO_07_Aug_2012T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-08
</xbrli:startDate>
<xbrli:endDate>
2012-08-07
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Aug_2012T00_00_00_TO_28_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-08-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2012T00_00_00_TO_28_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-08-01
</xbrli:startDate>
<xbrli:endDate>
2012-08-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_26_Sep_2012T00_00_00_TO_26_Sep_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-26
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2012T00_00_00_TO_26_Sep_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-09-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-26
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2012T00_00_00_TO_22_Oct_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-10-01
</xbrli:startDate>
<xbrli:endDate>
2012-10-22
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_21_Nov_2012T00_00_00_TO_21_Nov_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfPennsylvaniaMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-11-21
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Dec_2012T00_00_00_TO_28_Dec_2012T00_00_00_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">atnm:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Dec_2012T00_00_00_TO_28_Dec_2012T00_00_00_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">atnm:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-12-25
</xbrli:startDate>
<xbrli:endDate>
2012-12-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2013T00_00_00_TO_16_May_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-05-01
</xbrli:startDate>
<xbrli:endDate>
2013-05-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2013T00_00_00_TO_30_Jun_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jul_2013T00_00_00_TO_31_Jul_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-07-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_03_Sep_2013T00_00_00_TO_04_Sep_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:SloanKetteringInstituteOfCancerResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-09-03
</xbrli:startDate>
<xbrli:endDate>
2013-09-04
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_25_Sep_2013T00_00_00_TO_25_Sep_2013T00_00_00_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">atnm:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-25
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2013T00_00_00_TO_25_Sep_2013T00_00_00_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">atnm:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-09-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-25
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-07-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-07-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00_StatementClassOfStockAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atnm:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2013T00_00_00_TO_09_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-09
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2013T00_00_00_TO_09_Dec_2013T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-09
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_27_Dec_2013T00_00_00_TO_27_Dec_2013T00_00_00_AgreementAxis_UnitPurchaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:UnitPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-27
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Dec_2013T00_00_00_TO_27_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-02
</xbrli:startDate>
<xbrli:endDate>
2013-12-27
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Dec_2013T00_00_00_TO_27_Dec_2013T00_00_00_AgreementAxis_UnitPurchaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:UnitPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-02
</xbrli:startDate>
<xbrli:endDate>
2013-12-27
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Dec_2013T00_00_00_TO_28_Dec_2013T00_00_00_AgreementAxis_PremiumFinanceAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:PremiumFinanceAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atnm:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfPennsylvaniaMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AgreementAxis_PremiumFinanceAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:PremiumFinanceAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_DerivativeByNatureAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_10_Jan_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-10
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Jan_2014T00_00_00_TO_27_Jan_2014T00_00_00_AgreementAxis_ManufacturingAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ManufacturingAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-25
</xbrli:startDate>
<xbrli:endDate>
2014-01-27
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atnm:LaidlawAndCoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_AgreementAxis_PremiumFinanceAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:PremiumFinanceAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atnm:LaidlawAndCoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2014T00_00_00_TO_28_Feb_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-02-01
</xbrli:startDate>
<xbrli:endDate>
2014-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_04_Mar_2014T00_00_00_TO_24_Mar_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-03-04
</xbrli:startDate>
<xbrli:endDate>
2014-03-24
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_09_Feb_2014T00_00_00_TO_28_Apr_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-02-09
</xbrli:startDate>
<xbrli:endDate>
2014-04-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Jun_2014T00_00_00_TO_20_Jun_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_05_Jul_2014T00_00_00_TO_07_Jul_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-05
</xbrli:startDate>
<xbrli:endDate>
2014-07-07
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_10_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-07-10
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_03_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00_StatementClassOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-03
</xbrli:startDate>
<xbrli:endDate>
2014-07-10
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00_AgreementAxis_AlbertEinsteinMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:AlbertEinsteinMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:SloanKetteringInstituteOfCancerResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfPennsylvaniaMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementClassOfStockAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atnm:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AgreementAxis_ManufacturingAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ManufacturingAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseFirstClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:PhaseFirstClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_NewDrugApplicationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:NewDrugApplicationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_ReceiptOfRegulatoryApprovalFromUSFdaMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:ReceiptOfRegulatoryApprovalFromUSFdaMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:AfterFirstNetSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ProductDevelopmentAndPatentLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember_PeriodAxis_TwoThousandAndThirteenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:PeriodAxis">atnm:TwoThousandAndThirteenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember_PeriodAxis_TwoThousandAndFourteenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:PeriodAxis">atnm:TwoThousandAndFourteenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_TitleOfIndividualAxis_InvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseSecondClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbviewBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:PhaseSecondClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseThirdClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbviewBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:PhaseThirdClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_BiologicalLicenseApplicationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbviewBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:BiologicalLicenseApplicationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_FirstCommercialSaleMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbviewBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:FirstCommercialSaleMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbviewBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:AfterFirstNetSalesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseFirstClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbviewBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:PhaseFirstClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbviewBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ProductDevelopmentAndPatentLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_AgreementAxis_PremiumFinanceAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:PremiumFinanceAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_AgreementAxis_AlbertEinsteinMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:AlbertEinsteinMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atnm:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atnm:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Oct_2014T00_00_00_TO_30_Oct_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-10-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_DerivativeByNatureAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-10-01
</xbrli:startDate>
<xbrli:endDate>
2014-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_DerivativeByNatureAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-10-01
</xbrli:startDate>
<xbrli:endDate>
2014-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevEkirxw79c444c555cT{h>F:H44:6H1I:;I18HI;1<F:41H6=788E98HI= -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="pures"><xbrli:measure>atnm:pures</xbrli:measure></xbrli:unit>
<xbrli:unit id="patients"><xbrli:measure>atnm:patients</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">Actinium Pharmaceuticals, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">0001388320</dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">false</dei:AmendmentFlag>
<dei:CurrentFiscalYearEndDate contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
<dei:DocumentType contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">10-Q</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">2014-09-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">2014</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">Q3</dei:DocumentFiscalPeriodFocus>
<dei:EntityFilerCategory contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_30_Oct_2014T00_00_00_TO_30_Oct_2014T00_00_00" unitRef="shares" decimals="INF">30005507</dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">5618669</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">5650328</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">3990063</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">5533366</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">11750675</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">218389</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">671903</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">5751755</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">12422578</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">13920</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">141011</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:SecurityDeposit contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:SecurityDeposit contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">34733</us-gaap:SecurityDeposit>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">5765675</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">12598322</us-gaap:Assets>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">378955</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">1731207</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">81185</us-gaap:AccountsPayableRelatedPartiesCurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">278291</us-gaap:AccountsPayableRelatedPartiesCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">157825</us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">6707255</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">8216935</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">7325220</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">10226433</us-gaap:LiabilitiesCurrent>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">7325220</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">10226433</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">24565</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">29620</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">64933145</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">88120950</us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-66517255</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-85778681</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-1559545</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">2371889</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">5765675</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">12598322</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">50000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="INF">50000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_28_Dec_2012T00_00_00_TO_28_Dec_2012T00_00_00_LegalEntityAxis_ActiniumMember" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="INF">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">24565447</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="INF">29619495</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">24565447</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="INF">29619495</us-gaap:CommonStockSharesOutstanding>
<us-gaap:SalesRevenueNet contextRef="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">778232</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">2373200</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">75000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">3773438</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">8236343</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="-5">100000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="-5">100000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">16000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">830730</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">2730233</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">3257147</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">7347827</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:Depreciation contextRef="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:Depreciation contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:Depreciation contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">14326</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">23783</us-gaap:Depreciation>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">-4122</us-gaap:GainLossOnDispositionOfAssets1>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">1608962</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">5107555</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">7044911</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">15607953</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">-1608962</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">-5107555</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-7044911</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-15607953</us-gaap:OperatingIncomeLoss>
<us-gaap:InterestExpense contextRef="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">1299</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">2508</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">189348</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">216112</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">967887</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-3653473</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">188049</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">213604</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">967887</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-3653473</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">-1420913</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">-4893951</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-6077024</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-19261426</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD_per_Share" decimals="2">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD_per_Share" decimals="2">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.73</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="shares" decimals="0">23601895</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="shares" decimals="0">22401711</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="0">28496902</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="0">26540368</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">284371</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">5221673</us-gaap:ShareBasedCompensation>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">23783</us-gaap:DepreciationDepletionAndAmortization>
<atnm:GainOnChangeInFairValueOfDerivatives contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">216112</atnm:GainOnChangeInFairValueOfDerivatives>
<atnm:GainOnChangeInFairValueOfDerivatives contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-3653473</atnm:GainOnChangeInFairValueOfDerivatives>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">-114143</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">453514</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-34733</us-gaap:IncreaseDecreaseInSecurityDeposits>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">-585043</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">1352252</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">344501</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">197106</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">-4947969</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-9301386</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">8030</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">150874</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">-8030</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-150874</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">140000</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">157825</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_Custom_05_Jul_2014T00_00_00_TO_07_Jul_2014T00_00_00" unitRef="USD" decimals="0">48000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">15435305</us-gaap:ProceedsFromIssuanceOfCommonStock>
<atnm:ProceedsFromExerciseOfOptionsAndWarrantsForCash contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">3467393</atnm:ProceedsFromExerciseOfOptionsAndWarrantsForCash>
<atnm:ProceedsFromExerciseOfOptionsAndWarrantsForCash contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">392089</atnm:ProceedsFromExerciseOfOptionsAndWarrantsForCash>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">3327393</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">15669569</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">-1628606</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">6217309</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:InterestPaid contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">561</us-gaap:InterestPaid>
<us-gaap:InterestPaid contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<atnm:FairValueOfTransferFromLiabilityClassificationToEquityClassification contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">600880</atnm:FairValueOfTransferFromLiabilityClassificationToEquityClassification>
<atnm:FairValueOfTransferFromLiabilityClassificationToEquityClassification contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">2143793</atnm:FairValueOfTransferFromLiabilityClassificationToEquityClassification>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Note 1 &amp;#8211; Description of Business and Summary of Significant Accounting Policies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Nature of Business &amp;#8211;&lt;/b&gt;&amp;#160;Actinium Pharmaceuticals, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Actinium&amp;#8221;) is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &amp;#8220;Actinium&amp;#8221;) initiated collaborative efforts with large institutions to establish the proof of concept of APIT and has supported one Phase 1/2 clinical trial and one Phase 1 clinical trial at Memorial Sloan-Kettering Cancer Center (&amp;#8220;MSKCC&amp;#8221;) under an MSKCC Physician IND Application. In 2012, Actinium launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. &amp;#160;Actinium&amp;#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&amp;#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that Actinium&amp;#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;On December 28, 2012, the Company entered into a transaction (the &amp;#8220;Share Exchange&amp;#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&amp;#8220;API&amp;#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &amp;#8220;Exchange Ratio&amp;#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&amp;#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&amp;#160;&amp;#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API was considered the acquirer for accounting and financial reporting purposes.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;As a result of the Share Exchange, the Company was then considered a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;On March 20, 2013, the Company&amp;#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&amp;#160;&amp;#160;On April&amp;#160;11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space:
 normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &amp;#8220;Merger&amp;#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company was cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company&amp;#8217;s common stock.&amp;#160;&amp;#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Basis of Presentation - Unaudited Interim Financial Information &amp;#8211;&lt;/b&gt;&amp;#160;The accompanying unaudited interim consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary&amp;#160;for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2013 and notes thereto contained in the Company&amp;#8217;s annual report on Form 10-K for the year ended December 31, 2013, as filed with the SEC on February 28, 2014.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Principles of Consolidation &amp;#8211;&lt;/b&gt;&amp;#160;The consolidated financial statements include the Company&amp;#8217;s accounts and those of the Company&amp;#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Use of Estimates in Financial Statement Presentation &amp;#8211;&lt;/b&gt;&amp;#160;The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Reclassification &amp;#8211;&lt;/b&gt;&amp;#160;Certain prior period amounts have been reclassified to conform to current period presentation.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Cash and Cash Equivalents &amp;#8211;&lt;/b&gt;&amp;#160;The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are
 usually in excess of FDIC insured limits. At September 30, 2014 and December 31, 2013, all of the Company&amp;#8217;s cash was deposited in one bank.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Property and Equipment &amp;#8211;&lt;/b&gt;&amp;#160;Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three to seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Impairment of Long-Lived Assets &amp;#8211;&amp;#160;&lt;/b&gt;Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&amp;#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Derivatives &amp;#8211;&lt;/b&gt;&amp;#160;All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Fair Value of Financial Instruments &amp;#8211;&lt;/b&gt;&amp;#160;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.55in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Level 1 Inputs &amp;#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.55in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.55in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Level 2 Inputs &amp;#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or
 indirectly. These might include quoted prices for similar assets or liabilities&amp;#160;in&amp;#160;active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.55in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.55in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Level 3 Inputs &amp;#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of September 30, 2014 and December 31, 2013. As required by ASC 820 &amp;#8220;&lt;i&gt;Fair Value Measurements and Disclosures&amp;#8221;&lt;/i&gt;, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 802px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Derivative liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 406px; padding-left: 0.125in;"&gt;At September 30, 2014&lt;/td&gt;&lt;td style="width: 8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 72px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 72px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 72px; text-align: right;"&gt;8,216,935&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 72px; text-align: right;"&gt;8,216,935&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 0.125in;"&gt;At December 31, 2013&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6,707,255&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6,707,255&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font:
 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Income Taxes &amp;#8211;&lt;/b&gt;&amp;#160;The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&amp;#8217;s assessment as to their realization.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Research and Development Costs &amp;#8211;&lt;/b&gt;&amp;#160;Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Share-Based Payments &amp;#8211;&lt;/b&gt;&amp;#160;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Earnings (Loss) Per Common Share &amp;#8211;&lt;/b&gt;&amp;#160;The Company calculates net loss per common share in accordance with ASC 260 &amp;#8220;Earnings Per Share&amp;#8221; (&amp;#8220;ASC 260&amp;#8221;). Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. The Company&amp;#8217;s potentially dilutive shares, which include outstanding common stock options and warrants have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 802px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;September&amp;#160;30,&lt;br /&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;September&amp;#160;30,&lt;br /&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 610px; text-align: justify;"&gt;Options&lt;/td&gt;&lt;td style="width: 8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 72px; text-align: right;"&gt;2,280,184&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 72px; text-align: right;"&gt;2,998,084&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black;
 border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;9,441,942&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;7,933,747&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;11,722,126&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;10,931,831&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Recent Accounting Pronouncements &amp;#8211;&amp;#160;&lt;/b&gt;In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers. Amendments in this Update create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition&amp;#8212;Construction-Type and Production-Type Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs&amp;#8212;Contracts with Customers. In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The amendments in this Update are effective for the Company for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the effects of ASU 2014-09 on the consolidated financial statements&lt;b&gt;.&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-10, Development Stage Entities. The amendments in this Update remove the definition of a development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows, and shareholder&amp;#8217;s equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.&amp;#160; Finally, the amendments also remove paragraph 810-10-15-16, which states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity (VIE) if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities it is currently engaged in and (2) the entity&amp;#8217;s governing documents and contractual arrangements allow additional equity investments. Under the amendments, all entities within the scope of the Variable Interest Entities Subsections of Subtopic 810-10, Consolidation&amp;#8212;Overall, would be required to evaluate whether the total equity investment at risk is sufficient using the guidance provided in paragraphs 810-10-25-45 through 25-47, which requires both qualitative and quantitative evaluations. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein, and early adoption is required. The Company evaluated and adopted ASU 2014 10&amp;#160;at June 30, 2014.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal;
 font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-12, Compensation- Stock Compensation. The amendments in this update apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target can be achieved after the requisite service period.&amp;#160;The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, and early adoption is permitted. The Company is currently evaluating the effects of ASU 2014-12 on the consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-15, Presentation of Financial Statements- Going Concern. The Update provides U.S. GAAP guidance on management&amp;#8217;s responsibility in evaluating whether there is substantial doubt about a company&amp;#8217;s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company&amp;#8217;s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently evaluating the effects of ASU 2014-15 on the consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Subsequent Events &amp;#8211;&lt;/b&gt;&amp;#160;The Company&amp;#8217;s management reviewed all material events through the date of the consolidated financial statements were issued for subsequent event disclosure consideration.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 2 &amp;#8211; Related Party Transactions&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;MSKCC:&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;In 2010, General Atlantic Group Limited donated all of the equity shares of its wholly owned subsidiary, Actinium Holdings Ltd. (formerly named General Atlantic Investments Limited) to Memorial Sloan Kettering Cancer Center (MSKCC).&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;On February 11, 2002, the Company entered into a License, Development and Commercialization Agreement with Sloan-Kettering Institute of Cancer Research (SKI),&amp;#160;an entity related to MSKCC (&amp;#8220;License Agreement&amp;#8221;).&amp;#160;&amp;#160;The agreement was amended in August 2006.&amp;#160;&amp;#160;Pursuant to the agreement, the Company licensed certain intellectual property from SKI, including critical patents with respect to the Company&amp;#8217;s core technology, and also supports ongoing research and clinical development of related drug candidates.&amp;#160;&amp;#160;MSKCC agreed, subject to certain conditions, to utilize the funds paid for certain clinical and preclinical programs and activities related to the Company&amp;#8217;s drug development and clinical study programs, including the payment of certain costs and expenses that would otherwise have been borne by the Company.&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;The Company is obligated to make the following milestone payments:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1.5pt solid;"&gt;Milestones&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1.5pt solid;" colspan="2"&gt;Payments&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 88%; text-align: left;"&gt;(1) filing of an New Drug Application (&amp;#8220;NDA&amp;#8221;) or regulatory approval&amp;#160;for each licensed product&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 9%; text-align: right;"&gt;750,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;(2) upon the receipt of regulatory approval from the U.S. FDA for each&amp;#160;licensed product&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,750,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Certain amounts due under the License Agreement were deferred and then forgiven under a forbearance-related arrangement.&amp;#160;&amp;#160;On June 19, 2011, the Company nonetheless agreed to pay SKI (a) $50,000 in 2011, (b) $200,000 in 2012 and (c) $250,000 in 2013 under this agreement, in respect of the $50,000 annual maintenance fees and research payments.&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;On September 4, 2013, the Company entered into a letter agreement with SKI to set forth the amount that the Company owes SKI for the period from 2011 to 2014 under the License Agreement.&amp;#160;&amp;#160;The total amount that the Company owes SKI for the period from 2011 to 2014 is $815,100 plus all relevant licensed intellectual property related pass through costs to be determined.&amp;#160;&amp;#160;The amount owed does not include amounts the Company may owe for patent expenses under the
 License Agreement.&amp;#160;&amp;#160;During 2014, the annual maintenance fee is $189,000 plus pass through costs.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;On March 27, 2012, the Company entered into an additional clinical trial agreement with MSKCC Cancer Center with respect to conducting a Phase 1/2 trial of combination therapy of low dose cytarabine and fractionated dose of Lintuzumab-Ac225.&amp;#160;&amp;#160;The Company will pay $31,185 for each patient that has completed the clinical trial.&amp;#160;&amp;#160;Upon execution of the agreement, the Company paid a start-up fee of $79,623 in 2012.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;For the three months ended September 30, 2014 and 2013, the Company incurred approximately $26,000 and $0, respectively, for maintenance fees and research conducted by MSKCC For the nine months ended September 30, 2014 and 2013, the Company incurred $197,106 and $218,604, respectively, for maintenance fees and research conducted by MSKCC.&amp;#160;&amp;#160;As of September 30, 2014 and December 31, 2013, the Company has a payable to MSKCC covering the annual maintenance costs, clinical trials expense and patent costs totaling $278,291 and $81,185, respectively.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Placement Agent:&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;On August 7, 2012, the Company entered into an engagement agreement with a Healthcare Investment Bank as its placement agent for the 2012 Common Stock Offering whereby a director of the Company, is the Head of its Healthcare Investment Banking team.&amp;#160;&amp;#160;&amp;#160;Pursuant to the agreement, the placement agent was engaged as the exclusive agent for the 2012 Common Stock Offering. &amp;#160;&amp;#160;In consideration for its services, the placement agent received (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.&amp;#160;&amp;#160;The placement agent or its designees also received warrants to purchase shares of the Company&amp;#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.&amp;#160;&amp;#160;The placement agent also received the same fee and expense schedule for any cash exercise of warrants within 6 months of the final closing of the 2012 Common Stock Offering and a 5% solicitation fee for any warrants exercised as a result of being called for redemption by the Company.&amp;#160;&amp;#160;Upon the final closing of the 2012 Common Stock Offering of the units, the placement agent was engaged by the Company to provide certain financial advisory services to the Company for a period of at least 6 months for a monthly fee of $25,000.&amp;#160;&amp;#160;The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company&amp;#8217;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.&amp;#160;&amp;#160;For a period ending one year after the expiration of all lock-up agreements entered into in connection with the Share Exchange, any change in the size of the Company board of directors must be approved by the placement agent.&amp;#160;&amp;#160;The placement agent also was engaged by the Company as placement agent for its Stock Offering and Convertible Notes financing in 2011 and, as a part of the fee for that engagement, designees of the placement agent also hold warrants to purchase 1,251,015 shares of the Company&amp;#8217;s Common Stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;On December 9, 2013, the Company entered into another engagement agreement with its placement agent for the 2013 Common Stock Offering, (&amp;#8220;the Offering&amp;#8221;). The Offering was completed in two tranches, December 9, 2013 and January 10, 2014. The agreement entered in on December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company&amp;#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued or issuable. Subsequent to the closing of the 2013 offering, the placement agent continued to provide certain financial advisory services to the Company until three months after the Company had up-listed its securities for trading on a U.S. National Exchange for a monthly fee of $25,000.&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;On December 27, 2013,&amp;#160;the Company completed the first sale of
 the Offering pursuant to a Unit Purchase Agreement, with certain accredited investors (the &amp;#8220;Investors&amp;#8221;)&amp;#160;pursuant to which the Investors agreed to purchase (i) an aggregate of 554,310 shares (the &amp;#8220;Shares&amp;#8221;) of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 138,577 shares of common stock at an exercise price of $9.00 per share. The Company received $3,325,860&amp;#160;in gross proceeds from the sale of securities.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;On January 10, 2014,&amp;#160; the Company conducted the final closing (the &amp;#8220;Final Closing&amp;#8221;) of the Offering pursuant to a Unit Purchase Agreement, dated as of January 10, 2014 (the &amp;#8220;Purchase Agreement&amp;#8221;) and Subscription Agreement, dated as of January 10, 2014 (the &amp;#8220;Subscription Agreement&amp;#8221;), with certain accredited investors (the &amp;#8220;Investors&amp;#8221;)&amp;#160;&amp;#160;pursuant to which the Investors at the Final Closing agreed to purchase (i) an aggregate of 551,810 shares ( the &amp;#8220;Shares&amp;#8221;) of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 137,952 shares of common stock at an exercise price of $9.00 per share. The Company received $3,310,860&amp;#160;in gross proceeds from the sale of securities under the Purchase Agreement at the Final Closing, bringing the total gross proceeds received by the Company in the Offering to $6,636,720. &amp;#160;The aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;During the nine months ended September 30, 2014, the placement agent received a cash fee of approximately $0.4 million from the sale of securities and was issued warrants to purchase 68,976 shares of the Company&amp;#8217;s Common Stock at $9.00 per share for a period of 5 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;On May 28, 2014, the Company and the placement agent agreed to terminate the December 9, 2013 engagement agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"&gt;On July 10, 2014 the Company completed a public offering that totaled 1,827,123 common shares, representing gross proceeds of approximately $13.7 million and a net amount of approximately $12.6 million after deducting the underwriting discount and the other offering expenses. The Placement Agent acted as sole book-running manager for the offering, the Placement Agent acted as lead manager and MLV &amp;amp; Co. acted as co-manager. The offering was made pursuant to a shelf registration statement previously filed with and declared effective by the U.S. Securities and Exchange Commission.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Note 3 &amp;#8211; Property and Equipment&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Property and equipment consisted of the following at September 30, 2014 and December 31, 2013:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;September&amp;#160;30,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Lives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 1003px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;3-5 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;166,354&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;15,480&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(25,343&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(1,560&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;141,011&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;13,920&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal;
 word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Depreciation expense for the three months ended September 30, 2014 and 2013 was $14,326 and $0, respectively. Depreciation expense for the nine months ended September 30, 2014 and 2013 was $23,783 and $0, respectively. The Company wrote off certain undepreciated property and equipment during the nine months ended September 30, 2013 and recorded a loss of $4,122 on the disposition.&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:DebtDisclosureTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Note 4 &amp;#8211; Note Payable&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;On December 28, 2013, the Company entered into a premium finance agreement to pay a premium of $157,825 for its director and officer liability insurance policy. Pursuant to the agreement, the Company paid a down payment of $15,995 in January 2014 and&amp;#160;was required&amp;#160;to pay $15,995 in monthly installment for nine months. During the nine months ended September 30, 2014, the Company paid $157,825. As of September 30, 2014 and December 31, 2013, the outstanding balance related to the premium finance agreement was $0 and $157,825, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Note 5 &amp;#8211; Derivatives&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&amp;#8217;s common stock at prices below such warrants&amp;#8217; respective exercise prices and these provisions could result in modification of the warrants&amp;#8217; exercise price based on a variable that is not an input to the fair value of a &amp;#8220;fixed-for-fixed&amp;#8221; option as defined under FASB ASC Topic No. 815 &amp;#8211; 40. The warrants granted in connection with the issuance of the 2012 Common Stock Offering, and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a &amp;#8220;Lower Price&amp;#8221;) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;Activities for derivative warrant instruments during the nine months ended September 30, 2014 were as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1081.81px;"&gt;Balance, December 31, 2013&lt;/td&gt;&lt;td style="width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 128.18px; text-align: right;"&gt;1,968,623&lt;/td&gt;&lt;td style="width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 127.27px; text-align: right;"&gt;6,707,255&lt;/td&gt;&lt;td style="width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Transfer from liability classification to equity classification&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(306,900&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(2,143,793&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom:
 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;3,653,473&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Balance, September 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,661,723&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;8,216,935&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;During the nine months ended September 30, 2014, 2,117,304 warrants were exercised, of which 306,900 were derivative warrants. The fair value of these warrants totaling $2,143,793 were measured on the various exercise dates and reclassified to additional paid-in capital.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at each balance sheet date.&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;September&amp;#160;30,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1081.81px; text-align: left;"&gt;Market value of common stock on measurement date (1)&lt;/td&gt;&lt;td style="width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 14.54px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 128.18px; text-align: right;"&gt;6.70&lt;/td&gt;&lt;td style="width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 127.27px; text-align: right;"&gt;5.89&lt;/td&gt;&lt;td style="width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Adjusted exercise price&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.48&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.48&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate (2)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.07&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.27&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Warrant lives in years&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;3.2 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:
 right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;0.5 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected volatility (3)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;74&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;73&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yield (4)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Probability of stock offering in any period over 5 years (5)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;25&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;25&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Range of percentage of existing shares offered (6)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;35&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Offering price range (7)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;7.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;9&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="width: 42.72px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;(1)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The market value of common stock at the above measurement dates is based on the Company&amp;#8217;s trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for September 30, 2014.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="width: 42.72px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;(2)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="width: 42.72px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;(3)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;
 font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="padding: 0px; width: 42.72px; text-indent: 0px;"&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;(4)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="padding: 0px; width: 42.72px; text-indent: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;(5)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Management determines the probability of future stock offering at each evaluation date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="padding: 0px; width: 42.72px; text-indent: 0px;"&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;(6)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at September 30, 2014 and December 31, 2013, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="padding: 0px; width: 42.72px; text-indent: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;(7)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Represents the estimated offering price range in future offerings as determined by management.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Note 6 &amp;#8211; Commitments and Contingencies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;License and Research Agreements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 47px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-top: 0px; padding-right: 0px; padding-bottom: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;a.&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1472px; text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;AbbView Biotherapeutics Corp&amp;#160;&lt;font style="line-height: 15.3333320617676px;"&gt;(&lt;font style="color: black;"&gt;formerly Abbott Biotherapeutics Corp)&lt;/font&gt;&amp;#160;&amp;#8211;&amp;#160;&lt;/font&gt;The Company entered into a Product Development and Patent License Agreement with AbbVie Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt;
 line-height: normal; font-family: 'times new roman', times, serif;"&gt;The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Milestones&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left;"&gt;(1) when Company initiates a Phase I Clinical Trial of a licensed product&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;750,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;(2) when Company initiates a Phase II Clinical Trial of a licensed product&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;750,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;(3) when Company initiates a Phase III Clinical Trial of a licensed product&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;(4) Biological License Application filing with U.S. FDA&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,750,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;(5) First commercial sale&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;(6) after the first $10,000,000 in net sales&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;Under the agreement, the Company shall pay to AbbVie Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;The Company met its first milestone in 2012 and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012.&amp;#160;&amp;#160;The milestone payment for the Phase 1 Clinical Trial was recorded as research and development expense. The Company has not initiated a Phase 2 Clinical Trial and no payment has been made to Abbott Biotherapeutics Corp. since the July 24, 2012 payment.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt;
 line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 47px; text-align: left; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;b.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1472px; text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Memorial Sloan Kettering Cancer Center (MSKCC) &amp;#8211; see related party disclosure.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;c.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Oak Ridge National Laboratory (ORNL) &amp;#8211; The Company is contracted to purchase radioactive material to be used for research and development, with a renewal option at the contract end.&amp;#160;&amp;#160;For 2013, the Company was obligated and paid approximately $0.3 million to purchase of radioactive material with ORNL.&amp;#160;&amp;#160;During 2014, the Company signed a contract with ORNL to purchase $0.4 million of radioactive material.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;d.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;AptivSolutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab-A) used in the Company&amp;#8217;s Phase 1 and Phase 2 clinical trials.&amp;#160;&amp;#160;The total project is estimated to cost approximately $1.9 million and requires a 12.5% down payment of the total estimated project cost.&amp;#160;&amp;#160;The down payment totaling $239,000 was paid in 2007 and 2012.&amp;#160;&amp;#160;On August 6, 2012, October 22, 2012 and May 16, 2013, the agreement was amended to provide for additional services.&amp;#160;&amp;#160;The total project is now estimated at approximately $2.2 million. As of September 30,
 2014, approximately $1.2 million has been expensed to date. &amp;#160;AptivSolutions bills the Company when services are rendered and the Company records the related expense to research and development costs.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;e.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (FHCRC) to build upon previous and ongoing clinical trials, with BC8 (licensed antibody).&amp;#160;&amp;#160;FHCRC has currently completed Phase 1 and Phase 2 of the clinical trial and the Company intends to start preparation for a pivotal trial leading to an FDA approval.&amp;#160;&amp;#160;The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC.&amp;#160;&amp;#160;The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA.&amp;#160;&amp;#160;Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter.&amp;#160;&amp;#160;Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year.&amp;#160;&amp;#160;A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug.&amp;#160;&amp;#160;Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&lt;/font&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;During the nine months ended September 30, 2014 and 2013, the Company recorded fees of approximately $0.1 million and $75,000, respectively, related to this agreement.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 47px; text-align: center; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;f.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1472px; text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC.&amp;#160;&amp;#160;The Company will pay $31,366 for each patient that has completed the clinical trial. The Company paid a start-up fee of $19,749 in
 2013.&amp;#160;&amp;#160;During the clinical trial additional fees apply and will be invoiced when applicable. For the nine months ended September&amp;#160;30, 2014, the Company paid approximately $16,000 for patient enrollment.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;g.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center.&amp;#160;&amp;#160;The total estimated cost of conducting the clinical trial is approximately $500,000, which includes a non- refundable institutional fee of $14,500.&amp;#160;&amp;#160;The estimated cost is based on treating 24 patients through 2013.&amp;#160;&amp;#160;Upon execution of the agreement, the Company paid $33,946. During 2013, there was one patient treated and the Company paid $34,383 in July 2013. During the nine months ended September 30, 2014, the Company recorded an expense of approximately $0.1 million.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;h.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University.&amp;#160;&amp;#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&amp;#160;&amp;#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&amp;#160;&amp;#160;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable. The Company paid the start-up fee in February 2013. There were no payments made during the nine months ended September 30, 2014 for this agreement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height:
 normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;i.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania.&amp;#160;&amp;#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&amp;#160;&amp;#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&amp;#160;&amp;#160;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable.&amp;#160;&amp;#160;The Company accrued the $16,000 fee at December 31, 2013 and paid the fee in January 2014. During the nine months ended September 30, 2014, the Company recorded an expense of approximately $16,000.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;j.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On January 27, 2014, the Company entered into a manufacturing agreement with Goodwin Biotechnology Inc.&amp;#160;&amp;#160;(&amp;#8220;Goodwin&amp;#8221;). Goodwin will oversee the current Good Manufacturing Practices (cGMP) production of a monoclonal antibody anticipated to be used in an upcoming phase 3 clinical trial of Iomab-B. Total cost of the agreement is $3.3 million. The Company paid a non-refundable payment of $562,790 upon execution of the agreement. Periodic payments will be made upon reaching certain milestones. As of September 30, 2014, the remaining cost of the agreement is approximately $2.3 million. Goodwin bills the Company when services are rendered and the Company records the related expense to research and development costs.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 47px; text-align: center; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;k.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1472px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal;
 font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On June 20, 2014, the Company entered into a CRO agreement with Act Oncology. Act Oncology provides project management services for the study of Iomab-B used for the intended Phase 3 clinical trial.&amp;#160;&amp;#160;The total project is estimated to cost approximately $0.8 million. The Company paid approximately $0.3 million during the nine months ended September 30, 2014. Act Oncology bills the Company when services are rendered and the Company records the related expense to research and development costs.&lt;/font&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;l.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;"&gt;On September 30, 2014, the Company entered into a research agreement with the Albert Einstein College of Medicine of Yeshiva University (&amp;#8220;Einstein&amp;#8221;). According to the agreement, Einstein will use certain materials provided by the Company to complete a research project. The research project will explore the feasibility of using Actinium 225 to prepare patients with blood borne cancers to receive a hematopoietic stem cell transplant. Einstein will periodically provide the Company with reports showing project data or research. The total fixed price of the project is $183,391 which is payable to Einstein in three payments. A payment of approximately $92,000 was made subsequent to September&amp;#160;30, 2014.&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Lease Agreements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue,&amp;#160;New York, NY. The agreement was terminated on May 31, 2013. On June 4, 2013 and amended on October&amp;#160;4, 2013, the Company entered into two rental agreements for office space at 546 Fifth Avenue,&amp;#160;New York, NY. One of the agreements was terminated on July 6, 2014. The Company plans to maintain office space at 546 Fifth Avenue, New York, NY at least until December 31, 2014. The Company paid a one month refundable deposit on the space that it maintains in New York, NY. &amp;#160;On April 22, 2014, the Company entered into a sublease agreement for office space located at 379 Thornall Street, Edison, NJ. This agreement expires on September 30, 2016. The Company issued a security deposit of $34,733 to the existing tenant.&lt;/font&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Note 7 &amp;#8211; Equity&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On December 9, 2013, the Company entered into another engagement agreement with its placement agent for the 2013 Common Stock Offering, &amp;#8216;the Offering&amp;#8221;) The Offering was completed in two tranches, on December 9, 2013 and January 10, 2014. The agreement entered&amp;#160;on December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company&amp;#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued or issuable. Subsequent to the closing of the 2013 offering, the placement agent continued to provide certain financial advisory services to the Company until three months after the Company had up-listed its securities for trading on a U.S. National Exchange for a monthly fee of $25,000.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On December 27, 2013,&amp;#160;the Company completed the first sale of the Offering pursuant to a Unit Purchase Agreement, with certain accredited investors (the &amp;#8220;Investors&amp;#8221;)&amp;#160;pursuant to which: the Investors agreed to purchase (i) an aggregate of 554,310 shares (the &amp;#8220;Shares&amp;#8221;) of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 138,577 shares of common stock at an exercise price of $9.00 per share. The Company received $3,325,860&amp;#160;in gross proceeds from the sale of securities.&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 27.5pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;In January 2014, the Company completed the final tranche of a private placement of the Company&amp;#8217;s common stock and warrants and received approximately $3.3 million total gross proceeds from accredited investors (&amp;#8220;2014 Closing&amp;#8221;). The Company paid its placement agent total cash fees of approximately $395,000 and paid attorney fees of $40,000 for their services resulting in net proceeds of $2,873,557. In the 2014 Closing, the Company sold 551,810 shares of common stock at $6.00 per share and granted 137,952 units of five-year warrants with an exercise price of $9.00 per share. The warrants are exercisable for a period of five years from the date of issuance. The transaction date fair value of the warrants of $0.6 million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rate - 1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5 years. During the nine months ended September 30, 2014, 83,332 warrants were exercised.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;
 -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 27.5pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On March 24, 2014, the Company filed a shelf registration statement on Form S-3 (the &amp;#8220;Registration Statement&amp;#8221;) which was effective on April 17, 2014. This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to $200,000,000 of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the &amp;#8220; Sales Agreement &amp;#8221; ) with MLV &amp;amp; Co. LLC ( &amp;#8220; MLV &amp;#8221; ) dated March 24, 2014. The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. On April 28, 2014, the Company issued 500 shares and received net proceeds of $6,000 under the Sales Agreement with MLV.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Placement Agent &amp;#8211;&amp;#160;&lt;/b&gt;During January 2014, in connection with the Common Stock Offering, the Company issued the Placement Agent warrants to purchase an aggregate of 68,976 shares of common stock with an exercise price of $9.00 per share. The transaction date fair value of the warrants of $0.2 million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rate &amp;#8211; 1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5 years.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Public Offering&lt;/b&gt;&amp;#160;- On June 30, 2014, the Company received gross proceeds of $12,525,000 from the public offering of 1,670,000 shares of the Company&amp;#8217;s common stock, $0.001 par value per share at a price to the public of $7.50 per share less underwriting discounts. The Company paid an underwriting discount of $876,750, paid the other offering expenses of $125,000, and paid attorney and auditor fees of $72,000 resulting in net proceeds of $11,451,250.. Under the terms of the underwriting agreement, the Company also granted the underwriters a 30-day option to purchase up to an additional 250,000 shares of common stock to cover over-allotments, if any, at the offering price.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On July 10, 2014, the underwriter exercised their over-allotment option to purchase an additional 157,123 shares from the Company for $7.50 per share. Including the exercise of the over-allotment option of $1.2 million, in gross proceeds, Actinium&amp;#8217;s offering totaled 1,827,123 shares,
 representing gross proceeds of approximately $13.7 million and approximately $12.6 million net after deducting the underwriting discount and the other offering expenses.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&amp;#160;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Approval of the Equity Incentive Plan&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;During the nine months ended September 30, 2013, the Company granted employees, consultants and board members 180,000 shares of restricted stock. During the nine months ended September 30, 2014, the Company granted 602,907 shares of restricted stock and cancelled 50,000 shares of restricted stock. Of the total shares of restricted stock granted, 20,000 shares vest 3 months from the grant date, 30,240 shares vest 1 year from the grant date, 202,667 shares have a vesting period of 4 years and 350,000 shares vest at the date of grant. The remaining restricted shares granted are performance based and upon the achievement of certain milestones.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;/font&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Stock Option Plan&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.55in; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Following is a summary of option activities for the nine months ended September 30, 2014:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 29.7pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of Units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:
 center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Remaining Contractual Term (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px;"&gt;Outstanding, December 31, 2013&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,985,384&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;3.23&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;8.34&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;5,908,696&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 0.125in;"&gt;Issued&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,323,100&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8.89&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt;"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(310,400&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.96&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Outstanding, September 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;2,998,084&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.98&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8.60&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,731,296&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Exercisable, September 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;643,206&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.04&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6.27&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,734,610&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal;
 widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;During the nine months ended September 30, 2014, the Company granted employees and its board members 1,323,100 options to purchase the Company&amp;#8217;s common stock with exercise prices ranging from $5.55 to $11.95 and a term of 10 years with vesting over a 4-year period.&amp;#160;&amp;#160;The options have an aggregated fair value of $8.6 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.84% - 2.07% (2) expected life of 6 years, (3) expected volatility of 86.56% to 87.76%, and (4) zero expected dividends.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;During the nine months ended September 30, 2014, the Company received gross proceeds of $275,153 for exercise of options for 310,400 shares of the Company&amp;#8217;s common stock.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at September 30, 2014 was $10,953,856. During the three months ended September 30, 2014 and 2013, the Company recorded option expense of $734,799 and $95,971, respectively. During the nine months ended September 30, 2014 and 2013, the Company recorded option expense of $1,623,994 and $284,371, respectively.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Following is a summary of warrant activities for the nine months ended September 30, 2014:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new
 roman',;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of Units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Remaining Contractual Term (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px;"&gt;Outstanding, December 31, 2013&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;9,673,290&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1.06&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;4.89&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;47,396,307&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 0.125in;"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;406,928&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8.81&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;7.46&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 0.125in;"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(2,117,304&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.96&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0.125in;"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;(29,167&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6.70&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Outstanding, September 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;7,933,747&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.47&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4.15&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;42,641,772&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Exercisable, September 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align:
 left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;7,733,747&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4.01&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;42,641,772&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;During the nine months ended September 30, 2014, the Company granted warrants to purchase 137,952 shares of the Company&amp;#8217;s common stock to investors and warrants to purchase 68,976 shares of the Company&amp;#8217;s common stock to its placement agent in connection with the January 2014 closing.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 27.5pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;During the nine months ended September 30, 2014, the Company also granted two consultants warrants to purchase 200,000 shares of the Company&amp;#8217;s common stock with exercise prices ranging from $5.55 to $11.66 per share and a term of 10 years. These warrants vest when certain milestones are met. The fair value of the February 2014 and June 2014 were $0.6 million and $1.2 million, respectively.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 27.5pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;During the nine months ended September 30, 2014, 2,117,304 warrants were exercised by the warrant holders. The Company issued 1,984,524 shares of common stock and received gross proceeds of $116,936.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 27.5pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;During the three months ended September 30, 2014 and 2013, the Company did not record any stock-based compensation related to the warrants. During the nine months ended September 30, 2014 and 2013, the Company recorded stock-based compensation related to the warrants of $98,224 and $0, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;p style="font: 10pt times new roman, times, serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify;"&gt;&lt;b&gt;Note 8 &amp;#8211; Subsequent Events&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.5in;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.5in;"&gt;During October 2014, the Company issued approximately 386,000 shares of common stock for the conversion of approximately 485,000 warrants and approximately $18,000.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:BusinessCombinationsPolicy contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Nature of Business &amp;#8211;&lt;/b&gt;&amp;#160;Actinium Pharmaceuticals, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Actinium&amp;#8221;) is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &amp;#8220;Actinium&amp;#8221;) initiated collaborative efforts with large institutions to establish the proof of concept of APIT and has supported one Phase 1/2 clinical trial and one Phase 1 clinical trial at Memorial Sloan-Kettering Cancer Center (&amp;#8220;MSKCC&amp;#8221;) under an MSKCC Physician IND Application. In 2012, Actinium launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. &amp;#160;Actinium&amp;#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&amp;#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that Actinium&amp;#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On December 28, 2012, the Company entered into a transaction (the &amp;#8220;Share Exchange&amp;#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&amp;#8220;API&amp;#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &amp;#8220;Exchange Ratio&amp;#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&amp;#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&amp;#160;&amp;#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API was considered the acquirer for accounting and financial reporting purposes.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;As a result of the Share Exchange, the Company was then considered a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On March 20, 2013, the Company&amp;#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&amp;#160;&amp;#160;On April&amp;#160;11, 2013, the Company changed its domicile
 from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &amp;#8220;Merger&amp;#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company was cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company&amp;#8217;s common stock.&amp;#160;&amp;#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.&lt;/font&gt;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Basis of Presentation - Unaudited Interim Financial Information &amp;#8211;&lt;/b&gt;&amp;#160;The accompanying unaudited interim consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary&amp;#160;for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2013 and notes thereto contained in the Company&amp;#8217;s annual report on Form 10-K for the year ended December 31, 2013, as filed with the SEC on February 28, 2014.&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:ConsolidationPolicyTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Principles of Consolidation &amp;#8211;&lt;/b&gt;&amp;#160;The consolidated financial statements include the Company&amp;#8217;s accounts and those of the Company&amp;#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Use of Estimates in Financial Statement Presentation &amp;#8211;&lt;/b&gt;&amp;#160;The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/div&gt;</us-gaap:UseOfEstimates>
<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Reclassification &amp;#8211;&lt;/b&gt;&amp;#160;Certain prior period amounts have been reclassified to conform to current period presentation.&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Cash and Cash Equivalents &amp;#8211;&lt;/b&gt;&amp;#160;The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At September 30, 2014 and December 31, 2013, all of the Company&amp;#8217;s cash was deposited in one bank.&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Property and Equipment &amp;#8211;&lt;/b&gt;&amp;#160;Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three to seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Impairment of Long-Lived Assets &amp;#8211;&amp;#160;&lt;/b&gt;Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&amp;#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:DerivativesPolicyTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Derivatives &amp;#8211;&lt;/b&gt;&amp;#160;All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Fair Value of Financial Instruments &amp;#8211;&lt;/b&gt;&amp;#160;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.55in; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 1 Inputs &amp;#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.55in; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.55in; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 2 Inputs &amp;#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities&amp;#160;in&amp;#160;active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.55in; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.55in; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 3 Inputs &amp;#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch:
 normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of September 30, 2014 and December 31, 2013. As required by ASC 820 &amp;#8220;&lt;i&gt;Fair Value Measurements and Disclosures&amp;#8221;&lt;/i&gt;, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Derivative liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 803px; padding-left: 0.125in;"&gt;At September 30, 2014&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;8,216,935&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;8,216,935&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 0.125in;"&gt;At December 31, 2013&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6,707,255&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6,707,255&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Income Taxes &amp;#8211;&lt;/b&gt;&amp;#160;The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&amp;#8217;s assessment as to their realization.&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Research and Development Costs &amp;#8211;&lt;/b&gt;&amp;#160;Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Share-Based Payments &amp;#8211;&lt;/b&gt;&amp;#160;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Earnings (Loss) Per Common Share &amp;#8211;&lt;/b&gt;&amp;#160;The Company calculates net loss per common share in accordance with ASC 260 &amp;#8220;Earnings Per Share&amp;#8221; (&amp;#8220;ASC 260&amp;#8221;). Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. The Company&amp;#8217;s potentially dilutive shares, which include outstanding common stock options and warrants have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;September&amp;#160;30,&lt;br /&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;September&amp;#160;30,&lt;br /&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: justify;"&gt;Options&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;2,280,184&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;2,998,084&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;9,441,942&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;7,933,747&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;11,722,126&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;10,931,831&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Recent Accounting Pronouncements &amp;#8211;&amp;#160;&lt;/b&gt;In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers. Amendments in this Update create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition&amp;#8212;Construction-Type and Production-Type Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs&amp;#8212;Contracts with Customers. In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The amendments in this Update are effective for the Company for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the effects of ASU 2014-09 on the consolidated financial statements&lt;b&gt;.&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-10, Development Stage Entities. The amendments in this Update remove the definition of a development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows, and shareholder&amp;#8217;s equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.&amp;#160; Finally, the amendments also remove paragraph 810-10-15-16, which states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity (VIE) if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities it is currently engaged in and (2) the entity&amp;#8217;s governing documents and contractual arrangements allow additional equity investments. Under the amendments, all entities within the scope of the Variable Interest Entities Subsections of Subtopic 810-10, Consolidation&amp;#8212;Overall, would be required to evaluate whether the total equity investment at risk is sufficient using the guidance provided in paragraphs 810-10-25-45 through 25-47, which requires both qualitative and quantitative evaluations. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein, and early adoption is required. The Company evaluated and adopted ASU 2014-10 at June 30, 2014.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-12, Compensation- Stock Compensation. The amendments in this update apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target can be achieved after the requisite service period. The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, and early adoption is permitted. The Company is currently evaluating the effects of ASU 2014-12 on the consolidated financial
 statements.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-15, Presentation of Financial Statements- Going Concern. The Update provides U.S. GAAP guidance on management&amp;#8217;s responsibility in evaluating whether there is substantial doubt about a company&amp;#8217;s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company&amp;#8217;s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently evaluating the effects of ASU 2014-15 on the consolidated financial statements.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Subsequent Events &amp;#8211;&lt;/b&gt;&amp;#160;The Company&amp;#8217;s management reviewed all material events through the date of the consolidated financial statements were issued for subsequent event disclosure consideration.&lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 802px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Derivative liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 406px; padding-left: 0.125in;"&gt;At September 30, 2014&lt;/td&gt;&lt;td style="width: 8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 72px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 72px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 72px; text-align: right;"&gt;8,216,935&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 72px; text-align: right;"&gt;8,216,935&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 0.125in;"&gt;At December 31, 2013&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6,707,255&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6,707,255&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 802px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;September&amp;#160;30,&lt;br /&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;September&amp;#160;30,&lt;br /&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 610px; text-align: justify;"&gt;Options&lt;/td&gt;&lt;td style="width: 8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 72px; text-align: right;"&gt;2,280,184&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 72px; text-align: right;"&gt;2,998,084&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;9,441,942&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;7,933,747&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;11,722,126&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;10,931,831&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 821px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Milestones&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 723px; text-align: left;"&gt;(1) filing of an New Drug Application (&amp;#8220;NDA&amp;#8221;) or regulatory approval&amp;#160;for each licensed product&lt;/td&gt;&lt;td style="width: 9px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 73px; text-align: right;"&gt;750,000&lt;/td&gt;&lt;td style="width: 8px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;(2) upon the receipt of regulatory approval from the U.S. FDA for each&amp;#160;licensed product&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,750,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;September&amp;#160;30,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Lives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 1003px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;3-5 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;166,354&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;15,480&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(25,343&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(1,560&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;141,011&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;13,920&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:ScheduleOfDerivativeInstrumentsTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1081.81px;"&gt;Balance, December 31, 2013&lt;/td&gt;&lt;td style="width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 128.18px; text-align: right;"&gt;1,968,623&lt;/td&gt;&lt;td style="width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 127.27px; text-align: right;"&gt;6,707,255&lt;/td&gt;&lt;td style="width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Transfer from liability classification to equity classification&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(306,900&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(2,143,793&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;3,653,473&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Balance, September 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,661,723&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;8,216,935&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
<atnm:FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;September&amp;#160;30,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1081.81px; text-align: left;"&gt;Market value of common stock on measurement date (1)&lt;/td&gt;&lt;td style="width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 14.54px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 128.18px; text-align: right;"&gt;6.70&lt;/td&gt;&lt;td style="width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 127.27px; text-align: right;"&gt;5.89&lt;/td&gt;&lt;td style="width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Adjusted exercise price&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.48&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.48&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate (2)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.07&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.27&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Warrant lives in years&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;3.2 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;0.5 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected volatility (3)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;74&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;73&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yield (4)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Probability of stock offering in any period over 5 years (5)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;25&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;25&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Range of percentage of existing shares offered (6)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;35&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Offering price range (7)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;7.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;9&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="width: 42.72px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;(1)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The market value of common stock at the above measurement dates is based on the
 Company&amp;#8217;s trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for September 30, 2014.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="width: 42.72px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;(2)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="width: 42.72px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;(3)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="padding: 0px; width: 42.72px; text-indent: 0px;"&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;(4)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="padding: 0px; width: 42.72px; text-indent: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;(5)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Management determines the probability of future stock offering at each evaluation date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="padding: 0px; width: 42.72px; text-indent: 0px;"&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;(6)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify;
 text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at September 30, 2014 and December 31, 2013, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="padding: 0px; width: 42.72px; text-indent: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;(7)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Represents the estimated offering price range in future offerings as determined by management.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</atnm:FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock>
<atnm:MilestonePaymentsMilestoneMethodTableTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Milestones&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1252.72px; text-align: left;"&gt;(1) when Company initiates a Phase I Clinical Trial of a licensed product&lt;/td&gt;&lt;td style="width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 14.54px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 127.27px; text-align: right;"&gt;750,000&lt;/td&gt;&lt;td style="width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;(2) when Company initiates a Phase II Clinical Trial of a licensed product&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;750,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;(3) when Company initiates a Phase III Clinical Trial of a licensed product&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;(4) Biological License Application filing with U.S. FDA&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,750,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;(5) First commercial sale&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;(6) after the first $10,000,000 in net sales&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</atnm:MilestonePaymentsMilestoneMethodTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of Units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Remaining Contractual Term (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px;"&gt;Outstanding, December 31, 2013&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,985,384&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;3.23&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;8.34&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;5,908,696&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 0.125in;"&gt;Issued&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,323,100&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8.89&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt;"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(310,400&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.96&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Outstanding, September 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;2,998,084&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.98&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8.60&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,731,296&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Exercisable, September 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;643,206&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.04&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6.27&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,734,610&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal;
 line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember">&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of Units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Remaining Contractual Term (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px;"&gt;Outstanding, December 31, 2013&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;9,673,290&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1.06&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;4.89&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;47,396,307&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 0.125in;"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;406,928&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8.81&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;7.46&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 0.125in;"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(2,117,304&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.96&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0.125in;"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;(29,167&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6.70&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Outstanding, September 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;7,933,747&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.47&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4.15&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;42,641,772&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Exercisable, September 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;7,733,747&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4.01&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;42,641,772&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;/p&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">6707255</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">6707255</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">8216935</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">8216935</us-gaap:DerivativeLiabilities>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="shares" decimals="0">11722126</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">9441942</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionMember" unitRef="shares" decimals="0">2280184</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="0">10931831</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">7933747</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionMember" unitRef="shares" decimals="0">2998084</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_28_Dec_2012T00_00_00_TO_28_Dec_2012T00_00_00_LegalEntityAxis_ActiniumMember" unitRef="pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_25_Sep_2013T00_00_00_TO_25_Sep_2013T00_00_00_LegalEntityAxis_ActiniumMember" unitRef="pure" decimals="4">0.9370</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<atnm:CommonStockIssuableInConsiderationForEquityInterestAcquisition contextRef="Context_Custom_25_Dec_2012T00_00_00_TO_28_Dec_2012T00_00_00_LegalEntityAxis_ActiniumMember" unitRef="pure" decimals="2">0.99</atnm:CommonStockIssuableInConsiderationForEquityInterestAcquisition>
<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">Three years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">Three to seven years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
<atnm:SharesExchangeRatio contextRef="Context_Custom_25_Dec_2012T00_00_00_TO_28_Dec_2012T00_00_00_LegalEntityAxis_ActiniumMember" unitRef="pures" decimals="3">0.333</atnm:SharesExchangeRatio>
<atnm:SharesExchangeRatio contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_25_Sep_2013T00_00_00_LegalEntityAxis_ActiniumMember" unitRef="pures" decimals="3">0.333</atnm:SharesExchangeRatio>
<atnm:CommonStockShares contextRef="Context_As_Of_25_Sep_2013T00_00_00_TO_25_Sep_2013T00_00_00_LegalEntityAxis_ActiniumMember" unitRef="shares" decimals="INF">3970137</atnm:CommonStockShares>
<atnm:ExchangedInCommonStockShares contextRef="Context_As_Of_25_Sep_2013T00_00_00_TO_25_Sep_2013T00_00_00_LegalEntityAxis_ActiniumMember" unitRef="shares" decimals="INF">1322055</atnm:ExchangedInCommonStockShares>
<atnm:RelatedPartyMilestonesPayment contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_NewDrugApplicationMember" unitRef="USD" decimals="0">750000</atnm:RelatedPartyMilestonesPayment>
<atnm:RelatedPartyMilestonesPayment contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_ReceiptOfRegulatoryApprovalFromUSFdaMember" unitRef="USD" decimals="0">1750000</atnm:RelatedPartyMilestonesPayment>
<atnm:NumberOfPatients contextRef="Context_Custom_01_Aug_2012T00_00_00_TO_28_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="patients" decimals="INF">24</atnm:NumberOfPatients>
<atnm:AmountPaidUnderAgreementInYearTwoThousandEleven contextRef="Context_Custom_20_May_2011T00_00_00_TO_19_Jun_2011T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">50000</atnm:AmountPaidUnderAgreementInYearTwoThousandEleven>
<atnm:AmountPaidUnderAgreementInYearTwoThousandTwelve contextRef="Context_Custom_20_May_2011T00_00_00_TO_19_Jun_2011T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">200000</atnm:AmountPaidUnderAgreementInYearTwoThousandTwelve>
<atnm:AmountPaidUnderAgreementInYearTwoThousandThirteen contextRef="Context_Custom_20_May_2011T00_00_00_TO_19_Jun_2011T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">250000</atnm:AmountPaidUnderAgreementInYearTwoThousandThirteen>
<atnm:OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen contextRef="Context_Custom_03_Sep_2013T00_00_00_TO_04_Sep_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">815100</atnm:OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen>
<atnm:MaintenanceFeesAndResearchPayments contextRef="Context_Custom_20_May_2011T00_00_00_TO_19_Jun_2011T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">50000</atnm:MaintenanceFeesAndResearchPayments>
<atnm:MaintenanceFeesAndResearchPayments contextRef="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember" unitRef="USD" decimals="0">0</atnm:MaintenanceFeesAndResearchPayments>
<atnm:MaintenanceFeesAndResearchPayments contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember" unitRef="USD" decimals="0">218604</atnm:MaintenanceFeesAndResearchPayments>
<atnm:MaintenanceFeesAndResearchPayments contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">81185</atnm:MaintenanceFeesAndResearchPayments>
<atnm:MaintenanceFeesAndResearchPayments contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember" unitRef="USD" decimals="0">26000</atnm:MaintenanceFeesAndResearchPayments>
<atnm:MaintenanceFeesAndResearchPayments contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">189000</atnm:MaintenanceFeesAndResearchPayments>
<atnm:MaintenanceFeesAndResearchPayments contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">278291</atnm:MaintenanceFeesAndResearchPayments>
<atnm:MaintenanceFeesAndResearchPayments contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember" unitRef="USD" decimals="0">197106</atnm:MaintenanceFeesAndResearchPayments>
<atnm:PlacementAgentServicesFees contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="-5">400000</atnm:PlacementAgentServicesFees>
<atnm:WarrantsIssuedToPurchaseCommonStock contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="shares" decimals="INF">68976</atnm:WarrantsIssuedToPurchaseCommonStock>
<atnm:WarrantsIssuedToPurchaseCommonStock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="shares" decimals="INF">68976</atnm:WarrantsIssuedToPurchaseCommonStock>
<atnm:WarrantsIssuedToPurchaseCommonStock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_TitleOfIndividualAxis_InvestorMember" unitRef="shares" decimals="0">137952</atnm:WarrantsIssuedToPurchaseCommonStock>
<atnm:CommonStockExercisePriceParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD_per_Share" decimals="2">9.00</atnm:CommonStockExercisePriceParOrStatedValuePerShare>
<atnm:CommonStockExercisePriceParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD_per_Share" decimals="0">9</atnm:CommonStockExercisePriceParOrStatedValuePerShare>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of_27_Mar_2012T00_00_00_TO_27_Mar_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">31185</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of_19_Jul_2012T00_00_00_TO_19_Jul_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">31366</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of_28_Aug_2012T00_00_00_TO_28_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">500000</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of_26_Sep_2012T00_00_00_TO_26_Sep_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">38501</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of_21_Nov_2012T00_00_00_TO_21_Nov_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">31771</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of_31_Jul_2013T00_00_00_TO_31_Jul_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">34383</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">16000</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" xsi:nil="true"/>
<atnm:StartUpFeeForClinicalTrial contextRef="Context_As_Of_28_Aug_2012T00_00_00_TO_28_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">33946</atnm:StartUpFeeForClinicalTrial>
<atnm:StartUpFeeForClinicalTrial contextRef="Context_As_Of_26_Sep_2012T00_00_00_TO_26_Sep_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">22847</atnm:StartUpFeeForClinicalTrial>
<atnm:StartUpFeeForClinicalTrial contextRef="Context_As_Of_21_Nov_2012T00_00_00_TO_21_Nov_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">16000</atnm:StartUpFeeForClinicalTrial>
<atnm:StartUpFeeForClinicalTrial contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">79623</atnm:StartUpFeeForClinicalTrial>
<atnm:StartUpFeeForClinicalTrial contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">19749</atnm:StartUpFeeForClinicalTrial>
<atnm:StartUpDueCostPaidDate contextRef="Context_Custom_01_Aug_2012T00_00_00_TO_28_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">2013-12-31</atnm:StartUpDueCostPaidDate>
<atnm:DescriptionOfReceivablesOfPlacementAgentForServices contextRef="Context_Custom_08_Jul_2012T00_00_00_TO_07_Aug_2012T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">&lt;div&gt;Placement agent received (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.&lt;/div&gt;</atnm:DescriptionOfReceivablesOfPlacementAgentForServices>
<atnm:DescriptionOfReceivablesOfPlacementAgentForServices contextRef="Context_Custom_01_Dec_2013T00_00_00_TO_09_Dec_2013T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">Agreement entered in on December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company's Common Stock</atnm:DescriptionOfReceivablesOfPlacementAgentForServices>
<atnm:DescriptionOfWarrantsReceivablesByPlacement contextRef="Context_Custom_08_Jul_2012T00_00_00_TO_07_Aug_2012T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">The placement agent or its designees also received warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.</atnm:DescriptionOfWarrantsReceivablesByPlacement>
<atnm:DescriptionOfWarrantsReceivablesByPlacement contextRef="Context_Custom_01_Dec_2013T00_00_00_TO_09_Dec_2013T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">Warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued or issuable</atnm:DescriptionOfWarrantsReceivablesByPlacement>
<atnm:PeriodOfExerciseOfWarrants contextRef="Context_Custom_08_Jul_2012T00_00_00_TO_07_Aug_2012T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">Within 6 months of the final closing of the 2012 common stock Offering</atnm:PeriodOfExerciseOfWarrants>
<atnm:PeriodOfExerciseOfWarrants contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">5 years</atnm:PeriodOfExerciseOfWarrants>
<atnm:PercentageOfSolicitationFee contextRef="Context_Custom_08_Jul_2012T00_00_00_TO_07_Aug_2012T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="pure" decimals="2">0.05</atnm:PercentageOfSolicitationFee>
<atnm:PeriodicFeeForFinancialAdvisoryServices contextRef="Context_Custom_08_Jul_2012T00_00_00_TO_07_Aug_2012T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="0">25000</atnm:PeriodicFeeForFinancialAdvisoryServices>
<atnm:PeriodicFeeForFinancialAdvisoryServices contextRef="Context_Custom_01_Dec_2013T00_00_00_TO_09_Dec_2013T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="0">25000</atnm:PeriodicFeeForFinancialAdvisoryServices>
<atnm:DescriptionOfAdditionalReceivableByPlacementAgent contextRef="Context_Custom_08_Jul_2012T00_00_00_TO_07_Aug_2012T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company's financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.</atnm:DescriptionOfAdditionalReceivableByPlacementAgent>
<atnm:CommonStockPurchaseByHoldingOfWarrant contextRef="Context_Custom_08_Jul_2012T00_00_00_TO_07_Aug_2012T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="shares" decimals="0">1251015</atnm:CommonStockPurchaseByHoldingOfWarrant>
<us-gaap:ArtistAdvancesAndRoyaltyGuaranteesCommitments contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</us-gaap:ArtistAdvancesAndRoyaltyGuaranteesCommitments>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_02_Dec_2013T00_00_00_TO_27_Dec_2013T00_00_00_AgreementAxis_UnitPurchaseAgreementMember" unitRef="shares" decimals="0">554310</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="0">551810</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_09_Feb_2014T00_00_00_TO_28_Apr_2014T00_00_00" unitRef="shares" decimals="0">500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="shares" decimals="INF">1670000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_05_Jul_2014T00_00_00_TO_07_Jul_2014T00_00_00" unitRef="shares" decimals="0">61538</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_03_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="shares" decimals="INF">1827123</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="0">1984524</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="shares" decimals="0">386000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_WarrantMember" unitRef="shares" decimals="0">137952</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of_27_Dec_2013T00_00_00_TO_27_Dec_2013T00_00_00_AgreementAxis_UnitPurchaseAgreementMember" unitRef="USD_per_Share" decimals="2">6.00</us-gaap:SaleOfStockPricePerShare>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">9.00</us-gaap:SaleOfStockPricePerShare>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember" unitRef="USD_per_Share" decimals="2">6.00</us-gaap:SaleOfStockPricePerShare>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD_per_Share" decimals="2">7.50</us-gaap:SaleOfStockPricePerShare>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of_10_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00" unitRef="USD_per_Share" decimals="2">7.50</us-gaap:SaleOfStockPricePerShare>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD_per_Share" decimals="2">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD_per_Share" decimals="2">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">5.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">11.66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="Context_Custom_02_Dec_2013T00_00_00_TO_27_Dec_2013T00_00_00_AgreementAxis_UnitPurchaseAgreementMember" unitRef="USD" decimals="0">3325860</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
<us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_10_Jan_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="0">3310860</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
<atnm:UnderwritingDiscount contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD" decimals="0">876750</atnm:UnderwritingDiscount>
<atnm:UnderwritingDiscount contextRef="Context_Custom_03_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD" decimals="-5">13700000</atnm:UnderwritingDiscount>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_10_Jan_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="0">6636720</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD" decimals="0">11451250</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="Context_Custom_03_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD" decimals="-5">12600000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:SaleOfStockDescriptionOfTransaction contextRef="Context_Custom_02_Dec_2013T00_00_00_TO_27_Dec_2013T00_00_00_AgreementAxis_UnitPurchaseAgreementMember">Five-year warrants to purchase an aggregate of 138,577 shares of common stock at an exercise price of $9.00 per share.</us-gaap:SaleOfStockDescriptionOfTransaction>
<us-gaap:SaleOfStockDescriptionOfTransaction contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_10_Jan_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">Aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments</us-gaap:SaleOfStockDescriptionOfTransaction>
<us-gaap:SaleOfStockDescriptionOfTransaction contextRef="Context_Custom_04_Mar_2014T00_00_00_TO_24_Mar_2014T00_00_00">The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. On April 28, 2014, the Company issued 500 shares and received net proceeds of $6,000 under the Sales Agreement with MLV.</us-gaap:SaleOfStockDescriptionOfTransaction>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RangeAxis_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RangeAxis_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">15480</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">166354</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">1560</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">25343</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:NotesPayable contextRef="Context_As_Of_28_Dec_2013T00_00_00_TO_28_Dec_2013T00_00_00_AgreementAxis_PremiumFinanceAgreementMember" unitRef="USD" decimals="0">157825</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AgreementAxis_PremiumFinanceAgreementMember" unitRef="USD" decimals="0">157825</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_AgreementAxis_PremiumFinanceAgreementMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_AgreementAxis_PremiumFinanceAgreementMember" unitRef="USD" decimals="0">15995</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
<us-gaap:DueToOfficersOrStockholdersCurrentAndNoncurrent contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_AgreementAxis_PremiumFinanceAgreementMember" unitRef="USD" decimals="0">15995</us-gaap:DueToOfficersOrStockholdersCurrentAndNoncurrent>
<atnm:DerivativeWarrantsUnits contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">1968623</atnm:DerivativeWarrantsUnits>
<atnm:DerivativeWarrantsUnits contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="INF">1661723</atnm:DerivativeWarrantsUnits>
<atnm:TransferFromLiabilityClassificationToEquityClassification contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="INF">-306900</atnm:TransferFromLiabilityClassificationToEquityClassification>
<us-gaap:DerivativeFairValueOfDerivativeNet contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">6707255</us-gaap:DerivativeFairValueOfDerivativeNet>
<us-gaap:DerivativeFairValueOfDerivativeNet contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">8216935</us-gaap:DerivativeFairValueOfDerivativeNet>
<atnm:ChangeInFairValueOfDerivativeWarrants contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">3653473</atnm:ChangeInFairValueOfDerivativeWarrants>
<atnm:MarketValueOfCommonStockOnMeasurementDate contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2" id="Item_1">5.89</atnm:MarketValueOfCommonStockOnMeasurementDate>
<atnm:MarketValueOfCommonStockOnMeasurementDate contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD_per_Share" decimals="2" id="Item_3">6.70</atnm:MarketValueOfCommonStockOnMeasurementDate>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2">2.48</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD_per_Share" decimals="2">2.48</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" decimals="4" id="Item_4">0.0127</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="pure" decimals="4">0.0164</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="pure" decimals="4" id="Item_6">0.0107</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00">P6M</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">P3Y2M12D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">P10Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P6Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" decimals="2" id="Item_7">0.73</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="pure" decimals="2">0.88</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="pure" decimals="2" id="Item_9">0.74</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.8656</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.8776</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" xsi:nil="true" id="Item_10"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="pure" xsi:nil="true" id="Item_12"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueInputsProbabilityOfDefault contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" decimals="2" id="Item_13">0.25</us-gaap:FairValueInputsProbabilityOfDefault>
<us-gaap:FairValueInputsProbabilityOfDefault contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="pure" decimals="2" id="Item_15">0.25</us-gaap:FairValueInputsProbabilityOfDefault>
<atnm:RangeOfPercentageOfExistingSharesOffered contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" decimals="2" id="Item_16">0.35</atnm:RangeOfPercentageOfExistingSharesOffered>
<atnm:RangeOfPercentageOfExistingSharesOffered contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="pure" xsi:nil="true" id="Item_18"/>
<atnm:FairValueAssumptionOfferingPrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="0" id="Item_19">9</atnm:FairValueAssumptionOfferingPrice>
<atnm:FairValueAssumptionOfferingPrice contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD_per_Share" decimals="2" id="Item_21">7.50</atnm:FairValueAssumptionOfferingPrice>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="USD" decimals="0">2143793</us-gaap:FairValueAdjustmentOfWarrants>
<atnm:NumberOfSharesWarrantExercise contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="shares" decimals="INF">2117304</atnm:NumberOfSharesWarrantExercise>
<atnm:DerivativeNumberOfWarrants contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="shares" decimals="INF">306900</atnm:DerivativeNumberOfWarrants>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_Custom_01_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="-6">1000000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseFirstClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">750000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseSecondClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">750000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseThirdClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">1500000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_BiologicalLicenseApplicationMember" unitRef="USD" decimals="0">1750000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_FirstCommercialSaleMember" unitRef="USD" decimals="0">1500000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember" unitRef="USD" decimals="0">1500000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseFirstClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">750000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">7750000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
<atnm:PaymentOfLicenseFee contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">3000000</atnm:PaymentOfLicenseFee>
<atnm:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">Royalty payments of 2% of net sales will be due to FHCRC.</atnm:DescriptionOfRoyaltyPaymentToRelatedParty>
<atnm:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">Company shall pay to AbbVie Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</atnm:DescriptionOfRoyaltyPaymentToRelatedParty>
<atnm:RoyaltyOfNetSalesPercentage contextRef="Context_Custom_01_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="pure" decimals="2">0.02</atnm:RoyaltyOfNetSalesPercentage>
<atnm:RoyaltyOfNetSalesPercentage contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="pure" decimals="2">0.12</atnm:RoyaltyOfNetSalesPercentage>
<atnm:FirstCommercialSalePeriod contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbviewBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">P12Y6M</atnm:FirstCommercialSalePeriod>
<atnm:PurchaseOfRadioactiveMaterial contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember_PeriodAxis_TwoThousandAndThirteenMember" unitRef="USD" decimals="-5">300000</atnm:PurchaseOfRadioactiveMaterial>
<atnm:PurchaseOfRadioactiveMaterial contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember_PeriodAxis_TwoThousandAndFourteenMember" unitRef="USD" decimals="-5">400000</atnm:PurchaseOfRadioactiveMaterial>
<atnm:ProjectEstimatedCost contextRef="Context_Custom_07_Jul_2012T00_00_00_TO_06_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-5">2200000</atnm:ProjectEstimatedCost>
<atnm:ProjectEstimatedCost contextRef="Context_Custom_01_Oct_2012T00_00_00_TO_22_Oct_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-5">2200000</atnm:ProjectEstimatedCost>
<atnm:ProjectEstimatedCost contextRef="Context_Custom_01_May_2013T00_00_00_TO_16_May_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-5">2200000</atnm:ProjectEstimatedCost>
<atnm:ProjectEstimatedCost contextRef="Context_Custom_25_Jan_2014T00_00_00_TO_27_Jan_2014T00_00_00_AgreementAxis_ManufacturingAgreementMember" unitRef="USD" decimals="-5">3300000</atnm:ProjectEstimatedCost>
<atnm:ProjectEstimatedCost contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-5">1200000</atnm:ProjectEstimatedCost>
<atnm:ProjectEstimatedCost contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AgreementAxis_ManufacturingAgreementMember" unitRef="USD" decimals="-5">2300000</atnm:ProjectEstimatedCost>
<atnm:DownPaymentOfProjectEstimatedCostPercentage contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="pure" decimals="3">0.125</atnm:DownPaymentOfProjectEstimatedCostPercentage>
<atnm:DownPaymentForProject contextRef="Context_Custom_01_Dec_2007T00_00_00_TO_31_Dec_2007T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="0">239000</atnm:DownPaymentForProject>
<atnm:DownPaymentForProject contextRef="Context_Custom_07_Jul_2012T00_00_00_TO_06_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-5">1900000</atnm:DownPaymentForProject>
<atnm:DownPaymentForProject contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="0">239000</atnm:DownPaymentForProject>
<atnm:ClinicalTrialCostForApprovalForFoodAndDrugAdministration contextRef="Context_As_Of_15_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_RangeAxis_MaximumMember" unitRef="USD" decimals="-5">23500000</atnm:ClinicalTrialCostForApprovalForFoodAndDrugAdministration>
<atnm:ClinicalTrialCostForApprovalForFoodAndDrugAdministration contextRef="Context_As_Of_15_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_RangeAxis_MinimumMember" unitRef="USD" decimals="-5">13200000</atnm:ClinicalTrialCostForApprovalForFoodAndDrugAdministration>
<atnm:FundToRelatedPartyUnderAgreementForFirstTwoYear contextRef="Context_As_Of_15_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">150000</atnm:FundToRelatedPartyUnderAgreementForFirstTwoYear>
<atnm:FundToRelatedPartyUnderAgreementAfterYearTwo contextRef="Context_As_Of_15_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">250000</atnm:FundToRelatedPartyUnderAgreementAfterYearTwo>
<atnm:NonRefundableInstitutionalFee contextRef="Context_Custom_01_Aug_2012T00_00_00_TO_28_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">14500</atnm:NonRefundableInstitutionalFee>
<atnm:NonRefundableInstitutionalFee contextRef="Context_Custom_25_Jan_2014T00_00_00_TO_27_Jan_2014T00_00_00_AgreementAxis_ManufacturingAgreementMember" unitRef="USD" decimals="0">562790</atnm:NonRefundableInstitutionalFee>
<atnm:PharmacyFee contextRef="Context_Custom_01_Sep_2012T00_00_00_TO_26_Sep_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">2025</atnm:PharmacyFee>
<atnm:AmendmentProcessingFee contextRef="Context_Custom_01_Sep_2012T00_00_00_TO_26_Sep_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">500</atnm:AmendmentProcessingFee>
<us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">16000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
<us-gaap:LegalFees contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">16000</us-gaap:LegalFees>
<us-gaap:DevelopmentInProcess contextRef="Context_As_Of_20_Jun_2014T00_00_00_TO_20_Jun_2014T00_00_00" unitRef="USD" decimals="-5">800000</us-gaap:DevelopmentInProcess>
<us-gaap:DevelopmentInProcess contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_AgreementAxis_AlbertEinsteinMember" unitRef="USD" decimals="0">183391</us-gaap:DevelopmentInProcess>
<us-gaap:ResearchAndDevelopmentInProcess contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="-5">300000</us-gaap:ResearchAndDevelopmentInProcess>
<us-gaap:ResearchAndDevelopmentInProcess contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00_AgreementAxis_AlbertEinsteinMember" unitRef="USD" decimals="0">92000</us-gaap:ResearchAndDevelopmentInProcess>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1985384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="shares" decimals="INF">9673290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">2998084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="shares" decimals="INF">7933747</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">312500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1323100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="shares" decimals="INF">406928</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">-310400</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="shares" decimals="INF">-2117304</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="shares" decimals="INF">-29167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">643206</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="shares" decimals="INF">7733747</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">3.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">5.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">8.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">8.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">5.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">11.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">6.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P8Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember">P4Y10M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<atnm:Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P10Y</atnm:Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
<atnm:Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember">P7Y5M16D</atnm:Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
<atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P8Y7M6D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
<atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember">P4Y1M24D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P6Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember">P4Y4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">5908696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="USD" decimals="0">47396307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">5731296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="USD" decimals="0">42641772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_WarrantMember" unitRef="USD" decimals="-5">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="-5">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="-5">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">3734610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="USD" decimals="0">42641772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
<atnm:FairValueAssumptionsExpectedDiscountRate contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.0184</atnm:FairValueAssumptionsExpectedDiscountRate>
<atnm:FairValueAssumptionsExpectedDiscountRate contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.0207</atnm:FairValueAssumptionsExpectedDiscountRate>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="0">180000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="0">602907</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod contextRef="Context_Custom_03_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="shares" decimals="INF">157123</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">Of the total shares of restricted stock granted, 20,000 shares vest 3 months from the grant date, 30,240 shares vest 1 year from the grant date, 202,667 shares have a vesting period of 4 years and 350,000 shares vest at the date of grant. The remaining restricted shares granted are performance based and upon the achievement of certain milestones.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="-5">8600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">2873557</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_Custom_03_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD" decimals="-5">1200000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="INF">275153</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">95971</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">284371</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00_StatementClassOfStockAxis_WarrantMember" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">734799</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">1623994</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementClassOfStockAxis_WarrantMember" unitRef="USD" decimals="0">98224</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">10953856</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_02_Dec_2013T00_00_00_TO_27_Dec_2013T00_00_00" unitRef="USD" decimals="0">3325860</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_09_Feb_2014T00_00_00_TO_28_Apr_2014T00_00_00" unitRef="USD" decimals="0">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD" decimals="0">12525000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_03_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD" decimals="-5">13700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember" unitRef="USD" decimals="0">116936</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<atnm:UnderwritingAgreementDescription contextRef="Context_Custom_01_Dec_2013T00_00_00_TO_09_Dec_2013T00_00_00">The agreement entered in on December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued or issuable. Subsequent to the closing of the 2013 offering, the placement agent continued to provide certain financial advisory services to the Company until three months after the Company had up-listed its securities for trading on a U.S. National Exchange for a monthly fee of $25,000.</atnm:UnderwritingAgreementDescription>
<atnm:UnderwritingAgreementDescription contextRef="Context_Custom_02_Dec_2013T00_00_00_TO_27_Dec_2013T00_00_00">Investors agreed to purchase (i) an aggregate of 554,310 shares ( the "Shares") of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 138,577 shares of common stock at an exercise price of $9.00 per share. The Company received $3,325,860 in gross proceeds from the sale of securities.</atnm:UnderwritingAgreementDescription>
<atnm:UnderwritingAgreementDescription contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember">Under the terms of the underwriting agreement entered into with Canaccord Genuity Inc. as representative (the "Representative") of the several underwriters (collectively, the "Underwriters"), the Company also granted the Underwriters a 30-day option to purchase up to an additional 250,000 shares of common stock to cover over-allotments, if any, at the offering price.</atnm:UnderwritingAgreementDescription>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="-5">3300000</us-gaap:ProceedsFromIssuanceOfWarrants>
<atnm:PlacementAgentCashFees contextRef="Context_Custom_01_Dec_2013T00_00_00_TO_09_Dec_2013T00_00_00" unitRef="USD" decimals="0">25000</atnm:PlacementAgentCashFees>
<atnm:PlacementAgentCashFees contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">395000</atnm:PlacementAgentCashFees>
<atnm:PlacementAgentAttorneyFees contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">40000</atnm:PlacementAgentAttorneyFees>
<us-gaap:EquityFairValueAdjustment contextRef="Context_Custom_01_Feb_2014T00_00_00_TO_28_Feb_2014T00_00_00" unitRef="USD" decimals="-5">600000</us-gaap:EquityFairValueAdjustment>
<us-gaap:EquityFairValueAdjustment contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-5">1200000</us-gaap:EquityFairValueAdjustment>
<atnm:WarrantsExercisedByWarrantHolders contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="0">83332</atnm:WarrantsExercisedByWarrantHolders>
<atnm:WarrantsExercisedByWarrantHolders contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementClassOfStockAxis_WarrantMember" unitRef="shares" decimals="INF">2117304</atnm:WarrantsExercisedByWarrantHolders>
<atnm:RegistrationStatementDescription contextRef="Context_Custom_04_Mar_2014T00_00_00_TO_24_Mar_2014T00_00_00">This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to $200,000,000 of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the "Sales Agreement") with MLV &amp;amp; Co. LLC ("MLV") dated March 24, 2014.</atnm:RegistrationStatementDescription>
<atnm:MaximumOfferingPrice contextRef="Context_Custom_04_Mar_2014T00_00_00_TO_24_Mar_2014T00_00_00" unitRef="shares" decimals="INF">75000000</atnm:MaximumOfferingPrice>
<us-gaap:OtherExpenses contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD" decimals="0">125000</us-gaap:OtherExpenses>
<us-gaap:ProfessionalFees contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD" decimals="0">72000</us-gaap:ProfessionalFees>
<us-gaap:CommonStockConversionBasis contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_DerivativeByNatureAxis_WarrantMember">Common stock for the conversion of approximately 485,000 warrants and approximately $18,000</us-gaap:CommonStockConversionBasis>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Item_1" xlink:label="lab_Item_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_1" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_3" xlink:label="lab_Item_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_3" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_4" xlink:label="lab_Item_4"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_4" xlink:to="Footnote_5" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_6" xlink:label="lab_Item_6"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_6" xlink:to="Footnote_5" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_7" xlink:label="lab_Item_7"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_7" xlink:to="Footnote_8" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_9" xlink:label="lab_Item_9"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_9" xlink:to="Footnote_8" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_10" xlink:label="lab_Item_10"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_10" xlink:to="Footnote_11" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_12" xlink:label="lab_Item_12"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_12" xlink:to="Footnote_11" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_13" xlink:label="lab_Item_13"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_13" xlink:to="Footnote_14" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_15" xlink:label="lab_Item_15"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_15" xlink:to="Footnote_14" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_16" xlink:label="lab_Item_16"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_16" xlink:to="Footnote_17" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_18" xlink:label="lab_Item_18"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_18" xlink:to="Footnote_17" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_19" xlink:label="lab_Item_19"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_19" xlink:to="Footnote_20" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_21" xlink:label="lab_Item_21"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_21" xlink:to="Footnote_20" order="1.0"/>
<link:footnote xlink:type="resource" xlink:label="Footnote_2" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">The market value of common stock at the above measurement dates is based on the Company's trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for September 30, 2014.</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_5" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_8" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_11" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_14" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Management determines the probability of future stock offering at each evaluation date.</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_17" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at September 30, 2014 and December 31, 2013, respectively.</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_20" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Represents the estimated offering price range in future offerings as determined by management.</link:footnote>
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>atnm-20140930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<schema targetNamespace="http://actiniumpharmaceuticals.com/20140930" elementFormDefault="qualified"
xmlns:atnm="http://actiniumpharmaceuticals.com/20140930"
 xmlns="http://www.w3.org/2001/XMLSchema"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:negated="http://www.xbrl.org/2009/role/negated"
 xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31"
 xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes"
 xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
 xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:us-types="http://fasb.org/us-types/2014-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
 xmlns:ref="http://www.xbrl.org/2006/ref"
 xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
>
<annotation><appinfo>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited" id="ConsolidatedBalanceSheetsUnaudited">
<link:definition>002 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" id="ConsolidatedBalanceSheetsUnauditedParenthetical">
<link:definition>003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited" id="ConsolidatedStatementsOfOperationsUnaudited">
<link:definition>004 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" id="ConsolidatedStatementsOfCashFlowsUnaudited">
<link:definition>005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
<link:definition>006 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>007 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>008 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/NotePayable" id="NotePayable">
<link:definition>009 - Disclosure - Note Payable</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Derivatives" id="Derivatives">
<link:definition>010 - Disclosure - Derivatives</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>011 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Equity" id="Equity">
<link:definition>012 - Disclosure - Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>013 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies">
<link:definition>014 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
<link:definition>015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
<link:definition>016 - Disclosure - Related Party Transactions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables" id="PropertyandEquipmentTables">
<link:definition>017 - Disclosure - Property and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativesTables" id="DerivativesTables">
<link:definition>018 - Disclosure - Derivatives (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesTables" id="CommitmentsandContingenciesTables">
<link:definition>019 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityTables" id="EquityTables">
<link:definition>020 - Disclosure - Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails" id="Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails">
<link:definition>021 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails1" id="Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails1">
<link:definition>022 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
<link:definition>023 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
<link:definition>024 - Disclosure - Related Party Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual" id="RelatedPartyTransactionsDetailsTextual">
<link:definition>025 - Disclosure - Related Party Transactions (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails" id="PropertyandEquipmentDetails">
<link:definition>026 - Disclosure - Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual" id="PropertyAndEquipmentDetailsTextual">
<link:definition>027 - Disclosure - Property and Equipment (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/NotePayableDetails" id="NotePayableDetails">
<link:definition>028 - Disclosure - Note Payable (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetails" id="DerivativesDetails">
<link:definition>029 - Disclosure - Derivatives (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetails1" id="DerivativesDetails1">
<link:definition>030 - Disclosure - Derivatives (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual" id="DerivativesDetailsTextual">
<link:definition>031 - Disclosure - Derivatives (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails" id="CommitmentsandContingenciesDetails">
<link:definition>032 - Disclosure - Commitments and Contingencies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual" id="Commitmentsandcontingenciesdetailstextual">
<link:definition>033 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails" id="EquityDetails">
<link:definition>034 - Disclosure - Equity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" id="EquityDetailsTextual">
<link:definition>035 - Disclosure - Equity (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
<link:definition>036 - Disclosure - Subsequent Events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20140930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20140930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20140930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20140930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="atnm_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SeriesCTwoPreferredStockMember" id="atnm_SeriesCTwoPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SeriesCThreePreferredStockMember" id="atnm_SeriesCThreePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SeriesCFourPreferredStockMember" id="atnm_SeriesCFourPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="GainOnChangeInFairValueOfDerivatives" id="atnm_GainOnChangeInFairValueOfDerivatives" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ProceedsFromExerciseOfOptionsAndWarrantsForCash" id="atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueOfTransferFromLiabilityClassificationToEquityClassification" id="atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" id="atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentsMilestoneMethodTableTextBlock" id="atnm_MilestonePaymentsMilestoneMethodTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" id="atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" id="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ActiniumMember" id="atnm_ActiniumMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" id="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" id="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockIssuableInConsiderationForEquityInterestAcquisition" id="atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SharesExchangeRatio" id="atnm_SharesExchangeRatio" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockShares" id="atnm_CommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="ExchangedInCommonStockShares" id="atnm_ExchangedInCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="MemorialSloanKetteringCancerCenterMember" id="atnm_MemorialSloanKetteringCancerCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NewDrugApplicationMember" id="atnm_NewDrugApplicationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ReceiptOfRegulatoryApprovalFromUSFdaMember" id="atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RelatedPartyMilestonesPayment" id="atnm_RelatedPartyMilestonesPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SloanKetteringInstituteOfCancerResearchMember" id="atnm_SloanKetteringInstituteOfCancerResearchMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" id="atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RosemaryMazanetMember" id="atnm_RosemaryMazanetMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LaidlawAndCompanyMember" id="atnm_LaidlawAndCompanyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="JamessCapitalGroupMember" id="atnm_JamessCapitalGroupMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="GuagentiAndAssociatesMember" id="atnm_GuagentiAndAssociatesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AgreementAxis" id="atnm_AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" id="atnm_AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ClinicalTrialAgreementMember" id="atnm_ClinicalTrialAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LicenseDevelopmentAndCommercializationAgreementMember" id="atnm_LicenseDevelopmentAndCommercializationAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConsultingServicesAgreementMember" id="atnm_ConsultingServicesAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EngagementAgreementMember" id="atnm_EngagementAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TransactionManagementAgreementMember" id="atnm_TransactionManagementAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="UnitPurchaseAgreementMember" id="atnm_UnitPurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgentMember" id="atnm_PlacementAgentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionsTextualAbstract" id="atnm_RelatedPartyTransactionsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NumberOfPatients" id="atnm_NumberOfPatients" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountPaidUnderAgreementInYearTwoThousandEleven" id="atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountPaidUnderAgreementInYearTwoThousandTwelve" id="atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountPaidUnderAgreementInYearTwoThousandThirteen" id="atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" id="atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="MaintenanceFeesAndResearchPayments" id="atnm_MaintenanceFeesAndResearchPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgentServicesFees" id="atnm_PlacementAgentServicesFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedToPurchaseCommonStock" id="atnm_WarrantsIssuedToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockExercisePriceParOrStatedValuePerShare" id="atnm_CommonStockExercisePriceParOrStatedValuePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountPaidUnderAgreement" id="atnm_AmountPaidUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AdditionalAmountDueUnderAgreement" id="atnm_AdditionalAmountDueUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfConditionForTerminationOfForbearancePeriod" id="atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TerminationDateOfForbearanceAgreement" id="atnm_TerminationDateOfForbearanceAgreement" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" id="atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="NewEquityFinanceRaisedByCompany" id="atnm_NewEquityFinanceRaisedByCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ForgivenAmountOfObligations" id="atnm_ForgivenAmountOfObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountPaidToEachPatient" id="atnm_AmountPaidToEachPatient" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="StartUpFeeForClinicalTrial" id="atnm_StartUpFeeForClinicalTrial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="StartUpDueCostPaidDate" id="atnm_StartUpDueCostPaidDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfSharesTransferTerm" id="atnm_DescriptionOfSharesTransferTerm" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OptionExercisePriceRange" id="atnm_OptionExercisePriceRange" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OptionsReceivedToPurchaseCommonStock" id="atnm_OptionsReceivedToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfReceivablesOfPlacementAgentForServices" id="atnm_DescriptionOfReceivablesOfPlacementAgentForServices" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfWarrantsReceivablesByPlacement" id="atnm_DescriptionOfWarrantsReceivablesByPlacement" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PeriodOfExerciseOfWarrants" id="atnm_PeriodOfExerciseOfWarrants" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfSolicitationFee" id="atnm_PercentageOfSolicitationFee" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PeriodicFeeForFinancialAdvisoryServices" id="atnm_PeriodicFeeForFinancialAdvisoryServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAdditionalReceivableByPlacementAgent" id="atnm_DescriptionOfAdditionalReceivableByPlacementAgent" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockPurchaseByHoldingOfWarrant" id="atnm_CommonStockPurchaseByHoldingOfWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PeriodicFeeReceivedByManagementFirm" id="atnm_PeriodicFeeReceivedByManagementFirm" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfFullyDilutedCapitalStockEqualToCommonStock" id="atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MaximumAmountOfOutOfPocketExpenses" id="atnm_MaximumAmountOfOutOfPocketExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PeriodicAmountOfRent" id="atnm_PeriodicAmountOfRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountPaidToPursuantLeaseAgreement" id="atnm_AmountPaidToPursuantLeaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConsultingFee" id="atnm_ConsultingFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SettlementPaymentOfConsultingFee" id="atnm_SettlementPaymentOfConsultingFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="UnderwritingDiscount" id="atnm_UnderwritingDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsToPurchaseCommonStockDescription" id="atnm_WarrantsToPurchaseCommonStockDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PropertyAndEquipmentTextualAbstract" id="atnm_PropertyAndEquipmentTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PremiumFinanceAgreementMember" id="atnm_PremiumFinanceAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ManagementFirmMember" id="atnm_ManagementFirmMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NotePayableAndConvertibleNotesTextualAbstract" id="atnm_NotePayableAndConvertibleNotesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockPurchaseDueToIssuanceOfWarrants" id="atnm_CommonStockPurchaseDueToIssuanceOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmortizationPeriodOfNote" id="atnm_AmortizationPeriodOfNote" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PremiumFinanceAgreementPrincipalAmount" id="atnm_PremiumFinanceAgreementPrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PaymentUnderPremiumFinanceAgreement" id="atnm_PaymentUnderPremiumFinanceAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PeriodicPaymentUnderPremiumFinanceAgreement" id="atnm_PeriodicPaymentUnderPremiumFinanceAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DurationOfPeriodicPaymentsForPremiumFinanceAgreement" id="atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PremiumFinanceAgreementOutstandingAmount" id="atnm_PremiumFinanceAgreementOutstandingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ProceedsFromConvertibleNotes" id="atnm_ProceedsFromConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" id="atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" id="atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativeWarrantsIssuedWithConvertibleNotes" id="atnm_DerivativeWarrantsIssuedWithConvertibleNotes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="InvestmentWarrantGrantDateFairValue" id="atnm_InvestmentWarrantGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentDiscountRelatedToBeneficialConversionFeature" id="atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentFairValuePerShare" id="atnm_DebtInstrumentFairValuePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ExtendedMaturityPeriodOfConvertibleNotes" id="atnm_ExtendedMaturityPeriodOfConvertibleNotes" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfExtendedMaturityDate" id="atnm_DescriptionOfExtendedMaturityDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" id="atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativeWarrantsUnits" id="atnm_DerivativeWarrantsUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="TransferFromLiabilityClassificationToEquityClassification" id="atnm_TransferFromLiabilityClassificationToEquityClassification" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ChangeInFairValueOfDerivativeWarrants" id="atnm_ChangeInFairValueOfDerivativeWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" id="atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MarketValueOfCommonStockOnMeasurementDate" id="atnm_MarketValueOfCommonStockOnMeasurementDate" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="RangeOfPercentageOfExistingSharesOffered" id="atnm_RangeOfPercentageOfExistingSharesOffered" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionOfferingPrice" id="atnm_FairValueAssumptionOfferingPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativeTextualAbstract" id="atnm_DerivativeTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NumberOfSharesWarrantExercise" id="atnm_NumberOfSharesWarrantExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativeNumberOfWarrants" id="atnm_DerivativeNumberOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AbbviewBiotherapeuticsCorpMember" id="atnm_AbbviewBiotherapeuticsCorpMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PhaseFirstClinicalTrialOfLicensedProductMember" id="atnm_PhaseFirstClinicalTrialOfLicensedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PhaseSecondClinicalTrialOfLicensedProductMember" id="atnm_PhaseSecondClinicalTrialOfLicensedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PhaseThirdClinicalTrialOfLicensedProductMember" id="atnm_PhaseThirdClinicalTrialOfLicensedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="BiologicalLicenseApplicationMember" id="atnm_BiologicalLicenseApplicationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FirstCommercialSaleMember" id="atnm_FirstCommercialSaleMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AfterFirstNetSalesMember" id="atnm_AfterFirstNetSalesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentAbstract" id="atnm_MilestonePaymentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LongTermPurchaseCommitmentMilestonesPayment" id="atnm_LongTermPurchaseCommitmentMilestonesPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesTable" id="atnm_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AbbottBiotherapeuticsCorpMember" id="atnm_AbbottBiotherapeuticsCorpMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OakRidgeNationalLaboratoryMember" id="atnm_OakRidgeNationalLaboratoryMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AptivSolutionsMember" id="atnm_AptivSolutionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FredHutchinsonCancerResearchCenterMember" id="atnm_FredHutchinsonCancerResearchCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" id="atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="UniversityOfTexasMDAndersonCancerCenterMember" id="atnm_UniversityOfTexasMDAndersonCancerCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="JohnsHopkinsUniversityMember" id="atnm_JohnsHopkinsUniversityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LaidlawAndCoMember" id="atnm_LaidlawAndCoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="UniversityOfPennsylvaniaMember" id="atnm_UniversityOfPennsylvaniaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FormerChiefExecutiveOfficerMember" id="atnm_FormerChiefExecutiveOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PeriodAxis" id="atnm_PeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" />
<element name="PeriodDomain" id="atnm_PeriodDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndThirteenMember" id="atnm_TwoThousandAndThirteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndFourteenMember" id="atnm_TwoThousandAndFourteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ProductDevelopmentAndPatentLicenseAgreementMember" id="atnm_ProductDevelopmentAndPatentLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementMember" id="atnm_LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LicenseAndSponsoredResearchAgreementMember" id="atnm_LicenseAndSponsoredResearchAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgentAgreementMember" id="atnm_PlacementAgentAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SeparationAndSettlementAgreementMember" id="atnm_SeparationAndSettlementAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ManufacturingAgreementMember" id="atnm_ManufacturingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RentalAgreementMember" id="atnm_RentalAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ActOncologyMember" id="atnm_ActOncologyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AlbertEinsteinMember" id="atnm_AlbertEinsteinMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesLineItems" id="atnm_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesTextualAbstract" id="atnm_CommitmentsAndContingenciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PaymentOfLicenseFee" id="atnm_PaymentOfLicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentDate" id="atnm_MilestonePaymentDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfRoyaltyPaymentToRelatedParty" id="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RoyaltyOfNetSalesPercentage" id="atnm_RoyaltyOfNetSalesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FirstCommercialSalePeriod" id="atnm_FirstCommercialSalePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ResearchAndDevelopmentArrangement" id="atnm_ResearchAndDevelopmentArrangement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PurchaseOfRadioactiveMaterial" id="atnm_PurchaseOfRadioactiveMaterial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ProjectEstimatedCost" id="atnm_ProjectEstimatedCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DownPaymentOfProjectEstimatedCostPercentage" id="atnm_DownPaymentOfProjectEstimatedCostPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DownPaymentForProject" id="atnm_DownPaymentForProject" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ClinicalTrialCostForApprovalForFoodAndDrugAdministration" id="atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FundToRelatedPartyUnderAgreementForFirstTwoYear" id="atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FundToRelatedPartyUnderAgreementAfterYearTwo" id="atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AgreementConsideration" id="atnm_AgreementConsideration" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PerformanceBonusPayableUnderAgreementForService" id="atnm_PerformanceBonusPayableUnderAgreementForService" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantExercisableNoticePeriodDescription" id="atnm_WarrantExercisableNoticePeriodDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfSharesAvailabilityByExerciseOfWarrant" id="atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NonRefundableInstitutionalFee" id="atnm_NonRefundableInstitutionalFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PharmacyFee" id="atnm_PharmacyFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmendmentProcessingFee" id="atnm_AmendmentProcessingFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="NoticePeriodForTerminationOfAgreement" id="atnm_NoticePeriodForTerminationOfAgreement" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AgreementRenewalDescription" id="atnm_AgreementRenewalDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PaymentOfAggregateAmount" id="atnm_PaymentOfAggregateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PaymentOfFinalInstallmentForServicesByCompany" id="atnm_PaymentOfFinalInstallmentForServicesByCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PaymentOfPerformanceBonusForServicesByCompany" id="atnm_PaymentOfPerformanceBonusForServicesByCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" id="atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" id="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EmployeesDirectorsAndConsultantsMember" id="atnm_EmployeesDirectorsAndConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EquityTextualsAbstract" id="atnm_EquityTextualsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionsExpectedDiscountRate" id="atnm_FairValueAssumptionsExpectedDiscountRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="UnderwritingAgreementDescription" id="atnm_UnderwritingAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgentCashFees" id="atnm_PlacementAgentCashFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgentAttorneyFees" id="atnm_PlacementAgentAttorneyFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsExercisedByWarrantHolders" id="atnm_WarrantsExercisedByWarrantHolders" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RegistrationStatementDescription" id="atnm_RegistrationStatementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MaximumOfferingPrice" id="atnm_MaximumOfferingPrice" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SubsequentEventsTextualAbstract" id="atnm_SubsequentEventsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>atnm-20140930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_SecurityDeposit" order="30" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_NotesPayableCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_Depreciation" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1" order="40" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="10" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" order="10" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1" order="40" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_atnm_GainOnChangeInFairValueOfDerivatives" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_atnm_GainOnChangeInFairValueOfDerivatives" order="50" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="60" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInSecurityDeposits" order="70" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="80" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="90" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable" order="10" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" xlink:label="loc_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" order="30" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="30" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#PropertyandEquipmentDetails" roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" order="20" use="optional" weight="1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>atnm-20140930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" >
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#EquityTables" roleURI="http://actiniumpharmaceuticals.com/role/EquityTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails" roleURI="http://actiniumpharmaceuticals.com/role/Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails1" roleURI="http://actiniumpharmaceuticals.com/role/Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails1"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#RelatedPartyTransactionsDetails" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#PropertyandEquipmentDetails" roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#NotePayableDetails" roleURI="http://actiniumpharmaceuticals.com/role/NotePayableDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#DerivativesDetails1" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetails1"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#DerivativesDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#CommitmentsandContingenciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#Commitmentsandcontingenciesdetailstextual" roleURI="http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#EquityDetails" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#EquityDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#SubsequentEventsDetails" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventsDetails"/>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SeriesCTwoPreferredStockMember" xlink:label="loc_atnm_SeriesCTwoPreferredStockMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCTwoPreferredStockMember_9" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SeriesCThreePreferredStockMember" xlink:label="loc_atnm_SeriesCThreePreferredStockMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCThreePreferredStockMember_10" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SeriesCFourPreferredStockMember" xlink:label="loc_atnm_SeriesCFourPreferredStockMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCFourPreferredStockMember_11" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_12" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12" xlink:to="loc_us-gaap_AssetsCurrentAbstract_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_14" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_15" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13" xlink:to="loc_us-gaap_AssetsCurrent_16" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_17" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12" xlink:to="loc_us-gaap_SecurityDeposit_18" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12" xlink:to="loc_us-gaap_Assets_19" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_21" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_22" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_23" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_NotesPayableCurrent_24" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_25" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_LiabilitiesCurrent_26" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_Liabilities_27" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_CommitmentsAndContingencies_28" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_StockholdersEquityAbstract_29" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_PreferredStockValue_30" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_CommonStockValue_31" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_AdditionalPaidInCapital_32" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_StockholdersEquity_34" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_35" order="40" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_DerivativeByNatureAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeByNatureAxis_5" xlink:to="loc_us-gaap_DerivativeNameDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeByNatureAxis_5" xlink:to="loc_us-gaap_DerivativeNameDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeNameDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8" order="10" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:label="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_7" xlink:to="loc_us-gaap_DerivativeLiabilities_8" order="0" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaap_OptionMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_OptionMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6" order="10" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_0" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ActiniumMember" xlink:label="loc_atnm_ActiniumMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_atnm_ActiniumMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9" xlink:to="loc_us-gaap_ClassOfStockDomain_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_10_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9" xlink:to="loc_us-gaap_ClassOfStockDomain_10_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_10" xlink:to="loc_us-gaap_CommonStockMember_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_12" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_12" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:label="loc_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_12" xlink:to="loc_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition_14" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_12" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_15" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_16" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SharesExchangeRatio" xlink:label="loc_atnm_SharesExchangeRatio_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_12" xlink:to="loc_atnm_SharesExchangeRatio_17" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommonStockShares" xlink:label="loc_atnm_CommonStockShares_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_12" xlink:to="loc_atnm_CommonStockShares_18" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ExchangedInCommonStockShares" xlink:label="loc_atnm_ExchangedInCommonStockShares_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_12" xlink:to="loc_atnm_ExchangedInCommonStockShares_19" order="60" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NewDrugApplicationMember" xlink:label="loc_atnm_NewDrugApplicationMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" xlink:to="loc_atnm_NewDrugApplicationMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" xlink:to="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RelatedPartyMilestonesPayment" xlink:label="loc_atnm_RelatedPartyMilestonesPayment_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_9" xlink:to="loc_atnm_RelatedPartyMilestonesPayment_10" order="0" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_atnm_SloanKetteringInstituteOfCancerResearchMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_SloanKetteringInstituteOfCancerResearchMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RosemaryMazanetMember" xlink:label="loc_atnm_RosemaryMazanetMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_RosemaryMazanetMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LaidlawAndCompanyMember" xlink:label="loc_atnm_LaidlawAndCompanyMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_LaidlawAndCompanyMember_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_JamessCapitalGroupMember" xlink:label="loc_atnm_JamessCapitalGroupMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JamessCapitalGroupMember_9" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_GuagentiAndAssociatesMember" xlink:label="loc_atnm_GuagentiAndAssociatesMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_GuagentiAndAssociatesMember_10" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11" xlink:to="loc_us-gaap_ClassOfStockDomain_12" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_12_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11" xlink:to="loc_us-gaap_ClassOfStockDomain_12_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_12" xlink:to="loc_us-gaap_CommonStockMember_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_12" xlink:to="loc_us-gaap_WarrantMember_14" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_12" xlink:to="loc_us-gaap_IPOMember_15" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_atnm_AgreementAxis_16" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnm_AgreementAxis_16" xlink:to="loc_atnm_AgreementDomain_17" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_17_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_atnm_AgreementAxis_16" xlink:to="loc_atnm_AgreementDomain_17_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ClinicalTrialAgreementMember" xlink:label="loc_atnm_ClinicalTrialAgreementMember_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_17" xlink:to="loc_atnm_ClinicalTrialAgreementMember_18" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LicenseDevelopmentAndCommercializationAgreementMember" xlink:label="loc_atnm_LicenseDevelopmentAndCommercializationAgreementMember_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_17" xlink:to="loc_atnm_LicenseDevelopmentAndCommercializationAgreementMember_19" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ConsultingServicesAgreementMember" xlink:label="loc_atnm_ConsultingServicesAgreementMember_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_17" xlink:to="loc_atnm_ConsultingServicesAgreementMember_20" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_EngagementAgreementMember" xlink:label="loc_atnm_EngagementAgreementMember_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_17" xlink:to="loc_atnm_EngagementAgreementMember_21" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_TransactionManagementAgreementMember" xlink:label="loc_atnm_TransactionManagementAgreementMember_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_17" xlink:to="loc_atnm_TransactionManagementAgreementMember_22" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UnitPurchaseAgreementMember" xlink:label="loc_atnm_UnitPurchaseAgreementMember_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_17" xlink:to="loc_atnm_UnitPurchaseAgreementMember_23" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_24" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_24" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_25" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_25_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_24" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_25_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_25" xlink:to="loc_atnm_PlacementAgentMember_26" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_us-gaap_OfficersCompensation_28" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NumberOfPatients" xlink:label="loc_atnm_NumberOfPatients_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_NumberOfPatients_29" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven_30" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve_31" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen_32" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xlink:label="loc_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen_33" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MaintenanceFeesAndResearchPayments" xlink:label="loc_atnm_MaintenanceFeesAndResearchPayments_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_MaintenanceFeesAndResearchPayments_34" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentServicesFees" xlink:label="loc_atnm_PlacementAgentServicesFees_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_PlacementAgentServicesFees_35" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_atnm_WarrantsIssuedToPurchaseCommonStock_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_WarrantsIssuedToPurchaseCommonStock_36" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommonStockExercisePriceParOrStatedValuePerShare" xlink:label="loc_atnm_CommonStockExercisePriceParOrStatedValuePerShare_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_CommonStockExercisePriceParOrStatedValuePerShare_37" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidUnderAgreement" xlink:label="loc_atnm_AmountPaidUnderAgreement_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_AmountPaidUnderAgreement_38" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AdditionalAmountDueUnderAgreement" xlink:label="loc_atnm_AdditionalAmountDueUnderAgreement_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_AdditionalAmountDueUnderAgreement_39" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xlink:label="loc_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod_40" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_TerminationDateOfForbearanceAgreement" xlink:label="loc_atnm_TerminationDateOfForbearanceAgreement_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_TerminationDateOfForbearanceAgreement_41" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xlink:label="loc_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod_42" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NewEquityFinanceRaisedByCompany" xlink:label="loc_atnm_NewEquityFinanceRaisedByCompany_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_NewEquityFinanceRaisedByCompany_43" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ForgivenAmountOfObligations" xlink:label="loc_atnm_ForgivenAmountOfObligations_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_ForgivenAmountOfObligations_44" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidToEachPatient" xlink:label="loc_atnm_AmountPaidToEachPatient_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_AmountPaidToEachPatient_45" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_StartUpFeeForClinicalTrial" xlink:label="loc_atnm_StartUpFeeForClinicalTrial_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_StartUpFeeForClinicalTrial_46" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_StartUpDueCostPaidDate" xlink:label="loc_atnm_StartUpDueCostPaidDate_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_StartUpDueCostPaidDate_47" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfSharesTransferTerm" xlink:label="loc_atnm_DescriptionOfSharesTransferTerm_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_DescriptionOfSharesTransferTerm_48" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_OptionExercisePriceRange" xlink:label="loc_atnm_OptionExercisePriceRange_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_OptionExercisePriceRange_49" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_OptionsReceivedToPurchaseCommonStock" xlink:label="loc_atnm_OptionsReceivedToPurchaseCommonStock_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_OptionsReceivedToPurchaseCommonStock_50" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xlink:label="loc_atnm_DescriptionOfReceivablesOfPlacementAgentForServices_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_DescriptionOfReceivablesOfPlacementAgentForServices_51" order="230" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfWarrantsReceivablesByPlacement" xlink:label="loc_atnm_DescriptionOfWarrantsReceivablesByPlacement_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_DescriptionOfWarrantsReceivablesByPlacement_52" order="240" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodOfExerciseOfWarrants" xlink:label="loc_atnm_PeriodOfExerciseOfWarrants_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_PeriodOfExerciseOfWarrants_53" order="250" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PercentageOfSolicitationFee" xlink:label="loc_atnm_PercentageOfSolicitationFee_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_PercentageOfSolicitationFee_54" order="260" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodicFeeForFinancialAdvisoryServices" xlink:label="loc_atnm_PeriodicFeeForFinancialAdvisoryServices_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_PeriodicFeeForFinancialAdvisoryServices_55" order="270" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xlink:label="loc_atnm_DescriptionOfAdditionalReceivableByPlacementAgent_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_DescriptionOfAdditionalReceivableByPlacementAgent_56" order="280" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommonStockPurchaseByHoldingOfWarrant" xlink:label="loc_atnm_CommonStockPurchaseByHoldingOfWarrant_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_CommonStockPurchaseByHoldingOfWarrant_57" order="290" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_atnm_PeriodicFeeReceivedByManagementFirm_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_PeriodicFeeReceivedByManagementFirm_58" order="300" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_59" order="310" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_atnm_MaximumAmountOfOutOfPocketExpenses_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_MaximumAmountOfOutOfPocketExpenses_60" order="320" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodicAmountOfRent" xlink:label="loc_atnm_PeriodicAmountOfRent_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_PeriodicAmountOfRent_61" order="330" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidToPursuantLeaseAgreement" xlink:label="loc_atnm_AmountPaidToPursuantLeaseAgreement_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_AmountPaidToPursuantLeaseAgreement_62" order="340" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_63" order="350" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ConsultingFee" xlink:label="loc_atnm_ConsultingFee_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_ConsultingFee_64" order="360" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SettlementPaymentOfConsultingFee" xlink:label="loc_atnm_SettlementPaymentOfConsultingFee_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_SettlementPaymentOfConsultingFee_65" order="370" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:label="loc_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments_66" order="380" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_67" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_67" order="390" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_68" order="400" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_69" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_69" order="410" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_70" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_us-gaap_DebtInstrumentTerm_70" order="420" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71" order="430" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_72" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_72" order="440" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UnderwritingDiscount" xlink:label="loc_atnm_UnderwritingDiscount_73" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_UnderwritingDiscount_73" order="450" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_74" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_74" order="460" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_75" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_75" order="470" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_WarrantsToPurchaseCommonStockDescription" xlink:label="loc_atnm_WarrantsToPurchaseCommonStockDescription_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_27" xlink:to="loc_atnm_WarrantsToPurchaseCommonStockDescription_76" order="480" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_OfficeEquipmentMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_RangeAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_12" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_13" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_14" order="30" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/NotePayableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_atnm_AgreementAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnm_AgreementAxis_2" xlink:to="loc_atnm_AgreementDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_atnm_AgreementAxis_2" xlink:to="loc_atnm_AgreementDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PremiumFinanceAgreementMember" xlink:label="loc_atnm_PremiumFinanceAgreementMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_3" xlink:to="loc_atnm_PremiumFinanceAgreementMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_atnm_PlacementAgentMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ManagementFirmMember" xlink:label="loc_atnm_ManagementFirmMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_atnm_ManagementFirmMember_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NotePayableAndConvertibleNotesTextualAbstract" xlink:label="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_0" xlink:to="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xlink:label="loc_atnm_CommonStockPurchaseDueToIssuanceOfWarrants_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_atnm_CommonStockPurchaseDueToIssuanceOfWarrants_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmortizationPeriodOfNote" xlink:label="loc_atnm_AmortizationPeriodOfNote_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_atnm_AmortizationPeriodOfNote_14" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_us-gaap_NotesPayable_15" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_16" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_17" order="70" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_us-gaap_DerivativeTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_RangeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_atnm_MarketValueOfCommonStockOnMeasurementDate_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_atnm_MarketValueOfCommonStockOnMeasurementDate_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_10" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_11" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_12" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="loc_us-gaap_FairValueInputsProbabilityOfDefault_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueInputsProbabilityOfDefault_13" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_atnm_RangeOfPercentageOfExistingSharesOffered_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_atnm_RangeOfPercentageOfExistingSharesOffered_14" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FairValueAssumptionOfferingPrice" xlink:label="loc_atnm_FairValueAssumptionOfferingPrice_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_atnm_FairValueAssumptionOfferingPrice_15" order="80" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_DerivativeByNatureAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeByNatureAxis_2" xlink:to="loc_us-gaap_DerivativeNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeByNatureAxis_2" xlink:to="loc_us-gaap_DerivativeNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DerivativeTextualAbstract" xlink:label="loc_atnm_DerivativeTextualAbstract_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0" xlink:to="loc_atnm_DerivativeTextualAbstract_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_atnm_RangeOfPercentageOfExistingSharesOffered_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_9" xlink:to="loc_atnm_RangeOfPercentageOfExistingSharesOffered_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_9" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NumberOfSharesWarrantExercise" xlink:label="loc_atnm_NumberOfSharesWarrantExercise_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_9" xlink:to="loc_atnm_NumberOfSharesWarrantExercise_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DerivativeNumberOfWarrants" xlink:label="loc_atnm_DerivativeNumberOfWarrants_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_9" xlink:to="loc_atnm_DerivativeNumberOfWarrants_14" order="40" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AbbviewBiotherapeuticsCorpMember" xlink:label="loc_atnm_AbbviewBiotherapeuticsCorpMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AbbviewBiotherapeuticsCorpMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseSecondClinicalTrialOfLicensedProductMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseSecondClinicalTrialOfLicensedProductMember_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseThirdClinicalTrialOfLicensedProductMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseThirdClinicalTrialOfLicensedProductMember_10" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_BiologicalLicenseApplicationMember" xlink:label="loc_atnm_BiologicalLicenseApplicationMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_BiologicalLicenseApplicationMember_11" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FirstCommercialSaleMember" xlink:label="loc_atnm_FirstCommercialSaleMember_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_FirstCommercialSaleMember_12" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AfterFirstNetSalesMember" xlink:label="loc_atnm_AfterFirstNetSalesMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_AfterFirstNetSalesMember_13" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NewDrugApplicationMember" xlink:label="loc_atnm_NewDrugApplicationMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_NewDrugApplicationMember_14" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_15" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MilestonePaymentAbstract" xlink:label="loc_atnm_MilestonePaymentAbstract_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0" xlink:to="loc_atnm_MilestonePaymentAbstract_16" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_MilestonePaymentAbstract_16" xlink:to="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_17" order="0" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual">
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommitmentsAndContingenciesLineItems" xlink:label="loc_atnm_CommitmentsAndContingenciesLineItems_0" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommitmentsAndContingenciesTable" xlink:label="loc_atnm_CommitmentsAndContingenciesTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_atnm_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_atnm_CommitmentsAndContingenciesTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AbbviewBiotherapeuticsCorpMember" xlink:label="loc_atnm_AbbviewBiotherapeuticsCorpMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AbbviewBiotherapeuticsCorpMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AbbottBiotherapeuticsCorpMember" xlink:label="loc_atnm_AbbottBiotherapeuticsCorpMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AbbottBiotherapeuticsCorpMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_OakRidgeNationalLaboratoryMember" xlink:label="loc_atnm_OakRidgeNationalLaboratoryMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_OakRidgeNationalLaboratoryMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AptivSolutionsMember" xlink:label="loc_atnm_AptivSolutionsMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AptivSolutionsMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_atnm_FredHutchinsonCancerResearchCenterMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_FredHutchinsonCancerResearchCenterMember_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:label="loc_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UniversityOfTexasMDAndersonCancerCenterMember" xlink:label="loc_atnm_UniversityOfTexasMDAndersonCancerCenterMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_UniversityOfTexasMDAndersonCancerCenterMember_10" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_JohnsHopkinsUniversityMember" xlink:label="loc_atnm_JohnsHopkinsUniversityMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JohnsHopkinsUniversityMember_11" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LaidlawAndCoMember" xlink:label="loc_atnm_LaidlawAndCoMember_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_LaidlawAndCoMember_12" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UniversityOfPennsylvaniaMember" xlink:label="loc_atnm_UniversityOfPennsylvaniaMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_UniversityOfPennsylvaniaMember_13" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_JamessCapitalGroupMember" xlink:label="loc_atnm_JamessCapitalGroupMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JamessCapitalGroupMember_14" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FormerChiefExecutiveOfficerMember" xlink:label="loc_atnm_FormerChiefExecutiveOfficerMember_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_FormerChiefExecutiveOfficerMember_15" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AfterFirstNetSalesMember" xlink:label="loc_atnm_AfterFirstNetSalesMember_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_atnm_AfterFirstNetSalesMember_18" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_19" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RangeAxis_20" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_20" xlink:to="loc_us-gaap_RangeMember_21" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_21_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_20" xlink:to="loc_us-gaap_RangeMember_21_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_21" xlink:to="loc_us-gaap_MaximumMember_22" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_21" xlink:to="loc_us-gaap_MinimumMember_23" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodAxis" xlink:label="loc_atnm_PeriodAxis_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_atnm_PeriodAxis_24" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodDomain" xlink:label="loc_atnm_PeriodDomain_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnm_PeriodAxis_24" xlink:to="loc_atnm_PeriodDomain_25" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodDomain" xlink:label="loc_atnm_PeriodDomain_25_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_atnm_PeriodAxis_24" xlink:to="loc_atnm_PeriodDomain_25_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_TwoThousandAndThirteenMember" xlink:label="loc_atnm_TwoThousandAndThirteenMember_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_PeriodDomain_25" xlink:to="loc_atnm_TwoThousandAndThirteenMember_26" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_TwoThousandAndFourteenMember" xlink:label="loc_atnm_TwoThousandAndFourteenMember_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_PeriodDomain_25" xlink:to="loc_atnm_TwoThousandAndFourteenMember_27" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_atnm_AgreementAxis_28" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnm_AgreementAxis_28" xlink:to="loc_atnm_AgreementDomain_29" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_29_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_atnm_AgreementAxis_28" xlink:to="loc_atnm_AgreementDomain_29_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:label="loc_atnm_ProductDevelopmentAndPatentLicenseAgreementMember_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_ProductDevelopmentAndPatentLicenseAgreementMember_30" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LicenseAgreementMember" xlink:label="loc_atnm_LicenseAgreementMember_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_LicenseAgreementMember_31" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_atnm_LicenseAndSponsoredResearchAgreementMember_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_LicenseAndSponsoredResearchAgreementMember_32" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ClinicalTrialAgreementMember" xlink:label="loc_atnm_ClinicalTrialAgreementMember_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_ClinicalTrialAgreementMember_33" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentAgreementMember" xlink:label="loc_atnm_PlacementAgentAgreementMember_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_PlacementAgentAgreementMember_34" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_TransactionManagementAgreementMember" xlink:label="loc_atnm_TransactionManagementAgreementMember_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_TransactionManagementAgreementMember_35" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SeparationAndSettlementAgreementMember" xlink:label="loc_atnm_SeparationAndSettlementAgreementMember_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_SeparationAndSettlementAgreementMember_36" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ManufacturingAgreementMember" xlink:label="loc_atnm_ManufacturingAgreementMember_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_ManufacturingAgreementMember_37" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RentalAgreementMember" xlink:label="loc_atnm_RentalAgreementMember_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_RentalAgreementMember_38" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ActOncologyMember" xlink:label="loc_atnm_ActOncologyMember_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_ActOncologyMember_39" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AlbertEinsteinMember" xlink:label="loc_atnm_AlbertEinsteinMember_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_AlbertEinsteinMember_40" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_42" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TechnologyServicesCosts" xlink:label="loc_us-gaap_TechnologyServicesCosts_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_us-gaap_TechnologyServicesCosts_43" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_us-gaap_MaintenanceCosts_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_us-gaap_MaintenanceCosts_44" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PaymentOfLicenseFee" xlink:label="loc_atnm_PaymentOfLicenseFee_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_PaymentOfLicenseFee_45" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_46" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MilestonePaymentDate" xlink:label="loc_atnm_MilestonePaymentDate_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_MilestonePaymentDate_47" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_atnm_DescriptionOfRoyaltyPaymentToRelatedParty_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_DescriptionOfRoyaltyPaymentToRelatedParty_48" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RoyaltyOfNetSalesPercentage" xlink:label="loc_atnm_RoyaltyOfNetSalesPercentage_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_RoyaltyOfNetSalesPercentage_49" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FirstCommercialSalePeriod" xlink:label="loc_atnm_FirstCommercialSalePeriod_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_FirstCommercialSalePeriod_50" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ResearchAndDevelopmentArrangement" xlink:label="loc_atnm_ResearchAndDevelopmentArrangement_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_ResearchAndDevelopmentArrangement_51" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PurchaseOfRadioactiveMaterial" xlink:label="loc_atnm_PurchaseOfRadioactiveMaterial_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_PurchaseOfRadioactiveMaterial_52" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ProjectEstimatedCost" xlink:label="loc_atnm_ProjectEstimatedCost_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_ProjectEstimatedCost_53" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DownPaymentOfProjectEstimatedCostPercentage" xlink:label="loc_atnm_DownPaymentOfProjectEstimatedCostPercentage_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_DownPaymentOfProjectEstimatedCostPercentage_54" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DownPaymentForProject" xlink:label="loc_atnm_DownPaymentForProject_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_DownPaymentForProject_55" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:label="loc_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_56" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:label="loc_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear_57" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:label="loc_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo_58" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NumberOfPatients" xlink:label="loc_atnm_NumberOfPatients_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_NumberOfPatients_59" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidToEachPatient" xlink:label="loc_atnm_AmountPaidToEachPatient_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_AmountPaidToEachPatient_60" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_StartUpFeeForClinicalTrial" xlink:label="loc_atnm_StartUpFeeForClinicalTrial_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_StartUpFeeForClinicalTrial_61" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_StartUpDueCostPaidDate" xlink:label="loc_atnm_StartUpDueCostPaidDate_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_StartUpDueCostPaidDate_62" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementConsideration" xlink:label="loc_atnm_AgreementConsideration_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_AgreementConsideration_63" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PerformanceBonusPayableUnderAgreementForService" xlink:label="loc_atnm_PerformanceBonusPayableUnderAgreementForService_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_PerformanceBonusPayableUnderAgreementForService_64" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_atnm_PeriodicFeeReceivedByManagementFirm_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_PeriodicFeeReceivedByManagementFirm_65" order="230" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_66" order="240" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_WarrantExercisableNoticePeriodDescription" xlink:label="loc_atnm_WarrantExercisableNoticePeriodDescription_67" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_WarrantExercisableNoticePeriodDescription_67" order="250" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:label="loc_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant_68" order="260" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_atnm_MaximumAmountOfOutOfPocketExpenses_69" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_MaximumAmountOfOutOfPocketExpenses_69" order="270" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NonRefundableInstitutionalFee" xlink:label="loc_atnm_NonRefundableInstitutionalFee_70" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_NonRefundableInstitutionalFee_70" order="280" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PharmacyFee" xlink:label="loc_atnm_PharmacyFee_71" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_PharmacyFee_71" order="290" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmendmentProcessingFee" xlink:label="loc_atnm_AmendmentProcessingFee_72" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_AmendmentProcessingFee_72" order="300" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NoticePeriodForTerminationOfAgreement" xlink:label="loc_atnm_NoticePeriodForTerminationOfAgreement_73" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_NoticePeriodForTerminationOfAgreement_73" order="310" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_74" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_us-gaap_LeaseExpirationDate1_74" order="320" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementRenewalDescription" xlink:label="loc_atnm_AgreementRenewalDescription_75" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_AgreementRenewalDescription_75" order="330" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PaymentOfAggregateAmount" xlink:label="loc_atnm_PaymentOfAggregateAmount_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_PaymentOfAggregateAmount_76" order="340" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PaymentOfFinalInstallmentForServicesByCompany" xlink:label="loc_atnm_PaymentOfFinalInstallmentForServicesByCompany_77" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_PaymentOfFinalInstallmentForServicesByCompany_77" order="350" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PaymentOfPerformanceBonusForServicesByCompany" xlink:label="loc_atnm_PaymentOfPerformanceBonusForServicesByCompany_78" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_atnm_PaymentOfPerformanceBonusForServicesByCompany_78" order="360" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_79" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_79" order="370" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_80" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_us-gaap_LegalFees_80" order="380" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_81" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_81" order="390" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="loc_us-gaap_DevelopmentInProcess_82" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_us-gaap_DevelopmentInProcess_82" order="400" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_83" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_83" order="410" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_84" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_us-gaap_SecurityDeposit_84" order="420" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_DerivativeByNatureAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeByNatureAxis_5" xlink:to="loc_us-gaap_DerivativeNameDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeByNatureAxis_5" xlink:to="loc_us-gaap_DerivativeNameDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeNameDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_12" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_13" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_14" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_17" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_19" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_20" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_21" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_22" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_23" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_24" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_25" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_26" order="170" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_PrivatePlacementMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_WarrantMember_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_CommonStockMember_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_RestrictedStockMember_10" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_IPOMember_11" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_12" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_12" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LaidlawAndCoMember" xlink:label="loc_atnm_LaidlawAndCoMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13" xlink:to="loc_atnm_LaidlawAndCoMember_14" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_15" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" xlink:to="loc_atnm_PlacementAgentMember_17" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_18" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_18" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_18" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_atnm_EmployeesDirectorsAndConsultantsMember_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19" xlink:to="loc_atnm_EmployeesDirectorsAndConsultantsMember_20" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19" xlink:to="loc_us-gaap_InvestorMember_21" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_RangeAxis_22" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_22" xlink:to="loc_us-gaap_RangeMember_23" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_23_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_22" xlink:to="loc_us-gaap_RangeMember_23_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_23" xlink:to="loc_us-gaap_MinimumMember_24" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_23" xlink:to="loc_us-gaap_MaximumMember_25" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_EquityTextualsAbstract" xlink:label="loc_atnm_EquityTextualsAbstract_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_atnm_EquityTextualsAbstract_26" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_27" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_DebtInstrumentTerm_28" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_29" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_30" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_31" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_32" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_33" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FairValueAssumptionsExpectedDiscountRate" xlink:label="loc_atnm_FairValueAssumptionsExpectedDiscountRate_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_FairValueAssumptionsExpectedDiscountRate_34" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_atnm_WarrantsIssuedToPurchaseCommonStock_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_WarrantsIssuedToPurchaseCommonStock_35" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_36" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_37" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" xlink:label="loc_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod_38" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_39" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_40" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_41" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_42" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_43" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_44" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_45" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_46" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_47" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_48" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_49" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_50" order="230" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_51" order="240" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52" order="250" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_53" order="260" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UnderwritingDiscount" xlink:label="loc_atnm_UnderwritingDiscount_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_UnderwritingDiscount_54" order="270" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UnderwritingAgreementDescription" xlink:label="loc_atnm_UnderwritingAgreementDescription_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_UnderwritingAgreementDescription_55" order="280" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_56" order="290" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentCashFees" xlink:label="loc_atnm_PlacementAgentCashFees_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_PlacementAgentCashFees_57" order="300" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentAttorneyFees" xlink:label="loc_atnm_PlacementAgentAttorneyFees_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_PlacementAgentAttorneyFees_58" order="310" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityFairValueAdjustment" xlink:label="loc_us-gaap_EquityFairValueAdjustment_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_EquityFairValueAdjustment_59" order="320" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" order="330" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_WarrantsExercisedByWarrantHolders" xlink:label="loc_atnm_WarrantsExercisedByWarrantHolders_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_WarrantsExercisedByWarrantHolders_61" order="340" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RegistrationStatementDescription" xlink:label="loc_atnm_RegistrationStatementDescription_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_RegistrationStatementDescription_62" order="350" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MaximumOfferingPrice" xlink:label="loc_atnm_MaximumOfferingPrice_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_MaximumOfferingPrice_63" order="360" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_64" order="370" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaap_OtherExpenses_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_OtherExpenses_65" order="380" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ProfessionalFees_66" order="390" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_DerivativeByNatureAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeByNatureAxis_5" xlink:to="loc_us-gaap_DerivativeNameDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeByNatureAxis_5" xlink:to="loc_us-gaap_DerivativeNameDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeNameDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" xlink:to="loc_us-gaap_RelatedPartyDomain_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" xlink:to="loc_us-gaap_RelatedPartyDomain_9_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9" xlink:to="loc_us-gaap_InvestorMember_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SubsequentEventsTextualAbstract" xlink:label="loc_atnm_SubsequentEventsTextualAbstract_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_atnm_SubsequentEventsTextualAbstract_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_11" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_11" xlink:to="loc_us-gaap_CommonStockConversionBasis_13" order="10" use="optional"  />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>atnm-20140930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DocumentAndEntityInformationAbstract" xlink:label="loc_I74899F09IJ4_atnm_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_DocumentAndEntityInformationAbstract" xlink:to="lab_K96011H21KL6_atnm_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_G1I5517IJ12J9IJ23G15_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_dei_EntityRegistrantName" xlink:to="lab_I3K7739KL34L1KL45I37_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_I74899F09IJ4_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_dei_EntityCentralIndexKey" xlink:to="lab_K96011H21KL6_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_G1I5517IJ12J9IJ23G15_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_dei_AmendmentFlag" xlink:to="lab_I3K7739KL34L1KL45I37_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_I74899F09IJ4_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_dei_CurrentFiscalYearEndDate" xlink:to="lab_K96011H21KL6_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_G1I5517IJ12J9IJ23G15_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_dei_DocumentType" xlink:to="lab_I3K7739KL34L1KL45I37_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_I74899F09IJ4_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_dei_DocumentPeriodEndDate" xlink:to="lab_K96011H21KL6_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_G1I5517IJ12J9IJ23G15_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_dei_DocumentFiscalYearFocus" xlink:to="lab_I3K7739KL34L1KL45I37_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_I74899F09IJ4_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_dei_DocumentFiscalPeriodFocus" xlink:to="lab_K96011H21KL6_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_G1I5517IJ12J9IJ23G15_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_dei_EntityFilerCategory" xlink:to="lab_I3K7739KL34L1KL45I37_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_I74899F09IJ4_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_K96011H21KL6_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Balance Sheets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_I74899F09IJ4_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_StatementTable" xlink:to="lab_K96011H21KL6_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_StatementClassOfStockAxis" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_StatementClassOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_I74899F09IJ4_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ClassOfStockDomain" xlink:to="lab_K96011H21KL6_us-gaap_ClassOfStockDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_SeriesAPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_SeriesAPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_I74899F09IJ4_us-gaap_SeriesBPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_K96011H21KL6_us-gaap_SeriesBPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_SeriesCPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C-1 Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_SeriesCPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_I74899F09IJ4_us-gaap_SeriesDPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_SeriesDPreferredStockMember" xml:lang="en-US">Series D Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_SeriesDPreferredStockMember" xml:lang="en-US">Series D Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_SeriesDPreferredStockMember" xlink:to="lab_K96011H21KL6_us-gaap_SeriesDPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_SeriesEPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SeriesEPreferredStockMember" xml:lang="en-US">Series E Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SeriesEPreferredStockMember" xml:lang="en-US">Series E Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_SeriesEPreferredStockMember" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_SeriesEPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SeriesCTwoPreferredStockMember" xlink:label="loc_I74899F09IJ4_atnm_SeriesCTwoPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_SeriesCTwoPreferredStockMember" xml:lang="en-US">Series C Two Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_SeriesCTwoPreferredStockMember" xml:lang="en-US">Series C-2 Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_SeriesCTwoPreferredStockMember" xml:lang="en-US">Outstanding nonredeemable series C two preferred stock or outstanding series C two preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_SeriesCTwoPreferredStockMember" xlink:to="lab_K96011H21KL6_atnm_SeriesCTwoPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SeriesCThreePreferredStockMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_SeriesCThreePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_SeriesCThreePreferredStockMember" xml:lang="en-US">Series C Three Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_SeriesCThreePreferredStockMember" xml:lang="en-US">Series C-3 Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_SeriesCThreePreferredStockMember" xml:lang="en-US">Outstanding nonredeemable series C three preferred stock or outstanding series C three preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_SeriesCThreePreferredStockMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_SeriesCThreePreferredStockMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SeriesCFourPreferredStockMember" xlink:label="loc_I74899F09IJ4_atnm_SeriesCFourPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_SeriesCFourPreferredStockMember" xml:lang="en-US">Series C Four Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_SeriesCFourPreferredStockMember" xml:lang="en-US">Series C-4 Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_SeriesCFourPreferredStockMember" xml:lang="en-US">Outstanding nonredeemable series C four preferred stock or outstanding series C four preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_SeriesCFourPreferredStockMember" xlink:to="lab_K96011H21KL6_atnm_SeriesCFourPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_StatementLineItems" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_AssetsAbstract" xlink:to="lab_K96011H21KL6_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_AssetsCurrentAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_I74899F09IJ4_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_K96011H21KL6_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_K96011H21KL6_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_K96011H21KL6_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_I74899F09IJ4_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K96011H21KL6_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_AssetsCurrent" xlink:to="lab_K96011H21KL6_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net of accumulated depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_I74899F09IJ4_us-gaap_SecurityDeposit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_SecurityDeposit" xml:lang="en-US">Security deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_SecurityDeposit" xml:lang="en-US">Security deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_SecurityDeposit" xlink:to="lab_K96011H21KL6_us-gaap_SecurityDeposit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_Assets" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Equity (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_K96011H21KL6_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_I74899F09IJ4_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_K96011H21KL6_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_AccountsPayableRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts Payable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_AccountsPayableRelatedPartiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_I74899F09IJ4_us-gaap_NotesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_NotesPayableCurrent" xml:lang="en-US">Note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_NotesPayableCurrent" xlink:to="lab_K96011H21KL6_us-gaap_NotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_DerivativeLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_I74899F09IJ4_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K96011H21KL6_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_LiabilitiesCurrent" xlink:to="lab_K96011H21KL6_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_Liabilities" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_I74899F09IJ4_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_CommitmentsAndContingencies" xlink:to="lab_K96011H21KL6_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity (Deficit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_StockholdersEquityAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_I74899F09IJ4_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, 100,000,000 Shares .01 Par Authorized, 0 Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, 100,000,000 shares $.01 par authorized, 0 outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.01 par value; 50,000,000 authorized, none issued and outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_PreferredStockValue" xlink:to="lab_K96011H21KL6_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, 100,000,000 shares, $.01 par authorized, 11,155,008 outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 200,000,000 shares authorized; 29,619,495 and 24,565,447 shares issued and outstanding, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_CommonStockValue" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_I74899F09IJ4_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid In Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K96011H21KL6_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Paid in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_AdditionalPaidInCapital" xlink:to="lab_K96011H21KL6_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_I74899F09IJ4_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholder's Deficiency</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_StockholdersEquity" xml:lang="en-US">Total shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K96011H21KL6_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders' Equity (Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_K96011H21KL6_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_K96011H21KL6_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_StockholdersEquity" xlink:to="lab_K96011H21KL6_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Equity (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_I74899F09IJ4_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_K96011H21KL6_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_I74899F09IJ4_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_PreferredStockSharesIssued" xlink:to="lab_K96011H21KL6_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">No. of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_I74899F09IJ4_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_K96011H21KL6_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_I74899F09IJ4_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock shares issued in exchange of equity securities of company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_K96011H21KL6_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock sold, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_CommonStockSharesIssued" xlink:to="lab_K96011H21KL6_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Statements Of Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_IncomeStatementAbstract" xlink:to="lab_K96011H21KL6_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_SalesRevenueNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SalesRevenueNet" xml:lang="en-US">Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SalesRevenueNet" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_SalesRevenueNet" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_SalesRevenueNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_OperatingExpensesAbstract" xlink:to="lab_K96011H21KL6_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research recorded fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development, net of reimbursements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_I74899F09IJ4_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_K96011H21KL6_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_Depreciation" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_I74899F09IJ4_us-gaap_GainLossOnDispositionOfAssets1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Loss on disposition of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Loss on disposition of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K96011H21KL6_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Loss on disposition of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_K96011H21KL6_us-gaap_GainLossOnDispositionOfAssets1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_OperatingExpenses" xml:lang="en-US">Total expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_OperatingExpenses" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_I74899F09IJ4_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Net loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K96011H21KL6_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_OperatingIncomeLoss" xlink:to="lab_K96011H21KL6_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_I74899F09IJ4_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K96011H21KL6_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_InterestExpense" xlink:to="lab_K96011H21KL6_us-gaap_InterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_DerivativeGainLossOnDerivativeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) On Derivative, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Loss on change in fair value of the derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Gain (loss) on change in fair value of derivative liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Gain/loss on change in fair value of the derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeGainLossOnDerivativeNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_I74899F09IJ4_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Net Other income (expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K96011H21KL6_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income (expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_K96011H21KL6_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_NetIncomeLoss" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_I74899F09IJ4_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share - basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_K96011H21KL6_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_K96011H21KL6_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash Flows From Operating Activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_K96011H21KL6_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensation" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_I74899F09IJ4_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_K96011H21KL6_us-gaap_DepreciationDepletionAndAmortization"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_GainOnChangeInFairValueOfDerivatives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gain On Change In Fair Value Of Derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gain on change in fair value of the derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gain on change in fair value of the derivatives.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Loss (gain) on change in fair value of derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_GainOnChangeInFairValueOfDerivatives" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_GainOnChangeInFairValueOfDerivatives"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">(Increase) decrease in:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_K96011H21KL6_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xml:lang="en-US">(Increase) decrease in:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_I74899F09IJ4_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) In Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K96011H21KL6_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_K96011H21KL6_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_IncreaseDecreaseInSecurityDeposits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_IncreaseDecreaseInSecurityDeposits" xml:lang="en-US">Increase (Decrease) in Security Deposits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_IncreaseDecreaseInSecurityDeposits" xml:lang="en-US">Security deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_IncreaseDecreaseInSecurityDeposits"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xml:lang="en-US">Increase (Decrease) in Operating Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xml:lang="en-US">Increase (decrease) in:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="lab_K96011H21KL6_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_I74899F09IJ4_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xml:lang="en-US">Increase (Decrease) In Accounts Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xml:lang="en-US">Accounts payable and accrued expenses - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="lab_K96011H21KL6_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Used In Operating Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows From Investing Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_K96011H21KL6_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_I74899F09IJ4_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K96011H21KL6_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Used In Investing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_K96011H21KL6_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows From Financing Activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_I74899F09IJ4_us-gaap_RepaymentsOfNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayments of Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Payments on note payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K96011H21KL6_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Payments on note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_K96011H21KL6_us-gaap_RepaymentsOfNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Sales of common stock, net of offering costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Received proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" xlink:label="loc_I74899F09IJ4_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" xml:lang="en-US">Proceeds From Exercise Of Options And Warrants For Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" xml:lang="en-US">Proceeds from the exercise of options and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" xml:lang="en-US">Proceeds from the exercise of options and warrants for cash.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" xlink:to="lab_K96011H21KL6_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_I74899F09IJ4_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">INCREASE IN CASH AND CASH EQUIVALENTS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K96011H21KL6_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net change in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_K96011H21KL6_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_SupplementalCashFlowInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_I74899F09IJ4_us-gaap_InterestPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_InterestPaid" xlink:to="lab_K96011H21KL6_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_IncomeTaxesPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_IncomeTaxesPaid" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_IncomeTaxesPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_K96011H21KL6_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Fair Value Of Transfer From Liability Classification To Equity Classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer warrant derivatives from liability to equity classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Fair value of Transfer from liability classification to equity classification.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer from liability classification to equity classification, Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_K96011H21KL6_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_K96011H21KL6_us-gaap_RelatedPartyTransactionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property and Equipment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Note Payable [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Amortization of debt discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_DebtDisclosureAbstract" xlink:to="lab_K96011H21KL6_us-gaap_DebtDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Note Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_DebtDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivatives [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_K96011H21KL6_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_K96011H21KL6_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_EquityAbstract" xlink:to="lab_K96011H21KL6_us-gaap_EquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_SubsequentEventsAbstract" xlink:to="lab_K96011H21KL6_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_I74899F09IJ4_us-gaap_BusinessCombinationsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Nature of Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_K96011H21KL6_us-gaap_BusinessCombinationsPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation - Unaudited Interim Financial Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_I74899F09IJ4_us-gaap_ConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_K96011H21KL6_us-gaap_ConsolidationPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates in Financial Statement Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_UseOfEstimates" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_I74899F09IJ4_us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_K96011H21KL6_us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_I74899F09IJ4_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_I74899F09IJ4_us-gaap_DerivativesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_K96011H21KL6_us-gaap_DerivativesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_I74899F09IJ4_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_K96011H21KL6_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_I74899F09IJ4_us-gaap_CompensationRelatedCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Share-Based Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_K96011H21KL6_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings (Loss) Per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_I74899F09IJ4_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_K96011H21KL6_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_I74899F09IJ4_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Summary of set forth liabilities measured at fair value on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_K96011H21KL6_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of antidilutive securities excluded from computation of earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_I74899F09IJ4_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Schedule Of Related Party Transactions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Summary of activities related to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_K96011H21KL6_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Summary of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_I74899F09IJ4_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xml:lang="en-US">Schedule Of Derivative Instruments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xml:lang="en-US">Schedule of derivative warrant instruments activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_K96011H21KL6_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xml:lang="en-US">Fair Value Of Derivative Warrants On Basis Of Valuation Model [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xml:lang="en-US">Summary of fair values of derivative warrants on basis of valuation model</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xml:lang="en-US">Fair value of derivative warrants on basis of valuation model.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:label="loc_I74899F09IJ4_atnm_MilestonePaymentsMilestoneMethodTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xml:lang="en-US">Milestone Payments Milestone Method [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xml:lang="en-US">Summary of milestone payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xml:lang="en-US">Milestone payments milestone method.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:to="lab_K96011H21KL6_atnm_MilestonePaymentsMilestoneMethodTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_I74899F09IJ4_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_AwardTypeAxis" xlink:to="lab_K96011H21KL6_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_I74899F09IJ4_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_EmployeeStockOptionMember" xlink:to="lab_K96011H21KL6_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_DerivativeByNatureAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeByNatureAxis" xml:lang="en-US">Derivative, by Nature [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_DerivativeByNatureAxis" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeByNatureAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_I74899F09IJ4_us-gaap_DerivativeNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_DerivativeNameDomain" xml:lang="en-US">Derivative, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_DerivativeNameDomain" xlink:to="lab_K96011H21KL6_us-gaap_DerivativeNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_WarrantMember" xml:lang="en-US">A Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_WarrantMember" xml:lang="en-US">Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_WarrantMember" xml:lang="en-US">Warrant holders [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_WarrantMember" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of option activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of stock option activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_I74899F09IJ4_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_K96011H21KL6_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_I74899F09IJ4_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_K96011H21KL6_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueInputsLevel1Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_I74899F09IJ4_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_K96011H21KL6_us-gaap_FairValueInputsLevel2Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueInputsLevel3Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_I74899F09IJ4_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured On Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_K96011H21KL6_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xml:lang="en-US">Summary Of Liabilities Measured At Fair Value On Recurring Basis [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xml:lang="en-US">Summary of liabilities measured at fair value on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_I74899F09IJ4_us-gaap_DerivativeLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_DerivativeLiabilities" xlink:to="lab_K96011H21KL6_us-gaap_DerivativeLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_I74899F09IJ4_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_K96011H21KL6_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_I74899F09IJ4_us-gaap_OptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_OptionMember" xml:lang="en-US">Options Held [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_OptionMember" xml:lang="en-US">Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_OptionMember" xlink:to="lab_K96011H21KL6_us-gaap_OptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_I74899F09IJ4_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Potentially issuable shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_K96011H21KL6_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Description of business and summary of significant accounting policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_I74899F09IJ4_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_dei_LegalEntityAxis" xlink:to="lab_K96011H21KL6_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_G1I5517IJ12J9IJ23G15_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_dei_EntityDomain" xlink:to="lab_I3K7739KL34L1KL45I37_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ActiniumMember" xlink:label="loc_I74899F09IJ4_atnm_ActiniumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_ActiniumMember" xml:lang="en-US">Actinium [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_ActiniumMember" xml:lang="en-US">Actinium [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_ActiniumMember" xml:lang="en-US">Actinium</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_ActiniumMember" xlink:to="lab_K96011H21KL6_atnm_ActiniumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_I74899F09IJ4_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_MachineryAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_MachineryAndEquipmentMember" xml:lang="en-US">Machinery and Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_MachineryAndEquipmentMember" xml:lang="en-US">Machinery and equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_MachineryAndEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_I74899F09IJ4_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and fixtures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_K96011H21KL6_us-gaap_FurnitureAndFixturesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_CommonStockMember" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_I74899F09IJ4_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Description of business and summary of significant accounting policies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_K96011H21KL6_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_I74899F09IJ4_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Percentage of ownership interest acquired by company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_K96011H21KL6_us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xml:lang="en-US">Common Stock Issuable In Consideration For Equity Interest Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xml:lang="en-US">Common Stock issuable in consideration for equity interest acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xml:lang="en-US">Common Stock issuable in consideration for equity interest acquisition.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_I74899F09IJ4_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Estimated useful lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SharesExchangeRatio" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_SharesExchangeRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_SharesExchangeRatio" xml:lang="en-US">Shares Exchange Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_SharesExchangeRatio" xml:lang="en-US">Shares received by each API shareholder of Actinium common stock for each API share exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_SharesExchangeRatio" xml:lang="en-US">Shares exchange ratio.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_SharesExchangeRatio" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_SharesExchangeRatio"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommonStockShares" xlink:label="loc_I74899F09IJ4_atnm_CommonStockShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_CommonStockShares" xml:lang="en-US">Common Stock Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_atnm_CommonStockShares" xml:lang="en-US">Common stock shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_CommonStockShares" xml:lang="en-US">Common stock shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_CommonStockShares" xlink:to="lab_K96011H21KL6_atnm_CommonStockShares"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ExchangedInCommonStockShares" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_ExchangedInCommonStockShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ExchangedInCommonStockShares" xml:lang="en-US">Exchanged In Common Stock Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ExchangedInCommonStockShares" xml:lang="en-US">Common stock shares exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ExchangedInCommonStockShares" xml:lang="en-US">Common stock shares exchanged.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_ExchangedInCommonStockShares" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_ExchangedInCommonStockShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_I74899F09IJ4_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_K96011H21KL6_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_I74899F09IJ4_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_RelatedPartyDomain" xlink:to="lab_K96011H21KL6_us-gaap_RelatedPartyDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_MemorialSloanKetteringCancerCenterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">Memorial Sloan Kettering Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">MSKCC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">MSKCC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">Memorial sloan kettering cancer center.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_MemorialSloanKetteringCancerCenterMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_MemorialSloanKetteringCancerCenterMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_I74899F09IJ4_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category Of Item Purchased [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category of Item Purchased [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="lab_K96011H21KL6_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-Term Purchase Commitment, Category Of Item Purchased [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NewDrugApplicationMember" xlink:label="loc_I74899F09IJ4_atnm_NewDrugApplicationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_NewDrugApplicationMember" xml:lang="en-US">New Drug Application [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_NewDrugApplicationMember" xml:lang="en-US">New Drug Application [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_NewDrugApplicationMember" xml:lang="en-US">New drug application.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_NewDrugApplicationMember" xlink:to="lab_K96011H21KL6_atnm_NewDrugApplicationMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xml:lang="en-US">Receipt Of Regulatory Approval From U S Fda [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xml:lang="en-US">Receipt of Regulatory Approval From U.S. FDA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xml:lang="en-US">Receipt of regulatory approval from U.S. FDA.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_I74899F09IJ4_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_K96011H21KL6_us-gaap_RelatedPartyTransactionLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xml:lang="en-US">Related Party Transaction, Due From (To) Related Party, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xml:lang="en-US">Summary of milestone payments related to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RelatedPartyMilestonesPayment" xlink:label="loc_I74899F09IJ4_atnm_RelatedPartyMilestonesPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_RelatedPartyMilestonesPayment" xml:lang="en-US">Related Party Milestones Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_atnm_RelatedPartyMilestonesPayment" xml:lang="en-US">Milestones payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_RelatedPartyMilestonesPayment" xml:lang="en-US">Related party milestones payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_RelatedPartyMilestonesPayment" xlink:to="lab_K96011H21KL6_atnm_RelatedPartyMilestonesPayment"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_SloanKetteringInstituteOfCancerResearchMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_SloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">Sloan Kettering Institute Of Cancer Research [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_SloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">SKI [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_SloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">Sloan kettering institute of cancer research.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_SloanKetteringInstituteOfCancerResearchMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_SloanKetteringInstituteOfCancerResearchMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_I74899F09IJ4_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">Memorial Sloan Kettering Cancer Center Sloan Kettering Institute Of Cancer Research [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">MSKCC and SKI [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">Memorial sloan kettering cancer center sloan kettering institute of cancer research.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xlink:to="lab_K96011H21KL6_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RosemaryMazanetMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_RosemaryMazanetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_RosemaryMazanetMember" xml:lang="en-US">Rosemary Mazanet [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_RosemaryMazanetMember" xml:lang="en-US">Dr. Rosemary Mazanet [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_RosemaryMazanetMember" xml:lang="en-US">Rosemary mazanet.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_RosemaryMazanetMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_RosemaryMazanetMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LaidlawAndCompanyMember" xlink:label="loc_I74899F09IJ4_atnm_LaidlawAndCompanyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_LaidlawAndCompanyMember" xml:lang="en-US">Laidlaw and Company [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_LaidlawAndCompanyMember" xml:lang="en-US">Laidlaw and Company [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_LaidlawAndCompanyMember" xml:lang="en-US">Laidlaw and company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_LaidlawAndCompanyMember" xlink:to="lab_K96011H21KL6_atnm_LaidlawAndCompanyMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_JamessCapitalGroupMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_JamessCapitalGroupMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_JamessCapitalGroupMember" xml:lang="en-US">Jamess Capital Group [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_JamessCapitalGroupMember" xml:lang="en-US">Jamess Capital Group LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_JamessCapitalGroupMember" xml:lang="en-US">Jamess capital group.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_JamessCapitalGroupMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_JamessCapitalGroupMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_GuagentiAndAssociatesMember" xlink:label="loc_I74899F09IJ4_atnm_GuagentiAndAssociatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_GuagentiAndAssociatesMember" xml:lang="en-US">Guagenti and Associates [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_GuagentiAndAssociatesMember" xml:lang="en-US">Guagenti &amp; Associates LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_GuagentiAndAssociatesMember" xml:lang="en-US">Guagenti and associates.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_GuagentiAndAssociatesMember" xlink:to="lab_K96011H21KL6_atnm_GuagentiAndAssociatesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_IPOMember" xml:lang="en-US">Public Offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_IPOMember" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_IPOMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementAxis" xlink:label="loc_I74899F09IJ4_atnm_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_AgreementAxis" xml:lang="en-US">Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_AgreementAxis" xlink:to="lab_K96011H21KL6_atnm_AgreementAxis"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementDomain" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AgreementDomain" xml:lang="en-US">Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_AgreementDomain" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_AgreementDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ClinicalTrialAgreementMember" xlink:label="loc_I74899F09IJ4_atnm_ClinicalTrialAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_ClinicalTrialAgreementMember" xml:lang="en-US">Clinical Trial Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_ClinicalTrialAgreementMember" xml:lang="en-US">Clinical Trial Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_ClinicalTrialAgreementMember" xml:lang="en-US">Clinical trial agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_ClinicalTrialAgreementMember" xlink:to="lab_K96011H21KL6_atnm_ClinicalTrialAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LicenseDevelopmentAndCommercializationAgreementMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_LicenseDevelopmentAndCommercializationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_LicenseDevelopmentAndCommercializationAgreementMember" xml:lang="en-US">License Development and Commercialization Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_LicenseDevelopmentAndCommercializationAgreementMember" xml:lang="en-US">License, Development and Commercialization Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_LicenseDevelopmentAndCommercializationAgreementMember" xml:lang="en-US">License development and commercialization agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_LicenseDevelopmentAndCommercializationAgreementMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_LicenseDevelopmentAndCommercializationAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ConsultingServicesAgreementMember" xlink:label="loc_I74899F09IJ4_atnm_ConsultingServicesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_ConsultingServicesAgreementMember" xml:lang="en-US">Consulting Services Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_ConsultingServicesAgreementMember" xml:lang="en-US">Consulting Services Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_ConsultingServicesAgreementMember" xml:lang="en-US">Consulting services agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_ConsultingServicesAgreementMember" xlink:to="lab_K96011H21KL6_atnm_ConsultingServicesAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_EngagementAgreementMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_EngagementAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_EngagementAgreementMember" xml:lang="en-US">Engagement Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_EngagementAgreementMember" xml:lang="en-US">Engagement agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_EngagementAgreementMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_EngagementAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_TransactionManagementAgreementMember" xlink:label="loc_I74899F09IJ4_atnm_TransactionManagementAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_TransactionManagementAgreementMember" xml:lang="en-US">Transaction Management Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_TransactionManagementAgreementMember" xml:lang="en-US">Transaction management agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_TransactionManagementAgreementMember" xml:lang="en-US">Transaction management agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_TransactionManagementAgreementMember" xlink:to="lab_K96011H21KL6_atnm_TransactionManagementAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UnitPurchaseAgreementMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_UnitPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_UnitPurchaseAgreementMember" xml:lang="en-US">Unit Purchase Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_UnitPurchaseAgreementMember" xml:lang="en-US">Investors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_UnitPurchaseAgreementMember" xml:lang="en-US">Unit Purchase Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_UnitPurchaseAgreementMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_UnitPurchaseAgreementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_I74899F09IJ4_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Subsidiary, Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_K96011H21KL6_us-gaap_SubsidiarySaleOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentMember" xlink:label="loc_I74899F09IJ4_atnm_PlacementAgentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_PlacementAgentMember" xml:lang="en-US">Placement Agent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_PlacementAgentMember" xml:lang="en-US">Placement agent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_PlacementAgentMember" xml:lang="en-US">Placement agent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_PlacementAgentMember" xlink:to="lab_K96011H21KL6_atnm_PlacementAgentMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_RelatedPartyTransactionsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_RelatedPartyTransactionsTextualAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_RelatedPartyTransactionsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_I74899F09IJ4_us-gaap_OfficersCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_OfficersCompensation" xml:lang="en-US">Officers' Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_OfficersCompensation" xml:lang="en-US">Officers' Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_K96011H21KL6_us-gaap_OfficersCompensation" xml:lang="en-US">Base salary at annual rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_OfficersCompensation" xlink:to="lab_K96011H21KL6_us-gaap_OfficersCompensation"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NumberOfPatients" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_NumberOfPatients" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_NumberOfPatients" xml:lang="en-US">Number Of Patients</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_NumberOfPatients" xml:lang="en-US">Number of Patients enrolled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_NumberOfPatients" xml:lang="en-US">Number of Patients</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_NumberOfPatients" xml:lang="en-US">Number of patients.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_NumberOfPatients" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_NumberOfPatients"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xlink:label="loc_I74899F09IJ4_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xml:lang="en-US">Amount Paid Under Agreement In Year Two Thousand Eleven</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xml:lang="en-US">Amount paid under agreement in 2011</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xml:lang="en-US">Amount paid under agreement in year two thousand eleven.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xlink:to="lab_K96011H21KL6_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xml:lang="en-US">Amount Paid Under Agreement In Year Two Thousand Twelve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xml:lang="en-US">Amount paid under agreement in 2012</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xml:lang="en-US">Amount paid under agreement in year two thousand twelve.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xlink:label="loc_I74899F09IJ4_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xml:lang="en-US">Amount Paid Under Agreement In Year Two Thousand Thirteen</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xml:lang="en-US">Amount paid under agreement in 2013</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xml:lang="en-US">Amount paid under agreement in year two thousand thirteen.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xlink:to="lab_K96011H21KL6_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xml:lang="en-US">Owed Amount Under Agreement In Year Two Thousand Eleven To Fourteen</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xml:lang="en-US">Amount owed under agreement from 2011 to 2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xml:lang="en-US">Owed amount under agreement in year two thousand eleven to fourteen.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MaintenanceFeesAndResearchPayments" xlink:label="loc_I74899F09IJ4_atnm_MaintenanceFeesAndResearchPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_MaintenanceFeesAndResearchPayments" xml:lang="en-US">Maintenance Fees And Research Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_MaintenanceFeesAndResearchPayments" xml:lang="en-US">Maintenance fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_MaintenanceFeesAndResearchPayments" xml:lang="en-US">Maintenance fees and research payments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_MaintenanceFeesAndResearchPayments" xlink:to="lab_K96011H21KL6_atnm_MaintenanceFeesAndResearchPayments"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentServicesFees" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_PlacementAgentServicesFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PlacementAgentServicesFees" xml:lang="en-US">Placement Agent Services Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PlacementAgentServicesFees" xml:lang="en-US">Placement agent services fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PlacementAgentServicesFees" xml:lang="en-US">Placement agent services fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_PlacementAgentServicesFees" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_PlacementAgentServicesFees"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_I74899F09IJ4_atnm_WarrantsIssuedToPurchaseCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_WarrantsIssuedToPurchaseCommonStock" xml:lang="en-US">Warrants Issued To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_WarrantsIssuedToPurchaseCommonStock" xml:lang="en-US">Warrants issued to purchase common stock, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_WarrantsIssuedToPurchaseCommonStock" xml:lang="en-US">Warrants Issued To Purchase Aggregate Shares Of Common Stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_WarrantsIssuedToPurchaseCommonStock" xlink:to="lab_K96011H21KL6_atnm_WarrantsIssuedToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommonStockExercisePriceParOrStatedValuePerShare" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_CommonStockExercisePriceParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_CommonStockExercisePriceParOrStatedValuePerShare" xml:lang="en-US">Common Stock Exercise Price Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_CommonStockExercisePriceParOrStatedValuePerShare" xml:lang="en-US">Common stock exercise price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_CommonStockExercisePriceParOrStatedValuePerShare" xml:lang="en-US">Common stock exercise price par or stated value per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_CommonStockExercisePriceParOrStatedValuePerShare" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_CommonStockExercisePriceParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidUnderAgreement" xlink:label="loc_I74899F09IJ4_atnm_AmountPaidUnderAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_AmountPaidUnderAgreement" xml:lang="en-US">Amount Paid Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_AmountPaidUnderAgreement" xml:lang="en-US">Amount paid under agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_AmountPaidUnderAgreement" xml:lang="en-US">Amount paid under agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_AmountPaidUnderAgreement" xlink:to="lab_K96011H21KL6_atnm_AmountPaidUnderAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AdditionalAmountDueUnderAgreement" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_AdditionalAmountDueUnderAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AdditionalAmountDueUnderAgreement" xml:lang="en-US">Additional Amount Due Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AdditionalAmountDueUnderAgreement" xml:lang="en-US">Additional amount due under agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AdditionalAmountDueUnderAgreement" xml:lang="en-US">Additional amount due under agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_AdditionalAmountDueUnderAgreement" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_AdditionalAmountDueUnderAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xlink:label="loc_I74899F09IJ4_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xml:lang="en-US">Description Of Condition For Termination Of Forbearance Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xml:lang="en-US">Condition for termination of forbearance period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xml:lang="en-US">Description of condition for termination of forbearance period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xlink:to="lab_K96011H21KL6_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_TerminationDateOfForbearanceAgreement" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_TerminationDateOfForbearanceAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_TerminationDateOfForbearanceAgreement" xml:lang="en-US">Termination Date Of Forbearance Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_TerminationDateOfForbearanceAgreement" xml:lang="en-US">Termination date of forbearance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_TerminationDateOfForbearanceAgreement" xml:lang="en-US">Termination date of forbearance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_TerminationDateOfForbearanceAgreement" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_TerminationDateOfForbearanceAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xlink:label="loc_I74899F09IJ4_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xml:lang="en-US">Minimum New Equity Financing Needed Under Condition For Termination Forbearance Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xml:lang="en-US">Minimum new equity financing needed under condition for termination forbearance period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xml:lang="en-US">Minimum new Equity Financing needed under condition for termination Forbearance period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xlink:to="lab_K96011H21KL6_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NewEquityFinanceRaisedByCompany" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_NewEquityFinanceRaisedByCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_NewEquityFinanceRaisedByCompany" xml:lang="en-US">New Equity Finance Raised By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_NewEquityFinanceRaisedByCompany" xml:lang="en-US">New equity finance raised by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_NewEquityFinanceRaisedByCompany" xml:lang="en-US">New equity finance raised by company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_NewEquityFinanceRaisedByCompany" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_NewEquityFinanceRaisedByCompany"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ForgivenAmountOfObligations" xlink:label="loc_I74899F09IJ4_atnm_ForgivenAmountOfObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_ForgivenAmountOfObligations" xml:lang="en-US">Forgiven Amount Of Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_ForgivenAmountOfObligations" xml:lang="en-US">Forgiven amount of obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_ForgivenAmountOfObligations" xml:lang="en-US">Forgiven amount of obligations.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_ForgivenAmountOfObligations" xlink:to="lab_K96011H21KL6_atnm_ForgivenAmountOfObligations"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidToEachPatient" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_AmountPaidToEachPatient" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AmountPaidToEachPatient" xml:lang="en-US">Amount Paid To Each Patient</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AmountPaidToEachPatient" xml:lang="en-US">Amount paid to each patient after Completing clinical trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AmountPaidToEachPatient" xml:lang="en-US">Amount to be paid for each Patient that has completed the clinical trial.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_AmountPaidToEachPatient" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_AmountPaidToEachPatient"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_StartUpFeeForClinicalTrial" xlink:label="loc_I74899F09IJ4_atnm_StartUpFeeForClinicalTrial" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_StartUpFeeForClinicalTrial" xml:lang="en-US">Start Up Fee For Clinical Trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_StartUpFeeForClinicalTrial" xml:lang="en-US">Start-up fee for clinical trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_StartUpFeeForClinicalTrial" xml:lang="en-US">Start-up fee for clinical trial.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_StartUpFeeForClinicalTrial" xlink:to="lab_K96011H21KL6_atnm_StartUpFeeForClinicalTrial"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_StartUpDueCostPaidDate" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_StartUpDueCostPaidDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_StartUpDueCostPaidDate" xml:lang="en-US">Start Up Due Cost Paid Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_StartUpDueCostPaidDate" xml:lang="en-US">Due date of start-up fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_StartUpDueCostPaidDate" xml:lang="en-US">Start-up due cost paid date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_StartUpDueCostPaidDate" xml:lang="en-US">Start-up due cost paid date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_StartUpDueCostPaidDate" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_StartUpDueCostPaidDate"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfSharesTransferTerm" xlink:label="loc_I74899F09IJ4_atnm_DescriptionOfSharesTransferTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfSharesTransferTerm" xml:lang="en-US">Description Of Shares Transfer Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfSharesTransferTerm" xml:lang="en-US">Description of shares transfer term transfer by AHLB on behalf of AHL</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfSharesTransferTerm" xml:lang="en-US">Description of shares transfer term.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_DescriptionOfSharesTransferTerm" xlink:to="lab_K96011H21KL6_atnm_DescriptionOfSharesTransferTerm"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_OptionExercisePriceRange" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_OptionExercisePriceRange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_OptionExercisePriceRange" xml:lang="en-US">Option Exercise Price Range</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_OptionExercisePriceRange" xml:lang="en-US">Option Exercise Price Range</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_OptionExercisePriceRange" xml:lang="en-US">Option exercise price range.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_OptionExercisePriceRange" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_OptionExercisePriceRange"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_OptionsReceivedToPurchaseCommonStock" xlink:label="loc_I74899F09IJ4_atnm_OptionsReceivedToPurchaseCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_OptionsReceivedToPurchaseCommonStock" xml:lang="en-US">Options Received To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_OptionsReceivedToPurchaseCommonStock" xml:lang="en-US">Options received to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_OptionsReceivedToPurchaseCommonStock" xml:lang="en-US">Options received to purchase common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_OptionsReceivedToPurchaseCommonStock" xlink:to="lab_K96011H21KL6_atnm_OptionsReceivedToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_DescriptionOfReceivablesOfPlacementAgentForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xml:lang="en-US">Description Of Receivables Of Placement Agent For Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xml:lang="en-US">Description of receivables of placement agent for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xml:lang="en-US">Description of receivables of placement agent for services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_DescriptionOfReceivablesOfPlacementAgentForServices"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfWarrantsReceivablesByPlacement" xlink:label="loc_I74899F09IJ4_atnm_DescriptionOfWarrantsReceivablesByPlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfWarrantsReceivablesByPlacement" xml:lang="en-US">Description Of Warrants Receivables By Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfWarrantsReceivablesByPlacement" xml:lang="en-US">Description of warrants receivables by placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfWarrantsReceivablesByPlacement" xml:lang="en-US">Description of warrants receivables by placement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_DescriptionOfWarrantsReceivablesByPlacement" xlink:to="lab_K96011H21KL6_atnm_DescriptionOfWarrantsReceivablesByPlacement"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodOfExerciseOfWarrants" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_PeriodOfExerciseOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PeriodOfExerciseOfWarrants" xml:lang="en-US">Period Of Exercise Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PeriodOfExerciseOfWarrants" xml:lang="en-US">Period of exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PeriodOfExerciseOfWarrants" xml:lang="en-US">Period of exercise of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_PeriodOfExerciseOfWarrants" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_PeriodOfExerciseOfWarrants"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PercentageOfSolicitationFee" xlink:label="loc_I74899F09IJ4_atnm_PercentageOfSolicitationFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_PercentageOfSolicitationFee" xml:lang="en-US">Percentage Of Solicitation Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_PercentageOfSolicitationFee" xml:lang="en-US">Percentage of solicitation fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_PercentageOfSolicitationFee" xml:lang="en-US">Percentage of solicitation fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_PercentageOfSolicitationFee" xlink:to="lab_K96011H21KL6_atnm_PercentageOfSolicitationFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodicFeeForFinancialAdvisoryServices" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_PeriodicFeeForFinancialAdvisoryServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PeriodicFeeForFinancialAdvisoryServices" xml:lang="en-US">Periodic Fee For Financial Advisory Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PeriodicFeeForFinancialAdvisoryServices" xml:lang="en-US">Monthly fee for financial advisory services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PeriodicFeeForFinancialAdvisoryServices" xml:lang="en-US">Periodic fee for financial advisory services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_PeriodicFeeForFinancialAdvisoryServices" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_PeriodicFeeForFinancialAdvisoryServices"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xlink:label="loc_I74899F09IJ4_atnm_DescriptionOfAdditionalReceivableByPlacementAgent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xml:lang="en-US">Description Of Additional Receivable By Placement Agent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xml:lang="en-US">Description of additional receivable by placement agent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xml:lang="en-US">Description of additional receivable by placement agent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xlink:to="lab_K96011H21KL6_atnm_DescriptionOfAdditionalReceivableByPlacementAgent"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommonStockPurchaseByHoldingOfWarrant" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_CommonStockPurchaseByHoldingOfWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_CommonStockPurchaseByHoldingOfWarrant" xml:lang="en-US">Common Stock Purchase By Holding Of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_CommonStockPurchaseByHoldingOfWarrant" xml:lang="en-US">Warrant held by placement agent to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_CommonStockPurchaseByHoldingOfWarrant" xml:lang="en-US">Common stock purchase by holding of warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_CommonStockPurchaseByHoldingOfWarrant" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_CommonStockPurchaseByHoldingOfWarrant"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_I74899F09IJ4_atnm_PeriodicFeeReceivedByManagementFirm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_PeriodicFeeReceivedByManagementFirm" xml:lang="en-US">Periodic Fee Received By Management Firm</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_PeriodicFeeReceivedByManagementFirm" xml:lang="en-US">Monthly fee received by management firm</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_PeriodicFeeReceivedByManagementFirm" xml:lang="en-US">Periodic fee received by management firm.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_PeriodicFeeReceivedByManagementFirm" xlink:to="lab_K96011H21KL6_atnm_PeriodicFeeReceivedByManagementFirm"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xml:lang="en-US">Percentage Of Fully Diluted Capital Stock Equal To Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xml:lang="en-US">Percentage of fully diluted capital stock equal to common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xml:lang="en-US">Percentage of fully diluted capital stock equal to common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_I74899F09IJ4_atnm_MaximumAmountOfOutOfPocketExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_MaximumAmountOfOutOfPocketExpenses" xml:lang="en-US">Maximum Amount Of Out Of Pocket Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_MaximumAmountOfOutOfPocketExpenses" xml:lang="en-US">Maximum amount of out of pocket expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_MaximumAmountOfOutOfPocketExpenses" xml:lang="en-US">Maximum amount of out of pocket expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_MaximumAmountOfOutOfPocketExpenses" xlink:to="lab_K96011H21KL6_atnm_MaximumAmountOfOutOfPocketExpenses"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodicAmountOfRent" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_PeriodicAmountOfRent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PeriodicAmountOfRent" xml:lang="en-US">Periodic Amount Of Rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PeriodicAmountOfRent" xml:lang="en-US">Operating lease monthly amount of rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PeriodicAmountOfRent" xml:lang="en-US">Periodic amount of rent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_PeriodicAmountOfRent" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_PeriodicAmountOfRent"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidToPursuantLeaseAgreement" xlink:label="loc_I74899F09IJ4_atnm_AmountPaidToPursuantLeaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_AmountPaidToPursuantLeaseAgreement" xml:lang="en-US">Amount Paid To Pursuant Lease Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_AmountPaidToPursuantLeaseAgreement" xml:lang="en-US">Amount paid to pursuant lease agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_AmountPaidToPursuantLeaseAgreement" xml:lang="en-US">Amount paid to pursuant lease agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_AmountPaidToPursuantLeaseAgreement" xlink:to="lab_K96011H21KL6_atnm_AmountPaidToPursuantLeaseAgreement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_OtherResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_OtherResearchAndDevelopmentExpense" xml:lang="en-US">Other Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_OtherResearchAndDevelopmentExpense" xml:lang="en-US">Paid for research conducted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_OtherResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ConsultingFee" xlink:label="loc_I74899F09IJ4_atnm_ConsultingFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_ConsultingFee" xml:lang="en-US">Consulting Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_ConsultingFee" xml:lang="en-US">Consulting Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_ConsultingFee" xml:lang="en-US">Consulting expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_ConsultingFee" xlink:to="lab_K96011H21KL6_atnm_ConsultingFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SettlementPaymentOfConsultingFee" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_SettlementPaymentOfConsultingFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_SettlementPaymentOfConsultingFee" xml:lang="en-US">Settlement Payment Of Consulting Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_SettlementPaymentOfConsultingFee" xml:lang="en-US">Settlement Payment Of Consulting Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_SettlementPaymentOfConsultingFee" xml:lang="en-US">Settlement payment of consulting fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_SettlementPaymentOfConsultingFee" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_SettlementPaymentOfConsultingFee"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:label="loc_I74899F09IJ4_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xml:lang="en-US">Artist Advances and Royalty Guarantees, Commitments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xml:lang="en-US">Royalty description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:to="lab_K96011H21KL6_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock issued, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock sold, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock issued, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Warrants granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Warrants granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_SaleOfStockPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_I74899F09IJ4_us-gaap_DebtInstrumentTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt Instrument, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt instrument, term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_DebtInstrumentTerm" xlink:to="lab_K96011H21KL6_us-gaap_DebtInstrumentTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_I74899F09IJ4_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xml:lang="en-US">Gross proceeds from the sale of securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:to="lab_K96011H21KL6_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UnderwritingDiscount" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_UnderwritingDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_UnderwritingDiscount" xml:lang="en-US">Underwriting Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_UnderwritingDiscount" xml:lang="en-US">Underwriting discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_UnderwritingDiscount" xml:lang="en-US">Underwriting discount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_UnderwritingDiscount" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_UnderwritingDiscount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_I74899F09IJ4_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Net proceeds from the public offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Gross proceeds received in Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_K96011H21KL6_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_SaleOfStockDescriptionOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of Stock, Description of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Aggregate offering amount of securities sold to investors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Aggregate offering amount of securities sold to investors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_SaleOfStockDescriptionOfTransaction"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_WarrantsToPurchaseCommonStockDescription" xlink:label="loc_I74899F09IJ4_atnm_WarrantsToPurchaseCommonStockDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_WarrantsToPurchaseCommonStockDescription" xml:lang="en-US">Warrants To Purchase Common Stock Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_WarrantsToPurchaseCommonStockDescription" xml:lang="en-US">Warrants to purchase common stock description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_WarrantsToPurchaseCommonStockDescription" xml:lang="en-US">Warrants to purchase common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_WarrantsToPurchaseCommonStockDescription" xlink:to="lab_K96011H21KL6_atnm_WarrantsToPurchaseCommonStockDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule Of Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_I74899F09IJ4_us-gaap_OfficeEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_OfficeEquipmentMember" xlink:to="lab_K96011H21KL6_us-gaap_OfficeEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_RangeAxis" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_I74899F09IJ4_us-gaap_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_RangeMember" xlink:to="lab_K96011H21KL6_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_MaximumMember" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_I74899F09IJ4_us-gaap_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_MinimumMember" xlink:to="lab_K96011H21KL6_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_I74899F09IJ4_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xml:lang="en-US">Property, Plant and Equipment, Net, By Type [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xml:lang="en-US">Summary of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Useful Lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_I74899F09IJ4_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Office equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Equipment and parts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_K96011H21KL6_us-gaap_PropertyPlantAndEquipmentGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: Accumulated depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PropertyAndEquipmentTextualAbstract" xlink:label="loc_I74899F09IJ4_atnm_PropertyAndEquipmentTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_PropertyAndEquipmentTextualAbstract" xml:lang="en-US">Property and Equipment Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_PropertyAndEquipmentTextualAbstract" xml:lang="en-US">Property and Equipment (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_PropertyAndEquipmentTextualAbstract" xlink:to="lab_K96011H21KL6_atnm_PropertyAndEquipmentTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xml:lang="en-US">Schedule Of Trading Securities and Other Trading Assets [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xml:lang="en-US">Schedule of Trading Securities and Other Trading Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PremiumFinanceAgreementMember" xlink:label="loc_I74899F09IJ4_atnm_PremiumFinanceAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_PremiumFinanceAgreementMember" xml:lang="en-US">Premium Finance Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_PremiumFinanceAgreementMember" xml:lang="en-US">Premium finance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_PremiumFinanceAgreementMember" xlink:to="lab_K96011H21KL6_atnm_PremiumFinanceAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ManagementFirmMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_ManagementFirmMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ManagementFirmMember" xml:lang="en-US">Management Firm [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ManagementFirmMember" xml:lang="en-US">Management firm.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_ManagementFirmMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_ManagementFirmMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="loc_I74899F09IJ4_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xml:lang="en-US">Schedule Of Trading Securities and Other Trading Assets [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xml:lang="en-US">Schedule of Trading Securities and Other Trading Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="lab_K96011H21KL6_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NotePayableAndConvertibleNotesTextualAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_NotePayableAndConvertibleNotesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_NotePayableAndConvertibleNotesTextualAbstract" xml:lang="en-US">Note Payable and Convertible Notes Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_NotePayableAndConvertibleNotesTextualAbstract" xml:lang="en-US">Note Payable and Convertible Notes (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_NotePayableAndConvertibleNotesTextualAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_NotePayableAndConvertibleNotesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xlink:label="loc_I74899F09IJ4_atnm_CommonStockPurchaseDueToIssuanceOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xml:lang="en-US">Common Stock Purchase Due To Issuance Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xml:lang="en-US">Common stock shares purchasable through warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xml:lang="en-US">Common stock shares purchase due to issuance of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xlink:to="lab_K96011H21KL6_atnm_CommonStockPurchaseDueToIssuanceOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_G1I5517IJ12J9IJ23G15_invest_InvestmentWarrantsExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_invest_InvestmentWarrantsExpirationDate" xml:lang="en-US">Investment Warrants Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_invest_InvestmentWarrantsExpirationDate" xml:lang="en-US">Warrants expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_invest_InvestmentWarrantsExpirationDate" xlink:to="lab_I3K7739KL34L1KL45I37_invest_InvestmentWarrantsExpirationDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_I74899F09IJ4_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Convertible promissory note amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_K96011H21KL6_us-gaap_DebtInstrumentFaceAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_DebtInstrumentUnamortizedDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Amount of original issue discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Less: original issuance discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_DebtInstrumentUnamortizedDiscount"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmortizationPeriodOfNote" xlink:label="loc_I74899F09IJ4_atnm_AmortizationPeriodOfNote" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_AmortizationPeriodOfNote" xml:lang="en-US">Amortization Period Of Note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_AmortizationPeriodOfNote" xml:lang="en-US">Amortization period of note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_AmortizationPeriodOfNote" xml:lang="en-US">Amortization period of note.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_AmortizationPeriodOfNote" xlink:to="lab_K96011H21KL6_atnm_AmortizationPeriodOfNote"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_NotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_NotesPayable" xml:lang="en-US">Notes payable, outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_NotesPayable" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_NotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_I74899F09IJ4_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xml:lang="en-US">Down payment pursuant to the agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_K96011H21KL6_us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xml:lang="en-US">Due to Officers or Stockholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xml:lang="en-US">Amount required to pay in monthly installment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_I74899F09IJ4_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Promissory note interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_K96011H21KL6_us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PremiumFinanceAgreementPrincipalAmount" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_PremiumFinanceAgreementPrincipalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PremiumFinanceAgreementPrincipalAmount" xml:lang="en-US">Premium Finance Agreement Principal Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PremiumFinanceAgreementPrincipalAmount" xml:lang="en-US">Premium finance agreement principal amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PremiumFinanceAgreementPrincipalAmount" xml:lang="en-US">Premium finance agreement principal amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_PremiumFinanceAgreementPrincipalAmount" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_PremiumFinanceAgreementPrincipalAmount"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PaymentUnderPremiumFinanceAgreement" xlink:label="loc_I74899F09IJ4_atnm_PaymentUnderPremiumFinanceAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_PaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Payment Under Premium Finance Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_PaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Payment under premium finance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_PaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Payment under premium finance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_PaymentUnderPremiumFinanceAgreement" xlink:to="lab_K96011H21KL6_atnm_PaymentUnderPremiumFinanceAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_PeriodicPaymentUnderPremiumFinanceAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Periodic Payment Under Premium Finance Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Monthly amount payable under premium finance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Periodic amount payable under premium finance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_PeriodicPaymentUnderPremiumFinanceAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xlink:label="loc_I74899F09IJ4_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xml:lang="en-US">Duration Of Periodic Payments For Premium Finance Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xml:lang="en-US">Duration of periodic payments for premium finance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xml:lang="en-US">Duration of periodic payments for premium finance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xlink:to="lab_K96011H21KL6_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PremiumFinanceAgreementOutstandingAmount" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_PremiumFinanceAgreementOutstandingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PremiumFinanceAgreementOutstandingAmount" xml:lang="en-US">Premium Finance Agreement Outstanding Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PremiumFinanceAgreementOutstandingAmount" xml:lang="en-US">Premium finance agreement outstanding amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PremiumFinanceAgreementOutstandingAmount" xml:lang="en-US">Premium finance agreement outstanding amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_PremiumFinanceAgreementOutstandingAmount" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_PremiumFinanceAgreementOutstandingAmount"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ProceedsFromConvertibleNotes" xlink:label="loc_I74899F09IJ4_atnm_ProceedsFromConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_ProceedsFromConvertibleNotes" xml:lang="en-US">Proceeds From Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_ProceedsFromConvertibleNotes" xml:lang="en-US">Net proceeds of promissory note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_ProceedsFromConvertibleNotes" xml:lang="en-US">Proceeds from senior subordinated unsecured convertible promissory notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_ProceedsFromConvertibleNotes" xlink:to="lab_K96011H21KL6_atnm_ProceedsFromConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xml:lang="en-US">Percentage Of Principle Amount In Which Convertible Note Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xml:lang="en-US">Percentage of principle amount in which convertible note issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xml:lang="en-US">Percentage of principle amount in which convertible note issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_I74899F09IJ4_us-gaap_DebtInstrumentMaturityDateDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Debt Instrument, Maturity Date, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Convertible note maturity term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="lab_K96011H21KL6_us-gaap_DebtInstrumentMaturityDateDescription"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xml:lang="en-US">Gross Proceeds In Subsequent Offerings Of Common Stock Or Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xml:lang="en-US">Gross proceeds in subsequent offerings of common stock or equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xml:lang="en-US">Gross proceeds in subsequent offerings of common stock or equivalents.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xlink:label="loc_I74899F09IJ4_atnm_DerivativeWarrantsIssuedWithConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Derivative Warrants Issued With Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Common stock issued to investors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Warrants issued with Convertible Notes (See Note 5), Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Derivative warrants Issued With Convertible Notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xlink:to="lab_K96011H21KL6_atnm_DerivativeWarrantsIssuedWithConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_InvestmentWarrantGrantDateFairValue" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_InvestmentWarrantGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_InvestmentWarrantGrantDateFairValue" xml:lang="en-US">Investment Warrant Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_InvestmentWarrantGrantDateFairValue" xml:lang="en-US">Investment warrant grant date fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_InvestmentWarrantGrantDateFairValue" xml:lang="en-US">Investment warrant grant date fair value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_InvestmentWarrantGrantDateFairValue" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_InvestmentWarrantGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xlink:label="loc_I74899F09IJ4_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Debt Instrument Discount Related To Beneficial Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Beneficial conversion feature discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Debt Instrument Discount Related To Beneficial Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Debt instrument discount related to the beneficial conversion feature.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K96011H21KL6_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Less: discount related to the beneficial conversion feature</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xlink:to="lab_K96011H21KL6_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Conversion price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DebtInstrumentFairValuePerShare" xlink:label="loc_I74899F09IJ4_atnm_DebtInstrumentFairValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_DebtInstrumentFairValuePerShare" xml:lang="en-US">Debt Instrument Fair Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_DebtInstrumentFairValuePerShare" xml:lang="en-US">Convertible note fair value per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_DebtInstrumentFairValuePerShare" xml:lang="en-US">Debt instrument fair value per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_DebtInstrumentFairValuePerShare" xlink:to="lab_K96011H21KL6_atnm_DebtInstrumentFairValuePerShare"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ExtendedMaturityPeriodOfConvertibleNotes" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_ExtendedMaturityPeriodOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ExtendedMaturityPeriodOfConvertibleNotes" xml:lang="en-US">Extended Maturity Period Of Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ExtendedMaturityPeriodOfConvertibleNotes" xml:lang="en-US">Extended maturity Period of convertible notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ExtendedMaturityPeriodOfConvertibleNotes" xml:lang="en-US">Extended maturity Period of convertible notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_ExtendedMaturityPeriodOfConvertibleNotes" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_ExtendedMaturityPeriodOfConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfExtendedMaturityDate" xlink:label="loc_I74899F09IJ4_atnm_DescriptionOfExtendedMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfExtendedMaturityDate" xml:lang="en-US">Description Of Extended Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfExtendedMaturityDate" xml:lang="en-US">Description of extended maturity date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfExtendedMaturityDate" xml:lang="en-US">Description of extended maturity date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_DescriptionOfExtendedMaturityDate" xlink:to="lab_K96011H21KL6_atnm_DescriptionOfExtendedMaturityDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Convertible notes and the accrued interest converted into common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_DebtConversionConvertedInstrumentAmount1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_I74899F09IJ4_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Common stock issued by conversion of note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_K96011H21KL6_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xml:lang="en-US">Schedule Of Derivative Warrant Instruments Activity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xml:lang="en-US">Schedule of derivative warrant instruments activity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xml:lang="en-US">Schedule of derivative warrant instruments activity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DerivativeWarrantsUnits" xlink:label="loc_I74899F09IJ4_atnm_DerivativeWarrantsUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Derivative Warrants Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Derivative Warrants Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K96011H21KL6_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Total warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_K96011H21KL6_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Beginning balance, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_K96011H21KL6_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Balance, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Derivative warrants units.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_DerivativeWarrantsUnits" xlink:to="lab_K96011H21KL6_atnm_DerivativeWarrantsUnits"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_TransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_TransferFromLiabilityClassificationToEquityClassification" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_TransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer From Liability Classification To Equity Classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_TransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer From Liability Classification To Equity Classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_TransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer from liability classification to equity classification.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_TransferFromLiabilityClassificationToEquityClassification" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_TransferFromLiabilityClassificationToEquityClassification"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_I74899F09IJ4_us-gaap_DerivativeFairValueOfDerivativeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Derivative, Fair Value, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Derivative, Fair Value, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_K96011H21KL6_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Beginning balance, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_K96011H21KL6_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Balance, Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="lab_K96011H21KL6_us-gaap_DerivativeFairValueOfDerivativeNet"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ChangeInFairValueOfDerivativeWarrants" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_ChangeInFairValueOfDerivativeWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ChangeInFairValueOfDerivativeWarrants" xml:lang="en-US">Change In Fair Value Of Derivative Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ChangeInFairValueOfDerivativeWarrants" xml:lang="en-US">Change in fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ChangeInFairValueOfDerivativeWarrants" xml:lang="en-US">Change in fair value of derivative warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_ChangeInFairValueOfDerivativeWarrants" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_ChangeInFairValueOfDerivativeWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_I74899F09IJ4_us-gaap_DerivativeTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_DerivativeTable" xlink:to="lab_K96011H21KL6_us-gaap_DerivativeTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_DerivativeLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_DerivativeLineItems" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_I74899F09IJ4_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xml:lang="en-US">Summary Of Fair Value Of Derivative Warrants On Basis Of Valuation Model [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xml:lang="en-US">Summary of fair values of derivative warrants on basis of valuation model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:to="lab_K96011H21KL6_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_MarketValueOfCommonStockOnMeasurementDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_MarketValueOfCommonStockOnMeasurementDate" xml:lang="en-US">Market Value Of Common Stock On Measurement Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_MarketValueOfCommonStockOnMeasurementDate" xml:lang="en-US">Market value of common stock on measurement date (1)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_MarketValueOfCommonStockOnMeasurementDate" xml:lang="en-US">Market value of common stock on measurement date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_MarketValueOfCommonStockOnMeasurementDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_I74899F09IJ4_us-gaap_FairValueAssumptionsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_FairValueAssumptionsExercisePrice" xml:lang="en-US">Fair Value Assumptions, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_FairValueAssumptionsExercisePrice" xml:lang="en-US">Adjusted exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_FairValueAssumptionsExercisePrice" xlink:to="lab_K96011H21KL6_us-gaap_FairValueAssumptionsExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate (2)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair value assumptions, risk free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_I74899F09IJ4_us-gaap_FairValueAssumptionsExpectedTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Term of options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Warrant lives in years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_K96011H21KL6_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Contractual life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_K96011H21KL6_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair value assumptions, expected term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_K96011H21KL6_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Expected life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_K96011H21KL6_us-gaap_FairValueAssumptionsExpectedTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility (3)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair value assumptions, expected volatility rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_I74899F09IJ4_us-gaap_FairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield (4)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_K96011H21KL6_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair value assumptions, expected dividend rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="lab_K96011H21KL6_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_FairValueInputsProbabilityOfDefault" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueInputsProbabilityOfDefault" xml:lang="en-US">Fair Value Inputs, Probability Of Default</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueInputsProbabilityOfDefault" xml:lang="en-US">Probability of stock offering in any period over 5 years (5)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_FairValueInputsProbabilityOfDefault" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueInputsProbabilityOfDefault"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_I74899F09IJ4_atnm_RangeOfPercentageOfExistingSharesOffered" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_RangeOfPercentageOfExistingSharesOffered" xml:lang="en-US">Range Of Percentage Of Existing Shares Offered</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_atnm_RangeOfPercentageOfExistingSharesOffered" xml:lang="en-US">Range of percentage of existing shares offered</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_RangeOfPercentageOfExistingSharesOffered" xml:lang="en-US">Range of percentage of existing shares offered (6)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_RangeOfPercentageOfExistingSharesOffered" xml:lang="en-US">Range of percentage of existing shares offered.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_RangeOfPercentageOfExistingSharesOffered" xlink:to="lab_K96011H21KL6_atnm_RangeOfPercentageOfExistingSharesOffered"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FairValueAssumptionOfferingPrice" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_FairValueAssumptionOfferingPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FairValueAssumptionOfferingPrice" xml:lang="en-US">Fair Value Assumption Offering Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FairValueAssumptionOfferingPrice" xml:lang="en-US">Offering price range (7)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FairValueAssumptionOfferingPrice" xml:lang="en-US">Fair value assumption offering price.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_FairValueAssumptionOfferingPrice" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_FairValueAssumptionOfferingPrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_I74899F09IJ4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xml:lang="en-US">Derivative Instruments, Gain (Loss) By Hedging Relationship, By Income Statement Location, By Derivative Instrument Risk [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xml:lang="en-US">Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_K96011H21KL6_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_DerivativeInstrumentsGainLossLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeInstrumentsGainLossLineItems" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeInstrumentsGainLossLineItems" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_DerivativeInstrumentsGainLossLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DerivativeTextualAbstract" xlink:label="loc_I74899F09IJ4_atnm_DerivativeTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_DerivativeTextualAbstract" xml:lang="en-US">Derivative Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_DerivativeTextualAbstract" xml:lang="en-US">Derivatives (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_DerivativeTextualAbstract" xlink:to="lab_K96011H21KL6_atnm_DerivativeTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_FairValueAdjustmentOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair value of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_FairValueAdjustmentOfWarrants"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NumberOfSharesWarrantExercise" xlink:label="loc_I74899F09IJ4_atnm_NumberOfSharesWarrantExercise" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_NumberOfSharesWarrantExercise" xml:lang="en-US">Number Of Shares Warrant Exercise</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_atnm_NumberOfSharesWarrantExercise" xml:lang="en-US">Number of warrant exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_NumberOfSharesWarrantExercise" xml:lang="en-US">Number of shares warrant exercise.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_NumberOfSharesWarrantExercise" xlink:to="lab_K96011H21KL6_atnm_NumberOfSharesWarrantExercise"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DerivativeNumberOfWarrants" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_DerivativeNumberOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_DerivativeNumberOfWarrants" xml:lang="en-US">Derivative Number Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_DerivativeNumberOfWarrants" xml:lang="en-US">Derivative warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_DerivativeNumberOfWarrants" xml:lang="en-US">Derivative number of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_DerivativeNumberOfWarrants" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_DerivativeNumberOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_I74899F09IJ4_us-gaap_LongTermPurchaseCommitmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_LongTermPurchaseCommitmentTable" xml:lang="en-US">Long-Term Purchase Commitment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_LongTermPurchaseCommitmentTable" xml:lang="en-US">Long-term Purchase Commitment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_LongTermPurchaseCommitmentTable" xlink:to="lab_K96011H21KL6_us-gaap_LongTermPurchaseCommitmentTable"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AbbviewBiotherapeuticsCorpMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_AbbviewBiotherapeuticsCorpMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AbbviewBiotherapeuticsCorpMember" xml:lang="en-US">Abbview Biotherapeutics Corp [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AbbviewBiotherapeuticsCorpMember" xml:lang="en-US">Abbview Biotherapeutics Corp [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AbbviewBiotherapeuticsCorpMember" xml:lang="en-US">AbbView biotherapeutics corp.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_AbbviewBiotherapeuticsCorpMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_AbbviewBiotherapeuticsCorpMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_I74899F09IJ4_atnm_PhaseFirstClinicalTrialOfLicensedProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase First Clinical Trial Of Licensed Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase I Clinical Trial of a licensed product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase first clinical trial of a licensed product.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:to="lab_K96011H21KL6_atnm_PhaseFirstClinicalTrialOfLicensedProductMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_PhaseSecondClinicalTrialOfLicensedProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase Second Clinical Trial Of Licensed Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase II Clinical Trial of a licensed product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase second clinical trial of licensed product.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_PhaseSecondClinicalTrialOfLicensedProductMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:label="loc_I74899F09IJ4_atnm_PhaseThirdClinicalTrialOfLicensedProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase Third Clinical Trial Of Licensed Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase III Clinical Trial of a licensed product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase III clinical trial of licensed product.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:to="lab_K96011H21KL6_atnm_PhaseThirdClinicalTrialOfLicensedProductMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_BiologicalLicenseApplicationMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_BiologicalLicenseApplicationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_BiologicalLicenseApplicationMember" xml:lang="en-US">Biological License Application [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_BiologicalLicenseApplicationMember" xml:lang="en-US">Biological License Application filing with U.S. FDA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_BiologicalLicenseApplicationMember" xml:lang="en-US">Biological license application.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_BiologicalLicenseApplicationMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_BiologicalLicenseApplicationMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FirstCommercialSaleMember" xlink:label="loc_I74899F09IJ4_atnm_FirstCommercialSaleMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_FirstCommercialSaleMember" xml:lang="en-US">First Commercial Sale [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_FirstCommercialSaleMember" xml:lang="en-US">First Commercial Sale [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_FirstCommercialSaleMember" xml:lang="en-US">First commercial sale.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_FirstCommercialSaleMember" xlink:to="lab_K96011H21KL6_atnm_FirstCommercialSaleMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AfterFirstNetSalesMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_AfterFirstNetSalesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AfterFirstNetSalesMember" xml:lang="en-US">After First Net Sales [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AfterFirstNetSalesMember" xml:lang="en-US">After First Net Sales [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AfterFirstNetSalesMember" xml:lang="en-US">After first net sales.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_AfterFirstNetSalesMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_AfterFirstNetSalesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_I74899F09IJ4_us-gaap_LongTermPurchaseCommitmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_LongTermPurchaseCommitmentLineItems" xml:lang="en-US">Long-Term Purchase Commitment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_LongTermPurchaseCommitmentLineItems" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="lab_K96011H21KL6_us-gaap_LongTermPurchaseCommitmentLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MilestonePaymentAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_MilestonePaymentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_MilestonePaymentAbstract" xml:lang="en-US">Milestone Payment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_MilestonePaymentAbstract" xml:lang="en-US">Summary of milestone payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_MilestonePaymentAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_MilestonePaymentAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_I74899F09IJ4_atnm_LongTermPurchaseCommitmentMilestonesPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_LongTermPurchaseCommitmentMilestonesPayment" xml:lang="en-US">Long Term Purchase Commitment Milestones Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_LongTermPurchaseCommitmentMilestonesPayment" xml:lang="en-US">Milestones payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_LongTermPurchaseCommitmentMilestonesPayment" xml:lang="en-US">Long term purchase commitment milestones payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:to="lab_K96011H21KL6_atnm_LongTermPurchaseCommitmentMilestonesPayment"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommitmentsAndContingenciesTable" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_CommitmentsAndContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and contingencies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_CommitmentsAndContingenciesTable" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_CommitmentsAndContingenciesTable"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AbbottBiotherapeuticsCorpMember" xlink:label="loc_I74899F09IJ4_atnm_AbbottBiotherapeuticsCorpMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_AbbottBiotherapeuticsCorpMember" xml:lang="en-US">Abbott Biotherapeutics Corp [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_AbbottBiotherapeuticsCorpMember" xml:lang="en-US">Abbott Biotherapeutics Corp [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_AbbottBiotherapeuticsCorpMember" xml:lang="en-US">Abbott biotherapeutics corp.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_AbbottBiotherapeuticsCorpMember" xlink:to="lab_K96011H21KL6_atnm_AbbottBiotherapeuticsCorpMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_OakRidgeNationalLaboratoryMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_OakRidgeNationalLaboratoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_OakRidgeNationalLaboratoryMember" xml:lang="en-US">Oak Ridge National Laboratory [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_OakRidgeNationalLaboratoryMember" xml:lang="en-US">Oak Ridge National Laboratory [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_OakRidgeNationalLaboratoryMember" xml:lang="en-US">Oak ridge national laboratory.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_OakRidgeNationalLaboratoryMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_OakRidgeNationalLaboratoryMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AptivSolutionsMember" xlink:label="loc_I74899F09IJ4_atnm_AptivSolutionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_AptivSolutionsMember" xml:lang="en-US">Aptiv Solutions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_AptivSolutionsMember" xml:lang="en-US">Aptiv Solutions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_AptivSolutionsMember" xml:lang="en-US">Aptiv solutions.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_AptivSolutionsMember" xlink:to="lab_K96011H21KL6_atnm_AptivSolutionsMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_FredHutchinsonCancerResearchCenterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FredHutchinsonCancerResearchCenterMember" xml:lang="en-US">Fred Hutchinson Cancer Research Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FredHutchinsonCancerResearchCenterMember" xml:lang="en-US">Fred Hutchinson Cancer Research Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FredHutchinsonCancerResearchCenterMember" xml:lang="en-US">Fred hutchinson cancer research center.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_FredHutchinsonCancerResearchCenterMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_FredHutchinsonCancerResearchCenterMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:label="loc_I74899F09IJ4_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xml:lang="en-US">Phase I and Ii Clinical Trial For Actimab In Elderly Acute Myeloid Leukemia [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xml:lang="en-US">Phase I/II Clinical Trial For Actimab In Elderly Acute Myeloid Leukemia [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xml:lang="en-US">Phase I and II clinical trial for actimab in elderly acute myeloid leukemia.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:to="lab_K96011H21KL6_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UniversityOfTexasMDAndersonCancerCenterMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_UniversityOfTexasMDAndersonCancerCenterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_UniversityOfTexasMDAndersonCancerCenterMember" xml:lang="en-US">University Of Texas M D Anderson Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_UniversityOfTexasMDAndersonCancerCenterMember" xml:lang="en-US">University of Texas M.D. Anderson Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_UniversityOfTexasMDAndersonCancerCenterMember" xml:lang="en-US">University of texas M.D. anderson cancer center.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_UniversityOfTexasMDAndersonCancerCenterMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_UniversityOfTexasMDAndersonCancerCenterMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_JohnsHopkinsUniversityMember" xlink:label="loc_I74899F09IJ4_atnm_JohnsHopkinsUniversityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_JohnsHopkinsUniversityMember" xml:lang="en-US">Johns Hopkins University [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_JohnsHopkinsUniversityMember" xml:lang="en-US">Johns Hopkins University [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_JohnsHopkinsUniversityMember" xml:lang="en-US">Johns hopkins university.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_JohnsHopkinsUniversityMember" xlink:to="lab_K96011H21KL6_atnm_JohnsHopkinsUniversityMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LaidlawAndCoMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_LaidlawAndCoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_LaidlawAndCoMember" xml:lang="en-US">Laidlaw and Co [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_LaidlawAndCoMember" xml:lang="en-US">Laidlaw &amp; Co [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_LaidlawAndCoMember" xml:lang="en-US">Laidlaw and company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_LaidlawAndCoMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_LaidlawAndCoMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UniversityOfPennsylvaniaMember" xlink:label="loc_I74899F09IJ4_atnm_UniversityOfPennsylvaniaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_UniversityOfPennsylvaniaMember" xml:lang="en-US">University Of Pennsylvania [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_UniversityOfPennsylvaniaMember" xml:lang="en-US">University of Pennsylvania [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_UniversityOfPennsylvaniaMember" xml:lang="en-US">University of pennsylvania.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_UniversityOfPennsylvaniaMember" xlink:to="lab_K96011H21KL6_atnm_UniversityOfPennsylvaniaMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FormerChiefExecutiveOfficerMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_FormerChiefExecutiveOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FormerChiefExecutiveOfficerMember" xml:lang="en-US">Former Chief Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FormerChiefExecutiveOfficerMember" xml:lang="en-US">Former Chief Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FormerChiefExecutiveOfficerMember" xml:lang="en-US">former chief executive officer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_FormerChiefExecutiveOfficerMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_FormerChiefExecutiveOfficerMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodAxis" xlink:label="loc_I74899F09IJ4_atnm_PeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_PeriodAxis" xml:lang="en-US">Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_PeriodAxis" xlink:to="lab_K96011H21KL6_atnm_PeriodAxis"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodDomain" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_PeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PeriodDomain" xml:lang="en-US">Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_PeriodDomain" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_PeriodDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_TwoThousandAndThirteenMember" xlink:label="loc_I74899F09IJ4_atnm_TwoThousandAndThirteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_TwoThousandAndThirteenMember" xml:lang="en-US">Two Thousand And Thirteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_atnm_TwoThousandAndThirteenMember" xml:lang="en-US">2013 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_TwoThousandAndThirteenMember" xlink:to="lab_K96011H21KL6_atnm_TwoThousandAndThirteenMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_TwoThousandAndFourteenMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_TwoThousandAndFourteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_TwoThousandAndFourteenMember" xml:lang="en-US">Two Thousand And Fourteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_TwoThousandAndFourteenMember" xml:lang="en-US">2014 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_TwoThousandAndFourteenMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_TwoThousandAndFourteenMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:label="loc_I74899F09IJ4_atnm_ProductDevelopmentAndPatentLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xml:lang="en-US">Product Development and Patent License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xml:lang="en-US">Product development and patent license agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:to="lab_K96011H21KL6_atnm_ProductDevelopmentAndPatentLicenseAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LicenseAgreementMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_LicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_LicenseAgreementMember" xml:lang="en-US">License agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_LicenseAgreementMember" xml:lang="en-US">License agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_LicenseAgreementMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_LicenseAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_I74899F09IJ4_atnm_LicenseAndSponsoredResearchAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_LicenseAndSponsoredResearchAgreementMember" xml:lang="en-US">License and Sponsored Research Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_LicenseAndSponsoredResearchAgreementMember" xml:lang="en-US">license and sponsored research agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_LicenseAndSponsoredResearchAgreementMember" xml:lang="en-US">License and sponsored research agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_LicenseAndSponsoredResearchAgreementMember" xlink:to="lab_K96011H21KL6_atnm_LicenseAndSponsoredResearchAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentAgreementMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_PlacementAgentAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PlacementAgentAgreementMember" xml:lang="en-US">Placement Agent Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PlacementAgentAgreementMember" xml:lang="en-US">Placement Agent Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PlacementAgentAgreementMember" xml:lang="en-US">Placement agent agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_PlacementAgentAgreementMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_PlacementAgentAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SeparationAndSettlementAgreementMember" xlink:label="loc_I74899F09IJ4_atnm_SeparationAndSettlementAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_SeparationAndSettlementAgreementMember" xml:lang="en-US">Separation and Settlement Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_SeparationAndSettlementAgreementMember" xml:lang="en-US">Separation and Settlement Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_SeparationAndSettlementAgreementMember" xml:lang="en-US">Separation and Settlement Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_SeparationAndSettlementAgreementMember" xlink:to="lab_K96011H21KL6_atnm_SeparationAndSettlementAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ManufacturingAgreementMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_ManufacturingAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ManufacturingAgreementMember" xml:lang="en-US">Manufacturing Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_ManufacturingAgreementMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_ManufacturingAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RentalAgreementMember" xlink:label="loc_I74899F09IJ4_atnm_RentalAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_RentalAgreementMember" xml:lang="en-US">Rental Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_RentalAgreementMember" xml:lang="en-US">Rental Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_RentalAgreementMember" xml:lang="en-US">Rental agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_RentalAgreementMember" xlink:to="lab_K96011H21KL6_atnm_RentalAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ActOncologyMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_ActOncologyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ActOncologyMember" xml:lang="en-US">Act Oncology [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ActOncologyMember" xml:lang="en-US">Act Oncology [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_ActOncologyMember" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_ActOncologyMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AlbertEinsteinMember" xlink:label="loc_I74899F09IJ4_atnm_AlbertEinsteinMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_AlbertEinsteinMember" xml:lang="en-US">Albert Einstein [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_atnm_AlbertEinsteinMember" xml:lang="en-US">Einstein [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_AlbertEinsteinMember" xlink:to="lab_K96011H21KL6_atnm_AlbertEinsteinMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommitmentsAndContingenciesLineItems" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_CommitmentsAndContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and contingencies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_CommitmentsAndContingenciesLineItems" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_CommitmentsAndContingenciesLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_I74899F09IJ4_atnm_CommitmentsAndContingenciesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_CommitmentsAndContingenciesTextualAbstract" xlink:to="lab_K96011H21KL6_atnm_CommitmentsAndContingenciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Net sales in milestones payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TechnologyServicesCosts" xlink:label="loc_I74899F09IJ4_us-gaap_TechnologyServicesCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_TechnologyServicesCosts" xml:lang="en-US">Technology Services Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_TechnologyServicesCosts" xml:lang="en-US">Technology access fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_TechnologyServicesCosts" xlink:to="lab_K96011H21KL6_us-gaap_TechnologyServicesCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_MaintenanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_MaintenanceCosts" xml:lang="en-US">Maintenance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_MaintenanceCosts" xml:lang="en-US">Annual maintenance fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_MaintenanceCosts" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_MaintenanceCosts"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PaymentOfLicenseFee" xlink:label="loc_I74899F09IJ4_atnm_PaymentOfLicenseFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_PaymentOfLicenseFee" xml:lang="en-US">Payment Of License Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_PaymentOfLicenseFee" xml:lang="en-US">License fee payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_PaymentOfLicenseFee" xml:lang="en-US">License fee payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_PaymentOfLicenseFee" xlink:to="lab_K96011H21KL6_atnm_PaymentOfLicenseFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MilestonePaymentDate" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_MilestonePaymentDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_MilestonePaymentDate" xml:lang="en-US">Milestone Payment Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_MilestonePaymentDate" xml:lang="en-US">Milestone payment date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_MilestonePaymentDate" xml:lang="en-US">Milestone payment date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_MilestonePaymentDate" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_MilestonePaymentDate"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_I74899F09IJ4_atnm_DescriptionOfRoyaltyPaymentToRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xml:lang="en-US">Description Of Royalty Payment To Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xml:lang="en-US">Description of royalty payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xml:lang="en-US">Description of royalty payment to related party.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:to="lab_K96011H21KL6_atnm_DescriptionOfRoyaltyPaymentToRelatedParty"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RoyaltyOfNetSalesPercentage" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_RoyaltyOfNetSalesPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_RoyaltyOfNetSalesPercentage" xml:lang="en-US">Royalty Of Net Sales Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_RoyaltyOfNetSalesPercentage" xml:lang="en-US">Royalty of net sales percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_RoyaltyOfNetSalesPercentage" xml:lang="en-US">Royalty of net sales percentage.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_RoyaltyOfNetSalesPercentage" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_RoyaltyOfNetSalesPercentage"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FirstCommercialSalePeriod" xlink:label="loc_I74899F09IJ4_atnm_FirstCommercialSalePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_FirstCommercialSalePeriod" xml:lang="en-US">First Commercial Sale Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_FirstCommercialSalePeriod" xml:lang="en-US">First commercial sale period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_FirstCommercialSalePeriod" xml:lang="en-US">First commercial sale period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_FirstCommercialSalePeriod" xlink:to="lab_K96011H21KL6_atnm_FirstCommercialSalePeriod"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ResearchAndDevelopmentArrangement" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_ResearchAndDevelopmentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ResearchAndDevelopmentArrangement" xml:lang="en-US">Research and Development Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ResearchAndDevelopmentArrangement" xml:lang="en-US">Annual research funding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ResearchAndDevelopmentArrangement" xml:lang="en-US">Research and development arrangement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_ResearchAndDevelopmentArrangement" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_ResearchAndDevelopmentArrangement"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PurchaseOfRadioactiveMaterial" xlink:label="loc_I74899F09IJ4_atnm_PurchaseOfRadioactiveMaterial" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_PurchaseOfRadioactiveMaterial" xml:lang="en-US">Purchase Of Radioactive Material</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_PurchaseOfRadioactiveMaterial" xml:lang="en-US">Purchase of radioactive material used for research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_PurchaseOfRadioactiveMaterial" xml:lang="en-US">Purchase of radioactive material.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_PurchaseOfRadioactiveMaterial" xlink:to="lab_K96011H21KL6_atnm_PurchaseOfRadioactiveMaterial"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ProjectEstimatedCost" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_ProjectEstimatedCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ProjectEstimatedCost" xml:lang="en-US">Project Estimated Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ProjectEstimatedCost" xml:lang="en-US">Project estimated cost for clinical trials of drug Ac-225-HuM195</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_ProjectEstimatedCost" xml:lang="en-US">Project estimated cost.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_ProjectEstimatedCost" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_ProjectEstimatedCost"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DownPaymentOfProjectEstimatedCostPercentage" xlink:label="loc_I74899F09IJ4_atnm_DownPaymentOfProjectEstimatedCostPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_DownPaymentOfProjectEstimatedCostPercentage" xml:lang="en-US">Down Payment Of Project Estimated Cost Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_DownPaymentOfProjectEstimatedCostPercentage" xml:lang="en-US">Down payment of project estimated cost percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_DownPaymentOfProjectEstimatedCostPercentage" xml:lang="en-US">Percentage of total estimated project cost required for down payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_DownPaymentOfProjectEstimatedCostPercentage" xlink:to="lab_K96011H21KL6_atnm_DownPaymentOfProjectEstimatedCostPercentage"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DownPaymentForProject" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_DownPaymentForProject" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_DownPaymentForProject" xml:lang="en-US">Down Payment For Project</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_DownPaymentForProject" xml:lang="en-US">Down payment for project</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_DownPaymentForProject" xml:lang="en-US">Down payment for project.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_DownPaymentForProject" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_DownPaymentForProject"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:label="loc_I74899F09IJ4_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xml:lang="en-US">Clinical Trial Cost For Approval For Food and Drug Administration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xml:lang="en-US">Clinical trial cost for approval of food and drug administration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xml:lang="en-US">Clinical trial cost for approval of food and drug administration.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:to="lab_K96011H21KL6_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xml:lang="en-US">Fund To Related Party Under Agreement For First Two Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xml:lang="en-US">Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xml:lang="en-US">Fund to related party under agreement for first two Year.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:label="loc_I74899F09IJ4_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xml:lang="en-US">Fund To Related Party Under Agreement After Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xml:lang="en-US">Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xml:lang="en-US">Fund to related party under agreement after year two.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:to="lab_K96011H21KL6_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementConsideration" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_AgreementConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AgreementConsideration" xml:lang="en-US">Agreement Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AgreementConsideration" xml:lang="en-US">Agreement consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AgreementConsideration" xml:lang="en-US">Agreement Consideration.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_AgreementConsideration" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_AgreementConsideration"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PerformanceBonusPayableUnderAgreementForService" xlink:label="loc_I74899F09IJ4_atnm_PerformanceBonusPayableUnderAgreementForService" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_PerformanceBonusPayableUnderAgreementForService" xml:lang="en-US">Performance Bonus Payable Under Agreement For Service</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_PerformanceBonusPayableUnderAgreementForService" xml:lang="en-US">Performance bonus payable under agreement for service</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_PerformanceBonusPayableUnderAgreementForService" xml:lang="en-US">Performance Bonus Payable Under Agreement For Service.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_PerformanceBonusPayableUnderAgreementForService" xlink:to="lab_K96011H21KL6_atnm_PerformanceBonusPayableUnderAgreementForService"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_WarrantExercisableNoticePeriodDescription" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_WarrantExercisableNoticePeriodDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_WarrantExercisableNoticePeriodDescription" xml:lang="en-US">Warrant Exercisable Notice Period Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_WarrantExercisableNoticePeriodDescription" xml:lang="en-US">Warrant exercisable notice period description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_WarrantExercisableNoticePeriodDescription" xml:lang="en-US">Warrant exercisable notice period description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_WarrantExercisableNoticePeriodDescription" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_WarrantExercisableNoticePeriodDescription"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:label="loc_I74899F09IJ4_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xml:lang="en-US">Description Of Shares Availability By Exercise Of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xml:lang="en-US">Description of period of shares availability by exercise of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xml:lang="en-US">Description of shares availability by exercise of warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:to="lab_K96011H21KL6_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NonRefundableInstitutionalFee" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_NonRefundableInstitutionalFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_NonRefundableInstitutionalFee" xml:lang="en-US">Non Refundable Institutional Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_NonRefundableInstitutionalFee" xml:lang="en-US">Non - refundable institutional fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_NonRefundableInstitutionalFee" xml:lang="en-US">Non refundable institutional fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_NonRefundableInstitutionalFee" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_NonRefundableInstitutionalFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PharmacyFee" xlink:label="loc_I74899F09IJ4_atnm_PharmacyFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_PharmacyFee" xml:lang="en-US">Pharmacy Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_PharmacyFee" xml:lang="en-US">Annual pharmacy fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_PharmacyFee" xml:lang="en-US">Pharmacy fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_PharmacyFee" xlink:to="lab_K96011H21KL6_atnm_PharmacyFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmendmentProcessingFee" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_AmendmentProcessingFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AmendmentProcessingFee" xml:lang="en-US">Amendment Processing Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AmendmentProcessingFee" xml:lang="en-US">Amendment processing fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_AmendmentProcessingFee" xml:lang="en-US">Amendment processing fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_AmendmentProcessingFee" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_AmendmentProcessingFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NoticePeriodForTerminationOfAgreement" xlink:label="loc_I74899F09IJ4_atnm_NoticePeriodForTerminationOfAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_NoticePeriodForTerminationOfAgreement" xml:lang="en-US">Notice Period For Termination Of Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_NoticePeriodForTerminationOfAgreement" xml:lang="en-US">Notice period for termination of agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_NoticePeriodForTerminationOfAgreement" xml:lang="en-US">Notice Period for termination of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_NoticePeriodForTerminationOfAgreement" xlink:to="lab_K96011H21KL6_atnm_NoticePeriodForTerminationOfAgreement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_LeaseExpirationDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Sublease agreement termination date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Rent agreement termination date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_LeaseExpirationDate1" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_LeaseExpirationDate1"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementRenewalDescription" xlink:label="loc_I74899F09IJ4_atnm_AgreementRenewalDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_AgreementRenewalDescription" xml:lang="en-US">Agreement Renewal Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_AgreementRenewalDescription" xml:lang="en-US">Rental agreement renewal description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_AgreementRenewalDescription" xml:lang="en-US">Description regarding renewal of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_AgreementRenewalDescription" xlink:to="lab_K96011H21KL6_atnm_AgreementRenewalDescription"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PaymentOfAggregateAmount" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_PaymentOfAggregateAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PaymentOfAggregateAmount" xml:lang="en-US">Payment Of Aggregate Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PaymentOfAggregateAmount" xml:lang="en-US">Payment of aggregate amount in installments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PaymentOfAggregateAmount" xml:lang="en-US">Payment of aggregate amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_PaymentOfAggregateAmount" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_PaymentOfAggregateAmount"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PaymentOfFinalInstallmentForServicesByCompany" xlink:label="loc_I74899F09IJ4_atnm_PaymentOfFinalInstallmentForServicesByCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_PaymentOfFinalInstallmentForServicesByCompany" xml:lang="en-US">Payment Of Final Installment For Services By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_PaymentOfFinalInstallmentForServicesByCompany" xml:lang="en-US">Outstanding payment of final installment for services by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_PaymentOfFinalInstallmentForServicesByCompany" xml:lang="en-US">Outstanding payment of final installment for services by company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_PaymentOfFinalInstallmentForServicesByCompany" xlink:to="lab_K96011H21KL6_atnm_PaymentOfFinalInstallmentForServicesByCompany"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PaymentOfPerformanceBonusForServicesByCompany" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_PaymentOfPerformanceBonusForServicesByCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PaymentOfPerformanceBonusForServicesByCompany" xml:lang="en-US">Payment Of Performance Bonus For Services By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PaymentOfPerformanceBonusForServicesByCompany" xml:lang="en-US">Payment of performance bonus for services by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PaymentOfPerformanceBonusForServicesByCompany" xml:lang="en-US">Payment of performance bonus for services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_PaymentOfPerformanceBonusForServicesByCompany" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_PaymentOfPerformanceBonusForServicesByCompany"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_I74899F09IJ4_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xml:lang="en-US">Accrued Professional Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="lab_K96011H21KL6_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_LegalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_LegalFees" xml:lang="en-US">Legal Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_LegalFees" xml:lang="en-US">Accrued fees paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_LegalFees" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_LegalFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="loc_I74899F09IJ4_us-gaap_DevelopmentInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_DevelopmentInProcess" xml:lang="en-US">Development in Process</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_DevelopmentInProcess" xml:lang="en-US">Total project estimated to cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_DevelopmentInProcess" xlink:to="lab_K96011H21KL6_us-gaap_DevelopmentInProcess"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ResearchAndDevelopmentInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">Research and Development in Process</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">Research and development costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ResearchAndDevelopmentInProcess"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Summary of warrants activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Summary of stock option activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Units, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Units, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of stock option granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Units, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Warrants exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of option exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Warrants exercised by investor in a cashless exchange</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Stock option forfeitures during period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of stock option cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Stock option cancelled during period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Warrants expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Restricted common stock and options, Exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Stock option exercise prices</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_I74899F09IJ4_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Outstanding, Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_K96011H21KL6_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted average remaining contractual term for vested portions of options outstanding and currently granted or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_I74899F09IJ4_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Outstanding, Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_K96011H21KL6_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based compensation term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Fair value of warrants determined utilizing the Black-Scholes option pricing model</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_K96011H21KL6_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ScheduleOfStockByClassTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_I74899F09IJ4_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_PrivatePlacementMember" xlink:to="lab_K96011H21KL6_us-gaap_PrivatePlacementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_RestrictedStockMember" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_RestrictedStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_I74899F09IJ4_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_TypeOfArrangementAxis" xlink:to="lab_K96011H21KL6_us-gaap_TypeOfArrangementAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_I74899F09IJ4_us-gaap_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_TitleOfIndividualAxis" xlink:to="lab_K96011H21KL6_us-gaap_TitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_I74899F09IJ4_atnm_EmployeesDirectorsAndConsultantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees Directors And Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_atnm_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees, consultants and board members [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees directors and consultants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_EmployeesDirectorsAndConsultantsMember" xlink:to="lab_K96011H21KL6_atnm_EmployeesDirectorsAndConsultantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_InvestorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_InvestorMember" xml:lang="en-US">Investor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_InvestorMember" xml:lang="en-US">Investor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_InvestorMember" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_InvestorMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_I74899F09IJ4_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ClassOfStockLineItems" xlink:to="lab_K96011H21KL6_us-gaap_ClassOfStockLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_EquityTextualsAbstract" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_EquityTextualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_EquityTextualsAbstract" xml:lang="en-US">Equity Textuals [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_EquityTextualsAbstract" xml:lang="en-US">Equity (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_EquityTextualsAbstract" xml:lang="en-US">Equity textual.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_EquityTextualsAbstract" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_EquityTextualsAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FairValueAssumptionsExpectedDiscountRate" xlink:label="loc_I74899F09IJ4_atnm_FairValueAssumptionsExpectedDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_FairValueAssumptionsExpectedDiscountRate" xml:lang="en-US">Fair Value Assumptions Expected Discount Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_FairValueAssumptionsExpectedDiscountRate" xml:lang="en-US">Fair value assumptions, expected discount rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_FairValueAssumptionsExpectedDiscountRate" xml:lang="en-US">Fair Value Assumptions Expected Discount Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_FairValueAssumptionsExpectedDiscountRate" xlink:to="lab_K96011H21KL6_atnm_FairValueAssumptionsExpectedDiscountRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Number of shares of restricted stock, granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" xlink:label="loc_I74899F09IJ4_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Additional Grants In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" xml:lang="en-US">Number of additional stock option granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" xml:lang="en-US">Share based compensation arrangement by share based payment award options additional grants in period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" xlink:to="lab_K96011H21KL6_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Description and Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xml:lang="en-US">Description restricted stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_I74899F09IJ4_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based compensation term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_K96011H21KL6_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_I74899F09IJ4_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Fair value of stock option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_K96011H21KL6_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_ProceedsFromStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from the exercise of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_ProceedsFromStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_I74899F09IJ4_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Expense related to common stock granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_K96011H21KL6_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_I74899F09IJ4_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Proceeds from common stock issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_K96011H21KL6_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UnderwritingAgreementDescription" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_UnderwritingAgreementDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_UnderwritingAgreementDescription" xml:lang="en-US">Underwriting Agreement Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_UnderwritingAgreementDescription" xml:lang="en-US">Underwriting agreement description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_UnderwritingAgreementDescription" xml:lang="en-US">Underwriting agreement description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_UnderwritingAgreementDescription" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_UnderwritingAgreementDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_I74899F09IJ4_us-gaap_ProceedsFromIssuanceOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from issuance of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_K96011H21KL6_us-gaap_ProceedsFromIssuanceOfWarrants"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentCashFees" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_PlacementAgentCashFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PlacementAgentCashFees" xml:lang="en-US">Placement Agent Cash Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PlacementAgentCashFees" xml:lang="en-US">Placement agent cash fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_PlacementAgentCashFees" xml:lang="en-US">Placement agent cash fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_PlacementAgentCashFees" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_PlacementAgentCashFees"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentAttorneyFees" xlink:label="loc_I74899F09IJ4_atnm_PlacementAgentAttorneyFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_PlacementAgentAttorneyFees" xml:lang="en-US">Placement Agent Attorney Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_PlacementAgentAttorneyFees" xml:lang="en-US">Placement agent attorney fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_PlacementAgentAttorneyFees" xml:lang="en-US">Placement agent attorney fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_PlacementAgentAttorneyFees" xlink:to="lab_K96011H21KL6_atnm_PlacementAgentAttorneyFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityFairValueAdjustment" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_EquityFairValueAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_EquityFairValueAdjustment" xml:lang="en-US">Equity, Fair Value Adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_EquityFairValueAdjustment" xml:lang="en-US">Fair value adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_EquityFairValueAdjustment" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_EquityFairValueAdjustment"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_WarrantsExercisedByWarrantHolders" xlink:label="loc_I74899F09IJ4_atnm_WarrantsExercisedByWarrantHolders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_WarrantsExercisedByWarrantHolders" xml:lang="en-US">Warrants Exercised By Warrant Holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_WarrantsExercisedByWarrantHolders" xml:lang="en-US">Warrants exercised by warrant holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_WarrantsExercisedByWarrantHolders" xml:lang="en-US">Warrants exercised by warrant holders.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_WarrantsExercisedByWarrantHolders" xlink:to="lab_K96011H21KL6_atnm_WarrantsExercisedByWarrantHolders"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RegistrationStatementDescription" xlink:label="loc_G1I5517IJ12J9IJ23G15_atnm_RegistrationStatementDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_RegistrationStatementDescription" xml:lang="en-US">Registration Statement Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_RegistrationStatementDescription" xml:lang="en-US">Registration statement description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I3K7739KL34L1KL45I37_atnm_RegistrationStatementDescription" xml:lang="en-US">Registration statement description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_atnm_RegistrationStatementDescription" xlink:to="lab_I3K7739KL34L1KL45I37_atnm_RegistrationStatementDescription"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MaximumOfferingPrice" xlink:label="loc_I74899F09IJ4_atnm_MaximumOfferingPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_MaximumOfferingPrice" xml:lang="en-US">Maximum Offering Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_atnm_MaximumOfferingPrice" xml:lang="en-US">Maximum offering price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_MaximumOfferingPrice" xml:lang="en-US">Maximum offering price.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_MaximumOfferingPrice" xlink:to="lab_K96011H21KL6_atnm_MaximumOfferingPrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_OtherExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_OtherExpenses" xml:lang="en-US">Other Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_OtherExpenses" xml:lang="en-US">Other offering expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_OtherExpenses" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_OtherExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_I74899F09IJ4_us-gaap_ProfessionalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_ProfessionalFees" xml:lang="en-US">Professional Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K96011H21KL6_us-gaap_ProfessionalFees" xml:lang="en-US">Auditor fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_ProfessionalFees" xlink:to="lab_K96011H21KL6_us-gaap_ProfessionalFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_SubsequentEventTable" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_I74899F09IJ4_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_K96011H21KL6_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_I74899F09IJ4_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_us-gaap_SubsequentEventMember" xlink:to="lab_K96011H21KL6_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_SubsequentEventLineItems" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SubsequentEventsTextualAbstract" xlink:label="loc_I74899F09IJ4_atnm_SubsequentEventsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K96011H21KL6_atnm_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K96011H21KL6_atnm_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K96011H21KL6_atnm_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I74899F09IJ4_atnm_SubsequentEventsTextualAbstract" xlink:to="lab_K96011H21KL6_atnm_SubsequentEventsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_G1I5517IJ12J9IJ23G15_us-gaap_CommonStockConversionBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockConversionBasis" xml:lang="en-US">Common Stock, Conversion Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockConversionBasis" xml:lang="en-US">Common stock, conversion basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G1I5517IJ12J9IJ23G15_us-gaap_CommonStockConversionBasis" xlink:to="lab_I3K7739KL34L1KL45I37_us-gaap_CommonStockConversionBasis"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>atnm-20140930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#DocumentAndEntityInformation" roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#RelatedPartyTransactions" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactions"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#PropertyAndEquipment" roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipment"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#NotePayable" roleURI="http://actiniumpharmaceuticals.com/role/NotePayable"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#Derivatives" roleURI="http://actiniumpharmaceuticals.com/role/Derivatives"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#CommitmentsAndContingencies" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#Equity" roleURI="http://actiniumpharmaceuticals.com/role/Equity"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#SubsequentEvents" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#RelatedPartyTransactionsTables" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#PropertyandEquipmentTables" roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#DerivativesTables" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#CommitmentsandContingenciesTables" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#EquityTables" roleURI="http://actiniumpharmaceuticals.com/role/EquityTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails" roleURI="http://actiniumpharmaceuticals.com/role/Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails1" roleURI="http://actiniumpharmaceuticals.com/role/Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails1"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#RelatedPartyTransactionsDetails" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#PropertyandEquipmentDetails" roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#PropertyAndEquipmentDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#NotePayableDetails" roleURI="http://actiniumpharmaceuticals.com/role/NotePayableDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#DerivativesDetails" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#DerivativesDetails1" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetails1"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#DerivativesDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#CommitmentsandContingenciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#Commitmentsandcontingenciesdetailstextual" roleURI="http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#EquityDetails" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#EquityDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140930.xsd#SubsequentEventsDetails" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventsDetails"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DocumentAndEntityInformationAbstract" xlink:label="loc_atnm_DocumentAndEntityInformationAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_3" order="20" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_5" order="40" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_6" order="50" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_7" order="60" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8" order="70" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_9" order="80" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_10" order="90" use="optional" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SeriesCTwoPreferredStockMember" xlink:label="loc_atnm_SeriesCTwoPreferredStockMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCTwoPreferredStockMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SeriesCThreePreferredStockMember" xlink:label="loc_atnm_SeriesCThreePreferredStockMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCThreePreferredStockMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SeriesCFourPreferredStockMember" xlink:label="loc_atnm_SeriesCFourPreferredStockMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCFourPreferredStockMember_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_AssetsAbstract_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_AssetsCurrentAbstract_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_AssetsCurrent_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_SecurityDeposit_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_Assets_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_NotesPayableCurrent_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_LiabilitiesCurrent_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" xlink:to="loc_us-gaap_Liabilities_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" xlink:to="loc_us-gaap_CommitmentsAndContingencies_29" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" xlink:to="loc_us-gaap_StockholdersEquityAbstract_30" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30" xlink:to="loc_us-gaap_PreferredStockValue_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30" xlink:to="loc_us-gaap_CommonStockValue_32" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30" xlink:to="loc_us-gaap_AdditionalPaidInCapital_33" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30" xlink:to="loc_us-gaap_StockholdersEquity_35" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_36" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_SalesRevenueNet_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_Depreciation_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_OperatingExpenses_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_InterestExpense_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_ShareBasedCompensation_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_atnm_GainOnChangeInFairValueOfDerivatives_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_atnm_GainOnChangeInFairValueOfDerivatives_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9" xlink:to="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" xlink:label="loc_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_27" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_27" xlink:to="loc_us-gaap_InterestPaid_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_27" xlink:to="loc_us-gaap_IncomeTaxesPaid_29" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_30" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_30" xlink:to="loc_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/NotePayable">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Derivatives">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:label="loc_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:label="loc_atnm_MilestonePaymentsMilestoneMethodTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_atnm_MilestonePaymentsMilestoneMethodTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_DerivativeByNatureAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeByNatureAxis_5" xlink:to="loc_us-gaap_DerivativeNameDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeNameDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:label="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" xlink:to="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_8" xlink:to="loc_us-gaap_DerivativeLiabilities_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaap_OptionMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_OptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ActiniumMember" xlink:label="loc_atnm_ActiniumMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_atnm_ActiniumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9" xlink:to="loc_us-gaap_ClassOfStockDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_10" xlink:to="loc_us-gaap_CommonStockMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_12" xlink:to="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_13" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:label="loc_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_13" xlink:to="loc_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_13" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SharesExchangeRatio" xlink:label="loc_atnm_SharesExchangeRatio_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_13" xlink:to="loc_atnm_SharesExchangeRatio_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommonStockShares" xlink:label="loc_atnm_CommonStockShares_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_13" xlink:to="loc_atnm_CommonStockShares_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ExchangedInCommonStockShares" xlink:label="loc_atnm_ExchangedInCommonStockShares_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_13" xlink:to="loc_atnm_ExchangedInCommonStockShares_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NewDrugApplicationMember" xlink:label="loc_atnm_NewDrugApplicationMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" xlink:to="loc_atnm_NewDrugApplicationMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" xlink:to="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RelatedPartyMilestonesPayment" xlink:label="loc_atnm_RelatedPartyMilestonesPayment_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_10" xlink:to="loc_atnm_RelatedPartyMilestonesPayment_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_atnm_SloanKetteringInstituteOfCancerResearchMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_SloanKetteringInstituteOfCancerResearchMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RosemaryMazanetMember" xlink:label="loc_atnm_RosemaryMazanetMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_RosemaryMazanetMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LaidlawAndCompanyMember" xlink:label="loc_atnm_LaidlawAndCompanyMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_LaidlawAndCompanyMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_JamessCapitalGroupMember" xlink:label="loc_atnm_JamessCapitalGroupMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JamessCapitalGroupMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_GuagentiAndAssociatesMember" xlink:label="loc_atnm_GuagentiAndAssociatesMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_GuagentiAndAssociatesMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11" xlink:to="loc_us-gaap_ClassOfStockDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_12" xlink:to="loc_us-gaap_CommonStockMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_12" xlink:to="loc_us-gaap_WarrantMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_12" xlink:to="loc_us-gaap_IPOMember_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_atnm_AgreementAxis_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementAxis_16" xlink:to="loc_atnm_AgreementDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ClinicalTrialAgreementMember" xlink:label="loc_atnm_ClinicalTrialAgreementMember_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_17" xlink:to="loc_atnm_ClinicalTrialAgreementMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LicenseDevelopmentAndCommercializationAgreementMember" xlink:label="loc_atnm_LicenseDevelopmentAndCommercializationAgreementMember_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_17" xlink:to="loc_atnm_LicenseDevelopmentAndCommercializationAgreementMember_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ConsultingServicesAgreementMember" xlink:label="loc_atnm_ConsultingServicesAgreementMember_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_17" xlink:to="loc_atnm_ConsultingServicesAgreementMember_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_EngagementAgreementMember" xlink:label="loc_atnm_EngagementAgreementMember_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_17" xlink:to="loc_atnm_EngagementAgreementMember_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_TransactionManagementAgreementMember" xlink:label="loc_atnm_TransactionManagementAgreementMember_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_17" xlink:to="loc_atnm_TransactionManagementAgreementMember_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UnitPurchaseAgreementMember" xlink:label="loc_atnm_UnitPurchaseAgreementMember_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_17" xlink:to="loc_atnm_UnitPurchaseAgreementMember_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_24" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_25" xlink:to="loc_atnm_PlacementAgentMember_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_27" xlink:to="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_us-gaap_OfficersCompensation_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NumberOfPatients" xlink:label="loc_atnm_NumberOfPatients_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_NumberOfPatients_30" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven_31" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve_32" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen_33" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xlink:label="loc_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen_34" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MaintenanceFeesAndResearchPayments" xlink:label="loc_atnm_MaintenanceFeesAndResearchPayments_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_MaintenanceFeesAndResearchPayments_35" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentServicesFees" xlink:label="loc_atnm_PlacementAgentServicesFees_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_PlacementAgentServicesFees_36" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_atnm_WarrantsIssuedToPurchaseCommonStock_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_WarrantsIssuedToPurchaseCommonStock_37" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommonStockExercisePriceParOrStatedValuePerShare" xlink:label="loc_atnm_CommonStockExercisePriceParOrStatedValuePerShare_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_CommonStockExercisePriceParOrStatedValuePerShare_38" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidUnderAgreement" xlink:label="loc_atnm_AmountPaidUnderAgreement_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_AmountPaidUnderAgreement_39" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AdditionalAmountDueUnderAgreement" xlink:label="loc_atnm_AdditionalAmountDueUnderAgreement_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_AdditionalAmountDueUnderAgreement_40" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xlink:label="loc_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod_41" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_TerminationDateOfForbearanceAgreement" xlink:label="loc_atnm_TerminationDateOfForbearanceAgreement_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_TerminationDateOfForbearanceAgreement_42" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xlink:label="loc_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod_43" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NewEquityFinanceRaisedByCompany" xlink:label="loc_atnm_NewEquityFinanceRaisedByCompany_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_NewEquityFinanceRaisedByCompany_44" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ForgivenAmountOfObligations" xlink:label="loc_atnm_ForgivenAmountOfObligations_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_ForgivenAmountOfObligations_45" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidToEachPatient" xlink:label="loc_atnm_AmountPaidToEachPatient_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_AmountPaidToEachPatient_46" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_StartUpFeeForClinicalTrial" xlink:label="loc_atnm_StartUpFeeForClinicalTrial_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_StartUpFeeForClinicalTrial_47" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_StartUpDueCostPaidDate" xlink:label="loc_atnm_StartUpDueCostPaidDate_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_StartUpDueCostPaidDate_48" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfSharesTransferTerm" xlink:label="loc_atnm_DescriptionOfSharesTransferTerm_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_DescriptionOfSharesTransferTerm_49" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_OptionExercisePriceRange" xlink:label="loc_atnm_OptionExercisePriceRange_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_OptionExercisePriceRange_50" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_OptionsReceivedToPurchaseCommonStock" xlink:label="loc_atnm_OptionsReceivedToPurchaseCommonStock_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_OptionsReceivedToPurchaseCommonStock_51" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xlink:label="loc_atnm_DescriptionOfReceivablesOfPlacementAgentForServices_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_DescriptionOfReceivablesOfPlacementAgentForServices_52" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfWarrantsReceivablesByPlacement" xlink:label="loc_atnm_DescriptionOfWarrantsReceivablesByPlacement_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_DescriptionOfWarrantsReceivablesByPlacement_53" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodOfExerciseOfWarrants" xlink:label="loc_atnm_PeriodOfExerciseOfWarrants_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_PeriodOfExerciseOfWarrants_54" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PercentageOfSolicitationFee" xlink:label="loc_atnm_PercentageOfSolicitationFee_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_PercentageOfSolicitationFee_55" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodicFeeForFinancialAdvisoryServices" xlink:label="loc_atnm_PeriodicFeeForFinancialAdvisoryServices_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_PeriodicFeeForFinancialAdvisoryServices_56" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xlink:label="loc_atnm_DescriptionOfAdditionalReceivableByPlacementAgent_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_DescriptionOfAdditionalReceivableByPlacementAgent_57" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommonStockPurchaseByHoldingOfWarrant" xlink:label="loc_atnm_CommonStockPurchaseByHoldingOfWarrant_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_CommonStockPurchaseByHoldingOfWarrant_58" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_atnm_PeriodicFeeReceivedByManagementFirm_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_PeriodicFeeReceivedByManagementFirm_59" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_60" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_atnm_MaximumAmountOfOutOfPocketExpenses_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_MaximumAmountOfOutOfPocketExpenses_61" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodicAmountOfRent" xlink:label="loc_atnm_PeriodicAmountOfRent_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_PeriodicAmountOfRent_62" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidToPursuantLeaseAgreement" xlink:label="loc_atnm_AmountPaidToPursuantLeaseAgreement_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_AmountPaidToPursuantLeaseAgreement_63" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_64" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ConsultingFee" xlink:label="loc_atnm_ConsultingFee_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_ConsultingFee_65" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SettlementPaymentOfConsultingFee" xlink:label="loc_atnm_SettlementPaymentOfConsultingFee_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_SettlementPaymentOfConsultingFee_66" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:label="loc_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments_67" order="380" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_68" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_69" order="400" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_70" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_70" order="410" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_us-gaap_DebtInstrumentTerm_71" order="420" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72" order="430" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_73" order="440" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UnderwritingDiscount" xlink:label="loc_atnm_UnderwritingDiscount_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_UnderwritingDiscount_74" order="450" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_75" order="460" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_76" order="470" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_WarrantsToPurchaseCommonStockDescription" xlink:label="loc_atnm_WarrantsToPurchaseCommonStockDescription_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_28" xlink:to="loc_atnm_WarrantsToPurchaseCommonStockDescription_77" order="480" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_OfficeEquipmentMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_RangeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PropertyAndEquipmentTextualAbstract" xlink:label="loc_atnm_PropertyAndEquipmentTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_atnm_PropertyAndEquipmentTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_PropertyAndEquipmentTextualAbstract_1" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_PropertyAndEquipmentTextualAbstract_1" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/NotePayableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_atnm_AgreementAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementAxis_2" xlink:to="loc_atnm_AgreementDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PremiumFinanceAgreementMember" xlink:label="loc_atnm_PremiumFinanceAgreementMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_3" xlink:to="loc_atnm_PremiumFinanceAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_atnm_PlacementAgentMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ManagementFirmMember" xlink:label="loc_atnm_ManagementFirmMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_atnm_ManagementFirmMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NotePayableAndConvertibleNotesTextualAbstract" xlink:label="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_9" xlink:to="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xlink:label="loc_atnm_CommonStockPurchaseDueToIssuanceOfWarrants_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_atnm_CommonStockPurchaseDueToIssuanceOfWarrants_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmortizationPeriodOfNote" xlink:label="loc_atnm_AmortizationPeriodOfNote_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_atnm_AmortizationPeriodOfNote_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_us-gaap_NotesPayable_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PremiumFinanceAgreementPrincipalAmount" xlink:label="loc_atnm_PremiumFinanceAgreementPrincipalAmount_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_PremiumFinanceAgreementPrincipalAmount_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PaymentUnderPremiumFinanceAgreement" xlink:label="loc_atnm_PaymentUnderPremiumFinanceAgreement_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_PaymentUnderPremiumFinanceAgreement_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xlink:label="loc_atnm_PeriodicPaymentUnderPremiumFinanceAgreement_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_PeriodicPaymentUnderPremiumFinanceAgreement_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xlink:label="loc_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PremiumFinanceAgreementOutstandingAmount" xlink:label="loc_atnm_PremiumFinanceAgreementOutstandingAmount_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_PremiumFinanceAgreementOutstandingAmount_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ProceedsFromConvertibleNotes" xlink:label="loc_atnm_ProceedsFromConvertibleNotes_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_ProceedsFromConvertibleNotes_25" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xlink:label="loc_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued_26" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_27" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xlink:label="loc_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents_28" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xlink:label="loc_atnm_DerivativeWarrantsIssuedWithConvertibleNotes_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_DerivativeWarrantsIssuedWithConvertibleNotes_29" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_InvestmentWarrantGrantDateFairValue" xlink:label="loc_atnm_InvestmentWarrantGrantDateFairValue_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_InvestmentWarrantGrantDateFairValue_30" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xlink:label="loc_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature_31" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_32" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DebtInstrumentFairValuePerShare" xlink:label="loc_atnm_DebtInstrumentFairValuePerShare_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_DebtInstrumentFairValuePerShare_33" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ExtendedMaturityPeriodOfConvertibleNotes" xlink:label="loc_atnm_ExtendedMaturityPeriodOfConvertibleNotes_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_ExtendedMaturityPeriodOfConvertibleNotes_34" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfExtendedMaturityDate" xlink:label="loc_atnm_DescriptionOfExtendedMaturityDate_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_DescriptionOfExtendedMaturityDate_35" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_36" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_37" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_38" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xlink:label="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DerivativeWarrantsUnits" xlink:label="loc_atnm_DerivativeWarrantsUnits_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_DerivativeWarrantsUnits_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_TransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_atnm_TransferFromLiabilityClassificationToEquityClassification_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_TransferFromLiabilityClassificationToEquityClassification_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DerivativeWarrantsUnits" xlink:label="loc_atnm_DerivativeWarrantsUnits_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_DerivativeWarrantsUnits_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ChangeInFairValueOfDerivativeWarrants" xlink:label="loc_atnm_ChangeInFairValueOfDerivativeWarrants_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_ChangeInFairValueOfDerivativeWarrants_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_RangeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_DerivativeLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_6" xlink:to="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_atnm_MarketValueOfCommonStockOnMeasurementDate_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_atnm_MarketValueOfCommonStockOnMeasurementDate_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="loc_us-gaap_FairValueInputsProbabilityOfDefault_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueInputsProbabilityOfDefault_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_atnm_RangeOfPercentageOfExistingSharesOffered_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_atnm_RangeOfPercentageOfExistingSharesOffered_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FairValueAssumptionOfferingPrice" xlink:label="loc_atnm_FairValueAssumptionOfferingPrice_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_atnm_FairValueAssumptionOfferingPrice_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_DerivativeByNatureAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeByNatureAxis_2" xlink:to="loc_us-gaap_DerivativeNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DerivativeTextualAbstract" xlink:label="loc_atnm_DerivativeTextualAbstract_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9" xlink:to="loc_atnm_DerivativeTextualAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_atnm_RangeOfPercentageOfExistingSharesOffered_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_10" xlink:to="loc_atnm_RangeOfPercentageOfExistingSharesOffered_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_10" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_10" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NumberOfSharesWarrantExercise" xlink:label="loc_atnm_NumberOfSharesWarrantExercise_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_10" xlink:to="loc_atnm_NumberOfSharesWarrantExercise_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DerivativeNumberOfWarrants" xlink:label="loc_atnm_DerivativeNumberOfWarrants_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_10" xlink:to="loc_atnm_DerivativeNumberOfWarrants_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AbbviewBiotherapeuticsCorpMember" xlink:label="loc_atnm_AbbviewBiotherapeuticsCorpMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AbbviewBiotherapeuticsCorpMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseSecondClinicalTrialOfLicensedProductMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseSecondClinicalTrialOfLicensedProductMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseThirdClinicalTrialOfLicensedProductMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseThirdClinicalTrialOfLicensedProductMember_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_BiologicalLicenseApplicationMember" xlink:label="loc_atnm_BiologicalLicenseApplicationMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_BiologicalLicenseApplicationMember_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FirstCommercialSaleMember" xlink:label="loc_atnm_FirstCommercialSaleMember_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_FirstCommercialSaleMember_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AfterFirstNetSalesMember" xlink:label="loc_atnm_AfterFirstNetSalesMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_AfterFirstNetSalesMember_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NewDrugApplicationMember" xlink:label="loc_atnm_NewDrugApplicationMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_NewDrugApplicationMember_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MilestonePaymentAbstract" xlink:label="loc_atnm_MilestonePaymentAbstract_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_16" xlink:to="loc_atnm_MilestonePaymentAbstract_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_MilestonePaymentAbstract_17" xlink:to="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommitmentsAndContingenciesTable" xlink:label="loc_atnm_CommitmentsAndContingenciesTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_atnm_CommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AbbviewBiotherapeuticsCorpMember" xlink:label="loc_atnm_AbbviewBiotherapeuticsCorpMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AbbviewBiotherapeuticsCorpMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AbbottBiotherapeuticsCorpMember" xlink:label="loc_atnm_AbbottBiotherapeuticsCorpMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AbbottBiotherapeuticsCorpMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_OakRidgeNationalLaboratoryMember" xlink:label="loc_atnm_OakRidgeNationalLaboratoryMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_OakRidgeNationalLaboratoryMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AptivSolutionsMember" xlink:label="loc_atnm_AptivSolutionsMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AptivSolutionsMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_atnm_FredHutchinsonCancerResearchCenterMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_FredHutchinsonCancerResearchCenterMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:label="loc_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UniversityOfTexasMDAndersonCancerCenterMember" xlink:label="loc_atnm_UniversityOfTexasMDAndersonCancerCenterMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_UniversityOfTexasMDAndersonCancerCenterMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_JohnsHopkinsUniversityMember" xlink:label="loc_atnm_JohnsHopkinsUniversityMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JohnsHopkinsUniversityMember_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LaidlawAndCoMember" xlink:label="loc_atnm_LaidlawAndCoMember_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_LaidlawAndCoMember_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UniversityOfPennsylvaniaMember" xlink:label="loc_atnm_UniversityOfPennsylvaniaMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_UniversityOfPennsylvaniaMember_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_JamessCapitalGroupMember" xlink:label="loc_atnm_JamessCapitalGroupMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JamessCapitalGroupMember_14" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FormerChiefExecutiveOfficerMember" xlink:label="loc_atnm_FormerChiefExecutiveOfficerMember_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_FormerChiefExecutiveOfficerMember_15" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AfterFirstNetSalesMember" xlink:label="loc_atnm_AfterFirstNetSalesMember_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_atnm_AfterFirstNetSalesMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RangeAxis_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_20" xlink:to="loc_us-gaap_RangeMember_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_21" xlink:to="loc_us-gaap_MaximumMember_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_21" xlink:to="loc_us-gaap_MinimumMember_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodAxis" xlink:label="loc_atnm_PeriodAxis_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_atnm_PeriodAxis_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodDomain" xlink:label="loc_atnm_PeriodDomain_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_PeriodAxis_24" xlink:to="loc_atnm_PeriodDomain_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_TwoThousandAndThirteenMember" xlink:label="loc_atnm_TwoThousandAndThirteenMember_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_PeriodDomain_25" xlink:to="loc_atnm_TwoThousandAndThirteenMember_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_TwoThousandAndFourteenMember" xlink:label="loc_atnm_TwoThousandAndFourteenMember_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_PeriodDomain_25" xlink:to="loc_atnm_TwoThousandAndFourteenMember_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_atnm_AgreementAxis_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementAxis_28" xlink:to="loc_atnm_AgreementDomain_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:label="loc_atnm_ProductDevelopmentAndPatentLicenseAgreementMember_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_ProductDevelopmentAndPatentLicenseAgreementMember_30" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LicenseAgreementMember" xlink:label="loc_atnm_LicenseAgreementMember_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_LicenseAgreementMember_31" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_atnm_LicenseAndSponsoredResearchAgreementMember_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_LicenseAndSponsoredResearchAgreementMember_32" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ClinicalTrialAgreementMember" xlink:label="loc_atnm_ClinicalTrialAgreementMember_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_ClinicalTrialAgreementMember_33" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentAgreementMember" xlink:label="loc_atnm_PlacementAgentAgreementMember_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_PlacementAgentAgreementMember_34" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_TransactionManagementAgreementMember" xlink:label="loc_atnm_TransactionManagementAgreementMember_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_TransactionManagementAgreementMember_35" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SeparationAndSettlementAgreementMember" xlink:label="loc_atnm_SeparationAndSettlementAgreementMember_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_SeparationAndSettlementAgreementMember_36" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ManufacturingAgreementMember" xlink:label="loc_atnm_ManufacturingAgreementMember_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_ManufacturingAgreementMember_37" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RentalAgreementMember" xlink:label="loc_atnm_RentalAgreementMember_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_RentalAgreementMember_38" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ActOncologyMember" xlink:label="loc_atnm_ActOncologyMember_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_ActOncologyMember_39" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AlbertEinsteinMember" xlink:label="loc_atnm_AlbertEinsteinMember_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_AlbertEinsteinMember_40" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommitmentsAndContingenciesLineItems" xlink:label="loc_atnm_CommitmentsAndContingenciesLineItems_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_atnm_CommitmentsAndContingenciesLineItems_41" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_43" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TechnologyServicesCosts" xlink:label="loc_us-gaap_TechnologyServicesCosts_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_TechnologyServicesCosts_44" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_us-gaap_MaintenanceCosts_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_MaintenanceCosts_45" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PaymentOfLicenseFee" xlink:label="loc_atnm_PaymentOfLicenseFee_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PaymentOfLicenseFee_46" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_47" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MilestonePaymentDate" xlink:label="loc_atnm_MilestonePaymentDate_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_MilestonePaymentDate_48" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_atnm_DescriptionOfRoyaltyPaymentToRelatedParty_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_DescriptionOfRoyaltyPaymentToRelatedParty_49" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RoyaltyOfNetSalesPercentage" xlink:label="loc_atnm_RoyaltyOfNetSalesPercentage_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_RoyaltyOfNetSalesPercentage_50" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FirstCommercialSalePeriod" xlink:label="loc_atnm_FirstCommercialSalePeriod_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_FirstCommercialSalePeriod_51" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ResearchAndDevelopmentArrangement" xlink:label="loc_atnm_ResearchAndDevelopmentArrangement_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_ResearchAndDevelopmentArrangement_52" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PurchaseOfRadioactiveMaterial" xlink:label="loc_atnm_PurchaseOfRadioactiveMaterial_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PurchaseOfRadioactiveMaterial_53" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ProjectEstimatedCost" xlink:label="loc_atnm_ProjectEstimatedCost_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_ProjectEstimatedCost_54" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DownPaymentOfProjectEstimatedCostPercentage" xlink:label="loc_atnm_DownPaymentOfProjectEstimatedCostPercentage_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_DownPaymentOfProjectEstimatedCostPercentage_55" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DownPaymentForProject" xlink:label="loc_atnm_DownPaymentForProject_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_DownPaymentForProject_56" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:label="loc_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_57" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:label="loc_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear_58" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:label="loc_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo_59" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NumberOfPatients" xlink:label="loc_atnm_NumberOfPatients_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_NumberOfPatients_60" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmountPaidToEachPatient" xlink:label="loc_atnm_AmountPaidToEachPatient_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_AmountPaidToEachPatient_61" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_StartUpFeeForClinicalTrial" xlink:label="loc_atnm_StartUpFeeForClinicalTrial_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_StartUpFeeForClinicalTrial_62" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_StartUpDueCostPaidDate" xlink:label="loc_atnm_StartUpDueCostPaidDate_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_StartUpDueCostPaidDate_63" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementConsideration" xlink:label="loc_atnm_AgreementConsideration_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_AgreementConsideration_64" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PerformanceBonusPayableUnderAgreementForService" xlink:label="loc_atnm_PerformanceBonusPayableUnderAgreementForService_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PerformanceBonusPayableUnderAgreementForService_65" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_atnm_PeriodicFeeReceivedByManagementFirm_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PeriodicFeeReceivedByManagementFirm_66" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_67" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_WarrantExercisableNoticePeriodDescription" xlink:label="loc_atnm_WarrantExercisableNoticePeriodDescription_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_WarrantExercisableNoticePeriodDescription_68" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:label="loc_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant_69" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_atnm_MaximumAmountOfOutOfPocketExpenses_70" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_MaximumAmountOfOutOfPocketExpenses_70" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NonRefundableInstitutionalFee" xlink:label="loc_atnm_NonRefundableInstitutionalFee_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_NonRefundableInstitutionalFee_71" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PharmacyFee" xlink:label="loc_atnm_PharmacyFee_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PharmacyFee_72" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AmendmentProcessingFee" xlink:label="loc_atnm_AmendmentProcessingFee_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_AmendmentProcessingFee_73" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_NoticePeriodForTerminationOfAgreement" xlink:label="loc_atnm_NoticePeriodForTerminationOfAgreement_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_NoticePeriodForTerminationOfAgreement_74" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_LeaseExpirationDate1_75" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_AgreementRenewalDescription" xlink:label="loc_atnm_AgreementRenewalDescription_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_AgreementRenewalDescription_76" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PaymentOfAggregateAmount" xlink:label="loc_atnm_PaymentOfAggregateAmount_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PaymentOfAggregateAmount_77" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PaymentOfFinalInstallmentForServicesByCompany" xlink:label="loc_atnm_PaymentOfFinalInstallmentForServicesByCompany_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PaymentOfFinalInstallmentForServicesByCompany_78" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PaymentOfPerformanceBonusForServicesByCompany" xlink:label="loc_atnm_PaymentOfPerformanceBonusForServicesByCompany_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PaymentOfPerformanceBonusForServicesByCompany_79" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_80" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_LegalFees_81" order="380" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_82" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="loc_us-gaap_DevelopmentInProcess_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_DevelopmentInProcess_83" order="400" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_84" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_84" order="410" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_85" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_SecurityDeposit_85" order="420" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_DerivativeByNatureAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeByNatureAxis_5" xlink:to="loc_us-gaap_DerivativeNameDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeNameDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_18" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_19" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_20" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_22" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_23" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_24" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_25" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_26" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_27" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_28" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_29" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_30" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_PrivatePlacementMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_WarrantMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_CommonStockMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_RestrictedStockMember_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_IPOMember_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_12" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_LaidlawAndCoMember" xlink:label="loc_atnm_LaidlawAndCoMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13" xlink:to="loc_atnm_LaidlawAndCoMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" xlink:to="loc_atnm_PlacementAgentMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_18" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_atnm_EmployeesDirectorsAndConsultantsMember_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19" xlink:to="loc_atnm_EmployeesDirectorsAndConsultantsMember_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19" xlink:to="loc_us-gaap_InvestorMember_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_RangeAxis_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_22" xlink:to="loc_us-gaap_RangeMember_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_23" xlink:to="loc_us-gaap_MinimumMember_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_23" xlink:to="loc_us-gaap_MaximumMember_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_EquityTextualsAbstract" xlink:label="loc_atnm_EquityTextualsAbstract_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_26" xlink:to="loc_atnm_EquityTextualsAbstract_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_DebtInstrumentTerm_29" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_31" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_32" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_33" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_34" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_FairValueAssumptionsExpectedDiscountRate" xlink:label="loc_atnm_FairValueAssumptionsExpectedDiscountRate_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_FairValueAssumptionsExpectedDiscountRate_35" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_atnm_WarrantsIssuedToPurchaseCommonStock_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_WarrantsIssuedToPurchaseCommonStock_36" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_37" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_38" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" xlink:label="loc_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod_39" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_41" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_42" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_43" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_44" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_45" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_46" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_47" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_48" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_49" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_50" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_51" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_52" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_54" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UnderwritingDiscount" xlink:label="loc_atnm_UnderwritingDiscount_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_UnderwritingDiscount_55" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_UnderwritingAgreementDescription" xlink:label="loc_atnm_UnderwritingAgreementDescription_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_UnderwritingAgreementDescription_56" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_57" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentCashFees" xlink:label="loc_atnm_PlacementAgentCashFees_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_PlacementAgentCashFees_58" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_PlacementAgentAttorneyFees" xlink:label="loc_atnm_PlacementAgentAttorneyFees_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_PlacementAgentAttorneyFees_59" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityFairValueAdjustment" xlink:label="loc_us-gaap_EquityFairValueAdjustment_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_EquityFairValueAdjustment_60" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_61" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_WarrantsExercisedByWarrantHolders" xlink:label="loc_atnm_WarrantsExercisedByWarrantHolders_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_WarrantsExercisedByWarrantHolders_62" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_RegistrationStatementDescription" xlink:label="loc_atnm_RegistrationStatementDescription_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_RegistrationStatementDescription_63" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_MaximumOfferingPrice" xlink:label="loc_atnm_MaximumOfferingPrice_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_MaximumOfferingPrice_64" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_65" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaap_OtherExpenses_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_OtherExpenses_66" order="380" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ProfessionalFees_67" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_DerivativeByNatureAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeByNatureAxis_5" xlink:to="loc_us-gaap_DerivativeNameDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeNameDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" xlink:to="loc_us-gaap_RelatedPartyDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9" xlink:to="loc_us-gaap_InvestorMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="atnm-20140930.xsd#atnm_SubsequentEventsTextualAbstract" xlink:label="loc_atnm_SubsequentEventsTextualAbstract_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_11" xlink:to="loc_atnm_SubsequentEventsTextualAbstract_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_12" xlink:to="loc_us-gaap_CommonStockConversionBasis_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0!,"'?^XP$``$,7```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F,U.XS`4A?=(O$/D+6I<
M._S-J"D+?I:`!#R`)[YMHB:V91MHWQXG!810IZB:2G,VC=K8]WRUE$_*F5PL
MNS9[(1\::THF\C'+R%16-V9>LJ?'F]$YRT)41JO6&BK9B@*[F!X>3!Y7CD*6
M=IM0LCI&]YOS4-74J9!;1R;=F5G?J9B^^CEWJEJH.7$Y'I_RRII()HYB/X--
M)U<T4\]MS*Z7Z><UB:<VL.QRO;#/*IERKFTJ%1,I?S'Z6\KH/2%/.X<UH6Y<
M.$H8C&],Z._\/>!]WUTZ&M]HRNZ5C[>J2QA\V?)7ZQ=_K%WDVX=LH+2S65.1
MMM5SETX@#\Z3TJ$FBEV;#]>\4XWYX-Z2/RP.?+B(/8/T_V\8O".'!.$H0#B.
M03A.0#A.03C.0#C.03A^@7"(,0H(BE$%BE(%BE,%BE0%BE4%BE8%BE<%BE@%
MBEDEBEDEBEDEBEDEBEDEBEDEBEDEBEDEBEDEBEDEBED+%+,6*&8M4,Q:H)BU
M0#%K@6+6XG^9-::*DOCP^>_/RS#FAXXLQ%5+8<_OM>NA/R77RI-^B#Z5N7L'
M^#I[&T>J.N^]=2&5OIYV/X6/5K??/7)I$/G8T&>ONZD?_4Q,A?'N@=\*6NHK
M:4UZ0S8?*O#I&P```/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`
M"`)?<F5L<R\N<F5L<R"B!`(HH``"````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````",DL].PS`,
MQN](O$/D^^IN2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'VY\\_6][N
MYFE4'QQB+T[#NBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7
M^ZBRBXL:NI3\(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0+3S5P6H(
M!WL'JC[Z//FRMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1
MR?LB8P.>)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X
M8<'%#U1?````__\#`%!+`P04``8`"````"$`+K7Y<_$!```Z%@``&@`(`7AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````O)C!;MLP$$3O!?H/`N\UO;N)DQ21<PD*Y)JD
M'T!(M&7$E@22:>N_#^$T5`VTTXNP%P%<P=1@=CU/U.W=K\.^^N%#W`U];6BQ
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M9=9(CNFXSXPK>'A?(SNT1Q=/KC80"`*!\_N$*BYY"5LU*Y]*_$_34DH?1+A!
M<K3Y!/&D/3AP;DC=&N@-:Z.;(;I%.W($9H[,2LN4SPY^^D>=EO9TA2W21B0D
M)&FK(2B'M8'-$-@\*[!+Y$XS4TH?*0S/4**=?(*C3QN9!)%)VL@DB$S1!H/`
MU-'F`L2"=J=@HTC;&H+>L#8R&2*39T5FR3L0@?"`*=J9(S!S1!N?`O&IC2M,
MJ]QCS<^AA>3V[(OO^@T``/__`P!02P,$%``&``@````A`(KFQ1E+`P``3`L`
M``\```!X;"]W;W)K8F]O:RYX;6R4EDU/XS`0AN\K[7^(<E_RU;"`:)&@72T7
M%FT+'",W<:F%8P?;:>F_WW%*PR0N$7MJ)^F\GGGGL>O+J[>2>QNJ-)-B[$<G
MH>]1D<N"B>>Q_[#X]>/,][0AHB!<"CKV=U3[5Y/OWRZW4KTLI7SQ0$#HL;\V
MIKH(`IVO:4GTB:RH@#<KJ4IB(%3/@:X4)85>4VI*'L1A>!J4A`E_KW"AOJ(A
M5RN6TZG,ZY(*LQ=1E!,#Y>LUJ[0_N5PQ3A_W'7FDJNY("76_<=_C1)M9P0PM
MQGX*H=S2S@-55]<UX_#V/`D3/YBT3=XKKZ`K4G.S@/8.ZN!7/(KC4_M+:\4C
MHUO]D61#[^V)B4)N[4_!VET;)5#`MGGUQ`JSAO=A&+;/?E/VO#:'AR`?(/W&
M05BG^?1$T][!D0PFE<V$86:7W8J]^TS""*WKM]!9Y'OJ@L$7=5M$MG"L<@,F
M2LX*`A9EUX03D=-L;E-U]@"#:E5BI!+_GPH4T,HD2*;Q^]-BY@9JLB/7F5QE
M?RJ*5$9(93183%?EAFBD`MZWQJ1]E2G5N6*5I<RN?UUK)JC6C=OS&JDD/Y%,
M`P9NZ:\E%:R])PKFLU!$:)(WZ&()V'%M)3_[E=PKV%DVNQGT:\TJZPI./T?I
M9_WT.VDH++\C2]ZQ$-ALUSSO)TVI8AO88AO8^Q_#&W50"OM)-[(LF=F/S-8*
M;!DX5.!P85T9S%+D(#F#%LT.+XNAB1SXYO52T]<:/,EF&\L+3L6D1`YPPT/&
MW(XP+)'#W+`0]-MN@-$I\CURL/N<EVQ!EE@'8Q<YW!V'QFKP[BPP>I'#'N+@
M2"[F+G+`&\0A0ZVD&,7(87'/@[M\BFF$H[9WL@V/!)!J1Q)WA!P>AX4`L`\A
M#';L@#HL!("U0FE'R,%V`)(IQ2=#C/&'H&?1L`[&/\5;,':H_80V*(8PCO=C
MVBGHJ]2^Z^""8HP_!+W.\*&7'2D#[^;8(1=3[R;'&'L(>DL?2<YPY0FF'8(O
MI"_HFZD)7&=:0!*,+`0]D>&MUZD&DY8XR`X+06Y;48K/M<1!]GT3NVXFF`@(
M>IUT\S+7B12#`%>L7K[SYW",!GP&)@V40=,7W+ARPG.X"MH/>Y=JQA4<+L*3
M?P```/__`P!02P,$%``&``@````A`')SU,(M!0``#!0``!@```!X;"]W;W)K
M<VAE971S+W-H965T-"YX;6R4F-MNJS@4AN]'FG=`W#=@`P:B)%OET)DM[9%&
MHSE<4^(DJ(`CH$WWV\\R)F";-J$W34,^?M:_UO(!;[Z]5Z7Q1INV8/761"O;
M-&B=LWU1'[?F/W\_/02FT799O<]*5M.M^9.VYK?=K[]L+JQY:4^4=@8HU.W6
M/'7=>6U9;7ZB5=:NV)G6\,N!-576P=?F:+7GAF;[_J:JM+!M$ZO*BMH4"NMF
MB08['(J<)BQ_K6C="9&&EED'\;>GXMQ>U:I\B5R5-2^OYX><56>0>"[*HOO9
MBYI&E:^_'VO69,\E^'Y';I9?M?LO,_FJR!O6LD.W`CE+!#KW'%JA!4J[S;X`
M!SSM1D,/6_,1K5,4F-9NTR?HWX)>6NE_HSVQRV]-L?]1U!2R#77B%7AF[(6C
MW_?\$MQLS>Y^ZBOP9V/LZ2%[+;N_V.5W6AQ/'93;`T?<V'K_,Z%M#AD%F17V
MN%+.2@@`_AI5P5L#,I*]]Y^78M^=MJ9#5IYO.PAPXYFVW5/!)4TC?VT[5OTG
M(#1("1$\B#@0_?`[7N'`0Q[Y@HH[J,#GI/+54"#HW@]\3B)+0[%$<OI<)UF7
M[38-NQC0P&"_/6=\.*`U*%^3+%(RIOVSK$.ZN<@C5]F:OFE`0EMHE;>=%VZL
M-ZAN/B#1'"&VBL17A->2RR;7"Y,L4F])KP1O)'`TVH*ZR;8^[IEK]!SFT5^?
M&XD+H#W:P>ISXSE!M-"2.:*)I'-"$E'L0/LMM\-A:'8I>J(].1((M.-HT-,,
MWB62NT1ZBU#L02#+[7%X:T+NQMB)HP8?"42VYV@9B.\CR7TDO8DH%F%L+;?(
M8:V"KF91(+)%O8)WB>0ND=XB%'M$M<>G$0=F_-OCCM^D55(S$0F$]%.*X_N.
MZP1J(F*9\/T`ZY5.9`!^)J"A2J0R@1W?@85^)!27,,$M+R*'-7=DE.WGMT@@
M@SOL^<CU52*6B<"Q?6>*3$R1,@#I@01H$JE,8!#`SN1?<<<W3M)2<+MV'-;<
M:0^.!"+<(=?!FOM8_"ZW\*QVL@14)I@B[]VG-R44<^%7S'%8,Z>U72206\''
M]Y'D/I(*1&3117B:QQ1["`;;\N+UM&9PMEYSQ:TI'NS;KALB;86+!YFAPL0.
M0GVA253$([8?>GH1%<9#MN]YTS2@NN3+_>(616)S(*\4OC9\HH$1%AX^L2ET
M!@9][%-E/C&J0+>=\KW!<J=B)P'K[;@F^EJQ(B08N6.G+/>C*;Z/)/>1]":B
MEI-O$):;%-L)I9S3:!`3*IIO.?0Y)1Z8:SEQJ'5^LD`D546P9T_S@VH1\BU;
M7+8P(GZ7.CY];=1$`R-LA,0/`FW^C14"!:'C3D&*Q4,A'ASBP0*B/2=5&(P(
M0E/25:M\L["\FF)KH513W^/PM[UQ"OK8HDR@(+#=63%EXC.+,H.10^PI$M4B
MWRDLMRCV%8I%;<A%2#!!O\%Y@.G1M_'T\&%8*@QRL1TBK4J)JH-"3(#3%MQ4
MA5SHB-";I@G5*=\U2$X7]JW8:RB.M2`B))A0.(9W]RF"P:X&V)I"HBO,6U93
M^'31Y-N'KYL4FP[%I#;T(C@7F3H7!VY(0GL:-H-/A8&F@R&JM4>BZA#/M1VB
M#6)^!B,]"[LV\J656E15'+*(%_^*-D<:T[)LC9R]\@,4!VHQ7AT/=QXQ?R'6
MKD=H#:_I\^L)/PSBUZWQ!CB+.6='^D?6'(NZ-4IZ@$?9*Q\&6R-.<\27CIW[
M8XAGUL$I3/_O"4[=*!P`V"N`#XQUUR_\`>,YWNY_````__\#`%!+`P04``8`
M"````"$`5:*Q]#`$``#7#@``&0```'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6RL5UV/JS80?:_4_X!XOX`A"4F4Y&KYV/9*MU)5]=X^$W`2M(`1)IO=?]^Q
MC0DV"=FM^K(LDS.'.3-C>[SY^E86QBMN:$ZJK8DLQS1PE9(LKXY;\\??SU^6
MID';I,J2@E1X:[YC:G[=_?K+YD*:%WK"N#6`H:);\]2V]=JV:7K"94(M4N,*
M?CF0IDQ:>&V.-JT;G&3<J2QLUW$6=IGDE2D8ULU'.,CAD*<X(NFYQ%4K2!I<
M)"W$3T]Y325;F7Z$KDR:EW/])25E#13[O,C;=TYJ&F6Z_G:L2)/L"]#]AF9)
M*KGYRXB^S-.&4')H+:"S1:!CS2M[90/3;I/EH("EW6CP86L^H76,/-/>;7B"
M?N;X0@?_&_1$+K\U>?8]KS!D&^K$*K`GY(5!OV7,!,[VR/N95^#/QLCP(3D7
M[5_D\CO.CZ<6RCT'14S8.GN/,$TAHT!CN7/&E)("`H"_1IFSUH",)&_\><FS
M]K0UO84U]QT/`=S88]H^YXS2--(S;4GYCP"ACDJ0N!T)/&^03#AZG2,\.T<$
M'!,.L\X!GI_[$HCA.N$IOS2W?.2L/!],XR_:(D\\[5'2)KM-0RX&]#)D@M8)
M6QEH#9XRWX*AK\"]`D#F&<D38]F:OFE`;BETS>MNMIQM[%>H=-IA@C$&J8A0
M(EA9&6TD#5=:;^6H3K'$L*X"3;TP2/S_((RQ,&$RI$`:KB&Y:D"A1$B72!H&
M+G/5)Y80700TTE#$[54@B\#`T.]*$;0/!0(#[=872D.$$M&'+PUW76*)T*.'
MSPRC9[WEP8XPK8(Y;4U(2!_A;+E0TQ4(S%"%IU=!0!8*CZ^U9-2!$.]8Q_*T
M7,0/2)1^@\6CBT4^VZ0>Z&5^NEY?TRLPDWH%1-.KZ8D>\\0/>!3)"U7R=%T9
M6-7IS;6U'`C,4*>F()2(OCNEX=HNFDLL$7IWPFXU+-AT]`S\:&T)S%3T$M%'
M+PWWHY<(/7HV\`SV[>GH&5C-_6RYU'I,8!9\*;AHYODK3T6$`C'K]\)(&NY'
M+Q%Z]*O/1,_`>O0K-;9`8&3TR/<<;:V'`C&(7AKN1R\1>O0(-K&/)Y^CM?CU
M4RSH0$*`YRQ6CK8VP@XQ$-!;[BOH(2,)[-C\</\@<<AZ?/#C1W,P-H5C4S0V
MQ8I)V4[8K#2,29X7GYU%Q&$ZN?,'_%NPH(>KU75'.1=4@(+\=2/)R!1?N499
M9B?C(,O_59$X8%5%VC87P%3.MRA%$=)6>7A%717UCM+$)OR.JU<D)G8Q.I:X
M.>(0%P4U4G)FT_@2MHW>*FX*D&*X*K@L<Z-?/'F)T'Z!V\73;8\U#(=CIHC=
M1F[8`W<-8]@-/(1TR_Z$&!%GLON0X%I1)T?\1](<\XH:!3Z`4,=B\W4C+B;B
MI24U'Z/WI(4+!?_W!!=(#`.L8P'X0$@K7U@Z^ROI[E\```#__P,`4$L#!!0`
M!@`(````(0#P7X\0>`4```H6```9````>&PO=V]R:W-H965T<R]S:&5E=#,P
M+GAM;*Q876^K1A!]K]3_@'@/>`%C;-F^"A]IK]1*5=6/9X+7-HIA+2!Q[K_O
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M9V+:ZV6;H']R?JH'?QOU7IQ^J?+-;WG)(=M0)ZS`LQ`O"/V^01,XVR/OI[8"
M?U3&AF_3UT/SISC]RO/=OH%R3T$1"EML?L2\SB"C0&,Y4V3*Q`$"@-]&D6-K
M0$;2]_;SE&^:_<IT?6LZF[@,X,8SKYNG'"E-(WNM&U'\*T&LHY(D3D<"GQ=(
MKCBZG2-\=HZ^Y013-O7QZ5<<O<X1/M43V7V>P-L*AL_.,[`\9SH+6L'C1]HR
M86W^X[1)U\M*G`QH:DA)?4QQB[`%D*G$2X:^%!]5`DJ`)(_(LC)GI@%)KJ%]
MWM;>S%W:;U#RK,.$8PS3$9%"8'V1-E:&,ZT[G^A.B<)@>X&F7AA4\7\0ABPH
M3(44*L,Y)$</*%((Y1(KP\!EJOLD"D)%0$=1$2YLKLO;0A4#G6`##(KA>K[^
MP%!BH._Z@I&0(H7H92C#ARZ)0E`5\)C/JT"GE0F)Z2-T)B35H<3,VX;SK9FN
M,9*K_I#"FWDZ*!Y23*U@KB\G-SBTCH/M,Y1YO4@(IO+HCI$8*<^QO$"/+9++
M7M^;\75\,L!K<?MZW.T1,,-S]D:?H1^50-(;2HS/VA+!`/?GVD_R0$H:=0YZ
MT4AOQH35N<6:W&#5T@&GV/UE1##-`=UK$@.=U'>R-R.82&'ZW:8,0R?2X(G"
MT/V&;T7T3+^GH.A'Q9`-$4I,5]")1?=3U*WK]2.=&U,2TOC)#1*M7/,OBD4_
M(I:1V1)*S+!R+NU7"2&'#$E:?)LGN<&C268P`FB!;X^%UHLJ)B,X[$!]?1VR
M]2(%T`H<D,3%"B7W/;ZTZ6=7H@`?T>AZ<<:3AKY#KWPS&#[!8:1\(9.@JR7N
M,'J-`Y*Y6*&49'<D63[J0QI=,H1-);-[]C!#1UIELK_"#B0GR\PBD4;=,HF4
MI"[N4$%[M)..3VY1Z&+QQ6%0W^N3D\G7#-?M!U\X-D5C4SPV)9I)CPDG_R`F
MG(H>C,3/OA@CC5Z.T3M(R"3('7:A%Y"B16=4/R3&ID0SZ8IP_A-%N(L^JTB^
M1@RWE3<C'13B_VX@6U/D,#KTSJBSHMY1F1(-I2O"L4X4?:5&\NU`5T1&5L@D
MB"@B$SDZHU3X\=B4:"9=$8YTHN@K-9)O!KHBLD5#)D%$$=$=G5%G1;VC,B4:
M2E>$LYPHPHI^MNOD*X&FB$Z=D$D0441T1V>4"C\>FQ+-I"O"44T4?:7KY,37
M%9&A$C()TA4Y9-I&9]194>^H3(F&TA3!S<Y(T1>ZKJ4A9UU`ID;8@8@BHCLZ
MHU3X\=B$-U+=*0,HJ4C>,,D;CH)7.Q[QPZ$V,O&*MT=PW*^7O5E>;4%$ZFZ+
MKC!O@><ID(]6IK#27D2-5GQ8\2_ZS&"EO4D8^02P$ESTF</*_,(*7,@].A?L
M(5O`-<HXXA@N\"[90V<!%Q87\`XDY8+]D;E`U(Y>NY<!-W''=,=_3ZM=7M;&
M@6\AU_"_`6SS2M[ER2^-.+873L^B@3NX]L\]W+ERN.J96`#>"M&H+UC1_A9W
M_1\```#__P,`4$L#!!0`!@`(````(0"->2X"/@,``*<)```9````>&PO=V]R
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MAKA?W0#G9^_^XLJ^H3EG@I72`CM;@U['G-B)#4Z;=4$A`I5V@Y,R-1_<U=9U
M3'NS[A/TFY*C&/TV1,6.GS@MOM*60+:A3JH".\:>E?1+H99@LWVU^ZFOP'=N
M%*3$AUK^8,?/A.XK">4.(2(5V*IX>R0BAXR"C>6%RBEG-0#`I]%0U1J0$?S:
M?Q]I(:O4])$51H[O@MS8$2&?J+(TC?P@)&O^:)%[LM(FWLG$!_K3?<_RXM`-
MT?LNMB;J`WS$$F_6G!T-Z!IXINBPZD%W!<[GR#3'$.O_0H48E<F#<DG-R#0@
M"@'U>=D$"*WM%\AI?M)DUQIWJMB>%:H4@#<P0N1CQG]G_8RBQ`I%54&Q97H!
MO`<V;_;<:P6ZH$U(($-C$I4M'[IIF4AM`MT(P`_"*4*F-<%(,U-LEQ031C`9
M,RZS*7%J0@*&Y`0HFK%I#>K+ZB8H1IX_56RU`CX'EPO]A`VZ?<QV6_[4ICEC
M/"7(M$8SWOD.2AQGJMAJQ0V,:,JXG#\EGK,ETR=G6G/*'T)N=)4_K;B!#4[8
M.'_+;$H\8XMF6<FT)NYKBR(G\L)+Y?KCL]6*&]C4L)N]2=X_&VK3G/%R]O0!
MUII3;3TW\*-DWH`3"7*<.+X$.FG`9`JYG$`EGL*YR;SQM$;#^2CT@VC.IA4W
M)!`FV"2#RW"]>DH71+,W6W82Z?K&GHL2?U[?DV2)3\]%/38:PO=D2^I:&#D[
MJ)GG0?,,J\,\?O#4&WBVGJDYK=;MX0:,R0[OR3?,][051DU*L'2L"(XKUX-6
M7TC6]<-JQR0,R/YG!7^("+SA'0O$)6/R?*$>,/S%VOP%``#__P,`4$L#!!0`
M!@`(````(0#A>?`VB`,``,4,```9````>&PO=V]R:W-H965T<R]S:&5E=#(X
M+GAM;)2778^B2!2&[R?9_T"X'_D0:27JI!5A)YE--IN9W>L22JTT4*2J;+O_
M_9RBA*5*&^R^H*5\ZN6<]QS@N/SV5A;6*V:<T&IE>Q/7MG"5T9Q4QY7]ZV?R
M=6Y;7*`J1P6M\,I^Q]S^MO[CR_)"V0L_82PL4*CXRCX)44>.P[,3+A&?T!I7
M\,V!LA().&5'A]<,H[S95!:.[[JA4R)2V4HA8H]HT,.!9#BFV;G$E5`B#!=(
M0/S\1&K>JI79(W(E8B_G^FM&RQHD]J0@XKT1M:TRB[X?*\K0OH"\W[P`9:UV
M<W(C7Y*,44X/8@)RC@KT-N>%LW!`:;W,"60@;;<8/JSL9R]*Y[:S7C;^_$OP
MA?<^6_Q$+RDC^0]283`;RB0+L*?T1:+?<[D$FYV;W4E3@+^9E>,#.A?B'WKY
M$Y/C24"U9Y"0S"O*WV/,,S`49";^3"IEM(``X&B51'8&&(+>FO\7DHO3RIZ&
MD]F3._4`M_:8BX1(2=O*SES0\C\%>5<I)>)?1:80_?5[?^+/9]XL_(1*<%5Y
MZE0>#\51:34NQ4B@]9+1BP6=!X'S&LD^]B(0;NU1R72&?>07&"5%GJ7*RH;]
M8`6'&K^N@]EBZ;Q"8;(KL[EE/)W8MH2L@I2-U0(<.]GI?*YOVK5,NRDQ%]+>
M@@-9=ZE#5?JIW^^(-D,)RPS;RVS:A?]C\_7(MK=$:&0<*Z2?8.`:S.Z6,2Z4
MW"%F>BSI+1+T@M%L@2;MVR([8@JWW;`]<I-FC[FP-1=BM:#E'KIZV+L'F.0!
M)AUFM/3A+OM\^G(3V-1KU"`TJK11#!R[9C:*M!TEXE%B-THDHT0Z1&A>P1.P
M[]5PBTAX94,C=OD'X52O]T8Q</V.,3T:)>)18G=+3(UB)0J9-X\R;_8T]XTX
MT@%`LRC4+7KL;I*;3*L"PRK%#%DU2L2*"*]9+A9&DKM1A6242(<(S2EX>_2;
MZ3&GY";3*2.+C6*&G!HEXE%BIX@/O4Q&%=(A0G-*CJ:]=_;P;2=AW:&%\93=
M*.3C9M]J0.#"G]Z,L0(&+-Z-$LDH`6.B3.7^591!:@Q4`TZ)V1%O<5%P*Z-G
M.>(%T.C=:C=]/D_E2]U8WW@1C"-WUOUH<X_?^A&\X8!W.B&8(FMTQ'\A=B05
MMPI\@!#<R1,\.9B:0]6)H'4SANVI@/FQ^7B"GPL8!B!W`O"!4M&>R`MT/T#6
MOP$``/__`P!02P,$%``&``@````A`/5-M!+/`@``U@<``!D```!X;"]W;W)K
M<VAE971S+W-H965T,C<N>&ULE)5=;YLP%(;O)^T_6+XOGR%)44C5A'2KM$G3
MM(]K!PQ8!8QLIVG__8YQH`&V)KM)@O/ZX7W/,8?5W4M5HF<J).-UA%W+P8C6
M"4]9G4?XYX^'FR5&4I$Z)26O:81?J<1WZX\?5D<NGF1!J4)`J&6$"Z6:T+9E
M4M"*2(LWM(9_,BXJHN!2Y+9L!"5INZDJ;<]QYG9%6(T-(137,'B6L83&/#E4
MM%8&(FA)%/B7!6MD1ZN2:W`5$4^'YB;A50.(/2N9>FVA&%5)^)C77)!]";E?
MW!E).G9[,<%7+!%<\DQ9@+.-T6GF6_O6!M)ZE3)(H,N.!,TB?.^&NP#;ZU5;
MGU^,'N79;R0+?OPD6/J%U12*#6W2#=AS_J2ECZE>@LWV9/=#VX!O`J4T(X=2
M?>?'SY3EA8)N!Q!(YPK3UYC*!`H*&,MK;22\!`/PB2JF3P84A+RTWT>6JB+"
M_MP*%H[O@ASMJ50/3",Q2@Y2\>JW$;G:5`_Q3A#8<8*XGN4M`S>87Z;8QE$;
M,":*K%>"'Q$<&KBG;(@^@FX(Y"Z9\=%G_5=4L*<A]YH2X05&D$)">Y[7LV"Q
MLI^AILE)LYEJYLY0LNTD.K;FQMW"&]<=;MEU"MT^B-3G@FJ=Y_I[ISK[6JSM
M=_?=F`5@]WF\X7VW4\5\9"V>2D:0W51Q!AG$\?\GCA;#$3MS/PN60_\;HYF=
M:8*A8GM1$5]4[-Y3#/*!D>O;I<41AN+UW9F/#YN1+-NCZ,Y\;SX*9_Z'SQ[A
MCYH3GR,\?['TAXC=NXA!.'BNK@^GQ:-PX]X9R7OFMY<E\64)C%3MQ51QYGIO
M%3+QS+PTXZ2B(J=;6I82)?R@9Z$/Q>]7^S%][^FG;+2^<4-X]J?K,8SU=MWN
M-\!8;4A.OQ*1LUJBDF9P*\=:@%5A!K.Y4+QIA]N>*QBH[<\"WI\4IHIC@3CC
M7'47>G;T;^3U'P```/__`P!02P,$%``&``@````A`(,2QQ4N`P``(@H``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,C8N>&ULE)9;;YLP&(;O)^T_(.[+&9*@
MD*J!=*NT2=.TP[4#)E@%C&RG:?_]/N.$!))1>L/!?GCYWM?&9GG_6I7:"V:<
MT#K2;</2-5RG-"/U+M)__WJ\F^L:%ZC.4$EK'.EOF.OWJ\^?E@?*GGF!L=!`
MH>:17@C1A*;)TP)7B!NTP37TY)152,`MVYF\81AE[4-5:3J6%9@5(K6N%$(V
M18/F.4EQ0M-]A6NA1!@ND8#Z>4$:?E*KTBER%6+/^^8NI54#$EM2$O'6BNI:
ME89/NYHRM"W!]ZOMH?2DW=Y<R5<D99337!@@9ZI"KSTOS(4)2JME1L"!C%UC
M.(_T!SO<S'1SM6SS^4/P@5]<:[R@AR^,9-](C2%L&"8Y`%M*GR7ZE,DF>-B\
M>OJQ'8`?3,MPCO:E^$D/7S'9%0)&VP=#TE>8O268IQ`HR!B.+Y526D(!<-0J
M(F<&!()>V_.!9**(=#<P_)GEVH!K6\S%(Y&2NI;NN:#57P791RDEXAQ%7*C^
MV.\8SMRW_>`#*MY1!<XGE84Q]WTOF,^FUP)D:PC.9Y6)ADP53IMU@@1:+1D]
M:#!_P3YOD/P:[!"$3R&K2+K8_Y<ZQ"U%'J1*I,]T#0+E,%->5IYO+\T7&-[T
MR*RO&:=/Q#<(OX\D"H%C]Z*!R&:,,,%TYQR&]M+Y[6EU,BAA:5!.,^EX/6R(
MAPV):K@LU?.'Q=YBW,YRKUR8@=/+E3#,]XN87.^LJQPH!J9D%^4@[/A=(GF7
MV(P1/7]0R'1_$HYT2*^KW?.]+C?E3S%C_MXEDFO"<X=C>(/QSTGV/,('-MVC
MA/L>[=E95WE4S+S]XNP@<(<AQ#W`]^96/Z1$]8^$M!DC>N:"CYB3\-#<K%_;
M6C%!:^[.\:]F<-P#8$4>FE/]8^;&B)XY6-JFCYR$^^8\/QB84\QQY#S;L@?+
M9=P#W(4S-*?ZQ\R-$<J<VGO5?E!AML,Q+DNNI70O]U47DN]:NRW_P9&+X*!]
M;8>P(EZWQW8("R.TF]T#L$4W:(>_([8C-==*G,.K+$/N@TQM\NI&T*;=G;94
MP.;<7A;P+X9A\;4,@'-*Q>E&OJ#[NUO]`P``__\#`%!+`P04``8`"````"$`
MNW7010<1``"ZB```&0```'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6RDW=M2
MXT@2@.'[C=AW(+A?0+(-1M'TAHW/Y_/IC@;330S@#ML]/?/VFV5)X,K2Z!?L
M7`QTZ5-:EI3ILE0JOOSWKY?GDS_7V]W3YO7FU#N[.#U9O]YO'IY>O]^<3B>U
M_Q1/3W;[N]>'N^?-Z_KF]._U[O2_7__]KR^_-]L_=C_6Z_V)1'C=W9S^V.]_
M!N?GN_L?ZY>[W=GFY_I5ECQNMB]W>_GG]OOY[N=V??=P6.GE^=R_N+@\?[E[
M>CT-(P3;+#$VCX]/]^O*YO[7R_IU'P;9KI_O]K+]NQ]//W=QM)?[+.%>[K9_
M_/KYG_O-RT\)\>WI^6G_]R'HZ<G+?=#\_KK9WGU[EO?]EY>_NX]C'_[AA']Y
MNM]N=IO'_9F$.P\WU'W/U^?7YQ+IZY>')WD'9K>?;->/-Z<E+RB5<_[I^=<O
MASTT>UK_WAW]?K+[L?E=WSX]=)Y>U[*[Y4"90_!ML_G#T.:#:9*5SYVU:X=#
M,-B>/*P?[WX][T>;WXWUT_<?>SG>!7E+YIT%#W]7UKM[V:42YLPOF$CWFV?9
M`/G_R<N3.3=DE]S]=?CY^^EA_^/F-'=Y5KBZR'G"3[ZM=_O:DPEY>G+_:[??
MO,Q#Y$6APB!^%$1^1D&\PEG>+UP5/Q(E%T61GY_?E'P41'[^'YLB;_VP5^1G
M',4_\XL%KW#Y@=UR&461GW$4[^.[Y2J*<OT6Y1-'R),3*SS.Y@P+CZ$OVY7Q
M`'MOIXG\$JW^F:V(3Q3O_1C[^3,O?_&1W>K%Q]C\\HGW$A]<DR;Q<2E^>"/B
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MU3G=<4W^0NWCKFO4*_5<X43I9S`#USC[>.B:_(4Z#B/7J"T>N^)2O>V)2U20
MJ2MTD)E+5)!Y@E"GS,(E^0MURBR3C#IE5DE&G1"E4@+RU#:7HM0\/M'?B54"
MI)_W@1)@M%4"=,.M;JCHAJINJ.F&>MAPO/&Y:_4YWLA@FAE,*X-INR9_H>I[
M)\F\[_)#+>QF,+T,IN^:7$%MS\`U^0M54X<9S"C)J--_G,%,,IAI!C/+8.89
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M.8H%BB6*%8I2*227AW27<0`)^9X6Q,IW,S[A^)9->G_>:)WOZBM0.31I^8ZB
M@J**HH:BCJ*!HHFBA:*-HH.BBZ*'HH]B@&*(8H1BC&*"8HIBAF*.8H%BB6*%
MHE0*293OB9_O:4&L?)>;WU:^FTM..;FEG9[W9BV=]^K">#DT:7F/HH*BBJ*&
MHHZB@:*)HH6BC:*#HHNBAZ*/8H!BB&*$8HQB@F**8H9BCF*!8HEB%8HPJ8M>
MP7,Z[26,44I-.BOOS;@D*_'3$_[`=<:KVUSE"*6E/),*DRJ3&I,ZDP:3)I,6
MDS:3#I,NDQZ3/I,!DR&3442BS[%+I]LZ?HMAQORH[[`3:VWO^LK3%]^GEO"]
MXJ6^7SVSQ571U^,<YI8H>EY1?9U=1"#EI%\R63&1,2(F96].P]V5^*EO":]X
M?;Q'[>R7F[`?R7[#=?:K&]AE,U114,J.N&5285)E4F-29])@TF32BDAXV.0&
M\_%!.=P_;G.0#I,NDQZ3/I,!DR&3$9,QDPF3*9,9DSF3!9,EDQ43J028:C)8
M+,W8Q<",/#G^SI_M.X`7#EBQKNW[JDB7(Y1:%,(X*:3"4:I,:DSJ3!I,FDQ:
M$0F+PF7Q^DI=-6ESC`Z3+I,>DSZ3`9,ADQ&3,9,)DRF3&9,YDP63)9,5$ZD)
MF$92$]*,71/,J)7CF@!?#\)!+G8M4&,/RN;9`^H@(*EPE&I$PML?JIM2X_7K
M3!I,FDQ:$4G<T#:OWV'29=)CTF<R8#)D,F(R9C)A,F4R8S)GLF"R9+)B(A4`
MDT<J0)JQ*X!\(%L5(&.OP*RFOBKX:L!DV3P_1)4`286C5)G4F-29-)@TF;28
MM)ETF'29])CTF0R8#)F,F(R93)A,F<R8S)DLF"PC$G81<^Z5AQ7'D)J`:20U
M(<W8-<$,)/I`KR`<=V3W"O1P/_,P(-4")!6.4F528U)GTF#29-)BTF;28=)E
MTF/29S)@,F0R8C)F,F$R93)C,F>RB$B8Z%?7E[Y*D27'6#&16H!I)+4@S=BU
MP(PQ^D`M"(<DY:36O`\%]/500"]2TDMY4^J"ZVT&4\E@JAE,+8.I9S"-)"./
MZ=NCLIJ1.MY%BK22`BG3SF`Z&4PW@^EE,/T,9I#!##.8408SSF`F&<PT@YEE
M,/,,9I'!+#.8508CA8*S4"I%*K)+A1E]=%PJS%<)KX"C#,SC^-(UD)H1/]E1
MCIMR;TVW;E/%;:JZ336WJ>XV-=RF9M1TG*=Y7UW`:[GKM=VFCMO4=9MZ;E/?
M;1JX34.W:>0VC=VFB=LT=9MF;M/<;5JX34NW:>4VR8D8G0#O1UO.N^,V^S0S
M@UX^<YJ%@V7L;JH>S6*FBZ!N*I(*1ZDRJ3&I,VDDD+RO;NDW$Y&ZI-9*0,YG
M$NZ;#D?I,NDQZ3,9,!DR&3$9,YDPF3*9,9DS63!9,EDQD=3'$T9*09JQ2X,9
M.J-+`P]S\\(1-U9ER#FWN'!8SFT4Y_@#0R5(A4F528U)G4F#23.!Y'/J@G\K
M$:EK@>T$I/9-ATF728])G\F`R9#)B,F8R83)E,F,R9S)@LF2R8J)5`;,-ZD,
M:<:J#&;Z)JLRI-_H.G!U>3NGOJ^7(Y22[K=,*DRJ3&I,ZDP:3)H1N?0.3R%<
MG%VH+&YQC#:3#I,NDQZ3/I,!DR&3$9,QDPF3*9,9DSF3!9,EDQ43F3,E'!*7
MDFDR94J:L6N!&3+S\5Z"'XZTL7L)^LI6A%*V])9)A4F528U)G4DC(N%E2]^,
M1U27LPBT^$7:3#I,NDQZ3/I,!DR&3$9,QDPF3*9,9DSF3!9,EDQ63*0BI`U[
M.PRWE(J09NR*($F=4!'PRI5OUM/=!/6!6(Y0:DD(XZ20"D>I,JDQJ3-I,&DF
MD'Q.7SM+0&KGM9ETF'29])CTF0R8#)F,F(R93)A,F<R8S)DLF"R9K)A(8<!4
MDL*09NS"8,;1?**K$`Z_D9=YN[V5S^E+C7[:&)UH]D4D%8Y295)C4F?28-*,
M2-B;D,FKO0M/I7R+H[29=)ATF?28])D,F`R9C)B,F4R83)G,F,R9+)@LF:R8
M2%7`1)*JD&;LJB`?U$Y5\"[DGCI<53#KZ>Z"NA1?]D.4TA>X95)A4F528U)G
MTF#29-)BTF;28=)ETF/29S)@,F0R8C)F,DD@^9RZ`31-0*IXSYC,F2R8+)FL
MF$AAP&R3PI!F[,)@AM4<=Q>@'H2C<*QN0EY]O2Z;*=^E:(2?F)=>(:<*QFT$
M4@I&Y8V8!RSE*[S]#;[ZMOB]NZ*.:XU)G4F#29-)BTD[(N%.*Q3DGH5ZSQTE
MO*(674MXU\5\08]CZO&6])D,[!<J^E>>'AHVM,GEE?MTX8A?:,QDPF3*9,9D
MSF3!9,EDQ42J0)AC*2DD52#-V%7`#)GY0!4(1]C854#=8RO[(4K9PELF%295
M)C4F=28-)DTF+29M)ATF728])OV(1%]_<E?7!76?=,!!ADQ&3,9,)DRF3&9,
MYDP63)9,5DRD&&"J23%(,W8QT(/BH$L0#GNRBX$Z1\I^B%*+`9(*1ZDRJ47D
M^G`[\.I,]1OJ'*'!I,FDQ:0=D?`Q/'4MLI.VL,O!>TSZUDNHOO6`UQ]&Y!]V
M]8@CC)E,F$R9S)C,F2R8+)FLF$C.8[I(SJ<9.^?-@*7C#D"V9^K,GT[2EP?R
MSJ"#M,%0T55#))7HI5(J2)5)C4F=28-)DTF+29M)ATF722\BB86FS^L/F`R9
MC)B,F4R83)G,F,R9+)@LF:R82#W`%))ZD&;L>F"&*7VB'H2CF^R^@#/@(&T(
M5%0/D%1\)%4F-2;UB(0=X)Q\+9?9FNRK$0V.TF328M)6V^(7G&WI<)0NDQZ3
M/I,!DR&3$9,QDPF3*9,9DSF3!9,EDQ43J0J8)5(5THQ5%<RX9*LJI'\S.'!U
M\R"ONMOE"*5\KM\RJ3"I,JDQJ3-I,&DR:3%I,^DPZ3+I,>DS&43D[4J"N2*H
M*NG0,L6KRRO]9Z9&_$)C)A,F4R8S)G,F"R9+)BLF\E>AT@8<1D.04HU=#?2@
M1*@&"8,1\^H[;3F7-@`J[!LPJ3"I,JDQJ4<DZC9?YBZO]#QC#8[29-)BTF;2
M8=)ETF/29S*(2+CK/-_,L>E6@_!LB(R7+\CP"U4Q1OQ28R83)E,F,R9S)@LF
M2R8K)E(/,-M*Z1EIUP/I]EN]@\/#M#FY"0&%P:RGNPEZZ%$N1*G=!)?D\^K6
M8X7C5)G4F-032#ZO+J$U$I#J'S69M)BT$TA>IU(G`:FMZ3+I,>DS&3`9,ADQ
M&3.9,)DRF3&9,UDP63)9,9'BX*:3.AND.*29L#B<'_WQ]9?U]OOZ=OW\O#NY
MW_QZE9&&N2NY"O_6?+)=/]Z<RE0`@7GH6AZM5TO,!`#!X>'KA&7RW']P>`C;
M72:3)@3FP7%WB4R5$)CGQ]TE,D%"8!XC=Y?(M`B!>9K<72*3(03FH7)WB4R!
M$)AGR]TE,E%%8!ZC=Y?(]!2!>9K>72*34@3FH7IWB4Q%$9AGZ]TE,@%%8!ZQ
M=Y?(M!.!>=+>72(SB`1FY@%WB<P;$I@)"-PE,A%(8*88<)?(]!^!F6G`72*3
M?@1FP@%WB4SU$9AY!]PEAU,A<8DY$<S#^.XZ,D-+8&9E<)?(O"R!F9S!72*S
ML01FC@9WB<S!$IBI&MPE)2\H'::&4.=OW9.=EN#;GKS]A/:1)P<FH7WBR:F9
MT%[V@W+2Z][Z@?RE57<[*WX@?W#5;:_Z@?S=5;>]Y@?RYU>E_?SMC>V^?OEY
M]WW=O=M^?WK=G3RO'R6K+\ZNY%-_^_3=]`#"?^PW/V5FC=.3;YO]?O-R^/7'
M^NYA+7^O]>),\.-FLX__85[@]V;[QZ%R?/V?`````/__`P!02P,$%``&``@`
M```A`$/T4ZEQ`P``,0T``!D```!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
ME%?;;J,P$'U?:?\!^;T!$G(A"JG:K;I;:5=:K?;R[("36`6,;*=I_W[''D(A
M28.3!Q+@^,R<XV&8+&Y?B]Q[85)Q428D'`3$8V4J,EYN$O+G]^/-C'A*TS*C
MN2A90MZ8(K?+SY\6>R&?U98Q[0%#J1*RU;J:^[Y*MZR@:B`J5L*=M9`%U7`J
M-[ZJ)*.9753D_C`()GY!>4F082Y=.,1ZS5/V(-)=P4J-))+E5$/^:LLK=6`K
M4A>Z@LKG7763BJ("BA7/N7ZSI,0KTOG3IA22KG+0_1I&-#UPVY,3^H*G4BBQ
MU@.@\S'14\VQ'_O`M%QD'!08VSW)U@FY"^?WPX#XRX4UZ"]G>]7Z[:FMV'^5
M//O.2P9NPSZ9'5@)\6R@3YFY!(O]D]6/=@=^2B]C:[K+]2^Q_\;X9JMAN\>@
MR`B;9V\/3*7@*-`,AF/#E(H<$H"C5W!3&N`(?;7?>Y[I;4)&D\%X&HQ"@'LK
MIO0C-Y3$2W=*B^(?@L*:"DF&-0E\UR3A>!`-Q].9`XN/&5F!#U33Y4**O0=5
M`S%514T-AG-@-LI&X`_FT6C]2"IH-"1WAB4A4^+!<@7[\[*,XG#AOX"G:8VY
M1PP<&\P[PH=LFI0@C79*YTT^1#9@$]F8;E*YQPOM,,,FD4Z843?,0?GE<&91
M0B!&(R**W_DQ`\1$+<SX?`8`<1=JP+`W+=91-&MX,3)B'")#U;E'-N"NYM$L
M.HJ,F)G=^NDX@$\#Z)@^Z09V,]TLZB80Q:.&'Z4CQD$Z%*F[=`/N,QTQ#I'-
MVZ#UJ%TN-`/N:CXU'3&37M/C;F`WT\VB;@)1?+SKB'&0'D)+<==NT7VVUR"7
MX*;S.!L?8I]J/^*GSM<@M#ZT]?Y!P8>F'[6"NYEO5QV[_]Y%L.1KD(L#1[WN
M<NF%V,`NMYH:Y!(<,&T'>H(;=%?Y&?L15-M_J=^8M_05P4];711/CCJ-I4R(
MB_*C;M>C'%M8C^W.?2Z\JM%9=*_MV.I<JOZJ7A>>-KLHGA[;CB`7VX_Z78_M
MV,1Z;'?N=#"&7E%P%MUG>PW"E^OY9H.3*PYV!9,;]H7EN?)2L3-3:0AOB.9J
M,S'?#>W,V]R`@;6B&_:#R@TOE9>S-2P-!E-X)B2.O'BB167'QI70,*K:GUOX
M:\)@^`H&`%X+H0\G9JAN_NPL_P,``/__`P!02P,$%``&``@````A`*V\O+27
M%```0K0``!D```!X;"]W;W)K<VAE971S+W-H965T,S,N>&ULG-U;<]K(UL;Q
M^[?J_0XNWV_;2.!3Q=G5G,_G\QWCD,0UMDD!F<Q\^[V$)*"7-/JW,Q<S2<^/
MA9#T++>%&C[]]^^WUXN_UMO=R^;]Z3)W=7-YL7Y_WGQY>?_V=#D95_]S?WFQ
MVZ_>OZQ>-^_KI\M_UKO+_W[^___[]&NS_7/W?;W>7TB%]]W3Y??]_L?C]?7N
M^?OZ;;6[VOQ8O\O_^;K9OJWV\M?MM^O=C^UZ]>7PH+?7:^_FYO;Z;?7R?AE6
M>-RZU-A\_?KRO"YOGG^^K=_W89'M^G6UE^W??7_YL8NKO3V[E'M;;?_\^>,_
MSYNW'U+BCY?7E_T_AZ*7%V_/CXUO[YOMZH]7>=U_Y_*KY[CVX2^)\F\OS]O-
M;O-U?R7EKL,-3;[FA^N':ZGT^=.7%WD%P6Z_V*Z_/EV:W*/I^-[E]>=/ASTT
M?5G_VIW]^6+W??.KMGWYTGYY7\ONE@,5'((_-IL_`]KX$@S)@Z\3CZX>#D%_
M>_%E_77U\W4_W/RJKU^^?=_+\2[(2PI>V>.7?\KKW;/L4BESY16"2L^;5]D`
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M^"'5<"`,:%"CI@?J\<"IJ']_9Y=M)(UZXF92Z)?3"LGY7E%%VK&(M[ZC![IZ
MH*<'^GI@H`>&X8#\^WAT$B]X%#_HW*@C.(Y-O+43/3`-!^3?QV=2KWB6%/Z#
M.@WF*48?H$5H,O;M,A;QUIKH+#V=&B8Z)\]&HE/P;.1X#A[K),XY<SSI3J_;
MOU=[SQQ/Q!-2.\<<3\WC<Z6<B,G*QW/Q^+#HU)-=\&\'PD3GWMDKC4Z^P\BU
M](=CDY"?;U:32/_A&O>"0`>](-Z88CQPVA;/3ELI*6[5KBDGB2I220I=I)HD
M^8<'>UMJ2>,5;%(/R?G.+=RH<[B1-&I[FRA:*-HH.BBZ*'HH^B@&*(:AN/7#
M'Q^Y?$[MTE&R1$&;<9I1I](DS:B#,TT:)69)D;]1/T7F25/(^?;)M$@:]4S+
MI-`GMC%)HZJ8*(;G9ZT^L4T4Q'-3R-W:&VRB*-I(O2H3I3$;17FTD=J')@KD
M.=(O+2V0GCI[3$HB"YXZ-0R'TG`J35HL50\Q*<$L>/GCKK;ZKTQ@K?X;3-)\
MF5MG]^'@458?U@,E/5#6`Q4]4-4#-3U0#P?.#U?A1NWFAH-IIAEUX%MI1IV)
M;0?3<3#=-*,.:L_!]-.,BMC`P0S3C/I9-G(P8P<S<3!3!S-S,/,4DSOEXO!K
MP<+!+!V,,2ZHZ(*B+%FGO=YL$^4K&T69RT91#FV4F'"F;;A&:7G-:9066$^%
MT:0E-H'2(NNIR)JTS"906FC/D-5`Y3?WWVB@P:.L!JH'2GJ@K`<J>J"J!VIZ
MH!X.G.;E#3W0U`.M>.`TPR[<J,RTDR;_H'[6=M*,.LS=-*/J]-*,JM-/FH*>
M/PW2C#HWA[&)?]T8Z8&Q'ICH@:D>F.F!>3QPMH=SJOLO',S2P1B31/D;]2/"
M%%U0=(*>MXEDI>BDM5!!'2T3G<@VTKF-3FX+)38\.N&ST3$$I_V=W/!C,++0
M,2Q9*"5`R:=+2U#BU:5%Z`Q974FNVOU&5PH>974E/5#2`V4]4-$#53U0TP/U
M<."L*^F!IAYHZ8&V'NCH@6X\<#I8B4;6BTT<^+X>&.B!H1X8Z8&Q'ICH@:D>
MF.F!N1Y8Z(&E'C`F,5),C$3'\[3K371`SR,D[S4<?W<(+\E&!SD;10?>1FH6
M::*3X6P#$F>#:20V.W$^F,0)81)GA#D_):RPR%7SWPA+\"CY7>GL,EA!_]);
M#(VTT^.E,K4K2RC**"HHJBAJ*.HH&BB:*%HHVB@Z*+HH>BCZ*`8HABA&*,8H
M)BBF*&8HYB@6*)8HC&'"J3,<.\.Y,QP\P\DS'#W#V3,</L/I,QP_P_DSF0&T
M.J^\QV)UWNRK3H%^NI3+D:=NZJFY:S$T61T711E%!44510U%'44#11-%"T4;
M10=%-Q3WAPOPN9OP'WM6T<,B?10#%$,4(Q1C%!,44Q0S%',4"Q1+%,8PX=B9
M$E?AX!E.GN'H&<Z>X?`93I_A^!G.G^$`FLP$6BTWN#WM_*Z,[)8;:-URU169
M8FBR6BZ*,HH*BBJ*&HHZB@:*)HI6*&X/S=!/ZX5MK-%!T4710]%',4`Q1#%"
M,48Q03%%,4,Q1[%`L41A#!-.G2EQ%<Z=X>`93I[AZ!G.GN'P&4Z?B>*7T;`,
MY\]D!M#JN'+KVP<Z;J#MCNO?J^OMQ=!DO(`2BC**"HHJBAJ*.HH&BB:*5BC"
MCGMW)[?4Z)MJVN<B=P#J7?[.N4@KT<7-Z%&)/I88H!BB&*$8HYB@F**8H9B'
M(CQNT:\-]F\-"ZRQ1&$,$\Z<X=`93IWAV!G.G>'@&4Z>X>@9SIZ)PI?1KDR4
MOBP2Q2^=6/TVN$?<:KB'&X]OY"IR]ESW\#B[]18\]99@,4+IFW&X.EYB4F92
M85)E4F-29])@TF322B.>>D.@G8;LQ'>8=)GTF/29#)@,F8R8C)E,F$R9S)C,
MF2S2B*]^H"[3D'VLY;[J(,Q/EQEYDSNMV3B$TCBDTCC$4N[8YNUQ"*;<L<UU
M'*)I'+)I4L.ICH5#-DUV..TV+>\,6FT:NG/`57?VU<U_Q6!]3_;94F)29E)A
M4F528U)GTF#29-**R&WN<%7BYBJG;M-H<XT.DRZ3'I,^DP&3(9,1DS&3"9,I
MDQF3>42.!_%&'<0%UU@RD:Z,.9.NS,8AC-*5N8Y#'*4K<QV'0$I7YCH.D92N
MS'7B4&;]]'/(I73EK.>RNW)PM[_[]>%<N#C`>D_.5R==,4(9KZ+$I,RDPJ3*
MI,:DSJ3!I,FDE49\=6]<.PW9/[L[3+I,>DSZ3`9,ADQ&3,9,)DRF3&9,YDP6
M3)9,I#>'D<Q(F_1F-@Z1E-[,=1Q"*;V9ZSC$4GHSUW$(IO1FKI,:33MUL@Z2
MZV1'T^[-P4WWY[W9;;%.+KQ77S;E=-^$KR\I1RCCK"DQ*3.I,*DRJ3&I,VDP
M:3)I,6DSZ3#I,NDQZ4?D_-U'^[0=6")_>'_2%D-^FA&3,9,)DRF3&9,YDP63
M)1/ISV$<,Y(F_9F-0QRE/W,=AT!*?^8Z#I&4_LQU'$(I_9GK.,12^C/7R0ZF
MW9_EF/Y.?PX>IJ]LJ/N$B[D099PU)29E)A4F528U)O6(1'THO`W";C,-BWAI
MI,E/U&+29M)ATF728])G,F`RC$BX=SWYZ*C$.YXC)F,F$]Z6J54EE[8M,ZXR
M9[)@LF0B'1JS)AV:C4,@I4-S'8=(2H?F.@ZAE`[-=>)8BCQ-*.WD2H?F.@[!
ME`[-=;*C:7?H8"G);\R@PQ4H]@Q:WWD<?#0877M&4N8J%295)C4F=28-)DTF
M+29M)ATF728])GTF`R9#)B,F8R83)M.('*\;RX>8V8&><9$YDP63)1-IT)@C
M:=!L2@[&(9#RIB`_ET,DY5.<N(Y#*(U#*J5!\W,YY%(:--?)3J;=H(/E/><-
M&MX4#%<#V8U9WY^<PR5#)29E)A4F528U)G4F#29-)BTF;28=)ETF/29])@,F
M0R8C)N.(1+>N/:1,P"<6\>2SZO1-B5-^GAD6F7.1!9,E$^G+F#3IRVP<XB@3
M9Z[C$$B9.',=ATC*Q)GK.(12^C+7<8BE]&6NDQU,NR\'JW?.^[+CI>=PT8_=
MGQ.WU.'*H%(.29E)A4F528U)G4F#29-)BTF;28=)ETF/29_)@,F0R8C)F,F$
MR93)C,F<R8+)DHET:`R2=&@V#H&4#AW6B2Y!^6GWU,O4^1SE_+2+0]*C>8L<
M8BD]FNLX!%-Z--=QB*;T:*Z3'4Z[1P?K?72/SLOT'.;0X3(ANT>KVW*+P2=>
MT\4-)&6N4F%295)C4F?28-)DTF+29M)ATF728])G,F`R9#)B,F8R83)E,F,R
MCT@TGT]90;3@(DLFTJ(Q1]*BV90<C$,@I4/S<SE$4BYN<!V'4,K%#:[C$$NY
MXYGK.`13[JW+JF,WZ&"9D6[0_&&KN7!UDM6@\^I>^F*$,J[)EYB4F5285)G4
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MG\F`R9#)B,F8R83)E,F,R9S)@LF2B33G,$C1!93;Q)N=\BTR&#7Y%IGS*G[.
MOU6W8<E7R'`5ASB:.(_A]J9>O';(HS1G:X/S_KU:O26MV1+WB:\TD6^.2;XD
MO<A..G,2J9MXY,MCV,21#%^WG[N[.\UH[;XLK=7JRS!9#K@]6<Z??:?"H9,6
MO1!E]F,D9:Y285)E4F-29])@TF328M)FTF'29=)CTF<R8#)D,F(R9C)A,F4R
M8S)GLF"R9"+]&(,D'3DT4<]^N,NK]X6D'W,5ASS*5)GKQ(F,.I/_D->]WR&0
MTI#YF>)(AL_D>?=Y=4^9M&2NXA!)Z<A<)PYE=!2LGYQV1PY6LYS/E*$CAXM?
M9`-.MW'G]=KMX!MNX8T_)F4F%295)C4F=28-)DTF+29M)ATF728])GTF`R9#
M)B,F8R83)E,F,R9S)@LF2R;2D3%KTI'9E!R,0R*E)_-SQ9DL1-^L>>OKGQ`.
MD92>S,_D$$KIRES'(9;2E;E.=C#MOBSSV8_TY8#;,^5"7OW64/1"E#E31E+F
M*A4F528U)O6(A#_EY-OM[_1W-S>X2)-)BTF;28=)ETF/29_)@,F0R8C)F,F$
MR93)C,F<R8+)DHFT9<R1M&4V)0?C$$AIR_Q<<22C*6->+E_8ZWGDJV^Y2AQ)
MD:<9HJKC$$IIR_Q<#K&4MLQULH-IM^5@Y<H'ILOA0A=[NJP_1L/#U3`E)F4F
M%295)C4F=28-)DTF+29M)ATF728])GTF`R9#)B,F8R83)E,F,R9S)@LF2R;2
MES%KTI?9.`12+BIS'8=(RD5EKN,02IDP<YTXEM%%C!N]I%/:,A=Q2*6T9:Z3
MG4N[+0<+5S[0EL-U+G9;5A>^BQXNABDQ*3.I,*DRJ3&I,VDP:3)I,6DSZ3#I
M,NDQZ3,9,!DR&3$9,YDPF3*9,9DS63!9,I&VC%F3MLS&(9#2EKF.0R2E+7,=
MAU!*6^8ZIU@&-WPD)^8.F93W^OAY'%(I=V%DU;&[<K!4Y0-=.5S98G=E=;F^
MZ.'REQ*3,I,*DRJ3&I,ZDP:3)I,6DS:3#I,NDQZ3/I,!DR&3$9,QDPF3*9,9
MDSF3!9,E$^G*F#7IRFP<`BE=F>LX1%*Z,M=Q"*5T9:[C$$N9+W,=AV#*?#FL
MD_9^7GC77W8P[;X<K#[Y0%\.%ZO8?5F]N5GTLE:T'+:PQ*3,I,*DRJ3&I,ZD
MP:3)I,6DS:3#I,NDQZ3/9,!DR&3$9,QDPF3*9,9DSF3!9,E$^C)F3?HR&X=`
M2E_F.@Z1E+[,=1Q"*7V9ZSC$4OHRUXF#^>\]UR&7,E_.>B:[+P<+4S[0E\-U
M+'9?UA^4X84H?`W^W9TO=Q/:E^-+%KF[N_?T?8)E2\C_OY4J=I&*13S_+EB5
M;Y-J1#+>&:@QJ3-I,&DR:3%I,^DPZ3+I,>DS&3`9,ADQ&3.9,)DRF3&9,UE$
M),IYRJ<N+2UQ^!Y'^]R6GLR+RHH.)@YC1DBD)_-SQ7G,JN,02'G+[[Q_A-^F
MJ%ZZ0R+E?F7>9(=,RD4,:W.LV]K":;!#)J4E9VV-U9*#E=8?:,D'KF_#4'>W
M%".4<6A*3,I,*DRJ$0E/_?N44[_&1>I,&DR:UJ;D[GW_X703^>'8MKA(FTF'
M29=)CTF?R8#)D,F(R9C)A,F4R8S)G,F"R9*),0[&(8W&(8[&(8_&(9`F3F1&
M=S`.F30.H30.J31Q++.VQR&8QB&9)CN:=E\.%J6X3Y7]<`V+-54NJ/EI,4+1
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ML=GO-V^'/WY?K[ZLMP$0_'6SV<=_D0-P_6NS_?-P!#__3P````#__P,`4$L#
M!!0`!@`(````(0!)"?,?H04``-T8```9````>&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;)Q9VV[K-A!\+]!_$/0>W2CJ8M@^2!JD/4`+%$4OSXI,VT(LR9"4
MR_G[+KFT:%)63.<EB>WASNQR.5HSRV\?]<%Y8UU?M<W*#;W`=5A3MINJV:W<
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MB_W)ZB>Q`W]VSH9MB]?#\%?[_ANK=OL!MIM"1CRQQ>;'(^M+J"B$\2+*(Y7M
M`03`3Z>N>&M`18H/\?N]V@S[E4L2CZ8!"0'N/+-^>*IX2-<I7_NAK?]#4"A#
M89!(!H'?,D@4>W%$T\PBBH^*1(*/Q5"LEUW[[D#7`&=_+'@/A@N(?#DC2(5C
M[SEXY::N`V)[V(:W-:7ATG^#TI42\X`8^#EB%,('TI$9V.R9.9@S\]IR*0_X
MQCE--`K1:,@M-!R\<B'V*)[08(R+S(B)SS!T1&C,`+%/D(.A+<ZC4I41,B/&
M@AF:RIZ9@_6<*25C1LB,F$1L>9ZD),I55;2<DUN8.5AGCC(S9\0@<QPD>92-
MTC1B:$K[E#G8)#931@P2WT5AF)(@ODS-7=[Z"'&P09V;U(@Y4>=ADEXFSF\A
MYF"=F%*5$&XS8I`XS0E)XQGF$"S4/F>!-KG5H4%N"9+DZ6?DW&+."L[=F("@
M*]Z%QG1^MBE-QL)*$0C*1:/#`UU]KC5;R-WG=@7H6;H"56"I`$&H(/.R&?,,
M#5NSK,'4WRA5!THJ0!`J"+Q\K@:&O5DJ0`_3:Y";NX`@5)!XJD3Z)A@N9RG@
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M&&7*;&7'(0C)[X`ZGB4WC/`*^04#G(R&$8*0/,KS+)@K.Q_%[+M=H/5NIU3Y
M.V8N04B>Q"2:&\S(ESQ/K#(UF$\`"<(G,O$BM3O:OI,O^9U892I0CBJK@*:(
M"F`TG/%]8GB=W<-8K#(5F(\?"4(%\Z,AX>9TL^>+58:"R60F0:B`>KE2J.^"
M87J6-4!?TYXZD\F,(`@5P%>$&?,AAO/9#0%BE5D#]4R3?8`.J-EO.M>.A@=:
M%F+JA=/)C"!(ES%7#<,-+:LQ=44ZF<P(@G09RD#TMC!\T5+&!7^<3&8$0;H,
MY2&:C-AP2+M-$:N,WIA,9A*$3DGS($OFOK_%AE5^_HP0:)/<-"@).J\!4<VK
ME^!+-AFC`VH'=#(62I`L00IWK+,E,)SR2@ELID*XA>:C$4[&)"5Q$IH#`MXR
MXR5LS;H=^X4=#KU3MJ_\!CF$F7I\=[S=OH_$_?3X`5PN'XL=^Z/H=E73.P>V
MA:6!EX(W=7@]C2^&]BBN>)_;`:Z5Q9][^#<"@QO4P`/PMFV'TPM^`3[^8V+]
M/P```/__`P!02P,$%``&``@````A`*2GS8.E!```DA$``!@```!X;"]W;W)K
M<VAE971S+W-H965T,BYX;6R<F%UOLS84Q^\G[3L@[ANPC7F)DCQZDJK;(VW2
M-.WEFA(G00TX`MJTWW[''#?8IJ'I;MK2_'S\]WG%67Q[K8[>BVC:4M9+G\Q"
MWQ-U(;=EO5_Z?__U<)?Z7MOE]38_REHL_3?1^M]6/_^T.,OFJ3T(T7E@H6Z7
M_J'K3O,@:(N#J/)V)D^BAD]VLJGR#AZ;?=">&I%O^T75,:!A&`=57M8^6I@W
MM]B0NUU9B'M9/%>B[M!((XYY!_K;0WEJWZU5Q2WFJKQY>C[=%;(Z@8G'\EAV
M;[U1WZN*^8]]+9O\\0CG?B517KS;[A]&YJNR:&0K=]T,S`4H='SF+,@"L+1:
M;$LX@7*[UXC=TO].YAO*_&"UZ!WT3RG.K?&WUQ[D^9>FW/Y6U@*\#7%2$7B4
M\DFA/[;J7[`X&*U^Z"/P1^-MQ2Y_/G9_RO.OHMP?.@@WAQ.I@\VW;_>B+<"C
M8&9&N;)4R",(@)]>5:K4`(_DK_WO<[GM#DN?Q3.>A(P`[CV*MGLHE4G?*Y[;
M3E;_(D2T*31"M1$&ZO7G=$933GC\N94`%?4'O,^[?+5HY-F#K($]VU.N<I#,
MP;(Z&0/_?'PR.)):\UTMZI<"W4(X7E8T6@0OX,%"(^L/$)O8?$#P"Q*`O(M&
M.+FI<5J;@N$,OC=HBR]F>_EK1"(#&3;NB<T484F#?6Z7IN"E#[8':8DC#9&T
M]RDA"0_CQ-5F(IPSQN+A?)8V.*"I[;;0JD6.QM31B$C<:XP3DH7,!C8F0$G*
MTNP"6`(A]TV!TW%5L"-L,(MQ102%$1I1RA-'^\9$>,+!PX-[+6VQK>TVYZE%
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M$B;T:H15][[=>XIV\L]MRP09[9F0TC@:M1>+21CE]%KC4^]=7]`W'AO1T%%U
MYIE#@5S19S+3^IS),=W_R'AD1$[>KS4SG7UHYPICE\>71@?!Q@_I<VG\D=-^
MUYHQ-Q_EWWA^#(@MSYD?J@]&X/U/_#@>))$[2`@RILQQ%4\RME!GF"BA\>>O
MSC@0S'83N5.%((,%0[/8*`5=S180\?B*+ZDS4Z9]V--V+4>#8:P5S>A6D\(H
MR;A33QN+B:.,,6+8L7Q(G7'RB<#Q&(G<,=);?!\C=RE/DC1.G8K:V%`<PWO@
MU7Y(OS1->MKQH3M--*/#RQ*2&B_(&&`+N2.<9_RJ"YUQ<MM[`]R6W;X=N6-%
M,_HR0C]\\[*8CU^]\%:-E\Y3OA>_Y\V^K%OO*'90,>$L@>)N\$Z-#YT\]9?+
M1]G!7;C_\P#??0BX>88S@'=2=N\/ZM9^^39E]1\```#__P,`4$L#!!0`!@`(
M````(0`[E>\'XP(``$8)```8````>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
ME)9=;]HP%(;O)^T_6+YO/B`)#0*JDJY;I4Z:IGU<F\0A5I,XLDUI__V.8TJQ
MH1GT@A+R^,USCFW,[.:EJ=$S%9+Q=HY#+\"(MCDO6+N>X]^_[J^N,9**M`6I
M>4OG^)5*?+/X_&FVY>))5I0J!`FMG.-*J6[J^S*O:$.DQSO:PIV2BX8HN!1K
M7W:"DJ(?U-3^*`@2OR&LQ29A*L[)X&7)<GK'\TU#6V5"!*V)`G]9L4Z^I37Y
M.7$-$4^;[BKG30<1*U8S]=J'8M3DTX=URP59U5#W2QB1_"V[OSB*;U@NN.2E
M\B#.-Z+'-:=^ZD/28E8PJ$"W'0E:SO%M.,W"`/N+6=^@/XQNY<%[)"N^_2I8
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M5POM!R\-DO8]#;S`N9U]>-N2@LK.E]*P(^7,U-(@22\5!^;/]LX&$4L.%OSY
M<AIVY,;VDY<&@>?OFSIV_+-!Q))++I'3L",7.7(&&90;1"RYR25R&G;DWG>7
MV08&,6LM_'+E-#;[\+8EI8^X@^^/X;VI84<J<3IF$+/6X)0[N=B&&4LOO41/
MPX[>Q-$SR$XO3<(T2IVV9A82Q4D<1>\IEAP<61<TKZ<=O6M';\<,^MG,:4%S
M$IJ#HB-K^IV(-6LEJFD)VRSP)K"EA#D'S87B77\@K+B"\ZM_6\'O%0JG1>`!
M7'*NWB[T2;O_!;3X!P``__\#`%!+`P04``8`"````"$`+?7#/MAT```]?@$`
M%````'AL+W-H87)E9%-T<FEN9W,N>&ULS)W;;AS)M:;O!YAW2`CR-`44V611
MU,&[6QL4)=FR=>`6V?9L#.8B694DRRI6E>L@-7WE=YBY&<`#Z%GT*'Z2^?ZU
M(B(C,ZLH]L'=L^%MBUF1$2O6^121W_S[]U?CXD,U7XRFDV_O[.WLWBFJR6`Z
M'$TNOKWSW>F+[4=WBL6RG`S+\712?7OGNEK<^?<G__6_?+-8+`O>G2R^O7.Y
M7,Y^^_77B\%E=54N=J:S:L(OY]/Y5;GDS_G%UXO9O"J'B\NJ6EZ-O^[O[C[X
M^JH<3>X4@^EJLOSVSOV#_OT[Q6HR^NNJ.O)'#_8/[CSY9C%Z\LWRR;/I8'55
M398%<!3/)\O1\KIX.?$%@/N;KY=/OOE:0WWXX^+U=+*\7#!T6`W;OYY4LYUB
M?[=7]'?W[K=_?#M8;O[Q"V`4_^/P;+&<EX/E_VQ/^U7[0=C$N^IBI%?8VIOR
MJFJ/^NIPL!Q-1JNKXOBR!)N#:K4<#<KQHL?V!SOMX6'2(S`U+\<,&5;?%W^L
MKMOCOMK=W=W;?_1HO[_;_ND0-`\-U2_&Y47[UZ_.6;L#Y=%J/F?)XL5H`6S%
M?U;E7)@OGI7+SMBOMK?W^MO[>^V9$VI/KV?=E_9VM_]CXQO'U7PT%5NL7S'-
MG(/W`H9:M&?\:AU#M%\/JZV?X#_VVW,&DKP8C:MY<01"+J;S+CU.KLJQ!KRK
M9M,Y%+\HCJ97LW+2&1DI/+VZFDZ*D^5T\+Y7G,`;U:)XNUJ:H/)Z&XJCZ60Q
M'8^&K#\LGI;C<C*H>`UI7!1;WTW*U7#$+_?X]\FSXNZ]]NO/J@%"L6<2T]EA
MI/[A8L%TOVV_>U0N+DUL!_I']=?5Z$,YAELZV#^>5[-R-"RJ[U$?"_8C69\N
M+T'+(#!8:4NT5SB=+N&Z)ACM,<=SE-(<K:%)!<1,/-XK)M6RF)X7Y0#]LAH;
M>H85NFHP*I=K%,M)!2A2/@R:+D;+]C)???[T^5/[H</GZ&G_%J%^-2K/1N/1
M<E1U,7@X,"6Y*&;E=7DVKFP/0#Q?0<R(K?;$MWJIV"[FE>]Z5H*=]B1OILLJ
MKMK^[1E2]P$D?:B*<0U\>U23-MDNUP^\80`"<35:BFK.&0,T/)R.K0)G[=E,
M,"ZGXR%V[:OB.?2&9EO/JO/18+2\U^%16.^\0H<-L70F47=W=W;WV/F\@%E7
MU;\5![L]=*;^ORA7R\OI?/2W:@C[8!*+T6(A2AB[WB2")K+9`LT5L(EIB84+
M=+W2OQ7]Q[T'>X][]Q\?V$+]^[V#!P>]^_<?%F'P>BAZ$'@QJ[`B'ZIQA[Z'
M0^0>-D=\)'K;HTDQ*&<CQ*F-4-@I$Q!#8WN(D_IFS*]_)Z.Z;>Z'S7%KW7:,
MEL0KJ,R";M1U+>VXV:1WF":Q2WN7G9$=^M[V#2?R;4=/;\N-&R&7T&%G`M-^
M$>RUP]?#'(8:J7N1AV\$.+-@)TLTM:L"E/=;-+MIZUO9LOU;^X8=2Y<M^[:Q
M[&8F>5=]J":KCD,30,;.1_W=T4GOJ@5^U,!MYY!IQM.FS9I7HZNSU7SAB&CS
MQ.^J"5@9NZT87N%$RLV4&FB/?);9NPA.>\RKZ6)1P`C#T<+L'CI#9C,9TO9X
MUP4RN2R9[;(]SN8]GT^OBC`6/Z4]YJVY`"-BDJNJV`KXZNKPEY-EA:Y;;MK"
M[P@WBJTQ&[FGG0PN2XQ'P;/S<A34O+:$Q;BU67/GI`U9&_XWN!A:=M/S`BP1
M!KF@2?%CE<_*Q6A@M!N.QBM<L_;+?ZY&%Y=RYDI"MY*-Y!-`JEKR;S-;0X5F
M7`X^S'U[,9Y^O)5P9:-?B*HUGRN0^;#!OQG^9;4(EGTYQ6!AV@?XR^:<"7,%
M3^6HF0>Y6K!KR%8S%_'6IJE-O6R#3=X!0W(L35-L8A+CQZT+6.663-*FRQ9A
M&9'NHKH')_F_`+8CW'%4L15'W5LW3*QC*/U.&W@Y68O/-@AM&KR<?$`L)(4W
MT.!XA:H!;(G`;*VOW%ZF`]NZ==HOM6%[,9H0BGP)MO(ZZ/H)#M=FC_2$N`+6
M/T^RX+Z<.(>'TW-</*TTF"[6!1_3054-%X4I(S0.'%+-!R/'R'0F+\G]SH_E
M7.'Z6G&V[1%J?!@-H=?3:R+B[O[:.!$B:VTT($IJC[!IY5[JQSR$*LIE<48&
M83+1QD0ZMCCM*(L;WR?<W_SFR6HV&YN!P92@_`>(XTJQIK`L8,[1#'!NRL1T
M.-W6MKB.,8QT);UVA]DHT_7+\OLUGOUZB`00SOBV`35*'"^DG2<:W*`H3J'I
M`@8I`GDS.Q!X(@8YU])&,GQ$%(,Q$>D(;]B42GM3SZK%8#XRUA%X3U>+T:1"
MFPFHD]7553F_UO.3T<7$YB"#$J(V4?.8>'U=://SS'I#JNJ-1&RO^.??_U?Q
M\ZS5Q,M<^;PWY1(V:F"%]7P@`_2?8_YK\3?%7V0E=^]\_>2;P70,"R&;5Z0A
M]_1D_H(@T(<<E>/1V7RDI^?EU6A\[8_[>F!YR<H?X`E-YWKXM:VP?/+YD]3B
MYAQ;L25M\,^__^/(,S+__/O_+0"#!_$]GJ"]H6MQ-@)W@\L)@%[`'?Z"J:/1
M4L8:S@F>G"A\AJ%XO[R<3U<7E]K6G-`+T9*<C$?G%8\8L*Q,MI$]695%(2:Z
M*$8*@L>SRU(Q*O$,QG)T=;6:F$=2SHAU#X]?GMXK9@3WDDWC.7=78L`O+ER,
MP!1!;@*:]7?,3`@?/>"]J`18\7&TO+1%/Q)4@]OIQPG;6:S.%J/A"#[N%:^K
M8<2'YR:+K=>'+^_UBBW>KQ#!<R0?VQ[B;#`!.<<Q,"W*11>C$]P%R\AH9'DV
M=?>UJ,[9$?LWF(#>O#@,W)+4J)2TQ),\V-EXA'X2[;!GB!G_D5]1S<P:"#V&
M%(P>^Y@I[<:.%,Z3:47K[WW=1[SA"V4TE_-1<*6S`9V?ER#ABLP`0T_&TW*R
M_<<*JIO-.5+"C?P?\2?_LP7SO#[YX]&1<<Z*+.T<6`I[Q/+7^'XC_G[YYEEQ
MB/X-ZF5'#@`9RGXO4:@8EZL)27?<P(+TU7*T/?`5!M,Y.P)Y!?XZ@9-2&[X)
M/*=R@$=97%T349!N&U>K]]75J(1E7K^"8U!ERK'L%+5@_//O_P>-?_87IQ9L
M$7@60[`A1$$:(`.('ZY(-,)R9(C@T8&CX5R^J]C8!XB6ER,B'0@X)J]2$').
ML31*2V!I1V<4(^!\B/&>;1C96[P/_,(T0,Y#QK"<,?<,6KB[`#FP[0Z2C+,*
M'M?%#&E%?RS%0R:>409WBE/X!N+#@.,6G<WV158WS$C.*5FPP"7>.`:YFCB4
M$9=ZKNUN0+PD<;24!CD#441ZT.H2R]Y8Q!@VB?/'T7CLJWUD-W"/LXFE$*]-
M@PQ'\G=L>R34@\$V)OPH@83G2?.()NN1#:6`AIG85R@SH(^S$LO;"=9A4%V=
ML7K_D66&84R)6]"35)$@"7O!YD_A3Q4Y%B6JEN`KJM03"W>>?^_NCZ2A5\P(
M:5>JA_"6LT4^:3G`\FK6O=W=WTBF]>/ZU%<TT@O/V8J%&!^1NKZ@8J()JAT4
M9*4*L!E.XUJ6/6<N8[+O1Q2YR*T5CQ]_"2`8)<NFI*1+$;*-8'(AA/3BO@(F
MT<@R+D@;(AY_:Z+.,2]-'R<)R4_;\O%+:#F@O&380@LNYVA4<:2MEPW-4,VJ
MT`#LRN=C;*^H2F04Y.1O*5JK2"H,B]V=_?W]F,B)!(ZD+=[)0S)UE],@1XAA
MN+E$POZP"PSUDHB*%D@+A)+HL.NQF_S'.$<O-9;_B"&(U$:?^MZ;\!N(D^IC
MFAUU$\.!GDQ8%,,Q-)2R28M%#R-?<4>U@E,0W"0E,S*1I_Q!J[P!/0#1Z"P,
MT[)\7TWYY]=@WG.UH[^%F!:)'TB/G5'F<$JD'?60);/#1D`M`1M@O$U"1>4@
M6'-?T)<WG55[T*A"2C2A/L7>R`3A+C2]N^63P]OQ:N!MVRWKDY"IX2D+L:16
M!U\SJF!9L!]M#_0#Y4DW;V/Q<01PP&:(4%TH33-D?A>6>*ED4+!&2WE9%F!V
M]H*2>VTYN+Y7B_<;&LZ4?^X#W:Q;>B'*D[)?%!,3QVFMCXZ"R48_&F>P]B$&
M;/SYTUXHO#46;TPVG%[A,J#,4_1J21P)R)OJ0SE$^TY-EM/C9Y1]8%VO)0TL
M%Y;!9=,<H:Q7B^)/Z/$5NB=X=4QT\S;;_,`^*+B3KC5+<>`UQ!Y6P9A\/C1E
MZD8=_PAGUL(IBPW>XF7.%Y>C&8[5G"C7,QCFJF?8<@,C'KX9L&+K'!3)'F&Y
M?/=-C*([+_@]ZBZM6<U-9YD)@VK5.#,@.0A;9?%X?^<A!J#E&&/09-X39/E+
M`WGTV'K\U>_)SJY5\PY$YO'E$UA:/BR)S`L%N5@9?^-CH\T`P52KZ7NS"5$C
MY?,1/FR>K=:-4DD-;0^;A76C/Y3,G+'R(7M4B99Q^[W'#W=[>_NI;)6;@QP6
M)#]-8DJBN?Y>;[_?[^T>'$2+4\,@D4^OLGZ3(?%BED^>DEXU;^!8+NR$:H*\
MDNTB5<)QM7%>1E<Q@0/P6;N)8F.?58'J+QJKGIJJ9H=2BY*(52S>2PP,9"G2
M5.L/R0_@1T'&FHG8(8:!T!S'J'9<9ZK"N]O6%=#:+*"9R-N1&UH4E&!5:<`#
MPFI)TDW$Q(S?X4#SERD==[X0,:(9\[*^VSG9*7YW>'AL$B:>BANH8<X22RY'
M:[2&%IJO!(AOZT)E?`L$88DN%*&"+V]0XY.!AX&O\",;WNES#]!,.<$H*J-*
M6E\HH%9'BLUP&.+O1V)OVGG"\L7)]G]'HL'87)9L?&VZAL8!4MF(&=@;KXA#
M,C<FVZQ-?#Z=+ITZ<Z6;1!.$/*'-#+4884SL$I-<#3I[%/-C&.1\-:=>I+B2
M@%U!NL%99GGZ+3/71-VP(/LFIT('"Z-IC["`-QM[+[CQYME"0-%D.B.X0N1X
M]:J<8+EE?]6-,2!!1C[A\R?S>[PVDSA7PXW<Y@E[ID1_1\;Q["=]$B[5%6YC
ME&.>X#Q#<TR>\!]74J)H-!E:B$WLMF&!\Q7>YC6QKJ$4)^S'('5Q.5V-H:'B
MX=)D!!S^A?C=E(\QF383>G','[I9C`.P<.Y,/I(PI@D$)\'7$.JE""WV[AAC
M.5,Q=%[!S0`A;XC1@39A/E/EY62R,KK*[5/9+/+^'V^UG#G%;G73_DZ>']E$
MU=E\I0QH"![OKXDR35<?UYJ&#1\EY2;V^77UL$3@9@I%*1=9&FAU1>HJB&X2
M.*I)3$/^^ER;I^C@QT66-S8)D#(0(X3@(<Q>A]VYFB?10"84B[`NNC>\4W(2
M4,^1<06X"[''"T^EPQ&FTR6TQ7%N0G]=@B#WV"XWYHY/]G`;*FD0XD,6Z3KD
MEWXN2Q=4]R)3<S(A5P1QRE(&U,H244E8786HU=(_I85S0>%)_A#1\DJ]L69+
MO1?.!#J6)LRH>>`ZA&21I[Z,`:TO'O7PKKF.XDXZ&)R;8K=",5R9FJ]?DB%P
M_2NKMW2MX3J7[C7TGB>D8H0BED_[WR3Z[ZIF@>57E'=%)FA)3,L(->L;3=2H
MO2<,8"@)@417KN(K^V?H80SOPJO)\]RT_U2WLW^HBRVT3OZ*B#BM59F)EE((
M\(;2D61UL:9C6KA)*R<E9(J?K#CQ&WH#50+GJ,W1N7->6092O=K@%2_.LK38
M2"ODR>\)6]ZA9$;ZZ<Q[5UD10[XB42B_$[H0'>A=I/[%LY='/%&9DN0V6DZY
M;%)9=1`:6[]-=CHF$IM5IY9RI6T0*7,2>C^9GH55$#@K)^\WT?`X+Z:+A-;$
M\RL2\#59/,P]EE=2+PP[1$(H[(N[*OFG)$V9W(:D?EB>8W/)+)'*509_FQ2B
M-F^Q%!FI)-!#*%/A,X%^6@]J0LLS@1@OY%U:_4\0G(^^M_R"4?1?#``2N9`Z
M,Q\)2/ZLQ%-4I+;_I?G9L"*6G?Y.Z;>$B!@RP=I9+R2"')J%PPZNR,ZQ+;6_
MZ/4H"![`R#['>=1F8ERO%A?BT>!K![Y"3W@<LU.\4V.TI`QTZ=0$50O+FI@V
MIH-3Z1E;G$2.I3#89]U/M8DS7^(MC$@88\,1FU?3R<7V*\OD'EJ7M5@T!L^_
M<)C[.H4$X.3#J*+WB&K0!?PFS`9ZR=T=U5L@O3E1AK00?64AZ:FRM)8Y+H/1
M')H12%`!T0-S^)4.#WG>`4T=%DZ[@07+UQ8FH(APUBE*6:F$.1E/J8W@Y8HS
M&>X=HX"&M36D8C*G5OI7?%O"<>=]]\D)1B@9H*K44NQ.BA$="415.:]%DPC_
MK$Q"*+_0=2&CS\Y-`ZGC`FHO%E.Q'4^39VV(<3Z0)RC]!R,8#XJBGIN)&Q40
M($`%:>!D1X11!EZ&4]AB(:7K$P-LC)JN/;2D$JO8D&%BZ^S%CS'28?[@,A@<
ML2@U4)5L^5&%,H'7[,#+EA3#*UF:R&-0;V+H9R07O"-=Q>1?*T-SB/7`)B9(
MVGHUWZQO/]@T,EF<QT`]IGY$CW"S^A6*5]H9M2&T(>(3.'7^G@8B8:J]JK>]
MH;+_NB+)(]5A0W%A$`)3?JB\QD-C'H7'BE`5&I<?2AH$*!/V,B*YKDE\(VTO
M[R_,Y*MJ$7LX'59C21R&!1\6MF=DG'UZMJCF'[P*Z;#AMI:V%_>;-?@OJ^&%
M*2EM,<I'+#N@F%)-TJ(60]Z?C+?E"Z1XY>4$J[72/+\F;]2DE;X?<AQ!<3<N
MA<AI=.%?J)@D/]@6KZXA2&2?Q](?)HW4"'%#=5Q&(AZ;ETHLKI\C(=T$ES!:
M]GP.)?/R:Y2]2'MK(1G-U-6&JY11&I\.*T1GX#490I6G83A(`,4\.R0=G&FS
MR8RV4]_!A5E^;4MN(>^XYZP`"X`#0SHG&J`D04B_.$#.]CB6U/[5?6$;=O^P
M/FAB7*+Y48?MZ>F#J3EK9%"YPCI/HI7M#$JPMW,JHBC6T+^6\]7RR2MLRIB6
MJ)>^072+,L66#8-\/\=FDB'R"$Q\K]V#+>%=VPQD%?;P**R-;&D_7%%%P`$P
M$5'4%[1C?1C2H>_GT(>->$,0:R<5D2ABV4G3-''S!J*4689;T=^`DWT11V;L
M5]$RA`$<8MP&2QB07V5W_:^81[N2'RGM8,G0)B8U>6Q06LL"GS^-)I\_E0W6
MZ;7(85Y"XJ0OS2A6C#R8]BM]Z(M(IHS%-R(NO70K)!5;P=8Q[Y)L'%*"AE2I
M[<-TC*KT\V"T1"BO83VPM/.H2Y52(M:=GI'Y:/&>OZKE8.>>8[@60='*3`(\
M"EV5KK=HR3Q3,(%&GD^MJXH!9):#-C`5S)_ZF3*9)2<9[5N&V291][8Y;#_G
ML.^Z(F@9PV@UQ.'BG%HB+4Y82V<&HA-3)AH59*+Q%6]\-'68\B8TB:U<*I@H
M/;77U^BZH&:)541WL7Z$:BT8+<$R<W.J+9CFL%=ERF@G0Q;@.[S`,(\L5Y0,
M1;Y!9-'\#*Q5D@57R$=,H?.66EKK)QYJ09NQ*20Y?L$5R&:I53::`QMXV[@7
MS:\0Q+U1\</AR5'QJ+^+*_6/;^Q\-3O6?]28.5)7Y2_0G/E"V'%S_KK6<RAL
M</.L;D>FA-0!\9<`#Z\H>1@;:"TIS')"3B\V)1XF_WZM^!GY@_82AV#,G+X0
MS_2-\S]F*L_XRNPWY"=RE0R!6[L\>2'H%@LS$DRK-^O)\,9Y%EM)J5])4Z-'
MS+78N$;DE47RT#S"5>B4I2YK]X`U,C;=A"X("W0@B%XWVLO8C`4X-_&Y82MJ
M)9@S>83)<CMSM!56?_WC_?9C.\S4?O@LN?BY:'?:WP_7)9[:<VVW']QM/V":
M3J*J.89]+Y^\]$-2IVJ<_Q5#H%.8)C"?,D'!@3$?(5>%F!RZBSFY#W%#ED1:
MU$RV;\1.`.S@;&''8`M$P-_HR7?V`[L,V:1FW0!B6!7=8N*BH-51J%Q:#T-K
M.:X],,&JP$5]<ZR2@M!;).%Y4ZLG1>\1DL2.U(WU:&E&,_:FRVA'"8ZS=7:>
MF44*X;4R&R:Q.=R:79&USZ5#4^0^%E5#\/70DB?KD"4LEYGSCFLP_6A9)<?3
M:H9*8FE@1AW@HX%[VHAA]O=J=L2FVF$<_<,M;G<1!)>(A;VH?*JTEQ(I*LH>
MKEL7YXHZ<BP`\Y?JN.$D3:E4&=Y1=PV<GPS>NI;LU<M:Z<F+-HV)9@D9'7DV
MP:;G2L,$Z1W)^73X\IFLK1^^A*TY//0KBE8#L.Q4J&4I/3`/"1>+*V%?E1W`
M^<87F\=(C1LOB"?9I7@,Y\,SPC@$8M\HUN!3+8FT=[N#>,X?&<HZD&U"](D:
M7K>?FF@>QW->OU[R)M=<N..A/*>-9Z8+0^;-5#I?1A;&,*!N.G/H--@06%@-
M#KS5PO\4F_9^^V1`>R-:,;P9'<\KI4I<@+/%HL.,`D,S"<DBC1:QO+3$6'^$
MY:6QY,4-IIPI0M8*=8K:@'@&,)2?0L;2&ZP1Y8H^DNDUQ1A[/3B!2$P007S:
M^0?21E+5L1'+%'5:V]Q':R^[X;AE"[BDD0UZSK9P@B$T4^>Z3:`W._6,\8)=
MB?E%82*2C/3I='Y.!&J9\;0,!F1))4HYA?IWU\([JF-_&$U7"]-4"7]H_UDZ
M-"J,JY*+TP;&8_P/EF)L8MCPXF=K@80L]_LBO5QUTJP1$\5-,NVH/\EJ8EB+
M,Q+<YV1#35&2<,7="@(::"V9Q)*&.QVD[Y0@VH9DH5%XDQ`^+RG(3"XXX:OS
MK_>*8W@&05<3G<GGKZCO3N'MJ'.@VT#=51!>9SII2\=$`"HTLGX_J9+H2^1]
MI0ID^@\LD$D[U19M;X0.WO3O@]2,ML,-.:WCUS<LZ!7!VLN@&L!I9.M>3E#6
M?>&B2H17ZB/VW@?U^K%]K'NRLKY95([)ED5T^?N-D]Y9&<+%O.$.F$GT(R^<
M:H'-[6BYTFX^M5K$=0H'FV'9F/P,>7/)=;WU5@.?D"JQ)&&8PUP["07O$U"$
M9`*'[/U0>Q.K!H7)"="%$CL<[<H.Q:?##RDQJG-!VW$#:_AZ^23%O9\_4?!M
M.LO+)V]]#^W'?UY[N-=<@C6UL+-?*`K.EDZQ37!3=-[+N@Q7(`3GF7+SA&J1
M1T[FJ&0O\\XO=JSRI5KGZ>[BBC77W74N_K!NKJ&-B(OEYL-%\70J^QE.\JP=
M\=W,#*IFW-Y]W"O>X9;1F.*5UB,=:L&S#L<"CU9H>II-%Y@E8DB[T,P*@19$
MA)ET/)\NF5.:$0?%@]T'MYS2PUS.#,KAIH53_"WW6[`$RVL>0<BE*(2UI>,Z
MM,!'T-^YH=9PY18E=R+BE4KO)$O9Q/QZ6WVG:HI?N\@%O1;FM8=S$3'_]3*\
M[;LSM2$XCSA*%X\KVWG":"V<1IQ)B+AJ[L]\C;06%N5D=;8,>#O8WE^_I7_^
M_7]#%M5=S$G<ULUNYE_"I,%Q]&>)>([:0!<=M$G+[-_?W;[/(8RW[&).IDI7
MC=E<SV(@:)ZY+[F!$V!)DH(D`KT7%Z6$O0B94<Y.H&,CB1[(4;'(1JZ191LC
M:?^&]8G41I?3'#$:N!5/51@FPFVBFQC_ZV(ZA;EQ38(#96$(5\\Y=YJUPF1;
M5Y<O&%R)Z.+Y&1U7G"Q7'X@+4+F?9+/BD]C#<,:AY::IX:H#C-N'C.I0-I<0
M&52/0F4FY&$Y$WF?H?YN-(B*=]WP*+".UQ+XR=^4OMCS(R!(6\WPEOZFVSZ^
MG#*;Q)9U/+[&IHE.%N%,5&*(E77`$)P.N?'^X<EWIHI0'#'5]L6N.+<-TIE!
M;?Y2ZGZM.8-Y_["B2/\O4JA[R%8>YZ*8.4[U7*QO#:>GX',SGU!^(M`PI!.B
MV[E9?$?DH$1`ZN"9RB&3!LZU,H0+W&/QA`2[P@VRN<1)(B'-#Y@UCS%CJF;#
MC-;\*$=:$V5<8\OI1ULPM<_?K/U2>ZQ!T=#DXOH;0$!(M_8X1NV1FGB<(Q'H
M]^WE=-OL5][F'[*^X"4>S0!GO(+IHL03[]?`XU<JROPC]Q?-E5.J?HDJV^K?
MXQSX&15*8:Q.9&6SFA,5NHPWDX2I]N\)Y3KQ";G99N,""R-(AYQ6&O../K1'
M1T$AH-7D`KK3X:)=;-W/EC!U(YCG&#SK6]\PQ62*N\]]3<I9;4"^Y:1D-J72
MH9$UFRES=4FS?7!*G:?:6^AH0>XXQ4LG#SXZ#[-JZ[GY<[[M/Y3A4PG.MO:=
MCE>K2U0B8PFLIM^?.-$L2W*8Y5M7O$J5CGLYE:D,-HDP->OB^OS)VAEPW#NV
MVN`-,CBC`9KTP^RR>,01%?WG8'L/9>N$,9Z(IFTS)H=3Q5@X\U=TI!C2T);4
M&]5S+P2O6^/^5GE/T0UF2'E%CM[K='DJ;`:IW_K3R^=<EG%N0B*LAN<Z;SY$
MB\A=D%.6THK.Y<RCR!C<!)895Q>@)[P,CRU6Y_@UNKG`XE[E?.$%^\,EPK53
MSJS\WC`>SJ5:P/@4J:KA,X&[4#+%;^,(UQ$[W<&->1SJ>;;XP8^S\*-RJBD@
M%[PFLF$SYAC6R>U<OR(JA$"V.VFN9`X)U0:P1$P6_"EB^64L'S\/"EN.$WU#
M(IC9O^1'.5/T<`3CV06&X#6]96NL"9_$UJU4"H2FP;!6<)$GA(49/]/7V9**
MFBI+"[L95>HD6)*CD%LRFB:66D2^[1]LWS^`!'X]BOYZ&+DX@(:3@;*GX$]>
M&0TJ%T64XV]AP1]$EX#M=L3<6`DH0SC0=79^M'-#R"-(VFX-6--5*/XC^65<
MEG(8LH#`$3'>B-H3[DDN,J6-1PRB0\,Y-%H@ENX;Q,;FX$#4]:Z7_V+G@9L?
MCK)$V;9?3-QXMA'[*P_KI"I1MLJES<(1\\3_I@P\IPH*53P-V4HXS/+'GN$+
M/1(6;-5V2)F9%/]XFC0PGBL9ZI[5'*-.[8#\IM\%@NVUZR_4*HVU`.UV>XVX
MWHC$S;^(8DB)!K?TLYWEW^PC;62OZ/2NXY@D^6:0_3!6'/\E#QO;I"F[?,8$
M=E\*58%3=B3*6?]F0QN&NNT-KO1>_]:N]#J&/%Q=$`;]R_Q9=G_L/EC*.M49
MB)/D<&T7OYO*V40?8KPGCI&@$`*;H"#B4=7:!\`0MHI-+$;);#$*=["@7*+N
M8?I,;Q)2F6;DIGCI*:S"<$HP38.78G=N-'!R>`$K3(98R,B,E&*PRLN%`<TS
M`>V*P5Z/K>7Q[&CTYI0'I[,4M\@J%[6,.3/ULLVDJEU41Q+*=0:`C8BG`<(]
M`PMSD1:O3\@*E+H^;X$E^MEV&N1!AR[,74Q=]D-W&C;YOX9TW=*\40UM-`(2
M^F`('%G89<O2;(QK)759;!SE=9U\,SE)*"F7GRB+!S]6%BV/:-X"7U[`>WKN
M!/S_H@1G,E"+&;I7]6RI8[PC%8KLKJW$<NXIB%[&#812^C?\^853FA^A`3)I
MEWB+;N)8W!IAP^;.A,AFTY$G4RIK`_5W:IH#QF.Z:J^+T^SX93O9O'GDEV[G
MZZLB4VQ^O[V2W2S6Z4W!*R";0.`?[PH^7!*`T'-;_`Y4SHI7.CS%3H;<Q*7_
M%=8#4H/7YX4#/527_OKSJH0KASBB=FO'[_U:ET7Q:HDD;LGJ6G.R+D,9=L'P
M&T4]@1J`L1"C><T:'[C8<,V:;?M>Q_B\Y2!K/'WL=ZOLWGQUU2LJGWR1H)DA
MD3AC.MD`YS!T0L2BH\,+3K0)8G/:._?`J0U=%]69"W\DCV,.&4/A?.ODCUR8
MASN7Y1R=E]#`?CF<;HX+T!1I*:M9Q<N$"/XB`+(4@#($M5BC9&]W']BE'-SX
MFN[9,AT77_3P,GH%W#ZGO7/X))R`E%-K%_<IW,%$HM[@<U/$P)]G];C\TANX
M9["/K(*T-T*<+E+0LF$=$W5+R"[3!8KNOUAP&V[HP\1,W/0Q"XZ-SJ9`AG1/
M7YX:@"FC-1S.5UPEQ$C[`,;"MN_X-&R1F4#D=;N=3%W<9VW70,BTB'?3">;S
ME2Y[L^Y[Z8OT1KPN4##-*`7$O\$2WBM>J'[(0M`('].W46$@Y]MI['.Q7`VY
MOBY,F^-<\\1>83"00+/*M>8(Y?*0`_!HSU)F'V6LZY.L-`;K<!\N>4VDCB2=
MUK_)J9ER+N#"5`4[LB/.>KGNC^6R28)X&>_HJG=TTNLX9-'68;$[I/U<V3:N
M&)`3QX:1G3?4#9Z)XH>$%':Q`\Z:!.?-LT.)BK+Q<[^G@T^Q^"5N>+M^Y82Y
M1XGGP;`*%9TER0U8?Y2V!YTK+GG5XFMFK<\!FA/YXAG'*X(7]OG3E];Y+O2]
MX8"L%T[T+SH99(I#G:/9JWS(%2F)Z^VSZ^WPSW!,DYZ=Z74Y1F`!M_\;_;>*
MU(MX<[*F:T-%7P9&P;.+4D<ZU/9;R]_L[88L6W+#/).'"QO4HLUL9U64I<0+
M]DZVJ!!@1II@.VQU%%1-;+0;XO8B<JPLA+]RC53KO\(,>.H-$Y<SCHO=^?`4
M28%)>+?4@S.TAM0N7=6N6K.$C>D%C(/EV?G6AJPC5V]IS:@-];T/_K9SRJX[
MA'D1`-U7*`-VU[\4(HWKKV^=\3!\W",\[9LBV!KHA\;P_;1-I"FC.9-%M0G%
M!%!<)GBF^:G0\XJ4D9"0=&24-C;89F6VFPKE!6D+8-YO;AG-C7]DR0Q=X\AM
M,V*!!%RP<^P>1-2=[X(Q+VOE2-2!'<.7)$$_!+_:N$A(TU3\[_V$C35$-V*=
M\K*GH7[Z6F#\[B,*$5PL22)V!0J1!;B$T`=KGH1BO?F+W#2CK9DMN2?J[4+L
MY4P',<":]:$FP`/(8$,N%BB9D'#UFEC$G>:JF4^-1XPV!>(25&OS&\3#%GRV
MLOL:A%4G[WK&D1:_N_?HL7WHQK#0W5%'7.&AUWY+'ADZ5KC1F4(]U1^=218R
M7+`;M9PSE2NTX"4=&1]V7`A9:967T?YE=G.OSX>LH(K.:-$WWPQ<DA@WU:>\
M[%`YE<$U&1_.5F&3)#+GZB$@(VI&S`8PQRMHOOK;ZJH\VSX<]/L'B8)1*UB?
MJY3`7>[9V7MTD%0\FH%:`.P3,OYD6(CN=6&3J:C:<3%X;=[O2")`5DZ!&,Q!
MW).X-6737!`=R"?6V,9C1_2ETN\^Y&-!_?VH;3H$>Q'D#D;E!9+NNGZA,D>Q
M5@8QF6AX@:HMM0"C6F=IZQ+4N_T'_I$DD'F7T"*H+=2PZA82^)M55:`G^,'U
M<`:(T))Y_\G`WMU[_!`)?V";NMO?>]1[L(M`_'0HC7:'EF?<@,)4`(]W,35)
MJ7-^.H)Q;643E(9O?J":0ZR&KI%9TS'4"J.K:8RDBTQG\MIMFT%51&W$17R:
M[V[_X:->__&>8^*1\6T3$1VV.4XG,@ZY\VW9\=W0`R'(N)4>\+*@Q4J)O5V^
MR^+W](HO+^FXKSA4ILJ/#7O*/1O*?RG8I%86CH=06T3"HBV1_K&X##$ZL0;=
MM[H(65O&_;`*,R5$.X8(,P;Q"H)L-3MI7):WCDPMM!D4(TM57AGM/W_Z0D#5
M!EA]@Z$RJCUI65HV,#Q6Q[CEGG1+]^=/!/+*<J2\A"%#L"\\1;UP5FM#8)ZK
MLMOR6W`:K=Z,0B"X)[2#!?=VS4,4:!=SZ[:<AZ]D6&K/PDK]N!GGE)1Q?TH[
MQQ:.>!A_1_YL-)_7"[MG^I/6E3:7A]5<0<H1`V\J2AP3RHCQBX-)J86XIX6Q
MI/A;S^WD)>BF7LZ=7.9^J8*<\!OO"!9.TYW`=>Y$^PP<:&$P_[;66^->7#]B
MFN`KK*-,/0^VQ?I@_;WP43K%J;JZS=U&/K`JMB`-(^-P,^U,,VA(O4(3,E8P
M8EHHE'\N12\]33<C1Y_&EK0#KP;%1F1:P)]P9P"0QC#;)J)&UM%''8;<^VC,
MKOJ%\6\.1D)[R!H_B*8N($.%X3&JTZZWCAC:S,N&C[(X^(WP1ZV9&H+JX;*Y
M8B6!D%:,8!#N2ZUC7\+5W6?4_Y2+L&M9]1JN-=4LFZD5;$NRS1L0"GXHK#F]
MUTM_KG^:*QN;^M&;E$#P(KJJ%>7PPVBAP#DJ%PT7B(&%'1G1IP<.*@%CSFXN
MBX1_0Y<3@YI?=%KZ!Q++Q!:U33"&(!37Q?TA;[$ULB:"?%EI0'7WJ3U<M"`"
MI5^$'))NC*=@!ZTX*Z0RM!KJD97D%\H.,!.Q2)VL+;;"(YUSTC(GUEU..[Y=
M*D,LJUR6UI%XZ0HJ[E3'$Y5C-U7CP7H-LH$45G,/+`^[""/K1+V\P$%6@J6E
M[A%EDZL,?E2^:<"1(8K"N9\5MF*G/I8+7;"3P?4+U4T+4)RI`_MT:>TM06=L
MDWK5!U*B.0E279XM^+E8>!WLIE/\D74R0&V"MCZM/V^@Z;D[C$L"0"N^>325
M@=E,7W9XT[;N'2/F-YSA-T#>B*8&;#DHZ.:4$L6K)C$B2B1%4T>W07<VO9U@
MS9L.C;'S"ZF'*!'XV5(!J815EY8M&Y+P;ZD83@C(KT^R()<A"\>!`[;GT)SI
M#V/)+J^*$]".QK=1ZR_TF8U`Y"BW9]:!S</H'7'4115:HE>*\XB?.^5:H$6O
M)+.MYX30F,$;%`W*L?V*=(-L5,MW$S,?37$%N6U7?45O[-KBFI)@`LUMWBS[
M=5>Z-GM11UL85ON=.D8:+79`1AL<VX&:[FK=GAOQO5[_8*^WNW>0&<E,(CKF
MO.-3XS.GP,`S3OM-F6K0NR1%($55;Z%F#==(0EU[#T*I@`)!^^M=8]PT\J,:
M$YUE/P=SFCTQ.J(V0_@J$?B(XE<VC?M=5!L)7P,)VS`A_$/)_;'8"E696/[^
MCG4<)';.N%GUR\X4:MV+RD/Y$^CJGK)9Z31-G@#_,7XL'/-S>ZCBU^0-Y!Q3
M.U-"=Z[&^/?/YO9)B()[MN.]8%[/!!(MV_5Y]M$&'B:M-U&H&9(L^LRQ-O/C
MG8-52"5GB8=:`49-)+*O9ESWYAU_\ECK;[@8-W,/EBM1*&>)]3>F-W%/HH4.
M;HA9N'5.QII$:&*_OL>O^]3B,B+)9\AR-Y[J5N8\*M(H.XU/V``?/G=!<(@&
M)B(_C#DNM\G)P2(ZPA6T>JM;KBD7_L5/$7@,S!.)Y>=/N9VJ&YW2(-<)3JFX
MK!PFQ1')@T#?'1S<[^V3PP\L&1<[D:=C*VEC;+H.*G#E[C[848(4)62OF91O
MR<LX)V[=MJ:,M7S?7GQO_U'OX&'^&8#V2KP1W6@X3H=/`>?NX\;RKD\BWZ2@
MX>X^GP<XZ#UZ0',<BJH5O*9J121>S5WK]'-;A\$5)D1Q541#*4B)!J(EDU0'
M%1&G+^SID8<:7H3R@.R'\HPZ&RRH`!=MP!*[=)G-EI1.4J='^BAAQHNWFG?]
MRYK[)S#S+=@9YP_,-G!X>Q[?Z]'SFGC<9L+6_5),_K#W^*`?5U\C3C^1R;&K
M/YS)L[)*EU,4KG6P3>"D#)I4KG[SDDM+JI+PM8)).0J\DQ@=^W'W0>_!_H/>
MP_ZN\E>G_)KKI9"MB^413K[6RM\R%\Q0JTAYEZ1MZ*)2DX*)-M,32%J.I[&8
MG%^[#D\VS!*K=CQ^&T][NN$#0*%LH@W<)OV\WG8FS&2^":Q@3G7Z>AC?`+O/
MQ:)\EDLYA7AY;%=#F<*U37N"9ZVR??"(SZP\R-A.&PCZJN.3BN(MM=J)X0^\
MT+M./=HI3_\`7"@M1<4H?:.%V_ZH^6W\A"\20DY8BG')_D8/<IV;NPZ$/ZRP
M\-'%M*DB"(-DLHF_5K0G#)*?PSBQNCY,`^.@);#Z>Q1->,4,GEE!9<1G6$.\
M<#%_B^6[1-SC(T")BMH_CB5A9,W++:+O]7?(B@2JNR-$NTXH:`DG5M?[J$8:
MEH]7P1H/Z%>/!J+G%E-C"[>*QRE#;NEZ1<]N.A`B.CNFT_?;\Y5_.=A[[/S;
M7S9OPQ?<.!%I'=TJJN]W*/\U+%Z_^E/QW\JKV;_!;#OU@H/I=ACED"6`Q<=7
MY1`6:4;>5-BMFP('T#OMZJ_7X`JD>QJR+TMH]:$N7U>INCZR&'21N8@GM1K1
MZ.0HPBOARR\=WCJ.[4WV`GFDF:+[MNNX?M27>OCVK8=O_;LWKJ#>.X,#5B7I
M;SXRG"BZU:TVL/9MZU"=.DZ40P[.[W4.SNN*Z$YO#LI=_EF"K`W__G90(.T?
M7I&+^RV,PN7,=K.#B`B!PX7:[=%;^'3[]SOW<]WKC-OK'3S8;3]MH#J!JH_.
M="CZ+`,B2I7I1"'YAU5-+6R^2]5]OQ^JCJVJZ`YZK]YR9[7;F!V3/8ON)5!W
M^_N]AX_V[6&[!-OTES_.R:)((:8H1.HF`(,<S7+V3QC+;[N^!70."#0--\O[
MO1TP[-W[Z-MTA@#=QO<$+4W;$<,W`O/82Z-MJN:_?4GD[IO(Y6^T9\O3,>'#
M-#?F8Z2-KOA4<LAWRI&)[9>8-[4$8'?"$&UY[^`AAN;`>$FIFIAJ,V)!"*0H
MNT05AV6Q4H(%!:F2`]=NX["E%*68,:W7S!J%QH"A+L@$"LM)^OJ]QX\/Y`C%
MX$%9&:W^^9-X)_;\$_@Z^$`<WXBAM&[BPF6R.16,9SP`+WN?B4#+GI/GP:RM
MT4AKH(XXL@N%@/FV:LRGRB\MB?=JQ^8<.1S`%>GAR<,,A2ZJNRXX@5)?*(D_
MH[(<KAQOLU+VTY?X\L#X,GNA/=<I8$>71HT"=3>1>S%PC7V=I'8&6R^$[G9E
M<3B?*L&FB(.G&<HI_+TDB6R?W:S(.YC_&6Z@MSP2+&B]#<)?`,3\R.@L6<D1
MFV-QN@[_J\'&:A(1)(;#7=;ZJP)W,[(GKX=%9G(2)!EL_N&84#P#;&[(2K=7
M*!D@:/+YFY/6%_YEYU'-Z:/)::)+?768=?T]ETQ>0I1_\'&*:K@-EV_;OPAU
MXZU=1@58"+8V'ZUX<7CRM-!50WXV^`T.$.UD1MG[Q#DB8835[P?C3?8$23KY
M^XCRN$?+=LI-(31HYL6]RB,\M)WLM%:DN3K[PXTY3)-AV5!B?^.(2:#SB]V`
M4+.W,`MZ&L351FR8#H_P+S@A<$^#0;:8/`OF@"SE\ZF?\<T*,MO?JY]^875E
MP9*_3\F/6,_#'DUUADVY@B^U0_5MT;5`'&#(HT1`O@L2.T=F^2J^U`E=7]%'
M-^>`&/K64B.1+:RQDS]NL^L8*7-G6;AW,7/SJ;@8ANKOX`GX3&[!F!HB\GNJ
MC(RU9#89O-;T)BN8:70JK;EJ%].+7[PH*D/<4"<$X#Y#I>%),V0XB>((.=2Y
MKU"MSC/FX]C3EU"FJ0,S-C#6UG'^N?D/>`"05*0?)MV:WI?IB;?X9Y==W<;2
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M2586\2'-\?MQ:#X[R!`](/NRB&V/4FV;GO3NZ@LB6L)2[+G*554NH,W\/:6)
MU?K?GN,P7H88:>IZMSU,=V4@!A35U4:-8=<A4<W8[\SXF_:[?_:KV>C$)@"5
MP;$+/MJC]G?ZZW_8W=D0@CZ/M^A^B'?N7^L>E/;$:9C=[H?N+:Y'%65A[C-I
M#SWF6OWXN0992G..4LY#BE]M(V@W]6%@`8L`6;%UT)GK7<FM)V)RQG,0RR[0
MX2_[8+1XW(HP8C(4#`RS]:`SP]O8_N@U%)01$VX][(P3WX9+\M>S`DPECK.^
MCPY3R##7#I?&'9%Z8Z/F)F*>K5[G((3//`0I?'MZI/9Q6-#5?LP^%%&?FC$*
M@]_\Y\GSXO4?3\U`=%55)W)4#U6;/-JH+JC87L.(BH$R(TWZ*#M^JMXA3X"?
M*MV\HJ[]5#<<\PXDT9XS![<M-1W0GE:#<H7>RG!5'P.P<U@DQNC$1#PB^OS^
M4COLDX"T9HGL8M,XMN9F#XSJO]%.`ZY!16&B^CB.J)8I:[=>N]5LZC2%+#0[
M1E'0_&2NFOUSHN?!$URH92]>86<4I'.)@*.#AM?UM[[2GE"Y(+,E:&AA.E%V
M?Y/?]ZP06OV`@Z6WS;@;I[.7D&6"BZ\(/,[C[*69\2Z(-"IW,NT[6[<"RUL/
M\)1SZ0Y^;DO(HP*.5P#`OE*=-RT321%",F.GKO`;XC=)/[@WM=\")E[##>X4
M9NW3P1CX-6H//MNCBQC%WD#>E2M[KR.87XB-WRF3I,RYXRWN3[UG*"NME6LD
M8`^HC#]CB3<+8P>3J!M.*\M(N04_LH8%VJBY%*CCUMTX^$O1^@.+Z6Z<HJUR
M7A%GQ';\=^#$3LNDZFL'O%-XE/EGLA,*]]F4:7<+DL@#I;F$WW0*MG%:-*:A
MPJ%;+O7C=DVU*DI&/6"M/?JX%BJ\>X1S-2,;0`P0TDA&E8_V*2IR]_&TIDMX
M.%H81^ZH2\N$S$XU>;[!]`,+#1"'"SM_.:\Z&>BR15Z[I.#P[.Q/'/]'YUK9
MHYQ5')$9+,#4?/;YTY;C/+NN;]T'0.879]_>>?&"\B#_=X?K6^<OM#<,WK=W
MCC@809E33\]+=G;MC_MZH!Y`%)J-XQ37=*Z'7]MEJLLGJ!,_Q@Z$T^5R+8#!
MW'X!/(3^JOKVSM[/!=GG3]P3X!762.,&+W%DRD^XDH.NK^F3DCB&/"`F,F[B
M5?<\G11K-YH?ZW_!$0U'!V>ZI74=3>\G_MT>+;ZD'YK%U857O"K/N'R:OSDM
MN2^OVW(%BA/BL0CK!$6=Z"!BNA95B8VS*>>A[7@IR8"_K/P0LK?HCF>7)1<&
MC9960I,C,J5_><FY=>ID/^BTE56J](DU%T`U%>:YU?U8=0[,"ZW3;;W+)[E,
M6]+6X@H[)%U+490<=AB/Z3SL/0Q'1!43RRJ$2XEB3E>/SM,GB.JI1<68&<&^
MIT6ZD:].4!ON(H_8!8XP`+(>SM2]+([B":-3NW0#`Y(P@6+9?$[Z2Q/_R)FY
MJ/"+,__(J;F@$!4SGE[81?%)`F8S".]N1CAN;OP5CW6W53Z^/!TK<R*<`99)
M22W".)7S.P,?D(%)UTMY5QEG5"(S21[2$>WVN]^E0]%&=[%$,Z..@<<3@JTD
M,S=(K>*\VQX;W_OIY\;[,1CK[+R%K!]\=#P7,[X58]ZQXS0)@&L8NM\E(98_
MPYO7-Y'=MZ_'2;*B2%A!Y0;]3K6[%K&&6HCB"X:M3Z%/EX02NJEINEXP:I,H
MZ<?6,;C7ECTOU,1ZFHHV&[P`N<:X'<VBGQR*B9TT)M6&D`^3D/?;"PE!W+P9
MP=*;9_H$I"E"9ZA-]FZ'OEW5K83#QK;C;"T+OWQR9@AI<_@/N^K%/#,\>U`R
MMJWYX8QPI>EJS54#@[6KOBW?<Z_GD$`Y]95BG/3Y4GDL6V_?O7EUS];*V4U.
M3<A$@U300U/#P"AH1H>@2X6/=&T1`XAG5M:UA&;?1,306:></!=BHT/B]T8\
M&H\KJL)F6WG!7"H%-_6`6*9V[417KQ#.T-QY"])^:D;)X4?9K]V"*4`APU8.
M>4$5%)N+6XN]V"P!FUYLH*G1`K5AS0[;^*[;;'/(B:H/)].Q':*F(]X;ENT?
M=L]+%NJF8TQ1ZOQRE1`AV3TLAX/M/A=0_G[U>H_BZ=8AE+3#X-P"(O*92YM4
MA24\HN0*T_[O/FE=["K9/L)Y;('?0B/^\6XZ0/Q_[)W;;AQ7EJ9?)6'0(QH@
M:9X/70,#%"79+$L61Z3M*1ASD213,DL4DV!FVE9=]4/TQ0S0%WX6/TH_R7S_
M6OL4.R(R*4NV:C`%5#<L9L2.O==>YZ/M#"S*EA*7H++=.E5L8^T@W9.^4-3=
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M.T$,UGVOCFSUP?*3KXY>''VF,YW/KG"MFFR^#>E>!I;8_:DBI<`C'Q[M#Y;#
MU@1&-PL^L^/:VG9GN5T\ND;(Y^\BU\``FI]J78[\V(K#L6GKP@#&,JLU)*T9
MU@YNKWZ2-N]D3[C,7:&\0)11_8`,Q[`L$S)''$D89JU/@6&7(:1;TL'C<6V'
M$4W>4'8)]5W(7#]7\7SP$;`6KDV#2?JJ,1IV%1XQ%#1.Y=XT]QM[?BU9CHEZ
M='(RCE#H`CFIJ$JQ2>E37+;VY\MXK96<.C'+)!9)`@7;QK=)G677N6GK/`QK
M2AKS=*D[EWW6[YS6Z&ZTDECB2<$J7O#ND<&B<@51Y4P64S`0ILX\'`#]T%HT
MRIM\$H>4!26(L!-IQWPRZH_^/0&<.ALPWTHZILS6X[G8?"EH5,AD-7\!@K[5
M($B\:9&V8E`Y%&3AVT7?+/GOEC8BQ/V"^)SZ)*7%C'I*_(I./S^M!)L#71%D
M2*&T4>*C>@@O7^77T:^U#1!]C.466K+Z'2.'=@]92$2R<'X(W##`S1U:,>GU
MM0P9,:@ENK3C[6EZ*_4O5Q$!F(V\2$RKM>V7!J=.AJF\8\]6GMOTII+]12S?
M-*$F(<9S&DC!%.LJL[6[:S$/\^_>8H;*.V/N;G$)KJ^H3&JRK*;V[VI?NV,,
MI]C;/@BFT98=N+BMYHJE)+8[X`(`A&`=T8#\_#%N$OZ@1ESZ'<V'I`SO02N>
M,"=F;P.;)(0J/;)+946/X&X--!$JHYL[W"&RA5LWZ1C?<9.Q.:+GL;_/79YQ
M-E()".N1S&B]ALY&OW!%S]8>H6B(P14BT"6?05OOU2J:L62(#;VYS`FO;@.-
ML:*`':]^0"R6`[WDS=$\:3!?_"HX9@D`T8\2-0@))8^6<9;M%99(V\HZHVV(
M[Z6)>E-8H_G5-K=1#`TKI:AX_RN1KBWR3EXVN^6EK:V5@^W=E$^8N`"*DMDR
MUD,P4('V`*H)_X19D7["0F3>D@P+:W4S5'MZORS%Q'^0WU$/`VK5'11<J(6&
M/QI4.M`P1UYHH[18#:L0(7$PEW=_'?](?M]7X]O7J%T%3J9[#5K/Y[5IDJ@X
MX)W(6'J<[!YKXXHQE!:I]A`90'X55$/>ZF)0Y@F%C]&$P2C0[XJT!%-$REO3
M+3:J`6Y"!R!UEG0T30T>'_\26V<L'W_SB`J0_?6]SP84#]2KIMU&W"AX*V6(
MZQN6(!806&0S=E7QWFP5FDA*#0)%7+NC+1=6T+ZF&(`XH973+54F;X8711.,
ME772@P4$/003L]%E`IWF0$K'B$0J(F^S5[&1>$@C`,'6--/8'PQ*2-UOC4*5
MFBBRTO_+WIY0F'$YLTB=5IG#L0>I69@;T6)),0+5POZK/NS_AF0(FW:X2==%
MMO8^;%@;;K+AD]'-S>3M-=W\KH8)'_Y%`JY>[.V]-PE$RK\''02A;5B>FP$.
M+XFLA8H?'&72+-H(+A4<?$TXKK)IJTKG;TM1&4",8?&WXM5&5HDH1$>2"J%#
M`?A&=X)"Y[D/NC>MC_L)!M]DBRK^WD<5:8->E%[I1)5ACE]KIO0.I]I$@\Z_
MOV06W<\<60'4U&09[NH^4'6`"$\H)7:-P0C^N%VL\I3D6!5=!0O:'B!UI_SB
MB?5/5++X\L67STXT!RN.^I-F@8^<\91T'Y"V45BLQ'&OX+Y(`Y@GADQTJ\$#
M9[<HM^)[L$JR9;9J59I5C\?RQCU$T34[.VI-VFJ&`"QI:6LM^3<[M6)I1X5R
M%*PT4XEV=C=)K5QWGP1);CWM&2G0L+PNZ@R3C1<)PPS&9KPAYNTG`V\RSQFE
M`U%+0@*_X-%[S$H1V2P/'>_TG\@A];H7\7W<G8F"^5A_].)Y<=-15QD\9Y`:
M83RJ9M!<TK^$DMY)BO^XOS,X(%EVV.LVW/L#VKH<J9$SB9F6>S*KU""\W61U
M:^MK^]&\[T+56_;>[;=_1X%=P>:?""_<'S9728Y:1Y,-5RPQ^T>C1N+<4/=W
M>(USFID7RBM7(L(1AN.(J`],Y1F>FPMU'.6__S::_$B93ZE0B%O&UYQ='EHV
MOWF!O,XH\9Z5_`'C!7"W5'`7PT$I1E&KKN*(<$`S[^&?Z30!>1TYZK^Z!H]Q
M<JT1ISKI2Q(6XV@:3N2IC*5"K^_<FN]260W!DC-2.K]&$%`OK'[P--&'9YF[
M$VDW4D!KB,+-*<:WXZL1?!QE<_3&/8ZD(MY,J$O!$*\@X,FO"H;@-PCTV+#=
M[,/LADE0-'_Y<8S84KJ8TRM.]J%J1>*I'09.8U:FPY,X'W1S.GI\31)@8Y_.
M(#0]#8:QHAFIX6J\3FD%7N,963A$$MFY%JU(]6#37!`R2XW%%^-#@&DRZ;)7
MHY/A/54#@]P=II43AG\^."GNHQP33)#+.:&@.4A(K!-8)K>DY4A!DMWSY.JE
M+#OJ=F8C&IO(M/K;^.[URN";OSE8\Q(ZH/RRM#*1I,9KJ$!.S-)=@\%Z!`%>
M+;O"C1A9,/YP"`7]]FOX?0[1RA-;G\"S-UM'V-Z=?X3G3L'"@W02<N):1S'G
M@-O<H4E5LJ)`8$-X:URLZKF%F[`1!!&,@K3W/YP1D;ANJ:7UYX97V'Y`-_0Z
M!A#)6X-C726RT:WN%QES7N/V+`6W>8^__2KL@2BN8R!NOCP%@[7C`F1M_+D>
M*X./K4X'6WL'V)#P!^6:G.(2&DUA>03=U7'QF[\*CTJ#4$X3^N_BNJ6:C>&H
M;O,%7H[+YXR[BL`/14MJQH?6*8=:@@$>\*WME;VM+7$NW6_*BB4B(YY3BX['
M5EW3_==%.9][%NWO7@'8)E,C=*Z8@]M_7`NW__KW_RTP/`_9M5;7)EC&/QC6
M1U'B4>M&`S>NHSZ'T7`T0&*#C9HO!'G[VZ]="_RK@YM&<71V\XS)UU6/K8#R
MR#?]ESO-U7B)6@`@'9']__L.;C4=EU3X_US_MG\S!O:O!FY!IR1FAYKV^QJX
MM>M]CIM.GB9OSOQ0O%,M`:Y5;J.>EJ;J296DP!\M,G73"6IE$%$=9?"*@WFQ
M&FY0_I%.52F.A3L"LI:^5O47LFB[/%SMQH"8'_)8D;%GW:O=!!&WCY+3_%Q=
MW4#]2['9>U<`=>O``J:V=UMF."7O[69D7FI[86D[MU`';DQD3:DL"'9:74M=
M1U-2XBKJ]\5H1(H$<*,B<W]O:V5G9\_&KPODY2F:5S-1U]4=VJL6_=M8@QNS
M_DRQY4!70\*8,+&QY?W79M;VG)<[FA2:J8&CJ5FY:+OMZC68;Q;+*KQCH;20
M[&'N'[VM3X5\`KM''5;I0?K-.#N6E(M2LY-PVA'=\"=R^:@>UHOIJ_R;-+G<
M,TJ:;%$W122/471FA/+60W#V]>KI!?UKI6YYEW'91GK`"TF;+Q1YY+F:]-\&
M-LZYHUIN=;"QMKO]Z8HT.FJPT`93B=C;P>I@?[_\*99AA;K)54JY%`F1LDNP
M"!A8`3_9]2\-1*$F\G>X9&7B;6UFD#5KC5MJ(8(C3*]QPZ12C;W'%`KHO)Y4
M7-P3JAL&IZM;J0GC"^K=4ONJTRDWKY"T:65N?>KJ<J<JEG`-G5)I(XJ@-G<O
M8R##%@'D,I:@,>NL@6>!=DK6Z]-BM,4/P>2UMG>8,V`'9@S(>D."1T1'NP[E
MJ,?$G,A,P#JZ4*-GQT%69O$*D3'/2X)<X8LCEE7&EU6AX<$O6.'G:#5&BW^Q
M3UG?4$#+%XN`4;GIQOB3!1N>&8OQ?>)H'N(?HS%/1V=!48#A6,P,409!QV&`
M$M:-IB[AD@YJF1#6&).'-=N;CQT_!Z=VJL/D=.+F!Z%M?+--VM.G1X-E[(O_
M'.CO_I@8!>W4?*I2P,NF962>)!P4]A*L5@Q]Q=W3NER[1<Y47DXCKJJ'JBUZ
M8/)-4V'=6EO_-'*A+O'4]S'S!P2;L[,[8``H8<Q8Q-R0E2W1X8D>.9I<;=Z=
M>D"P(G`K':L[V%E5E&N071595G\EW['%K3]H158(,$6;2M)/W:M%SZTV,%!?
M5\<703P29@"B_E2?,=&=''LQ$UU!Y;(%<*M19`-?WE$TOKL<RUF$'U6.:9CN
M'R_)$KZEJC#'36]+&:WT])00\X3_E\H8_T"L_.W7U>2^ZW:J)QVVX@&PF"4"
M]3L^O,-;G`@;ZV:;/+>QLKOG:F.V?`M<;BG2*])TUI6;,;P+W2F4N6DOR^TT
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M-4D@8C]99-?CMY9O@AR6_8K_V&UW'XKRQGS4D\'&?LW``#79[6;[F+[[.^P5
MG35B5MS1+A/)#];+[OCUATR!MG"<C9(*J>V9_.KGT<<<K&[_]S\8F]/)"C$U
M/SRJ*7RD7Z"1:%IDH@G;L9FM*\H"V]Q.ZIR]L!$R[6-#Z_+Q30ZYNYL.Z3U/
M!GI-J.LQ0B'#=I&6O]4\J'TCL(YH7-LGG+'G;(D2'-;9.1[3:F_X%C1-\@SB
MQ'-;Q9\M5T.W4U5<=V1MU&AY:MZ)YVYQ=^'MDU2QK=`(O>*87$5I(:>-]7WX
M`XIF:-K&?3*26JT4OIE92AT+DP[7;G#V_4C#E6`DA`#OZ.-,6V35*A/[.9%P
MK<_5>OQ%RD<Y*HSX,\*$F*&A1U.KU=!A4D&/,?P)OA,V_D[MI^K//<^-2>[1
M:.W8^MG5:\0#7=8_+#/[8F6[W4BM\=%6@&J[7B:L+Q_02CN>U7K\W1A6Y8R(
M["$Q+.,",L(K/H7W=,LF&3LV6?PR&0$%PVDI76Y&)>EE&A:YK32B$4T:U2_M
MK.WLF#-@@T+$'=O"T"+#0M\T$]R,ATC,UN9J.-CV`2%.VBD[)N[1&4!AH5#B
M,<2WB$R8N;V^7WB^S#B7V7!1-U#3^;I<7ZLZC8YAKJ\U4(Y"3*Z-ABA%&>?B
M-['7).I'/@0]-66W3F:"P-K^]J>XOS;7UO<^56NS[!Z+SJU=YVB,7:*/09?S
MC&7V=]=V=C\5G/?WUO9V@[.,=F.#?XSNZ!4876[1K]8N]7LO5)NG\&]24;.Q
ML^4%*9%?L.5XD=*/`G%%'8I?YZ%=9;1/OS@DE!R7*UPO97M?%4WZ.$7Z;M+8
MYA]P,<,S/@36P/'EE)3B$+'0\2XH_;,;CCA^=6/OH:RJ5-XRS`VTUJVGLQ62
M4$[]&0YVME;V=W*)@H[W;JW!F\J(=G-WJ3.XU-`%:Q=`;FE/D>Z#`R.U);SS
M!WLD@>0#7I/B]HZ7;4LI3>/^F\!^@ZD<'&S[-C;WJ:QH[:/FCOUR+O@G$*X?
M1M!]"9-"D-4;4%M,7*ITGZQ_P6/[<J3JO/J'Y<V#E8W=O?K/[PCA)F`CY^[T
MRL0P15;*YM&*6$*>?R)%I7/1EFMGX9J(D=L4Y?*IRCV>J=)]14*NA:!:)/Q>
M\&I:I[BX2\6\\[PT#2K5U04,YUWE'.5W<(_H?+"HA2SN4N*9R@G!IMV9<FH%
M<&V-T=1.&I2XGMH4<[JHLD3#"<ZJLRU:9@&-1A1(2+!4%*=7S.&],3G14#Y<
M,ZH2`P;A[+&1>-.]$OCXQLH!K&.'BK&,[PUG@4XS3_QLD$)_L+4[#^'>AQ%?
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M%-&;:%`L@B9N*$C(O]"D0,K\.>6?KV/)*1^Y&]ZJQZ$0P-1ML0*B:58S@:ZN
MO$8I_'I5AM/0^L/A8B9WF<#GU9LW,XC?EJ'3S^')\1E%+-?#*>L13.1ZW>$;
M"5]_R1-*+WZ\L<9A:BT7SX4>,'XUTHHN<_11"@R5^4P;/(XS(;GKZO(*\W]%
M6>?Y/8?;L\/CSS`4>)\,=?>^I1"KN57Q_YB:JQ+L21NB6/W>YHF`%KT)U,1(
M.C&19TNN-C.-L4F8_LJ"#\7`9C#BB,$\HDK3*`GG'-C(_R"I"](V]9\"CP%%
M1>B3V:WRM:7!DKS:6UEG,,P/U/4\.'.:/9]6OQYQZU:%&!J'Q'XA(,^STZ^/
MC@QSS/_+7@;V)S[_%J_"%?]692BNQ=B\S1)/$*,4%T9(#ZZ',R7\0/Q,/"9Y
M954>1^X+A9P3*6<CMZ#P7A;H14-*@,C1?<NH"P3&]6CVFB:#0U#F&;VA;D,&
MO>;;Q<^X`_=<)2=<@-1#+Y-&C^]LXJFXO'`=P&NP./)(O>/!44_")\$$SXW0
MV!\PM+JBSZ*G=%CZ<%5J);J@"=%K3NJAO2;N6Y-$.?\A'<=R8X98S0(!L>;K
M\?`R;DDE-!A6^*QNJ2938J)PR,@STJ!+?ZJ50$"-Q.2_L-5#^R-#'R"A@N+H
MA;B%0?(!\P-8HS';982E_J[C]@!>>$5N-#`[!U"TLY3W'VQJ@-\0-I&SQ=#M
M:S]S&CH,.9I0!*-,8W$0YHV\A/!TO+<TC#3TMQ((5=["GR<T[+<[:=>U"=C<
ME'('7NI<08:T8AG9PT2TR#+G+0Q`VE=C.,1P<*39UV3PZS*@O><PCSOJ4FZA
MESOSSL23XDUVO)74LYZQXKWIUQ[^[(DN(/8C&F,@$@U#LV>:]B"O`&EDX_KF
MZ,YYMD9WP-4TLRU]I-P"(S<.F(OW:8O?P==T:YTO78A1&Z^WO&[XJ?RDT`H$
MJN/K2+Z)@I#+KYK*%#Y)LQL]'V0/2JQ=C=KB\`EMP=LFRS%<XF4#D%()G6%W
MK$9G'ANR@,<*K%E?V]I*T2/VFF3>_VEFRY@'[!`:5^X?SV%=$R'%&BPTXV[@
ME#EP.DWS^QNX_P@EXJ7+VE$\N\0H:&'0::DU#RD2,B0_$5.BA,1RTE9Q'0\5
MJP18.&SAQ6]L&"NME=GW\8U$HSW9H:*\YXH?49\Y`V%$A*9]B._,$A!4]B<@
MR"9%E?-D'1\G95T^@9LE>[D^&%4%$`B6D)G;K5=;629^B]JSL@C[!=#4?TT&
M=+-&O9'FP/.JG/`L?C8JWS[_LC0SN\!#Z!5687/=K47IEX>')T:N0M!X@+SG
MJWR+3I0FX9HL2"1T-[-<+4B&?NX:V0>/L0_JQ^8N%L];3-SD]+$+<>/WP:\E
MT?=$2M?&^NK_<#X1=+1]T0IY<>'S9-W]3ZE;VBSW=(T:Q6:H%!F;&1><M2AZ
M*;)8'-86?CD>3_UV4O$Z-)[`9C0M1+A&OEF.L&,^ZE&X9Y=TOP=!7L[NJ'F7
M[H%2)T7.]IFG!JF0&@B322@4Y-STGGX#U6&<SNY,*2J>54]<:0#&O+E`W<GX
M%A'KUD]N>JBAA^HG@<[YVZ]"B*%[VM.)]"6[;N.WKDWKWQ%Q@B<5U</XQ.A2
M:I43A;-H4!]>*IX9OZ2&V@P$D/R2_MGS@9<SKLE:7RDS`V_*[P$J!8,S]0"1
MSL2$4B`!#/^.CF?LS)!,AXD\;3$9A\U&'BJ(:0%K(C:R`K=4.1/KX0RQ'*EX
M]&X$-O,=35_+5!O6,_4G-`3QFD>51D7<_]K0;]'G(%INB3YA0;73\U"5+30Z
MOYLIN!@&&FYW:B(GF<UPVJ/$V<"=__[Y](N<@&&6YYRG/S++7GR9D2$(1(T;
M<)[K3'OZX]A][_53W:8;RAXL"-15K]-H\1NQB&_(?!6'G\6L@B)3KI0(Z*VA
MNK+SBK[U'3V&%ZALV`K]GF`3.C<RWJ\48R*W67AWW-WO6>8C7RIL!@O=M1&G
M14!QGYO60U`KCH.WP>3Y4((U2`K5_&K^L0$>&K>&[LI@\!N2;LF4KS28R2R2
M(38%C%Z8Y>0.T?KH.).D/*]9.'HU#@N3+5%E.>CMQ1#0(GW?H;&FJG[]2R':
M1#'!S*1*?DER)P1LI:DS9(]=2PN7+BLVZS92S`@1V:3S=Z+QBS1;2Z*@D[W4
MCWQ$])/5!=-&TEW!]1T0Z;:R,H<\;@P,"W@G)2:V2PGO@LM)M>Z$SQ&9W';[
M]A_*@B(`#EU7+EGCP[W/?D2(G66^:A@JTQHD@SG^B,<"+>#ZBC.!\I$CFD`>
M,]O!JJ\@'%"0!@1!K=2TL)!TQ`58+B=`1;8KX]U&Y@7PK.%Y1?D),\_X(@K(
MC`I*&PJI^AYI/-([GCPZ/D(IF,Q4I2"6.Q7S[@SVBGY:HAU9FW7)4H+8CF2.
MA2)EE_3RAIW3?+7CLH,L91;%'0Q*']-U^W#OC^?)?6;=\.7:T8ZH.PT[$D#!
M<X]2PXZ\;PF/<%S^[EY&-!?2F1!P\DZMXO.QC"I9E3B+$F?0K#OJVJ\!/U$R
M5P9UT=9_E2:1THK-`:X=T--!_^TW^@=O`-2:B"_&G7QO_2L#1[;S3ZE=Q\5)
M+)#Z-#,U,B"BJ0=J=PXT-YPD*0U8<*R8$Q<)P0TO*0MQG5?B/,+Z,9@+#(.-
M$/`*K''[:VWP`OG(L`F[,&L$,)):H`(U:\6;P8>;POPXG%-8%]YW+:'IFCI&
M;[EB8@L*!33SE-;+JYK]CKO&H-&A6"QX0RPI1G_XE/[W9^6WTZ0JRFBUDQ[]
MC!]4!Q+VF8".P^>N\J$5N`43P%F+A^D:W,=C>M?%U1U7C+T$E/4'LVN4`!+$
M]`553V\E.L-,6%41W6`-P;>P2:C1,Z\A:_(\7F=L-"M6NKEQ?G69I3#.PSM:
M=#`)#M\ZCEDWS-Q$.E;R-!LD0<J5(\,1"!84==2,HAATLT%GRO*^FI@JRLF-
M8;UD5C.8,YF,`PEG`TDW;3AK6JSP'KR1:F`ZBKMMXT$]2XO?4SFBYW834BD1
MR:?BVL)L-AJ')+!(;'@YG,XH*BA>_#D:=*P?$V.TC^B?!=7/1].?-9Q"?V[&
MTXM/BITH`).NQW;=QYD?X4,)T[T_HCR568$(33NIV7!Y6#]^8^PGW#0ET;DA
M7XQ@AD]?<JO)5P#\R$/5.%!!JOZJ!\#A\&&"8W@4U0@B6!O`*^&0C3\:\@CO
M98C+`S#\:7A%%$JYDGG?SMD3WD@XB'3"2OY5?<3^.+X<T4$4(RXZN7DRKCZF
M3<+=3^Z0]V/@FQO:65Q?UPI_GUV^,K9FTBVJZATX,/W"(/==3#_,MM9QGD/<
MP0?O\=9'1"?;G1,K!'@YP@=H/-`(QZ[2N5@B.22N&CT9[>/DOQ;+,?I?$4^T
MLA9Q!=*O;,JQQD(-/83B@0Q),#")RR_,WD2N$5TL`$L30/1<E+$".=`:D5-,
M4O%9>!87@JMQR>XWDS-&QPD,4`/=B5&)#ZN/NOYS9(HG[[@2+UN0#0<<=N05
M!0QQ#^&8\@TYI:"Z$K%7T,H.C**BH+*?SFPRB$3KPT'KY8DB9V2T,?.<ZZS)
MF_+)N`GY;RPI/`[H*L4Q_^TCQ/P1H;'%G8BZ0JN```D1MBBL+O>8IAX#D4QR
M<@PIG)*\B+SE[0_C7R`[=H4?]!H!>&W6<V`3Q2KY!&P?MIV#6;&,S(BOI4)S
MQ47'7#YR>'HTV-]<AR[^TRFJT!"N-(#O'SY\;^,/K((KZ/89T2=43K$)5ZH>
M(331PJ2&XD5O;?'/V!X<,SE[>NY:HJ&P0_V^R(45%N."I)#9@FK<?8&U?K]<
MGF&IDPXW7WJR1-]-U"W&VSI:EW:0=C>91-51;^;%D-02[_`->?-QX2L:`<U&
MS:)`KN(;8*II-9/$O5U9EEI5N%,R'^`;Q4I]X'+R!4`Y[U'*SSP\-VC%7.N2
M1*=?'".3&!)Y-OREGCAJY%O^_!'YOWA0N"P98<X@#4!&JI%U,/F8I!4:_QEG
M3*E+XK:2O9QSJG/F$D10QM_0`!""YJ8M#G_I8TM"U4+B)\3,&IT"^:[29;QW
M?YG8GVER:2-9H;N'(XU;U]<38W1M0VB*U62E7!S-!I,[[1,.#Q(EMG(%)D%5
ME95@M%'N6ZM+2_6UU,L..Z*>PQ8-D2Y@"<K#0JKA;V"`2*Y.LLHD/LV>N8ZI
M3$-2X)%#5Z]'DK/$HLW:2.9(^R,P=$3Y.;HR$1=9G#)*%,<Y[/HNDIS04XP9
M66:*BO60C\!25BK"M?V-R4I@.+;?["CU@$=F$L@.YS"6MF_6D1R#G2K9"[QG
M:>1M.;7TB#E672ZR^2]\1$)L;"PDM!G/E%_%5>)@Z@!CTWB)^.F&>E\D0^S-
M^0Q,RW++\LY]L>0Y0=P*V2,38&UI`C9A`LD`Y[PK8=S:6>>UG"IW8O6AB9>3
M,"*G0S7N>NPC7D')"Z.E[`RQ$!X`Q--#K*8O5&<H0X9K06P!20.RM^X!MIF=
M=)4220?-ADQ+)2Q8(KQ.%R$-1!\Q;YL8@_X1/@\G@_1UL:&.)=:_5"4OT:L?
MPL-PKU#QZJ^[PT`T&(@ZMG,2\X^I)2D,:=\V!6YBE^ZL&Y&@>A77PJ.)WMQ<
MXO&V`DF8I-HI3`+[*;FETN;=>1$QU)`S2*JXM"`1KPSGAM=RF)<P?:8879]_
M=[Y.GV[QW_%L8KPOP:]Q"J?#T/_%P^QN!<50O=V$AT2J#R1@N>85[\O1A8BQ
MJ$QOZZR29AX;H$VN.ZDE?\YQ/[W$5V&L%W<("@\<OKAKT2U*?"A;M]NC*<$J
M5W9!"BPI19V$^GB(:_7F%7D%3W$J?J9^Y>($R@DRXNP@VD6O_),0<*H#E%MI
MZCY3X`KA>,:397<%;>;NTJ2I>;ID>FSNFNF13BJH&#A0]BV')CRD#)JU`6R.
MBE7SD%PQ8A*DZ/^@AP.FUC>7!^$/E]3U*E$EOQ3S#LGMA`;C?L5NR!/&=#8S
M3.CR<ZS6':)0J%KW)E7W&BV:#5:^/R@+Y@JG8L2W,Q;E]F_!+Q/*GLM)$A-D
M@;^&5%(L8E]:LQB47(+VI^+'QLK-3UK]FI"SJ$RR2-F-.4!1F,(:R?'$^Y@`
MSCN@#/MR#57;A=&5HB]^`#[BS!%&J;S`Y+/`C7"U&@_020<O4&9P;1_F>/`)
M8^X)T5^X].R@@T6OB`X^DH/[V)LQ>SLA84KV514G)$6`N4]WEY/!P['$5RBL
MZ'SBVUM<9]Z>;W7]8`6EPZ+%'K4X"K7>9+)K,-#1C'1"$LZP!L@[\Y$UYB6W
MP6IA);H8:L$S$I(N!KOK]%J^UY)NYY%;+@T:M-/A8-V*7$=F:%D]P4!TS0<J
MC]\AIS9^A_N3G-3C\DS%=AUO-&$5#SZ'N'N[FL;*=WWD%7%+8QPA=QOJL@T=
MA[?]JR&>)<K"*K"$)TT9Y8XBLW;Q-LRP:I[/1'WZ%H>ABH8&ZP:WG=6M[B/]
MU[__!]?"&6;XL1AD<4;"LM$@>!UT._];NCP';;@7A@OGSVQMKZ_2XG'P'&C?
MA8"/K?4H6G9'TE']DWCU+M!1:DS@N.0]X$WS?#S8&N(+Y<>3&24`XQ7M2@LQ
M4P5Y)H&)HR+).:DW?MNP1@*-]-HPD"=_(PNAM;RALN-R\(I.]>:DDQM83FGC
MIQ$[N60.$2,R]L$@R:.&1:(=[-;Y$)]SAB>,"[MR-<56Q7*R/RKCBG4K+4E9
M$*W-N+)7W#KOE10B^9X;`DK!T:<#>W;.9_$A('*K@N>D-\A2)GAN)2Y>(9(<
M;AL@"UP!:LL(7R?Q)9<'ZFR]=,.YHWN2>Y"#2V<+WA:V82"RK!;#_</3;ZV%
M(8Q#?D;]2C[$_%19Y[>%U^_\3_+Z=4H'D#?56SJQ?E"&JM9%I>T*8U;K#:&^
M99*=`;%^//$`LH$5FYO0H3%`Z&`(@>"K'7L"`3YR%@V8:\%F)[@#X01W<C="
M&;&UA$FZ)"*#8)6QC^1[Z5DQ>K]C-51$2/N<?K0/IA3:^=POY;W9+AJ<7%0P
M9PL0Z?(&Y39N*`G'28L6]YN.Z5Z%N"E3?0,J`I>8G@W,>`71M5*$0H/$D;KH
MZI=I1O(_3F%EZN=```N/N""6/5/%JJ:3A/3!_BOQY@\*QN)7YKHY9J.FT"ZD
M=9T6I/#L&+A'BT%!H*.;5]P[X5_I7VH7D3YA[$9[OD/@6>YJSQ),@5-X'-;?
MOWV.#[M@`5@Z=V2)&W)%J>&[Q6C"UUJ7U^*"5NJ-U_KNZJ6YKH)-'44MZSC>
MJNO$X,75Y+6KEM]RUY::)9(QCU13C4Z8:!M-^J=4U1&O,F60=E(*?0691)"G
MR(CX[5=3H="#6[+:]AMH$"\V[=6&MS\.:%*\JO_MK(K9^L483D31UH?&2E2'
M7J0;OV%R@J$5W))R"_#8`-SUC>WEX6<2;H@A.0J]D0E/8VA@4D:J7_[N^/%G
M<MV)2(10@1NH+NF2-!2I"Z(2`Y'];EC..C),7;+ISPS%`3SA97!L,M,H$9]!
MB]-`Q@VXP-['@2)<3RN1E=\;PL.Q5.<S/(6J\OZ,X%[)E^%5FV-2+?BXWSNP
M,8V#1`DL8G6FB>XN.4F3BJ7]EH>Q!;*WNN2OD`H61<*7)`ZQ?"Y`B6BKQW8Q
M*'(!RH\#PY;B1%!=%V;R+ZEKCA0KR/`H_7@$K>FYS+?K:_`DYC4$IG<I$`;!
MBKD7/+R"C!<)M8XD%Y2U9V[>2O9!)34RN'9,6TEH.XEXN[FSNKW#%83)K?QK
M+V)Q"KV<P^R5AT)U'"H2AJ%NCG\+"OZ'J!)PW!:9&S]@E\$<:"L[C0SX=U%N
MMIW7U6H-4%/)K/^(SQB597@9W'?L(T*\J>%$V./;XW#V/&20%!JZ&P%P4PUB
M@#/H#Y,K@I3\G\)`?ZSN0.6J=,+H;%NEZ@=/0>-OO<"?N54G3@FO562B);B-
M%[A'$P@J>!B[X[DC(+1!B+.11,%9#$$8>6Z[.RD#WCF/(>Y7M%KSDE%$KU5)
MABYK0%W#UHT=V!TQ\09*=(4^.<K.((E^#:D7N9+;@,NM\271O8ECU[3C\XOT
M:R23\*6-9<X;8:5--&ORPL6*],;FO17I"A\M]&C\R>>'//9LMH^77:J;"S:-
M\?D<%@(;E9L'O8D?RS.,6(,Q^XXC;P(IW=6.\J;_7FA9^&3;X.N0/CG)TU1L
M[:@AX3VVU9(-V&D:?*C6#V=*4YJT&C^<YNX1.;4C!F6E6*>P)8RHC%(@2`%@
M(WNCZ<.:?L$D`,(\>!EE*\"UHX,,ZN(]URHQ9.7>PZ6N]%2TI=(Q!WZ[\QBT
M=FY0?^(%Q<-2'$X([[\=G"DI2%J`!./RXA,7"D-,@34FY6LBM:9OZP_BW6`S
M?$OT]QB)[\;//3X&8\IO2K#:F_7ZCXK,N]Y%"[A>IN=CKQP8C;PR08,!&+1U
M;!VCN/9\J:9,M!?DSS#,6*J;<QZLK5V]?T@-Y2RK3Z@B\AR@`@N9>D^4L3#-
M)E4'`*U3?T%`!_Y]2WWO_?\'/]#6@6F+_ZM^W=SL0:B4<FUPF)4[N<W+YT*$
M<7!H4;@?GBK+_!BC;M)>/1\D1N[\!CA]:R<F1Y\']W7??C\4_3\:45=R301F
M^=O31X.E>8S@`Y%_1N64(-;"PZ>R.`<;O;?EOV\N^'VK]_</#+W!1@MNAR5C
M*VJ0":T5C$V85D0<VH&?P3RL6H0C`><G?QH8SD:42`RO>Y&IKZ2C#\E["C#Z
M'L?=N!;+2S=KLCJ$X-3EHQ<8-";M(,;1+4NB5^&]W*J7_%!8%,%6KW]"#UPX
MG?QGB$IU??!.&\F^'E[`])3A!&.2C"1^5J\AQ@N?=N5<VH>E):,M2V%)*H:Y
M=9-5-W7KW59'[45L]JQJ[1O4A3YV1^T5R(\G'F1O5MS4RSXXHTM2*+_I^0U!
M7%3&U`\9=[94!,\5!BZ6-$'#%5<4W)4F<"9\`'""D)W%X8`)H)Y"_D;RJ;<:
M-`;0^HL6%VSQ\HY'^M>;I[1D-MUL2S3H:TL4:61ET,W7-9KST=WL5=F4J)<T
M"K6@)8<%;5>,%NE(SZ@+!UAT*(LRO`4OQ3:OO*E3Z*PPOB,K]U;6&SKX$RF#
MYLU]\NBP=[?W@.,@DER?V%L?/$-#H</X8]75UVBV,??7W;F_8D/-6YJ9`FN#
M=;P>"J+6WWTVO(,;X6CH^O'P5C^&(3?UF[9L'%70^G%(7+#OQY.J%V=$K'H1
M8[X*T79Q2F8&IU.U.+.S;3]RB\?F:81]'Z8+Z%J<_]N"6(/]]:UP?/*\%YEP
MLK`Z@9(ND'N3K[YECV*KJ3,S(/,,IKX7#!"A<T,+2G[W#J76CR2\`U]'C!8(
M3[\^[CW>4\*3M/=MQH%DPPAP:L&>TB#S4.C>Q0Q6&XX"&S5^S*/*2(WU.X<^
M!<J*.Z@84R0@#;)"A'$EK<\L?J4%O,6OM$`:7J'>`H%6;<PL5FU-GJU.K"%1
MU88#DX2NH2OUJ6N*2U'DKH>3CA<\"WPS=5B_*"3;BDNSUL<:$JK9<%U>KF[S
MNH08'S01>XOO%64EN,U85GUJY#]M=ERK#WN*]VVZRBP7#F?2=_[CE<J%IP%!
M;RX,R71B*9XW`YYH+^9F"3'X^L,/,CWR*!J/N:11!*!",Q$'@9=9+"DW5Y1G
M,:3[<+F;&2/+V#;#!%46KC.A52&Y@-+&^J?:HYQ%U3P4JI1)&\!W9[4OH0[7
M]+289MA(J<U+;LY?T9P1V*:X/XA:E)CAVDK<CBX+U?'!Q*@^:HLUP&JT=-@#
M-L6`?L^!Y;,5-`R,`0]/W?@-XW<(3IYK;94$?4"PW..[8H'+%Y^AVQ2YS((7
M/=>]P;-P*P2DO$5ZSHV6.JZ#5>A8N42G7U3(G&ZJQ&J62LO4-_(@$?^[WJU`
MC[M[6$W9*U`T8\A%P45BKA9GC[9$:U-G[9.K8$WUKI<C5>!HSE2(7H:2OG3R
M/_L<$++<>9$09B0Q$%;4Q->%.&+$I5O.D&K@<(2/SV])G#5P@(?1+6=8XQX!
M/FDUPK:+%K)@#%Y1!\/[Y5H1<JU;^-X+B!C1ZGIL^*XR!=0$TWJEQV,;`3:N
MN3D&+@>5'H1YJ/7GFI:J4FPNKA2,@Y?``^NG3?\E\A-9?DY?&%[^=#61RA]E
M7OUJ13(QDXTS9:(1^26:<4E0+X.A2>`FZ1*&C2%"%`+EFEY*Q%H7S+6*/9K%
M+#_>5/C+O]&/2$Z`;<L*=SN92A/%/-7A`WB>`VR#`>CO&2J6+N:>Z,%R^).J
M9/294\L,QC]D+1S#C$Y]QQS.(.34.[!:<)8H=S>3\3R!ZO@AP!LX-@RU3S#E
MJ8Q-]T!$S6+_$X\UV?#4JY=$:1WA++06$!7I&+`OQ-(L_3B`Q&';NO"0?W*.
M7*%+L#>HS5>0@L`<P:L043"`;A3/:;EBHUVLV,N.+!M#H*?IRX^6-L#51.$>
M;AVAV$)/(WU/3I`GVMJJH"I%(#5V5FX$Q0S_"R_`YNA.0I:%[F$2W?8YT!*8
M#U;3C"R*H/.3&J"4&OMB0MT6FP@B8<"<8',+U9A0<MB2Y&L*>3%^.[S&GP[+
MCBW&ZT<>?&N:KP"8]N/H%RD&UD@(#8>]3NS&$AQ!DY9G8//;U?.WJ^$_0R"!
MV%'X+OS*M1OEM$]LB"U_TG+P%IDLRIBQC%(J./"UHF*Q#SDBU)S"9^*D(4"F
MDNMW3SK2N=VVL96M@%P)5:F*#EV6>U4_TUO<:RT8<SSP.GB,O/^*$6]+N4[R
MV0+9;3_"*><2$S:M9X5B$(YFI1"V7`WOHVOJ(_5XO&,0_X4P=Z4:EU4\P_/A
MH=;FOF1:,^(OSD5/,!*PM4*.QM4;L7NO!U/6#U7+)VT1W.Z3+GD@5QHP&#24
MQG9<0(-1:?Q(_6UC[Q$)_S6BV*@GFSOBU(/VB.+I%YA$B,17(#_W_Q)]`^9Z
MOPNP7L;D,))<+\HT7%JRR0@V#(6[XE^[6TPMI;@>#+!6#&(*G>,X6]?YA#0?
MG]D5]9V&-2--MMCY8&-K?V5GKVQ?+(I/%$O$FC>2%D7B'50'ABT=,.<U&[TM
MLC\I([4*-X88;_;-=KM:GX49X'UNGV>A[4[?[]]ZCRJU/6H1\8,MSWFL0=;8
MJQS[G5'EQE/M$PVB7Z;/2]KW?GROWM4W]!XF)O_6;-OE17`[(;M1`9LG)NEI
M'9[TM3Y(N2?17:!;<S_N+BX-Y9A>J9F]=J8X=`A@=;UK7FOM''F1!P+63SXB
M3!/=VZU)YTE,UF\%ATI,!C/L1FI"*:9`H2LK>H_TZXI\/TJQ?DZP"*@/4XI^
M:,]#@$!63[VCL]A(Y8E\[D]C+Y6!":%43D).;!R0VORA7N[AD#37"T#7^;&.
M33U1MZ#OU/.F7BKMS+A,#$JCGDL\YIW!7(3WJ##-'U:\$5'GTFF7_5_O`C;A
MWSX*^6&CE0OPPV;K3Y&*!TEA1G5F[''K5AY$>ZX&R@];K45_V&[_::?]I]WV
MG_9:?SI#=_*.-%:6;^RRYJFF!TIEQS!*;4LL1PH;E]J0LN='D,THU^C'EY9E
M:5PX=,.!56NUYV='`]S>]('R/CC),]?H;AP>_N9OIX\'S[X^,Z=?NP%,BYMW
M7F2D_[[K;+P4'Z[OXH62@250\)\6\5L;(*"CHA43:781V]8)'\>.#5:@.<(/
M]?8*7;[^B&&HDF[L2U$LUD_EL:OAB23V6@OFHR771+T:MS8OB2>SGL/S<Z70
M#1XR0H?TU^&M3>&1>_'N-D4/^B*3#(:@$.$83H-<I)J6]"WEWP%/]71JZOYI
ML7JK89$/M,I[+@,8KL>O["PAWM*(NM(O6VAA:MG"X.83*YO0300+QFR(/H%X
M:#FL_LXW&%)ZN#\=Y'[WNU`KL#`04YL[@Q\6K=OLC6_>S%YB@\],]5PL[Q]+
M*I)<W8L&]T+$%NZX7=DHC9*^<&)6(;+0</`>Z@A?'T^G\ZF@_OCSX6N,NDL8
M"&.U\)^!^4]]7)+<8GWWC`>O/]F)'[=[WSPDS^RGP>E81=9*C^S[`G/1B"Z3
M]"UG8;UI#^]2<-+U8Q'57&]-L_20H>?7M)9]HJ#,5[/I!:V0)K#Y(ZD0F+.Q
M+\@11CK_[MMR8!;FK<F3DV"]Y(^2X9&4L=X%/&CN8:#6YNS,(=S>^A$M!]42
MGZ#-TD90X&A^MO:(PF2Y3(JS+#A""*JU]`#;692"]6U8,'BSYS;^.OZ16_YJ
M?/L:F$H;B_OL@V+Q""SX9'1S,WE[_=/PAB%3?:]\,_X)7&$V;!<Z+&`R?4)5
MW$N>"2OH3DDH*9.DAD$D4CG8>A)&*U=R=#SU//V`?=_*&]OP:4'AWUTQYKE+
MSH&P]_5T;;R_JVMS+;CFB[J%#^/M>A!=@0$RYH*J-QS;.%VBCZ!Y/_GJZ,51
M2^6*"X%'V:N7E:3Z#EUL7611I_L/I1?ULP]0F+WXKT]#/IE!]-(L^+ITSK'<
M\-9H$1XB!6-FG@O<99E#P/2+PL'ZFUB_FJ)6]'])S7&:06R#V*4E6UVL;E+C
M]-7LV<;!3KU>PW1DE[?=Z_<#K+&`XI-AA?I#2;/R*7)IU]3C>)X5'V<8#1YX
M`4#['EZJ-["5Z75D`SXA!<+4[GLR;`I7!\OFY[3R3^U4ZKZCZY0INWZ3K9S:
MW_<=::`C#T"T5LSZ,<)=Z0LM3IOR$X39!BG+1KE$%ZC!^@T4OPKVO`0<YN&0
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M!]N!.Q%<"L'-S8U.7TWK+/?<3_=E/M@+W]V)G]W8_:"?;8`AW%)P$=88G6'@
M>R$E]8-N90XQI4]W?S$',(X),,)_:59CGKY[W.R<=^<C[;P7^]'UP7ZXT.UX
MH3TNOQC%;-U"7&`O+M"-$/@,79YNQ>?V.F]K\3':+*;BV`M=`\R3[\]1?APK
M?&F#@2E*)RW+6Y/H.+=&46\L+Z_?1HVYPKV&"0R71OHPWI0GV&?"/$5"TG#5
M-*"C<?^",_I_7Z2`9N]S(:W-:KKT]7Z/181HGQW4[?=#346+14=#`_#!NV)[
M4JH6-W^L\2J)IQ08Z_,N%GO!]1ZG2ZT,K!/`2U5RI$H5]7>H/]3WNE08ZUG[
MTYAXOD_!_5WO"R3U1R,UU']?N)GDCOU=6U'W$R4]6-_'^MM9UVBH,SU)`\73
MT9$LDP5V9T"S)5:\&6B;8//+1>K4.W[54C2#RD71O,^OK<]46M?U[NIG'SSW
M9"!O+I'<XZU3Q4/)L6!QY?"HNH0,$G>SL)!0W[L'2%-?40;_YO9Z=+W;"QO&
M%CU673^^N;ZYLKN;(LB6*$2#$[XCNL(""QE.41D0C]K::6^*4+.6UAYD=]J.
MUJS_/K'-H)R4T/$+#1<_4/\`OH6R174Z,6H/H>A;ULE8*X=N!68@\`'<8S8F
M+#M(6D;XJ;X1"EVQK5,#AT$7M90/RP$2NSU4H&A=:(!+_?>"R-ALB7;UDZ<E
MDD4]%7L6A;EE-IRT4EC2"WS%$;7U4B:$@,GQG98RK(`,^49@8RISDD\"8\\/
MT$.FW][(D`H-<1N`#B9:?61YN,S&&UV&OE6ZX%N7,#$?HWX)B09B@"2.VO7/
MW%G>J#)2E6;N5%,_VH1BXX3^8OW"MW)EQBR@[$R=ES!V)HQ-47SSWB*PE`_R
MK[1[0.!(#SB4T/(!4K/7O".0=]S`0A<^M5-_MSP2"6/KSAU%%X/KR;?`$B"H
MVJTG1M/*C<RINWI<7P0'S7&*]+,L/>D%P7+*+5;B0^K;-;ME(I;W?5(V=FX*
M88ZB$"\&7$,O!4QQDI@Z:ZXHIEDI\3ED&<,'EJCB75]?;_'#!U%K)*E7J.G'
MC,Y"I0'7Z44[.]LK6VCE0?HLVRD_,58Y^>0S\?D&]2`#EG8;F46F55KB[$L\
MD']^8I,)H`CQE)BWM,6\]IV5?7H0@X)5B4H2JN:#%?-.U]*&J'$&@XIDBGD_
MA0BS;H:1V0`(8T%0XCRJ]J`U[)<T6)5+Z/CF8DV)N:D9.7HAOMME+?O)B]BA
MW/[H-Z`?5"=\)\=N_"Z1%\VQOM:`:UZ/3=4^29R,!S[!(U!BK:6&1X&L'\J'
M0<&M=3K\$>5QU5X4$E&'FB;^*>0)O;'9RF931ZA1A><[$^(H+5*KE+>D7+M"
M$<6!2\36#31YN=BWZ0]\KD^5SQ:15T[%\J66W*P?'$ZGX[L;YIQW>0L+>9_G
M@]=RY/M8H)0DL%+;8[Y":#U=O_2"-*;HCD8.HU^9"C1?^)"%TG@/WVYX3SP.
M=4S$C_L9)J?^NU,B`A,RB<4"3/<J?@C-INRV5#$@]>XE:J&8:(*W-#6CEY"J
M'TF.>W#D6-KT8B)39OFKJD]*WD%I/>YD'V)BR@9I]A%:+/XYCO.9DK?^DCD*
M>>46)<MB-I_&D2M:A@LV/#.Z#4A,\L\O/AJPR+/T\SH*BNLMT1D1#MMW&*`$
M]H8^]JY2V+:50.TT"ICKS3N%G]J1#J/F`(G''-;!?QN^N?T+,F9M\/3IT6#Y
M$_):^5D*]Z5RAXCSQGKI%I7$O,P("#])C6G/N5REE(?3]OK79[1*Y#ZZR*#=
M]RJYN%M?4Y@]!':WZQ_K=?K=#;FUU&-O6]6;V0A.MC5$EV7UY\M'S47SDT+<
M"&)K`E0_K8!I7CG&>""T^!888P$G$(O;0E!O[QO^-%"\>F1I8U_HE;_U^60R
M_>+_"@```/__`P!02P,$%``&``@````A`&U)CJ;E"P```FP```T```!X;"]S
M='EL97,N>&ULU%W_;^+(%?^]4O\'R]M6=U*S@#$!<B&GA<3M2MOT=)NJE7I5
M9<`DOO@+-68WN5/_][XW_O8&L#V&,9,>N@T8YKW/^S[S/+:OOW_Q/>V+$VW<
M,)CHO?==77."1;AT@\>)_K<'ZV*D:YO8#I:V%P;.1']U-OKW-[_]S?4F?O6<
MST^.$VM`(MA,]*<X7E]U.IO%D^/;F_?AV@G@FU48^78,'Z/'SF8=.?9R@X-\
MKV-TNY<=WW8#/:%PY2]$B/AV]+Q=7RQ"?VW'[MSUW/B5T=(U?W'U\3$((WON
M`=27GFDO,MKLPQYYWUU$X29<Q>^!7"=<K=R%LX]RW!EW@-+-=;#U+3_>:(MP
M&\03W<@/:<DW'Y<3_5+7$I%GX1)`_.$_VS#^[G?)GW=_?/>N^^]OO_OGC\[R
M7S]]L__=3]_JG8P-H0DVJ*;YOEM)%KY.*'=2"6ZN5V%`!!F"FE!;5\]!^#6P
M\#MP!A`/?W9SO?E%^V)[<*2'\!:A%T9:#%8&^=B1P/:=Y!<SVW/GD8L_6]F^
MZ[TFAPT\P!PC_9WO@IGP8"?A<%X^<T23R31"&)Q,?3Q"9?)!)!L/5LMD_WQ`
M)H[7H)[7*?KC>#$IJN62QFO?+_9T>`JOW%:$3_0XG^B6!3FDU^VB6JG!6F(V
MGG6!W]F870[.)EG?ZEM#J9)QOKAO-V38MV2JLH:A]6%X>S9URF=6)EV:AL\5
M`1AP<K7H0NA6Q/?0PM<Y_.3,!:T=BS&J7-)GH2<K-W)>V#(OSC%:YI4[8"V?
M!]=W-MJ]\U7[,?3M`!V33@J8MKDY33.5'46^F:8:LSBDG+SZGBL=M!&=L.R)
M/WCN8Y!,4C?;-:R#%I&[CM&LN=BD>,E%P?QD`P[D>EZ^J.@/<-H-1VZN87T3
M.U%@P0<M??_PNH9)=P!+,83827Y7\^O'R'[M&6SJ*39@$WKN$E$\SMA4/S7V
M[/+.FMTQO@29*(H2HI8U&[9`]&XZGLE'.AN/91,U+'A))OIA@"_)1"WX;R9-
MIVD@F;)`YO2TV,6E>??]<#P>CWJ7H]%H;/9[ILF4/$\]V@V6SHN#JW5I:MI'
M,``$X_YH?&D`D*XY8JS.BJ`/`(:#P6C0&QLF_,\R6?L(9.MTH*NV*D&@R*H$
M@2*KLM5A1T+F3R,%&F6*8Y4@4&15@D"158>2,S!T$A5;E2!09%6"0)%564]3
M8JQ"`UJQ50D"158E"!195=KD,\W`8^56)0@4694@.+=5LV75[.[.8AVN_9F9
MM/EQR@LG\<UYL54CK%/G8;2$%7)V^JO7AS5B<NSFVG-6,:Q((_?Q"?_&X1K^
MG8=Q#.?5;JZ7KOT8!K8';SO9B.QOQ4@X\P@G&2=Z_.0NGH$9U]A*=).P:(M#
MGO5,7$V80[,[-`?&9;)@D\3:=Y;NUM^7+N=]T"]!C:C;>L&)#H.<2>H.17.U
M@U9(S2<X@IF:65IP`/A$YA*"(V3(6)QH$)61C!"3D0P0E)&,$)410N=0<&6:
M7(9;..F]:V#+&G6[24]2E$\U00+\@,<<!D'&[.NS=L@!C=:.:2HKY)>]V)@:
M^&*SXP.2UHS8E[-FP`$I:T:(RLC[369=CGC>NL#T?`#)CKZYGQ\'`Q@E`PD>
MDN'3](2]Y>1DDW"V*Y6VDCJ1&0B<6*QVM-5,EK0Z0K%=.)[W&<O?/U9YQ84F
MULWURXKL#('M.KAU`C>>X%OH%*=OD^J:?`"9R@89I8,T>[WV7N^W_MR)++:'
MA[%@1[$C77R:LFE!\9FUU'V'M>'TA,P/41@[BYCM,6*G6,KP]$OP]%)"(GA.
MX6^6\`<]">OC%/[0YCEH1-"+4O[@7,+\9?H#[J9*G1I,0)VZ"H],!+"8SQ"`
M$50@P-U?J0[`/54@@$52A@`<M$``<"J\XI0XZ)%L!CY0L`3^;;&$')-)R;%L
M4<JR]`O\*Z2TN/1[DII)O@5'+]0,'RH`G,2R+,6J2C'$[!!IA0K@0X4*+*BZ
M<DI>KRSG*U,(2;J`H=`(I($JC<CS2I)S@6<!H%HC4XGS$.(4F(I40P`X2B`0
M0_04U=\>Q:"H`E-O4%2"*02N!I\Q)J@EN`JI"`/@41(5Q3RAQU6,,ZJ!0%"5
M(8DW&*I2),6@*D<6IC!4I4@"056&I)90E2(I!E4YDIA"58HD$$`C2C(DM82J
M%$DQJ,J1A2GZJE(D@:`J0Q)+]%M.D1W:-DV:J*1_>FD>U3_57E:UC=1>V:()
M[)X-3U9/R<H1;,'64F0IC=?;V;@=&7NGVE,8N;_`(A.ONUO``2?2\3K-V%W0
M(U\C>_W@O,!2-#G+\[(J[_4"DJR_L>N,/,)23`5_Z)CK6A/FTO5S`I;3%5$K
M.5O4US;F=SR#;V[7>D@M"&SNJ,:`NDXQ2'<!22&"D:M:35`DE6.@IH*"*98K
M+-`<)I^:;%;KJY0Y*B-M>,-A;@+#)ZJ6F?=W)]-5W).F;*TBJ,_B>64^BVJX
M,3U1*)RTZU1E<UQZ9EIJ`^BQ%FL#2[725&N*HF,G_GF;'H1'4G,#0QXN$'P4
M'.&'HJ!+8K2_N]Y[LV'2`M"CPZ0%+-01]W/+03]49%)1CRL+DVKEO<TPX4H9
MGE2H"I-I>BZC43W)E@G'^B2'L`9@Z1I!"G.XT8@<]1R+INTJ]O-V$[NK5X%*
M`7;(9H9<I:@.@9-K@F2`=?[.5ZVCO%\PXPFEE'VXS7/*44*()L8RK^!FK'C*
MKBK)J%=Z#=S_#Z5+29NT=I\<>](1'5-9T$6%5G%22LGIW$YH*/54+I?QK).8
MHOFB4*KVDUW1@.HM%5&3*BZ=>7OJV*\RO(6$*\BQ^FE[EB-8DC%VTP8<M5X;
MZ&HU1:8'#;`T+U1"T7?$;(`#W?(<\43SMH#N:/-68WF;YN6JO+1<0M/=,66?
M.B"'$#Y4349+`Z+6IB7I@V.N9$'Y!BLSIC>A21E?B4J-0[WEJ&FK='<Y&5'Y
M*KLNQBRV`S9KV0A7;XKXB(S/X>465#41Q\,5,O$Q":$<WQGTV;Q$*84K:GXR
M2VF"MWD=4^'$?.*N<6)A@$W*B/0SU8V8TQ-[W+SD[?=S:N"^,?_#_),M//"M
M4&$\+$-I]FQB>4/V'J):YG2;BKC3'U;!$3.&K)P4K9?LR"'D;&\7[.8BU\;R
M5\;F>[\TO-\IW)^]^WOM0ONP0*+Y"07LU<RWK@?WL\%-7;@O;P'-^-"?)@?3
MG515M/*VJH'EEM`"]V]*"R@DLV(#]VH26I`%FM("]@FM/DA+:,%EPXUIP?[9
ME!;NI"UPF>"C37'!D)06K_N!H.[-0W9D>\X+7"BR""Y*J[`CYBU""T1N2JNP
M(QB.T@*1F](J[`@("2T3F#2E5=@1K$!I@;LUI97;T03#$5H#0=U?'K0C[ZNX
M050$%Z55V)'WU;Z@KU):A1UY7T61F^(J[`A4B;Y,^*(IK<*.?)XP!?,$E;&P
M(Z_[@:#N=S,J[_&&H,<G5`K;P3NB(VS^B>@HH5)8C??ROJ"7)U0*>_'^;0KZ
M=T*EL!30(Q*9\(6X1+F-^KQV34'M3NUEEG5YA\$Z(P(#GN2QV'KPA)40G\_"
M-D!C$X4(A.T-(4I/SN)9F\']+')"?#Q@&14A=/>R]NS`CL/H5<--SSDYWN@#
M07)_"L-<1SP%G(B)`/HS/,T&'I2C@5X2#?$^C#.J)F3R6.#5@U=`-B$#HQ,T
MO/_A0K$)&1B=D.&3*LZ?1,A\#-;;W$)\+L72+4+BDQL\.TO><W@-&P!2A-*]
MLXTC._<_/J0,0<7<XUU0<AI\BDCN&Y_=LB6=?][#34\R)>),F\0.+CU$@/]U
M&Q,UXBA"!'MG(D0>W!AN#94%,4<"80F1".%"A)S$3D81I/%W.PHP6KC0W?'1
M$HF*RSI@]K]\*>Z(P_0>X_.>V+UR\O4`*&KIK.RM%S_D7T[TXOU?V$W7P)G2
M7_W@?@EC1F*B%^\_X=WL((IAZQRDFT\;N$,:_-6VD3O1?[V;#L>W=Y9Q,>I.
M1Q=FWQE<C`?3VXN!.9O>WEKCKM&=_1=4A@_'NH*G*YWP\"GVD"RXL*-G7FT\
M>$15E`J;@O]<')OHY$,"G]W""F##?N),B,XF?WC7S?\```#__P,`4$L#!!0`
M!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q9
M3V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#
MNF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:
M@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%
MFRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,<Q-N(BP@E<15,8"'P'=B%76JM5F
M)<(T]E",(R![>S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPET
MB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4
MP2AG6NO76U=V<OH&P-0RKM?K=7NUG)X!8-\'3:TL19KU_D:MD]$L@.SC,NUN
MM5&MN_@"_?4EF5N=3J?12F6Q1`W(/M:7\!O59GU[S<$;D,4WEO#USG:WVW3P
M!F3QS25\_TJK67?Q!A0R&D^7T-JA_7Y*/8=,.-LMA6\`?*.:PA<HB(8\NC2+
M"8_5JEB+\'TN^@#00(85C9&:)V2"?8CB+HY&@F+-`&\27)BQ0[Y<&M*\D/0%
M353;^S#!D!$+>J^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI??
M?O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O'
M)?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2<C<;X5PQ!39P4.@78)Z9X*'>"M.69E
MN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#<N9B
M5L0=8'Q8QKN+8\>UO5D"53,+2L?VW9`X8NXS'"L<D)@HI.?XE)`2[>Y1ZMAU
MC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(
MS$J$'Q+FF/$ZGBD<E9$<XH@5#7X3J[!,R,%<^$5<3RKP=$`81[TQD;)LS6T!
M^A:<?@-#O2IU^QZ;1RY2*#HMHWD3<UY$[O!I-\114H8=T#@L8C^04PA1C/:Y
M*H/O<3=#]#OX`<<KW7V7$L?=IQ>".S1P1%H$B)Z9B1)?7B?<B=_!G$TP,54&
M2KI3J2,:_UW99A3JMN7PKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\B_<)9,7R%O6N
M0K^KT-Y;7Z%7Y?+%U^5%*88JK1L2VVN;SCM:V7A/*&,#-6?DIC2]MX0-:-R'
M0;W.'#I)?A!+0GC4F0P,'%P@L%F#!%<?414.0IQ`WU[S-)%`IJ0#B1(NX;QH
MADMI:SST_LJ>-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$
M0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[
MF)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ['B*U0K<6IKL
M&W`[BY.*[.HKV&7>>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F<%2&
MQR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2(=4.EJ$-
M#3.5A@"+-2<K_UH#S'I1"I14H[-)L;X!P?"O20%V=%U+)A/BJZ*S"R/:=O8U
M+:5\IH@8A.,C-&(S<8#!_3I409\QE7#C82J"?H'K.6UM,^46YS3IBI=B!F?'
M,4M"G)9;G:)9)ENX*4BY#.:M(![H5BJ[4>[\JIB4OR!5BF'\/U-%[R=P!;$^
MUA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+
MPZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#
MFWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-
M36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U
M,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?<DV'D@7
M2#LX@L;)#MI@TJ2L:=/625LMVZPON-/-^9XPMI;L+/X^I['SYLQEY^3B11H[
MM;!C:SNVTM3@V9,I"D.3["!C'&.^E!4_9O'1?7#T#GPVF#$E33#!IRJ!H8<>
MF#R`Y+<<S=*MOP```/__`P!02P,$%``&``@````A`'3K;K9"`P``W@D``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,S8N>&ULE%9;;YLP&'V?M/^`_%ZN@20H
M2=5`NE7:I&G:Y=D!$ZP"1K;3M/]^GW$@0+HD?0GAX_APSG>Q6=R_EH7Q0KB@
MK%HBQ[210:J$I;3:+='O7X]W,V0(B:L4%ZPB2_1&!+I???ZT.##^+')"I`$,
ME5BB7,HZM"R1Y*3$PF0UJ>!)QGB))=SRG25J3G#:+"H+R[7MP"HQK9!F"/DM
M'"S+:$)BENQ+4DE-PDF!)>@7.:U%RU8FM]"5F#_OZ[N$E350;&E!Y5M#BHPR
M"9]V%>-X6X#O5V>"DY:[N3FC+VG"F6"9-('.TD+//<^MN05,JT5*P8%*N\%)
MMD0/3KB9(FNU:/+SAY*#Z/TW1,X.7SA-O]&*0+*A3*H`6\:>%?0I52%8;)VM
M?FP*\(,;*<GPOI`_V>$KH;M<0K5],*1\A>E;3$0""04:T_454\(*$`"_1DE5
M9T!"\&MS/=!4YDOD`7+F.WX`>&-+A'RDBA,9R5Y(5O[5*.?(I5G<(XL'\H_/
M?7/B^M.9\P&6R9$%KBW+_&8)(+8Q`M?62&#Z4]N[08&ED]+D.,82KQ:<'0SH
M6W`M:JRFP`F!N$VNSD27[O]E&]*L2!X4RQ)-D0%Y%-`A+ZO`G2VL%RAK<L2L
M-09^.XPWFPXQT3DFL(>0^/Q5WFSTJDV+46T%/CNS4,2^V?<[J/6DP,J3ZBAE
M<MT&>@;FSE!=]![&&V)BC>DG(G#G0\SF,F9@"CKR=E,*/#`U#D3C0*P#?;E>
M,+*T.<<$WJEP`[G0^K?+5>"!W'$@&@=B'=##J\JV:0.]LO7T#[3!`-RN38%A
M+^GU<^"-VF&M,:"@ZWE_6.CH*B*^BMA<0@S\!1_QI\!+!(W8:0\\=ZA^K3&!
MGGC']T:#&.GGD^:Y;Y\ZHAFHN+_:FP7V&+!IEY\DG-(W,`8[3[]P:A>;0%8N
M#[A:-#8X:NRUQEPJX%5$?!4!IZ=2TG]+X$VZ5&NG^GS4>W=)^(Y$I"B$D;"]
M.OM4BKMH=RP_3-3N-8K'<%PWXS&*K]UP_1X^<D.8,K65=@O@>*WQCGS'?$<K
M810D`PFV.864<WU`ZQO)ZN:$V3()YVKS-X?O*`)C:9L`SAB3[8UZ0?=EMOH'
M``#__P,`4$L#!!0`!@`(````(0`"UQA^.A\``+3\```9````>&PO=V]R:W-H
M965T<R]S:&5E=#,U+GAM;*R=67/;N+I%WV_5_0\NO[=MS98KR2EJGN?YS>TH
MB:OC.&6[.^?\^_M1)"`"(+G@W-,/G61[:9,2L;=`$I(__.O?3]\O_CF^O#X^
M__AX6;BZN;PX_GAX_OSXX^O'R_6J\\?MY<7KV_V/S_??GW\</U[^Y_AZ^:]/
M__L_'WX]O_SU^NUX?+L0AQ^O'R^_O;W]O+N^?GWX=GRZ?[UZ_GG\(3_Y\OSR
M=/\F_WSY>OWZ\^5X__GTH*?OU\6;F^KUT_WCC\O(X>[%Q^/YRY?'AV/K^>'O
MI^./M\CDY?C]_DWV__7;X\]7Y?;TX&/W=/_RU]\__WAX?OHI%G\^?G]\^\_)
M]/+BZ>&N__7'\\O]G]_E>?^[4+Y_4-ZG?SCV3X\/+\^OSU_>KL3N.MI1]SG7
MK^O7XO3IP^='>0;ARW[Q<OSR\3(HW`7#<OWR^M.'TRNT>3S^>DW\_>+UV_.O
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M+28B_/[71&6X=`Y?L?S>5[:DHE<Z'Y]WO"0E=6#"OZB7I/S^EZ2DCDSXE]\_
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M!BG#V?(-XM%<.TT-3Q'P&;M!RN"UG7W&;N`,WB`>O?)<$@//BD40CU\3LD9G
MH,?TV<G>QWB4)YZ]'M/R(EY+M^B"D>XU"B9]KJYZ)*3#'E&'HJ&$\[Z4ZM;>
M--.8HAFH5AICO3IMEZG4K!>GXS*ENL5T7<;:FYY+E.HE<X_[+E.UGOC`1<HW
M9=-FZ#+6SHP4H5[SL1+.K[F]Y8F+%"OFAJ<*4;8S)9QM2W5K;^<1DQR?UMXN
M7,+>N:6+V#NW2D',W5\CL4%BZQ*ENO4R[5S&>L9[ERC?6"/AX,$$@0M9FPKB
MN"5??_O5#>*X)1EG?X(X;TG(WE8<MR3B^L1YRX?BP"4A9V0%<>:2D!.6(`Y=
M$K)W.PY='A)G+ATQRE%FED8YAK.O<,Z;7Y+AHXR2M(6F+;1LH6T+'5OHVD+/
M%OJV,+"%H2V,;&%L"Q-;F-K"S!;FD9!\N2NWUE1HX<$L/9B5![/V8#9IC!7J
MK<N4ZE6SIG8>S-YE*K?6L#ZX3*EBO89!X`,U?*!X@"8/6?G&VJ4@'K3Y4#R0
M\Z%X<.=#\8!/0I5;Z_TIB$.0#\7!,"&K]X,X+/E0'*`LR.@2.;LTNB2_0T+:
MZ!!;:-I"RQ;:MM"QA:XM]&RA;PL#6QC:PL@6QK8PL86I+<QL81X)YS.CA2TL
M;6&EA/-\IERQ)G'K-,8:YQO%J(G2UA9VMK"WA8,M!(&C-!PE/L3G)QW$QSBA
MQ`<Y.0*=$@KB`Y^$*K?62Q'$@R'A'8^&A!(/AX02CX>DM?,JRTV'TV@VH?/+
M;,1$+J.\(R8A;<3$%IJVT+*%MBUT;*%K"SU;Z-O"P!:&MC"RA;$M3&QA:@LS
M6YA'POGX+&QA:0LK6UC;PL86MK:PLX6]+1QL(0@<I>$H\<$[/YT@/GH))3Y\
M"24^?LG1YD8B/J:)A\4'-:'$1S6AQ(<UH<3']:08XU@NM+YC'(>T3"T3%P<J
MM]94HA$Q$B5]`<%ZSVHBT4*BC40'B2X2/23Z2`R0&"(Q4H3J]K$2,E_D"1)3
M12C3F1(R3>=(+)!8(K%"8HW$!HDM$CLD]D@<D`@"1CA3`8<JX%0%'*N`<Q5P
ML`).5L#1"CA;06ZXC":4J_Q&$X8GT67I^OP)</BHCY=R2>3<=O;=B$;$Y#4B
M$BTDVDATD.@BT4.BC\0`B2$2(T6H\AHK(7$@S'/<"1)312C3F1(R3>=(+)!8
M(K%"8HW$!HDM$CLD]D@<(N+V='>O>A/^9QZG($"/@",5--F%0Q7$J8KV5M9I
MN7L;IRJ'X%0%'*L@)5>E\[E)=/N4DQ7D1LOHPW"Y6_*6;GX/AK3=@]:=TD;$
MY/4@$BTDVDATD.@BT4.BC\0`B2$2(T6HRAHK(;.R)DA,%:%,9TK(-)TCL4!B
MB<0J(NK1RH"KBG5BL4[^6%;T5*U3DPUN8(O$#HD]$@<D@H`1CE/09!<.5!`G
M*FYLJZSC,*7_D',4<)`"3E+`40IRLV04GZP:,HK/[VY*^"B[`*T[NHV(R2M`
M)%I(M)'H(-%%HH=$'XD!$L.(J!9.B9<UV=6Z\5_[#^LM<!0_(#DA+]>LR^]C
MW.[$VFZ1MCOUV>X,MSM'8H'$$HD5$FLD-DALD=@AL4?B@$00,,+)#)KLPMD,
M.)Q!G$X]YJOET[13_:_@C/F`TQIP7`/.:\"!#>+$IG><4;/ATNC?Z-G3PZRB
MM5>L-6(H?2].<^4F(RU&VHQT&.DRTF.DS\B`D6&,Q,/OYLHNSY$"S(JUIF)C
MWM)$&47E+ENR;O5,%9"[I1EO:<[(@I$E(RM&UHQL&-DRLF-DS\B!$5GF&"99
M+I8E+X)9TT2/1`8>D92%C[PMCU#*PL?(1P]S>S6G+(3D+7FD4I9!LH_*Y7EO
MJI7HTDC<^M8$)G!2>ENK&0\XQ]'L7+G;9'1N_DE]^*D3>U)K+YMLQ%#.T6\R
MTF*DS4B'D2XC/4;ZC`P8&:8@Y9IUTCK2D#H;'VLE\W1\DH*4:]9"U:F&E/-,
M*YG.\S3$?H]8I$%F(RP963&R9F3#R):1'2-[1@Z,2)M&H<O)DZP:9\8C=-*F
M[.,1.VE3UZ?L7)WTB)ZL+'>=SET67>5,#5_=.A$,//(G-9JW-;,Y91)B-*??
M58'P8W9.@UKSG$8,Y1SQ)B,M1MJ,=!CI,M)CI,_(@)%A"F*/NU',5,UII'5Q
M>ISB9`V\20IB;VSJM;%9BI.UL3DC"T:6C*P863.R863+R(Z1/2,'1J1EHV#F
M9$Y:EAF/8$K+LH]'-*5E(Q\U2S3?4&7"RIOQ"*9,6',WXY%*Z=6\73%[-5SG
MF[S-Y-FKT?)@V<SYOKO]*9!&^.GD_/.2)B,M1MJ,=!CI,M)CI,_(@)$A(R.-
MJ-GC6"N)@V(.T@DC4XTHWYE6,GWGC"P863*R8F3-R(:1+2,[1O:,'!B1ML0D
M25LRXQ$W:4OV\0B<M"7[>$1.9J3LXQ$ZF8]&/G%[%ZYNR^Z57)6[&"I>W=22
MD-F<\M[U.\T9/LR\?EHN6DLP&N$7,U!S(M)BES8C'4:ZC/08Z3,R8&3(R$@C
MJN'&6LELN`DC4XTHWYE6,GWGC"P863*R8F3-R"9&JM$-P5*M7K%._+9LLC-,
MJK=U^YK+GCT.C$AM8D:D-IEI>C`>80L\TB:U&>U/]`*GO#8RS^0]]HB;S#/9
MQR-P,MG,\S$K,URZGYQLPN7/:*6_.<FTSM,:X1?14%4BTF*7-B,=1KJ,]!CI
M,S)@9,C(2".JTL9:R:RT"2-3C2C?F58R?><Q$D4C;3'@@DV6ADGXC6'V^L<5
MFZP9V3"R963'R)Z1`R/2E1@2Z4IFFAZ,1]JD*WE;'GF3MF0?C\1)6T8^ZHVO
M6"K8`T>FF+RM_-"9;1E^,"'9EIZGYM'G&<S6M&YJ-,*OWJ+61*3%+FU&.HQT
M&>DQTF=DP,B0D9%&5+N-M9+9;A-&IAI1OC.M9/K.8R2>4-P4ZS?6?:B%011N
MPWN>YF6#)6]FQ<B:D0TC6T9VC.P9.3`BK8DAD=9DING!>*1-6I.WY9$W:4WV
M\4B<M";[>&1.YIAY/F9KAI\[^(W6C#ZN8+:F%91&`3_3T&2DQ4B;D0XC749Z
MC/09&3`R9&2D$=5N8ZUDMMN$D:E&E.],*YF^<T86C"P963&R9F3#R):1'2-[
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M2F:]31B9:D3YSK22Z3M/0609L7GRO4B!K(O@2T96C*P9V3"R963'R)Z1`R-2
MG9@EJ4YF/`(GU<D^'I&3ZF0?C]!)=;*/1^RD.MDG/WA&=1;#Y?C)ZLQOS!-N
MWBZOVE^;VH@AN0]U7HUDAJC)2(N1-B,=1KJ,]!CI,S)@9,C(2".JV<9:R7R]
M)XQ,-:)\9UK)])TSLF!DR<B*D34C&T:VC.P8V3-R8$2^6Y@_+..1-OER8?;Q
MR%O@$;C`(W&!1^3DFX5YGU-#9W_Z(O#(79`?/+,QPT7RR<;TNP]4C-;6)^>:
M5?O+61LQE-N<>6OT3Y\(:+%+FY$.(UU&>HST&1DP,F1DI!'5<&.M9#;<A)&I
M1I3O3"N9OG-&%HPL&5DQLF9DP\B6D1TC>T8.C$AS8DSD:]F9:7HP'GF3YN1M
M>21.FI-]/#(G7\GN^E1O[(NC'KF3YG2=SN=#9G-*^1G-"7/-$+?GFM9'/QO%
M",IM3$1:[-)FI,-(EY$>(WU&!HP,&1EI1#7;6"N9S39A9*H1Y3O32J;OG)$%
M(TM&5HRL&=DPLF5DQ\B>D0,CTI@8$VE,9IH>C$?>I#%Y6QZ)D\9D'X_,26-&
M/M$U]=O4K^KS2)WT9=[^F'T9+I%/SC2A+Z,5]6*O3[NK-^<J/LT-&^'OPX.5
M1HRT&&DSTF&DRTB/D3XC`T:&C(PTHGIMK)7S0;$.R821J4:4[TPKF;YS1A:,
M+!E9,;)F9,/(EI$=(WM&#HQ(7V*2I"^9:7HP'GF3ON1M>21.^I)]/#(G?1GY
M1-].>'-E_XX5.2U/`A7GZPNE*9.`?(%AXK<\F3T9KGA_1T^&N#VOM%=DAK_P
MDWH2D1:[M!GI,-)EI,=(GY$!(T-&1AI1?3;62F:?31B9:D3YSK22Z3MG9,'(
MDI$5(VM&-HQL&=DQLH^1:,)3O*V5*A5K!=Z!7:0G,2;2D\PT/1B/O$E/\K8\
M$B<]&?G$:XO2/O\@US!Y6RIT\<M<DU\S[IZ&LTU^ZLRZ#)?%OZ,NHU7TYK32
M&@B-\!<<4UTBTF*7-B,=1KJ,]!CI,S)@9,C(2".JUL9:R:RU"2-3C2C?F58R
M?>>,+!A9,K)B9,W(AI$M(SM&]HP<&)&ZQ)A(73+3]&`\\B9UR=OR2)S4)?MX
M9$ZFE9%/5)=_R,=^Y/M`S9O+,K/D;>7'SNS+<+%[LB\];_A$:^3-WK379(:_
M.9UZ$Y$6N[09Z3#2C9'HQ:^5RC7[M_3VV*1OF-0K]9KU&QH'[#$T/`K5HORZ
M8.O*\$B[J'(;&P\JWI9+]I8G^C&9]3?5B+*=:27S07-&%HPL&5DQLF9DP\B6
MD1TC>T8.C$AG1A&)AF7]MEBTQH(TI@K1IP__?++[HJE_FGD$Y5?O*H=LQB-D
M<GN<?53,9-:GK^19%XUD:LD^*FEY/AYADQ/QO&V971FN@D]V)5RRC!;-FQUI
M+\`LXLKZ)B,M1MJ,=!CIQD@T&`LW]4KIMF)=7>BQ39^1`2-#CYT9:1O5:&.M
M9(Z_"2-3C2C?F58R?>>,+!A9,K)B9,W(AI$M(SM&]HP<&)&FQ"Q)5S+C$3AI
M3/;QB)PT)ONHT.4UG4?H9';)V_*(G31FGH_9F.%*^'<T9K1PWFC,@O6&UBCB
MZOHF(RU&VHQT&.DRTF.DS\B`D2$C(XVH7AMK);/7)HQ,-:)\9UK)])TSLF!D
MR<B*D34C&T:V,1*]?U:KI6K-_CZN';OL&3DP(GV)29*^9,8C;M*7[.,1..E+
M]E&1BR<IQ=2[V2IT,50H5\*O9['.M3UB)^?CO$?YP3,;,UP`_X[&C-;+FXUI
MG7(VBKBHOLE(BY$V(QU&NHST&.DS,F!DR,A((ZK9QEK);+8)(U.-*-]9K$0W
M'6M7UEG37#\@<[,+1I:,K!A9,[)A9,O(CI$](X<8B7ZSF76*)CV)^9&>9$:%
M+/WWIWGD2ZY7\E8\$B;7*]E'92QCM,ELDCT\$B:SR3P?HQM+[_LXSPDW;X7;
MOT6P$3,Y4^LF(RU&VHQT&.G&2'1,Y+=#63?3>FS19V3`R!!V9*0M5'F-M9+9
M3A,PG6H+93K32J;IG)$%(TM&5HRL&=DPLF5DQ\B>D0,C0>#!>(0L\$A9X!&S
MP"-G@4?0`I6TG&((/-(6>,0M\,A;H`*7OC]F2X9+UOUGD*5HA;LY@[2^9[41
M0_%IB]S$MV[U-&,@??>B#^XPTF:DPTB7D9Y&PBOFSK<R]O6/,VMEP,B0D9%&
M5*.-M9*YZ0DC4XTHWYE6,GWGC"P863*R8F3-R(:1+2,[1O:,'!B1ILS[*$GT
MVVY4SG)B)$T9^419K%0*M_85,BG*)%*HWY8KSDTCCZQ)4?(NJ[3%Y]&WQ;2O
M(3+WIUISO[-%BI*WY1$Z*<H\'[,HI?/>4Y0A;DXGJP5K`M8H15#.`6PRTF*D
MS4@G1J(C4RH5*[*NW[S`T667GN$27DHQ+?IL,6!DR,A((ZK3QEK)[+0)(U.-
M*-^95C)]YXPL&%DRLF)DS<B&D2TC.T;VC!P8D:[$&`4>49.N9!\5MKC`"M5Z
MR;JA*9-*ME%IRTF^3"HCGWA3I5,/6GF26:4!%2OAMT;;D$?J9%K)>YV?.[,M
MP_7J[YA61LO;91?T7?YRV;IBU2A%4,YKUF2DQ4B;D0XC749ZC/09&3`R9&2D
M$55L8ZV<#XIU2":,3#6B?&=:R?2=,[)@9,G(BI$U(QM&MHSL&-DS<F!$"A.3
M)(7)C$?<9';)/AZ!D]DE^ZC(06-&1A%T6ZO6W!LY'MOR2)W,+O/VV>Q+:36C
M+\.%E<6:7,+,7S54"A]G3S.M)5^-&,HMSL@G!VFEN%0+5B&T4R`+Z:0@U8+U
M)MI-@2R?'B-]1@:,#!D9:425W%@KF24W862J$>4[TTJF[YR1!2-+1E:,K!G9
M,+)E9,?(GI$#(U*>&!4I3V::'DQ:YJP8R'23MY66.=O'(W(RVW2W52U8'X"1
MDW.7LK?FD3NISSP?LS[#5>[OF&Y&B^*3T\UJP;I(V2CARODF(RU&VHQT&.DR
MTF.DS\B`D2$C(XVH9AMK);/9)HQ,-:)\9UK)])TSLF!DR<B*D34C&T:VC.P8
MV<=(-%4JE<(+<=:YY8%=I#$Q2=*8S'C$3::;[.,1.)ENLH]'Y*0QV<<C=')Z
MSC[YL3/[,ES%_HZ^C!:]FWUI+7QHE/)6QI^N6#<9:<5(-.12+F:TV:/#2)>1
M'B-]1@:,#!D9:42UVE@KF:TV862J$>4[TTJF[YR1!2-+1E:,K!G9,+)E9,?(
M/D;BMJR[%^(.;")EB3&2LF3&(VM2ENSCD3<I2_;Q2)R4)?MX9$[*DGWR4V>6
M9;B`_1UE&:UW-\K27K;;*.4MBH_+$I$6N[09Z3#29:3'2)^1`2-#1D8:4;4V
MUDIFK4T8F6I$^<ZTDND[9V3!R)*1%2-K1C:,;!G9,;*/D:@NY9/+[M02`R!M
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M>C`><9/9)6_+(W!2E^SC$3FI2_;Q")W,+O-\C+HLO^]#/2?<NCU>M`YS(X9R
M"KW)2(N1-B,=1KJ,]!CI,S)@9!@C489N2[)LU%SO.=(>JM3&6LDLM0DC4XTH
MWYE6,GWGC"P863*R8F3-R(:1+2,[1O:,'!@)@IB)!D.Q4*B5;JR5*(%'U@*/
ML`4>:0L\XA9XY"WP"%S@D;C`(W*!1^8"%;KTOC+;,ES=GIQ<GE85%7!543E:
M%9^<9<KWBIG1;L10^FY$L\P4I&I_MJ"5`EGG`&U&.HQT&>DQTF=DP,B0D9%&
M5,6-M9)9<1-&IAI1OC.M9/K.&5DPLF1DQ<B:D0TC6T9VC.P9.3`BU9GW,913
MEJ0ZF6EZ,!YYD^KD;7DD3JJ3?3PR)]7)/AZID^K,\S&K4\K/J,[\=9CE$+<G
MFE:--6(HMS$CG^@]5%:FGOXSB[?%-FU&.HQT&>DQTF=DP,B0D9%&5+&-M9)9
M;!-&IAI1OC.M9/K.&5DPLF1DQ<B:D0TC6T9VC.P9.3`BA1GE)"=*4IC,-#T8
MC[Q)8?*V/!(GA<D^'IF3PF0?C]1)8>;YF(49KG6WYYJ%<-D2-&>T1EZVHR\!
ME\O6DM)&.6\A?3S7=)%RV5K3V6*?-B,=1KJ,]!CI,S)@9,C(2".JXL9:.1\6
MZ^ULPLA4(\IWII5,WSDC"T:6C*P863.R862;@I3+UOJY70IDO>)[1@Z,2'FZ
M4;&V).7)3-.#\4B<E"=ORR-S4I[LXY$Z*4_V\<B=E&>>CUF>\D9FE"=T9HC;
MLTWK(S2-<@3EO$4V&6DQTF:DPTB7D1XC?48&C`P9&6E$-=M8*YG--F%DJA'E
M.]-*IN^<D04C2T96C*P9V3"R963'R)Z1`R/2EY@DZ4MF/.(F%S;9QR-P<F&3
M?3PB)Q<V(Y_X+EG*@FRI2]Z41^BD+O-\S+H,%\,GYYI0E]':^>04LUITIIBX
MP+Y91J3%2)N1#B-=1GJ,]!D9,#)D9*0156MCK636VH21J4:4[TPKF;YS1A:,
M+!E9,;)F9,/(EI$=(WM&#HQ(76),I"Z9\8B;U"7[>`1.ZI)]/"(G=1GY1%_:
M*=_6;"]JE;;D+7ED3MHRS\=LRW`U_#O:,EH\+Y]=5YEJE!VIZ4HM5VJ[4L>5
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M,U>:N]+"E9:NM'*EM2MM7&GK2CM7VKO2P94D/?IPJP,IZ7&UE`,NZ7&YE$,N
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M+B_^?'Z3$Y737[\=[S\?7T):X"_/SV_J'S+NKW\]O_QU2LZG_Q,```#__P,`
M4$L#!!0`!@`(````(0"$5P8?>0,``*H+```8````>&PO=V]R:W-H965T<R]S
M:&5E=#$N>&ULE)9;;YLP%,??)^T[(+\W8')I$X54A:I;I4V:=GUVP$FL`F:V
MT[3??L>8$&.2B+TD7/X^Y^=SP\O[MR+W7JF0C)<1PJ,`>;1,><;*;81^_7RZ
MN4.>5*3,2,Y+&J%W*M']ZN.'Y8&+%[FC5'E@H901VBE5+7Q?ICM:$#GB%2WA
MS8:+@BBX%5M?5H*2K%Y4Y'X8!#._(*Q$QL)"#+'!-QN6TD>>[@M:*F-$T)PH
MX)<[5LFCM2(=8JX@XF5?W:2\J,#$FN5,O==&D5>DB^=MR059Y[#O-SPAZ=%V
M?=,S7[!4<,DW:@3F?`/:W_/<G_M@:;7,&.Q`A]T3=!.A![Q(\!CYJV4=H-^,
M'J1U[<D=/WP2+/O"2@K1ACPILOY!<YHJFD'FD*<SLN;\12]]AD<!.)&U0#N1
M?X]N'D+MQ6_=V-='ET]UVKX)+Z,;LL_5=W[X3-EVI\#3%,*@H['(WA^I3"$-
MX&L43K75E.=@`GZ]@NEZ@C"2-T/',K6+T'@VFMX&8PQR;TVE>F+:)/+2O52\
M^&-$N#%EC(2-$?@_F/?A?/#B<;,8_IO%&.Q<]^R;7=0!>B2*K):"'SPH3^"4
M%='%CA=@\'P48/M:^Z#%$;J%/$5(0BI>5\'2?X5@IXTB-@KX;16XJTB."ITO
M8&A!8`O#0;18@^CT:++8/+#]AH[?OF+<*CH@$`4;1-?'&$KS>F3T(M!9^YZT
MU@VA44PLQ;2K2*XI.H1@Q":\3J;%$8+=MQF9=?W&1F&3W78525]Q8N^000<,
M)]/B+ME=UV]L%#;9O*M(^HH+9+/_(=/B+AEV"]U(;#3L5GI?<H$-&FIXU+38
M87-*/3:2#MNIUNMJ3/J2"VSZ6SEX/FBQP^:V@9%TV$Z>#5M?<E)TJ@U&YG`V
M+7;8W$8PDFD]V"9XCIVX)N:]S7X!#,.\&$Y6JQTTIP/C1F/[QDZW)&<TE_CT
M$!Z<56Q&MCU"L-.'<:.Q^4*G99(SFDM\>E@/YS.CW>8+G5Z,]1<2TM_A<]-[
M1G.)3X]JBV_8-P*.0FX)ADY?QHW&YCPQF/9H)+.Z3,=!$$RGP:E<3(.8DY#Y
MT!=4;&E"\UQZ*=_KDPV&I>W3]JC6G*':%W#HJ<B6?B5BRTKIY70#2X/1+8Q<
M88Y-YD;QJCY&K+F"XTY]N8,S,87/<C`"\89S=;S1'_WVE+WZ!P``__\#`%!+
M`P04``8`"````"$`&,6=H*\"``!0!P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970R-"YX;6R455UOFS`4?9^T_V#YO1A":&@44K6KLE5:I6G:Q[-C#%C%&-E.
MTO[[7>.$D*3K6!X('\?GGG.NN2QN7V2-MEP;H9H,1T&($6^8RD539OCGC]55
MBI&QM,EIK1J>X5=N\.WRXX?%3NEG4W%N$3`T)L.5M>V<$,,J+JD)5,L;>%(H
M+:F%2UT2TVI.\VZ1K,DD#*^)I*+!GF&NQW"HHA",/RBVD;RQGD3SFEK0;RK1
MF@.;9&/H)-7/F_:**=D"Q5K4PKYVI!A)-G\L&Z7IN@;?+]&4L@-W=W%!+P73
MRJC"!D!'O-!+SS?DA@#3<I$+<.!B1YH7&;Z+YO<I)LM%E\\OP7=F<(Y,I7:?
MM<B_BH9#V-`FUX"U4L\.^IB[6["87*Q>=0WXIE'."[JI[7>U^\)%65GH=@*&
MG*]Y_OK`#8-`@2:8)(Z)J1H$P!%)X78&!$)?NO^=R&V5X?@Z2&9A'`$<K;FQ
M*^$H,6(;8Y7\[4'1GLJ33/8D\+\GB9)@.DEFZ0@6XA5U!A^HI<N%5CL$FP9J
MFI:Z+1C-@=DYBR$?KZ/W^C>KX-&1W#F6#,\P@N4&VK-=QFFT(%O(E.TQ]QX#
MQQYS1!!0TTL"&4-);X=\J.S`KK(+W4FY]S>&92:]D),R\?^4<>`,`W<O/DZ/
MO+ZRQTP'F.3MR@`9&CQD_KY1MPAZ,V"/T[CG]PH\9H0"V'5#!>]7=N!S[].S
MRAZ3=JV?)2'\>L!)Z->GA<=9=XO.!1RC]=8]9H1UV*1#Z^,4N$7_"M]C1BAP
M'X7!*_=^^`Y\[OT\?(_QX4=OIN\GFW_Q)=<E_\3KVB"F-FYJ1="V_FX_4.\F
MW4SL'\!`:VG)GZ@N16-0S0M8&@8S:+WV(]%?6-5V8V6M+(RR[K2"+Q>'ES,,
M`%PH90\7;NCVW\+E'P```/__`P!02P,$%``&``@````A`/0@D,0J`P``J`D`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C(N>&ULE)9=;YLP%(;O)^T_(-\W
M?(:$**1J4G6;M$G3M(]K!TRP"AC93M/^^YV#$XJ3E68W28#7+\]YC^%D>?M<
M5\X3DXJ+)B7^Q",.:S*1\V:7DE\_'V[FQ%&:-CFM1,-2\L(4N5U]_+`\"/FH
M2L:T`PZ-2DFI=;MP7965K*9J(EK6P)5"R)IJ.)0[5[62T;Q;5%=NX'FQ6U/>
M$..PD-=XB*+@&;L7V;YFC38FDE54`[\J>:M.;G5VC5U-Y>.^O<E$W8+%EE=<
MOW2FQ*FSQ9==(R3=5E#WLQ_1[.3='5S8USR30HE"3\#.-:"7-2=NXH+3:IES
MJ`!C=R0K4G+G+S:^1]S5L@OH-V<'-?CMJ%(</DF>?^4-@[2A3]B!K1"/*/V2
MXRE8[%ZL?N@Z\%TZ.2OHOM(_Q.$SX[M20[NG4!$6MLA?[IG*(%&PF013=,I$
M!0#PZ=0<MP8D0I^[[P//=9F2,)Y,9U[H@]S9,J4?.%H2)]LK+>H_1N0?K8Q)
M<#0)@?YX/9@$\ZD_C=]W<0U15^`]U72UE.+@P*Z!>ZJ6XA[T%^",E860C^'H
M:WVK5*@13>[0)24SXL!R!?UY6H6QMW2?(-/LJ%E?:GQ;L3DIL!6`US-"Y4/&
M?Z=^0D$QHF`7D&UM3H!WSQ:<W?=2$;^B6220T)`$TXK>W`<G(EP$J0X`PH&_
M@32::*"9GD&.*2Q&,!DRCJ>%XI1``'TX?A#;=UX;3=RUU?>2T)^'K_%T^!M+
MXL^"8.ABT4%:U].AV*8+X[/FK8T&`/H*SI,;4UALL<UV77=QT7O=-9HQQC&%
MQ0C/V/7YH=C.;]@7L_.,QG0W2)*Y-X_L_F\L13#W_('"8L-Q-WB7C.\\%-ML
M81S:=UX;S5AN8PJ++;'9KNLM+GJOMT8SQCBFL!AAA/U'@)W:3O"RNT>1:>\L
M"<-9-+-#QL&)51I)$D5^$KT^8X;/#$8S-VHF=VS#JDHYF=CCT`O@S="?[0?R
M78"OX+/S:QS4>-[M+\"<;.F.?:-RQQOE5*P`2V\R@Z=6FDEK#K1HNVFU%1HF
M9/>SA']$#%[QW@3$A1#Z=(`WZ/]CK?X"``#__P,`4$L#!!0`!@`(````(0"V
M.M1]4@P``"Q!```9````>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*R<7V_C
MN!7%WPOT.QA^WSB2+=L)DBQBD6P7V`)%L6V?/8Z2&!-;@>WYL]^^ER(IWLO#
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M)DXHSOEF<C.AD1[NGK8T`YOVT:%YOA\_%K=F68XG#W==@OZS;;X=V7^/CJ_M
MM[\=MD^_;_<-99O6R:[`I[;];$-_>[*(.D^@M^E6X)^'T5/SO/[R=OI7^^WO
MS?;E]43+7=&,[,1NG_Y4S7%#&:5AKLK*CK1IWT@`_7NTV]K2H(RLO]^/2SKP
M]NGT>C^>SJ^JQ?6TH/#1I^9X,EL[Y'BT^7(\M;O_NJ#"#^4&F?I!Z,\P2!SC
M3+^9[T=_AG[##TXRNQG0GWZ0Y=6RJF;SY8(0'GWB,M`E5*U/ZX>[0_MM1%5*
M<SR^KVW-%[?S\2ADTHW0Y_9'J:6<VD$>[2CWX\5X1%D[4CU\?2C+\F[RE=9P
MXV-6&%/(B#I$V`6SPZH4Z!08!B8THWY:M++_AVG94>RT@J!5`&R>R1Q"1.BB
M4J!38!@0<Z#"2N<PI5,E7^1A)6PG*F>Q$E.I<>5C>%`E0^H^I)\'$`W$<"*F
M0K6>3L6>KP.KS(Y"<Z,_SI29#R(I?5`ZN3ZDGQP0#<1P(B9'$^&3.[\^-KB;
M0SCVRI-I7V4U$`5$`S&<"'UT6G-]/WF*VU&D<$<J,M4^TV4Y2PJI#PKS54`T
M$,.)F`MM,7PNYW-M@Z5D3UBN@2@@&HCA1.BS5QAL.SVOSP9+?9XP?4`4$`W$
M<"+TW0S19X.E/D^8/B`*B`9B.!'Z"MK@>`)_LEB[8:1TCY)R3;>&&-77*R*-
MR`@DIV0]ZN*:*)RCT287!*P"8EE'I!!I1$8@*=/:T.4RG6D)F1YQF8!4`4@C
M,@))F=9C+I?I'8EGDYM4=YE1%X`4(HW(""1E6K=@,FT=SVB''NAXA3<=KK_W
M(;[MSI-M-W2,BZ$0:41&(#DE:S!L2N?W-FOOR>814-14(U*(-"(CD)1IO>-R
MF<YI1!U[Q&4"4@4@C<@()&5:"[E<IC<<7@?<@WP=`U(%((W(""1E6B=A,MU^
M/+VR=QD?%(#W("[9(=J#PMY6%SWBU;R0U:SR4<L^2DJVYL(D?R#36Q&7R=W)
M9Q:0*@!I1$8@(;-,G.Z\S"Y:&EI`K$X1*40:D1%(RASD7B6Z5T!<IH^*2&&4
M1F0$DC*MK;!%MW5J;Y8&[K>E=R=6#0&11[#+W)N^]ER!Q*A0V@J11F0$DE.R
MKL2F]$&!>`_CRL'6ZA*00J01&8&DS,3I/I")AE;VAA925R-2B#0B(Y"4.<B]
M[&.@Q+T"BD5;(U*(-"(CD)1I;84MNMMON^WV]+K=?%ZU5(1T^F2R/*7G+ETQ
M/I;>FW@M.%21'?157%3)(YK:=V0;M/+(EBGKF#Q1T#$JK*$18\DY6D\Z,\<_
MVO<?S9$2UT_2.QN?I$/D%D%%70)2`=WT4=HCV@5#1R.BI/R,)99S^Z`QMRI<
M,3IBZ>V/3H$^N^7T.MU<?%0L/97K6*0==8B:=X_D%M4U_2/'-B&D2Z.<IS6X
M9)DNFZ=W1KXR#EDW9/-,G_^5/BJNGPJ(+Y:+(B^PSQGSD^H/1^LI)F4]X:<F
MU764!NR1O6)FDTK/J1#%%B^@F"`=D%NIHENI=*E"#"[5-#%INVM<M%1=QV16
MSIR3I4I.^-IW9*>:"H@ME4=^J8KL6HEN<JT23\_L>>SLFJ)U>Y0L4/J$*D3Q
M!7)C4<>P'^@0=7:!>#<YE4%>/D4O]RA9E?3I18AB)U!`?%7<\&%5\K7F8NAX
M<`99NV;;P@>KXLT]9G)EG]]:;XWYKA$I1!J1$4AF?)#?3]'O`^(R?51$"J,T
M(B.0E)GX_0?91&.?>A0UU8@4(HW(""1E9BS[)QYG3-&S`Z)Z8YMH^C@C1H43
M4B'2B(Q`<DJ)C7^0>?3NJ4<\\X`41FE$1B`ITUK9Y:>;,SXZ+4*>5E./N$Q`
M"J,T(B.0D#E+?/5\-KMH:3L!,9F(%"*-R`@D96:,,OY@>O'/G3/GD3S-`<DZ
M3AYDU#$JK(]"I!$9@>24!KGD#%TR()YY'Q61PBB-R`@D95I#N;B.9\Y^1((]
MBIKJ$!610J01&8&DS$'N-D-W"RAJJA$I1!J1$4C*3-SMX@L^NVDG-[8>L9N^
M.B*^*<?G;=UMILI'Q2<C4O$@HYNAT7DD9+HHAI2(D@(R%E:4RPONVV;H6AZQ
M(]<1L9S-DFMXE8^*-T)2\B"+FJ%%>21DNBB&E(B2`A+SZ<K,GCP?;._H0C.'
MV&'KB'C"DMLGE8^*MR-";S7(A;IHZ4(><9F(E$!20,9?IM7B@L?E%5J*1_3H
M+9A%'1'/67)'HWP4S8)'Q9L%*7F0?U3H'QX)F2Z*(>6C\-ZU&F0,772R9LX8
MV,%J'\60\LBMK$S`H"V_PBW?(W:T&I'R*).`S%X^GUT1/7^65;B5>R24N"B&
ME(]*RB-><LOL#-JW*]RW`^)5[*,B4ABE$1F!I,S<[DY3'_C\WSX?3>PQ(*JR
M>(-2Q)/)/?^/4>%<58@T(B.0G-*@W=^^UY`J]RBFN0Y1$2E$&I$12,K,>$1A
M+U<_J%[TB`H](B*6_%ER5:WR4?%R1>B=#_*(+EKN-QYQCT"D!)(",AY17L\N
M\(@Y>H1'0HR+2D[O>%GF+MYB1Y;9*EZN2,F#/&*.'N&1D.FB&%(B2@I(3.+"
M"Y&YLP9^&^$1.VP=$4]%O";S"7-CR;2R7U"DWD&>,D=/\4C(=%$,*1$E!=AM
MG]UN79HP])2Y0^RP=40\8?&:S">L[\BCXK6*U#O(9N9H,QX)F2Z*(26BI(",
M@=`O,1?<'LS1,SQB1ZXCXME(;$3EHWY@S?-!!M%%)SL9&D2(8@:!2",R`LG,
M)@9QWA?FZ`L!14TU(H5((S(""9F+0;[01<ML!L1D(E*(-"(CD)29<8]B6G7N
M,?!B9X%VXA&[6JPCXH6;6G`^Z@<6O!AD)UUTDFKG'4(F(.4[NBB9Q,1.SI?D
M`EW$(R'`13&D1)04D/A#MSU?M-LLT"L\XKM-1'S1TFN`;-3\!]<`]C$I=Y0/
M<H9&T@U`Z\C/#Q\5D<(HC<@()#,[R$@6:"0!14TU(H5((S("29F)W7R03;28
MA4=<)B"%41J1$4C*3"S&UJE]]7+H3N.-AOTLL7#(WE?$VZIY<M%5QZC^M@J1
M1F0$DE,:9$<+M*.`>.9]5$0*HS0B(Y"0N1QD1UVTW",]H@2'U-6(%"*-R`@D
M929V=+Z.E^@X`<74U8@4(HW(""1E)H[3U;%]Z7%@(=-'C>E==D"T_;-"3AYC
MUC$JK(9"I!'9SRB[(W;Y<7-RGT6ZK_AVS>&EJ9NWM^-HTWZQGSS2`X6'NQZ[
M[S%7RS)\D)FV+.:W=ILB5="RH);NVS=H65)+5U?0<D,MW3L#:<ORFA1T[U=!
MB_U8M'LE.&VI2`%-)Z.M(@6NLM,^<VJA:]%,GSEIH\N_3,N"M-$55ZZEHI;N
M"]+T.#/J0[\S9OK,:#[T_"/70JM`OY#E6J;4TBTQ'&=&+=V^F;94M'+T0"PS
M6DG'H1?V<BUT''>%DHY6TG'H[<E<'\H!O6>3:9E2'W=OG8XVI3[TTD.F3T$M
MY""Y%IH/O2^?:Z$ZH%?4<RVTINX=E51!2>OCWN>#%EH?>O<E,QH-EJV/@L:B
M[WLR/0H:RUUWI4<I:`WH*Y9<'UH#^G`DUT+Y=.\<):/1]]2/^;&H0VXD6P`Y
M3H?.'?EQ=OM(&TU&DJV^'*=5S"XBK6%V">U>DAN'SM;<R4JOG=[:ETHSBJKB
M=D5/L+&%?ARYK;,MJP7UH8OQ3!]JJ;,MBEKL!3SV64UIDO2J3*Z%IDEOG.1:
M:*+TDD>NA:J.WJN@EDF_ZO2M^OOZI?G'^O"RW1]';\TS;>S7W3W>P7WM[OYR
M\F_*?FI/])5Z]]+L*_U?"1KZ=OK:_H#PW+:G\!=[@/[_<_#P/P```/__`P!0
M2P,$%``&``@````A``0(Y644#P``<5```!D```!X;"]W;W)K<VAE971S+W-H
M965T,3`N>&ULK)Q1;]LX$L??#[CO$/A]$TNVY21HLFA,B2)Q!QP.>W?/;N(T
M1I,XL-UV]]O?4.2('/[5V"[Z4C<_#H><X9`<TK(^_/[GR_/9M]5VM]Z\WHR*
M\_'H;/5ZOWE8OWZ^&?WGC^:WR]'9;K]\?5@^;UY7-Z._5KO1[[=__]N'[YOM
ME]W3:K4_(PVONYO1TW[_=GUQL;M_6KTL=^>;M]4KE3QNMB_+/?VY_7RQ>]NN
ME@]=I9?GBW(\KBY>ENO7D==PO3U&Q^;Q<7V_4IO[KR^KU[U7LET]+_?4_]W3
M^FW'VE[NCU'WLMQ^^?KVV_WFY8U4?%H_K_=_=4I'9R_WU^;SZV:[_/1,=O]9
M3)?WK+O[`]2_K.^WF]WF<7].ZBY\1]'FJXNK"])T^^%A318XMY]M5X\WHX_%
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MP\4WFA_W0>9N0$9*+%C"30:G5N6@SD&3`YV#-@<F!S8!%^26WC<T9WZ%;YP:
MYQNVZHY!=%:9.8(EN(K*09V#)@<Z!VT.3`YL`H0C:-[_"D<X-3<C^C<)DDMI
M^5V0285F4F31B_3>`5(#:8!H("T0`\2F1#B)UKA?X22GAIQ$'XF7\JD4A*@O
MO5#NI5ZD]Q*0&D@#1`-I@1@@-B7"2[3T"B\-[X:\K#CISAELQ%T@DWXV+8`H
M(#60!H@&T@(Q0&Q*A*&TZYQ@J).6A@9"^OLA+BZOLJG0"[%_%)`:2`-$`VF!
M&"`V)<)VV@=.L-U)2]L#2089B`)2`VF`:"`M$`/$ID08ZG+U=/=\/YJ=M#34
MDS(Q%(@"4@-I@&@@+1`#Q*9$&$H9R@F&.FEI:"")H4`4D!I(`T0#:8$8(#8E
MPE"7`PE+74(TIY29$[GC4R*G27JA4TYY?+IN%U?C;%)'J7Y6(ZH1-8@THA:1
M060%DAYRZ=+Q05_X[(HV-+;FCE$2#8@4HAI1@T@C:A$91%8@:;/+C$ZPV2=2
MPF:/TJE>`%*(:D0-(HVH160068&DS2[3.<'FD!BEXQQ0.LZ`5`&H1M0@THA:
M1`:1%4C:[/*6$VP.:4YJLT?9%"_R*=Y+\:10!:`:48-((VH1&416(.D&E]6<
MX(:0!*5N""@=>D#*78>X)3)*U8@:1!I1B\@@L@))FUTV<X+-(?E);?9(3'%`
MJ@!4(VH0:40M(H/("B1M=HG-"3:'/"BU.4V-NC/[H@"D$-6(&D0:48O((+("
M29M=CI/:[&\\SMW5SOYI??_E;D,[/FU:`[G<A&XVPGV'SY3$"N\1;2(\IQ<%
M(!5026M_S.NOLO-_':585X.Z-*(V5DS53^3R8Z(4J[="EW28RY7><]@?F[<?
M.8QNZ'J/A90K#1Z/J&GNQJ(`I!A=]5)U0&5W`=L-2(-2FE%4WS**N@SJLD)*
M^():E+X8")+$YDY<IH`!N2TH&?^I'*!%E&+/*$;1?S6CRE^X756759D-=<,R
ML9IF%%?=EA'M0;%7DRPQ-2SEVZOFXWDYRZX=+,MT[4G?G98WEI@W!I3&"R+%
M*(YQ'1#UC=W9H)1FE,0+HZC+H"XKI*3-+L7+YTY9N0O_H?4E#1V?'*8+C%LS
M:+=TVW8<I*ML`!8L%4=7,8HQ4#-RBUY_8WM5R3!L6$JT.,\N(31+Q19;1K%%
MPTBVF%UL69;Z48O2NRYS3+U[8#:&1#-VZLZE:<ZE<<@7B!2C&`5U0"*B@JXH
MI;EB5-\RBE(&=5DA)6TFSPB;?VK[*IV6;&'R*(NN['IV$2K2\L4S204TBVZM
M&8FQ+K.X:5A7K*@91?4MZXI2AI%?AR;5;#*=9^N>94U=->E!ZM6['CQN/W-3
M.'>A1R*:`*E0D389=F$=D(BF4#%*::Z81A-(&=1EN6*G2_K"):/I#/JY:/(I
MK5BK/,JVN2P"%F4OQ:Y0`971[CJ@R=AO<U55S'&;"YIBE&A4WD;ER:J'VUPP
MQ[=W61;5U21;92TK'PBO/*?.77ID>&&N74)BO4"D$-6(&D0:48O((+("R?#*
M<^T#"S0FU:5'M!YRA"P0*40UH@:11M0B,HBL0-+F/%T^8#.FQ13[W<J2V@Q(
MH52-J$&D$;6(#"(KD+"9IB8N(^7L)RY-.TUR8PK(;8E]JD*/LLA491&E.%`4
MHAI1@T@C:A$91%8@Z:'3DM\))K^,DJA`I!#5B!I$&E&+R""R`DF;\^3W_9DP
MP8PWH'3V(U*(:D0-(HVH160068&DS2X)3#?4`S;[G#'=.>DR+)_]B!2B&E&#
M2"-J$1E$5B!I<YZ2'K`9<T^RW]F<3?'\TC1*Q2G>5V14HU2#2"-J$1E$5B#I
M!I>+G3#T/G4C?=SUNTE`Z10'I%"J1M0@THA:1`:1%4C:[%*E$VP.F55JLT=B
MB@-2$T`UH@:11M0B,HBL0-+F/,$[$.Z8R$TPD4.D$-6(&D0:48O((+("29M/
M2^0FF,@%E-Z.(E)<D;:"?J\O)MFU1!VE>.HTJ$LC:F/%1'U^=#11BM5;H4MZ
M)D_W\G3_J.OD"6:!`0F'>:D$J2!%UR;NF;MR7&0WB7448&,:U*P1M;%BT)R=
ML$T48,U6J!%NF@YEB`4]LDCK6W?K?MRIJ%,CT\.`TD,W(L4H.58&E!ZZ44HS
M2@[=C*(N@[JLD)*^R'-!%S)'70I.,2T,2%S;E./L^X0%2\6=13&B'329:EE:
M7;.4N\?_=EN=9_=U#9?'%5TSBFVUC-YMR["4;VMVGC_M9%D`#]W3TU+-3CP+
M(Y]]4AA%=Y3C+.87H6(2;(H1S<WW_.C54[!UL^E\FEVL-5$-SR;-*`V]T,MW
M&S.AX@\;LZP9+X2FI^6OG7CF2)^_9@&9+4N+4#&]1V040ZEFY"."?BL!X3?8
M6'99HUE-&I%]17:W82ENK,P:LRR01G$YCHW)2>XRT^,SHZD3SQSID?LRJ@^L
M<ISMA8M0441D7Y%MJX,4142J*S.P85UQ8=.,TA@$]698?1;BEG4-1)W+<D]P
M5DB*8Z3<33W*HBZ_;V2I&`B*4=15,_*!,,]"M^%B<D,R+C$,NN\C-4O%IEI&
ML2G#*#25+3>6BW_4E(PXER.?X$2?4J?GCZE',N**;$M8L%0,"<4H!DX=D(BX
M`KX"P(J:453?,HKJS5'JK:@HG94G\<?OP9C/3SV2P5?DQU>6BA&A&,6(J!GY
MB"BSL&JX^$<1$8(O="@VU<:*O"@81L--62[^45/2G_D!X7A_XEEAZI'<BPO(
M:7HIMDAQQ1@H=4"'XC#HBA4UZTKC$*1,5._V=?B:@)7(-3P.JO0A29TR@9UX
MMF5X)+YU*8ML55E,>ZGHN(#2L2[R+T9JKAA6J_-HAW\&@\MC.&M&:20>TY;A
MBKZM;"&W7-JU))PXRP\:[Y_..W'I1$:QRPM$"E&-J$&D$;6(#"(KD+0Y/U`<
ML!E/$3./TEL81`I1C:A!I!&UB`PB*Y"T^;2,?^83YW2W8Y2.<Y"*2*%4C:A!
MI!&UB`PB*Y"T.4_.W2);3=W7+`=&W&>[POJ0`"=/J\UZY-:RW[+]2\7B).])
M[AMD5VDE.6$MHX<'\K6,41R+!2*%J$;4(-*(6D0&D15(VGQ:%CO#+#8@>0]>
M9,OL(DKUZS>B&E&#2"-J$1E$5B#IAM/RT!GFH8S2H0]2$2F4JA$UB#2B%I%!
M9`62-@^ED^XV[,"\Q%QR%E*W=%[VJ)N761ZD8HUT7L9SHNRH2V&./R3,?,8C
M%HZ`XD@L6"HBA:A&U"#2B%I$!I$52-KL$HX3;/;YB;#9([$]`E(S0#6B!I%&
MU"(RB*Q`PN;JM#2H$Y=I$*,XJ`M$"E&-J$&D$;6(#"(KD+0Y3X/<]CB?'_&P
M984944#)7?LBHFX>9FFUBL7I/(QW++*OIZ4O%:8OC-+QP?0%I6I$#2*-J$5D
M$%F!I,UY^O+^XEAATA+0@?TQ2O7[(Z(:48-((VH1&416(.F&TU*C"E,C1NG0
M!ZF(%$K5B!I$&E&+R""R`DF;T]2(NNIFYJSHOOTY$`28)%4>B9G9HVYF9C=V
M*M9(9V:\GI1=3=,7ZNJ!_F'V4GDD^@=("2G9@327"+XZG$I4F$H$)#HB4XDL
MLU2Q1NJH>/B6_4Q3B<..PDRB\DCT#Y`24K(#;K_E?3TXZIC34.7WZ72##TAT
MQ4L1ZF(JYE/=78>*-1)7E?&N5/1TGN[&!UW52<O-.*"T?XB40+(#Z=9X=$S1
MVY'R4UE`HB->BAT5-SSOJ%@C=50\7/I^^K<H^3?3O*RVGU>+U?/S[NQ^\]6]
M(8FNT6X_]-B_ONFN&E^[9(#6>"@IJ:0<+)E02;=&0ITIE73727G)C+31F7R@
MG1G5H>/@4,F,2KJ7.H&VBDJJP3J75-+=-D*=*RKIKB;SD@GUP,<QE%`/Z+F=
M@;Y-J`?T=,M0R9Q*NO?4Y-IFY&NZ?QJH,Z.W:-$MS4!)03V@GUL.E5`/Z$>)
M0R74`_KIWD!)227TH/%0"?F-'L<=*B&_T4.K`R54,,@+LI-^^3Y0HR`[?=3G
MOBDH/NA7U$-U*-K\-YQ0A\:-OB[`.O12LH_#NJC"@/P=-3XH3TT/Q?G'Z?5'
MFI'8\!WU:*A#=RZ2A^1I#`>'D,9I<)AHE(8&B7X0>>U^[H@]HM\R7KM?*F()
M/29T[1X"PA)ZPN?:/;^#)?2D#-49&G1ZTH7J#)7<32@<Z)E>U'8WH7"@)U^'
M2FA$Z/G0H1(W)MV@7/3Q0"]\>UM^7OUSN?V\?MV=/:\>:;D;=XG1UK\RSO^Q
M#[^Q_+39TYO>NI];/M&K_5;TDJRQN_][W&SV_`<U?=&_+/#V_P```/__`P!0
M2P,$%``&``@````A`!'OQT.R`@``D@<``!@```!X;"]W;W)K<VAE971S+W-H
M965T.2YX;6R45=MNG#`0?:_4?[#\'KRP=[1LM&F4-E(C554OSUYCP`K&R/9F
MD[_OV-X0R"8J>3%X.#YG9CPS;"X?98T>N#9"-1F.HPE&O&$J%TV9X=^_;BY6
M&!E+FYS6JN$9?N(&7VX_?]H<E;XW%><6`4-C,EQ9VZ:$&%9Q24VD6M[`ET)I
M22UL=4E,JSG-_2%9DV0R61!)18,#0ZK'<*BB$(Q?*W:0O+&!1/.:6O#?5*(U
MSVR2C:&35-\?V@NF9`L4>U$+^^1),9(LO2T;I>F^AK@?XQEES]Q^<T8O!=/*
MJ,)&0$>"H^<QK\F:`--VDPN(P*4=:5YD>!>G5_$$D^W&)^B/X$?3>T>F4L>O
M6N3?1<,AVW!/[@;V2MT[Z&WN3'"8G)V^\3?P0Z.<%_10VY_J^(V+LK)PW7.(
MR`66YD_7W##(*-!$R=PQ,56#`[`B*5QI0$;HHW\>16ZK#"=)-$OFRU4,>+3G
MQMX(QXD1.QBKY-^`BD]<@24YL<#SQ#)=1//E9#J"A`2/?(#7U-+M1JLC@JH!
M2=-25X-Q"L1O1P2A..S.@3.\Q`A\-7`-#]MX-=V0!T@=.V&N`@;6%TR'("#:
M*8/:>&4'=LHNM\Z5JV#HRR1ORTP_(N/`&8;UQ?G5K.,-R@$SZV'F'6(0($#&
M!^C`H-RG/<]M`/4Q[TA#48V7=F`OW24W6&:^)_I7MO@(K0,/:8,%&K6?WG<B
M@"(;'X$##Z6"Y3P"-Y%'E[L##VF#)?9].;CK]4=X'7C(&RSG[KI<]?WU@V?]
M_SYUQX8*G@F:O-\Q\6KQJG+#!`P#0G)=\B^\K@UBZN"F6P(MWUF[R;M+7)V\
MML_279C(I/L"$[&E);^CNA2-034O@',2+:':=)BI86-5Z^?27ED8A?ZU@G\?
MA[:?1``NE++/&U`FW=]T^P\``/__`P!02P,$%``&``@````A`(0FFSA$"```
M[R8``!@```!X;"]W;W)K<VAE971S+W-H965T."YX;6RLFMMRXK@6AN]WU7X'
MBOL!;(ZADDPU^'RJJ5VS9ZX).(%JP!1V.MUO/TNV9!U^#Q.F^B8FGY>6I%]+
M\I+LQU^_GXZ];_FU/!3GI[XU&/5[^7E;[`[GMZ?^_W_W?EGT>V6U.>\VQ^*<
M/_5_Y&7_U^?__N?QH[A^+?=Y7O7(P[E\ZN^KZK(<#LOM/C]MRD%QR<]TY[6X
MGC85_7M]&Y:7:[[9U85.QZ$]&LV&I\WAW&\\+*^?\5&\OAZVN5-LWT_YN6J<
M7//CIJ+VE_O#I13>3MO/N#MMKE_?+[]LB].%7+P<CH?J1^VTWSMME^';N;AN
M7H[4[^_69+,5ONM_P/WIL+T69?%:#<C=L&DH]OEA^#`D3\^/NP/U@,G>N^:O
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MS`W35RBS$D`*;AMB"@M1Q#&!:P+/!+X)`A.$)HA,$)L@,4%J@DP!FI@T4WZ&
MF,P-+:9JL,Y'NGHK;J,:3763=6O2*@S$!>(!\8$$0$(@$9`82`(D!9*I1!.;
M%H.?(39S0V+3Y<;2P(VH+:V1J79KTJH-Q`7B`?&!!$!"(!&0&$@")`62J413
MFQZ,FMK=28)8;IEU+:H08\5)G<[4:^<:B`/$!>(!\8$$0$(@$9`82`(D!9*I
M1!-L=I=@S%H7C!/RWX:<-;>,*=X:"9T=("X0#X@/)``2`HF`Q$`2("F03"6:
MAO2\OB/HF+6N(2=*T`%Q@+A`/"`^D`!(""0"$@-)@*1`,I5H@K&MF9HMW9ZE
MS%H7K"'-IJ.9I4`<("X0#X@/)``2`HF`Q$`2("F03"6:8)3)WR$8L]8%XT2)
M,"`.$!>(!\0'$@`)@41`8B`)D!1(IA)-,+:1N4.QVER7C",*,G5E,[-#:=4N
M;8A<1!XB'U&`*$04(8H1)8A21)F&=$E9;O[Y6<OV@T84"J2$(2('D8O(0^0C
M"A"%B")$,:($48HHTY"N'TO'[]"OR=XIXQ.1M6*[8Y)47?<0.8A<1!XB'U&`
M*$04(8H1)8A21)F&=/U8BGV'?CPC5_7C2(T_0`X[2&"!*ZU<1!XB'U&`*$04
M(8H1)8A21)F&=/U8TGR'?CS'5O5K$(6X",DU.^L@L13D<#2V6RL7D8<%?42!
M+*@LPN.9GEZ&TDJT*T)?,:)$%E3<S\>Z^U1:"?>9YDM7F67:JLK-2="`G?55
M^\/VZZJ@1)G6QHZ<9TPG/OP<B.?KJO@-4I1>LU-04_P&V;12*/GX1.^1RPN2
ME>B1A[Y\1($LR,ZF[)%E>`ZE@?`<H9L842(+<L\P"FW/A.=,<Z./`LO5;XW"
M[\7E[T:!#E?;8>`IOSH,#;(6K71K"Y`CT$-KY7)DUX?=]2A[:.4+)-T'`DE?
M(?J*T"H62/I*!)*^4O25:5:ZKBRE5W7MB&)5/[X#4/5K$)M`2H":IQ06MY)K
ML,/1E%9GI:"Q%+C22D2))WS)1O@"2?>!0%J[QL9Q5BBL9OQL=C:>&C,@$B:R
MNE@@65TBT,WJ4F'%JYM.%D:#,F%1UZ8/%=M,J$/U[Q:B9DNB92$-LBCW5@9B
MKB\Q:YH@]=HD@\\12`:?RY$V*5KW8@1]45#Z"D1!>90;<C35E[Z%WJY(^-);
M;YRQQ\)*UIA@C6EGC3A$;8=4O62-^JBQ'0V,&KUI(K'9TT.L6W<\2O@>2<;C
MB@T=>VYHP;<P#VV$E8Q:1R#IRQ6H>?/&WC9X`DDK7R#I*^#(U@8")QQO_:B9
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M3_GU+5_GQV/9VQ;O[-L.FZ5`+6X^/%G9(_KRI,ZGX0[[)J7>IL(=F^[4^QZX
M,Q;?L9AW%DLZF:6&FOQA20>0'=RB=M$Y6M<=:E>S@S-]6=0N.OOH*D/MHET]
MWJ&4>,D27KQ#G^1\Z?9%KCKL5TR4+DY5=]7\94+^NVZL)DMZ-X<-6DV7]`JJ
M@\^6]%JE@\^7]/8`.1TN4)>[:@CH#CL(P#*TRU^R/3S><:PI>>MJ%VUTR5O7
M'=JHDK?ZSK`=0_K<Z+)YR]/-]>UP+GO'_)5"=E0_^:_-!TO-/Q7?=;X4%7UG
M5&]`]_1A64Y9TXBM)Z]%48E_J+G#]E.UY[\```#__P,`4$L#!!0`!@`(````
M(0`[M(2>J0@``'(I```8````>&PO=V]R:W-H965T<R]S:&5E=#<N>&ULK)K;
M;N,V$(;O"_0=#-VO;1U\B!%G$5MD6Z`%BF+;7BNV'`MK6X:D;';?OC,B*7$X
M7,=.MQ?UYN-P-#.D^(N4[C]^/1X&7_*J+LK3,@B'XV"0GS;EMC@]+X._/\D/
M\V!0-]EIFQW*4[X,ON5U\/'AYY_N7\OJ<[W/\V8`'D[U,M@WS7DQ&M6;?7[,
MZF%YSD_0LBNK8];`G]7SJ#Y7>;9M.QT/HV@\GHZ.67$*E(=%=8V/<K<K-GE:
M;EZ.^:E13JK\D#40?[TOSK7Q=MQ<X^Z859]?SA\VY?$,+IZ*0]%\:YT&@^-F
M\=OSJ:RRIP/D_35,LHWQW?[!W!^+3576Y:X9@KN1"I3G?#>Z&X&GA_MM`1E@
MV0=5OEL&C^%")DDP>KAO"_1/D;_6UK\'];Y\_:4JMK\7IQRJ#>.$(_!4EI_1
M]+<M(N@\8KUE.P)_5H-MOLM>#LU?Y>NO>?&\;V"X)Y`1)K;8?DOS>@,5!3?#
M:(*>-N4!`H#_#XX%3@VH2/:U_7TMMLU^&<3),)I/PLD4[`=/>=W(`GT&@\U+
MW93'?Y55J'TI+Y'V`K_&RW0XF8WC\`8GL78"O]I).!^&R;@-Y,+%$]T/?LW%
M^VM?Z`?IM:G#K[G>9)A$D]F\C?I"SZGN";^FYZ5(1ZKF[1"F69,]W%?EZP#N
M"RAJ?<[P+@L7X,N,G;IR-YK?&TP8173RB%Z6P2P8P##5,`._/(3)Y'[T!6;-
M1MNL/#;48FTL<(J@V]0%P@72`B/(J$L+9L$/2`N]8%HFH)4!?9Z1DX.Q,%U2
M%P@72`N0'&`2_H`<T`O<461HIC3HE;:QC9S16W<F76*,"$:D34AN<*/\@-S0
M"ZX6)#DG\I4V@E"ZR>F8K#N3+CE&!"/2)B0YN)OMY/SKH+EUT+C-P5Q[I4AR
M9P4<)C,Z9.O.R'1+&1&,2)N0D.'6OSYD-*8A*Y+T=\J:D901P8BT"8D/EI;K
MXT-C&I\B$Y"V;@Z$R=PI:6?4E901P8BT"0D9'V^LE?7R+$!C&K(B$R5RN!JN
M&4D9$8Q(FY#X8'[9\>'*'\]1H;7*7KWXHR,:NR(0NUWN.Z?<G5%7;D8$(](F
M))T0!M?.YW*]6VL:M$9VQ3E*.1(<28)HF*A8UK3`LL_OWE/V4&D?K'ZF@"N-
M:.$G8Z?PO97IF'(D.)($T:Q0PZRLWBB^4CP2N4*D^`RE(4."(TD0#1/UZ/HP
MM7K9!5;(*7#H%KBSZ@O,D`@9D@31R%%LKH]<2Y,=N4*DP`RE(4."(TD0#1,%
MQ@I3/4X.9X";?;'YO"IANL.\]<R/&!X;]<.D4BDR/32"N[]?P"?NLQ=N.G`E
MZF4HU2@!8;$ZQG3`1&]E!DP27S1'%*D+.7XJS]_+$1;7+DDE=21)C?KPUR%#
MJ4;)O+OM!4>2=*3AHV`YX<=05\^0V.$JF2/A*I0049TDM+3K4%OU.I8:1#K&
MSBHEC%74;B=FDS'\1WU+8Z*VI_;C?XBJYR093=M5]HT\E5R2/!5*X':UII#[
M"-E><1FH?;;>O70=S:P2Q@KG`>R1_%G9W>C0H?A96;V1BI)*DHI"9!%@*`T9
M$AQ)@DB8D:/$N`A$DR'<G#?N*EM'5*0U<A9@9S^S[JU,Y5..!$>2()J4H]N7
M:Q]Q;=;(KCU'*4>"(TD0#1,5TIHB6'LLUJV55T)KSYVHTU[[-G"W);U57_FN
MHT&"6TF":$JHDU9*;U1>J2J)G`GM.F(HY4AP)`FB8:)T6F%BY:=Q*WVW%E^)
M,$FATV6[^.X&)NJL3*53C@1'DB":%4JJE=4;Q=<";#UWX'X"-)E,>X92;B4X
MD@31,#V:_)YIST4Y4@B=6:N_NY?IK?K*=QT-$MQ*$D13<G3ZC<IS?8X4(I5G
M*.56@B-)$`T3U<J:(/]CVBO=(]->(5K\J?,8L(XZ*U/IE"/!D22(9H42:&7U
M1O&58)+(F8:N(X92C@1'DB`29NPH[>4P6VLJIQK1@Y&INY_IK;H"<R0XD@31
MR&^2TYC+J4;VD1-'*4>"(TD0#=,CIS&\$L`-S8VK>LPE52-G>KN[FMZJKSZ7
M5&XE":)IW22I,9=4C>RUA:.4(\&1)(B&Z9'4<`RYWUIZ+JAPKVI9LI;UJ;,O
M7/=6?>F[C@8);B4)HCFA^%V]LL1**L&=N=I*(U)Z+JC<2G`D":)A>@3U?4\S
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M,H;8VF-3MT\$?6##X8L-^L`#O:\%Z@;/T+X6J!L\AOI:H&[PY.=K@;JI!QX6
M&_2!`QA/GPCZP"&&KP5J#><&OA:H-6R_?2U0:]CQ^EJ@UK!K]+2$$!N\OO&U
M0&SPQL37`K6&8U1/2P2UAK-(7PO4&H[_?"U0:SA%\[1`.MYL(!EO+A"6-ZH0
MHH(WFYXKA!`5O!WTM4!4\$*.M\"KF06^>/&U3*'%-S+P)=NCS]<*+^_QM,*2
M^#A./@]_3!:/L#+PD%9X+_LXS"Y?"BN86VT"HVX.PQ=OY^PY_R.KGHM3/3CD
M.UB&QNTS7:6^F5-_-/KUT5/9P*=N[9ND/7S;F,,7`&-<BW=EV9@_(-!1][7D
MPW\```#__P,`4$L#!!0`!@`(````(0#$X/2YD"```*WD```8````>&PO=V]R
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M7;Y\<?/GX]/]Y_\Y--J_HN-.UN-.]._`3I[IN!D[;H\=UWIG/M-!SVG_=/7O
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MH_MN@CDT+[+=U&+J$OD0^Y#XD/J0^9#[4/A0^E#Y4/O0^-#ZT/G0^S!8X`2B
MCQ$$LM4G1'@5F>:(Z:7UPIDC&W<&O!O;V(U.W2:[8Y-C*)`8DD!22`;)(06D
MA%20&M)`6D@'Z2&#+4Y&^N1&1F:E7_C!9G:CT/2O9S[9QD9Z+L=&?FK')L?4
M(#$D@:20#))#"D@)J2`UI(&TD`[20P9;G-04D)/:\S/*M-Z',PWJNU$VQP^Y
M'22"Q)`$DD(R2`XI("6D@M20!M)".D@/&6QQ!EX'*PL&WK1V!WX4[?\X!58G
M6^^CZ]AHRBN"Q)`$DD(R2`XI("6D@M20!M)".D@/&6QQLM!AU((L3&LWBU&L
M20")(#$D@:20#))#"D@)J2`UI(&TD`[20P9;G('7\>^"@3>MW8$_R-H:>$@$
MB2$))(5DD!Q20$I(!:DA#:2%=)`>,MCB#+S*Q@4#;UJ[`S^*-?"0"!)#$D@*
MR2`YI("4D`I20QI("^D@/62PQ1EX4W\[(V_JO\V%.?FQ]$AIORLWEHG<5<$_
M-)I;'9<%4DQ*2"DI(^6D@E22*E)-:D@MJ2/UI,$A-SI3+MJE^_/'2JM#=:DC
MV6F4WTUD31M21(I)"2DE9:2<5)!*4D6J20VI)76DGC0XY&9A*L4%61P*2R>+
M`]EKASF_I<\YBR)23$I(*2DCY:2"5)(J4DUJ2"VI(_6DP2$W"U,2+LABK"#M
M>6$7E?L343MSYM"L.?-4B4@Q*2&EI(R4DPI22:I(-:DAM:2.U)-TQMX:'#<+
M4^C969CE97WZZB=6E[%DM&,ZD.:'77.<>36'.87KSR)0S%8)*25EI)Q4D$I2
M1:I)#:DE=:2>-#CD)J>(G.2^L[J8YM[B/](\97;F_(L_BT`Q6R6DE)21<E)!
M*DD5J28UI);4D7K2X)";A:D4[5GTG2S&PM*>*@>REI*=^?.$/R]`,5LEI)24
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MJ2&UI([4DP:'W"Q,U;P@B['(M@ZMS`E^MQ3?D2)23$I(*2DCY:2"5)(J4DUJ
M2"VI(_6DP2$W"U,UVUG\]#FN]:'^=J;,L22W"Y1+?W4YMII7%U`\[EXS?&J5
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M(G=U\>]WGUO-J\NX+ZM`8:N$E)(R4DXJ2"6I(M6DAM22.E)/&AQRDS-E]X^?
M5SDUS;W%?R1[%H&BJ>/<*B8EI)24D7)202I)%:DF-:26U)%ZTN"0F\6R6OZ4
MM?Q(SNIR:&51Q%8Q*2&EI(R4DPI22:I(-:DAM:2.U),&A]PLEA7NIRS<)YK?
M\3M21(I)"2DE9:2<5)!*4D6J20VI)76DGC0XY&:QK'`_9>$^D3Z7K.M]_?O=
MYU;S$C+NRUY"0`D[IJ2,E),*4DFJ2#6I(;6DCM23!H?<>);5\J>LY2>RIPIK
M>;:*20DI)66DG%202E)%JDD-J25UI)XT..1D<;:LEM\W=Y?SD:SU8D>*2#$I
M(:6DC)23"E))JD@UJ2&UI([4DP:'W"R6%>YG+-PGLN8%*2+%I(24DC)23BI(
M):DBU:2&U)(Z4D\:''*S6%:XG[%PG\A=0OS[W>=6QR6$%),24DK*2#FI()6D
MBE23&E)+ZD@]:7#(C6=9+7_&6GXB>ZJPEF>KF)204E)&RDD%J215I)K4D%I2
M1^I)@T-N%GXM__S%6F<LV$=REI!#*XLBMHI)"2DE9:2<5)!*4D6J20VI)76D
MGC0XY&9A"ND?K\[/QKK;NNIA(GM>C*UFBM@J)B6DE)21<E)!*DD5J28UI);4
MD7K2X)";Q;+J_(S5^4B:!'85XM_4/K>:EQ#4\#%;):24E)%R4D$J216I)C6D
MEM21>M+@D!O/LH+]C`7[1/.\V)$B4DQ*2"DI(^6D@E22*E)-:D@MJ2/UI,$A
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M[N:/=_<&@K\GOGDY_9SX!>OYD?0[==,"L2-%(YEO79\O`EM[]\K'<ZMI7PGW
ME9*RN:.]>^\^RGQN->V^X+Y*4C5WM'?OW6-3SZVFW3?<5TOJYH[V[KV+K/NY
MU;3[P=F7&[=_;L"/^Q_W7[\5M[YV^I@WSQE<',C)&Q2-K?1MXM.3C4D)]Y62
M,G;,204[EJ2*'6M2PXXMJ6/'GC0X'=V,EITSN.`Y@Y',;T1:L\J_M')N-641
MC62M<3$I8<>4E+%C3BK8L215[%B3&G9L21T[]J3!Z>C&L^R<P07/&8QD?C;2
MBL>_;&EJ-:]QT43V[#GLWOQ@F[4O[^_7"3NF$\V[SR::=Y]/].SNBZG5W+&<
M:-Y]-9'>K_-3W7A_#*FG5F?ZL/GGVXOUZNQRXWVB-E.;^?':B>;'ZR9Z]O'Z
MJ=4SCS=,;?:/Y[X9EIVTN.!)BY',+XM9H^*?WYM:71P_-Z.)+H\4CV1^[F?>
MUQIOAL.3T`\T3?,^G?8U[SZ;:&Z5_]#N"W8L)YIW7TTT[[Z>=K_:)W]V?G*^
M/D7R>.[MM*=YY]U$\\[[']CYX'1S8UYV/N2"YT,FFM^?.U)$BDD)*25EI)Q4
MD$I21:I)#:DE=:2>-#CD9N&?#_E.)<>3'A<X=[$C1:28E)!24D;*206I)%6D
MFM206E)'ZDF#0VX6R\YP7/`,QT3VO!A;S12Q54Q*2"DI(^6D@E22*E)-:D@M
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MSQ\5']J[:_UDUFJR"U@4L#A@2<#2@&4!RP-6!*P,6!6P.F!-P-J`=0'K`S:X
MYL6SK)A?G;":/YHU6P*F>,:^<SO%`U,\,,4#4SPPQ0-3/##%`U,\,,4#4SPP
MQ0-3/##%`U,\MGGQ^/7]3R]"JQ/6_D=SER'OKQB::V/7N:11F#"%"5.8,(4)
M4Y@PA0E3F#"%"5.8,(4)4Y@PA0E3F#"%"5.8MGEA+CM!L#KA&8*CS7-(\?`<
M0<`4#]HI'ICB@2D>F.*!*1Z8XH$I'ICB@2D>F.*!*1Z8XH$I'MN\>):=,UB=
M\*3!9.Y*=6AGF68/3/'`%`],\<`4#TSQP!0/3/'`%`],\<`4#TSQP!0/3/'`
M%(]M7CRFO/_Q+S)8G8RG`^:_NK\[FC-[QG:S*1Z8XH$I'ICB@2D>F.*!*1Z8
MXH$I'ICB@2D>F.*!*1Z8XH$I'MN\>):=1EB=\#S"T:R+\"9S9\_85Q^U5O7D
M76FFQ([-IEI)B1W,VIT2@RFQ8]]G'D(A'IM-#Z$0[=UY@^37]_[U;#]T^>+J
MA'7_T9RQ.[2S7JS>VJ.M]Y<MK$]6WBE-#=NQQ?2:-&S8DX8-IF$[]C67PVCO
M7DFK$3NVF/:N$;/WY(U8J`JW+_C\L2L`5R>LP2?3A8)VQOYU9U.SE?,!<=C=
M:OYPT;B-=K@T9[V^.%E=>"]?`XF.&LC1Y@?00**=ALY]@,O+BQ/_`326=D=O
M+/VZ^"???:R75R<'6^NM;\U(_QJQJ=EJOOA%;\BQZ_GQ^AX-Y6@7^S?IY7:[
MNMQZ?[W54!X:V1<&'6U^``TE'D!#Z3S`^>5F<[[U@M=0V@_@#N7*KVKW0WGV
MRKR5S&7(T[ORQZ])7NUWZ16^H[GOT+7W0;>;NCKOT*GK?%%1/+73[ZZ;V;E:
MG:_7*W]OR=3*>F^G1[/?HGR$?&HW/<+)Y69UL?&N#BNF5H='\`;6U$+V*N^_
M1Z>1_<YI!',QJ?<G@]5D\XO0T-FUUXWYW>0H8!HZM--`P310L"Q@&BBTT[#`
MRH!5`:L#U@2L#5@7L#Y@@VM>;*;JL6/[7CQCE31_?KY;F0M,%9E6*_LSQ+L<
M4(D=FTT+B!*#*3&8$H,I,9@2@RDQF!*#*3&8$H,I,9@2@RDQF!*#*3&8$K/-
M2\P40DL2&PLG)S&[F-I/'L4#4SPPQ0-3/##%`U,\,,4#4SPPQ0-3/##%`U,\
M,,4#4SPPQ0-3/+9Y\9A"R(['?`YN+EZ9I>#FS\>G^\_9[=WO^P_'X,TNUMT/
M*WW.\K-P-.?89^M=W:PTC\VLR093FC"E"5.:,*4)4YHPI0E3FC"E"5.:,*4)
M4YHPI0E3FC"E:9N7IH;92?-['X^FO7\L,)JS>L$TV6"*!Z9X8(H'IGA@B@>F
M>&"*!Z9X8(H'IGA@B@>F>&"*!Z9X;//B,16;/=F^%\]8]3F?A7;5-WT6PA0/
M3/'`%`],\<`4#TSQP!0/3/'`%`],\<`4#TSQP!0/3/'`%(]M7CRF/%P2SZ&<
MW#CQC.;,'ICB@2D>F.*!*1Z8XH$I'ICB@2D>F.*!*1Z8XH$I'ICB@2D>F.*Q
MS8O'5)QV/&95,C^`M'B=.I2N;FX'<P\*MUY%H77JV,Q:IV"*$J8H88H2IBAA
MBA*F*&&*$J8H88H2IBAABA*F*&&*$J8H;?.B-!6O'>7W/@@/%;*;V&C.3(-I
MIL$4#TSQP!0/3/'`%`],\<`4#TSQP!0/3/'`%`],\<`4#TSQV.;&8^Z46A+/
MOKUW&#&:=4YPMZ)%`8L#E@0L#5@6L#Q@1<#*@%4!JP/6!*P-6!>P/F"#:UX\
MIGY?,'O68[UOKU.3V;.'IGAPKD#QP!0/3/'`%`],\<`4#TSQP!0/3/'`%`],
M\<`4#TSQP!2/;5X\IABVXS'KU/K4G+-;NE*9+P#PC\]'\U8J[ZREYII=DH\G
MG&@*$^T4)DQAPA0F3&'"%"9,8<(4)DQAPA0F3&'"%"9,8<(4IFU>F*9TML/\
MSDIE8D%B=OD]'K)/[>;YI[F&=HH'IGA@B@>F>&"*!Z9X8(H'IGA@B@>F>&"*
M!Z9X8(H'IGAL\^(QM?"2>,;:V?DH/)@>93JFT^R!*1Z8XH$I'ICB@2D>F.*!
M*1Z8XH$I'ICB@2D>F.*!*1Z8XH$I'MN\>$PMO"2>L79VXK'KZ6GVP!0/3/'`
M%`],\<`4#TSQP!0/3/'`%`],\<`4#TSQP!0/3/'`%(]M7CRF%K;C^3^L5(>R
MVCE"-W^EPXGVK?=W8,VU8[-I_BE,F,*$*4R8PH0I3)C"A"E,F,*$*4R8PH0I
M3)C"A"E,F,*$*4S;O#!-Y6R'^;V5:JRTG;EF5]_37(,I'ICB@2D>F.*!*1Z8
MXH$I'ICB@2D>F.*!*1Z8XH$I'ICB@2D>V[QX3#6\))Y#]>Q.*+NBGN*!*1Z8
MXH$I'ICB@2D>F.*!*1Z8XH$I'ICB@2D>F.*!*1Z8XH$I'MN\>$PUO"2>L7IV
M9H]=44_QP!0/3/'`%`],\<`4#TSQP!0/3/'`%`],\<`4#TSQP!0/3/'`%(]M
M;CSZ0_^B>/;MO3,2DVD]G*\=V7I7SNQ6<[-Y.:+%@79)P-*`90'+`U8$K`Q8
M%;`Z8$W`VH!U`>L#-KCF)68*Y`43:C,6U/:$FLP^,J=%*YKBL0OT_614/##%
M`U,\,,4#4SPPQ0-3/##%`U,\,,4#4SPPQ0-3/+8=XGG]^/'V]BFZ?KI^^^;S
M[</OM[O;3Y\>7]S<__E%DV*UW>J2G:._>+C]\,O+=XKY:I^U)@2WK<RV_=6`
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M;,)]--:;X%AO--:;X%AO-=;;X%AO-=;;X%B;`QX=\P?&8*,^X:.=C<9Z$QSK
MC<9Z$QSKC<;Z4.'[:_U&8[T)CK4YJ`H?4YE#JO`1U5IC'3Z>6FNLPT=3:XUU
M^%AJK;'^QI&4^GSC.$I]PD=1YB`J?`RUUEB'CZ#6&NOP\=-:8_V-HR?U^<:Q
MD_I\X\A)8_V-XR:-]3>.FC36WSAFTEB'CYC4)3@3U"$X#S3,P5F@00[.@97&
M6)?1!][/A\.CP!9S:]+5_L8C]C+WWYAMH>=F[DNZVM]JPWZ_KJY^#<X0!1V<
MAR;FP'-[9R94P'_=7OWZC5K$?*@%>KQ3C*%9IJ]\OC+?\<S7H"]POC+?V,PM
M^CKF*_/]R]RB+U>^,M^FS"WOS&CI'Z&1U`VW9U?Z1VB;;F<YN]K?><9]FGNO
MS+90/W-CVM7^-BOV,S>H7>UOM^(V?2.]QB.4A;Y,7N,1VJ+O@==XA+;H*]PU
M'J$M^B9T/4XH6WVON1XGM$7?4J['"6W1=X[K<?9;7A\_8!_?OOEZ_?MM??WP
M^]V7QQ>?;C^H\#W9?[/_P^%*Y\/_/(U?^?[;_9.N@MY_^_O'V^OWM[IUX\3\
M+?_#_?W3]#\:L-=_W3_\L2^NW_ZO`````/__`P!02P,$%``&``@````A``#N
M1V73!0``VA<``!@```!X;"]W;W)K<VAE971S+W-H965T-2YX;6R<6%N/LS80
M?:_4_X!X3\`VURC)IX75MI_42E75RS-+G`1M"!&PE^_?=\PX8)L-2[H/F]MA
M?'QF/`=F_>VC/%EOO&Z*ZKRQR=*U+7[.JUUQ/FSLO_]Z6D2VU;39>9>=JC/?
MV#]X8W_;_OS3^KVJ7YHCYZT%$<[-QCZV[67E.$U^Y&76+*L+/\,O^ZHNLQ8^
MU@>GN=0\VW47E2>'NF[@E%EQMC'"JIX3H]KOBYP_5OEKR<\M!JGY*6N!?W,L
M+LTU6IG/"5=F]<OK99%7Y05"/!>GHOW1!;6M,E]]/YRK.GL^P;X_B)?EU]C=
MAU'XLLCKJJGV[1+".4ATO.?8B1V(M%WO"MB!D-VJ^7YC/Y!5RJCM;->=0/\4
M_+U1WEO-L7K_I2YVOQ5G#FI#GD0&GJOJ14"_[\17<+$SNOJIR\`?M;7C^^SU
MU/Y9O?_*B\.QA73[L".QL=7NQR-O<E`4PBRI+R+EU0D(P'^K+$1I@"+91_?Z
M7NS:X\9FP=(/748`;CWSIGTJ1$C;RE^;MBK_11"1H3`(E4'@508A].X@3`:!
MUR$(C7SB!U]3<7!;G4J/69MMUW7U;D'I`?'FDHE")BN(?)4'-],+=DLO$$H$
M>1!1-G9H6R!%`TE^VX;1VGF#O.02DHPA1$>D5X1()[#K*8)J*L7/,W=E(L""
MB<BDH);@%Q"[IT:-=<>(8*"F,0&!YC,18*@69>$PUE=.$.(I$%]'I%,(C1H$
MF4]-@#<V[+O7)#063A`2=;E<D)@&Q*.!04[#>%',8O^&<'!45':BRA@<Y>E4
MBHMT`2-79Y`@!'CT&S'VD4XA-`$#G>(T-0'6!8R&G6/=(23H!/0I)4'(=/*I
MBJ"1Q\(AA,8,CI4JWC0S`=:9!:&^;H(09$99&)F\\'=55#8<&8V9,$FE>4PS
M$V"#F=DC$')CY4[6%"%(WB/T!K%8)S:OWL1%.L%H"(])10BNS@*?>:.DJH@%
M9)V0(8:F'8'ZGR]>AS8.@Y&W1&)4^<S3,`G1Z8ENK.1VGH0$>[C:6:B99(E!
M$1>>SWSBZ16::A!"/.(->]59BMZML)RN0(*=7F7'AC.'&988R4XD>%@:*U`B
M5)EOG0\BVO=\>MCLX7_?S2)#F:2+N+'5Q4<YGNT9!,*H]&;F6%REGQ-F<$BZ
MR!L;520,^I\_'`,I(X:10ON1[]Y,\O]R#W&39](T#"R1&$DS#HEK(%(-P3S/
M=X>"T2OQ+O\@GQC(2$/5'Q8Q<PF+1O0TC!=[81P,-QDZP;MLA*`):+5H+)Y(
MS&0MCKUDV*9.[RXO(6,SB4R;DQA98,1WH]`X3:D.B5PVW%_HY`P_^:+-?&(D
MHR:H^<3GY#3(;7+T+B/IT(:1#!6#/5!BIA(["=&THX:13&O7H?7F$@])D?30
M9/K$AA$=B@J;BPQSA7@N_/4>H],S'&1>#Z1C)XF'QB!I(D8V%]]C/G-'/!&C
M*GW+2ZAHZXJ7S"2*9@#+])X2&YTXZ2)?FS6+J1L9!9'J"`]N9>/!%74Y15>_
MGZ6XRLCZL("4$S%7.8,@]I56)].N8ABC$SP-3_FB*L=>$AN])!'/X+`'Y!=0
M$C)W)*,*69"`1H%B.+J.AIW,S/;85F*CY!*J6H;O,\8"H[&G.B0@$8A]X_08
MIC*3)KJ"5I0&AX0B1J:;A+X;F,^HJ89A<0R3M:%J=#D-=YG)$UU&-<'8=!F*
M&"B\_H`9BJ>3$)WF73Y#QSX3FSXC,2H]I<'(4X-Q/'Q4O3G[N,MFQ-.]>:*'
M&L(3+3&3W*8QFGC,,)IY.>ZNTOV0*%XAF:+CJ$S-),LXGT-TGJ+GW]TB849J
M"DJ4>U')$T$XM:'PU!0J?1J3+>,@)'#=2)FI($T<I>*0L.3U@:?\=&JLO'H5
M8U(*5=)_VX]P'[H)KO%]`J/=;@[J]#_`9/62'?CO67THSHUUXGL(Z2Y#:(PU
MSF;Q0UM=NM'D<]7"3+5[>X09.H>!GKL$\+ZJVNL',2[LI_+;_P```/__`P!0
M2P,$%``&``@````A`$`WN4,P!```V!```!D```!X;"]W;W)K<VAE971S+W-H
M965T,C,N>&ULE)C;CJ,X$(;O1]IW0-PWASA`$B49->&P(\U(H]4>K@DX"6K`
M")-.]]M/&0,!)XN9ODB"^?SC^EUE[-Y^_<@SY1U7-"7%3C4U0U5P$9,D+<X[
M]9^_@Y>5JM`Z*I(H(P7>J9^8JE_W?WS9WDCU1B\8UPHH%'2G7NJZW.@ZC2\X
MCZA&2ES`G1.I\JB&R^JLT[+"4=)TRC-]81BVGD=IH7*%335'@YQ.:8P]$E]S
M7-1<I,)95,/XZ24M::>6QW/D\JAZNY8O,<E+D#BF65I_-J*JDL>;;^>"5-$Q
M@[@_S&44=]K-Q8-\GL85H>14:R"G\X$^QKS6USHH[;=)"A$PVY4*GW;JJ[D)
M35/5]]O&H']3?*.#WPJ]D%M8I<GWM,#@-LP3FX$C(6\,_9:P)NBL/_0.FAGX
M62D)/D77K/Z+W/[$Z?E2PW1;$!$+;)-\>IC&X"C(:`N+*<4D@P'`IY*G+#7`
MD>BC^;ZE27W9J<C6+,=`)N#*$=,Z2)FDJL176I/\/PXU$?4BBU8$P>C;^PMM
ML;),R_X-E66K`M_=4);:RK*6]LJ9/Q8@FX#@NU,Q?CL@NQ5Q>A%S-7LH.K>X
MF3$OJJ/]MB(W!<H`3*1EQ(K*W(!R-U7<V'[R_F_N8-*8R"M3V:G0'Z:%0L*]
M[Y&]W.KOD"1QR[B/S&),')X0UACQ.`*?_8,$$5]*!(\$LIWQ<\(GC&/TC`[F
M]0Y"H@T=?)[DG5$,9D:QI&?.N6+#06SP>,,P9&0+MOC/&+L?;O.DX!FS&C/A
M-#,*&^IJ?M@,'H4M-AS$!H\W\)IF3OEB0]`UW',!V6LAH&EF%!"4^#`@5@E+
M*-CI^62=8'D:Y"-RS/$87,[`9Y^SPO0=I(0G)7PI$4B)<(H8>06^B%XA>$U,
M>\4Z[51(L=X'Y`C5ZW(&QM$SHE=2PI,2OI0(.&&;S5HF3&@XNFEH:^08P[][
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MXCH3B"=7\>5(($?8@9+%Q+TRT6)A6/?JY5[Q`R,_?N2X.N,#SC*JQ.3*#H,(
M7.Y;^X/J*V)[9:'=-3?NL_:#N8&-)#N:]AW@7%E&9_PCJLYI094,G^!1AL8.
M;Q4_F?*+FI3-8>A(:CA1-C\O\!\$##M/.*JIRHF0NKM@#^C_)['_!0``__\#
M`%!+`P04``8`"````"$`\_HLZ%4=``"3P@``&0```'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6RLW=MRV\::AN'SJ9I[</E\))&4N%'97A43^SU0:V:.%5NV
M5;$LEZ0D:]W]_$WB9V]>1!(UR4&4/.ANDOVA`723(-_]XU^WW]_\<7W_<'/W
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MFCO=/U&^YLWIYE1:^O#N\XV\`M/M;^ZOO[Q_^\OL<IB=K=^>?GBWZZ'_N;G^
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MLMUAIMUN_D/[??[")ZH)S&P$B\DG>KH?`[LA%5T]7GUX=W_WYQLY4,F>]/#S
MRASV9I>F%1U,^S0.P^NO1I<,*]/*+Z:9]V_E%<BX>9!CPA\?YLO%N],_9!A_
M&LM\9)F97V*K)<R8-<U&(<0A)"&D(60AY"$4(90A5"'4(30AM"%T(?0A#`Z<
M2CR'C&2G_SLR,LV8C+1W/RHXH06!:`FM$H40AY"$D(:0A9"'4(10AE"%4(?0
MA-"&T(70AS`XX`4BAY2_(Q#3S/NW\F]GT)S["7P<R[B%+OPBVT.10TJ0&))`
M4D@&R2$%I(14D!K20%I(!^DA@RM>:')0_SM",\U(:/+'22T\U(V%Y+D<"H6I
M'8H<4H/$D`220C)(#BD@):2"U)`&TD(Z2`\97/%2DS.PE]KT19Z>ADSI73C:
MJ1]'61R.>EM(!(DA"22%9)`<4D!*2`6I(0VDA720'C*XXG6\7,=X'?_*"P/3
MC)_(7B[D6N,P-N;+<'0<"FF0$22&))`4DD%R2`$I(16DAC20%M)!>LC@BA>2
M7'!Y(3T].DQI/XM1G-$!B2`Q)(&DD`R20PI(":D@-:2!M)`.TD,&5[R.E[WW
MB(XWI?V.WXL,`MV_MY`($D,22`K)(#FD@)20"E)#&D@+Z2`]9'#%ZWB9*![1
M\::TW_&C.'L\)(+$D`220C)(#BD@):2"U)`&TD(Z2`\97/$ZWLS!O9XW)P0[
MV7SY3-&TXV>R:UK(O5R:+Y?!9:XMI6,F(L6DA)22,E).*D@EJ2+5I(;4DCI2
M3QH\\G,SLTIWAO_T.6*VGX3*]:WV\D<E9\R0(E),2D@I*2/EI()4DBI236I(
M+:DC]:3!(S\+,Z$\(HO]_-/+8B0W"U`T`\6DA)22,E).*D@EJ2+5I(;4DCI2
M3QH\\K,P$\4CLACGE>ZX&,G-`A29]4=SO+.E8E)"2DD9*2<5I))4D6I20VI)
M':DG#1[Y69CIGYO%:\\MXS32#>DPLW2G&ZOPW'(HI4>]R"P"A[F!$I9*21DI
M)Q6DDE21:E)#:DD=J2<-'OFYF=FCF]LSYY9QLNG&X\X_=VN^6_-6CM_Q$2DF
M):24E)%R4D$J216I)C6DEM21>M+@D9^%F20>D<5^3NF=6T:R1ZJM>3<CS`(4
MLU1"2DD9*2<5I))4D6I20VI)':DG#1[Y69AYXQ%9C--,=URX,\]Q7(`B\Y:1
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M69AYMIO%*]?$YN-\W0UI3_Y;\*NS\-QR*&7/+:!X;-X9?`DI)66DG%202E)%
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M%:225)%J4D-J21VI)PT>^;D=-_=?<.ZO9`?,EA218E)"2DD9*2<5I))4D6I2
M0VI)':DG#1[Y681S_]>.(2X*+/84S'&">\"VMI0=0X>*2C%+):24E)%R4D$J
M216I)C6DEM21>M+@D9_;<>L$"ZX3*+ECB.L$+!63$E)*RD@YJ2"5I(I4DQI2
M2^I(/6GPR,OB/%PG>'J.LRON7U<K.5F0(E),2D@I*2/EI()4DBI236I(+:DC
M]:3!(S^+X^;^YYS[*[E9C*4L12P5DQ)22LI(.:D@E:2*5),:4DOJ2#UI\,C/
M(IS[OW+][)R+`DK>]=DJN"M\:TOIB20BQ:2$E)(R4DXJ2"6I(M6DAM22.E)/
M&CSR<S,3?_>Z^IGCF2D>',]&L@-F>PZ*2#$I(:6DC)23"E))JD@UJ2&UI([4
MDP:/_"S"=8)GLN!RP/EA.4`'P984D6)20DI)&2DG%:225)%J4D-J21VI)PT>
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MDQ)22LI(.:D@E:2*5),:4DOJ2#UI\,C/(IS[/WUNN>`47\G-8BQE*6*IF)20
M4E)&RDD%J215I)K4D%I21^I)@T=^%F;J_?+Y_,4X4W?>#E.R';\E1:28E)!2
M4D;*206I)%6DFM206E)'ZDF#1WX6X7Q^?VXY,5^I^_CMYM-O'^_,!P$FOTAT
M(=\8NKM![Y<+3O-'DF_5T'/&EA2-9.[Y<,X_P7W^L2VE;25L*R5EMJ+;?'"K
M9VY+:?,%VRI)E:WH-A_<[5/;4MI\P[9:4F<K.LVO@P]\][:4-C]X;?EQATL&
M8=S_O/OY5W'+A]X/>7,IX6)/YMLB;)+K\!.$MI0^V4C)#N]8:;G[2MK99GVQ
M6`=KJ8F6L=52)7M4R)1D_SP\J]DBZ,)<2YD7^,>'Q<D\>%.PT`+VP4HE^V"5
MDBU5*^U;7I\L@I?1:`%;IU6R+7=*3[Z,7DOMN^UB<[9>;H)+N4'+[![/WS7"
M%8QGSI!<J+C8D[FI^]#9\W7X01\M9;]$+5+:'(X5\4AR$Y^)9+:8+V9G06P)
MJZ5*MO%,R3:>:^-GN\;7)^M@R!:L4RK9EBLEVW+MMSP+GG'#&JV2;;=3LNWV
MMEW;M;-Y\+0'KZ(?;KC,$8[[EQWFN?IQL2?SA3U.YL'XV6HINTM'(\FA2H\$
ML9(Y]1R^CYH#?WQ$;RRL@JY(^8B9DGW$7&D_/,].PN%2:`%;IU2RKZ52LJ5J
M)?>U(+!&2]F*K9)MOE.RI7JE)YL?M-2NHK\_A$LMN_U!OOI<NMZ<]?4T<,0E
M`%=CS(JE+#B;+PMP\@P7+FTIW1&BD2[L`(A'6NZ'['RS69]QSQ@?SU9+V7BF
M9$OE(\G=V^9@<W&R":X0"M8IE>RXK91LR[7?\OHD.!PWK-(JV88[)=MPKPWO
MCX\7*_G]@G#G';QJ?OSAZDYX.-#\GSD'<-5',MME;G??+2E2LGMTK+3_Z0?S
M-?*)DBV5*MGF,R5;*E>R;15*ME2I9-NJE&RI6LFVU2C94JV2;:M3LJ5Z)=O6
MH+0KY64DN[H_2PHS>M$A>]>*O^8S4C`L@SUS:TL=AN5(\I25XI'DCQDYR_/%
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MIIW@M#:2OP`1',:W6M%&&9%B4D)*21DI)Q6DDE21:E)#:DD=J2<-'OFYR<3`
MR^WI"\.E*1[$,Y+M^*V6LA218E)"2DD9*2<5I))4D6I20VI)':DG#1[Y61RW
M4+/D0HV2[?@M*2+%I(24DC)23BI():DBU:2&U)(Z4D\://*S"-=5GAD77$!9
MCN1F`8I8*B8EI)24D7)202I)%:DF-:26U)%ZTN"1GX69_H?GEE?<PKC<+R.X
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M9;-<+7!]F+!:JF2/T)F2'"L.UYK\=*B6VG^:7SX=&GP4M=`"]CF62O;!*B5;
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MDA\V48JU^7U0J\UBL3H/PDJT)3ML4B4[N#(E6RI7TNN`L.5""]@ZI9)MN5*R
MI6HEO0Z879RY_P2[=J/%;0NMDGV<3LF6ZI7&D_Y\>3Y;A=^8/VBA73U_=PA7
MC\*CP\LNU3=<51K)&89;4J3D!KYO2^[<T7T@8:E4R8Z63,FVE8_DM%6P5*ED
MVZJ4;%LUVVI8JE6R;75*MJV>;0U>*3^C<%4IS.A%1_`-%YM&"H9I<,FRM:4T
MCV@D;YB.S8_#=#4Y3/=E9G;W3=EXIN2=]7$COI;2D1M>'19:P#Y8J61'5*5D
M2]5*.G+/@JO#1@O8.JV2;;E3>O)E]%KJZ>'K]IN_:X2+7.&N\<+AR\6OS4CV
M%6U)$2DF):24E)%R4D$J216I)C6DEM21>M+@D9^1[`%'+$1N3/'@=#J2FP4H
MTHJV5$Q*2"DI(^6D@E22*E)-:D@MJ2/UI,$C/PNS6/3R1>&-*1YD,9+MY:V6
MLA218E)"2DD9*2<5I))4D6I20VI)':DG#1[Y680K4/MCU]$?E-QP:4I)CF&'
MB<)\@^O/L:*;&RBV;>GI+R&EI(R4DPI22:I(-:DAM:2.U),&C_S<CELGVG"=
M2,EV_)84D6)20DI)&2DG%:225)%J4D-J21VI)PT>^5D<MZJSX:J.DIO%6,I2
MQ%(Q*2&EI(R4DPI22:I(-:DAM:2.U),&C_PLPH66IU?4-UQ14;(=OR5%I)B4
MD%)21LI)!:DD5:2:U)!:4D?J28-'7A;R#5#!B?Z5)Y=]0_XEP,'\TTLX;W**
MZ9DCFK!XPI()2R<LF[!\PHH)*R>LFK!ZPIH):R>LF[!^P@;?@BC#)8JGQ]7L
MC&L1!W-&UH1)/&-=6T[B@4D\,(D')O'`)!Z8Q`.3>&`2#TSB@4D\,(D')O'`
M)!Z8Q.-:$(^9G+[\DGIV-BX4V-GSQX/9;M].F,0SUK7E)!Z8Q`.3>&`2#TSB
M@4D\,(D')O'`)!Z8Q`.3>&`2#TSB@4D\K@7QF'G\,?&,\WXOGM%LMTL\,(D'
M)O'`)!Z8Q`.3>&`2#TSB@4D\,(D')O'`)!Z8Q`.3>&`2#TSB<2V()UP<>/5Y
MBLL&L[/#(H$[#0H6SR7*0S'G/`63*&$2)4RBA$F4,(D2)E'")$J81`F3*&$2
M)4RBA$F4,(D2)E&Z%D1YW-K"[(R+"P?S1AI6'&2DP20>F,0#DWA@$@],XH%)
M/#")!R;QP"0>F,0#DWA@$@],XH%)/*X%\83+#<]=1G!987:&Y0$9/3")!R;Q
MP"0>F,0#DWA@$@],XH%)/#")!R;QP"0>F,0#DWA@$@],XG$MB.>X5879&9<5
M#N:-GK&<-8D')O'`)!Z8Q`.3>&`2#TSB@4D\,(D')O'`)!Z8Q`.3>&`2#TSB
M<2V()UQH>/5YBDL0L[/#@H-[G@H^[B,C[5#,.4_!)$J81`F3*&$2)4RBA$F4
M,(D2)E'")$J81`F3*&$2)4RBA$F4KNVC/'WX=GW]&%T]7GUX=WM]__5Z>_W]
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MW`RD"?_E_/*7O[C:,@>SB1KRDSF7Y@=Q^%SEUVXNS6_9<(O\4,VE^1D:;I'?
MF+DTOR##+7)_E?3PU!:Y-4IZ>&J+W-4D/3RU16Y(DAZ>VO)Q:7:BR;UH*;N1
M?-V?/+?3PT[\\.'=SZNOU_75_=>;'P]OOE]_D<O<L]T]9_<W7\W\9?\_C^/O
MV/QZ]_AX=[O[29MOUU>?K^5[Y<_,KQQ\N;M[U/\Q#_#GW?UONTOI#_\G````
M`/__`P!02P,$%``&``@````A``QS?>PE&P``*[<``!D```!X;"]W;W)K<VAE
M971S+W-H965T,30N>&ULK-U9;]M*EL#Q]P'F.QA^[]B4O"-)PQ+WG43/S+.O
MHR3&C>/`]EWZV\\IB<5:_M5V9.0ERZ\64758).N(HM[_\^_[;P=_;AZ?[AZ^
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M^"O?W'WY^BSQ/I6WI-[9U:=_QYNG6QE2Z>;=XE3U=/OP339`_CRXOU/[A@S)
MS=_;O_^Z^_3\]</A\NS=Z?GQ,I+J![]MGI[3.]7EX<'M'T_/#_?_MZNT?4=S
M)XNI$_D[T,D+#9=3PY.YX4+VS!<:R#9M-U?^UJ]T_"XZ.3Y36_M"N[.IG?0^
MM7OEA2ZG!O+W7B\4201W`RI#]G,O%>GA4_^8FLCVOO!N(CUNZA_Z1<Y_9APB
M&>G=YID1?&4D(CUVZA\_MWGG^D7D'_MMGL1GMWFO!>IHMQ]OIT5\\WSS\?WC
MPU\'<K"187_Z<:,.7=%5)+WH";$;SGF*_*<9(E-#]7*MNOEP*-LO._^3S.L_
M/RZ/E^^/_I2I>#O56;%.Y-98ZQIJWJEN8Q\2'U(?,A]R'PH?2A\J'VH?&A]:
M'SH?>A\&'T8+CB0\<XQD/_\5,5+=J!CIT5UI,$%;>`'1-723V(?$A]2'S(?<
MA\*'TH?*A]J'QH?6A\Z'WH?!A]$")R!R&$%`3N0($3Z+Z#FB6LGYPIHC$>;(
M5,>N=.K%9*XR!P620%)(!LDA!:2$5)`:TD!:2`?I(0-DM,6)D1RY$2-UIM_S
MP*:ZD:#)7]:1[<0-R6JJ)-LR5_*C-E>9HP9)("DD@^20`E)"*D@-:2`MI(/T
MD`$RVN)$30+D1.WE&:5J;X.C!W4UR7(^R*TA,22!I)`,DD,*2`FI(#6D@;20
M#M)#!LAHBS/P<K'B#+RZ#E"'M#VGB^K&C<A.3N728IX;RV-_=LR5="!C2`))
M(1DDAQ20$E)!:D@#:2$=I(<,D-$6)TAR?>4$Z>79H6J[L9C$FAV0&))`4D@&
MR2$%I(14D!K20%I(!^DA`V2TQ1EXV7OW&'A5VQWX2:R!A\20!))",D@.*2`E
MI(+4D`;20CI(#QD@HRW.P,MZ<H^!5[7=@9_$&GA(#$D@*22#Y)`"4D(J2`UI
M("VD@_20`3+:X@R\6I@[(__&$\*V'S<FFNS+I>CXS+VF6IM:\SF!E)!24D;*
M206I)%6DFM206E)'ZDD#:73(C9M:1-H+^I?/$=%NS2G7MWJ45YJL.4.*20DI
M)66DG%202E)%JDD-J25UI)XTD$:'W%BH]>,>L=@M-YU83&3'`A2K1)@Z[IE:
M"2DE9:2<5)!*4D6J20VI)76DGC201H?<6*B%XAZQF-:5]KR8R(SR6N43W8&/
M20DI)66DG%202E)%JDD-J25UI)XTD$:'W%BHY9\=B[<F':=EI!VD>65IEAO1
M\;E_;IEKZ:->K#*];B@34DK*2#FI()6DBE23&E)+ZD@]:2"-#KEQ4ZM'.VZO
MG%NFQ:8='GO]N4WQKE5.QAWXF)204E)&RDD%J215I)K4D%I21^I)`VETR(V%
M6B3N$8O=FM(YMTQD'\]`L?H4PPU/0DI)&2DG%:225)%J4D-J21VI)PVDT2$W
M%FK=N$<LIF6F/2_LE><T+T!Q!$I(*2DCY:2"5)(J4DUJ2"VI(_6D@30ZY,9"
M+27M6+SUW#(M2>T@S:M4^]QRX9];YEKFW`)*U$=M[K1*21DI)Q6DDE21:E)#
M:DD=J2<-I-$A-VYJ)6K'[95SR[1PM<-CKV6G.02*(U!"2DD9*2<5I))4D6I2
M0VI)':DG#:31(2<6"W_M_W(LMM7=);XFZ]Q"BDD)*25EI)Q4D$I21:I)#:DE
M=:2>-)!&A]Q8[+>>7W`]K\F.Q53+4,Q:"2DE9:2<5)!*4D6J20VI)76DGC20
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MU)!:4D?J20-I=,@-I,H&_(I`3ED%>P+NR)V`T;$;V_5BKJ4C$I,24DK*2#FI
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M*2<5I))4D6I20VI)':DG#:31(3>0H23,&XZD2R9A)O(FH)^$,;5,W'9]V6=`
MUDI)&2DG%:225)%J4D-J21VI)PVDT2$W;BJ_\0O.@'*7RW9U9Y\!HS-_#:AK
MO3@!IYZL+*AIIF.;D%)21LI)!:DD5:2:U)!:4D?J20-I=,@-I(P\`JD.O'MF
MT]1W*M0RW;H$G<B;@%Z";6UJZ2#%I(24DC)23BI():DBU:2&U)(Z4D\:2*-#
M;MQ4?N-73,`I3V)/P&7D9<I6RSF;\L(9<*YC`@E*3$^Z5DK*2#FI()6DBE23
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MG$">^$F8EV]0V59WKS0UF6O_-2DF):24E)%R4D$J216I)C6DEM21>M)`&AUR
M8_&+$BLG<V)%[^2KB=SEP,+/2)M:NF%,2D@I*2/EI()4DBI236I(+:DC]:2!
M-#KDQLW/H[PRAY@N.9G(GD.@F+424DK*2#FI()6DBE23&E)+ZD@]:2"-#KFQ
M\',CK\1B3H'H/7YU@ES&FA23$E)*RD@YJ2"5I(I4DQI22^I(/6D@C0ZYL5!I
M"?LBX958J.K>N64B>UZ`XA-00DI)&2DG%:225)%J4D-J21VI)PVDT2$W%BH;
M8,?BC4E[=8N0'Z0YT6"NSB*L='5#$\J8E)!24D;*206I)%6DFM206E)'ZDD#
M:73(C9N?H7AE#C$1<3*1&?@U*28EI)24D7)202I)%:DF-:26U)%ZTD`:'7)C
MH1;T]AQZ)1;3^M]:DYX@);`FQ:2$E)(R4DXJ2"6I(M6DAM22.E)/&DBC0VXL
M_,3!*[%@?N!D(GM>@&+62D@I*2/EI()4DBI236I(+:DC]:2!-#KDQD*ML^UY
M\<:;N4^F];H]8>8EO'5N01)'-S2AC$D)*25EI)Q4D$I21:I)#:DE=:2>-)!&
MAYRXG>ZW]M]6=Z_/-)F!7Y-B4D)*21DI)Q6DDE21:E)#:DD=J2<-I-$A-Q;^
MVO_EX]DIE_B:[%A,M0S%K)604E)&RDD%J215I)K4D%I21^I)`VETR(W%?NOY
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M)U`?D'GI34WV'&*>@+424DK*2#FI()6DBE23&E)+ZD@]:2"-#KFQ\/,$KUP3
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M&Q:DD@TK4LV&#:EEPX[4L^%`&IV&;HQ4NN#GEZ]GJKIW>-R1>J2I-:N\6TO7
M4T,K8O%$\N@&$YY=7Q:E;)B1<O95D$HVK$@U&S:DE@T[4L^&`VET&KKAV2^[
M<,;LPD3J*:=6>+Q;[]>ZEHE%K,F>/;ONU3>GK+Z\6[U3-LPTF>YS3:;[0M.+
MW9>ZEFE8:3+=UYIDB\VF+KV;8AM=ZVS[\T,7"_E2T-([HK:ZCGF]3I-YO5[3
MBZ\WZ%HOO-ZHZVQ?S]T95"IAC[FJJGMS=4?J47C6J'AWH:[/IEK6$TLT75IS
M=5=+/8;*]+7`SC#U91IFNB_3?:[)U"HF>KG[D@TK3:;[6I/IOM'=1]O(GYT?
MGR].$7EL>Z=[,IWWFDSGPT]T/CK-W##OEPTY8S9$D]D_UZ28E)!24D;*206I
M)%6DFM206E)'ZDD#:73(C44H&_*&;XZ>S=D0,UF6"^_:<*5KR5EPGE+>3KDV
M=?19,R8EI)24D7)202I)%:DF-:26U)%ZTD`:'7(#Z:='WIC6.F/>9"*5#IBC
MMEP@;KN&4LO$#928OG2ME)21<E)!*DD5J28UI);4D7K20!H=<N/FIU)V:XB]
MOSEZ-N=8["!YRYN5KO7B!$1J)C;-=-024DK*2#FI()6DBE23&E)+ZD@]:2"-
M#CF!//?S,&\,Y+8?]ZIF(F\"^BL04TL'*28EI)24D7)202I)%:DF-:26U)%Z
MTD`:'7+C%L[9[#T!S^>LC3T!O77(2M=Z:0*:.B:04^?F@B=AK924D7)202I)
M%:DF-:26U)%ZTD`:'7(#J1(D]NKAC6?`\UVBQ?X&XD3>!/26`FM3R\1MUY=U
M4DQ8*R5EI)Q4D$I21:I)#:DE=:2>-)!&A]RXJ9R('[<W7(*>JWZV!TYK`OHK
MXI6N]>($G'HRLRTVS71L$U)*RD@YJ2"5I(I4DQI22^I(/6D@C0ZY@539$SN0
M@2RWE?8\WR5;G'DVD1GXM:YE*"8EI)24D7)202I)%:DF-:26U)%ZTD`:'7)C
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M7AS[G9>Z#C\HNP@M=:-3,X`_=9_)MA=O/]NM5]5#LZWQ\Y(8ZZFA_'"1&;^I
MX?E,R51+GO_[\?V?'R]/3J++$^\Y%:GNR7RVE&DRG>>Z)]-YH6G7^?GE<GE^
MXH6YU#UM.W=WP."2\^R=VFW4;3IZ__OY>W8NYL6G'I+51.Z^N/`.7^NIEK,O
M[OJ2Y^WJOA+=_?%V+*/H?+&(_*Y2W979S3)-]LZ(W@NO]^-+>72=?T%?ZJX"
M>Z._[MME/LW>J(?SY?/$!=>#FLSFKTDQ*2&EI(R4DPI22:I(-:DAM:2.U),&
MTNB0N\>KY9A]_?3&[/3%;EDG%U;F`+%<>M-ZI6O)KC8?1OS/BTP=O9?'I(24
MDC)23BI():DBU:2&U)(Z4D\:2*-#;B#W6R!><(&HR9Y44RU#,6LEI)24D7)2
M02I)%:DF-:26U)%ZTD`:'7)CX2\0U:123X#8\ZFO%UPY3N0E6;SKN;6I9>;0
MKB\K[Y*P5DK*2#FI()6DBE23&E)+ZD@]:2"-#KEQ4XL\^V#XRHEI6A.:\^KJ
M`LO$-2DF):24E)%R4D$J216I)C6DEM21>M)`&AUR8['?8O*"BTE-YN"U)L6D
MA)22,E).*D@EJ2+5I(;4DCI23QI(HT-.+"[]Y>O+\V);W5T_:+)B08I)"2DE
M9:2<5)!*4D6J20VI)76DGC201H?<6(36R"IOO.>YY9*+9$WVU=ERZ2UMUZ;6
M?&XA):24E)%R4D$J216I)C6DEM21>M)`&AURX^8OS5^90[MULYVHO)S(GD.@
MF+424DK*2#FI()6DBE23&E)+ZD@]:2"-#KFQ4$O=GS_/7^Y6QDXL)K)C`8IU
M0U,K(:6DC)23"E))JD@UJ2&UI([4DP;2Z)`;"S])\,J\8#+@<B(SRFM23$I(
M*2DCY:2"5)(J4DUJ2"VI(_6D@30ZY,8BE`QXP\/R+^=D@#Y%K#3)))E7_DO_
M*P=K4TLWC$D)*25EI)Q4D$I21:I)#:DE=:2>-)!&A]RX[;?VO^3:7Y,]A[CV
M9ZV$E)(R4DXJ2"6I(M6DAM22.E)/&DBC0VXL_+7_*\<S+O$O)[)C`8I9*R&E
MI(R4DPI22:I(-:DAM:2.U),&TNB0&XO]UO.77,]KLF.!)7[,6@DI)66DG%20
M2E)%JDD-J25UI)XTD$:'W%CXZ_DWWGATR86^)OO<$IWX.3%3RYQ;IKY,=!/6
M2DD9*2<5I))4D6I20VI)':DG#:31(2=NT;&_^'_C)P2[CKS[,!>7WLVRJ[F:
M'4W_,P*KTAS,@"4!2P.6!2P/6!&P,F!5P.J`-0%K`]8%K`_8$+#1-2^VH63"
M&VZQC8Z93=#FI:K]SSFM:E8H=]W9R>I`/0DEZDDH81)*F(02)J&$22AA$DJ8
MA!(FH81)*&$22IB$$B:AM&T7RJ.GKYO-<WSS?//Q_?WF\<MFO?GV[>G@]N&/
M[W*A'<F'Q98?/&X^?SB\EEWB2O[8WC0RM]F5J?EWM=UG)!HLBU19L-WER95:
M601:79Y*R6FPY$Q*SH(EYU*R_5C?WX;+"RG9W@.`DDLIV7XV[I5<7YQ>70=+
MY`/)*_696F"K+V3;Y!.>4(ELFWR&$"J1;9.,=JA$MDWRJX&22QENR?:%2F2P
M)9\4*EE(R2)8LI22[>G,'X/SY=6U?`P<Z$U*U,W;H1*)J=Q*'"J1<9.D8ZA$
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MMB#8YGHI>WPPVBLI43\`%>CM1+9-?HXH5"(QE1^\"95(3.7G5T(E$E/Y,9!0
MB<14?IJ")==+.>[L,J?^'B\EZI=3V6:UE-Z";:Z7<B27'PT,M9']0'X&,E0B
M^T&PS?5"1E326X$V4J)^USQ0LI01#;:Y7LHQ1.Y)#;61L98?:0Z5R%@'VUPO
MY)W*[7:!-E(RRLUCH1)YI\$VUPO9$^6&NU`;V1,7P3UQ(7MBN$TD);N;_/R8
M1C)N47#<%C)N\DR+T!;(Z"R"H[.0T9&'5K'-]4+VJMWCC?PMD))Q=^\K2F2O
M"K>)Y'7D.3%\G54DO>UNP?-[BZ2W*+3'KR*)CUQ#AWJ3^$3!F$82!7DX2:"-
M-`FVD`;!^A*:8)PE,,&X1!*7*!B72.*R>VR1]][E#NDK=?\SMU;N![Y2M_RR
M1&Z.OE)W_K+D6J9->.SEY0/U5VJG"+DZG`3\^D3Z#S90QZQ`@Y7$+Q0^>6[3
M52)/+.);D*<P7:G'+K%$GJETI1ZBQ!)Y0M*5>B022U8R5*O@4*VE9!TLD7OB
MK]0=[^PMEI`DP39R._R5NLV;;>2N^"MUMS=+Y%%R,@:AL,A3X&0,0B7R`#<9
M@U")/'M-QB!4(H\PD]<)14T>2":O$RJ1QXO)ZX1*Y&%A\CK;DJ-Y7W[Z^/['
MS9=-<_/XY>[[T\&WS6=9+QUO;TY]O/NBDAR[_SQ/SVK[[>'Y^>%^^]BVKYN;
M3YM'54$^Z/C\\/"L_R,#=O37P^/OVS79Q_\7````__\#`%!+`P04``8`"```
M`"$`YQRYSPT#``"R"@``&0```'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6R4
MEEUOVC`4AN\G[3]$OF\^"5\B5"U5MTF;-$W[N#:)0ZPF<62;TO[['<=`8\.<
M[@9(>?WRG/.ZQU[=OC2U]TRXH*S-4.2'R"-MS@K:[C+TZ^?CS1QY0N*VP#5K
M289>B4"WZX\?5@?&GT1%B/3`H149JJ3LED$@\HHT6/BL(RU\4S+>8`F/?!>(
MCA-<](N:.HC#<!HTF+9(.RSY>SQ86=*</+!\WY!6:A-.:BR!7U2T$R>W)G^/
M78/YT[Z[R5G3@<66UE2^]J;(:_+EEUW+.-[64/=+-,'YR;M_N+!O:,Z98*7T
MP2[0H)<U+X)%`$[K54&A`M5VCY,R0W?1<A/%*%BO^@;]IN0@!I\]4;'#)TZ+
MK[0ET&W(226P9>Q)2;\4ZD^P.+A8_=@G\)U[!2GQOI8_V.$SH;M*0MPI5*0*
M6Q:O#T3DT%&P\>-4.>6L!@!X]1JJM@9T!+_T[P=:R"I#R=1/9V$2@=S;$B$?
MJ;)$7KX7DC5_M"@Z6FF3^&B2`/WQ^]B/YVF43L==`DW4%_B`)5ZO.#MXL&O@
M-T6'U1Z,EN"L*IO\LS(H2:VY4XOZI:`6$,?S.DDGJ^`96I@?-?>7FMA4;*XH
MTK,D`+XS))1N0R80XO7VGR#5(F@T\@:0;_Y](?=:,QEH+,7&I3`8X8>&C&XV
M)<X0>`_8IN?:-9O6S/OVSN-HNDALMJ%B.@MG<?JF,-B@P/>S*;'--K/8M,;5
M-Y?"8(/--F13&W`\6[5H+%NM<3&Z%`;CU&1T9ZO$=O_L;+5FR);8_QU.B4$W
M^Q\Z);;IYE:Z6C.D>]M7_=[<N!0&FSH!K?$RGJY:-):NUK@870J#<6$RNM-5
M8KM_=KI:,V2[2-<I,>@B&'3#%KKQ>K7-M[#R/8J&@';`3HG)=^4$&8\XTL,?
M)MA@`EH0]T>1DU/[7)>8G&J2#[;B2!_UW'=/:+ARJ,W@&M&&Y/J,UK<.?2AW
M>$>^8;ZCK?!J4D)O0G\&8XKK.X=^D*SK#]\MDW!7Z#]6<#<D<#*'/HA+QN3I
M0=UJSK?-]5\```#__P,`4$L#!!0`!@`(````(0!`!<-,,`T```Q!```9````
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M>?#Y97_8?'JBZ_[3&F[N6+OZ`^2?=W>'_7'_<.J3W'5]HGC-L^O9-2G=?KC?
MT16H;K\Z;!]N>A^M>>G8O>O;#U4'_7>W_7[L_'YU?-Q_]PZ[^WCWLJ7>ICBI
M"'S:[[\HT^!>(7*^!F^WBD!^N+K?/FR^/IW*_7=_N_O\>*)PC^B*U(7-[_]:
M;8]WU*,DT[='2NEN_T0G0/]>/>_4T*`>V?Q9?7[?W9\>;WK.N#^:#!R+S*\^
M;8\G=Z<D>U=W7X^G_?/_:B.KD:I%[$:$/AL1>_)N$6JN.A/Z;$1F_:$]FDS?
M<R;C1H0^&Q'KW2="J5&="'TV&IV+N=`+L\://KEM^O6"@\7]IGYI7)Q!WQH.
MQJKS+WDZ35L6_<*-C3O==<F7^\B23G+>Z#KA9ND7;G9RX82OZ]%6#=[5YK2Y
M_7#8?[^B&8'&T_%UH^87:VY11_.PK<^['<C_-(YI`"N5CTKFID<G0T/T2,GW
M[=89SCY<?Z.$N6ML%FACZ19+ME#9H617)EB;P#6!9P+?!($)0A-$)HA-D)@@
M-4%F@MP$A0G*#KBF\+0QHD'Y*V*D9%2,N'<7#"1HMA$0MF"7E0G6)G!-X)G`
M-T%@@M`$D0EB$R0F2$V0F2`W06&"L@.T@%"N_XJ`*)F;'C4B23,:Z!%8U#8.
M?;1&(]UDV9JT40*R!N("\8#X0`(@(9`(2`PD`9("R8#D0`H@99=H01N>"=J0
M9O?S-VB>V)07W8H[W>^,C&EKT=ATC<P8M29MC("L@;A`/"`^D`!(""0"$@-)
M@*1`,B`YD`)(V25:C"@<OR*QE`P%C9IID\89&7/;HC&Z%+76I(T:D#40%X@'
MQ`<2``F!1$!B(`F0%$@&)`=2`"F[1(L:+5^TJ%W.*&5=!8<[==$0I[TS+8&L
M@*R!N$`\(#Z0`$@()`(2`TF`I$`R(#F0`DC9)5K'TWI+Z_AZ\=:?4*1.C[N[
M+XL]C7]:59P)B$.+M'KIID3T>-3$JA\MU#IL"615$[M[\[(G$_W.M&Z-.-0N
M"'E`_-9+LM>>3'7IH#5BZ1"$(B!QZ]65-M:I26O$TBD(94#RUJLC/37NYD5K
MQ-)E5TB+K:H+X,)<8OO'_O6?8DO/+!Q<I:('MR;=X`)9U<0>M@FY!N*"EP?$
M!Z\`2`A>$9`8O!(@*7AE0'+P*H"472\M(/0(J07D3%)U.EY9ZQU?$_6<V-Z4
M[*FQE%BV1CQ`5@WIQ*(AX^HQ:S:>./;,&&<N.'D@[+<V<CZ68P@%C9$:4-]N
MJ7HUUM,P;$7X?"-H*`:;1%,=]J?36??'F$52\,^@C;RUN7`Q16-4=]QPXLS&
MSL!HK&R%Z(*T\%M4$7I'_"MS?0`TR**4EQ$P,T<`6TW;Y%LQFK5HW2#;J@)#
M=8J9;<R0+GIYC$3;9R3:`6L/*NUIWQRD(?I$C$0Y9B3*B:X\Z0^-X92B3\9(
ME'-&HER(LO2M91LS>ZDYZM%5S][=Z?9R=M/T::9W@U0%2:([=?1\6;*5K'56
MC#H9SDC=Q[F>8L^,!:S+5MUEKC4QKMEC*VG19R0M!HSJ1!_T9T9D0C80GXB1
M*,>,Q"IAU+T6B$S*5N*8,1+YG)%8%8PNRI=L53GJ@5?/^-W`_]0:2D7=F.X;
M9&0[C(?:D2IO/(&N&D=;"C7K!HVTL34;ZF/+Y19I"FM'S9GQ`"WZXL@G$?!)
MU'/`N&],DR&Z1(SD4F)&DJB)"'=.TDS4%!TS1B*?,Q+YXDWRI>:H#P>Z/>-P
MH$(\]:E:4?.JZ^W+:W7#-X=&C8RE@%DR:!SI@Z.R:I`M%[QND%,':C)SG,G0
M");+2I(V'B,1]QF)5<"(;_^F<L@&XA,Q$N68D5@EC&KE8=\:#;H_QM!.V5P4
M,D;23LY(K`I&S3W?'@^MR<282$LVJOSTX:`J%9=F!QX//[A=-`4/.;&%5:-.
MXB\1K1AU`UX[VM5N5/4$YZ*5QTBRQ6<D6D&#.EHA6D6,1"MF)%H):J5HE3$2
MK9R1:!6H56I6>HPH-R_&Z$U/P6JKSDS3&JG1T<ZG]M2X,2X;1[*2-*T=M31M
MY)LTG9Q-TZ8]&24>BON,:!BT9X7K=K;BS#57AR$;2&,1([F2F)%8)8PX<P?&
M`C9E`_')&(ERSNCB911L=3E]N_VF#PU5.?D%Z=L48.2*%FK+3@T7N:(EHA6B
M-2(7D8?(1Q0@"A%%B&)$":(4488H1U0@*C6DQTA50+HQ^L%46A=,J+;+Z;90
M2RR*Q4CFE"6B%:(U(A>1A\A'%"`*$46(8D0)HA11ABA'5"`J-:3'0A4_WA&+
MNE:BQ:)!W;P`M%(;S7KVK!&YB#Q$/J(`48@H0A0C2A"EB#)$.:("4:DA/1:J
M$O&.6-2%"RT6#>K&`M#*`K1&Y"+R$/F(`D0AH@A1C"A!E"+*$.6("D2EAK18
MT`))C\5/?DNBTC%W?(U'PD5C=''+5VQX%EPA6B-R$7F(?$0!HA!1A"A&E"!*
M$66(<D0%HE)#>AS-*H^*XX_W@*G*5DU7G147;@*S47>U:#[2B8V$K=&6)%VC
ME8O(0^0C"A"%B")$,:($48HH0Y0C*A"5&M+#IDH6W:GP9].O+GW\8%]8[6G5
M-R=98$,@6QL))*"U*+&5B\A#Y",*$(6((D0QH@11BBA#E",J$)4:T@.I"A_=
M0%Y>Z]EUG:1[3V,DZ;)$M$*T1N0B\A#YB`)$(:((48PH090BRA#EB`I$I8;T
M6*@Z0C<6/U7XI#W"*EDZR_$&4<F51_T2T:I!:JRTC[&X@2Q6K.6BEH?(%\>N
MO+%%$H@5RX>H%2&*Q;$K;Y3>$[%B^12U,D2Y.';D83-9K%B^U+3T<*N'Y$OA
M?ELEBW8X(=[-XW?WQH<;FXUCMTS"2,;.FE']O&_-IB-G:M0"7;81-X^1S`H^
MHXOUA8"MZF*&T[>-Q5C(!M)8Q$@:BQF)5<*H5I[V'>,R4C80GXR1*.>,+EY&
MP59UMXUF@^G8W,`IV:9J3Q\:9I7D![,R5D/L&JD'2TGFJ5%F7;*5/*>O&$GM
M;]T@6@U46\Z.[5@#8U?:13>/D8C[C$0\8/%V:]-(V1!](D:B'#,2Y417MHPS
M3M$C8R2Z.2/1+417NA:VSTK-40^N65[YN6D>JRZT/Z5F`K65THFYD3]+MI(A
MO6K02`;^FA'-)!TM(V-<UM)R`?8[V4I:]!E)BP&C.CW/['>R@?A$C$0Y9B16
M":/NM4#`4K82QXR1R.>,Q*I@=%&^9*O*41\/JO0"]X'_9X/+;HHY<I*+!JGB
M1B>>L(BN'<F*[U^KQG$D";!NT+A.67LVFP[PEM`HB9LGI\#B/B.Q"AI$3XQJ
MLAGU9\8*(42?B)&<=LQ(E!-=>=HWM@U2=,D8B7#.2(0+%J[GQ]&$W@_"N;[;
M'WKX5;4'PC]Z[]?*:&L#E@$UZMS@EXU5!ZT8R6!9,ZI?BE)?-W09B97'2++#
M9R16`2/1"AF)5<1(M&)&8I4P$JV4D5AEC$0K9R16!2/1*AE55EJ,:"_W<HS>
MM*%5J>A?0&J0D9;&R%R*%6?.JD'=M&Q0DY;CH6.;WPUS64@&K\=(AKC/B(9/
M.U?@?E9CU20J?1'-N#F$(L-G'3&2QF)&<DJ)KCSNV\;N>8H^&2-1SAE=O(R"
M&ZN3UYDXP[&Y5"A%B:Y$'QCGRE?6NY/7:4I.,CX7C&04+Q&M$*T1N8@\1#ZB
M`%&(*$(4(TH0I8@R1#FB`E&I(3U&J@S4G6`O+Z;IC51S(F74C45C)6B%5FM$
M+B(/D8\H0!0BBA#%B!)$*:(,48ZH0*1>ZJVZL.J<.A;U2[KU>X[/V\/G[7+[
M]'2\NMM_52_@4O!N/[2X?CN8JNYS53BFE(,C].(P/8W@D8^V/?](K>.1!1U1
M9;!S1QPZ4IVJV8ZC7E`^U\["(;7S[8SF975+,;7&\W)\KG6+#M!6[)GSLB9T
MI/K*F:EE3>E(-=/!D1D=J:92XPA5=^9KJD5@.U28F:NR"QZAFLI<54SP")5#
MYL79(_1.]\>SO4Q=>;8G55C.M+"@H)R-R7!>GCNCCZ/YQ_,7/IG32P]X"?YD
M3F\L((\G<WK=`'D^F1?G^&HZIZ_BH[T_G=-7ZY''TSE]51YY/IT7%;]N(T?O
MHK]N/F^3S>'S[N5X];1]H%095`O#0_TV>_W'J7GOX-/^1&^A5Z\@/-+_.K"E
M==M`?4WN8;\_\1_4\'7[_QC<_@T``/__`P!02P,$%``&``@````A`!Y(._!X
M`@``,08``!D```!X;"]W;W)K<VAE971S+W-H965T,3,N>&ULE%1=;YLP%'V?
MM/]@^;T82),L**1*5G6KM$K3M(]GQUS`"L;(=IKVW^\:)X@V[92]`#;'Y]QS
M/[R\>5(->01CI6YSFD0Q)=`*7<BVRNFOGW=7GRBQCK<%;W0+.7T&2V]6'S\L
M#]KL;`W@"#*T-J>U<UW&F!4U*&XCW4&+?TIM%'>X-!6SG0%>](=4P](XGC'%
M94L#0V8NX=!E*07<:K%7T+I`8J#A#N.WM>SLB4V)2^@4-[M]=R6TZI!B*QOI
MGGM22I3([JM6&[YMT/=3<LW%B;M?G-$K*8RVNG01TK$0Z+GG!5LP9%HM"XD.
M?-J)@3*GZR3;S"A;+?O\_)9PL*-O8FM]^&)D\4VV@,G&,OD";+7>>>A]X;?P
M,#L[?=<7X+LA!91\W[@?^O`59%4[K/84#7E?6?%\"U9@0I$F2J>>2>@&`\`G
M4=)W!B:$/_7O@RQ<G=-T'DWG\21!.-F"=7?24U(B]M9I]2>`DB-5($F/)/@^
MDDQFEY*P$%#O[Y8[OEH:?2#8,RAI.^X[,,F0^&U#Z,1CUQZ<TSDE&*O%(CRN
MTL5BR1XQ<^*(V00,/@=,,B`8B@[*J':YL@=[99]:'\HF;(QETK=E)O\CX\$Y
MQ><0_"2.!]Z@'##7(\QT0+PPB)#+#7HP*H]ISW,;0&/,.]+85)=+>W`O/23W
MN#,;>9S$[Y0106,I/QG3))HCQ;][R9][J7K<P2MSE/W750TC&EI8@:G@,S2-
M)4+O_?BEV)3#[G`SK%/?-Z_WK[-U?V.PX0=.;,<K>."FDJTE#91(&?=>3)CY
ML'"ZZP=GJQW.:O]9X]4,V)=QA,9+K=UI@<)LN.Q7?P$``/__`P!02P,$%``&
M``@````A`,6E]>&5!```0Q```!D```!X;"]W;W)K<VAE971S+W-H965T,3DN
M>&ULK%==KZ)($'W?9/\#X7W$!E$O42<BL#O);++9S.X^([9*+M`&\'KOO]]J
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MG0,^YM>J_XO<?L?EZ=Q#N4-01(5%AX\$=P5D%-Q,_"&,@E00`/QWZI*V!F0D
M?U^[/BQ<'OKSV@WFDW`Q#1#0G3WN^JRD+EVGN'8]J?]E)$2#DDYFW`E\<B?@
M[DE;6&4(`#ZY[7*R#,/9?+GX;@`>$S/D)LG[?+-JR<V!AH-PNTM.VQ=%<]<1
M26$29)K^+TN@C#K94B]K=^$ZD(`.2ONV"6:+E?<&Y2@X)[8Y2&?L!(,FC+I-
M3"`U@4P!/%`D94%6?X(LZH7*$@'%`AAU^H8&P1`FB0FD)I`I@*8AL#4$T/7W
M^U54@AI!9RJ5\/U`CS'F')44ZI2=I$@=%I):2*8BFA1H]Y]0#NH%M,&'TF9+
M/?*8DR`423+%28H49R&IA60JHHF#S:>*>UP?2AXTB+5CC@2RRW86DEA(:B&9
MBFCQP;9^/CY*UN-CB*\FU$=F2B5)R$HL)+603$6TD.$D>3YD2M9#YHB24@M)
M+"2UD$Q%M/CH.X%U:D[H,=R?R^(U)FP0W&F%`$Y'=F92'WK8#`EA5=FZ*#0/
M&$9";*P,IR1#?#A&%#-CSZ>2)`J4J8XT<2^/Q7TCEV%LW!$'@U"HHTYT=0Q!
MR['/+23AR(ODI`SQA]$^Y"U3.5K<"`Y'LRK^G`[S[YR9@Z$>+(<0;'J95#^8
MZF?-3K#&1DL$I!HBTS`5K/DP*Q?A%/YTWYF@S&@N=)UTZ!G=]YQ.-BWA`!5-
M$$,?T3HA2*JBTQK,G#76+AD-A:^40SYZ($HN9XFB4_"'1+'QJ8EBD%$\<R,A
MSE*+)PU'41QBE4)#I:Q2J69ZJ>A$_"%5?)2JI6*042ICG^\09ZFEDH:C*@;Q
M4J'[#:B:Z:KH*%14/3X):!F,HX!#1H%F^@[8"99:(.8+?AFE<.AA@50S70J=
MFL]+X3-V7#ZF-PA[`YGC4;#4JDC#40J#1%7N]YIJQJ2P&P][JZ]Q>\([7%6=
M4Y`KO<W`.;)929A=M9)E!`,!UC5PN()M_3MX3*]F]W`_@K=7VT\<1/`N:./;
M6;1E5SQCX7@6P?N5;1"'$;S7W,'G$;P\W,$7$0QMP#VY`%SA+OD)_Y&WI[+I
MG`H?(2G385:W[!+('GH^UO:DA\O;,.'.<%G'<`^93B#I1T)Z\4`7D-?_S7\`
M``#__P,`4$L#!!0`!@`(````(0!@^TZ^'@8``)\8```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$W+GAM;*R976^C.!2&[U?:_X"XGQ`@GZCIJ`F?`:+5:G;W
MFA*2H(80`6UG_OT>@VVP3S9J5[V9-$^.7YO7Q^;8\_#]9W%6WK*JSLO+2M5'
M8U7)+FFYSR_'E?K7#_?;0E7J)KGLDW-YR5;JKZQ6OS_^_MO#>UF]U*<L:Q10
MN-0K]=0T5TO3ZO24%4D]*J_9!7XYE%61-/"U.FKUM<J2?=NH.&O&>#S3BB2_
MJ)V"57U$HSP<\C2SR_2UR"Y-)U)EYZ2!\=>G_%HSM2+]B%R15"^OUV]I65Q!
MXCD_Y\VO5E15BM0*CI>R2I[/\-P_]4F2,NWV"Y(O\K0JZ_+0C$!.ZP:*GWFI
M+350>GS8Y_`$Q':ER@XK]4FW=KJI:H\/K4%_Y]E[/?A;J4_ENU?E^RB_9.`V
MS!.9@>>R?"&AP9X@:*RAUFX[`W]4RCX[)*_GYL_RW<_RXZF!Z9["$Y$'L_:_
M[*Q.P5&0&1E3HI269Q@`_*L4.4D-<"3YV7Z^Y_OFM%+-R6@Z'YLZA"O/6=VX
M.9%4E?2U;LKBGRY(IU*=B$%%X).*&+.1L9CJT]DG5"`EVZ'`)U,938SI?-$.
MY4[W2]H0/FG#Y:#W.PUUL+M[>N([?;)//[W.'I_\P4?./;S7O\GZAS]HR\5H
MKH^7YAS<O]=RPEK"'Y\=N=;E0)M2=M(DCP]5^:[`.H59KJ\)6?6ZI8,P2Z9N
M(#R]_BN[(*V(RA.16:ES58'$J6%)O#V:$^-!>X,T3FG,&L?H8L2&19"<);*V
M#!P9N#+P9.#+()#!5@:A#"(9Q#+8#8`&UG)_(3^^PE\B0_QESJP9Z`V7[-ZP
M"-;$EH$C`U<&G@Q\&00RV,H@E$$D@U@&NP$0S(0E\Q5F$AG8]`;)JL_'8BJN
M:<PP:"J&;'@(=Q@1!Q$7$0\1'Y$`D2TB(2(1(C$BNR$1S(;-X"O,)C+D#3-P
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M&%!>\->,/I^(+CD\B#V*BX0\1'S>BM2^QEB75`/^.U/=(HT0D8BWHJJR[?QW
MIKH;:@BVDX//7=]_E-?V.'##=SC1,>-;&=%YBO0%3^(-1C9#2Q[E4&2TQ]UV
M7ET<Y3'4R_L,]5H!UMKBJ)"A7BMBJ->*L=9.B!)])97_Q[<)2%`Y<RDBIZ]!
M6LKU#XOJ]U^;HNFP;-+GTJIW^BB6)"[3FO"Y\!CJY7V&A'&94J$<L*A9>^K3
M9S-S*N7^EH7TW84,]=U%#-WM+F91M+OI9"$-:,<BVM[$J2+GBN%4_:^MAQSY
MI;V'(AT6WV`&Y^+&LF%1??+9#/7)YU`D+(JN1Y!G,^BQAKV6SQKVA\2`HJFX
MX2W$<6V9ECCZI1@5LJB^QPCW&-_L$4\1?Z"A7WV/XJR1$PJ:M=F(O2_8OO7Q
MEP=<SJ$9[)"X!A?H?H)&]5EK4RUHR.;&8:B[>R,O?I>A/LICJ-?R*3*$B<`+
MCHY^W"VXB3[6I7%NF7;?7<A0WUWTH>YB&F72[LRE@18<]PXLZ*:NN[OL+IJ*
MK#IFF^Q\KI6T?"7WDCI9O!QWEZ:PF5EDJP()Z1>X3GUJZR.)K\DUZXWXM6'!
M!0+669L6''8Q?YI83_"0^(?UQ(+SV@T^M>!8<H//+*B^;_"Y!44FYO;"@FH/
M<W]A0:F&>;2PH,["W%Y:4+1@[B\M*#LPCY96W'*-.PK7P]?DF,5)=<POM7+.
M#C!-X[8FJ[H+YNY+0VN$Y[*!B^&V7#C!?P1DD.-CLB`/9=FP+]"QQO]KX?%?
M````__\#`%!+`P04``8`"````"$`!&"JZCL)```O+```&0```'AL+W=O<FMS
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M<;\[9WGV4MR0W*!J*#[S?#`?D-+#W?.>GH"%O7=.7^[[CYJ1Z*/^X.&N#-!_
M]^EGWOJ[E[]EG\YY_QSL3RE%F_+$,O"49=^8J??,$#D/P-LN,Q"=>\_IR_;C
M4"39IYON7]\*2O<M/1%[,./YIYGF.XHHR=SHMTQIEQVH`?1O[[AG78,BLOU1
M_G[NGXNW^_YH<G,['8XT,N\]I7EA[YEDO[?[R(OL^'=EI-52E8A>B]!O+:+3
M@USH3+<I6T"_M?/\9G9[.Y[,II>W8%Z+T.^OBVC\.=@?_$$N?@YMQ$-)?]3>
ML^N?1)MP&?KC^D9,N3?]<74C!E7G*/N:N2VV#W?G[+-'`YC2G[]OV72@&1I-
M';R757VBZ7?_K]M1?V,JCTSFOD\MHQZ5TUCY_C`:3>\&WZE_[VJ;!=IHLL62
M6[#.S&1-%5@JL%7@J,!5@:<"7P4K%00J"%6P5L%&!9$*8A4D+3"@]#0YHC[[
M;^2(R;`<\>@N.!!)TY6$<`ON8JK`4H&M`D<%K@H\%?@J6*D@4$&H@K4*-BJ(
M5!"K(&D!*2$T#4!"QC2E=4_-?(PP+YJ$6V-$&X[D@"]JF[;1K6RR;$R:I`"Q
M@-A`'"`N$`^(#V0%)``2`ED#V0")@,1`DC:1<C3NR!%[?5XYL3$92AK]M&:V
MF9R216U$;6F,U*PU)DW6@%A`;"`.$!>(!\0'L@(2``F!K(%L@$1`8B!)FTA9
MHP1)(^OK$<6LR^3PH"XJ4BW+RE?($H@)Q`)B`W&`N$`\(#Z0%9``2`AD#60#
M)`(2`TG:1`H\+4FDP%?K@!NV4"O>]KMOBZQ:*W8D9$3O^VH5P$3D?%1$JQ:5
M[)6^!&)61*?)MAD]FJY,C%9CQ%-M@Y`#Q&V\VM)C>?1ZC1&7]D%H!21HO-K2
MRJ@/&R,NO0:A#9"H\6I+3^16QXT1ET[:0E)N:5GV96[_RM[+A6!';JE4X,EE
M*G)R*]).+A"S(OJX67580&SP<H"XX.4!\<%K!20`KQ#(&KPV0"+PBH$D;2\I
M(:Q$;R^ZOPX\LY8#7Q$*?+N#*,OM96/$.XA9D=;D:`&QP<L!XH*7!\0'KQ60
M`+Q"(&OPV@")P"L&DK2]I%Q077E%+IBUG(N*L+JR-7LI"X1E;53N%E2534U:
MXZ(F;,+E-92FS^51;X.;`](NV'B72/O@M@+IH+%IM7$TE-L8UD:3L@R<Z=ID
M/E+FQ76CP_OF!NX5-39?W"O^YWLEC0[=2\J\1CL95Z2^-)=S7R.-!KK(V0BJ
M6G8?FF!GS1QH<L=Y@ZP:L>T5H07Y1T>'(R'O<B3DO8OD?71<<23D`XZ$?,CE
MM3+ID^EPJM^J24>W#4="/.)(B,<7B">2FYQF5E9?/MNR6549XAR)X;M$9"*R
M$-F('$0N(@^1CVB%*$`4(EHCVB"*$,6($@G)N6`5]16YJ`IPJK[X/+%@$RVE
MI_426R(R$5F(;$0.(A>1A\A'M$(4(`H1K1%M$$6(8D2)A.1<L-+YBES4E78[
M%^WBNZJVV%8I&SUBJ)B(+$0V(@>1B\A#Y"-:(0H0A8C6B#:((D0QHD1"<BY8
M0=S.Q:]NP]:%-?TT+Y'12%E$++2F_!96RF2]%#9\Z)F(+$0V(@>1B\A#Y"-:
M(0H0A8C6B#:((D0QHD1"<B)9@=U.Y-=+>[8AI;YL*B1-<(#,VK%E92&R$3F(
M7$0>(A_1"E&`*$2T1K1!%"&*$242DG/!"N(K<E'5S]++ID:M[0MVB"._?\P:
MC:028*34ZY:PX@/*1BT'D2L<Q6C55'E/6'%Y7]*2(\,JTW9D?FFWARU[U<Y;
MHW;`*M3JJ6;M2#L^[*!('VKJ9H\PX`]C<R1>+`XBEZ-&6=WK$09<V>>H5);#
MQ(K&K\)TV<8).U93XU07J#2PFWE:4P_,EK4CO39X8TV.Q%O8XJBJMW1]-M1F
MRF/;W$:X.1P)<9<C8>5Q5(O/Y[.A*NYSF])-#B"KO;X*X$6[BEI5P4D#LT(Z
M#<96_-2JNW:D]HGXU8[B%,RJK?19V1OGX[$V'ROG8#97$D6)PY$0=[F2$/<X
MJL2G<SH5'2L;-3Y7*L6E^+%B$.-'I_CTV&Q3EO>_RW=H2T6YB*T1^RA`Q%)7
MIJ]E;=7NB]Q1!,7B\L,REIHVU75-E;*YE.AF#D>MSHCJGJ(^G(^TF5IM^UP*
M>Z.N%H+JK,?#^?4[NY110EC7C*+Y2VXED(G(0F0C<A"YB#Q$/J(5H@!1B&B-
M:(,H0A0C2B0D]_CK"D1V:*!,K36B]TVK.ZM+X*6P:J8&1!8B&Y&#R$7D(?(1
MK1`%B$)$:T0;1!&B&%$B(3D]K+QK3^C_,%3J:E",]`7+"\N8&!=+1"8B"Y&-
MR$'D(O(0^8A6B`)$(:(UH@VB"%&,B'UA)N)5Y:+Z8JSZBN>8GE_397HXY+U=
M]L&^!AM-:>YM</6IVD*C;]5H5X;Z.ES1Z8K>>65$5\HT*3Z/VMAXI'9UJ8W)
MI\RVXK/0;NE*^9F:>D5GW]%UMDVGME%?[+B/3FWK;`&ME@VV%D8?6AO2E?+5
MK+2`%LH&6P6B#WWB]]AY?Q;.#OL%:W`7I^9VQ>N1`MD9X@7%L3.,%,6N()HS
M@\YR\`'<F4%G,\B#F4%G+<BCF1%W\06%:-$9HB5=679>H;K(8%4/WH4*`+K2
M%7`JB0RVU$<?JHP,MN+'*R;=INLN+O6$+AY,##J719UH8L1=W*3&=MW7I?[4
MQ8.I06>*'?I3(R[YH.E_]+GF^_8U#;?GU_TI[QW2%QK`P_+0_5Q]\%G]IZ@/
M:)^R@C[4+,]JW^C#W)3.TX=L,?B2907_#]UXT'SJ^_`_````__\#`%!+`P04
M``8`"````"$`[UHU_KX#``"4"P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6RL5EN/FS@4?J^T_P'YO2'<<D%)JA!@MU(K5:ON[C,!)U@#&-G.9.;?
M]QB#:R#=SL/,PS!\<\[G\YT;WGUZJ2OK&3-.:+-'SF*)+-SDM"#-=8_^^9Y^
MW""+BZPILHHV>(]>,4>?#G]\V-TI>^(EQL("AH;O42E$&]HVSTM<9WQ!6]S`
M?RZ4U9F`5W:U><MP5G1.=66[R^7*KC/2(,40LK=PT,N%Y#BF^:W&C5`D#%>9
M@/AY25H^L-7Y6^CJC#W=VH\YK5N@.).*B->.%%EU'GZ^-I1EYPITOSA^E@_<
MW<N,OB8YHYQ>Q`+H;!7H7//6WMK`=-@5!!3(M%L,7_;HZ(3I%MF'79>??PF^
M<^-OBY?T_B<CQ1?28$@VE$D6X$SIDS3]7$@(G.V9=]H5X!NS"GS);I7XF][_
MPN1:"JAV`(*DKK!XC3'/(:%`LW`#R933"@*`WU9-9&=`0K*7/7+A8%*(<H^\
MU2)8+ST'S*TSYB(EDA)9^8T+6O^GC)R>2I'X/0D\>Q*@>Z,OG-(%`,_>=[/8
M!(&_VJQ_&X"MQ'2YB3.1'7:,WBWH-PB7MYGL7B=<(6M(BI*@T_2K+$%Z),E1
MLNS1&EF0``Z5?3YX_G)G/T,Y\MXFFMLX8XO38"%S+VGC*9!,@=0`;%"D94%6
MWT&69)&RAH"B`?BITYUH&"P&EW@*)%,@-8"1!N]=-$@6:%6C-(Z_&@<=]3:F
M43`V.6D3+6R&)#,D-9&1-NC_=ZB/9`%M\##Z;M)546\$H6BCJ3AMHL7-D&2&
MI"8R$@?3:(I[O&"&T9'&G8;A[$@AKJ?;[C1#XAF2S)#41$;QP9R;\:F97\@E
M(DJ2/T54K;$'<7LPVVKB)<<X;(4$YA)P@NEX*"-'+<5NQA7BPA#H\CB!-^Z^
M1!L-24I-HI$X./__Q'VG;;?T'HB#-3ZHDR1C=0HQ`C_-D%@AKJ\+E\R0U/0:
MQ2UO&9-%[&U_MW>ETSA.A3C0FT8Z_7$Z3[W1SPZ+'[EYDPV>]$:K;L&O@R7\
MC(E330-U&JD#)5-U[DI^9W_Q^1T*(?W&`A7BP,,0.!WHWFBC*Q%KMZ&#$H6X
M3J?&>2C'=%)RU.U"?4%KS*[XA*N*6SF]R9O#%K@TJBXU\2J$[H5#I_@ZA.Z8
MXW`).KH/\`@N1]W43'@B-X0/R)PG\D+8OG/\Z(?'[I(UY?%#6&AS^R@(89$`
M;FL'N!2UV15_S=B5--RJ\`6D+[O]P=2U2KV(?M3.5,!UJ)NZ$FZ_&+[LRP54
M_D*I&%[D`?H^??@!``#__P,`4$L#!!0`!@`(````(0!0G=@JU`P``#)````9
M````>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;*R;VV[C.!*&[Q?8=S!\/[8E
MGXTD@UC4$;O`8C&[>^UVG,3HV`YL=_?,VV]19(DL_DIL-_IF//E8++)*1?*7
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MYK2FC)*;7CS6GM:'-YH`_;>SV^K2H(RL_KSOQC3P]NG\>M\=3GKCZ6`8D7GG
MR^9TSK;:9;>S_G8Z'W;_,T:1=66<#*T3^K5.XIM]C*P/^OWYB="4ZVCHUSJ9
M]6;C\6@RFUX?S<0ZH=\FFG@VCL:3&U)"ZZN>"?VRDZO3.;=]Z=?VG?=&\7@Z
MN^6:1%1*]0ST__`4>M?&T3=E4E>=6IU7#W?'PX\.+64JA-/[2F\,T4)[YGHS
MU=%4X$<%2)6GO3QJ-_?=:;=#M76B5?/]83@:W?6_4Z6OK<T2;2)ID;"%+FOM
M5H4@#4$6@CP$10C*$%0>Z%-:FMS0&OH5N=%N=&XXJB4#EZPX2`1;<!<5@C0$
M60CR$!0A*$-0>4`D@O:!7Y$([8;V(Z](HME,1KZT-K[16)HDC4F3'2`ID`Q(
M#J0`4@*I?"*21!O=KTB2=D-)HA]O*04I6%HCFDMC%)@DC4F3)2`ID`Q(#J0`
M4@*I?"*R1-NVR%+[N<;;BK:ND\%!+"T9-JLI`:*`I$`R(#F0`D@)I/*)")1.
MFQL"U=8R4$-B+U`@"D@*)`.2`RF`E$`JGXA`:=._(5!M+0.UQ`L4B`*2`LF`
MY$`*("60RB<B4"VQ\:CL:25R?MVNORX/1EBUE/20CD1S4&HG,GY#(J/`]*F7
M`%&&Q+0_-^L]F@>'1MH8\6+)P%$.I&AZ^:Z'<LLM&R-V7?F.1)9(Y'R:I3\.
M[[7J:,D2R3%.D_8BTV1(-',+'XBR9-[8I(;$M>:N+T`&-CGX*<"F!#^5;R,2
MH%64R,#GD=;F,E2+(G][C^:!G$J<%5\4Q6CD$L!H4HNR:#Z93>+@ZF9LX[KE
MC-RJ+!C1UNZ*<#@(*H6MS'B3Z6`:CX.CJ6*;>CR9.RW%_#5V(7=&N=%AR2E8
MTCK2E>/7"2+%R*L4B_Q20:N<D2O#@I'S5:*O2EC)F+7J\F/6$CR>Z-N[#^[Z
M>)%$1J^)\`V*Q$6:!Q<@L1VIP#AOBI%+9<I([V^LZJF`Y`7/V$J,.)U+JYRM
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MJ@22,6OQZ,?\LT_=C`BE9+A:'8Z"$WI)NTB]"_GK+*C5Q-FX5=9T8Y2B588H
M1U0@*A%5`HF$T:XG$_9YD=3F4E,S\HH$D4*4(LH0Y8@*1"6B2B`9\VU:.$8M
M;)&W"A)$"E&**$.4(RH0E8@J@63,H1:^<)U1`.M[9'WD^M<9D$*K%%&&*$=4
M("H150+)F+7:\S>#"S$;<>AO@'2!=<QTB\$K-4&D+!I2-MQQ.PPVB]19L:\,
M?>6("M?1<Q]*KM)9L?M*^)*9^24Z-D8=:Y%(F+'RD+)6=.7TOV?$@RBX`T^=
M`0>3H><<4>$Z6L^!,BV=`7NNA!N9)BWP_`(*!=IU:D+?;P9BU2(ZR'@:"2+%
MR)-C%M'FQATSM,H9.?<%(^>K1%^5L)*YT+HLS,55-].Q572>F+)(WR8T*R8>
M!(_=$K9R.XYBY'>,0@V9LI5^ZO7]8=(+[G,S;G<SRAFYL0I&GXY5LI49:]R;
M!3*[8@,4JW$H5B_L3RA*:P_U,QD_CT'-)\Z*:T8Q(B727("6/)H1J=CJU=0;
M!3>DF7/#GG-&?ND9-UJ$?#Q8:3M^.%C%GO%&*KY-Z=;F@8@QLC8HR&!;2FQ'
MNJ_B<!4C5THI(U,1]$8)E%_K8(%PS-F-&ZQ@Y`8K&?%@<3!8Q09^%<<#-YA<
MY%J9^HO\0D5:(>OFL]1W=_K$]*]U/`C.PH2M7)$H1FY_2BW20JZIFQBSV8S(
M%R5G7\Y]P<BY+]O=!R5>B8XB672+>DNR:G-9=18%51=L(`E;N4)0C%SB4T:F
M$*9!Z6;<_%$9U'>T.5NYH0I&;JB2D1TJV&XJ;OYH*)G$V[3X$+6X1;+BHN#I
M><)6KB04(U<2J46BXB)X=(8=<T;.?<'(N2^O<E^)CC)96F_[RU/KD:O.8*U-
M`PEBD2R^*'QQA*U<12A&KB)21J8B8K>[F'\9XN:/*L(6GYFCM[L6KB.O[9)1
M^U`5-W\TE,QG>(-P?3[Q7H%NC.J=CS9WMUM%H:9Q5AR18N0*);7H4AW:$5W'
MG'WY=0A6I7.OSW5XO,9.Y![N+JK,(65:U.3G1X9^HA(6HD'B:64<!;M*8CMZ
MU:$8^=<:10Q;V=VJY^*PQ6F'=^6<<Q=7]`6C3\<JV<J,%6SD%;?6(\DDAC<:
M%Y*(-Q1#B]R4$T0*48HH0Y0C*A"5B"J!9,SA#<6%F/$N8F@0W>;R6DH0*40I
MH@Q1CJA`5"*J!)(QWZ;XAZCX&?DQ6RN'%%JEB#)$.:("48FH$DC&'(ISO<E.
M1CTJV`M7W,AD6C5\>9=#JYR]YS$.Z;WLM^#\4J[9WY6=.I)3U5+2/U\O3-`H
M3S%!B]RU2(:`%*(4488H1U0@*A%5`HF81[>IV-I<JEB+]-,F[^`+MMG$6?'5
M5(A21!FB'%&!J$14"233<)L.':$.9>1=>D0*48HH0Y0C*A"5B"J!9,QM<E)7
MRN=E/T(M:9'WC"]QJ%Z7@0Y2KMDO&G>?*">J)<SUZW)D%(^_+AGY%\=:.:30
M*D64(<H1%8A*1)5`,F8M2VZ(V:@8$;-!_O$X`J00I8@R1#FB`E&)J!)(QGR;
M#!JA#&+D+FJ"2"%*$66(<D0%HA)1)9",.91!^GB<3J]X26F$BL@BL0Z-%:%Z
M'0:R6KD>_CIT#Y'D7&^3+R.4+XS\ZX/R!:U21!FB'%&!J$14"21C#N7+A<T1
M1<O(H$OG8V/ESD=`J?/%5AFB'%&!J$14"233H%7,#=N1%3V>=AN!#DH0*40I
MH@Q1CJA`5"*J!!(QCT-II)?F.*K?]OJ\"NJ>4B59Y"]-A^JEZ41I?6.J7+._
M--WS23G7V_3+&/6+16*"QLI#2EC)&?R<FABCFK#(&S9QJ$Y5("Z5:_93Y>Z_
MY41O4Q-C5!,6B0D:*P\I825G$)[MU]X2T6M^X=,3B[R!$X?J9#E19>O*.*$>
M7K)B]\!43O6V(WF,1[)%8H+&RD-*6,D9M!V0EU4J?4H*J6J.0MX\$VM%,ZE3
MY<X]FZJFAY\J=X]I)FH^.34?_^TVQY=-LGE[.W76AV_Z<U*29`]W#3;?NBY'
M\X7>>&@>T$*?P9)D;VL94DM]<$*?$;746RVTC*FE_IH56J;44G\Z!RTS:JD?
M(`8MC]%\\6@^T0U:Z$VHA7[)J&76\6"A7\5I:Z%(Z865MI:86N*VEB'%0X^4
M6OH,)]12?SX<SFU(D=+CB;8^-&NJI):6$<V:;A:QA;Y2?FR=&073'@N%TN)G
M21>S[5H^CA:/YJV`,`Q]C=L<449:$T+Y:$T'9:,U&1$UT,N$&+*:+>@+&.3%
M;$&?KR"G]V$6^FT7;*%761;Z115LH5="J$];?/1*!_5I:UE&5*@F5_TF6?3%
M]OOJ9?//U?%ENS]UWC;/M`0']9%]--]\FS_.]F.9+X<S?:M-_V!)'^C2M_D;
M^DIHH!]-/1\.9_Z#IMMOOO9_^#\```#__P,`4$L#!!0`!@`(````(0`6(V7N
M,@$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@H@0!**```0``````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````"<D4%/PR`8AN\F_H>&>TM9%YVD98F:
MG5QBXLR,-X1O&[%0`FBW?R_MNCJC)X_D?7EXOH]ROM=U\@G.J\94B&0Y2L"(
M1BJSK=#S:I'.4.(#-Y+7C8$*'<"C.;N\*(6EHG'PZ!H++BCP22093X6MT"X$
M2S'V8@>:^RPV3`PWC=,\Q*/;8LO%.]\"GN3Y%=80N.2!XPZ8VI&(!J04(])^
MN+H'2(&A!@TF>$PR@K^[`9SV?U[HD[.F5N%@XTR#[CE;BF,XMO=>C<6V;;.V
MZ#6B/\$ORX>G?M14F6Y7`A#K]E-S'Y9QE1L%\O;`]F^N3KS?E?AW5DK1VU'A
M@`>027R/'NU.R;JXNU\M$)OD9)J2/"W(BMS0Z34M9J\E/K6&^VP$ZD'@W\03
M@/7>/_^<?0$``/__`P!02P,$%``&``@````A`,A_!TJ\`@``:`D``!``"`%D
M;V-0<F]P<R]A<'`N>&UL(*($`2B@``$`````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````G%913]LP$'Z?M/\0Y1U2*$,3<H-&VXE)VZB6P!XM-[E0"]?.
M;">B^_4[)[0DPW@:;XY]]]UWWYU](9>/6Q&UH`U7<A:?'$_B"&2A2B[O9_%M
M_OGH8QP9RV3)A)(PBW=@XLOT_3NRTJH&;3F8""&DF<4;:^N+)#'%!K;,'..Q
MQ)-*Z2VS^*GO$U55O("%*IHM2)N<3B;G"3Q:D"641_4!,.X1+UK[5M!2%8Z?
MN<MW-1).R:>Z%KQ@%K-,O_%"*Z,J&RT?"Q`D&1X29)=!T6AN=^F$),-/DA5,
MP!R!TXH)`R1YWB#7P)QH*\:U24EK+UHHK-*1X;]1MM,X6C,#CLXL;IGF3%JD
MY<SZCVXM:F-U^E/I![,!L(8D:-!O=LNA[7#-S]+I>6>!J[&E0^B9X,&88\ZM
M`'-3K9BV'LK3\R'GCD7/N">TKR+%WJ!+:5$O^D7VU>9JR/R0PUQ)HP0OF862
M7C'!9`$TZS*EM_(-+B?_]LDL1G/=9JBJZ$V-13OP<?+WR8R8C5WF;%2&@\L"
M3*%Y[3K*(5\UADLPII,C:[Q1?H#H4G>"[VBNF32L<`#^"$\W;-<K_*OAM<O#
MB_Q=6:`KMF-KX4]P`9JWV/XM^&/-U7;+;:^3*R@*8K&;\2G`"^X-N41"=N<]
MRIJU@5\-DJ7+UDGOM0H+Z"]MV.?4&^=UU6G.UEX7O_+.'"^,UV.@;\@L*#/U
M(O<ZAT##HDR]J&&?LS?X?/#Z!,1?@+^7PR[^OGBE8!B"<>&O6-C%'V9XS6@(
M?-@._VE'_:$]B#3'V=DP'&"'1VGXH@4N]"LQPMWIOUU/[1E*<FP29/WBY?"I
M/!II?PVQKUP^F-LZ5PM\:?=3>KQ)L@W34.+\VI\_;Y!K'-!:.)#YAN'[5^YM
M7AZX?XJ[_L<I/3D[GDPG^+LPV"/)4XOA"YK^`0``__\#`%!+`0(M`!0`!@`(
M````(0!,"'?^XP$``$,7```3``````````````````````!;0V]N=&5N=%]4
M>7!E<UTN>&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L`````````
M````````'`0``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`"ZU^7/Q`0``
M.A8``!H`````````````````0@<``'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L!`BT`%``&``@````A`(KFQ1E+`P``3`L```\`````````````````
M<PH``'AL+W=O<FMB;V]K+GAM;%!+`0(M`!0`!@`(````(0!R<]3"+04```P4
M```8`````````````````.L-``!X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"+0`4``8`"````"$`5:*Q]#`$``#7#@``&0````````````````!.$P``
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+`0(M`!0`!@`(````(0#P7X\0
M>`4```H6```9`````````````````+47``!X;"]W;W)K<VAE971S+W-H965T
M,S`N>&UL4$L!`BT`%``&``@````A`(UY+@(^`P``IPD``!D`````````````
M````9!T``'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"+0`4``8`"```
M`"$`X7GP-H@#``#%#```&0````````````````#9(```>&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+`0(M`!0`!@`(````(0#U3;02SP(``-8'```9````
M`````````````)@D``!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L!`BT`
M%``&``@````A`(,2QQ4N`P``(@H``!D`````````````````GB<``'AL+W=O
M<FMS:&5E=',O<VAE970R-BYX;6Q02P$"+0`4``8`"````"$`NW7010<1``"Z
MB```&0`````````````````#*P``>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM
M;%!+`0(M`!0`!@`(````(0!#]%.I<0,``#$-```9`````````````````$$\
M``!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L!`BT`%``&``@````A`*V\
MO+27%```0K0``!D`````````````````Z3\``'AL+W=O<FMS:&5E=',O<VAE
M970S,RYX;6Q02P$"+0`4``8`"````"$`20GS'Z$%``#=&```&0``````````
M``````"W5```>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+`0(M`!0`!@`(
M````(0"DI\V#I00``)(1```8`````````````````(]:``!X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"+0`4``8`"````"$`.Y7O!^,"``!&"0``&```
M``````````````!J7P``>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!`BT`
M%``&``@````A`"WUPS[8=```/7X!`!0`````````````````@V(``'AL+W-H
M87)E9%-T<FEN9W,N>&UL4$L!`BT`%``&``@````A`&U)CJ;E"P```FP```T`
M````````````````C=<``'AL+W-T>6QE<RYX;6Q02P$"+0`4``8`"````"$`
M^V*E;90&``"G&P``$P````````````````"=XP``>&PO=&AE;64O=&AE;64Q
M+GAM;%!+`0(M`!0`!@`(````(0!TZVZV0@,``-X)```9````````````````
M`&+J``!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L!`BT`%``&``@````A
M``+7&'XZ'P``M/P``!D`````````````````V^T``'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"+0`4``8`"````"$`A%<&'WD#``"J"P``&```````
M``````````!,#0$`>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!`BT`%``&
M``@````A`!C%G:"O`@``4`<``!D`````````````````^Q`!`'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"+0`4``8`"````"$`]""0Q"H#``"H"0``
M&0````````````````#A$P$`>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M`0(M`!0`!@`(````(0"V.M1]4@P``"Q!```9`````````````````$(7`0!X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L!`BT`%``&``@````A``0(Y644
M#P``<5```!D`````````````````RR,!`'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"+0`4``8`"````"$`$>_'0[("``"2!P``&```````````````
M```6,P$`>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!`BT`%``&``@````A
M`(0FFSA$"```[R8``!@`````````````````_C4!`'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+`0(M`!0`!@`(````(0`[M(2>J0@``'(I```8````````
M`````````'@^`0!X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"+0`4``8`
M"````"$`Q.#TN9`@``"MY```&`````````````````!71P$`>&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L!`BT`%``&``@````A``#N1V73!0``VA<``!@`
M````````````````'6@!`'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+`0(M
M`!0`!@`(````(0!`-[E#,`0``-@0```9`````````````````"9N`0!X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L!`BT`%``&``@````A`//Z+.A5'0``
MD\(``!D`````````````````C7(!`'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"+0`4``8`"````"$`#'-]["4;```KMP``&0`````````````````9
MD`$`>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+`0(M`!0`!@`(````(0#G
M'+G/#0,``+(*```9`````````````````'6K`0!X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L!`BT`%``&``@````A`$`%PTPP#0``#$$``!D`````````
M````````N:X!`'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"+0`4``8`
M"````"$`'D@[\'@"```Q!@``&0`````````````````@O`$`>&PO=V]R:W-H
M965T<R]S:&5E=#$S+GAM;%!+`0(M`!0`!@`(````(0#%I?7AE00``$,0```9
M`````````````````,^^`0!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!
M`BT`%``&``@````A`&#[3KX>!@``GQ@``!D`````````````````F\,!`'AL
M+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"+0`4``8`"````"$`!&"JZCL)
M```O+```&0````````````````#PR0$`>&PO=V]R:W-H965T<R]S:&5E=#$U
M+GAM;%!+`0(M`!0`!@`(````(0#O6C7^O@,``)0+```9````````````````
M`&+3`0!X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!`BT`%``&``@````A
M`%"=V"K4#```,D```!D`````````````````5]<!`'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"+0`4``8`"````"$`%B-E[C(!``!``@``$0``````
M``````````!BY`$`9&]C4')O<',O8V]R92YX;6Q02P$"+0`4``8`"````"$`
MR'\'2KP"``!H"0``$`````````````````#+Y@$`9&]C4')O<',O87!P+GAM
7;%!+!08`````+0`M`"T,``"]Z@$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELYEM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="7">9 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 20, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jan. 27, 2014

</div>
          <div>Manufacturing Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Manufacturing Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Einstein [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Abbview Biotherapeutics Corp [Member]

</div>
          <div>Product Development and Patent License Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Abbview Biotherapeutics Corp [Member]

</div>
          <div>After First Net Sales [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Abbview Biotherapeutics Corp [Member]

</div>
          <div>Phase I Clinical Trial of a licensed product [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>After First Net Sales [Member]

</div>
          <div>Product Development and Patent License Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>Phase I Clinical Trial of a licensed product [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Oak Ridge National Laboratory [Member]

</div>
          <div>2013 [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Oak Ridge National Laboratory [Member]

</div>
          <div>2014 [Member]</div>
        </th>
        <th class="th">
          <div>May 16, 2013

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 22, 2012

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 06, 2012

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 19, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Maximum [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Minimum [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 28, 2012

</div>
          <div>University of Texas M.D. Anderson Cancer Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]

</div>
          <div>patients</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>University of Texas M.D. Anderson Cancer Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2013

</div>
          <div>University of Texas M.D. Anderson Cancer Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 26, 2012

</div>
          <div>Johns Hopkins University [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Johns Hopkins University [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>University of Pennsylvania [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>University of Pennsylvania [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Nov. 21, 2012

</div>
          <div>University of Pennsylvania [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Net sales in milestones payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PaymentOfLicenseFee', window );">License fee payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,750,000<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="nump">750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfRoyaltyPaymentToRelatedParty', window );">Description of royalty payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Company shall pay to AbbVie Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Royalty payments of 2% of net sales will be due to FHCRC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RoyaltyOfNetSalesPercentage', window );">Royalty of net sales percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FirstCommercialSalePeriod', window );">First commercial sale period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">12 years 6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PurchaseOfRadioactiveMaterial', window );">Purchase of radioactive material used for research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ProjectEstimatedCost', window );">Project estimated cost for clinical trials of drug Ac-225-HuM195</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,300,000<span></span></td>
        <td class="nump">2,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,200,000<span></span></td>
        <td class="nump">2,200,000<span></span></td>
        <td class="nump">2,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DownPaymentOfProjectEstimatedCostPercentage', window );">Down payment of project estimated cost percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DownPaymentForProject', window );">Down payment for project</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,900,000<span></span></td>
        <td class="nump">239,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">239,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration', window );">Clinical trial cost for approval of food and drug administration</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">23,500,000<span></span></td>
        <td class="nump">13,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear', window );">Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo', window );">Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NumberOfPatients', window );">Number of Patients</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">24<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmountPaidToEachPatient', window );">Amount paid to each patient after Completing clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,366<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">34,383<span></span></td>
        <td class="nump">38,501<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,771<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StartUpFeeForClinicalTrial', window );">Start-up fee for clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19,749<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">33,946<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">22,847<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StartUpDueCostPaidDate', window );">Start-up due cost paid date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Dec. 31,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NonRefundableInstitutionalFee', window );">Non - refundable institutional fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">562,790<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PharmacyFee', window );">Annual pharmacy fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,025<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmendmentProcessingFee', window );">Amendment processing fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Accrued fees paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research recorded fees</a></td>
        <td class="nump">3,773,438<span></span></td>
        <td class="nump">778,232<span></span></td>
        <td class="nump">8,236,343<span></span></td>
        <td class="nump">2,373,200<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">75,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentInProcess', window );">Total project estimated to cost</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">183,391<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development costs</a></td>
        <td class="nump">300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">92,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
        <td class="nump">$ 34,733<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 34,733<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmendmentProcessingFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amendment processing fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmendmentProcessingFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmountPaidToEachPatient">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount to be paid for each Patient that has completed the clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmountPaidToEachPatient</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Clinical trial cost for approval of food and drug administration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommitmentsAndContingenciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_CommitmentsAndContingenciesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfRoyaltyPaymentToRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of royalty payment to related party.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DescriptionOfRoyaltyPaymentToRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DownPaymentForProject">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Down payment for project.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DownPaymentForProject</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DownPaymentOfProjectEstimatedCostPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of total estimated project cost required for down payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DownPaymentOfProjectEstimatedCostPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FirstCommercialSalePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>First commercial sale period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FirstCommercialSalePeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fund to related party under agreement after year two.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FundToRelatedPartyUnderAgreementAfterYearTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fund to related party under agreement for first two Year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongTermPurchaseCommitmentMilestonesPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Long term purchase commitment milestones payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_LongTermPurchaseCommitmentMilestonesPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NonRefundableInstitutionalFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non refundable institutional fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_NonRefundableInstitutionalFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NumberOfPatients">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of patients.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_NumberOfPatients</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PaymentOfLicenseFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License fee payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PaymentOfLicenseFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PharmacyFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Pharmacy fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PharmacyFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ProjectEstimatedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Project estimated cost.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ProjectEstimatedCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PurchaseOfRadioactiveMaterial">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase of radioactive material.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PurchaseOfRadioactiveMaterial</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RoyaltyOfNetSalesPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty of net sales percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RoyaltyOfNetSalesPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StartUpDueCostPaidDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Start-up due cost paid date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_StartUpDueCostPaidDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StartUpFeeForClinicalTrial">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Start-up fee for clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_StartUpFeeForClinicalTrial</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentInProcess">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current amount of expenditures for a real estate project that has not yet been completed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.10)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentInProcess</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LegalFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentInProcess</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8,17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SecurityDeposit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E26GK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="3">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 07, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 24, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 28, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jul. 10, 2014</div>
        </th>
        <th class="th">
          <div>Jan. 10, 2014

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 09, 2013

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 07, 2012

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 27, 2013

</div>
          <div>Investors [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Common Stock [Member]

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 10, 2014

</div>
          <div>IPO [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>IPO [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>MSKCC [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>MSKCC [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>MSKCC [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>MSKCC [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>MSKCC [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>MSKCC [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>MSKCC [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 27, 2012

</div>
          <div>MSKCC [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 04, 2013

</div>
          <div>SKI [Member]

</div>
          <div>License, Development and Commercialization Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2011

</div>
          <div>SKI [Member]

</div>
          <div>License, Development and Commercialization Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>SKI [Member]

</div>
          <div>License, Development and Commercialization Agreement [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven', window );">Amount paid under agreement in 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve', window );">Amount paid under agreement in 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen', window );">Amount paid under agreement in 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen', window );">Amount owed under agreement from 2011 to 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">815,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaintenanceFeesAndResearchPayments', window );">Maintenance fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">26,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">197,106<span></span></td>
        <td class="nump">218,604<span></span></td>
        <td class="nump">278,291<span></span></td>
        <td class="nump">81,185<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="nump">189,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PlacementAgentServicesFees', window );">Placement agent services fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantsIssuedToPurchaseCommonStock', window );">Warrants issued to purchase common stock, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">68,976<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommonStockExercisePriceParOrStatedValuePerShare', window );">Common stock exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 9.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmountPaidToEachPatient', window );">Amount paid to each patient after Completing clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,185<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StartUpFeeForClinicalTrial', window );">Start-up fee for clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">79,623<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfReceivablesOfPlacementAgentForServices', window );">Description of receivables of placement agent for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Agreement entered in on December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company's Common Stock<span></span></td>
        <td class="text"><div>Placement agent received (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.</div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfWarrantsReceivablesByPlacement', window );">Description of warrants receivables by placement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued or issuable<span></span></td>
        <td class="text">The placement agent or its designees also received warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PeriodOfExerciseOfWarrants', window );">Period of exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Within 6 months of the final closing of the 2012 common stock Offering<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PercentageOfSolicitationFee', window );">Percentage of solicitation fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PeriodicFeeForFinancialAdvisoryServices', window );">Monthly fee for financial advisory services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000<span></span></td>
        <td class="nump">25,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfAdditionalReceivableByPlacementAgent', window );">Description of additional receivable by placement agent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company's financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommonStockPurchaseByHoldingOfWarrant', window );">Warrant held by placement agent to purchase common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,251,015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments', window );">Royalty description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold, Shares</a></td>
        <td class="nump">61,538<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">554,310<span></span></td>
        <td class="nump">551,810<span></span></td>
        <td class="nump">1,984,524<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,827,123<span></span></td>
        <td class="nump">1,670,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Warrants granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">137,952<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 7.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 9.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 7.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities', window );">Gross proceeds from the sale of securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,310,860<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,325,860<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_UnderwritingDiscount', window );">Underwriting discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13,700,000<span></span></td>
        <td class="nump">876,750<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds received in Offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6,636,720<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 12,600,000<span></span></td>
        <td class="nump">$ 11,451,250<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Aggregate offering amount of securities sold to investors</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. On April 28, 2014, the Company issued 500 shares and received net proceeds of $6,000 under the Sales Agreement with MLV.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Five-year warrants to purchase an aggregate of 138,577 shares of common stock at an exercise price of $9.00 per share.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmountPaidToEachPatient">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount to be paid for each Patient that has completed the clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmountPaidToEachPatient</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount paid under agreement in year two thousand eleven.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmountPaidUnderAgreementInYearTwoThousandEleven</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount paid under agreement in year two thousand thirteen.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount paid under agreement in year two thousand twelve.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommonStockExercisePriceParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock exercise price par or stated value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_CommonStockExercisePriceParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommonStockPurchaseByHoldingOfWarrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock purchase by holding of warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_CommonStockPurchaseByHoldingOfWarrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfAdditionalReceivableByPlacementAgent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of additional receivable by placement agent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DescriptionOfAdditionalReceivableByPlacementAgent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfReceivablesOfPlacementAgentForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of receivables of placement agent for services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DescriptionOfReceivablesOfPlacementAgentForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfWarrantsReceivablesByPlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of warrants receivables by placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DescriptionOfWarrantsReceivablesByPlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MaintenanceFeesAndResearchPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maintenance fees and research payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_MaintenanceFeesAndResearchPayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Owed amount under agreement in year two thousand eleven to fourteen.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PercentageOfSolicitationFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of solicitation fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PercentageOfSolicitationFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PeriodicFeeForFinancialAdvisoryServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Periodic fee for financial advisory services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PeriodicFeeForFinancialAdvisoryServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PeriodOfExerciseOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period of exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PeriodOfExerciseOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PlacementAgentServicesFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent services fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PlacementAgentServicesFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RelatedPartyTransactionsTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RelatedPartyTransactionsTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StartUpFeeForClinicalTrial">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Start-up fee for clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_StartUpFeeForClinicalTrial</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_UnderwritingDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Underwriting discount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_UnderwritingDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantsIssuedToPurchaseCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Issued To Purchase Aggregate Shares Of Common Stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_WarrantsIssuedToPurchaseCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the commitments made for future artist advances payable and royalty guarantees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 928<br><br> -SubTopic 440<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceInitialPublicOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 23<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569655-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4582445-111684<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockDescriptionOfTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note Payable<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Note Payable [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Note Payable</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Note 4 &#8211; Note Payable</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On December 28, 2013, the Company entered into a premium finance agreement to pay a premium of $157,825 for its director and officer liability insurance policy. Pursuant to the agreement, the Company paid a down payment of $15,995 in January 2014 and&#160;was required&#160;to pay $15,995 in monthly installment for nine months. During the nine months ended September 30, 2014, the Company paid $157,825. As of September 30, 2014 and December 31, 2013, the outstanding balance related to the premium finance agreement was $0 and $157,825, respectively.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]B.3$U9C@P-U]B,S$T7S0S.#1?86$P9%]A.3$Y
M-#AF9F1C,#DB#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]B.3$U9C@P-U]B,S$T7S0S.#1?86$P9%]A
M.3$Y-#AF9F1C,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8CDQ
M-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S7U5N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U5N,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED
M871E9%]3=&%T96UE;G1S7V]F7T]P93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E<V-R
M:7!T:6]N7V]F7T)U<VEN97-S7V%N9%]3=3PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E)E;&%T961?4&%R='E?5')A;G-A8W1I;VYS
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O<&5R
M='E?86YD7T5Q=6EP;65N=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/DYO=&5?4&%Y86)L93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P.2YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D1E<FEV871I=F5S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E
M;F-I97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y%
M<75I='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3
M=6)S97%U96YT7T5V96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/D1E<V-R:7!T:6]N7V]F7T)U<VEN97-S7V%N9%]3=3$\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$97-C<FEP=&EO
M;E]O9E]"=7-I;F5S<U]A;F1?4W4R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4F5L871E9%]087)T>5]4<F%N<V%C=&EO;G-?5&%B
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#$V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O<&5R
M='E?86YD7T5Q=6EP;65N=%]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3<N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y$97)I=F%T:79E<U]486)L97,\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?
M0V]N=&EN9V5N8VEE<U\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y%<75I='E?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^1&5S8W)I<'1I;VY?;V9?0G5S:6YE<W-?86YD7U-U
M,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E<V-R
M:7!T:6]N7V]F7T)U<VEN97-S7V%N9%]3=30\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C(N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y$97-C<FEP=&EO;E]O9E]"=7-I;F5S<U]A
M;F1?4W4U/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#(S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4F5L871E9%]087)T>5]4<F%N<V%C=&EO;G-?1&5T/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(T
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^4F5L871E9%]087)T>5]4<F%N<V%C
M=&EO;G-?1&5T,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E!R;W!E<G1Y7V%N9%]%<75I<&UE;G1?1&5T86EL<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970R-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R;W!E<G1Y7V%N9%]%<75I
M<&UE;G1?1&5T86EL<S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C<N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y.;W1E7U!A>6%B;&5?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R."YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E<FEV871I=F5S7T1E=&%I;',\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,CDN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$97)I=F%T:79E
M<U]$971A:6QS7S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,S`N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y$97)I=F%T:79E<U]$971A:6QS7U1E>'1U86P\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,S$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N
M=&EN9V5N8VEE<U\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#,R+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E;F-I97-?,CPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970S,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D5Q=6ET>5]$971A:6QS
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#,T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^17%U:71Y
M7T1E=&%I;'-?5&5X='5A;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-U8G-E<75E;G1?179E;G1S7T1E=&%I;',\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,S8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z
M17AC96Q7;W)K<VAE971S/@T*("`\>#I3='EL97-H965T($A2968],T0B5V]R
M:W-H965T<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z
M06-T:79E4VAE970^#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z
M4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\
M+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM
M;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES
M('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E;"!8
M4"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]B.3$U9C@P-U]B,S$T7S0S.#1?86$P9%]A.3$Y-#AF9F1C
M,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8CDQ-68X,#=?8C,Q
M-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y+U=O<FMS:&5E=',O4VAE970P,2YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P15%!044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&]C
M=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D]C="X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@86YD($5N
M=&ET>2!);F9O<FUA=&EO;B!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%)E9VES=')A;G0@
M3F%M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)T%C=&EN:75M
M(%!H87)M86-E=71I8V%L<RP@26YC+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X
M($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S`P,#$S.#@S
M,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!;65N9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)V9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)RTM,3(M,S$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U
M;65N="!4>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3`M
M43QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^4V5P(#,P+`T*"0DR,#$T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES
M8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<R,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U$S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A
M=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG4VUA;&QE
M<B!297!O<G1I;F<@0V]M<&%N>3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H
M87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,P+#`P-2PU,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V(Y,35F.#`W7V(S,31?-#,X-%]A83!D7V$Y,3DT.&9F9&,P
M.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B.3$U9C@P-U]B,S$T
M7S0S.#1?86$P9%]A.3$Y-#AF9F1C,#DO5V]R:W-H965T<R]3:&5E=#`R+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%4%E!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYS
M;VQI9&%T960@0F%L86YC92!3:&5E=',@*%5N875D:71E9"D@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0W5R<F5N="!!<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I
M=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,2PW
M-3`L-C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`U+#4S,RPS-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R
M(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV-S$L.3`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C$X+#,X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($-U<G)E;G0@07-S971S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPT,C(L-3<X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PW-3$L-S4U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970@;V8@86-C=6UU;&%T960@
M9&5P<F5C:6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-#$L,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3,L.3(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y396-U<FET>2!D97!O<VET/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS-"PW,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPU.3@L
M,S(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-2PW-C4L-C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@3&EA8FEL:71I97,Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW,S$L,C`W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<X+#DU-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N
M=',@<&%Y86)L92!A;F0@86-C<G5E9"!E>'!E;G-E<R`M(')E;&%T960@<&%R
M='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W."PR.3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,2PQ
M.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYO=&4@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$U-RPX,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I=F4@;&EA8FEL:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,C$V+#DS-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L
M-S`W+#(U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L($-U<G)E;G0@3&EA8FEL:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#(R-BPT,S,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#,R-2PR,C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L($QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,"PR,C8L-#,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-RPS,C4L,C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM:71M96YT<R!A;F0@8V]N=&EN
M9V5N8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%
M<75I='D@*$1E9FEC:70I.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@)#`N,#$@<&%R('9A
M;'5E.R`U,"PP,#`L,#`P(&%U=&AO<FEZ960L(&YO;F4@:7-S=65D(&%N9"!O
M=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@)#`N,#`Q
M('!A<B!V86QU93L@,C`P+#`P,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960[(#(Y
M+#8Q.2PT.34@86YD(#(T+#4V-2PT-#<@<VAA<F5S(&ES<W5E9"!A;F0@;W5T
M<W1A;F1I;F<L(')E<W!E8W1I=F5L>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,CDL-C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C0L-38U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('!A:60M:6X@8V%P
M:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#@L,3(P+#DU
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8T+#DS,RPQ-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#@U+#<W."PV.#$I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C8L-3$W+#(U-2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!3=&]C:VAO;&1E<G,G($5Q=6ET>2`H1&5F:6-I="D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S<Q+#@X.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-34Y+#4T-2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!,:6%B:6QI=&EE<R!A;F0@4W1O8VMH;VQD97)S)R!%<75I='D@*$1E
M9FEC:70I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R+#4Y
M."PS,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#4L-S8U+#8W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D
M8S`Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(Y,35F.#`W7V(S
M,31?-#,X-%]A83!D7V$Y,3DT.&9F9&,P.2]7;W)K<VAE971S+U-H965T,#,N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4V3D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O
M;G-O;&ED871E9"!"86QA;F-E(%-H965T<R`H56YA=61I=&5D*2`H4&%R96YT
M:&5T:6-A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0F%L86YC92!3:&5E=',@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E
M9"!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@
M<W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@
M<W1O8VLL('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO
M;B!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@875T
M:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@:7-S=65D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PV,3DL-#DU/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0L
M-38U+#0T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N(%-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y+#8Q.2PT.34\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-"PU-C4L
M-#0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B
M.3$U9C@P-U]B,S$T7S0S.#1?86$P9%]A.3$Y-#AF9F1C,#D-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?
M83DQ.30X9F9D8S`Y+U=O<FMS:&5E=',O4VAE970P-"YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14I#04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N<V]L:61A=&5D(%-T
M871E;65N=',@;V8@3W!E<F%T:6]N<R`H56YA=61I=&5D*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3=&%T96UE;G1S($]F($]P97)A=&EO;G,@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY/<&5R871I;F<@97AP96YS97,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E
M87)C:"!A;F0@9&5V96QO<&UE;G0L(&YE="!O9B!R96EM8G5R<V5M96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPW-S,L-#,X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S<X+#(S
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@L,C,V+#,T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L,S<S+#(P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A;F0@861M:6YI<W1R871I
M=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C4W+#$T-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@S
M,"PW,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW+#,T-RPX,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#<S,"PR,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!E>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PS,C8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C,L-S@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!O;B!D:7-P;W-I=&EO
M;B!O9B!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,3(R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@;W!E<F%T:6YG(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW+#`T-"PY,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8P."PY-C(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PV,#<L.34S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PQ
M,#<L-34U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&]S<R!F<F]M(&]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#<L,#0T+#DQ,2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#8P."PY-C(I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,34L-C`W+#DU
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@U+#$P-RPU-34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R(&EN8V]M92`H97AP96YS92DZ
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);G1E<F5S="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,2PR.3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L-3`X*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1V%I;B`H;&]S<RD@;VX@8VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@9&5R:79A
M=&EV92!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.38W+#@X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$X.2PS-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@S+#8U,RPT-S,I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$V+#$Q,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&]T
M:&5R(&EN8V]M92`H97AP96YS92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDV-RPX.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ.#@L,#0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,RPV-3,L-#<S*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q,RPV,#0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@V+#`W-RPP
M,C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@Q+#0R,"PY,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@Q.2PR-C$L-#(V*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-"PX.3,L.34Q*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M(&QO<W,@<&5R(&-O;6UO;B!S:&%R92`M(&)A<VEC(&%N9"!D:6QU=&5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,C$I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C`V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,"XW,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#`N,C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(&-O;6UO;B!S:&%R97,@
M;W5T<W1A;F1I;F<@+2!B87-I8R!A;F0@9&EL=71E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C@L-#DV+#DP,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#8P,2PX.34\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BPU-#`L
M,S8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C(L-#`Q+#<Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(Y,35F.#`W7V(S,31?
M-#,X-%]A83!D7V$Y,3DT.&9F9&,P.2]7;W)K<VAE971S+U-H965T,#4N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$4S1T%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G-O
M;&ED871E9"!3=&%T96UE;G1S(&]F($-A<V@@1FQO=W,@*%5N875D:71E9"D@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0V%S:"!&;&]W<R!&<F]M($]P97)A=&EN9R!!8W1I=FET
M:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#$Y+#(V,2PT,C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@T+#@Y,RPY-3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S
M('1O(')E8V]N8VEL92!N970@;&]S<R!T;R!N970@8V%S:"!U<V5D(&EN(&]P
M97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E
M>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#(R,2PV
M-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR.#0L,S<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$97!R96-I871I;VX@97AP96YS93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C,L-S@S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!O
M;B!D:7-P;W-I=&EO;B!O9B!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#$R,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R`H9V%I;BD@
M;VX@8VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@9&5R:79A=&EV93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPV-3,L-#<S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C$V+#$Q,BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^*$EN8W)E87-E*2!D96-R96%S92!I;CH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S
M(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-#4S+#4Q-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,30L,30S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y396-U<FET>2!D97!O<VET
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-"PW,S,I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY);F-R96%S92`H9&5C<F5A<V4I(&EN.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U
M;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,S4R+#(U,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4X-2PP-#,I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT
M<R!P87EA8FQE(&%N9"!A8V-R=65D(&5X<&5N<V5S("T@<F5L871E9"!P87)T
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DW+#$P-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T-"PU
M,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@0V%S:"!5<V5D($EN($]P97)A=&EN9R!!8W1I=FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y+#,P,2PS.#8I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PY-#<L
M.38Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#87-H($9L;W=S($9R;VT@26YV97-T:6YG($%C=&EV
M:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4'5R8VAA<V4@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,34P+#@W-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X+#`S,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@0V%S:"!5<V5D($EN($EN=F5S=&EN9R!!8W1I=FET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-3`L.#<T*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L,#,P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY#87-H($9L;W=S($9R;VT@1FEN86YC:6YG($%C=&EV:71I97,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y;65N
M=',@;VX@;F]T92!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q-3<L.#(U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$T,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE<R!O9B!C;VUM;VX@<W1O8VLL
M(&YE="!O9B!O9F9E<FEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,34L-#,U+#,P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R
M;VT@=&AE(&5X97)C:7-E(&]F(&]P=&EO;G,@86YD('=A<G)A;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.3(L,#@Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT-C<L,SDS/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F5T($-A<V@@4')O=FED960@0GD@1FEN86YC:6YG($%C=&EV:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#8V.2PU-CD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,R-RPS
M.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@8VAA;F=E(&EN(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8L,C$W+#,P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$L-C(X+#8P-BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@
M97%U:79A;&5N=',@870@8F5G:6YN:6YG(&]F('!E<FEO9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-2PU,S,L,S8V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PV,3@L-C8Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H
M(&%N9"!C87-H(&5Q=6EV86QE;G1S(&%T(&5N9"!O9B!P97)I;V0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#<U,"PV-S4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#DY,"PP-C,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4W5P<&QE;65N=&%L(&1I<V-L;W-U<F5S(&]F(&-A<V@@9FQO
M=R!I;F9O<FUA=&EO;CH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#87-H('!A:60@9F]R(&EN=&5R97-T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-38Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H
M('!A:60@9F]R(&EN8V]M92!T87AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4W5P<&QE;65N=&%L(&1I<V-L;W-U<F4@;V8@;F]N+6-A<V@@:6YV97-T:6YG
M(&%N9"!F:6YA;F-I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%N<V9E<B!W87)R86YT(&1E
M<FEV871I=F5S(&9R;VT@;&EA8FEL:71Y('1O(&5Q=6ET>2!C;&%S<VEF:6-A
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#$T,RPW
M.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#8P,"PX.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7V(Y,35F.#`W7V(S,31?-#,X-%]A83!D7V$Y,3DT.&9F9&,P.0T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B.3$U9C@P-U]B,S$T7S0S
M.#1?86$P9%]A.3$Y-#AF9F1C,#DO5V]R:W-H965T<R]3:&5E=#`V+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5S8W)I<'1I
M;VX@;V8@0G5S:6YE<W,@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C
M;W5N=&EN9R!0;VQI8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D1E<V-R:7!T:6]N(&]F($)U<VEN97-S(&%N
M9"!3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,@86YD(%-U;6UA<GD@
M;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQB/DYO=&4@,2`F(S@R,3$[
M($1E<V-R:7!T:6]N(&]F($)U<VEN97-S(&%N9"!3=6UM87)Y(&]F(%-I9VYI
M9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\+V(^/"]F;VYT/CPO<#X\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E
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M;G0M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
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M3F%T=7)E(&]F($)U<VEN97-S("8C.#(Q,3L\+V(^)B,Q-C`[06-T:6YI=6T@
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M=VYE9"!S=6)S:61I87)Y+"!-961!8W1I;FEU;2P@26YC+B`H34%)*2P@*&AE
M<F5I;F%F=&5R(')E9F5R<F5D('1O(&-O;&QE8W1I=F5L>2!A<R`F(S@R,C`[
M06-T:6YI=6TF(S@R,C$[*2!I;FET:6%T960@8V]L;&%B;W)A=&EV92!E9F9O
M<G1S('=I=&@@;&%R9V4@:6YS=&ET=71I;VYS('1O(&5S=&%B;&ES:"!T:&4@
M<')O;V8@;V8@8V]N8V5P="!O9B!!4$E4(&%N9"!H87,@<W5P<&]R=&5D(&]N
M92!0:&%S92`Q+S(@8VQI;FEC86P@=')I86P@86YD(&]N92!0:&%S92`Q(&-L
M:6YI8V%L('1R:6%L(&%T($UE;6]R:6%L(%-L;V%N+4ME='1E<FEN9R!#86YC
M97(@0V5N=&5R("@F(S@R,C`[35-+0T,F(S@R,C$[*2!U;F1E<B!A;B!-4TM#
M0R!0:'ES:6-I86X@24Y$($%P<&QI8V%T:6]N+B!);B`R,#$R+"!!8W1I;FEU
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M97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG
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M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
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M<B`R."P@,C`Q,BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@=')A;G-A
M8W1I;VX@*'1H92`F(S@R,C`[4VAA<F4@17AC:&%N9V4F(S@R,C$[*2P@<'5R
M<W5A;G0@=&\@=VAI8V@@=&AE($-O;7!A;GD@86-Q=6ER960@,3`P)2!O9B!T
M:&4@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!E<75I='D@<V5C=7)I=&EE<R!O
M9B!!8W1I;FEU;2!0:&%R;6%C975T:6-A;',L($EN8RX@*"8C.#(R,#M!4$DF
M(S@R,C$[*2P@:6X@97AC:&%N9V4@9F]R('1H92!I<W-U86YC92!O9B!A<'!R
M;WAI;6%T96QY(#DY)2!O9B!T:&4@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!C
M;VUM;VX@<W1O8VLL('!A<B!V86QU92`D,"XP,2!P97(@<VAA<F4L(&]F('1H
M92!#;VUP86YY+B!!<R!A(')E<W5L="!O9B!T:&4@4VAA<F4@17AC:&%N9V4L
M('1H92!F;W)M97(@<VAA<F5H;VQD97)S(&]F($%022!B96-A;64@=&AE(&-O
M;G1R;VQL:6YG('-H87)E:&]L9&5R<R!O9B!T:&4@0V]M<&%N>2X@070@=&AE
M(&-L;W-I;F<L(&5A8V@@05!)('-H87)E:&]L9&5R(')E8V5I=F5D(#`N,S,S
M('-H87)E<R`H=&AE("8C.#(R,#M%>&-H86YG92!2871I;R8C.#(R,3LI(&]F
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M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,"XU-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N
M;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[
M/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
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M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
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M+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US=')E
M=&-H.B!N;W)M86P[)SY/;B!-87)C:"`R,"P@,C`Q,RP@=&AE($-O;7!A;GDF
M(S@R,3<[<R!S=6)S:61I87)Y+"!!8W1I;FEU;2!0:&%R;6%C975T:6-A;',L
M($EN8RXL(&-H86YG960@:71S(&YA;64@=&\@06-T:6YI=6T@0V]R<&]R871I
M;VXN)B,Q-C`[)B,Q-C`[3VX@07!R:6PF(S$V,#LQ,2P@,C`Q,RP@=&AE($-O
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M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
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M+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H-"B!N
M;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#LG/D]N(%-E<'1E;6)E<B`R-2P@,C`Q,RP@:6X@86-C
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M(&YO="!O=VYE9"!B>2!T:&4@0V]M<&%N>2!W87,@97AC:&%N9V5D(&9O<B`P
M+C,S,R!S:&%R97,@;V8@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:RXF
M(S$V,#LF(S$V,#M!('1O=&%L(&]F(#,L.3<P+#$S-R!S:&%R97,@;V8@06-T
M:6YI=6T@0V]R<&]R871I;VX@8V]M;6]N('-T;V-K('=A<R!E>&-H86YG960@
M9F]R(#$L,S(R+#`U-2!S:&%R97,@;V8@0V]M<&%N>2!C;VUM;VX@<W1O8VLN
M)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
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M;G0M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
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M86YC:6%L($EN9F]R;6%T:6]N("8C.#(Q,3L\+V(^)B,Q-C`[5&AE(&%C8V]M
M<&%N>6EN9R!U;F%U9&ET960@:6YT97)I;2!C;VYS;VQI9&%T960@9FEN86YC
M:6%L('-T871E;65N=',@86YD(')E;&%T960@;F]T97,@:&%V92!B965N('!R
M97!A<F5D(&EN(&%C8V]R9&%N8V4@=VET:"!A8V-O=6YT:6YG('!R:6YC:7!L
M97,@9V5N97)A;&QY(&%C8V5P=&5D(&EN('1H92!5;FET960@4W1A=&5S(&]F
M($%M97)I8V$@*"8C.#(R,#M5+E,N($=!05`F(S@R,C$[*2!F;W(@:6YT97)I
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M:6YI;VX@;V8@;6%N86=E;65N="P@;F5C97-S87)Y)B,Q-C`[9F]R(&$@9F%I
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M($1E8V5M8F5R(#,Q+"`R,#$S(&%N9"!N;W1E<R!T:&5R971O(&-O;G1A:6YE
M9"!I;B!T:&4@0V]M<&%N>28C.#(Q-SMS(&%N;G5A;"!R97!O<G0@;VX@1F]R
M;2`Q,"U+(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,RP@
M87,@9FEL960@=VET:"!T:&4@4T5#(&]N($9E8G)U87)Y(#(X+"`R,#$T+CPO
M9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-35I;CL@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M
M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N
M-35I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQB/E!R:6YC:7!L
M97,@;V8@0V]N<V]L:61A=&EO;B`F(S@R,3$[/"]B/B8C,38P.U1H92!C;VYS
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M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO
M9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-35I;CL@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M
M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T
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M<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
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M;6%L.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[
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M;B`F(S@R,3$[/"]B/B8C,38P.T-E<G1A:6X@<')I;W(@<&5R:6]D(&%M;W5N
M=',@:&%V92!B965N(')E8VQA<W-I9FEE9"!T;R!C;VYF;W)M('1O(&-U<G)E
M;G0@<&5R:6]D('!R97-E;G1A=&EO;BX\+V9O;G0^/"]P/CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
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M+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG
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M.#(Q,3L\+V(^)B,Q-C`[5&AE($-O;7!A;GD@8V]N<VED97)S(&%L;"!H:6=H
M;'D@;&EQ=6ED(&%C8V]U;G1S('=I=&@@;W)I9VEN86P@;6%T=7)I=&EE<R!O
M9B!T:')E92!M;VYT:',@;W(@;&5S<R!T;R!B92!C87-H(&5Q=6EV86QE;G1S
M+B!3=6-H(&)A;&%N8V5S(&%R90T*('5S=6%L;'D@:6X@97AC97-S(&]F($9$
M24,@:6YS=7)E9"!L:6UI=',N($%T(%-E<'1E;6)E<B`S,"P@,C`Q-"!A;F0@
M1&5C96UB97(@,S$L(#(P,3,L(&%L;"!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS
M(&-A<V@@=V%S(&1E<&]S:71E9"!I;B!O;F4@8F%N:RX\+V9O;G0^/"]P/CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
M<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US=')E=&-H.B!N;W)M86P[
M)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M9F]N="US=')E=&-H.B!N;W)M86P[)SX\8CY0<F]P97)T>2!A;F0@17%U:7!M
M96YT("8C.#(Q,3L\+V(^)B,Q-C`[36%C:&EN97)Y(&%N9"!E<75I<&UE;G0@
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M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,"XU-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N
M;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[
M/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
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M<V5T<R`F(S@R,3$[)B,Q-C`[/"]B/DUA;F%G96UE;G0@<F5V:65W<R!L;VYG
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
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M)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU-6EN.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R<^/&(^1&5R:79A=&EV97,@)B,X,C$Q.SPO
M8CXF(S$V,#M!;&P@9&5R:79A=&EV97,@87)E(')E8V]R9&5D(&%T(&9A:7(@
M=F%L=64@;VX@=&AE(&)A;&%N8V4@<VAE970N($9A:7(@=F%L=65S(&9O<B!S
M96-U<FET:65S('1R861E9"!I;B!T:&4@;W!E;B!M87)K970@86YD(&1E<FEV
M871I=F5S(&%R92!B87-E9"!O;B!Q=6]T960@;6%R:V5T('!R:6-E<RX@5VAE
M<F4@;6%R:V5T('!R:6-E<R!A<F4@;F]T(')E861I;'D@879A:6QA8FQE+"!F
M86ER('9A;'5E<R!A<F4@9&5T97)M:6YE9"!U<VEN9R!M87)K970@8F%S960@
M<')I8VEN9R!M;V1E;',@:6YC;W)P;W)A=&EN9R!R96%D:6QY(&]B<V5R=F%B
M;&4@;6%R:V5T(&1A=&$@86YD(')E<75I<FEN9R!J=61G;65N="!A;F0@97-T
M:6UA=&5S+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-35I;CL@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#`N-35I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQB
M/D9A:7(@5F%L=64@;V8@1FEN86YC:6%L($EN<W1R=6UE;G1S("8C.#(Q,3L\
M+V(^)B,Q-C`[1F%I<B!V86QU92!I<R!D969I;F5D(&%S('1H92!P<FEC92!T
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M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
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M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X(#!P>"`P
M<'@@,"XU-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P
M,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@9F]N="US=')E=&-H.B!N;W)M86P[)SY,979E;"`Q($EN<'5T<R`F(S@R
M,3$[(%5N861J=7-T960@<75O=&5D('!R:6-E<R!I;B!A8W1I=F4@;6%R:V5T
M<R!F;W(@:61E;G1I8V%L(&%S<V5T<R!O<B!L:6%B:6QI=&EE<R!T:&%T('1H
M92!R97!O<G1I;F<@96YT:71Y(&AA<R!T:&4@86)I;&ET>2!T;R!A8V-E<W,@
M870@=&AE(&UE87-U<F5M96YT(&1A=&4N/"]F;VYT/CPO<#X\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>"`P<'@@,'!X(#`N-35I;CL@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
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M;6%L.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>"`P<'@@,'!X(#`N-35I;CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
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M)B,Q-C`[86-T:79E(&UA<FME=',L('%U;W1E9"!P<FEC97,@9F]R(&ED96YT
M:6-A;"!O<B!S:6UI;&%R(&%S<V5T<R!O<B!L:6%B:6QI=&EE<R!I;B!M87)K
M971S('1H870@87)E(&YO="!A8W1I=F4L(&EN<'5T<R!O=&AE<B!T:&%N('%U
M;W1E9"!P<FEC97,@=&AA="!A<F4@;V)S97)V86)L92!F;W(@=&AE(&%S<V5T
M(&]R(&QI86)I;&ET>2`H<W5C:"!A<R!I;G1E<F5S="!R871E<RP@=F]L871I
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M(&UA<F=I;CH@,'!X(#!P>"`P<'@@,"XU-6EN.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M
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M(#!P>"`P<'@@,"XU-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@
M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
M<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@9F]N="US=')E=&-H.B!N;W)M86P[)SY,979E;"`S($EN<'5T
M<R`F(S@R,3$[(%5N;V)S97)V86)L92!I;G!U=',@9F]R(&1E=&5R;6EN:6YG
M('1H92!F86ER('9A;'5E<R!O9B!A<W-E=',@;W(@;&EA8FEL:71I97,@=&AA
M="!R969L96-T(&%N(&5N=&ET>2=S(&]W;B!A<W-U;7!T:6]N<R!A8F]U="!T
M:&4@87-S=6UP=&EO;G,@=&AA="!M87)K970@<&%R=&EC:7!A;G1S('=O=6QD
M('5S92!I;B!P<FEC:6YG('1H92!A<W-E=',@;W(@;&EA8FEL:71I97,N/"]F
M;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z
M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
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M:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG.B!N
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M8F5R(#,P+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q,RX@07,@<F5Q=6ER
M960@8GD@05-#(#@R,"`F(S@R,C`[/&D^1F%I<B!686QU92!-96%S=7)E;65N
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M<B!V86QU92!H:65R87)C:'D@;&5V96QS+CPO9F]N=#X\+W`^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO<#X\=&%B;&4@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@=VED=&@Z(#@P,G!X.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[
M(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
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M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CY,979E
M;"`R/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW
M:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L
M<W!A;CTS1#(^3&5V96P@,SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O
M<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE
M.B!S;VQI9#LG(&-O;'-P86X],T0R/E1O=&%L/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S
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M9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=W:61T:#H@-#`V<'@[
M('!A9&1I;F<M;&5F=#H@,"XQ,C5I;CLG/D%T(%-E<'1E;6)E<B`S,"P@,C`Q
M-#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`X<'@[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=W:61T:#H@.'!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#<R<'@[('1E>'0M86QI9VXZ
M(')I9VAT.R<^+3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`X<'@[('1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M.'!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#AP>#L@=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`W,G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@.'!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#AP>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`X<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#<R<'@[('1E>'0M86QI9VXZ(')I9VAT.R<^."PR
M,38L.3,U/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#AP>#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`X<'@[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@.'!X.R!T97AT+6%L
M:6=N.B!L969T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`W,G!X.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/C@L,C$V+#DS-3PO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`X<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO
M='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#H@,"XQ,C5I;CLG/D%T($1E8V5M8F5R(#,Q+"`R,#$S/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT
M9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXM
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C8L-S`W+#(U-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXV+#<P-RPR-34\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T
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M:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
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M97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E<BUS<&%C
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M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
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M<W1S+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-35I;CL@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O
M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#`N-35I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQB/E-H
M87)E+4)A<V5D(%!A>6UE;G1S("8C.#(Q,3L\+V(^)B,Q-C`[5&AE($-O;7!A
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M<&ET86PN/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
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M;G0M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
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M;VX@<VAA<F4@:6X@86-C;W)D86YC92!W:71H($%30R`R-C`@)B,X,C(P.T5A
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M=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@
M,'!X.R<^)B,Q-C`[/"]P/CQT86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@
M.#`R<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE+6%D:G5S=#H@
M;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O
M;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/E-E<'1E
M;6)E<B8C,38P.S,P+#QB<B`O/C(P,3,\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CY397!T96UB97(F(S$V,#LS
M,"P\8G(@+SXR,#$T/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#$N-7!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^
M/'1D('-T>6QE/3-$)W=I9'1H.B`V,3!P>#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3LG/D]P=&EO;G,\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@.'!X.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#AP>#L@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`W,G!X.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/C(L,C@P+#$X-#PO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`X<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=W:61T:#H@.'!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#AP>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`W,G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG
M/C(L.3DX+#`X-#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`X<'@[('1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#LG/E=A<G)A;G1S/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[
M#0H@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM
M<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
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M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O
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M.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B8C,38P.SPO
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M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O
M;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R
M9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z
M(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^,3`L.3,Q+#@S
M,3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,CDN-W!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US=')E=&-H
M.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^)B,Q
M-C`[/&(^)B,Q-C`[/"]B/CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-35I
M;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQB/E)E8V5N="!!8V-O
M=6YT:6YG(%!R;VYO=6YC96UE;G1S("8C.#(Q,3LF(S$V,#L\+V(^26X@36%Y
M(#(P,30L('1H92!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A
M<F0@:7-S=65D($%C8V]U;G1I;F<@4W1A;F1A<F1S(%5P9&%T92`R,#$T+3`Y
M+"!2979E;G5E(&9R;VT@0V]N=')A8W1S('=I=&@@0W5S=&]M97)S+B!!;65N
M9&UE;G1S(&EN('1H:7,@57!D871E(&-R96%T92!4;W!I8R`V,#8L(%)E=F5N
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M92!T:&4@8V]S="!G=6ED86YC92!I;B!3=6)T;W!I8R`V,#4M,S4L(%)E=F5N
M=64@4F5C;V=N:71I;VXF(S@R,3([0V]N<W1R=6-T:6]N+51Y<&4@86YD(%!R
M;V1U8W1I;VXM5'EP92!#;VYT<F%C=',L(&%N9"!C<F5A=&4@;F5W(%-U8G1O
M<&EC(#,T,"TT,"P@3W1H97(@07-S971S(&%N9"!$969E<G)E9"!#;W-T<R8C
M.#(Q,CM#;VYT<F%C=',@=VET:"!#=7-T;VUE<G,N($EN('-U;6UA<GDL('1H
M92!C;W)E('!R:6YC:7!L92!O9B!4;W!I8R`V,#8@:7,@=&AA="!A;B!E;G1I
M='D@<F5C;V=N:7IE<R!R979E;G5E('1O(&1E<&EC="!T:&4@=')A;G-F97(@
M;V8@<')O;6ES960@9V]O9',@;W(@<V5R=FEC97,@=&\@8W5S=&]M97)S(&EN
M(&%N(&%M;W5N="!T:&%T(')E9FQE8W1S('1H92!C;VYS:61E<F%T:6]N('1O
M('=H:6-H('1H92!E;G1I='D@97AP96-T<R!T;R!B92!E;G1I=&QE9"!I;B!E
M>&-H86YG92!F;W(@=&AO<V4@9V]O9',@;W(@<V5R=FEC97,N(%1H92!A;65N
M9&UE;G1S(&EN('1H:7,@57!D871E(&%R92!E9F9E8W1I=F4@9F]R('1H92!#
M;VUP86YY(&9O<B!A;FYU86P@<F5P;W)T:6YG('!E<FEO9',@8F5G:6YN:6YG
M(&%F=&5R($1E8V5M8F5R(#$U+"`R,#$V+"!I;F-L=61I;F<@:6YT97)I;2!P
M97)I;V1S('=I=&AI;B!T:&%T(')E<&]R=&EN9R!P97)I;V0N(%1H92!#;VUP
M86YY(&ES(&-U<G)E;G1L>2!E=F%L=6%T:6YG('1H92!E9F9E8W1S(&]F($%3
M52`R,#$T+3`Y(&]N('1H92!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E
M;65N=',\8CXN/"]B/CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-35I;CL@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W`^
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@
M=&5X="UI;F1E;G0Z(#`N-35I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#LG/DEN($IU;F4@,C`Q-"P@=&AE($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T
M86YD87)D<R!";V%R9"!I<W-U960@06-C;W5N=&EN9R!3=&%N9&%R9',@57!D
M871E(#(P,30M,3`L($1E=F5L;W!M96YT(%-T86=E($5N=&ET:65S+B!4:&4@
M86UE;F1M96YT<R!I;B!T:&ES(%5P9&%T92!R96UO=F4@=&AE(&1E9FEN:71I
M;VX@;V8@82!D979E;&]P;65N="!S=&%G92!E;G1I='D@9G)O;2!4;W!I8R`Y
M,34L('1H97)E8GD@<F5M;W9I;F<@=&AE(&1I<W1I;F-T:6]N(&)E='=E96X@
M9&5V96QO<&UE;G0@<W1A9V4@96YT:71I97,@86YD(&]T:&5R(')E<&]R=&EN
M9R!E;G1I=&EE<R!F<F]M(%4N4RX@1T%!4"X@26X@861D:71I;VXL('1H92!A
M;65N9&UE;G1S(&5L:6UI;F%T92!T:&4@<F5Q=6ER96UE;G1S(&9O<B!D979E
M;&]P;65N="!S=&%G92!E;G1I=&EE<R!T;R`H,2D@<')E<V5N="!I;F-E<'1I
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M8FQE(&EN=&5R97-T(&5N=&ET>2`H5DE%*2!I9B`H,2D@=&AE(&5N=&ET>2!C
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M:&4@9W5I9&%N8V4@<')O=FED960@:6X@<&%R86=R87!H<R`X,3`M,3`M,C4M
M-#4@=&AR;W5G:"`R-2TT-RP@=VAI8V@@<F5Q=6ER97,@8F]T:"!Q=6%L:71A
M=&EV92!A;F0@<75A;G1I=&%T:79E(&5V86QU871I;VYS+B!4:&4@86UE;F1M
M96YT<R!I;B!T:&ES(%5P9&%T92!A<F4@969F96-T:79E(&9O<B!A;FYU86P@
M<F5P;W)T:6YG('!E<FEO9',@8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R(#$U
M+"`R,#$T+"!A;F0@:6YT97)I;2!P97)I;V1S('1H97)E:6XL(&%N9"!E87)L
M>2!A9&]P=&EO;B!I<R!R97%U:7)E9"X@5&AE($-O;7!A;GD@979A;'5A=&5D
M(&%N9"!A9&]P=&5D($%352`R,#$T(#$P)B,Q-C`[870@2G5N92`S,"P@,C`Q
M-"X\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E<BUS<&%C
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M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.PT*(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/DEN($IU
M;F4@,C`Q-"P@=&AE($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD87)D<R!"
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M(&%F=&5R('1H92!R97%U:7-I=&4@<V5R=FEC92!P97)I;V0N)B,Q-C`[5&AE
M(&%M96YD;65N=',@:6X@=&AI<R!5<&1A=&4@87)E(&5F9F5C=&EV92!F;W(@
M86YN=6%L('!E<FEO9',@86YD(&EN=&5R:6T@<&5R:6]D<R!W:71H:6X@=&AO
M<V4@86YN=6%L('!E<FEO9',@8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R(#$U
M+"`R,#$U+"!A;F0@96%R;'D@861O<'1I;VX@:7,@<&5R;6ET=&5D+B!4:&4@
M0V]M<&%N>2!I<R!C=7)R96YT;'D@979A;'5A=&EN9R!T:&4@969F96-T<R!O
M9B!!4U4@,C`Q-"TQ,B!O;B!T:&4@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S
M=&%T96UE;G1S+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-35I;CL@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI
M=&4[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@9F]N="US=')E=&-H.B!N;W)M86P[)SY);B!!=6=U<W0@,C`Q-"P@=&AE
M($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD87)D<R!";V%R9"!I<W-U960@
M06-C;W5N=&EN9R!3=&%N9&%R9',@57!D871E(#(P,30M,34L(%!R97-E;G1A
M=&EO;B!O9B!&:6YA;F-I86P@4W1A=&5M96YT<RT@1V]I;F<@0V]N8V5R;BX@
M5&AE(%5P9&%T92!P<F]V:61E<R!5+E,N($=!05`@9W5I9&%N8V4@;VX@;6%N
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M('1H92!A;FYU86P@<&5R:6]D(&5N9&EN9R!A9G1E<B!$96-E;6)E<B`Q-2P@
M,C`Q-BP@86YD(&9O<B!A;FYU86P@<&5R:6]D<R!A;F0@:6YT97)I;2!P97)I
M;V1S('1H97)E869T97(N(%1H92!#;VUP86YY(&ES(&-U<G)E;G1L>2!E=F%L
M=6%T:6YG('1H92!E9F9E8W1S(&]F($%352`R,#$T+3$U(&]N('1H92!C;VYS
M;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',N/"]F;VYT/CPO<#X\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
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M)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
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M:61E<F%T:6]N+CPO9F]N=#X\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B.3$U9C@P-U]B,S$T7S0S.#1?86$P
M9%]A.3$Y-#AF9F1C,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y+U=O<FMS:&5E
M=',O4VAE970P-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5L871E9"!0
M87)T>2!4<F%N<V%C=&EO;G,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5L871E9"!087)T>2!4<F%N
M<V%C=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG/CQB/DYO=&4@,B`F(S@R,3$[(%)E;&%T
M960@4&%R='D@5')A;G-A8W1I;VYS/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#`[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SX\8CX\:3Y-4TM#0SH\+VD^/"]B/CPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-35I;CLG/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG
M/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SY);B`R,#$P+"!'96YE
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M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C4U:6X[)SX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN
M.R<^3VX@1F5B<G5A<GD@,3$L(#(P,#(L('1H92!#;VUP86YY(&5N=&5R960@
M:6YT;R!A($QI8V5N<V4L($1E=F5L;W!M96YT(&%N9"!#;VUM97)C:6%L:7IA
M=&EO;B!!9W)E96UE;G0@=VET:"!3;&]A;BU+971T97)I;F<@26YS=&ET=71E
M(&]F($-A;F-E<B!297-E87)C:"`H4TM)*2PF(S$V,#MA;B!E;G1I='D@<F5L
M871E9"!T;R!-4TM#0R`H)B,X,C(P.TQI8V5N<V4@06=R965M96YT)B,X,C(Q
M.RDN)B,Q-C`[)B,Q-C`[5&AE(&%G<F5E;65N="!W87,@86UE;F1E9"!I;B!!
M=6=U<W0@,C`P-BXF(S$V,#LF(S$V,#M0=7)S=6%N="!T;R!T:&4@86=R965M
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M;F4@8GD@=&AE($-O;7!A;GDN/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I
M;CLG/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU-6EN.R<^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/E1H92!#;VUP86YY(&ES(&]B;&EG871E9"!T;R!M86ME('1H92!F;VQL
M;W=I;F<@;6EL97-T;VYE('!A>6UE;G1S.CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQT
M86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M
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M9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D/B8C,38P
M.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$,CXF(S$V
M,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@.#@E.R!T97AT+6%L:6=N
M.B!L969T.R<^*#$I(&9I;&EN9R!O9B!A;B!.97<@1')U9R!!<'!L:6-A=&EO
M;B`H)B,X,C(P.TY$028C.#(R,3LI(&]R(')E9W5L871O<GD@87!P<F]V86PF
M(S$V,#MF;W(@96%C:"!L:6-E;G-E9"!P<F]D=6-T/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@<FEG:'0[)SXW-3`L,#`P/"]T
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M(&9O<B!E86-H)B,Q-C`[;&EC96YS960@<')O9'5C=#PO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$L
M-S4P+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^56YD97(@=&AE(&%G<F5E;65N="P@=&AE
M($-O;7!A;GD@<VAA;&P@<&%Y('1O($U32T-#(&]N(&$@8V]U;G1R>2UB>2UC
M;W5N=')Y(&)A<VES(&$@<F]Y86QT>2!O9B`R)2!O9B!N970@<V%L97,@;V8@
M86QL(&QI8V5N<V5D('!R;V1U8W1S('5N=&EL('1H92!L871E<B!O9CH@*#$I
M(#$P('EE87)S(&9R;VT@=&AE(&9I<G-T(&-O;6UE<F-I86P@<V%L92P@;W(@
M*#(I('=H96X@=&AE('!A=&5N=',@97AP:7)E+CPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY#97)T86EN(&%M;W5N
M=',@9'5E('5N9&5R('1H92!,:6-E;G-E($%G<F5E;65N="!W97)E(&1E9F5R
M<F5D(&%N9"!T:&5N(&9O<F=I=F5N('5N9&5R(&$@9F]R8F5A<F%N8V4M<F5L
M871E9"!A<G)A;F=E;65N="XF(S$V,#LF(S$V,#M/;B!*=6YE(#$Y+"`R,#$Q
M+"!T:&4@0V]M<&%N>2!N;VYE=&AE;&5S<R!A9W)E960@=&\@<&%Y(%-+22`H
M82D@)#4P+#`P,"!I;B`R,#$Q+"`H8BD@)#(P,"PP,#`@:6X@,C`Q,B!A;F0@
M*&,I("0R-3`L,#`P(&EN(#(P,3,@=6YD97(@=&AI<R!A9W)E96UE;G0L(&EN
M(')E<W!E8W0@;V8@=&AE("0U,"PP,#`@86YN=6%L(&UA:6YT96YA;F-E(&9E
M97,@86YD(')E<V5A<F-H('!A>6UE;G1S+B8C,38P.SPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-35I;CLG/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C4U:6X[)SY/;B!397!T96UB97(@-"P@,C`Q,RP@=&AE($-O;7!A;GD@96YT
M97)E9"!I;G1O(&$@;&5T=&5R(&%G<F5E;65N="!W:71H(%-+22!T;R!S970@
M9F]R=&@@=&AE(&%M;W5N="!T:&%T('1H92!#;VUP86YY(&]W97,@4TM)(&9O
M<B!T:&4@<&5R:6]D(&9R;VT@,C`Q,2!T;R`R,#$T('5N9&5R('1H92!,:6-E
M;G-E($%G<F5E;65N="XF(S$V,#LF(S$V,#M4:&4@=&]T86P@86UO=6YT('1H
M870@=&AE($-O;7!A;GD@;W=E<R!32TD@9F]R('1H92!P97)I;V0@9G)O;2`R
M,#$Q('1O(#(P,30@:7,@)#@Q-2PQ,#`@<&QU<R!A;&P@<F5L979A;G0@;&EC
M96YS960@:6YT96QL96-T=6%L('!R;W!E<G1Y(')E;&%T960@<&%S<R!T:')O
M=6=H(&-O<W1S('1O(&)E(&1E=&5R;6EN960N)B,Q-C`[)B,Q-C`[5&AE(&%M
M;W5N="!O=V5D(&1O97,@;F]T(&EN8VQU9&4@86UO=6YT<R!T:&4@0V]M<&%N
M>2!M87D@;W=E(&9O<B!P871E;G0@97AP96YS97,@=6YD97(@=&AE#0H@3&EC
M96YS92!!9W)E96UE;G0N)B,Q-C`[)B,Q-C`[1'5R:6YG(#(P,30L('1H92!A
M;FYU86P@;6%I;G1E;F%N8V4@9F5E(&ES("0Q.#DL,#`P('!L=7,@<&%S<R!T
M:')O=6=H(&-O<W1S+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU-6EN.R<^3VX@36%R8V@@,C<L(#(P,3(L('1H92!#
M;VUP86YY(&5N=&5R960@:6YT;R!A;B!A9&1I=&EO;F%L(&-L:6YI8V%L('1R
M:6%L(&%G<F5E;65N="!W:71H($U32T-#($-A;F-E<B!#96YT97(@=VET:"!R
M97-P96-T('1O(&-O;F1U8W1I;F<@82!0:&%S92`Q+S(@=')I86P@;V8@8V]M
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M92!#;VUP86YY('!A:60@82!S=&%R="UU<"!F964@;V8@)#<Y+#8R,R!I;B`R
M,#$R+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^1F]R('1H92!T:')E
M92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$T(&%N9"`R,#$S+"!T
M:&4@0V]M<&%N>2!I;F-U<G)E9"!A<'!R;WAI;6%T96QY("0R-BPP,#`@86YD
M("0P+"!R97-P96-T:79E;'DL(&9O<B!M86EN=&5N86YC92!F965S(&%N9"!R
M97-E87)C:"!C;VYD=6-T960@8GD@35-+0T,@1F]R('1H92!N:6YE(&UO;G1H
M<R!E;F1E9"!397!T96UB97(@,S`L(#(P,30@86YD(#(P,3,L('1H92!#;VUP
M86YY(&EN8W5R<F5D("0Q.3<L,3`V(&%N9"`D,C$X+#8P-"P@<F5S<&5C=&EV
M96QY+"!F;W(@;6%I;G1E;F%N8V4@9F5E<R!A;F0@<F5S96%R8V@@8V]N9'5C
M=&5D(&)Y($U32T-#+B8C,38P.R8C,38P.T%S(&]F(%-E<'1E;6)E<B`S,"P@
M,C`Q-"!A;F0@1&5C96UB97(@,S$L(#(P,3,L('1H92!#;VUP86YY(&AA<R!A
M('!A>6%B;&4@=&\@35-+0T,@8V]V97)I;F<@=&AE(&%N;G5A;"!M86EN=&5N
M86YC92!C;W-T<RP@8VQI;FEC86P@=')I86QS(&5X<&5N<V4@86YD('!A=&5N
M="!C;W-T<R!T;W1A;&EN9R`D,C<X+#(Y,2!A;F0@)#@Q+#$X-2P@<F5S<&5C
M=&EV96QY+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/CQI/E!L86-E;65N="!!
M9V5N=#H\+VD^/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#`[
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SY/;B!!=6=U<W0@-RP@,C`Q,BP@=&AE($-O
M;7!A;GD@96YT97)E9"!I;G1O(&%N(&5N9V%G96UE;G0@86=R965M96YT('=I
M=&@@82!(96%L=&AC87)E($EN=F5S=&UE;G0@0F%N:R!A<R!I=',@<&QA8V5M
M96YT(&%G96YT(&9O<B!T:&4@,C`Q,B!#;VUM;VX@4W1O8VL@3V9F97)I;F<@
M=VAE<F5B>2!A(&1I<F5C=&]R(&]F('1H92!#;VUP86YY+"!I<R!T:&4@2&5A
M9"!O9B!I=',@2&5A;'1H8V%R92!);G9E<W1M96YT($)A;FMI;F<@=&5A;2XF
M(S$V,#LF(S$V,#LF(S$V,#M0=7)S=6%N="!T;R!T:&4@86=R965M96YT+"!T
M:&4@<&QA8V5M96YT(&%G96YT('=A<R!E;F=A9V5D(&%S('1H92!E>&-L=7-I
M=F4@86=E;G0@9F]R('1H92`R,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN9RX@
M)B,Q-C`[)B,Q-C`[26X@8V]N<VED97)A=&EO;B!F;W(@:71S('-E<G9I8V5S
M+"!T:&4@<&QA8V5M96YT(&%G96YT(')E8V5I=F5D("AA*2!A(&-A<V@@9F5E
M(&5Q=6%L('1O(#$P)2!O9B!T:&4@9W)O<W,@<')O8V5E9',@<F%I<V5D(&EN
M('1H92`R,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN9RP@*&(I(&$@;F]N+6%C
M8V]U;G1A8FQE(&5X<&5N<V4@<F5I;6)U<G-E;65N="!E<75A;"!T;R`R)2!O
M9B!T:&4@9W)O<W,@<')O8V5E9',@<F%I<V5D(&EN('1H92`R,#$R($-O;6UO
M;B!3=&]C:R!/9F9E<FEN9RP@86YD("AC*2!R96EM8G5R<V5M96YT(&]F("0Q
M,#`L,#`P(&9O<B!L96=A;"!E>'!E;G-E<R!I;F-U<G)E9"!B>2!T:&4@<&QA
M8V5M96YT(&%G96YT+B8C,38P.R8C,38P.U1H92!P;&%C96UE;G0@86=E;G0@
M;W(@:71S(&1E<VEG;F5E<R!A;'-O(')E8V5I=F5D('=A<G)A;G1S('1O('!U
M<F-H87-E('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS($-O;6UO;B!3
M=&]C:R!I;B!A;B!A;6]U;G0@97%U86P@=&\@,3`E(&]F('1H92!S:&%R97,@
M;V8@8V]M;6]N('-T;V-K(&ES<W5E9"!A<R!P87)T(&]F('1H92!U;FET<R!S
M;VQD(&EN('1H92`R,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN9R!A;F0@=&AE
M('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@:7-S=6%B;&4@=7!O;B!E>&5R8VES
M92!O9B!T:&4@0B!W87)R86YT<R!I;F-L=61E9"!I;B!S=6-H('5N:71S+B8C
M,38P.R8C,38P.U1H92!P;&%C96UE;G0@86=E;G0@86QS;R!R96-E:79E9"!T
M:&4@<V%M92!F964@86YD(&5X<&5N<V4@<V-H961U;&4@9F]R(&%N>2!C87-H
M(&5X97)C:7-E(&]F('=A<G)A;G1S('=I=&AI;B`V(&UO;G1H<R!O9B!T:&4@
M9FEN86P@8VQO<VEN9R!O9B!T:&4@,C`Q,B!#;VUM;VX@4W1O8VL@3V9F97)I
M;F<@86YD(&$@-24@<V]L:6-I=&%T:6]N(&9E92!F;W(@86YY('=A<G)A;G1S
M(&5X97)C:7-E9"!A<R!A(')E<W5L="!O9B!B96EN9R!C86QL960@9F]R(')E
M9&5M<'1I;VX@8GD@=&AE($-O;7!A;GDN)B,Q-C`[)B,Q-C`[57!O;B!T:&4@
M9FEN86P@8VQO<VEN9R!O9B!T:&4@,C`Q,B!#;VUM;VX@4W1O8VL@3V9F97)I
M;F<@;V8@=&AE('5N:71S+"!T:&4@<&QA8V5M96YT(&%G96YT('=A<R!E;F=A
M9V5D(&)Y('1H92!#;VUP86YY('1O('!R;W9I9&4@8V5R=&%I;B!F:6YA;F-I
M86P@861V:7-O<GD@<V5R=FEC97,@=&\@=&AE($-O;7!A;GD@9F]R(&$@<&5R
M:6]D(&]F(&%T(&QE87-T(#8@;6]N=&AS(&9O<B!A(&UO;G1H;'D@9F5E(&]F
M("0R-2PP,#`N)B,Q-C`[)B,Q-C`[5&AE(&%G<F5E;65N="!A;'-O('!R;W9I
M9&5S('1H870@*&DI(&EF('1H92!#;VUP86YY(&-O;G-U;6UA=&5S(&%N>2!M
M97)G97(L(&%C<75I<VET:6]N+"!B=7-I;F5S<R!C;VUB:6YA=&EO;B!O<B!O
M=&AE<B!T<F%N<V%C=&EO;B`H;W1H97(@=&AA;B!T:&4@4VAA<F4@17AC:&%N
M9V4I('=I=&@@86YY('!A<G1Y(&EN=')O9'5C960@=&\@:70@8GD@=&AE('!L
M86-E;65N="!A9V5N="P@=&AE('!L86-E;65N="!A9V5N="!W;W5L9"!R96-E
M:79E(&$@9F5E(&5Q=6%L('1O(#$P)2!O9B!T:&4@86=G<F5G871E(&-O;G-I
M9&5R871I;VX@:6X@<W5C:"!T<F%N<V%C=&EO;G,L(&%N9"`H:6DI(&EF+"!W
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M964@<V-H961U;&4@<V5T(&9O<G1H(&EN('1H92!!=6=U<W0@-RP@,C`Q,B!E
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M;F<@86YD($-O;G9E<G1I8FQE($YO=&5S(&9I;F%N8VEN9R!I;B`R,#$Q(&%N
M9"P@87,@82!P87)T(&]F('1H92!F964@9F]R('1H870@96YG86=E;65N="P@
M9&5S:6=N965S(&]F('1H92!P;&%C96UE;G0@86=E;G0@86QS;R!H;VQD('=A
M<G)A;G1S('1O('!U<F-H87-E(#$L,C4Q+#`Q-2!S:&%R97,@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!#;VUM;VX@4W1O8VLN/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-35I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-35I;CLG/D]N($1E8V5M8F5R(#DL(#(P,3,L('1H
M92!#;VUP86YY(&5N=&5R960@:6YT;R!A;F]T:&5R(&5N9V%G96UE;G0@86=R
M965M96YT('=I=&@@:71S('!L86-E;65N="!A9V5N="!F;W(@=&AE(#(P,3,@
M0V]M;6]N(%-T;V-K($]F9F5R:6YG+"`H)B,X,C(P.W1H92!/9F9E<FEN9R8C
M.#(R,3LI+B!4:&4@3V9F97)I;F<@=V%S(&-O;7!L971E9"!I;B!T=V\@=')A
M;F-H97,L($1E8V5M8F5R(#DL(#(P,3,@86YD($IA;G5A<GD@,3`L(#(P,30N
M(%1H92!A9W)E96UE;G0@96YT97)E9"!I;B!O;B!$96-E;6)E<B`Y+"`R,#$S
M(&AA9"!S:6UI;&%R('1E<FUS(&%S('1H92`R,#$R(&%G<F5E;65N="P@:6YC
M;'5D:6YG(&$@8V%S:"!F964@97%U86P@=&\@,3`E(&]F('1H92!G<F]S<R!P
M<F]C965D<R!R86ES960L(&$@;F]N+6%C8V]U;G1A8FQE(&5X<&5N<V4@<F5I
M;6)U<G-E;65N="!E<75A;"!T;R`R)2!O9B!T:&4@9W)O<W,@<')O8V5E9',@
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M;G1H;'D@9F5E(&]F("0R-2PP,#`N)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6X[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-35I;CLG/D]N($1E8V5M8F5R(#(W+"`R,#$S+"8C,38P.W1H92!#;VUP
M86YY(&-O;7!L971E9"!T:&4@9FER<W0@<V%L92!O9@T*('1H92!/9F9E<FEN
M9R!P=7)S=6%N="!T;R!A(%5N:70@4'5R8VAA<V4@06=R965M96YT+"!W:71H
M(&-E<G1A:6X@86-C<F5D:71E9"!I;G9E<W1O<G,@*'1H92`F(S@R,C`[26YV
M97-T;W)S)B,X,C(Q.RDF(S$V,#MP=7)S=6%N="!T;R!W:&EC:"!T:&4@26YV
M97-T;W)S(&%G<F5E9"!T;R!P=7)C:&%S92`H:2D@86X@86=G<F5G871E(&]F
M(#4U-"PS,3`@<VAA<F5S("AT:&4@)B,X,C(P.U-H87)E<R8C.#(R,3LI(&]F
M(&-O;6UO;B!S=&]C:R!A="`D-BXP,"!P97(@<VAA<F4@86YD("AI:2D@9FEV
M92UY96%R('=A<G)A;G1S('1O('!U<F-H87-E(&%N(&%G9W)E9V%T92!O9B`Q
M,S@L-3<W('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@870@86X@97AE<F-I<V4@
M<')I8V4@;V8@)#DN,#`@<&5R('-H87)E+B!4:&4@0V]M<&%N>2!R96-E:79E
M9"`D,RPS,C4L.#8P)B,Q-C`[:6X@9W)O<W,@<')O8V5E9',@9G)O;2!T:&4@
M<V%L92!O9B!S96-U<FET:65S+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN
M.R<^3VX@2F%N=6%R>2`Q,"P@,C`Q-"PF(S$V,#L@=&AE($-O;7!A;GD@8V]N
M9'5C=&5D('1H92!F:6YA;"!C;&]S:6YG("AT:&4@)B,X,C(P.T9I;F%L($-L
M;W-I;F<F(S@R,C$[*2!O9B!T:&4@3V9F97)I;F<@<'5R<W5A;G0@=&\@82!5
M;FET(%!U<F-H87-E($%G<F5E;65N="P@9&%T960@87,@;V8@2F%N=6%R>2`Q
M,"P@,C`Q-"`H=&AE("8C.#(R,#M0=7)C:&%S92!!9W)E96UE;G0F(S@R,C$[
M*2!A;F0@4W5B<V-R:7!T:6]N($%G<F5E;65N="P@9&%T960@87,@;V8@2F%N
M=6%R>2`Q,"P@,C`Q-"`H=&AE("8C.#(R,#M3=6)S8W)I<'1I;VX@06=R965M
M96YT)B,X,C(Q.RDL('=I=&@@8V5R=&%I;B!A8V-R961I=&5D(&EN=F5S=&]R
M<R`H=&AE("8C.#(R,#M);G9E<W1O<G,F(S@R,C$[*28C,38P.R8C,38P.W!U
M<G-U86YT('1O('=H:6-H('1H92!);G9E<W1O<G,@870@=&AE($9I;F%L($-L
M;W-I;F<@86=R965D('1O('!U<F-H87-E("AI*2!A;B!A9V=R96=A=&4@;V8@
M-34Q+#@Q,"!S:&%R97,@*"!T:&4@)B,X,C(P.U-H87)E<R8C.#(R,3LI(&]F
M(&-O;6UO;B!S=&]C:R!A="`D-BXP,"!P97(@<VAA<F4@86YD("AI:2D@9FEV
M92UY96%R('=A<G)A;G1S('1O('!U<F-H87-E(&%N(&%G9W)E9V%T92!O9B`Q
M,S<L.34R('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@870@86X@97AE<F-I<V4@
M<')I8V4@;V8@)#DN,#`@<&5R('-H87)E+B!4:&4@0V]M<&%N>2!R96-E:79E
M9"`D,RPS,3`L.#8P)B,Q-C`[:6X@9W)O<W,@<')O8V5E9',@9G)O;2!T:&4@
M<V%L92!O9B!S96-U<FET:65S('5N9&5R('1H92!0=7)C:&%S92!!9W)E96UE
M;G0@870@=&AE($9I;F%L($-L;W-I;F<L(&)R:6YG:6YG('1H92!T;W1A;"!G
M<F]S<R!P<F]C965D<R!R96-E:79E9"!B>2!T:&4@0V]M<&%N>2!I;B!T:&4@
M3V9F97)I;F<@=&\@)#8L-C,V+#<R,"X@)B,Q-C`[5&AE(&%G9W)E9V%T92!O
M9F9E<FEN9R!A;6]U;G0@;V8@<V5C=7)I=&EE<R!S;VQD('1O(&EN=F5S=&]R
M<R!W87,@:6YC<F5A<V5D(&9R;VT@)#8L,#`P+#`P,"!T;R`D-BPV,S8L-S(P
M(&EN(&]R9&5R('1O(&-O=F5R(&]V97(M86QL;W1M96YT<RX\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY$=7)I;F<@=&AE(&YI
M;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q-"P@=&AE('!L86-E
M;65N="!A9V5N="!R96-E:79E9"!A(&-A<V@@9F5E(&]F(&%P<')O>&EM871E
M;'D@)#`N-"!M:6QL:6]N(&9R;VT@=&AE('-A;&4@;V8@<V5C=7)I=&EE<R!A
M;F0@=V%S(&ES<W5E9"!W87)R86YT<R!T;R!P=7)C:&%S92`V."PY-S8@<VAA
M<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@0V]M;6]N(%-T;V-K(&%T("0Y
M+C`P('!E<B!S:&%R92!F;W(@82!P97)I;V0@;V8@-2!Y96%R<RX\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^3VX@
M36%Y(#(X+"`R,#$T+"!T:&4@0V]M<&%N>2!A;F0@=&AE('!L86-E;65N="!A
M9V5N="!A9W)E960@=&\@=&5R;6EN871E('1H92!$96-E;6)E<B`Y+"`R,#$S
M(&5N9V%G96UE;G0@86=R965M96YT+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C4U:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^
M3VX@2G5L>2`Q,"P@,C`Q-"!T:&4@0V]M<&%N>2!C;VUP;&5T960@82!P=6)L
M:6,@;V9F97)I;F<@=&AA="!T;W1A;&5D(#$L.#(W+#$R,R!C;VUM;VX@<VAA
M<F5S+"!R97!R97-E;G1I;F<@9W)O<W,@<')O8V5E9',@;V8@87!P<F]X:6UA
M=&5L>2`D,3,N-R!M:6QL:6]N(&%N9"!A(&YE="!A;6]U;G0@;V8@87!P<F]X
M:6UA=&5L>2`D,3(N-B!M:6QL:6]N(&%F=&5R(&1E9'5C=&EN9R!T:&4@=6YD
M97)W<FET:6YG(&1I<V-O=6YT(&%N9"!T:&4@;W1H97(@;V9F97)I;F<@97AP
M96YS97,N(%1H92!0;&%C96UE;G0@06=E;G0@86-T960@87,@<V]L92!B;V]K
M+7)U;FYI;F<@;6%N86=E<B!F;W(@=&AE(&]F9F5R:6YG+"!T:&4@4&QA8V5M
M96YT($%G96YT(&%C=&5D(&%S(&QE860@;6%N86=E<B!A;F0@34Q6("9A;7`[
M($-O+B!A8W1E9"!A<R!C;RUM86YA9V5R+B!4:&4@;V9F97)I;F<@=V%S(&UA
M9&4@<'5R<W5A;G0@=&\@82!S:&5L9B!R96=I<W1R871I;VX@<W1A=&5M96YT
M('!R979I;W5S;'D@9FEL960@=VET:"!A;F0@9&5C;&%R960@969F96-T:79E
M(&)Y('1H92!5+E,N(%-E8W5R:71I97,@86YD($5X8VAA;F=E($-O;6UI<W-I
M;VXN/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(Y,35F.#`W7V(S,31?-#,X-%]A
M83!D7V$Y,3DT.&9F9&,P.2]7;W)K<VAE971S+U-H965T,#@N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0<F]P97)T>2!A;F0@
M17%U:7!M96YT/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N="!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]P97)T>2!A;F0@17%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#LG/CQB/DYO=&4@,R`F(S@R,3$[(%!R;W!E<G1Y(&%N9"!%<75I
M<&UE;G0\+V(^/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
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M)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
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M;VYS:7-T960@;V8@=&AE(&9O;&QO=VEN9R!A="!397!T96UB97(@,S`L(#(P
M,30@86YD($1E8V5M8F5R(#,Q+"`R,#$S.CPO9F]N=#X\+W`^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO<#X\=&%B;&4@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
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M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C
M;VQS<&%N/3-$,CY,:79E<SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
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M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O
M='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CXR,#$S/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\
M+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=W:61T:#H@,3`P
M,W!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#)P
M>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I
M9VAT.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,35P>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$T,7!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY/9F9I8V4@97%U:7!M96YT/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
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M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ-2PT.#`\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
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M;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T
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M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/BD\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU
M<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXH,2PU-C`\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,2XU<'0[
M)SXI/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[)SY0<F]P
M97)T>2!A;F0@97%U:7!M96YT+"!N970\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P861D:6YG+6)O
M='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M
M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B
M;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M(&1O=6)L93LG/C$T,2PP,3$\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB
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M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
M+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO9F]N
M=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#`N-35I;CL@;&5T=&5R+7-P86-I;F<Z(&YO
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M92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$T(&%N9"`R,#$S('=A
M<R`D,30L,S(V(&%N9"`D,"P@<F5S<&5C=&EV96QY+B!$97!R96-I871I;VX@
M97AP96YS92!F;W(@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S
M,"P@,C`Q-"!A;F0@,C`Q,R!W87,@)#(S+#<X,R!A;F0@)#`L(')E<W!E8W1I
M=F5L>2X@5&AE($-O;7!A;GD@=W)O=&4@;V9F(&-E<G1A:6X@=6YD97!R96-I
M871E9"!P<F]P97)T>2!A;F0@97%U:7!M96YT(&1U<FEN9R!T:&4@;FEN92!M
M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"!R96-O<F1E9"!A
M(&QO<W,@;V8@)#0L,3(R(&]N('1H92!D:7-P;W-I=&EO;BX\+V9O;G0^/"]P
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8CDQ
M-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V(Y,35F.#`W7V(S,31?-#,X-%]A83!D7V$Y
M,3DT.&9F9&,P.2]7;W)K<VAE971S+U-H965T,#DN:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(%!A>6%B;&4\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;W1E
M(%!A>6%B;&4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F]T92!087EA8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/CQB/DYO=&4@-"`F(S@R,3$[($YO=&4@4&%Y
M86)L93PO8CX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#`N-35I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/D]N
M($1E8V5M8F5R(#(X+"`R,#$S+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@
M82!P<F5M:75M(&9I;F%N8V4@86=R965M96YT('1O('!A>2!A('!R96UI=6T@
M;V8@)#$U-RPX,C4@9F]R(&ET<R!D:7)E8W1O<B!A;F0@;V9F:6-E<B!L:6%B
M:6QI='D@:6YS=7)A;F-E('!O;&EC>2X@4'5R<W5A;G0@=&\@=&AE(&%G<F5E
M;65N="P@=&AE($-O;7!A;GD@<&%I9"!A(&1O=VX@<&%Y;65N="!O9B`D,34L
M.3DU(&EN($IA;G5A<GD@,C`Q-"!A;F0F(S$V,#MW87,@<F5Q=6ER960F(S$V
M,#MT;R!P87D@)#$U+#DY-2!I;B!M;VYT:&QY(&EN<W1A;&QM96YT(&9O<B!N
M:6YE(&UO;G1H<RX@1'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T
M96UB97(@,S`L(#(P,30L('1H92!#;VUP86YY('!A:60@)#$U-RPX,C4N($%S
M(&]F(%-E<'1E;6)E<B`S,"P@,C`Q-"!A;F0@1&5C96UB97(@,S$L(#(P,3,L
M('1H92!O=71S=&%N9&EN9R!B86QA;F-E(')E;&%T960@=&\@=&AE('!R96UI
M=6T@9FEN86YC92!A9W)E96UE;G0@=V%S("0P(&%N9"`D,34W+#@R-2P@<F5S
M<&5C=&EV96QY+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%]B.3$U9C@P-U]B,S$T7S0S.#1?86$P9%]A.3$Y
M-#AF9F1C,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8CDQ-68X
M,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y+U=O<FMS:&5E=',O4VAE
M970Q,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D1E<FEV871I=F5S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1&5R:79A=&EV97,@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M
M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&(^3F]T92`U
M("8C.#(Q,3L@1&5R:79A=&EV97,\+V(^/"]F;VYT/CPO<#X\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\
M+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG
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M9&5R($9!4T(@05-#(%1O<&EC($YO+B`X,34@)B,X,C$Q.R`T,"X@5&AE('=A
M<G)A;G1S(&=R86YT960@:6X@8V]N;F5C=&EO;B!W:71H('1H92!I<W-U86YC
M92!O9B!T:&4@,C`Q,B!#;VUM;VX@4W1O8VL@3V9F97)I;F<L(&%N9"!T:&4@
M<&QA8V5M96YT(&%G96YT('=A<G)A;G1S(&-O;G1A:6X@86YT:2UD:6QU=&EO
M;B!P<F]V:7-I;VYS('1H870@<')O=FED92!F;W(@82!R961U8W1I;VX@:6X@
M=&AE(&5X97)C:7-E('!R:6-E(&]F('-U8V@@=V%R<F%N=',@:6X@=&AE(&5V
M96YT('1H870@9G5T=7)E(&-O;6UO;B!S=&]C:R`H;W(@<V5C=7)I=&EE<R!C
M;VYV97)T:6)L92!I;G1O(&]R(&5X97)C:7-A8FQE(&9O<B!C;VUM;VX@<W1O
M8VLI(&ES(&ES<W5E9"`H;W(@8F5C;VUE<R!C;VYT<F%C='5A;&QY(&ES<W5A
M8FQE*2!A="!A('!R:6-E('!E<B!S:&%R92`H82`F(S@R,C`[3&]W97(@4')I
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M8V]M;6]N('-T;V-K(&ES<W5E9"`H;W(@9&5E;65D(&ES<W5E9"D@870@=&AE
M($QO=V5R(%!R:6-E(&%N9"!T:&4@97AT96YT('1O('=H:6-H('1H92!,;W=E
M<B!0<FEC92!I<R!L97-S('1H86X@=&AE(&5X97)C:7-E('!R:6-E(&]F('1H
M92!W87)R86YT(&%T('1H92!T:6UE+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R
M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z
M(#(Y+C=P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO
M9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R
M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z
M(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M
M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[06-T
M:79I=&EE<R!F;W(@9&5R:79A=&EV92!W87)R86YT(&EN<W1R=6UE;G1S(&1U
M<FEN9R!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$T
M('=E<F4@87,@9F]L;&]W<SH\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W`^/'1A8FQE('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[('=I9'1H.B`Q-#(R+C<R<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N
M="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
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M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CY&86ER(%9A;'5E
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9#XF(S$V,#L\+W1D
M/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG
M/CQT9"!S='EL93TS1"=W:61T:#H@,3`X,2XX,7!X.R<^0F%L86YC92P@1&5C
M96UB97(@,S$L(#(P,3,\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30N-31P
M>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-"XU-'!X.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$R."XQ.'!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$L.38X+#8R,SPO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-"XU-'!X.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T+C4T<'@[
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M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY4<F%N<V9E<B!F
M<F]M(&QI86)I;&ET>2!C;&%S<VEF:6-A=&EO;B!T;R!E<75I='D@8VQA<W-I
M9FEC871I;VX\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXH,S`V+#DP,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXI/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T
M<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@,2XU<'0[)SY#:&%N9V4@:6X@9F%I
M<B!V86QU93PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R
M+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N
M-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/BT\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H-"B`Q
M+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/C,L-C4S
M+#0W,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M;W1T;VTZ(#1P=#LG/D)A;&%N8V4L(%-E<'1E;6)E<B`S,"P@,C`Q-#PO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D
M97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@
M8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@9&]U8FQE.R<^,2PV-C$L-S(S/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T
M.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXD/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T
M;VTM<W1Y;&4Z(&1O=6)L93LG/C@L,C$V+#DS-3PO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V
M,#L\+W1D/CPO='(^/"]T86)L93X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
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M,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E
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M(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q-"P@,BPQ,3<L,S`T('=A<G)A;G1S
M('=E<F4@97AE<F-I<V5D+"!O9B!W:&EC:"`S,#8L.3`P('=E<F4@9&5R:79A
M=&EV92!W87)R86YT<RX@5&AE(&9A:7(@=F%L=64@;V8@=&AE<V4@=V%R<F%N
M=',@=&]T86QI;F<@)#(L,30S+#<Y,R!W97)E(&UE87-U<F5D(&]N('1H92!V
M87)I;W5S(&5X97)C:7-E(&1A=&5S(&%N9"!R96-L87-S:69I960@=&\@861D
M:71I;VYA;"!P86ED+6EN(&-A<&ET86PN/"]F;VYT/CPO<#X\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,CDN-W!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N
M;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[
M/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
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M87-S=6UP=&EO;G,@870@96%C:"!B86QA;F-E('-H965T(&1A=&4N)B,Q-C`[
M/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
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M>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M
M<W!A8VEN9SH@,'!X.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT
M+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,#X\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CY397!T
M96UB97(F(S$V,#LS,"P\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N
M/3-$,CY$96-E;6)E<B8C,38P.S,Q+#PO=&0^/'1D/B8C,38P.SPO=&0^/"]T
M<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQT9#XF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS
M<&%N/3-$,CXR,#$T/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R
M+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O
M;&ED.R<@8V]L<W!A;CTS1#(^,C`Q,SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO
M='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\=&0@<W1Y;&4],T0G=VED=&@Z(#$P
M.#$N.#%P>#L@=&5X="UA;&EG;CH@;&5F=#LG/DUA<FME="!V86QU92!O9B!C
M;VUM;VX@<W1O8VL@;VX@;65A<W5R96UE;G0@9&%T92`H,2D\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,30N-31P>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-"XU-'!X.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q,C@N,3AP>#L@=&5X="UA;&EG;CH@<FEG
M:'0[)SXV+C<P/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T+C4T<'@[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,30N-31P>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M,RXV,W!X.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q,C<N,C=P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXU+C@Y/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$S+C8S<'@[('1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D/D%D
M:G5S=&5D(&5X97)C:7-E('!R:6-E/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/C(N-#@\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C(N-#@\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY2
M:7-K(&9R964@:6YT97)E<W0@<F%T92`H,BD\+W1D/CQT9#XF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ+C`W/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B4\+W1D/CQT9#XF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ+C(W/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B4\+W1D/CPO='(^/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SY787)R86YT(&QI=F5S(&EN('EE87)S/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
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M=F]L871I;&ET>2`H,RD\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXW-#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXE/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y
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M8FEL:71Y(&]F('-T;V-K(&]F9F5R:6YG(&EN(&%N>2!P97)I;V0@;W9E<B`U
M('EE87)S("@U*3PO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/C(U/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B4\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
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M.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^,S4\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)3PO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9#Y/
M9F9E<FEN9R!P<FEC92!R86YG92`H-RD\+W1D/CQT9#XF(S$V,#L\+W1D/CQT
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M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
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M)SXF(S$V,#L\+V9O;G0^/"]P/CQT86)L92!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T
M:#H@,30R,BXW,G!X.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG
M.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ92UA
M9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/CQT<B!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!V97)T:6-A;"UA;&EG;CH@
M=&]P.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQT9"!S='EL93TS1"=W:61T
M:#H@-#(N-S)P>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('!A
M9&1I;F<Z(#!P>#L@=VED=&@Z(#0R+C<R<'@[('1E>'0M:6YD96YT.B`P<'@[
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M=&AE($]40R!-87)K971S(&9O<B!$96-E;6)E<B`S,2P@,C`Q,R!A;F0@;VX@
M=&AE($Y94T4@34M4(&9O<B!397!T96UB97(@,S`L(#(P,30N/"]F;VYT/CPO
M=&0^/"]T<CX\+W1A8FQE/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.R8C,38P.SPO9F]N=#X\+W`^/'1A
M8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q-#(R+C<R<'@[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E
M.B!C;VQL87!S93L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E
M=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`T,BXW,G!X.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@<&%D9&EN9SH@,'!X.R!W:61T:#H@-#(N
M-S)P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US=')E=&-H.B!N;W)M86P[
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG
M/B@R*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG.B`P
M<'@[('=I9'1H.B`Q,S,W+C(W<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@
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M93X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
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M86P[)SXF(S$V,#L\+V9O;G0^/"]P/CQT86)L92!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W
M:61T:#H@,30R,BXW,G!X.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ
M92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
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M=#X\+W1D/CPO='(^/"]T86)L93X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
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M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!W:61T:#H@,30R,BXW,G!X.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[
M(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!V97)T
M:6-A;"UA;&EG;CH@=&]P.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQT9"!S
M='EL93TS1"=P861D:6YG.B`P<'@[('=I9'1H.B`T,BXW,G!X.R!T97AT+6EN
M9&5N=#H@,'!X.R<^/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@<&%D9&EN9SH@
M,'!X.R!W:61T:#H@-#(N-S)P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B@T*3PO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG.B`P<'@[('=I9'1H.B`Q
M,S,W+C(W<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@9F]N="US=')E=&-H.B!N;W)M86P[)SY-86YA9V5M96YT(&1E=&5R;6EN
M960@=&AE(&1I=FED96YD('EI96QD('1O(&)E(#`E(&)A<V5D('5P;VX@:71S
M(&5X<&5C=&%T:6]N('1H870@:70@=VEL;"!N;W0@<&%Y(&1I=FED96YD<R!F
M;W(@=&AE(&9O<F5S965A8FQE(&9U='5R92X\+V9O;G0^/"]T9#X\+W1R/CQT
M<B!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#LG/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E
M>'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@
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M:6YD96YT.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y
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M+6EN9&5N=#H@,'!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H@
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M:6=N.B!T;W`[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/'1D('-T>6QE/3-$
M)W!A9&1I;F<Z(#!P>#L@=VED=&@Z(#0R+C<R<'@[('1E>'0M:6YD96YT.B`P
M<'@[)SX\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG.B`P<'@[('=I
M9'1H.B`T,BXW,G!X.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@
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M="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/DUA;F%G96UE;G0@97-T:6UA=&5S('1H870@
M=&AE(')A;F=E(&]F('!E<F-E;G1A9V5S(&]F(&5X:7-T:6YG('-H87)E<R!O
M9F9E<F5D(&EN(&5A8V@@<W1O8VL@;V9F97)I;F<@=VEL;"!B92`P)2!A;F0@
M,S4E(&]F('1H92!S:&%R97,@;W5T<W1A;F1I;F<@870@4V5P=&5M8F5R(#,P
M+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q,RP@<F5S<&5C=&EV96QY+CPO
M9F]N=#X\+W1D/CPO='(^/'1R('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('9E<G1I8V%L+6%L
M:6=N.B!T;W`[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/'1D('-T>6QE/3-$
M)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[('!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@
M;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG.B`P<'@[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#LG/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('=I9'1H.B`T,BXW
M,G!X.R!T97AT+6EN9&5N=#H@,'!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@<&%D9&EN9SH@,'!X.R!W:61T:#H@-#(N-S)P>#L@=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US=')E=&-H.B!N
M;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#LG/B@W*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D
M:6YG.B`P<'@[('=I9'1H.B`Q,S,W+C(W<'@[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^
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M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8CDQ-68X,#=?8C,Q-%\T,S@T7V%A
M,&1?83DQ.30X9F9D8S`Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V(Y,35F.#`W7V(S,31?-#,X-%]A83!D7V$Y,3DT.&9F9&,P.2]7;W)K<VAE
M971S+U-H965T,3$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI
M=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI=&UE;G1S
M(&%N9"!#;VYT:6YG96YC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M
M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C
M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&(^3F]T92`V("8C.#(Q,3L@0V]M;6ET;65N=',@86YD($-O;G1I;F=E
M;F-I97,\+V(^/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P
M,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N
M<SH@875T;SL@=&5X="UA;&EG;CH@<W1A<G0[('1E>'0M:6YD96YT.B`P<'@[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W
M:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G
M:6XZ(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C
M;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO
M<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@<W1A<G0[('1E>'0M
M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C
M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!M87)G:6XZ(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&(^3&EC96YS92!A;F0@4F5S
M96%R8V@@06=R965M96YT<SPO8CX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O
M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R=#L@=&5X="UI
M;F1E;G0Z(#!P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E
M.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N="US=')E=&-H.B!N
M;W)M86P[(&UA<F=I;CH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P
M=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]P/CQP
M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F
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M,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
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M(&-A=&5G;W)Y(&%R93H\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C
M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O
M<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R=#L@=&5X="UI;F1E;G0Z
M(#!P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M
M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P
M<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@=&]P.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/CQT9"!S='EL93TS1"=W:61T:#H@-#AP>#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`T-W!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@<&%D9&EN9RUT;W`Z(#!P
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M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
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M:68[)SY!8F)6:65W($)I;W1H97)A<&5U=&EC<R!#;W)P)B,Q-C`[/&9O;G0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$U+C,S,S,S,C`V,3<V-S9P>#LG/B@\
M9F]N="!S='EL93TS1"=C;VQO<CH@8FQA8VL[)SYF;W)M97)L>2!!8F)O='0@
M0FEO=&AE<F%P975T:6-S($-O<G`I/"]F;VYT/B8C,38P.R8C.#(Q,3LF(S$V
M,#L\+V9O;G0^5&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@4')O9'5C="!$
M979E;&]P;65N="!A;F0@4&%T96YT($QI8V5N<V4@06=R965M96YT('=I=&@@
M06)B5FEE($)I;W1H97)A<&5U=&EC<R!#;W)P+B`H9F]R;65R;'D@1F%C970@
M0FEO=&5C:"!F;W)M97)L>2!K;F]W;B!A<R!0<F]T96EN($1E<VEG;B!,86)S
M*2!I;B`R,#`S('1O('-E8W5R92!E>&-L=7-I=F4@<FEG:'1S('1O(&$@<W!E
M8VEF:6,@86YT:6)O9'D@=VAE;B!C;VYJ=6=A=&5D('=I=&@@86QP:&$@96UI
M='1I;F<@<F%D:6]I<V]T;W!E<RX@57!O;B!E>&5C=71I;VX@;V8@=&AE(&%G
M<F5E;65N="P@=&AE($-O;7!A;GD@;6%D92!A(&QI8V5N<V4@9F5E('!A>6UE
M;G0@;V8@)#,L,#`P+#`P,"X\+V9O;G0^/"]T9#X\+W1R/CPO=&%B;&4^/'`@
M<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O
M=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ
M(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I
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M;F4@<&%Y;65N=',@=&]T86QI;F<@)#<L-S4P+#`P,"!F;W(@=&AE(&%C:&EE
M=F5M96YT(&]F('1H92!F;VQL;W=I;F<@86=R965D('1O(&%N9"!C;VYT<F%C
M=&5D(&UI;&5S=&]N97,Z/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@
M(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@
M;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@<W1A<G0[('1E>'0M:6YD96YT
M.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!M87)G:6XZ(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\=&%B;&4@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O
M;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/E!A>6UE
M;G1S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9#XF(S$V,#L\
M+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q,S<Y<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXH,2D@
M=VAE;B!#;VUP86YY(&EN:71I871E<R!A(%!H87-E($D@0VQI;FEC86P@5')I
M86P@;V8@82!L:6-E;G-E9"!P<F]D=6-T/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$V<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P
M>#L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I9VAT.R<^-S4P+#`P,#PO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^*#(I('=H96X@0V]M<&%N>2!I;FET:6%T97,@
M82!0:&%S92!)22!#;&EN:6-A;"!4<FEA;"!O9B!A(&QI8V5N<V5D('!R;V1U
M8W0\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SXW-3`L,#`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*#,I('=H96X@0V]M<&%N
M>2!I;FET:6%T97,@82!0:&%S92!)24D@0VQI;FEC86P@5')I86P@;V8@82!L
M:6-E;G-E9"!P<F]D=6-T/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^,2PU,#`L,#`P/"]T9#X\=&0@<W1Y;&4]
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M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXQ+#<U,"PP,#`\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXH-2D@1FER
M<W0@8V]M;65R8VEA;"!S86QE/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,2PU,#`L,#`P/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B@V*2!A9G1E<B!T:&4@9FER<W0@)#$P+#`P,"PP,#`@:6X@;F5T('-A;&5S
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^,2PU,#`L,#`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE/CQP('-T>6QE/3-$)V-O
M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R=#L@=&5X="UI
M;F1E;G0Z(#!P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E
M.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW
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M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F
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M,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SY5;F1E<B!T
M:&4@86=R965M96YT+"!T:&4@0V]M<&%N>2!S:&%L;"!P87D@=&\@06)B5FEE
M($)I;W1H97)A<&5U=&EC<R!#;W)P(&]N(&$@8V]U;G1R>2UB>2UC;W5N=')Y
M(&)A<VES(&$@<F]Y86QT>2!O9B`Q,B4@;V8@;F5T('-A;&5S(&]F(&%L;"!L
M:6-E;G-E9"!P<F]D=6-T<R!U;G1I;"!T:&4@;&%T97(@;V8Z("@Q*2`Q,BXU
M('EE87)S(&%F=&5R('1H92!F:7)S="!C;VUM97)C:6%L('-A;&4L(&]R("@R
M*2!W:&5N('1H92!P871E;G1S(&5X<&ER92X\+W`^/'`@<W1Y;&4],T0G8V]L
M;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T
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M;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED
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M)SY4:&4@0V]M<&%N>2!M970@:71S(&9I<G-T(&UI;&5S=&]N92!I;B`R,#$R
M(&%N9"!U<&]N(')E86-H:6YG('1H92!M:6QE<W1O;F4@=&AE($-O;7!A;GD@
M<&%I9"!!8F)O='0@0FEO=&AE<F%P975T:6-S($-O<G`N(&$@;6EL97-T;VYE
M('!A>6UE;G0@;V8@)#<U,"PP,#`@;VX@2G5L>2`R-"P@,C`Q,BXF(S$V,#LF
M(S$V,#M4:&4@;6EL97-T;VYE('!A>6UE;G0@9F]R('1H92!0:&%S92`Q($-L
M:6YI8V%L(%1R:6%L('=A<R!R96-O<F1E9"!A<R!R97-E87)C:"!A;F0@9&5V
M96QO<&UE;G0@97AP96YS92X@5&AE($-O;7!A;GD@:&%S(&YO="!I;FET:6%T
M960@82!0:&%S92`R($-L:6YI8V%L(%1R:6%L(&%N9"!N;R!P87EM96YT(&AA
M<R!B965N(&UA9&4@=&\@06)B;W1T($)I;W1H97)A<&5U=&EC<R!#;W)P+B!S
M:6YC92!T:&4@2G5L>2`R-"P@,C`Q,B!P87EM96YT+CPO9F]N=#X\+W`^/'`@
M<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[
M(&9O;G0M<VEZ93H@,3!P=#L-"B!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO9F]N=#X\+W`^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q
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M1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/'1D('-T>6QE/3-$)W=I9'1H
M.B`T.'!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#0W<'@[
M('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/F(N)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q-#<R<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG.B`P<'@[('1E>'0M:6YD96YT
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/DUE;6]R:6%L(%-L;V%N($ME='1E<FEN9R!#86YC97(@
M0V5N=&5R("A-4TM#0RD@)B,X,C$Q.R!S964@<F5L871E9"!P87)T>2!D:7-C
M;&]S=7)E+CPO9F]N=#X\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG
M.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
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M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
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M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
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M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
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M)SY/86L@4FED9V4@3F%T:6]N86P@3&%B;W)A=&]R>2`H3U).3"D@)B,X,C$Q
M.R!4:&4@0V]M<&%N>2!I<R!C;VYT<F%C=&5D('1O('!U<F-H87-E(')A9&EO
M86-T:79E(&UA=&5R:6%L('1O(&)E('5S960@9F]R(')E<V5A<F-H(&%N9"!D
M979E;&]P;65N="P@=VET:"!A(')E;F5W86P@;W!T:6]N(&%T('1H92!C;VYT
M<F%C="!E;F0N)B,Q-C`[)B,Q-C`[1F]R(#(P,3,L('1H92!#;VUP86YY('=A
M<R!O8FQI9V%T960@86YD('!A:60@87!P<F]X:6UA=&5L>2`D,"XS(&UI;&QI
M;VX@=&\@<'5R8VAA<V4@;V8@<F%D:6]A8W1I=F4@;6%T97)I86P@=VET:"!/
M4DY,+B8C,38P.R8C,38P.T1U<FEN9R`R,#$T+"!T:&4@0V]M<&%N>2!S:6=N
M960@82!C;VYT<F%C="!W:71H($]23DP@=&\@<'5R8VAA<V4@)#`N-"!M:6QL
M:6]N(&]F(')A9&EO86-T:79E(&UA=&5R:6%L+CPO9F]N=#X\+W1D/CPO='(^
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/'1D/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
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M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQT
M9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
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M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@<&%D9&EN9SH@,'!X.R!T
M97AT+6EN9&5N=#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@
M;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SY!<'1I=E-O;'5T:6]N<R!P<F]V:61E
M<R!P<F]J96-T(&UA;F%G96UE;G0@<V5R=FEC97,@9F]R('1H92!S='5D>2!O
M9B!T:&4@9')U9R!!8RTR,C4M2'5-,3DU("A!8W1I;6%B+4$I('5S960@:6X@
M=&AE($-O;7!A;GDF(S@R,3<[<R!0:&%S92`Q(&%N9"!0:&%S92`R(&-L:6YI
M8V%L('1R:6%L<RXF(S$V,#LF(S$V,#M4:&4@=&]T86P@<')O:F5C="!I<R!E
M<W1I;6%T960@=&\@8V]S="!A<'!R;WAI;6%T96QY("0Q+CD@;6EL;&EO;B!A
M;F0@<F5Q=6ER97,@82`Q,BXU)2!D;W=N('!A>6UE;G0@;V8@=&AE('1O=&%L
M(&5S=&EM871E9"!P<F]J96-T(&-O<W0N)B,Q-C`[)B,Q-C`[5&AE(&1O=VX@
M<&%Y;65N="!T;W1A;&EN9R`D,C,Y+#`P,"!W87,@<&%I9"!I;B`R,#`W(&%N
M9"`R,#$R+B8C,38P.R8C,38P.T]N($%U9W5S="`V+"`R,#$R+"!/8W1O8F5R
M(#(R+"`R,#$R(&%N9"!-87D@,38L(#(P,3,L('1H92!A9W)E96UE;G0@=V%S
M(&%M96YD960@=&\@<')O=FED92!F;W(@861D:71I;VYA;"!S97)V:6-E<RXF
M(S$V,#LF(S$V,#M4:&4@=&]T86P@<')O:F5C="!I<R!N;W<@97-T:6UA=&5D
M(&%T(&%P<')O>&EM871E;'D@)#(N,B!M:6QL:6]N+B!!<R!O9B!397!T96UB
M97(@,S`L#0H@,C`Q-"P@87!P<F]X:6UA=&5L>2`D,2XR(&UI;&QI;VX@:&%S
M(&)E96X@97AP96YS960@=&\@9&%T92X@)B,Q-C`[07!T:793;VQU=&EO;G,@
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M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SX\=&0^)B,Q-C`[/"]T9#X\
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M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.V4N)B,Q-C`[
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG.B`P<'@[('1E>'0M:6YD96YT
M.B`P<'@[)SX\<"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/D]N($IU;F4@,34L(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960@:6YT
M;R!A(&QI8V5N<V4@86YD('-P;VYS;W)E9"!R97-E87)C:"!A9W)E96UE;G0@
M=VET:"!&<F5D($AU=&-H:6YS;VX@0V%N8V5R(%)E<V5A<F-H($-E;G1E<B`H
M1DA#4D,I('1O(&)U:6QD('5P;VX@<')E=FEO=7,@86YD(&]N9V]I;F<@8VQI
M;FEC86P@=')I86QS+"!W:71H($)#."`H;&EC96YS960@86YT:6)O9'DI+B8C
M,38P.R8C,38P.T9(0U)#(&AA<R!C=7)R96YT;'D@8V]M<&QE=&5D(%!H87-E
M(#$@86YD(%!H87-E(#(@;V8@=&AE(&-L:6YI8V%L('1R:6%L(&%N9"!T:&4@
M0V]M<&%N>2!I;G1E;F1S('1O('-T87)T('!R97!A<F%T:6]N(&9O<B!A('!I
M=F]T86P@=')I86P@;&5A9&EN9R!T;R!A;B!&1$$@87!P<F]V86PN)B,Q-C`[
M)B,Q-C`[5&AE($-O;7!A;GD@:&%S(&)E96X@9W)A;G1E9"!E>&-L=7-I=F4@
M<FEG:'1S('1O('1H92!"0S@@86YT:6)O9'D@86YD(')E;&%T960@;6%S=&5R
M(&-E;&P@8F%N:R!D979E;&]P960@8GD@1DA#4D,N)B,Q-C`[)B,Q-C`[5&AE
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M;&%B('=I=&@@)#$U,"PP,#`@<&5R('EE87(@9F]R('1H92!F:7)S="!T=V\@
M>65A<G,@86YD("0R-3`L,#`P('1H97)E869T97(N)B,Q-C`[)B,Q-C`[4&%Y
M;65N=',@;6%D92!T;W=A<F0@9G5N9&EN9R!T:&4@;&%B('=I;&P@8F4@8W)E
M9&ET960@=&]W87)D(')O>6%L='D@<&%Y;65N=',@;W=E9"!T;R!&2$-20R!I
M;B!T:&4@9VEV96X@>65A<BXF(S$V,#LF(S$V,#M!(&UI;&5S=&]N92!P87EM
M96YT(&]F("0Q(&UI;&QI;VX@=VEL;"!B92!D=64@=&\@1DA#4D,@=7!O;B!&
M1$$@87!P<F]V86P@;V8@=&AE(&9I<G-T(&1R=6<N)B,Q-C`[)B,Q-C`[57!O
M;B!C;VUM97)C:6%L('-A;&4@;V8@=&AE(&1R=6<L(')O>6%L='D@<&%Y;65N
M=',@;V8@,B4@;V8@;F5T('-A;&5S('=I;&P@8F4@9'5E('1O($9(0U)#+CPO
M9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^1'5R
M:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,30@
M86YD(#(P,3,L('1H92!#;VUP86YY(')E8V]R9&5D(&9E97,@;V8@87!P<F]X
M:6UA=&5L>2`D,"XQ(&UI;&QI;VX@86YD("0W-2PP,#`L(')E<W!E8W1I=F5L
M>2P@<F5L871E9"!T;R!T:&ES(&%G<F5E;65N="X\+V9O;G0^/"]P/CPO=&0^
M/"]T<CX\+W1A8FQE/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O
M.R!T97AT+6%L:6=N.B!S=&%R=#L@=&5X="UI;F1E;G0Z(#!P>#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@
M875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M
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M<V5R:68[)SXF(S$V,#L\+V9O;G0^)B,Q-C`[/"]P/CQT86)L92!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R86YS9F]R;3H@;F]N93L@
M=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R
M9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O
M;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@=&]P.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQT
M9"!S='EL93TS1"=W:61T:#H@-#AP>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`T-W!X.R!T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P
M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/F8N)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#<R<'@[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG
M.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
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M(&$@<W1A<G0M=7`@9F5E(&]F("0Q.2PW-#D@:6X-"B`R,#$S+B8C,38P.R8C
M,38P.T1U<FEN9R!T:&4@8VQI;FEC86P@=')I86P@861D:71I;VYA;"!F965S
M(&%P<&QY(&%N9"!W:6QL(&)E(&EN=F]I8V5D('=H96X@87!P;&EC86)L92X@
M1F]R('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@
M,C`Q-"P@=&AE($-O;7!A;GD@<&%I9"!A<'!R;WAI;6%T96QY("0Q-BPP,#`@
M9F]R('!A=&EE;G0@96YR;VQL;65N="X\+V9O;G0^/"]T9#X\+W1R/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
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M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
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M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQT9#XF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E
M>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/F<N)B,Q-C`[)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG.B`P<'@[('1E
M>'0M:6YD96YT.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/D]N($%U9W5S="`R."P@,C`Q,BP@=&AE
M($-O;7!A;GD@96YT97)E9"!I;G1O(&$@8VQI;FEC86P@=')I86P@86=R965M
M96YT('=I=&@@5&AE(%5N:79E<G-I='D@;V8@5&5X87,@32Y$+B!!;F1E<G-O
M;B!#86YC97(@0V5N=&5R+B8C,38P.R8C,38P.U1H92!T;W1A;"!E<W1I;6%T
M960@8V]S="!O9B!C;VYD=6-T:6YG('1H92!C;&EN:6-A;"!T<FEA;"!I<R!A
M<'!R;WAI;6%T96QY("0U,#`L,#`P+"!W:&EC:"!I;F-L=61E<R!A(&YO;BT@
M<F5F=6YD86)L92!I;G-T:71U=&EO;F%L(&9E92!O9B`D,30L-3`P+B8C,38P
M.R8C,38P.U1H92!E<W1I;6%T960@8V]S="!I<R!B87-E9"!O;B!T<F5A=&EN
M9R`R-"!P871I96YT<R!T:')O=6=H(#(P,3,N)B,Q-C`[)B,Q-C`[57!O;B!E
M>&5C=71I;VX@;V8@=&AE(&%G<F5E;65N="P@=&AE($-O;7!A;GD@<&%I9"`D
M,S,L.30V+B!$=7)I;F<@,C`Q,RP@=&AE<F4@=V%S(&]N92!P871I96YT('1R
M96%T960@86YD('1H92!#;VUP86YY('!A:60@)#,T+#,X,R!I;B!*=6QY(#(P
M,3,N($1U<FEN9R!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P
M+"`R,#$T+"!T:&4@0V]M<&%N>2!R96-O<F1E9"!A;B!E>'!E;G-E(&]F(&%P
M<')O>&EM871E;'D@)#`N,2!M:6QL:6]N+CPO9F]N=#X\+W1D/CPO='(^/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GD[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO9F]N=#X\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!T;W`[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/'1D
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M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^3VX@4V5P=&5M8F5R(#(V+"`R,#$R
M+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!C;&EN:6-A;"!T<FEA;"!A
M9W)E96UE;G0@=VET:"!*;VAN<R!(;W!K:6YS(%5N:79E<G-I='DN)B,Q-C`[
M)B,Q-C`[5&AE(%!H87-E(#$O,B!C;&EN:6-A;"!T<FEA;"!W:6QL(&)E(&-O
M;F1U8W1E9"!W:71H($%C=&EN:75M(#(R-2XF(S$V,#LF(S$V,#M4:&4@8VQI
M;FEC86P@=')I86P@=VEL;"!B92!C;VYD=6-T960@=6YD97(@=&AE('!R;W1O
M8V]L<R!E<W1A8FQI<VAE9"!B>2!T:&4@0V]M<&%N>2!A;F0@<'5R<W5A;G0@
M=&\@86X@26YV97-T:6=A=&EO;F%L($YE=R!$<G5G($5X96UP=&EO;B`H24Y$
M(#$P.#`W*2!H96QD(&)Y('1H92!#;VUP86YY+B8C,38P.R8C,38P.U1H92!#
M;VUP86YY('=I;&P@<&%Y("0S."PU,#$@<&5R('!A=&EE;G0L('=H;R!H87,@
M8V]M<&QE=&5D('1H92!C;&EN:6-A;"!T<FEA;"X@5&AE($-O;7!A;GD@:7,@
M<F5Q=6ER960@=&\@<&%Y(&$@<W1A<G0M=7`@9F5E(&]F("0R,BPX-#<L(&%N
M(&%N;G5A;"!P:&%R;6%C>2!F964@;V8@)#(L,#(U(&%N9"!A;B!A;65N9&UE
M;G0@<')O8V5S<VEN9R!F964@;V8@)#4P,"P@=VAE;B!A<'!L:6-A8FQE+B!4
M:&4@0V]M<&%N>2!P86ED('1H92!S=&%R="UU<"!F964@:6X@1F5B<G5A<GD@
M,C`Q,RX@5&AE<F4@=V5R92!N;R!P87EM96YT<R!M861E(&1U<FEN9R!T:&4@
M;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$T(&9O<B!T:&ES
M(&%G<F5E;65N="X\+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@=&]P.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P
M861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
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M/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
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M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M;G9E<W1I9V%T:6]N86P@3F5W($1R=6<@17AE;7!T:6]N("A)3D0@,3`X,#<I
M(&AE;&0@8GD@=&AE($-O;7!A;GDN)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@
M=VEL;"!P87D@)#,Q+#<W,2!P97(@<&%T:65N="P@=VAO(&AA<R!C;VUP;&5T
M960@=&AE(&-L:6YI8V%L('1R:6%L+B!4:&4@0V]M<&%N>2!W:6QL(&)E(')E
M<75I<F5D('1O('!A>2!A('-T87)T+75P(&9E92!O9B`D,38L,#`P(&%N9"!A
M9&1I=&EO;F%L(&%D;6EN:7-T<F%T:79E(&9E97,L('=H96X@87!P;&EC86)L
M92XF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!A8V-R=65D('1H92`D,38L,#`P
M(&9E92!A="!$96-E;6)E<B`S,2P@,C`Q,R!A;F0@<&%I9"!T:&4@9F5E(&EN
M($IA;G5A<GD@,C`Q-"X@1'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E9"!3
M97!T96UB97(@,S`L(#(P,30L('1H92!#;VUP86YY(')E8V]R9&5D(&%N(&5X
M<&5N<V4@;V8@87!P<F]X:6UA=&5L>2`D,38L,#`P+CPO9F]N=#X\+W1D/CPO
M='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
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M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
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M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^3VX@2F%N=6%R>2`R-RP@
M,C`Q-"P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@;6%N=69A8W1U<FEN
M9R!A9W)E96UE;G0@=VET:"!';V]D=VEN($)I;W1E8VAN;VQO9WD@26YC+B8C
M,38P.R8C,38P.R@F(S@R,C`[1V]O9'=I;B8C.#(R,3LI+B!';V]D=VEN('=I
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M<&%I9"!A(&YO;BUR969U;F1A8FQE('!A>6UE;G0@;V8@)#4V,BPW.3`@=7!O
M;B!E>&5C=71I;VX@;V8@=&AE(&%G<F5E;65N="X@4&5R:6]D:6,@<&%Y;65N
M=',@=VEL;"!B92!M861E('5P;VX@<F5A8VAI;F<@8V5R=&%I;B!M:6QE<W1O
M;F5S+B!!<R!O9B!397!T96UB97(@,S`L(#(P,30L('1H92!R96UA:6YI;F<@
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M<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
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M=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@
M=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P
M=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]P/CQT
M86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R86YS
M9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@
M8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/CQT9"!S='EL93TS1"=W:61T:#H@-#AP>#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`T-W!X.R!T97AT+6%L:6=N.B!C96YT
M97([('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/FLN)B,Q-C`[)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#<R<'@[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG.B`P<'@[('1E
M>'0M:6YD96YT.B`P<'@[)SX\<"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.PT*(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^3VX@2G5N92`R,"P@,C`Q-"P@=&AE($-O;7!A;GD@
M96YT97)E9"!I;G1O(&$@0U)/(&%G<F5E;65N="!W:71H($%C="!/;F-O;&]G
M>2X@06-T($]N8V]L;V=Y('!R;W9I9&5S('!R;VIE8W0@;6%N86=E;65N="!S
M97)V:6-E<R!F;W(@=&AE('-T=61Y(&]F($EO;6%B+4(@=7-E9"!F;W(@=&AE
M(&EN=&5N9&5D(%!H87-E(#,@8VQI;FEC86P@=')I86PN)B,Q-C`[)B,Q-C`[
M5&AE('1O=&%L('!R;VIE8W0@:7,@97-T:6UA=&5D('1O(&-O<W0@87!P<F]X
M:6UA=&5L>2`D,"XX(&UI;&QI;VXN(%1H92!#;VUP86YY('!A:60@87!P<F]X
M:6UA=&5L>2`D,"XS(&UI;&QI;VX@9'5R:6YG('1H92!N:6YE(&UO;G1H<R!E
M;F1E9"!397!T96UB97(@,S`L(#(P,30N($%C="!/;F-O;&]G>2!B:6QL<R!T
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO<#X\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/'1D/B8C
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M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/D]N(%-E<'1E;6)E<B`S
M,"P@,C`Q-"P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@<F5S96%R8V@@
M86=R965M96YT('=I=&@@=&AE($%L8F5R="!%:6YS=&5I;B!#;VQL96=E(&]F
M($UE9&EC:6YE(&]F(%EE<VAI=F$@56YI=F5R<VET>2`H)B,X,C(P.T5I;G-T
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M;65N="!O9B!A<'!R;WAI;6%T96QY("0Y,BPP,#`@=V%S(&UA9&4@<W5B<V5Q
M=65N="!T;R!397!T96UB97(F(S$V,#LS,"P@,C`Q-"XF(S$V,#LF(S$V,#L\
M+W`^/"]T9#X\+W1R/CPO=&%B;&4^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P
M,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
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M9VEN.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G
M8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M86QI9VXZ('-T87)T.R!T97AT
M+6EN9&5N=#H@,'!X.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@=VED;W=S.B!A=71O.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@;6%R9VEN.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQB/DQE87-E($%G<F5E;65N
M=',\+V(^/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@
M875T;SL@=&5X="UA;&EG;CH@<W1A<G0[('1E>'0M:6YD96YT.B`P<'@[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O
M=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ
M(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^/&(^)B,Q-C`[/"]B/CPO9F]N=#X\+W`^/'`@<W1Y;&4]
M,T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A
M8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT
M+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^3VX@075G=7-T
M(#$L(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(')E;G1A;"!A
M9W)E96UE;G0@9F]R(&]F9FEC92!S<&%C92!A="`U,#$@1FEF=&@@079E;G5E
M+"8C,38P.TYE=R!9;W)K+"!.62X@5&AE(&%G<F5E;65N="!W87,@=&5R;6EN
M871E9"!O;B!-87D@,S$L(#(P,3,N($]N($IU;F4@-"P@,C`Q,R!A;F0@86UE
M;F1E9"!O;B!/8W1O8F5R)B,Q-C`[-"P@,C`Q,RP@=&AE($-O;7!A;GD@96YT
M97)E9"!I;G1O('1W;R!R96YT86P@86=R965M96YT<R!F;W(@;V9F:6-E('-P
M86-E(&%T(#4T-B!&:69T:"!!=F5N=64L)B,Q-C`[3F5W(%EO<FLL($Y9+B!/
M;F4@;V8@=&AE(&%G<F5E;65N=',@=V%S('1E<FUI;F%T960@;VX@2G5L>2`V
M+"`R,#$T+B!4:&4@0V]M<&%N>2!P;&%N<R!T;R!M86EN=&%I;B!O9F9I8V4@
M<W!A8V4@870@-30V($9I9G1H($%V96YU92P@3F5W(%EO<FLL($Y9(&%T(&QE
M87-T('5N=&EL($1E8V5M8F5R(#,Q+"`R,#$T+B!4:&4@0V]M<&%N>2!P86ED
M(&$@;VYE(&UO;G1H(')E9G5N9&%B;&4@9&5P;W-I="!O;B!T:&4@<W!A8V4@
M=&AA="!I="!M86EN=&%I;G,@:6X@3F5W(%EO<FLL($Y9+B`F(S$V,#M/;B!!
M<')I;"`R,BP@,C`Q-"P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@<W5B
M;&5A<V4@86=R965M96YT(&9O<B!O9F9I8V4@<W!A8V4@;&]C871E9"!A="`S
M-SD@5&AO<FYA;&P@4W1R965T+"!%9&ES;VXL($Y*+B!4:&ES(&%G<F5E;65N
M="!E>'!I<F5S(&]N(%-E<'1E;6)E<B`S,"P@,C`Q-BX@5&AE($-O;7!A;GD@
M:7-S=65D(&$@<V5C=7)I='D@9&5P;W-I="!O9B`D,S0L-S,S('1O('1H92!E
M>&ES=&EN9R!T96YA;G0N/"]F;VYT/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V(Y,35F.#`W7V(S,31?-#,X-%]A83!D
M7V$Y,3DT.&9F9&,P.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B
M.3$U9C@P-U]B,S$T7S0S.#1?86$P9%]A.3$Y-#AF9F1C,#DO5V]R:W-H965T
M<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^17%U:71Y/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^17%U:71Y(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6ET>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V-O;&]R.B`C
M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[
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M,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/CQB/DYO=&4@-R`F(S@R,3$[($5Q=6ET
M>3PO8CX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
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M+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/CQB/B8C,38P.SPO8CX\+V9O;G0^/"]P/CQP('-T>6QE
M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T
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M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/D]N($1E8V5M
M8F5R(#DL(#(P,3,L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A;F]T:&5R
M(&5N9V%G96UE;G0@86=R965M96YT('=I=&@@:71S('!L86-E;65N="!A9V5N
M="!F;W(@=&AE(#(P,3,@0V]M;6]N(%-T;V-K($]F9F5R:6YG+"`F(S@R,38[
M=&AE($]F9F5R:6YG)B,X,C(Q.RD@5&AE($]F9F5R:6YG('=A<R!C;VUP;&5T
M960@:6X@='=O('1R86YC:&5S+"!O;B!$96-E;6)E<B`Y+"`R,#$S(&%N9"!*
M86YU87)Y(#$P+"`R,#$T+B!4:&4@86=R965M96YT(&5N=&5R960F(S$V,#MO
M;B!$96-E;6)E<B`Y+"`R,#$S(&AA9"!S:6UI;&%R('1E<FUS(&%S('1H92`R
M,#$R(&%G<F5E;65N="P@:6YC;'5D:6YG(&$@8V%S:"!F964@97%U86P@=&\@
M,3`E(&]F('1H92!G<F]S<R!P<F]C965D<R!R86ES960L(&$@;F]N+6%C8V]U
M;G1A8FQE(&5X<&5N<V4@<F5I;6)U<G-E;65N="!E<75A;"!T;R`R)2!O9B!T
M:&4@9W)O<W,@<')O8V5E9',@<F%I<V5D(&%N9"!W87)R86YT<R!T;R!P=7)C
M:&%S92!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!#;VUM;VX@4W1O
M8VL@:6X@86X@86UO=6YT(&5Q=6%L('1O(#$P)2!O9B!T:&4@<VAA<F5S(&]F
M(&-O;6UO;B!S=&]C:R!I<W-U960@;W(@:7-S=6%B;&4N(%-U8G-E<75E;G0@
M=&\@=&AE(&-L;W-I;F<@;V8@=&AE(#(P,3,@;V9F97)I;F<L('1H92!P;&%C
M96UE;G0@86=E;G0@8V]N=&EN=65D('1O('!R;W9I9&4@8V5R=&%I;B!F:6YA
M;F-I86P@861V:7-O<GD@<V5R=FEC97,@=&\@=&AE($-O;7!A;GD@=6YT:6P@
M=&AR964@;6]N=&AS(&%F=&5R('1H92!#;VUP86YY(&AA9"!U<"UL:7-T960@
M:71S('-E8W5R:71I97,@9F]R('1R861I;F<@;VX@82!5+E,N($YA=&EO;F%L
M($5X8VAA;F=E(&9O<B!A(&UO;G1H;'D@9F5E(&]F("0R-2PP,#`N/"]F;VYT
M/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ
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M875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P
M,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA
M;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@
M;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^3VX@1&5C96UB97(@,C<L(#(P,3,L)B,Q
M-C`[=&AE($-O;7!A;GD@8V]M<&QE=&5D('1H92!F:7)S="!S86QE(&]F('1H
M92!/9F9E<FEN9R!P=7)S=6%N="!T;R!A(%5N:70@4'5R8VAA<V4@06=R965M
M96YT+"!W:71H(&-E<G1A:6X@86-C<F5D:71E9"!I;G9E<W1O<G,@*'1H92`F
M(S@R,C`[26YV97-T;W)S)B,X,C(Q.RDF(S$V,#MP=7)S=6%N="!T;R!W:&EC
M:#H@=&AE($EN=F5S=&]R<R!A9W)E960@=&\@<'5R8VAA<V4@*&DI(&%N(&%G
M9W)E9V%T92!O9B`U-30L,S$P('-H87)E<R`H=&AE("8C.#(R,#M3:&%R97,F
M(S@R,C$[*2!O9B!C;VUM;VX@<W1O8VL@870@)#8N,#`@<&5R('-H87)E(&%N
M9"`H:6DI(&9I=F4M>65A<B!W87)R86YT<R!T;R!P=7)C:&%S92!A;B!A9V=R
M96=A=&4@;V8@,3,X+#4W-R!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%T(&%N
M(&5X97)C:7-E('!R:6-E(&]F("0Y+C`P('!E<B!S:&%R92X@5&AE($-O;7!A
M;GD@<F5C96EV960@)#,L,S(U+#@V,"8C,38P.VEN(&=R;W-S('!R;V-E961S
M(&9R;VT@=&AE('-A;&4@;V8@<V5C=7)I=&EE<RXF(S$V,#L\+V9O;G0^/"]P
M/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
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M:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R-RXU<'0[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z
M(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^26X@2F%N=6%R>2`R,#$T+"!T:&4@0V]M<&%N
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M<R!O9B!A<'!R;WAI;6%T96QY("0S.34L,#`P(&%N9"!P86ED(&%T=&]R;F5Y
M(&9E97,@;V8@)#0P+#`P,"!F;W(@=&AE:7(@<V5R=FEC97,@<F5S=6QT:6YG
M(&EN(&YE="!P<F]C965D<R!O9B`D,BPX-S,L-34W+B!);B!T:&4@,C`Q-"!#
M;&]S:6YG+"!T:&4@0V]M<&%N>2!S;VQD(#4U,2PX,3`@<VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:R!A="`D-BXP,"!P97(@<VAA<F4@86YD(&=R86YT960@,3,W
M+#DU,B!U;FET<R!O9B!F:79E+7EE87(@=V%R<F%N=',@=VET:"!A;B!E>&5R
M8VES92!P<FEC92!O9B`D.2XP,"!P97(@<VAA<F4N(%1H92!W87)R86YT<R!A
M<F4@97AE<F-I<V%B;&4@9F]R(&$@<&5R:6]D(&]F(&9I=F4@>65A<G,@9G)O
M;2!T:&4@9&%T92!O9B!I<W-U86YC92X@5&AE('1R86YS86-T:6]N(&1A=&4@
M9F%I<B!V86QU92!O9B!T:&4@=V%R<F%N=',@;V8@)#`N-B!M:6QL:6]N('=A
M<R!D971E<FUI;F5D('5T:6QI>FEN9R!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I
M;VX@<')I8VEN9R!M;V1E;"!U=&EL:7II;F<@=&AE(&9O;&QO=VEN9R!A<W-U
M;7!T:6]N<SH@<FES:R!F<F5E(&EN=&5R97-T(')A=&4@+2`Q+C8T)2P@97AP
M96-T960@=F]L871I;&ET>2`M(#@X)2P@97AP96-T960@9&EV:61E;F0@>6EE
M;&0@+2`P)2P@86YD(&$@8V]N=')A8W1U86P@;&EF92!O9B`U('EE87)S+B!$
M=7)I;F<@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q
M-"P@.#,L,S,R('=A<G)A;G1S('=E<F4@97AE<F-I<V5D+CPO9F]N=#X\+W`^
M/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM
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M)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
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M;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/D]N($UA<F-H(#(T+"`R,#$T+"!T:&4@0V]M
M<&%N>2!F:6QE9"!A('-H96QF(')E9VES=')A=&EO;B!S=&%T96UE;G0@;VX@
M1F]R;2!3+3,@*'1H92`F(S@R,C`[4F5G:7-T<F%T:6]N(%-T871E;65N="8C
M.#(R,3LI('=H:6-H('=A<R!E9F9E8W1I=F4@;VX@07!R:6P@,3<L(#(P,30N
M(%1H:7,@4F5G:7-T<F%T:6]N(%-T871E;65N="!C;VYT86EN960@='=O('!R
M;W-P96-T=7-E<SH@*&DI(&$@8F%S92!P<F]S<&5C='5S('=H:6-H(&-O=F5R
M<R!T:&4@;V9F97)I;F<L(&ES<W5A;F-E(&%N9"!S86QE(&)Y('1H92!#;VUP
M86YY(&]F('5P('1O("0R,#`L,#`P+#`P,"!O9B!I=',@8V]M;6]N('-T;V-K
M+"!P<F5F97)R960@<W1O8VLL('=A<G)A;G1S(&%N9"]O<B!U;FET<SL@86YD
M("AI:2D@82!S86QE<R!A9W)E96UE;G0@<')O<W!E8W1U<R!C;W9E<FEN9R!T
M:&4@;V9F97)I;F<L(&ES<W5A;F-E(&%N9"!S86QE(&)Y('5S(&]F('5P('1O
M(&$@;6%X:6UU;2!A9V=R96=A=&4@;V9F97)I;F<@<')I8V4@;V8@)#<U+#`P
M,"PP,#`@;V8@:71S(&-O;6UO;B!S=&]C:R!T:&%T(&UA>2!B92!I<W-U960@
M86YD('-O;&0@=6YD97(@82!S86QE<R!A9W)E96UE;G0@*'1H92`F(S@R,C`[
M(%-A;&5S($%G<F5E;65N="`F(S@R,C$[("D@=VET:"!-3%8@)F%M<#L@0V\N
M($Q,0R`H("8C.#(R,#L@34Q6("8C.#(R,3L@*2!D871E9"!-87)C:"`R-"P@
M,C`Q-"X@5&AE($-O;7!A;GD@=VEL;"!P87D@34Q6(&EN(&-A<V@L('5P;VX@
M=&AE('-A;&4@;V8@8V]M;6]N('-T;V-K('!U<G-U86YT('1O('1H92!386QE
M<R!!9W)E96UE;G0L(&%N(&%M;W5N="!E<75A;"!T;R`S+C`E(&]F('1H92!G
M<F]S<R!P<F]C965D<R!F<F]M('1H92!S86QE(&]F(&-O;6UO;B!S=&]C:RX@
M3VX@07!R:6P@,C@L(#(P,30L('1H92!#;VUP86YY(&ES<W5E9"`U,#`@<VAA
M<F5S(&%N9"!R96-E:79E9"!N970@<')O8V5E9',@;V8@)#8L,#`P('5N9&5R
M('1H92!386QE<R!!9W)E96UE;G0@=VET:"!-3%8N/"]F;VYT/CPO<#X\<"!S
M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH
M96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UI;F1E;G0Z(#!P
M>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[
M('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X
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M,#L\+V(^/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@
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M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M
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M,38P.SPO8CY$=7)I;F<@2F%N=6%R>2`R,#$T+"!I;B!C;VYN96-T:6]N('=I
M=&@@=&AE($-O;6UO;B!3=&]C:R!/9F9E<FEN9RP@=&AE($-O;7!A;GD@:7-S
M=65D('1H92!0;&%C96UE;G0@06=E;G0@=V%R<F%N=',@=&\@<'5R8VAA<V4@
M86X@86=G<F5G871E(&]F(#8X+#DW-B!S:&%R97,@;V8@8V]M;6]N('-T;V-K
M('=I=&@@86X@97AE<F-I<V4@<')I8V4@;V8@)#DN,#`@<&5R('-H87)E+B!4
M:&4@=')A;G-A8W1I;VX@9&%T92!F86ER('9A;'5E(&]F('1H92!W87)R86YT
M<R!O9B`D,"XR(&UI;&QI;VX@=V%S(&1E=&5R;6EN960@=71I;&EZ:6YG('1H
M92!";&%C:RU38VAO;&5S(&]P=&EO;B!P<FEC:6YG(&UO9&5L('5T:6QI>FEN
M9R!T:&4@9F]L;&]W:6YG(&%S<W5M<'1I;VYS.B!R:7-K(&9R964@:6YT97)E
M<W0@<F%T92`F(S@R,3$[(#$N-C0E+"!E>'!E8W1E9"!V;VQA=&EL:71Y("T@
M.#@E+"!E>'!E8W1E9"!D:79I9&5N9"!Y:65L9"`M(#`E+"!A;F0@82!C;VYT
M<F%C='5A;"!L:69E(&]F(#4@>65A<G,N/"]F;VYT/CPO<#X\<"!S='EL93TS
M1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
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M:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N
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M;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S
M.B!A=71O.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P
M<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/CQB/E!U8FQI8R!/9F9E<FEN9SPO8CXF(S$V,#LM($]N($IU;F4@
M,S`L(#(P,30L('1H92!#;VUP86YY(')E8V5I=F5D(&=R;W-S('!R;V-E961S
M(&]F("0Q,BPU,C4L,#`P(&9R;VT@=&AE('!U8FQI8R!O9F9E<FEN9R!O9B`Q
M+#8W,"PP,#`@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N
M('-T;V-K+"`D,"XP,#$@<&%R('9A;'5E('!E<B!S:&%R92!A="!A('!R:6-E
M('1O('1H92!P=6)L:6,@;V8@)#<N-3`@<&5R('-H87)E(&QE<W,@=6YD97)W
M<FET:6YG(&1I<V-O=6YT<RX@5&AE($-O;7!A;GD@<&%I9"!A;B!U;F1E<G=R
M:71I;F<@9&ES8V]U;G0@;V8@)#@W-BPW-3`L('!A:60@=&AE(&]T:&5R(&]F
M9F5R:6YG(&5X<&5N<V5S(&]F("0Q,C4L,#`P+"!A;F0@<&%I9"!A='1O<FYE
M>2!A;F0@875D:71O<B!F965S(&]F("0W,BPP,#`@<F5S=6QT:6YG(&EN(&YE
M="!P<F]C965D<R!O9B`D,3$L-#4Q+#(U,"XN(%5N9&5R('1H92!T97)M<R!O
M9B!T:&4@=6YD97)W<FET:6YG(&%G<F5E;65N="P@=&AE($-O;7!A;GD@86QS
M;R!G<F%N=&5D('1H92!U;F1E<G=R:71E<G,@82`S,"UD87D@;W!T:6]N('1O
M('!U<F-H87-E('5P('1O(&%N(&%D9&ET:6]N86P@,C4P+#`P,"!S:&%R97,@
M;V8@8V]M;6]N('-T;V-K('1O(&-O=F5R(&]V97(M86QL;W1M96YT<RP@:68@
M86YY+"!A="!T:&4@;V9F97)I;F<@<')I8V4N/"]F;VYT/CPO<#X\<"!S='EL
M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
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M<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@
M9F]N="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O
M=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ
M(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I
M;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^3VX@2G5L>2`Q,"P@,C`Q-"P@=&AE('5N9&5R=W)I=&5R(&5X
M97)C:7-E9"!T:&5I<B!O=F5R+6%L;&]T;65N="!O<'1I;VX@=&\@<'5R8VAA
M<V4@86X@861D:71I;VYA;"`Q-3<L,3(S('-H87)E<R!F<F]M('1H92!#;VUP
M86YY(&9O<B`D-RXU,"!P97(@<VAA<F4N($EN8VQU9&EN9R!T:&4@97AE<F-I
M<V4@;V8@=&AE(&]V97(M86QL;W1M96YT(&]P=&EO;B!O9B`D,2XR(&UI;&QI
M;VXL(&EN(&=R;W-S('!R;V-E961S+"!!8W1I;FEU;28C.#(Q-SMS(&]F9F5R
M:6YG('1O=&%L960@,2PX,C<L,3(S('-H87)E<RP-"B!R97!R97-E;G1I;F<@
M9W)O<W,@<')O8V5E9',@;V8@87!P<F]X:6UA=&5L>2`D,3,N-R!M:6QL:6]N
M(&%N9"!A<'!R;WAI;6%T96QY("0Q,BXV(&UI;&QI;VX@;F5T(&%F=&5R(&1E
M9'5C=&EN9R!T:&4@=6YD97)W<FET:6YG(&1I<V-O=6YT(&%N9"!T:&4@;W1H
M97(@;V9F97)I;F<@97AP96YS97,N/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C
M;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
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M.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N="US
M=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^)B,Q-C`[/&9O;G0@<W1Y;&4]
M,T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O
M;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T
M97AT+6%L:6=N.B!S=&%R=#L@=&5X="UI;F1E;G0Z(#!P>#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T
M;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED
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M/"]B/CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F
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M+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M:6YD96YT.B`P
M+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO
M<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA
M;#L@;W)P:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E
M+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P
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M;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,RP@=&AE($-O;7!A;GD@
M9W)A;G1E9"!E;7!L;WEE97,L(&-O;G-U;'1A;G1S(&%N9"!B;V%R9"!M96UB
M97)S(#$X,"PP,#`@<VAA<F5S(&]F(')E<W1R:6-T960@<W1O8VLN($1U<FEN
M9R!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$T+"!T
M:&4@0V]M<&%N>2!G<F%N=&5D(#8P,BPY,#<@<VAA<F5S(&]F(')E<W1R:6-T
M960@<W1O8VL@86YD(&-A;F-E;&QE9"`U,"PP,#`@<VAA<F5S(&]F(')E<W1R
M:6-T960@<W1O8VLN($]F('1H92!T;W1A;"!S:&%R97,@;V8@<F5S=')I8W1E
M9"!S=&]C:R!G<F%N=&5D+"`R,"PP,#`@<VAA<F5S('9E<W0@,R!M;VYT:',@
M9G)O;2!T:&4@9W)A;G0@9&%T92P@,S`L,C0P('-H87)E<R!V97-T(#$@>65A
M<B!F<F]M('1H92!G<F%N="!D871E+"`R,#(L-C8W('-H87)E<R!H879E(&$@
M=F5S=&EN9R!P97)I;V0@;V8@-"!Y96%R<R!A;F0@,S4P+#`P,"!S:&%R97,@
M=F5S="!A="!T:&4@9&%T92!O9B!G<F%N="X@5&AE(')E;6%I;FEN9R!R97-T
M<FEC=&5D('-H87)E<R!G<F%N=&5D(&%R92!P97)F;W)M86YC92!B87-E9"!A
M;F0@=7!O;B!T:&4@86-H:65V96UE;G0@;V8@8V5R=&%I;B!M:6QE<W1O;F5S
M+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W
M:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G
M:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^/"]F;VYT/B8C,38P.SPO<#X\<"!S='EL93TS1"=C;VQO
M<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA
M;#L@;W)P:&%N<SH@875T;SL@=&5X="UI;F1E;G0Z(#!P>#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T
M;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED
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M;CPO8CX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A
M=71O.R!T97AT+6%L:6=N.B!S=&%R=#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C
M:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N
M="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X.R!T97AT+6EN9&5N=#H@
M,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L
M;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UI;F1E;G0Z(#`N-35I
M;CL@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^1F]L;&]W:6YG(&ES(&$@
M<W5M;6%R>2!O9B!O<'1I;VX@86-T:79I=&EE<R!F;W(@=&AE(&YI;F4@;6]N
M=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q-#H\+V9O;G0^/"]P/CQP('-T
M>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
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M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R.2XW<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO9F]N=#X\+W`^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q-38W
M<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@8F]R
M9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE+6%D:G5S=#H@;F]N
M93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A
M;CTS1#(^3G5M8F5R(&]F(%5N:71S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH-"B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CY796EG:'1E9"!!=F5R86=E
M($5X97)C:7-E(%!R:6-E/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M('-O;&ED.R<@8V]L<W!A;CTS1#(^5V5I9VAT960@079E<F%G92!296UA:6YI
M;F<@0V]N=')A8W1U86P@5&5R;2`H:6X@>65A<G,I/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E
M<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^06=G<F5G871E
M($EN=')I;G-I8R!686QU93PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CLG/CQT9"!S='EL93TS1"=W:61T:#H@.#$U<'@[)SY/=71S=&%N9&EN9RP@
M1&5C96UB97(@,S$L(#(P,3,\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P
M>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$T,G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$L.3@U+#,X-#PO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG
M/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30R<'@[('1E>'0M86QI9VXZ
M(')I9VAT.R<^,RXR,SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$U<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P
M>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXX+C,T/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T
M.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG
M;CH@<FEG:'0[)SXU+#DP."PV.38\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,35P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`P+C$R
M-6EN.R<^27-S=65D/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^,2PS,C,L,3`P/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C@N.#D\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,3`N,#`\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^+3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.B`P+C$R-6EN.R!P861D:6YG+6)O='1O;3H@,2XU<'0[
M)SY%>&5R8VES960\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O
M;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXH,S$P+#0P
M,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#LG/BD\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXP+CDV/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SXM/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P
M.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#1P=#LG/D]U='-T86YD:6YG+"!397!T96UB97(@,S`L
M(#(P,30\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@
M8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O
M<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C(L.3DX+#`X-#PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[('1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^-2XY.#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[
M('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^."XV,#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`T<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T
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M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
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M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@-'!T.R<^17AE<F-I<V%B;&4L(%-E<'1E;6)E
M<B`S,"P@,C`Q-#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[('1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/C$N,#0\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/C8N,C<\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@-'!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXS+#<S-"PV,3`\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/'`@<W1Y;&4],T0G8V]L;W(Z
M(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E
M>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S
M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
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M,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/D1U
M<FEN9R!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$T
M+"!T:&4@0V]M<&%N>2!G<F%N=&5D(&5M<&QO>65E<R!A;F0@:71S(&)O87)D
M(&UE;6)E<G,@,2PS,C,L,3`P(&]P=&EO;G,@=&\@<'5R8VAA<V4@=&AE($-O
M;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@=VET:"!E>&5R8VES92!P<FEC
M97,@<F%N9VEN9R!F<F]M("0U+C4U('1O("0Q,2XY-2!A;F0@82!T97)M(&]F
M(#$P('EE87)S('=I=&@@=F5S=&EN9R!O=F5R(&$@-"UY96%R('!E<FEO9"XF
M(S$V,#LF(S$V,#M4:&4@;W!T:6]N<R!H879E(&%N(&%G9W)E9V%T960@9F%I
M<B!V86QU92!O9B`D."XV(&UI;&QI;VX@=&AA="!W87,@8V%L8W5L871E9"!U
M<VEN9R!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VXM<')I8VEN9R!M;V1E;"X@
M5F%R:6%B;&5S('5S960@:6X@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N+7!R
M:6-I;F<@;6]D96P@:6YC;'5D93H@*#$I(&1I<V-O=6YT(')A=&4@;V8@,2XX
M-"4@+2`R+C`W)2`H,BD@97AP96-T960@;&EF92!O9B`V('EE87)S+"`H,RD@
M97AP96-T960@=F]L871I;&ET>2!O9B`X-BXU-B4@=&\@.#<N-S8E+"!A;F0@
M*#0I('IE<F\@97AP96-T960@9&EV:61E;F1S+CPO9F]N=#X\+W`^/'`@<W1Y
M;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF
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M9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US
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M;6)E<B`S,"P@,C`Q-"P@=&AE($-O;7!A;GD@<F5C96EV960@9W)O<W,@<')O
M8V5E9',@;V8@)#(W-2PQ-3,@9F]R(&5X97)C:7-E(&]F(&]P=&EO;G,@9F]R
M(#,Q,"PT,#`@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N
M('-T;V-K+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z
M(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS
M1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z
M(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C
M:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N
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M,S`L(#(P,30@=V%S("0Q,"PY-3,L.#4V+B!$=7)I;F<@=&AE('1H<F5E(&UO
M;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,30@86YD(#(P,3,L('1H92!#
M;VUP86YY(')E8V]R9&5D(&]P=&EO;B!E>'!E;G-E(&]F("0W,S0L-SDY(&%N
M9"`D.34L.3<Q+"!R97-P96-T:79E;'DN($1U<FEN9R!T:&4@;FEN92!M;VYT
M:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$T(&%N9"`R,#$S+"!T:&4@0V]M
M<&%N>2!R96-O<F1E9"!O<'1I;VX@97AP96YS92!O9B`D,2PV,C,L.3DT(&%N
M9"`D,C@T+#,W,2P@<F5S<&5C=&EV96QY+CPO9F]N=#X\+W`^/'`@<W1Y;&4]
M,T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M
M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT
M+6EN9&5N=#H@,'!X.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@=VED;W=S.B!A=71O.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/CQB/E=A<G)A;G1S/"]B/CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L
M;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U
M=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&(^)B,Q-C`[/"]B/CPO9F]N
M=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z
M(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P
M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^1F]L;&]W:6YG(&ES(&$@<W5M;6%R>2!O9B!W87)R86YT(&%C=&EV
M:71I97,@9F]R('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L
M(#(P,30Z/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@
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M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M
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M;B<L.R<^)B,Q-C`[/"]F;VYT/CPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M=VED=&@Z(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
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M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
M:60[)R!C;VQS<&%N/3-$,CY.=6UB97(@;V8@56YI=',\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CY796EG:'1E
M9"!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T
M;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^5V5I9VAT960@079E<F%G
M92!296UA:6YI;F<@0V]N=')A8W1U86P@5&5R;2`H:6X@>65A<G,I/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU
M<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^
M06=G<F5G871E($EN=')I;G-I8R!686QU93PO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y
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M=&@Z(#@Q-7!X.R<^3W5T<W1A;F1I;F<L($1E8V5M8F5R(#,Q+"`R,#$S/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#)P>#L@=&5X="UA;&EG;CH@
M<FEG:'0[)SXY+#8W,RPR.3`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P
M>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$T,G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$N,#8\+W1D/CQT
M9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30Q<'@[('1E>'0M
M86QI9VXZ(')I9VAT.R<^-"XX.3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-7!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$U<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I9VAT.R<^-#<L,SDV+#,P
M-SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S
M='EL93TS1"=P861D:6YG+6QE9G0Z(#`N,3(U:6X[)SY'<F%N=&5D/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M-#`V+#DR.#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXX+C@Q/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/C<N-#8\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V5E9F8[)SX\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`P+C$R-6EN
M.R<^17AE<F-I<V5D/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^*#(L,3$W+#,P-#PO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,"XY-CPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,2XU<'0[('!A9&1I;F<M;&5F=#H@,"XQ,C5I;CLG/D9O<F9E:71E
M9#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O
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M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M-BXW,#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,2XU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SY/=71S=&%N9&EN9RP@
M4V5P=&5M8F5R(#,P+"`R,#$T/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXW+#DS
M,RPW-#<\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/C$N-#<\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@-'!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C0N,34\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/C0R+#8T,2PW-S(\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M-'!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET93LG/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[
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M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R<^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SY%>&5R8VES
M86)L92P@4V5P=&5M8F5R(#,P+"`R,#$T/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93L@=&5X="UA;&EG
M;CH-"B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/C<L-S,S+#<T-SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`T<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/C$N,C@\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@-'!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C0N,#$\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXT
M,BPV-#$L-S<R/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P
M=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE
M/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
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M;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\+W`^/'`@
M<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M:6YD96YT.B`P
M<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L
M.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M
M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X\
M<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE
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M=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
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M=7)I;F<@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q
M-"P@=&AE($-O;7!A;GD@9W)A;G1E9"!W87)R86YT<R!T;R!P=7)C:&%S92`Q
M,S<L.34R('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S
M=&]C:R!T;R!I;G9E<W1O<G,@86YD('=A<G)A;G1S('1O('!U<F-H87-E(#8X
M+#DW-B!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O
M8VL@=&\@:71S('!L86-E;65N="!A9V5N="!I;B!C;VYN96-T:6]N('=I=&@@
M=&AE($IA;G5A<GD@,C`Q-"!C;&]S:6YG+CPO9F]N=#X\+W`^/'`@<W1Y;&4]
M,T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#(W+C5P=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT
M+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
M;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI
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M<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O
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M<B`S,"P@,C`Q-"P@=&AE($-O;7!A;GD@86QS;R!G<F%N=&5D('1W;R!C;VYS
M=6QT86YT<R!W87)R86YT<R!T;R!P=7)C:&%S92`R,#`L,#`P('-H87)E<R!O
M9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!W:71H(&5X97)C
M:7-E('!R:6-E<R!R86YG:6YG(&9R;VT@)#4N-34@=&\@)#$Q+C8V('!E<B!S
M:&%R92!A;F0@82!T97)M(&]F(#$P('EE87)S+B!4:&5S92!W87)R86YT<R!V
M97-T('=H96X@8V5R=&%I;B!M:6QE<W1O;F5S(&%R92!M970N(%1H92!F86ER
M('9A;'5E(&]F('1H92!&96)R=6%R>2`R,#$T(&%N9"!*=6YE(#(P,30@=V5R
M92`D,"XV(&UI;&QI;VX@86YD("0Q+C(@;6EL;&EO;BP@<F5S<&5C=&EV96QY
M+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W
M:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G
M:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#(W
M+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO
M<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA
M;#L@;W)P:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E
M+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P
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M;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q-"P@,BPQ,3<L,S`T('=A
M<G)A;G1S('=E<F4@97AE<F-I<V5D(&)Y('1H92!W87)R86YT(&AO;&1E<G,N
M(%1H92!#;VUP86YY(&ES<W5E9"`Q+#DX-"PU,C0@<VAA<F5S(&]F(&-O;6UO
M;B!S=&]C:R!A;F0@<F5C96EV960@9W)O<W,@<')O8V5E9',@;V8@)#$Q-BPY
M,S8N/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N
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M('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X
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M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N
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M<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/D1U<FEN9R!T:&4@=&AR
M964@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q-"!A;F0@,C`Q,RP@
M=&AE($-O;7!A;GD@9&ED(&YO="!R96-O<F0@86YY('-T;V-K+6)A<V5D(&-O
M;7!E;G-A=&EO;B!R96QA=&5D('1O('1H92!W87)R86YT<RX@1'5R:6YG('1H
M92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,30@86YD(#(P
M,3,L('1H92!#;VUP86YY(')E8V]R9&5D('-T;V-K+6)A<V5D(&-O;7!E;G-A
M=&EO;B!R96QA=&5D('1O('1H92!W87)R86YT<R!O9B`D.3@L,C(T(&%N9"`D
M,"P@<F5S<&5C=&EV96QY+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B.3$U9C@P-U]B,S$T7S0S.#1?86$P
M9%]A.3$Y-#AF9F1C,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y+U=O<FMS:&5E
M=',O4VAE970Q,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-U8G-E<75E;G0@179E;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N=',@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W5B<V5Q=65N="!%=F5N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XM=&]P.B`P.R!M87)G:6XM
M8F]T=&]M.B`V<'0[(&UA<F=I;BUL969T.B`P<'0[('1E>'0M:6YD96YT.B`P
M<'0[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\8CY.;W1E(#@@)B,X,C$Q.R!3
M=6)S97%U96YT($5V96YT<R8C,38P.SPO8CX\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU:6X[)SX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[)SY$=7)I
M;F<@3V-T;V)E<B`R,#$T+"!T:&4@0V]M<&%N>2!I<W-U960@87!P<F]X:6UA
M=&5L>2`S.#8L,#`P('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@9F]R('1H92!C
M;VYV97)S:6]N(&]F(&%P<')O>&EM871E;'D@-#@U+#`P,"!W87)R86YT<R!A
M;F0@87!P<F]X:6UA=&5L>2`D,3@L,#`P+CPO<#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V(Y,35F.#`W7V(S,31?-#,X-%]A
M83!D7V$Y,3DT.&9F9&,P.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]B.3$U9C@P-U]B,S$T7S0S.#1?86$P9%]A.3$Y-#AF9F1C,#DO5V]R:W-H
M965T<R]3:&5E=#$T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4$-!13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY$97-C<FEP=&EO;B!O9B!"=7-I;F5S<R!A;F0@4W5M;6%R
M>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A0;VQI8VEE
M<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY$97-C<FEP=&EO;B!O9B!"=7-I;F5S<R!A;F0@4W5M;6%R>2!O9B!3
M:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYA='5R
M92!O9B!"=7-I;F5S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
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M:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/CQB/DYA='5R92!O9B!"=7-I;F5S<R`F(S@R,3$[/"]B/B8C,38P.T%C=&EN
M:75M(%!H87)M86-E=71I8V%L<RP@26YC+B`H=&AE("8C.#(R,#M#;VUP86YY
M)B,X,C(Q.R!O<B`F(S@R,C`[06-T:6YI=6TF(S@R,C$[*2!I<R!A(&)I;W1E
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M0V%N8V5R($-E;G1E<B`H)B,X,C(P.TU32T-#)B,X,C(Q.RD@=6YD97(@86X@
M35-+0T,@4&AY<VEC:6%N($E.1"!!<'!L:6-A=&EO;BX@26X@,C`Q,BP@06-T
M:6YI=6T@;&%U;F-H960@82!M=6QT:2UC96YT97(@8V]R<&]R871E('-P;VYS
M;W)E9"!T<FEA;"!I;B!A8W5T92!M>65L;VED(&QE=6ME;6EA("A!34PI('!A
M=&EE;G1S+B`F(S$V,#M!8W1I;FEU;28C.#(Q-SMS(&]B:F5C=&EV92P@=&AR
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M9F]U;F0N/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@
M875T;SL@=&5X="UI;F1E;G0Z(#!P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C
M:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N
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M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N
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M<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/D]N($1E8V5M8F5R(#(X
M+"`R,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!T<F%N<V%C=&EO
M;B`H=&AE("8C.#(R,#M3:&%R92!%>&-H86YG928C.#(R,3LI+"!P=7)S=6%N
M="!T;R!W:&EC:"!T:&4@0V]M<&%N>2!A8W%U:7)E9"`Q,#`E(&]F('1H92!I
M<W-U960@86YD(&]U='-T86YD:6YG(&5Q=6ET>2!S96-U<FET:65S(&]F($%C
M=&EN:75M(%!H87)M86-E=71I8V%L<RP@26YC+B`H)B,X,C(P.T%0228C.#(R
M,3LI+"!I;B!E>&-H86YG92!F;W(@=&AE(&ES<W5A;F-E(&]F(&%P<')O>&EM
M871E;'D@.3DE(&]F('1H92!I<W-U960@86YD(&]U='-T86YD:6YG(&-O;6UO
M;B!S=&]C:RP@<&%R('9A;'5E("0P+C`Q('!E<B!S:&%R92P@;V8@=&AE($-O
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M8FQE+"!T;R!P=7)C:&%S92!!8W1I;FEU;2!C;VUM;VX@<W1O8VLN)B,Q-C`[
M)B,Q-C`[5&AE(%-H87)E($5X8VAA;F=E('=A<R!A8V-O=6YT960@9F]R(&%S
M(&$@<F5V97)S92!T86ME;W9E<B]R96-A<&ET86QI>F%T:6]N(&5F9F5C=&5D
M(&)Y(&$@<VAA<F4@97AC:&%N9V4L('=H97)E:6X@05!)('=A<R!C;VYS:61E
M<F5D('1H92!A8W%U:7)E<B!F;W(@86-C;W5N=&EN9R!A;F0@9FEN86YC:6%L
M(')E<&]R=&EN9R!P=7)P;W-E<RX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O
M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N
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M<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
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M=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^07,@82!R97-U;'0@;V8@=&AE(%-H87)E($5X8VAA;F=E+"!T:&4@0V]M
M<&%N>2!W87,@=&AE;B!C;VYS:61E<F5D(&$@:&]L9&EN9R!C;VUP86YY(&]P
M97)A=&EN9R!T:')O=6=H($%022P@82!C;&EN:6-A;"US=&%G92!B:6]P:&%R
M;6%C975T:6-A;"!C;VUP86YY(&1E=F5L;W!I;F<@8V5R=&%I;B!C86YC97(@
M=')E871M96YT<RX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P
M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
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M<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y
M;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M
M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^3VX@36%R
M8V@@,C`L(#(P,3,L('1H92!#;VUP86YY)B,X,C$W.W,@<W5B<VED:6%R>2P@
M06-T:6YI=6T@4&AA<FUA8V5U=&EC86QS+"!);F,N+"!C:&%N9V5D(&ET<R!N
M86UE('1O($%C=&EN:75M($-O<G!O<F%T:6]N+B8C,38P.R8C,38P.T]N($%P
M<FEL)B,Q-C`[,3$L(#(P,3,L('1H92!#;VUP86YY(&-H86YG960@:71S(&1O
M;6EC:6QE#0H@9G)O;2!T:&4@4W1A=&4@;V8@3F5V861A('1O('1H92!3=&%T
M92!O9B!$96QA=V%R92!A;F0@8VAA;F=E9"!I=',@;F%M92!F<F]M($-A8W1U
M<R!696YT=7)E<RP@26YC+B!T;R!!8W1I;FEU;2!0:&%R;6%C975T:6-A;',L
M($EN8RX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
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M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G
M8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^3VX@4V5P=&5M8F5R
M(#(U+"`R,#$S+"!I;B!A8V-O<F1A;F-E('=I=&@@82!#97)T:69I8V%T92!O
M9B!/=VYE<G-H:7`@365R9VEN9R!!8W1I;FEU;2!#;W)P;W)A=&EO;B!I;G1O
M('1H92!!8W1I;FEU;2!0:&%R;6%C975T:6-A;',L($EN8RX@*&9I;&5D(&EN
M($1E;&%W87)E+"!T:&4@0V]M<&%N>2!M97)G960@*'1H92`F(S@R,C`[365R
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M<R!E>&-H86YG960@9F]R(#`N,S,S('-H87)E<R!O9B!#;VUP86YY)B,X,C$W
M.W,@8V]M;6]N('-T;V-K+B8C,38P.R8C,38P.T$@=&]T86P@;V8@,RPY-S`L
M,3,W('-H87)E<R!O9B!!8W1I;FEU;2!#;W)P;W)A=&EO;B!C;VUM;VX@<W1O
M8VL@=V%S(&5X8VAA;F=E9"!F;W(@,2PS,C(L,#4U('-H87)E<R!O9B!#;VUP
M86YY(&-O;6UO;B!S=&]C:RX\+V9O;G0^/"]P/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:7,@;V8@4')E<V5N
M=&%T:6]N("T@56YA=61I=&5D($EN=&5R:6T@1FEN86YC:6%L($EN9F]R;6%T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX\8B!S
M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3-P>#L@9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N
M<SH@875T;SL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#4R
M+C<Y.3DY.3(S-S`V,#9P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E
M+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P
M<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/D)A<VES(&]F
M(%!R97-E;G1A=&EO;B`M(%5N875D:71E9"!);G1E<FEM($9I;F%N8VEA;"!)
M;F9O<FUA=&EO;B`F(S@R,3$[/"]B/B8C,38P.U1H92!A8V-O;7!A;GEI;F<@
M=6YA=61I=&5D(&EN=&5R:6T@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T
M96UE;G1S(&%N9"!R96QA=&5D(&YO=&5S(&AA=F4@8F5E;B!P<F5P87)E9"!I
M;B!A8V-O<F1A;F-E('=I=&@@86-C;W5N=&EN9R!P<FEN8VEP;&5S(&=E;F5R
M86QL>2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E<R!O9B!!;65R:6-A
M("@F(S@R,C`[52Y3+B!'04%0)B,X,C(Q.RD@9F]R(&EN=&5R:6T@9FEN86YC
M:6%L(&EN9F]R;6%T:6]N+"!A;F0@:6X@86-C;W)D86YC92!W:71H('1H92!R
M=6QE<R!A;F0@<F5G=6QA=&EO;G,@;V8@=&AE(%5N:71E9"!3=&%T97,@4V5C
M=7)I=&EE<R!A;F0@17AC:&%N9V4@0V]M;6ES<VEO;B`H=&AE("8C.#(R,#M3
M14,F(S@R,C$[*2!W:71H(')E<W!E8W0@=&\@1F]R;2`Q,"U1(&%N9"!!<G1I
M8VQE(#@@;V8@4F5G=6QA=&EO;B!3+5@N($%C8V]R9&EN9VQY+"!T:&5Y(&1O
M(&YO="!I;F-L=61E(&%L;"!O9B!T:&4@:6YF;W)M871I;VX@86YD(&9O;W1N
M;W1E<R!R97%U:7)E9"!B>2!5+E,N($=!05`@9F]R(&-O;7!L971E(&9I;F%N
M8VEA;"!S=&%T96UE;G1S+B!4:&4@=6YA=61I=&5D(&EN=&5R:6T@8V]N<V]L
M:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&9U<FYI<VAE9"!R969L96-T
M(&%L;"!A9&IU<W1M96YT<R`H8V]N<VES=&EN9R!O9B!N;W)M86P@<F5C=7)R
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M<B`S,2P@,C`Q,R!A;F0@;F]T97,@=&AE<F5T;R!C;VYT86EN960@:6X@=&AE
M($-O;7!A;GDF(S@R,3<[<R!A;FYU86P@<F5P;W)T(&]N($9O<FT@,3`M2R!F
M;W(@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3,L(&%S(&9I;&5D
M('=I=&@@=&AE(%-%0R!O;B!&96)R=6%R>2`R."P@,C`Q-"X\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M:6YC:7!L97,@;V8@0V]N<V]L:61A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78^/&(@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$S<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`U,BXW.3DY.3DR,S<P-C`V<'@[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z
M(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SY0<FEN8VEP;&5S(&]F($-O;G-O;&ED871I;VX@)B,X
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M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y5<V4@;V8@17-T:6UA=&5S(&EN($9I;F%N8VEA;"!3=&%T96UE
M;G0@4')E<V5N=&%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=CX\8B!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3-P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO
M<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#4R+C<Y.3DY.3(S-S`V,#9P>#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R
M9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
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M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-L87-S:69I8V%T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX\8B!S
M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3-P>#L@9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N
M<SH@875T;SL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#4R
M+C<Y.3DY.3(S-S`V,#9P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E
M+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P
M<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/E)E8VQA<W-I
M9FEC871I;VX@)B,X,C$Q.SPO8CXF(S$V,#M#97)T86EN('!R:6]R('!E<FEO
M9"!A;6]U;G1S(&AA=F4@8F5E;B!R96-L87-S:69I960@=&\@8V]N9F]R;2!T
M;R!C=7)R96YT('!E<FEO9"!P<F5S96YT871I;VXN/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N
M9"!#87-H($5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/&1I=CX\8B!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M
M<VEZ93H@,3-P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z
M(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#4R+C<Y.3DY.3(S-S`V,#9P>#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@
M=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
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M:6UI=',N($%T(%-E<'1E;6)E<B`S,"P@,C`Q-"!A;F0@1&5C96UB97(@,S$L
M(#(P,3,L(&%L;"!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-A<V@@=V%S(&1E
M<&]S:71E9"!I;B!O;F4@8F%N:RX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!%<75I
M<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/CQB
M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,W!X.R!F
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M='D@86YD($5Q=6EP;65N="`F(S@R,3$[/"]B/B8C,38P.TUA8VAI;F5R>2!A
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M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26UP86ER;65N="!O9B!,;VYG+4QI=F5D($%S<V5T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^/&(@<W1Y;&4],T0G8V]L;W(Z(",P
M,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$S<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`U,BXW.3DY.3DR,S<P-C`V<'@[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W
M:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SY);7!A:7)M96YT(&]F($QO;F<M3&EV960@
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M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV
M871I=F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX\
M8B!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3-P>#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P
M:&%N<SH@875T;SL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#4R+C<Y.3DY.3(S-S`V,#9P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H
M:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG
M.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/D1E<FEV
M871I=F5S("8C.#(Q,3L\+V(^)B,Q-C`[06QL(&1E<FEV871I=F5S(&%R92!R
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M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@;V8@
M1FEN86YC:6%L($EN<W1R=6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O
M=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ
M(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I
M;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M86ER('9A;'5E(&AI97)A<F-H>2!I<R!A<R!F;VQL;W=S.CPO9F]N=#X\+W`^
M/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM
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M('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@
M875T;SL@=&5X="UI;F1E;G0Z(#!P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C
M:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N
M="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X(#!P>"`P<'@@,"XU-6EN
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@
M,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY,979E;"`Q($EN<'5T<R`F
M(S@R,3$[(%5N861J=7-T960@<75O=&5D('!R:6-E<R!I;B!A8W1I=F4@;6%R
M:V5T<R!F;W(@:61E;G1I8V%L(&%S<V5T<R!O<B!L:6%B:6QI=&EE<R!T:&%T
M('1H92!R97!O<G1I;F<@96YT:71Y(&AA<R!T:&4@86)I;&ET>2!T;R!A8V-E
M<W,@870@=&AE(&UE87-U<F5M96YT(&1A=&4N/"]F;VYT/CPO<#X\<"!S='EL
M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
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M9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA<F=I
M;CH@,'!X(#!P>"`P<'@@,"XU-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H
M.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA
M;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P
M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
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M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@@,'!X(#!P>"`P
M+C4U:6X[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/DQE=F5L(#(@26YP
M=71S("8C.#(Q,3L@26YP=71S(&]T:&5R('1H86X@<75O=&5D('!R:6-E<R!I
M;F-L=61E9"!I;B!,979E;"`Q('1H870@87)E(&]B<V5R=F%B;&4@9F]R('1H
M92!A<W-E="!O<B!L:6%B:6QI='DL(&5I=&AE<B!D:7)E8W1L>2!O<B!I;F1I
M<F5C=&QY+B!4:&5S92!M:6=H="!I;F-L=61E('%U;W1E9"!P<FEC97,@9F]R
M('-I;6EL87(@87-S971S(&]R(&QI86)I;&ET:65S)B,Q-C`[:6XF(S$V,#MA
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M:&5R(&UE86YS+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P
M,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA
M;G,Z(&%U=&\[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M
M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>"`P<'@@,'!X(#`N
M-35I;CL@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ
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M.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N="US=')E=&-H.B!N
M;W)M86P[(&UA<F=I;CH@,'!X(#!P>"`P<'@@,"XU-6EN.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH
M96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SY,979E;"`S($EN<'5T<R`F(S@R,3$[(%5N;V)S
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M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
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M:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G
M:6XZ(#!P>#L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G
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M<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C
M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[
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M(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-T<F5T8V@Z#0H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^5&AE(&9O;&QO=VEN9R!T86)L
M97,@<V5T(&9O<G1H(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@;65A<W5R960@
M870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!A;F0@;F]N+7)E8W5R<FEN
M9R!B87-I<R!B>2!L979E;"!W:71H:6X@=&AE(&9A:7(@=F%L=64@:&EE<F%R
M8VAY(&%S(&]F(%-E<'1E;6)E<B`S,"P@,C`Q-"!A;F0@1&5C96UB97(@,S$L
M(#(P,3,N($%S(')E<75I<F5D(&)Y($%30R`X,C`@)B,X,C(P.SQI/D9A:7(@
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M;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT
M+6%L:6=N.B!S=&%R=#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P
M86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N="US=')E=&-H
M.B!N;W)M86P[(&UA<F=I;CH@,'!X.R!T97AT+6EN9&5N=#H@,"XU:6X[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W`^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I
M9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE+6%D
M:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O
M='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED
M.R<@8V]L<W!A;CTS1#(^3&5V96P@,3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
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M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CY,979E
M;"`S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW
M:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L
M<W!A;CTS1#(^5&]T86P\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(^
M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
M8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R/CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D/D1E<FEV
M871I=F4@;&EA8FEL:71I97,Z/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L
M<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(^
M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`X,#-P>#L@<&%D9&EN9RUL969T
M.B`P+C$R-6EN.R<^070@4V5P=&5M8F5R(#,P+"`R,#$T/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$V<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-#)P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXM
M/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T,G!X
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$T,7!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C@L,C$V
M+#DS-3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[
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M;&5F=#H@,"XQ,C5I;CLG/D%T($1E8V5M8F5R(#,Q+"`R,#$S/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXM/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C8L-S`W+#(U-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXV+#<P-RPR-34\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^
M/&1I=CXF(S$V,#L\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M92!487AE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^/&(@<W1Y;&4],T0G8V]L;W(Z(",P
M,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$S<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`U,BXW.3DY.3DR,S<P-C`V<'@[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W
M:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SY);F-O;64@5&%X97,@)B,X,C$Q.SPO8CXF
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M:&5I<B!R96%L:7IA=&EO;BX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!$979E;&]P
M;65N="!#;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD
M:78^/&(@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$S
M<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&]R<&AA;G,Z(&%U=&\[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`U,BXW.3DY.3DR,S<P-C`V<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A
M8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SY2
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M(&-O<W1S+CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAA<F4M0F%S960@4&%Y;65N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/CQB('-T>6QE/3-$)V-O;&]R
M.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,W!X.R!F;VYT+7-T>6QE.B!N;W)M
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M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5A<FYI
M;F=S("A,;W-S*2!097(@0V]M;6]N(%-H87)E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U
M=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L
M.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M
M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^/&(^16%R;FEN9W,@*$QO<W,I(%!E<B!#;VUM;VX@
M4VAA<F4@)B,X,C$Q.SPO8CXF(S$V,#M4:&4@0V]M<&%N>2!C86QC=6QA=&5S
M(&YE="!L;W-S('!E<B!C;VUM;VX@<VAA<F4@:6X@86-C;W)D86YC92!W:71H
M($%30R`R-C`@)B,X,C(P.T5A<FYI;F=S(%!E<B!3:&%R928C.#(R,3L@*"8C
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M:6QU=&EV92X\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
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M;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C4U:6X[)SXF(S$V,#L\+W`^/'1A8FQE('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M('=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE
M+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R
M9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z
M(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X]
M,T0R/E-E<'1E;6)E<B8C,38P.S,P+#QB<B`O/C(P,3,\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CY397!T96UB
M97(F(S$V,#LS,"P\8G(@+SXR,#$T/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-E969F.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,3DQ<'@[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[)SY/<'1I;VYS/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$V<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-#)P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXR+#(X,"PQ.#0\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q-C`[
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M(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/E=A<G)A;G1S/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[
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M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N
M-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
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M;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I
M;F<M8F]T=&]M.B`T<'0[)SY4;W1A;#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D
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M,3$L-S(R+#$R-CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T
M<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P
M=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/C$P+#DS,2PX,S$\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@-'!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R
M/CPO=&%B;&4^/&1I=CXF(S$V,#L\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V5N="!!8V-O=6YT:6YG
M(%!R;VYO=6YC96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
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M=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&(^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',@)B,X,C$Q
M.R8C,38P.SPO8CY);B!-87D@,C`Q-"P@=&AE($9I;F%N8VEA;"!!8V-O=6YT
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M97%U:7)E;65N=',@:6X@5&]P:6,@-C`U+"!2979E;G5E(%)E8V]G;FET:6]N
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M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
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M9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
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M,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
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M9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/DEN($IU;F4@,C`Q-"P@=&AE($9I;F%N8VEA;"!!8V-O
M=6YT:6YG(%-T86YD87)D<R!";V%R9"!I<W-U960@06-C;W5N=&EN9R!3=&%N
M9&%R9',@57!D871E(#(P,30M,3`L($1E=F5L;W!M96YT(%-T86=E($5N=&ET
M:65S+B!4:&4@86UE;F1M96YT<R!I;B!T:&ES(%5P9&%T92!R96UO=F4@=&AE
M(&1E9FEN:71I;VX@;V8@82!D979E;&]P;65N="!S=&%G92!E;G1I='D@9G)O
M;2!4;W!I8R`Y,34L('1H97)E8GD@<F5M;W9I;F<@=&AE(&1I<W1I;F-T:6]N
M(&)E='=E96X@9&5V96QO<&UE;G0@<W1A9V4@96YT:71I97,@86YD(&]T:&5R
M(')E<&]R=&EN9R!E;G1I=&EE<R!F<F]M(%4N4RX@1T%!4"X@26X@861D:71I
M;VXL('1H92!A;65N9&UE;G1S(&5L:6UI;F%T92!T:&4@<F5Q=6ER96UE;G1S
M(&9O<B!D979E;&]P;65N="!S=&%G92!E;G1I=&EE<R!T;R`H,2D@<')E<V5N
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M92!A('9A<FEA8FQE(&EN=&5R97-T(&5N=&ET>2`H5DE%*2!I9B`H,2D@=&AE
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M="!U<VEN9R!T:&4@9W5I9&%N8V4@<')O=FED960@:6X@<&%R86=R87!H<R`X
M,3`M,3`M,C4M-#4@=&AR;W5G:"`R-2TT-RP@=VAI8V@@<F5Q=6ER97,@8F]T
M:"!Q=6%L:71A=&EV92!A;F0@<75A;G1I=&%T:79E(&5V86QU871I;VYS+B!4
M:&4@86UE;F1M96YT<R!I;B!T:&ES(%5P9&%T92!A<F4@969F96-T:79E(&9O
M<B!A;FYU86P@<F5P;W)T:6YG('!E<FEO9',@8F5G:6YN:6YG(&%F=&5R($1E
M8V5M8F5R(#$U+"`R,#$T+"!A;F0@:6YT97)I;2!P97)I;V1S('1H97)E:6XL
M(&%N9"!E87)L>2!A9&]P=&EO;B!I<R!R97%U:7)E9"X@5&AE($-O;7!A;GD@
M979A;'5A=&5D(&%N9"!A9&]P=&5D($%352`R,#$T+3$P(&%T($IU;F4@,S`L
M(#(P,30N/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@
M875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M
M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M
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M)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE
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M+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/DEN($IU;F4@,C`Q
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M97)I;V1S(&)E9VEN;FEN9R!A9G1E<B!$96-E;6)E<B`Q-2P@,C`Q-2P@86YD
M(&5A<FQY(&%D;W!T:6]N(&ES('!E<FUI='1E9"X@5&AE($-O;7!A;GD@:7,@
M8W5R<F5N=&QY(&5V86QU871I;F<@=&AE(&5F9F5C=',@;V8@05-5(#(P,30M
M,3(@;VX@=&AE(&-O;G-O;&ED871E9"!F:6YA;F-I86P-"B!S=&%T96UE;G1S
M+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W
M:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G
M:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/B8C,38P.SPO
M9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O
M=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ
M(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I
M;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^26X@075G=7-T(#(P,30L('1H92!&:6YA;F-I86P@06-C;W5N
M=&EN9R!3=&%N9&%R9',@0F]A<F0@:7-S=65D($%C8V]U;G1I;F<@4W1A;F1A
M<F1S(%5P9&%T92`R,#$T+3$U+"!0<F5S96YT871I;VX@;V8@1FEN86YC:6%L
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M<R!O9B!!4U4@,C`Q-"TQ-2!O;B!T:&4@8V]N<V]L:61A=&5D(&9I;F%N8VEA
M;"!S=&%T96UE;G1S+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)S97%U96YT($5V96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^/&(@<W1Y;&4]
M,T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$S<'@[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U
M=&\[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`U,BXW.3DY
M.3DR,S<P-C`V<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C
M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SY3=6)S97%U96YT($5V
M96YT<R`F(S@R,3$[/"]B/B8C,38P.U1H92!#;VUP86YY)B,X,C$W.W,@;6%N
M86=E;65N="!R979I97=E9"!A;&P@;6%T97)I86P@979E;G1S('1H<F]U9V@@
M=&AE(&1A=&4@;V8@=&AE(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M
M96YT<R!W97)E(&ES<W5E9"!F;W(@<W5B<V5Q=65N="!E=F5N="!D:7-C;&]S
M=7)E(&-O;G-I9&5R871I;VXN/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%]B.3$U9C@P-U]B,S$T7S0S.#1?86$P9%]A
M.3$Y-#AF9F1C,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8CDQ
M-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y+U=O<FMS:&5E=',O
M4VAE970Q-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P13)&/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D1E<V-R:7!T:6]N(&]F($)U<VEN97-S(&%N9"!3=6UM87)Y(&]F(%-I
M9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*%1A8FQE<RD\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$97-C
M<FEP=&EO;B!O9B!"=7-I;F5S<R!A;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N
M="!!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@<V5T
M(&9O<G1H(&QI86)I;&ET:65S(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@
M82!R96-U<G)I;F<@8F%S:7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\9&EV/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^/"]P/CQT86)L92!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T
M:#H@.#`R<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE+6%D:G5S
M=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\
M=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N
M-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O
M;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@
M8V]L<W!A;CTS1#(^3&5V96P@,3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
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M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CY,979E;"`S
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A
M;CTS1#(^5&]T86P\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,2XU<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X\=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(^)B,Q
M-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L
M<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D/D1E<FEV871I
M=F4@;&EA8FEL:71I97,Z/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A
M;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X\=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(^)B,Q
M-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`T,#9P>#L@<&%D9&EN9RUL969T.B`P
M+C$R-6EN.R<^070@4V5P=&5M8F5R(#,P+"`R,#$T/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#AP>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`X<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@-S)P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#AP>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`X<'@[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@.'!X.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#<R<'@[('1E>'0M86QI
M9VXZ(')I9VAT.R<^+3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`X<'@[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@.'!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#AP>#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M-S)P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXX+#(Q-BPY,S4\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@.'!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#AP>#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`X<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#<R<'@[('1E>'0M86QI9VXZ(')I9VAT
M.R<^."PR,38L.3,U/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#AP>#L@=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI
M=&4[)SX\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`P+C$R-6EN.R<^070@
M1&5C96UB97(@,S$L(#(P,3,\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
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M/C8L-S`W+#(U-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SX\+W1D/CPO='(^/"]T86)L93X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
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M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@86YT:61I
M;'5T:79E('-E8W5R:71I97,@97AC;'5D960@9G)O;2!C;VUP=71A=&EO;B!O
M9B!E87)N:6YG<R!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\9&EV/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T
M<F]K92UW:61T:#H@,'!X.R<^/"]P/CQT86)L92!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W
M:61T:#H@.#`R<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE+6%D
M:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R
M+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N
M-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R
M/E-E<'1E;6)E<B8C,38P.S,P+#QB<B`O/C(P,3,\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CY397!T96UB97(F
M(S$V,#LS,"P\8G(@+SXR,#$T/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`V,3!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3LG/D]P=&EO;G,\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@.'!X
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#AP>#L@=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`W
M,G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C(L,C@P+#$X-#PO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`X<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@.'!X.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#AP>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`W,G!X.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/C(L.3DX+#`X-#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`X<'@[
M('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M('=H:71E.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/E=A<G)A;G1S/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
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M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[
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M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`T
M<'0[)SY4;W1A;#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T
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M=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB
M;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/C$P+#DS
M,2PX,S$\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@-'!T.R<^/"]T9#X\+W1R/CPO=&%B;&4^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O
M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#(Y+C=P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P
M.SQB/B8C,38P.SPO8CX\+V9O;G0^/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8CDQ-68X,#=?8C,Q-%\T,S@T
M7V%A,&1?83DQ.30X9F9D8S`Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V(Y,35F.#`W7V(S,31?-#,X-%]A83!D7V$Y,3DT.&9F9&,P.2]7;W)K
M<VAE971S+U-H965T,38N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<R`H5&%B;&5S
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA
M<GD@;V8@86-T:79I=&EE<R!R96QA=&5D('1O(')E;&%T960@<&%R='D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P/CQT
M86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
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M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E
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M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P
M=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CY0
M87EM96YT<SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
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M9R!!<'!L:6-A=&EO;B`H)B,X,C(P.TY$028C.#(R,3LI(&]R(')E9W5L871O
M<GD@87!P<F]V86PF(S$V,#MF;W(@96%C:"!L:6-E;G-E9"!P<F]D=6-T/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#EP>#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`X<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#<S<'@[('1E>'0M86QI9VXZ(')I9VAT.R<^
M-S4P+#`P,#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`X<'@[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXH,BD@=7!O;B!T:&4@
M<F5C96EP="!O9B!R96=U;&%T;W)Y(&%P<')O=F%L(&9R;VT@=&AE(%4N4RX@
M1D1!(&9O<B!E86-H)B,Q-C`[;&EC96YS960@<')O9'5C=#PO=&0^/'1D/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$L-S4P
M+#`P,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V(Y,35F.#`W7V(S,31?-#,X-%]A83!D
M7V$Y,3DT.&9F9&,P.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B
M.3$U9C@P-U]B,S$T7S0S.#1?86$P9%]A.3$Y-#AF9F1C,#DO5V]R:W-H965T
M<R]3:&5E=#$W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N="`H5&%B;&5S*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E
M<G1Y(&%N9"!%<75I<&UE;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!P<F]P97)T
M>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO
M<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C
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M;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL
M93H@<V]L:60[)R!C;VQS<&%N/3-$,CY,:79E<SPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T
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M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P
M=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CXR
M,#$S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS
M1"=W:61T:#H@,3`P,W!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$V<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P
M>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q-#)P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30Q<'@[('1E
M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,35P>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$T,7!X.R!T97AT+6%L:6=N.B!R:6=H=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY/9F9I8V4@97%U
M:7!M96YT/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
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M)SXQ-2PT.#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
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M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU
M<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^*#(U+#,T,SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#LG/BD\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O
M;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXH,2PU-C`\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O
M='1O;3H@,2XU<'0[)SXI/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`T<'0[)SY0<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B;W)D
M97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@
M-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXD/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/C$T,2PP,3$\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E
M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T
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M.SPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X
M9F9D8S`Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(Y,35F.#`W
M7V(S,31?-#,X-%]A83!D7V$Y,3DT.&9F9&,P.2]7;W)K<VAE971S+U-H965T
M,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$4R1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$
M97)I=F%T:79E<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E<FEV871I=F5S(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C
M:&5D=6QE(&]F(&1E<FEV871I=F4@=V%R<F%N="!I;G-T<G5M96YT<R!A8W1I
M=FET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W`^/'1A8FQE('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[('=I9'1H.B`Q-#(R+C<R<'@[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL
M87!S93L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N
M;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
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M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P
M=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CY&
M86ER(%9A;'5E/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N
M-7!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9#XF
M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C965F9CLG/CQT9"!S='EL93TS1"=W:61T:#H@,3`X,2XX,7!X.R<^0F%L
M86YC92P@1&5C96UB97(@,S$L(#(P,3,\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,30N-31P>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-"XU-'!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$R."XQ.'!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$L
M.38X+#8R,SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-"XU-'!X.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
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M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY4
M<F%N<V9E<B!F<F]M(&QI86)I;&ET>2!C;&%S<VEF:6-A=&EO;B!T;R!E<75I
M='D@8VQA<W-I9FEC871I;VX\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXH,S`V+#DP,#PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
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M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,2XU<'0[)SY#:&%N
M9V4@:6X@9F%I<B!V86QU93PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
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M('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[
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M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`T<'0[)SY"86QA;F-E+"!397!T96UB97(@,S`L(#(P
M,30\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F]R9&5R
M+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P
M=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E
M<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/C$L-C8Q+#<R,SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
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M.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@9F%I<B!V
M86QU97,@;V8@9&5R:79A=&EV92!W87)R86YT<R!O;B!B87-I<R!O9B!V86QU
M871I;VX@;6]D96P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,"XU-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US
M=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG/B8C,38P.SPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$T
M,C(N-S)P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
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M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CXR,#$T
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A
M;CTS1#(^,C`Q,SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0^
M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M;VX@;65A<W5R96UE;G0@9&%T92`H,2D\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,30N-31P>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-"XU-'!X.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q,C@N,3AP>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXV+C<P/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T+C4T<'@[('1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30N-31P>#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,RXV,W!X.R!T97AT
M+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,C<N
M,C=P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXU+C@Y/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$S+C8S<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D/D%D:G5S=&5D(&5X97)C
M:7-E('!R:6-E/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/C(N-#@\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/C(N-#@\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY2:7-K(&9R964@:6YT
M97)E<W0@<F%T92`H,BD\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXQ+C`W/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B4\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ+C(W/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B4\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY787)R86YT(&QI
M=F5S(&EN('EE87)S/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M>'0M86QI9VXZ(&QE9G0[)SY%>'!E8W1E9"!D:79I9&5N9"!Y:65L9"`H-"D\
M+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SXM/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/BT\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY0<F]B86)I;&ET>2!O9B!S=&]C
M:R!O9F9E<FEN9R!I;B!A;GD@<&5R:6]D(&]V97(@-2!Y96%R<R`H-2D\+W1D
M/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXR-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXE/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^,C4\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)3PO
M=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0^4F%N9V4@;V8@<&5R8V5N
M=&%G92!O9B!E>&ES=&EN9R!S:&%R97,@;V9F97)E9"`H-BD\+W1D/CQT9#XF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T
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M<F%N9V4@*#<I/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/C<N-3`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/CD\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N
M-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT
M/CPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$T,C(N-S)P>#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E
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M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG.B`P<'@[('=I
M9'1H.B`T,BXW,G!X.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T<F5T8V@Z
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M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG
M/E1H92!M87)K970@=F%L=64@;V8@8V]M;6]N('-T;V-K(&%T('1H92!A8F]V
M92!M96%S=7)E;65N="!D871E<R!I<R!B87-E9"!O;B!T:&4-"B!#;VUP86YY
M)B,X,C$W.W,@=')A9&EN9R!P<FEC92!Q=6]T960@;VX@=&AE($]40R!-87)K
M971S(&9O<B!$96-E;6)E<B`S,2P@,C`Q,R!A;F0@;VX@=&AE($Y94T4@34M4
M(&9O<B!397!T96UB97(@,S`L(#(P,30N/"]F;VYT/CPO=&0^/"]T<CX\+W1A
M8FQE/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#LG/B8C,38P.R8C,38P.SPO9F]N=#X\+W`^/'1A8FQE('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[('=I9'1H.B`Q-#(R+C<R<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@
M9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('9E<G1I
M8V%L+6%L:6=N.B!T;W`[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/'1D('-T
M>6QE/3-$)W=I9'1H.B`T,BXW,G!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@<&%D9&EN9SH@,'!X.R!W:61T:#H@-#(N-S)P>#L@=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B@R*3PO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG.B`P<'@[('=I9'1H.B`Q
M,S,W+C(W<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
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M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
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M+V9O;G0^/"]P/CQT86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,30R,BXW
M,G!X.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O
M<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO
M;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M/CQT<B!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
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M/"]T86)L93X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z
M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^
M)B,Q-C`[/"]F;VYT/CPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z
M(#$T,C(N-S)P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
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M+C<R<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N
M="US=')E=&-H.B!N;W)M86P[)SXH-"D\+V9O;G0^/"]T9#X\=&0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@<&%D9&EN9SH@,'!X.R!W:61T:#H@,3,S-RXR-W!X.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R<^36%N86=E;65N="!D971E<FUI;F5D('1H92!D:79I9&5N
M9"!Y:65L9"!T;R!B92`P)2!B87-E9"!U<&]N(&ET<R!E>'!E8W1A=&EO;B!T
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M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
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M<F]M86XG+"!T:6UE<RP@<V5R:68[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R<^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P
M>#L@=VED=&@Z(#0R+C<R<'@[('1E>'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG.B`P<'@[('=I9'1H.B`T
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M=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#LG/DUA;F%G96UE;G0@9&5T97)M:6YE<R!T:&4@<')O8F%B
M:6QI='D@;V8@9G5T=7)E('-T;V-K(&]F9F5R:6YG(&%T(&5A8V@@979A;'5A
M=&EO;B!D871E+CPO9F]N=#X\+W1D/CPO='(^/'1R('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M('9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^
M/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#!P>#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('!A9&1I;F<Z(#!P>#L@
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US=')E
M=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P
M861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\+W1R
M/CQT<B!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[
M('=I9'1H.B`T,BXW,G!X.R!T97AT+6EN9&5N=#H@,'!X.R<^/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@<&%D9&EN9SH@,'!X.R!W:61T:#H@-#(N-S)P>#L@
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US=')E
M=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#LG/B@V*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!P861D:6YG.B`P<'@[('=I9'1H.B`Q,S,W+C(W<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[#0H@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US=')E=&-H.B!N
M;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#LG/DUA;F%G96UE;G0@97-T:6UA=&5S('1H870@=&AE(')A;F=E(&]F
M('!E<F-E;G1A9V5S(&]F(&5X:7-T:6YG('-H87)E<R!O9F9E<F5D(&EN(&5A
M8V@@<W1O8VL@;V9F97)I;F<@=VEL;"!B92`P)2!A;F0@,S4E(&]F('1H92!S
M:&%R97,@;W5T<W1A;F1I;F<@870@4V5P=&5M8F5R(#,P+"`R,#$T(&%N9"!$
M96-E;6)E<B`S,2P@,C`Q,RP@<F5S<&5C=&EV96QY+CPO9F]N=#X\+W1D/CPO
M='(^/'1R('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O
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M/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!V97)T
M:6-A;"UA;&EG;CH@=&]P.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQT9"!S
M='EL93TS1"=P861D:6YG.B`P<'@[('=I9'1H.B`T,BXW,G!X.R!T97AT+6EN
M9&5N=#H@,'!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@<&%D
M9&EN9SH@,'!X.R!W:61T:#H@-#(N-S)P>#L@=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B@W*3PO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG.B`P<'@[('=I
M9'1H.B`Q,S,W+C(W<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@9F]N="US=')E=&-H.B!N;W)M86P[)SY297!R97-E;G1S('1H
M92!E<W1I;6%T960@;V9F97)I;F<@<')I8V4@<F%N9V4@:6X@9G5T=7)E(&]F
M9F5R:6YG<R!A<R!D971E<FUI;F5D(&)Y(&UA;F%G96UE;G0N/"]F;VYT/CPO
M=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D
M8S`Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(Y,35F.#`W7V(S
M,31?-#,X-%]A83!D7V$Y,3DT.&9F9&,P.2]7;W)K<VAE971S+U-H965T,3DN
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM
M:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`H5&%B;&5S*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE
M;G1S(&%N9"!#;VYT:6YG96YC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@;6EL
M97-T;VYE('!A>6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
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M;6%L.R<^)B,Q-C`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO<#X\=&%B;&4@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@=VED=&@Z(#$T,C(N-S)P>#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O
M;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/E!A>6UE
M;G1S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9#XF(S$V,#L\
M+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q,C4R+C<R<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXH
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M+#`P,#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,RXV,W!X.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*#(I('=H96X@0V]M
M<&%N>2!I;FET:6%T97,@82!0:&%S92!)22!#;&EN:6-A;"!4<FEA;"!O9B!A
M(&QI8V5N<V5D('!R;V1U8W0\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXW-3`L,#`P/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M*#,I('=H96X@0V]M<&%N>2!I;FET:6%T97,@82!0:&%S92!)24D@0VQI;FEC
M86P@5')I86P@;V8@82!L:6-E;G-E9"!P<F]D=6-T/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,2PU,#`L,#`P
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M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ+#<U,"PP,#`\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R
M/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXH-2D@1FER<W0@8V]M;65R8VEA;"!S86QE/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,2PU,#`L
M,#`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B@V*2!A9G1E<B!T:&4@9FER<W0@)#$P+#`P,"PP
M,#`@:6X@;F5T('-A;&5S/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^,2PU,#`L,#`P/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8CDQ
M-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V(Y,35F.#`W7V(S,31?-#,X-%]A83!D7V$Y
M,3DT.&9F9&,P.2]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5'
M1D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D5Q=6ET>2`H5&%B;&5S*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B
M>2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R
M>2!O9B!O<'1I;VX@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQD:78^)B,Q-C`[/"]D:78^/'1A8FQE('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[('=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US
M:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M('-O;&ED.R<@8V]L<W!A;CTS1#(^3G5M8F5R(&]F(%5N:71S/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T
M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^5V5I
M9VAT960@079E<F%G92!%>&5R8VES92!0<FEC93PO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO
M<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M
M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/E=E:6=H=&5D($%V
M97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT@*&EN('EE87)S*3PO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C
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M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS
M1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$
M)W=I9'1H.B`X,35P>#LG/D]U='-T86YD:6YG+"!$96-E;6)E<B`S,2P@,C`Q
M,SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X\
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M9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-#)P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXQ+C`V/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T,7!X.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/C0N.#D\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`P+C$R-6EN.R<^1W)A;G1E9#PO
M=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C0P-BPY,C@\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^."XX,3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXW+C0V/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,"XQ
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M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`N.38\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT
M9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXM
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#$N-7!T.R!P861D:6YG+6QE9G0Z(#`N,3(U:6X[)SY&;W)F
M96ET960\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[
M(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.B!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXH,CDL,38W/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!T97AT+6%L:6=N
M.B!L969T.R<^*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C8N-S`\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU
M<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^3W5T<W1A;F1I
M;F<L(%-E<'1E;6)E<B`S,"P@,C`Q-#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D
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M)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXQ+C0W/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#1P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXT+C$U/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#L@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SXT,BPV-#$L-S<R/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#1P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\
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M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CLG/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^17AE
M<F-I<V%B;&4L(%-E<'1E;6)E<B`S,"P@,C`Q-#PO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW
M:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[('1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9`T*('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T
M<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93L@=&5X="UA;&EG;CH@
M<FEG:'0[)SXW+#<S,RPW-#<\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@-'!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ+C(X/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#1P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXT+C`Q/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^-#(L-C0Q+#<W,CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`T<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/"]T
M86)L93X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ
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M.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW
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M(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
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M=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R<^/"]P/CQD:78^)B,Q-C`[/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C
M:R!/<'1I;VYS(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A
M;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W5M;6%R>2!O9B!O<'1I;VX@86-T:79I=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^)B,Q-C`[/"]D:78^/'1A8FQE('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[('=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S
M93L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M
M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T
M;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^3G5M8F5R(&]F(%5N:71S
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A
M;CTS1#(^5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC93PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O
M='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T
M.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/E=E
M:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT@*&EN
M('EE87)S*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
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M(#@Q-7!X.R<^3W5T<W1A;F1I;F<L($1E8V5M8F5R(#,Q+"`R,#$S/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#)P>#L@=&5X="UA;&EG;CH@<FEG
M:'0[)SXQ+#DX-2PS.#0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V
M<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$T,G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C,N,C,\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30Q<'@[('1E>'0M86QI
M9VXZ(')I9VAT.R<^."XS-#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SXX+C@Y/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/C$P+C`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-E969F.R<^/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,"XQ,C5I;CL@
M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^17AE<F-I<V5D/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@
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M<W1Y;&4Z('-O;&ED.R<^*#,Q,"PT,#`\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,2XU<'0[)SXI/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,"XY-CPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
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M:71E.R<^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SY/=71S
M=&%N9&EN9RP@4V5P=&5M8F5R(#,P+"`R,#$T/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93L@=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0[)SXR+#DY."PP.#0\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@-'!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C4N.3@\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@-'!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C@N-C`\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/C4L-S,Q+#(Y-CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`T<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO
M='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[
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M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG
M/D5X97)C:7-A8FQE+"!397!T96UB97(@,S`L(#(P,30\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T
M;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z
M(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/C8T,RPR,#8\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@-'!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ+C`T/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#1P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXV+C(W/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^,RPW,S0L-C$P/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#1P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\+W1A
M8FQE/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
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M(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V(Y,35F.#`W7V(S,31?-#,X-%]A83!D7V$Y,3DT
M.&9F9&,P.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B.3$U9C@P
M-U]B,S$T7S0S.#1?86$P9%]A.3$Y-#AF9F1C,#DO5V]R:W-H965T<R]3:&5E
M=#(Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%1$M!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N
M9SY$97-C<FEP=&EO;B!O9B!"=7-I;F5S<R!A;F0@4W5M;6%R>2!O9B!3:6=N
M:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$971A:6QS*2`H55-$("0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F(&QI86)I;&ET:65S(&UE87-U<F5D
M(&%T(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E
M(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X
M+#(Q-BPY,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#8L-S`W+#(U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3&5V96P@,2!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O
M9B!L:6%B:6QI=&EE<R!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C
M=7)R:6YG(&)A<VES/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5R:79A=&EV92!L:6%B:6QI='D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y,979E;"`R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F(&QI86)I;&ET:65S(&UE87-U
M<F5D(&%T(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T
M:79E(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE=F5L(#,@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U
M;6UA<GD@;V8@;&EA8FEL:71I97,@;65A<W5R960@870@9F%I<B!V86QU92!O
M;B!A(')E8W5R<FEN9R!B87-I<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I=F4@;&EA8FEL:71Y/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L,C$V+#DS-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BPW,#<L
M,C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B
M.3$U9C@P-U]B,S$T7S0S.#1?86$P9%]A.3$Y-#AF9F1C,#D-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?
M83DQ.30X9F9D8S`Y+U=O<FMS:&5E=',O4VAE970R,BYH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M13)"044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5S8W)I<'1I;VX@;V8@
M0G5S:6YE<W,@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN
M9R!0;VQI8VEE<R`H1&5T86EL<R`Q*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT:61I;'5T:79E(%-E8W5R
M:71I97,@17AC;'5D960@9G)O;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG<R!0
M97(@4VAA<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P+#DS,2PX,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PW,C(L,3(V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O
M;7!U=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY.3@L,#@T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPR.#`L,3@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y787)R86YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT:61I;'5T:79E(%-E8W5R
M:71I97,@17AC;'5D960@9G)O;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG<R!0
M97(@4VAA<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<L.3,S+#<T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDL-#0Q+#DT,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8CDQ-68X,#=?8C,Q-%\T,S@T
M7V%A,&1?83DQ.30X9F9D8S`Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V(Y,35F.#`W7V(S,31?-#,X-%]A83!D7V$Y,3DT.&9F9&,P.2]7;W)K
M<VAE971S+U-H965T,C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,5D%%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/D1E<V-R:7!T:6]N(&]F($)U<VEN97-S(&%N9"!3=6UM
M87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*$1E=&%I
M;',@5&5X='5A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CY-86-H:6YE
M<GD@86YD(&5Q=6EP;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/D9U<FYI='5R92!A;F0@
M9FEX='5R97,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`R."P@,C`Q,CQB<CY!8W1I;FEU;2!;365M8F5R73QB<CYP
M=7)E<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#(U
M+"`R,#$S/&)R/D%C=&EN:75M(%M-96UB97)=/&)R/G!U<F5S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E<V-R:7!T
M:6]N(&]F($)U<VEN97-S(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C
M8V]U;G1I;F<@4&]L:6-I97,@*%1E>'1U86PI/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@
M;W=N97)S:&EP(&EN=&5R97-T(&%C<75I<F5D(&)Y(&-O;7!A;GD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3,N-S`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@4W1O8VL@:7-S=6%B;&4@:6X@8V]N<VED97)A=&EO;B!F;W(@97%U
M:71Y(&EN=&5R97-T(&%C<75I<VET:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3DN,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L
M=64@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17-T:6UA=&5D('5S969U;"!L:79E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG5&AR964@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG5&AR964@=&\@<V5V96X@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(')E8V5I=F5D(&)Y
M(&5A8V@@05!)('-H87)E:&]L9&5R(&]F($%C=&EN:75M(&-O;6UO;B!S=&]C
M:R!F;W(@96%C:"!!4$D@<VAA<F4@97AC:&%N9V5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,"XS,S,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C,S,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#DW,"PQ,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!S:&%R97,@97AC:&%N9V5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S(R+#`U-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8CDQ-68X,#=?
M8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V(Y,35F.#`W7V(S,31?-#,X-%]A83!D7V$Y,3DT.&9F
M9&,P.2]7;W)K<VAE971S+U-H965T,C0N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5*2D%#/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I
M;VYS("A$971A:6QS*2`H365M;W)I86P@4VQO86X@2V5T=&5R:6YG($-A;F-E
M<B!#96YT97(@6TUE;6)E<ETL(%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.97<@1')U9R!!<'!L:6-A=&EO;B!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY3=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT<R!R96QA=&5D('1O(')E
M;&%T960@<&%R='D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DUI;&5S=&]N97,@<&%Y;65N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-S4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C96EP="!O9B!296=U;&%T
M;W)Y($%P<')O=F%L($9R;VT@52Y3+B!&1$$@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!M
M:6QE<W1O;F4@<&%Y;65N=',@<F5L871E9"!T;R!R96QA=&5D('!A<G1Y/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE
M<W1O;F5S('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$L-S4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(Y,35F.#`W7V(S,31?
M-#,X-%]A83!D7V$Y,3DT.&9F9&,P.2]7;W)K<VAE971S+U-H965T,C4N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$4R-D=+/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)E;&%T
M960@4&%R='D@5')A;G-A8W1I;VYS("A$971A:6QS(%1E>'1U86PI("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,"!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5L+B`P-RP@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#(T+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D%P<BX@,C@L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#$P+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,3`L(#(P,30\8G(^
M4&QA8V5M96YT(&%G96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,#DL(#(P,3,\8G(^4&QA8V5M96YT(&%G96YT
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%U
M9RX@,#<L(#(P,3(\8G(^4&QA8V5M96YT(&%G96YT(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^
M4&QA8V5M96YT(&%G96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,C<L(#(P,3,\8G(^26YV97-T;W)S(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,S$L
M(#(P,30\8G(^0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^0V]M;6]N(%-T
M;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIA;BX@,S$L(#(P,30\8G(^0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/E!L
M86-E;65N="!A9V5N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$T/&)R/E=A<G)A;G0@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`Q,"P@,C`Q
M-#QB<CY)4$\@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CY)4$\@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CY-4TM#
M0R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/DU32T-#(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^35-+0T,@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,SQB<CY-4TM#0R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/DU32T-#(%M-96UB97)=
M/&)R/D-L:6YI8V%L(%1R:6%L($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/DU3
M2T-#(%M-96UB97)=/&)R/D-L:6YI8V%L(%1R:6%L($%G<F5E;65N="!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$R/&)R/DU32T-#(%M-96UB97)=/&)R/D-L:6YI8V%L(%1R:6%L($%G
M<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#(W+"`R,#$R/&)R/DU32T-#(%M-96UB97)=/&)R/D-L:6YI
M8V%L(%1R:6%L($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#`T+"`R,#$S/&)R/E-+22!;365M8F5R
M73QB<CY,:6-E;G-E+"!$979E;&]P;65N="!A;F0@0V]M;65R8VEA;&EZ871I
M;VX@06=R965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;BX@,3DL(#(P,3$\8G(^4TM)(%M-96UB97)=/&)R/DQI
M8V5N<V4L($1E=F5L;W!M96YT(&%N9"!#;VUM97)C:6%L:7IA=&EO;B!!9W)E
M96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q-#QB<CY32TD@6TUE;6)E<ET\8G(^3&EC96YS92P@
M1&5V96QO<&UE;G0@86YD($-O;6UE<F-I86QI>F%T:6]N($%G<F5E;65N="!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<R`H5&5X='5A;"D\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO=6YT('!A:60@=6YD97(@86=R
M965M96YT(&EN(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W5N="!P
M86ED('5N9&5R(&%G<F5E;65N="!I;B`R,#$R/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%M;W5N="!P86ED('5N9&5R(&%G<F5E;65N="!I;B`R,#$S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%M;W5N="!O=V5D('5N9&5R(&%G<F5E;65N="!F
M<F]M(#(P,3$@=&\@,C`Q-#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#$U+#$P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-86EN=&5N
M86YC92!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$Y-RPQ,#8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3@L-C`T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<X+#(Y,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Q+#$X
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$X.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!L86-E;65N="!A9V5N="!S97)V:6-E<R!F
M965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9"!T;R!P
M=7)C:&%S92!C;VUM;VX@<W1O8VLL('-H87)E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV."PY-S8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!S=&]C:R!E>&5R8VES92!P<FEC92!P97(@<VAA<F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%M;W5N="!P86ED('1O(&5A8V@@<&%T:65N="!A
M9G1E<B!#;VUP;&5T:6YG(&-L:6YI8V%L('1R:6%L/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q+#$X
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4W1A<G0M=7`@9F5E(&9O<B!C;&EN:6-A;"!T<FEA;#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<Y+#8R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E<V-R:7!T:6]N(&]F(')E8V5I=F%B;&5S(&]F('!L
M86-E;65N="!A9V5N="!F;W(@<V5R=FEC97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B=!9W)E96UE;G0@96YT97)E9"!I;B!O;B!$
M96-E;6)E<B`Y+"`R,#$S(&AA9"!S:6UI;&%R('1E<FUS(&%S('1H92`R,#$R
M(&%G<F5E;65N="P@:6YC;'5D:6YG(&$@8V%S:"!F964@97%U86P@=&\@,3`E
M(&]F('1H92!G<F]S<R!P<F]C965D<R!R86ES960L(&$@;F]N+6%C8V]U;G1A
M8FQE(&5X<&5N<V4@<F5I;6)U<G-E;65N="!E<75A;"!T;R`R)2!O9B!T:&4@
M9W)O<W,@<')O8V5E9',@<F%I<V5D(&%N9"!W87)R86YT<R!T;R!P=7)C:&%S
M92!S:&%R97,@;V8@=&AE($-O;7!A;GDG<R!#;VUM;VX@4W1O8VL\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CY0
M;&%C96UE;G0@86=E;G0@<F5C96EV960@*&$I(&$@8V%S:"!F964@97%U86P@
M=&\@,3`E(&]F('1H92!G<F]S<R!P<F]C965D<R!R86ES960@:6X@=&AE(#(P
M,3(@0V]M;6]N(%-T;V-K($]F9F5R:6YG+"`H8BD@82!N;VXM86-C;W5N=&%B
M;&4@97AP96YS92!R96EM8G5R<V5M96YT(&5Q=6%L('1O(#(E(&]F('1H92!G
M<F]S<R!P<F]C965D<R!R86ES960@:6X@=&AE(#(P,3(@0V]M;6]N(%-T;V-K
M($]F9F5R:6YG+"!A;F0@*&,I(')E:6UB=7)S96UE;G0@;V8@)#$P,"PP,#`@
M9F]R(&QE9V%L(&5X<&5N<V5S(&EN8W5R<F5D(&)Y('1H92!P;&%C96UE;G0@
M86=E;G0N/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5S8W)I<'1I;VX@
M;V8@=V%R<F%N=',@<F5C96EV86)L97,@8GD@<&QA8V5M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG5V%R<F%N=',@=&\@<'5R
M8VAA<V4@<VAA<F5S(&]F('1H92!#;VUP86YY)W,@0V]M;6]N(%-T;V-K(&EN
M(&%N(&%M;W5N="!E<75A;"!T;R`Q,"4@;V8@=&AE('-H87)E<R!O9B!C;VUM
M;VX@<W1O8VL@:7-S=65D(&]R(&ES<W5A8FQE/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U1H92!P;&%C96UE;G0@86=E
M;G0@;W(@:71S(&1E<VEG;F5E<R!A;'-O(')E8V5I=F5D('=A<G)A;G1S('1O
M('!U<F-H87-E('-H87)E<R!O9B!T:&4@0V]M<&%N>2=S($-O;6UO;B!3=&]C
M:R!I;B!A;B!A;6]U;G0@97%U86P@=&\@,3`E(&]F('1H92!S:&%R97,@;V8@
M8V]M;6]N('-T;V-K(&ES<W5E9"!A<R!P87)T(&]F('1H92!U;FET<R!S;VQD
M(&EN('1H92`R,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN9R!A;F0@=&AE('-H
M87)E<R!O9B!#;VUM;VX@4W1O8VL@:7-S=6%B;&4@=7!O;B!E>&5R8VES92!O
M9B!T:&4@0B!W87)R86YT<R!I;F-L=61E9"!I;B!S=6-H('5N:71S+CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!E<FEO9"!O9B!E>&5R8VES92!O9B!W87)R86YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=7:71H
M:6X@-B!M;VYT:',@;V8@=&AE(&9I;F%L(&-L;W-I;F<@;V8@=&AE(#(P,3(@
M8V]M;6]N('-T;V-K($]F9F5R:6YG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!E<F-E;G1A9V4@;V8@<V]L:6-I=&%T:6]N(&9E93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^36]N=&AL>2!F964@9F]R(&9I;F%N8VEA;"!A9'9I<V]R>2!S
M97)V:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5S8W)I<'1I;VX@
M;V8@861D:71I;VYA;"!R96-E:79A8FQE(&)Y('!L86-E;65N="!A9V5N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=4:&4@86=R
M965M96YT(&%L<V\@<')O=FED97,@=&AA="`H:2D@:68@=&AE($-O;7!A;GD@
M8V]N<W5M;6%T97,@86YY(&UE<F=E<BP@86-Q=6ES:71I;VXL(&)U<VEN97-S
M(&-O;6)I;F%T:6]N(&]R(&]T:&5R('1R86YS86-T:6]N("AO=&AE<B!T:&%N
M('1H92!3:&%R92!%>&-H86YG92D@=VET:"!A;GD@<&%R='D@:6YT<F]D=6-E
M9"!T;R!I="!B>2!T:&4@<&QA8V5M96YT(&%G96YT+"!T:&4@<&QA8V5M96YT
M(&%G96YT('=O=6QD(')E8V5I=F4@82!F964@97%U86P@=&\@,3`E(&]F('1H
M92!A9V=R96=A=&4@8V]N<VED97)A=&EO;B!I;B!S=6-H('1R86YS86-T:6]N
M<RP@86YD("AI:2D@:68L('=I=&AI;B!A('!E<FEO9"!O9B`Q,B!M;VYT:',@
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M="`W+"`R,#$R(&5N9V%G96UE;G0@86=R965M96YT+CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G0@:&5L9"!B>2!P;&%C96UE;G0@86=E;G0@=&\@<'5R
M8VAA<V4@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PR-3$L,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F]Y
M86QT>2!D97-C<FEP=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)U5N9&5R('1H92!A9W)E96UE;G0L('1H
M92!#;VUP86YY('-H86QL('!A>2!T;R!-4TM#0R!O;B!A(&-O=6YT<GDM8GDM
M8V]U;G1R>2!B87-I<R!A(')O>6%L='D@;V8@,B4@;V8@;F5T('-A;&5S(&]F
M(&%L;"!L:6-E;G-E9"!P<F]D=6-T<R!U;G1I;"!T:&4@;&%T97(@;V8Z("@Q
M*2`Q,"!Y96%R<R!F<F]M('1H92!F:7)S="!C;VUM97)C:6%L('-A;&4L(&]R
M("@R*2!W:&5N('1H92!P871E;G1S(&5X<&ER92X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-T;V-K('-O;&0L(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C$L-3,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4U-"PS,3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-3$L.#$P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY.#0L-3(T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#@R-RPQ,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#8W,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@9W)A
M;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$S-RPY-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE(&]F(%-T;V-K+"!0<FEC
M92!097(@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#<N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<N-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;&%S
M<R!O9B!787)R86YT(&]R(%)I9VAT+"!%>&5R8VES92!0<FEC92!O9B!787)R
M86YT<R!O<B!2:6=H=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S<R!P<F]C965D
M<R!F<F]M('1H92!S86QE(&]F('-E8W5R:71I97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPS,3`L.#8P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPS,C4L.#8P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E5N9&5R=W)I=&EN9R!D:7-C;W5N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPW,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#<V+#<U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S<R!P<F]C965D<R!R96-E:79E
M9"!I;B!/9F9E<FEN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#8L-C,V+#<R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,BPV,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,2PT-3$L
M,C4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!O9F9E<FEN9R!A;6]U;G0@;V8@
M<V5C=7)I=&EE<R!S;VQD('1O(&EN=F5S=&]R<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B=4:&4@0V]M<&%N>2!W:6QL('!A>2!-3%8@:6X@
M8V%S:"P@=7!O;B!T:&4@<V%L92!O9B!C;VUM;VX@<W1O8VL@<'5R<W5A;G0@
M=&\@=&AE(%-A;&5S($%G<F5E;65N="P@86X@86UO=6YT(&5Q=6%L('1O(#,N
M,"4@;V8@=&AE(&=R;W-S('!R;V-E961S(&9R;VT@=&AE('-A;&4@;V8@8V]M
M;6]N('-T;V-K+B!/;B!!<')I;"`R."P@,C`Q-"P@=&AE($-O;7!A;GD@:7-S
M=65D(#4P,"!S:&%R97,@86YD(')E8V5I=F5D(&YE="!P<F]C965D<R!O9B`D
M-BPP,#`@=6YD97(@=&AE(%-A;&5S($%G<F5E;65N="!W:71H($U,5BX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M06=G<F5G871E(&]F9F5R:6YG(&%M;W5N="!O9B!S96-U<FET:65S('-O;&0@
M=&\@:6YV97-T;W)S('=A<R!I;F-R96%S960@9G)O;2`D-BPP,#`L,#`P('1O
M("0V+#8S-BPW,C`@:6X@;W)D97(@=&\@8V]V97(@;W9E<BUA;&QO=&UE;G1S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)T9I=F4M>65A<B!W87)R86YT<R!T;R!P=7)C:&%S92!A;B!A9V=R96=A
M=&4@;V8@,3,X+#4W-R!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%T(&%N(&5X
M97)C:7-E('!R:6-E(&]F("0Y+C`P('!E<B!S:&%R92X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(Y,35F.#`W7V(S,31?-#,X-%]A83!D
M7V$Y,3DT.&9F9&,P.2]7;W)K<VAE971S+U-H965T,C8N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$553D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%
M<75I<&UE;G0@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^
M36%X:6UU;2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$T/&)R/DUI;FEM=6T@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R
M>2!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<V5F=6P@3&EV97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,R!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3V9F:6-E(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q-C8L,S4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q-2PT.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5S<SH@86-C=6UU;&%T960@
M9&5P<F5C:6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M-2PS-#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,2PU-C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$T,2PP,3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$S+#DR,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B.3$U
M9C@P-U]B,S$T7S0S.#1?86$P9%]A.3$Y-#AF9F1C,#D-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ
M.30X9F9D8S`Y+U=O<FMS:&5E=',O4VAE970R-RYH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14M(
M04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP
M;65N="`H1&5T86EL<R!497AT=6%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY0<F]P97)T>2!A;F0@17%U:7!M96YT("A497AT=6%L*3PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C
M:6%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,30L,S(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C,L-S@S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&]S<R!O;B!D:7-P;W-I=&EO;B!O9B!E<75I<&UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-"PQ,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V(Y,35F.#`W7V(S,31?-#,X-%]A83!D7V$Y,3DT
M.&9F9&,P.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B.3$U9C@P
M-U]B,S$T7S0S.#1?86$P9%]A.3$Y-#AF9F1C,#DO5V]R:W-H965T<R]3:&5E
M=#(X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%3DA!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY.;W1E(%!A>6%B;&4@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N+B`S,2P@,C`Q-#QB<CY0
M<F5M:75M($9I;F%N8V4@06=R965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^4')E;6EU
M;2!&:6YA;F-E($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/E!R96UI=6T@1FEN
M86YC92!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`R."P@,C`Q,SQB<CY0<F5M:75M($9I;F%N8V4@
M06=R965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&4@4&%Y86)L92!A;F0@0V]N=F5R=&EB
M;&4@3F]T97,@*%1E>'1U86PI/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO=&5S('!A>6%B;&4L(&]U='-T86YD
M:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q-3<L.#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q-3<L.#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;W=N('!A>6UE;G0@<'5R<W5A
M;G0@=&\@=&AE(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-2PY.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W5N="!R97%U:7)E9"!T;R!P87D@:6X@
M;6]N=&AL>2!I;G-T86QL;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,34L.3DU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!A>6UE;G1S(&]N(&YO=&4@<&%Y86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-3<L.#(U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(Y,35F.#`W7V(S,31?-#,X-%]A
M83!D7V$Y,3DT.&9F9&,P.2]7;W)K<VAE971S+U-H965T,CDN:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$533$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1E<FEV871I=F5S
M("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!D97)I=F%T:79E
M('=A<G)A;G0@:6YS=')U;65N=',@86-T:79I='D\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@8F%L86YC
M92P@56YI=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.38X
M+#8R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1R86YS9F5R($9R;VT@3&EA8FEL:71Y($-L87-S:69I8V%T:6]N
M(%1O($5Q=6ET>2!#;&%S<VEF:6-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,S`V+#DP,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E+"!5;FET<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV-C$L-S(S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG
M(&)A;&%N8V4L($9A:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-BPW,#<L,C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5')A;G-F97(@9G)O;2!L:6%B:6QI='D@
M8VQA<W-I9FEC871I;VX@=&\@97%U:71Y(&-L87-S:69I8V%T:6]N+"!&86ER
M(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#$T,RPW
M.3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-C`P+#@X,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F86ER('9A;'5E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS+#8U,RPT-S,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E+"!&86ER
M(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L,C$V
M+#DS-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V(Y,35F.#`W7V(S,31?-#,X-%]A83!D7V$Y,3DT.&9F9&,P.0T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B.3$U9C@P-U]B,S$T7S0S.#1?86$P
M9%]A.3$Y-#AF9F1C,#DO5V]R:W-H965T<R]3:&5E=#,P+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%-4%!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$97)I=F%T:79E<R`H
M1&5T86EL<R`Q*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/E-E<"X@,S`L(#(P,30\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^
M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F(&9A:7(@=F%L=65S(&]F(&1E<FEV
M871I=F4@=V%R<F%N=',@;VX@8F%S:7,@;V8@=F%L=6%T:6]N(&UO9&5L/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^36%R:V5T('9A;'5E(&]F(&-O;6UO;B!S=&]C:R!O;B!M
M96%S=7)E;65N="!D871E("@Q*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`V+C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-2XX.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!9&IU<W1E9"!E>&5R8VES92!P<FEC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C0X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R+C0X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y2:7-K(&9R964@:6YT97)E<W0@<F%T92`H,BD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,#<E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S)=/"]S=7`^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C(W)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELR73PO<W5P
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(&QI
M=F5S(&EN('EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M,R!Y96%R<R`R(&UO;G1H<R`Q,B!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)S8@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>'!E8W1E9"!V;VQA=&EL:71Y("@S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S0N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S-=/"]S=7`^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW,RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,UT\+W-U<#X\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@9&EV:61E;F0@
M>6EE;&0@*#0I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CQS=7`^6S1=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S1=/"]S=7`^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V)A8FEL:71Y(&]F('-T;V-K(&]F
M9F5R:6YG(&EN(&%N>2!P97)I;V0@;W9E<B`U('EE87)S("@U*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S5=/"]S=7`^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2XP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;-5T\+W-U
M<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@;V8@
M<&5R8V5N=&%G92!O9B!E>&ES=&EN9R!S:&%R97,@;V9F97)E9"`H-BD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;
M-ET\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M<W5P/ELV73PO<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/9F9E<FEN9R!P<FEC92!R86YG92`H-RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-RXU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CQS=7`^6S==/"]S=7`^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;-UT\+W-U<#X\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1D(&-O;'-P86X],T0U/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T
M;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;,5T\+W1D/@T*("`@
M("`@("`\=&0@8V]L<W!A;CTS1#0@=F%L:6=N/3-$=&]P/E1H92!M87)K970@
M=F%L=64@;V8@8V]M;6]N('-T;V-K(&%T('1H92!A8F]V92!M96%S=7)E;65N
M="!D871E<R!I<R!B87-E9"!O;B!T:&4@0V]M<&%N>2=S('1R861I;F<@<')I
M8V4@<75O=&5D(&]N('1H92!/5$,@36%R:V5T<R!F;W(@1&5C96UB97(@,S$L
M(#(P,3,@86YD(&]N('1H92!.65-%($U+5"!F;W(@4V5P=&5M8F5R(#,P+"`R
M,#$T+CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN
M97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;,ET\+W1D
M/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#0@=F%L:6=N/3-$=&]P/E1H92!R
M:7-K+69R964@:6YT97)E<W0@<F%T92!W87,@9&5T97)M:6YE9"!B>2!M86YA
M9V5M96YT('5S:6YG('1H92!4<F5A<W5R>2!":6QL(&%S(&]F('1H92!R97-P
M96-T:79E(&UE87-U<F5M96YT(&1A=&4N/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1I;FYE<D9O;W1N;W1E/@T*("`@("`@("`\=&0@
M=F%L:6=N/3-$=&]P/ELS73PO=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$
M-"!V86QI9VX],T1T;W`^0F5C875S92!T:&4@0V]M<&%N>2!D;V5S(&YO="!H
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M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-
M"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;-%T\+W1D/@T*("`@("`@("`\
M=&0@8V]L<W!A;CTS1#0@=F%L:6=N/3-$=&]P/DUA;F%G96UE;G0@9&5T97)M
M:6YE9"!T:&4@9&EV:61E;F0@>6EE;&0@=&\@8F4@,"4@8F%S960@=7!O;B!I
M=',@97AP96-T871I;VX@=&AA="!I="!W:6QL(&YO="!P87D@9&EV:61E;F1S
M(&9O<B!T:&4@9F]R97-E96%B;&4@9G5T=7)E+CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@
M/'1D('9A;&EG;CTS1'1O<#Y;-5T\+W1D/@T*("`@("`@("`\=&0@8V]L<W!A
M;CTS1#0@=F%L:6=N/3-$=&]P/DUA;F%G96UE;G0@9&5T97)M:6YE<R!T:&4@
M<')O8F%B:6QI='D@;V8@9G5T=7)E('-T;V-K(&]F9F5R:6YG(&%T(&5A8V@@
M979A;'5A=&EO;B!D871E+CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS
M1'1O<#Y;-ET\+W1D/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#0@=F%L:6=N
M/3-$=&]P/DUA;F%G96UE;G0@97-T:6UA=&5S('1H870@=&AE(')A;F=E(&]F
M('!E<F-E;G1A9V5S(&]F(&5X:7-T:6YG('-H87)E<R!O9F9E<F5D(&EN(&5A
M8V@@<W1O8VL@;V9F97)I;F<@=VEL;"!B92`P)2!A;F0@,S4E(&]F('1H92!S
M:&%R97,@;W5T<W1A;F1I;F<@870@4V5P=&5M8F5R(#,P+"`R,#$T(&%N9"!$
M96-E;6)E<B`S,2P@,C`Q,RP@<F5S<&5C=&EV96QY+CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-"B`@("`@
M("`@/'1D('9A;&EG;CTS1'1O<#Y;-UT\+W1D/@T*("`@("`@("`\=&0@8V]L
M<W!A;CTS1#0@=F%L:6=N/3-$=&]P/E)E<')E<V5N=',@=&AE(&5S=&EM871E
M9"!O9F9E<FEN9R!P<FEC92!R86YG92!I;B!F=71U<F4@;V9F97)I;F=S(&%S
M(&1E=&5R;6EN960@8GD@;6%N86=E;65N="X\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(Y,35F.#`W7V(S,31?
M-#,X-%]A83!D7V$Y,3DT.&9F9&,P.2]7;W)K<VAE971S+U-H965T,S$N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5504%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1E<FEV
M871I=F5S("A$971A:6QS(%1E>'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^
M4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,CY$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E<FEV871I=F5S("A497AT
M=6%L*3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)A;F=E(&]F('!E<F-E;G1A9V4@;V8@97AI
M<W1I;F<@<VAA<F5S(&]F9F5R960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,U+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!D:79I9&5N9"!Y
M:65L9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\<W5P/ELR73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\<W5P/ELR73PO<W5P/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY$97)I=F%T:79E<R`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A
M;'5E(&]F('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#X@,BPQ-#,L-SDS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('=A<G)A
M;G0@97AE<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#$Q-RPS,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E('=A<G)A;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#8L.3`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1D(&-O;'-P86X],T0U/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-"B`@
M("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;,5T\+W1D/@T*("`@("`@("`\=&0@
M8V]L<W!A;CTS1#0@=F%L:6=N/3-$=&]P/DUA;F%G96UE;G0@97-T:6UA=&5S
M('1H870@=&AE(')A;F=E(&]F('!E<F-E;G1A9V5S(&]F(&5X:7-T:6YG('-H
M87)E<R!O9F9E<F5D(&EN(&5A8V@@<W1O8VL@;V9F97)I;F<@=VEL;"!B92`P
M)2!A;F0@,S4E(&]F('1H92!S:&%R97,@;W5T<W1A;F1I;F<@870@4V5P=&5M
M8F5R(#,P+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q,RP@<F5S<&5C=&EV
M96QY+CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN
M97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;,ET\+W1D
M/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#0@=F%L:6=N/3-$=&]P/DUA;F%G
M96UE;G0@9&5T97)M:6YE9"!T:&4@9&EV:61E;F0@>6EE;&0@=&\@8F4@,"4@
M8F%S960@=7!O;B!I=',@97AP96-T871I;VX@=&AA="!I="!W:6QL(&YO="!P
M87D@9&EV:61E;F1S(&9O<B!T:&4@9F]R97-E96%B;&4@9G5T=7)E+CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B.3$U9C@P-U]B,S$T7S0S.#1?86$P
M9%]A.3$Y-#AF9F1C,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y+U=O<FMS:&5E
M=',O4VAE970S,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15-7044^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@*$1E=&%I
M;',I("A!8F)V:65W($)I;W1H97)A<&5U=&EC<R!#;W)P(%M-96UB97)=+"!5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4&AA<V4@22!#;&EN:6-A;"!4<FEA;"!O9B!A(&QI8V5N<V5D('!R;V1U8W0@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4W5M;6%R>2!O9B!M:6QE<W1O;F4@<&%Y;65N=#PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EL97-T;VYE<R!P
M87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W-3`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0:&%S92!)22!#;&EN:6-A;"!4<FEA;"!O9B!A(&QI8V5N<V5D('!R
M;V1U8W0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!M:6QE<W1O;F4@<&%Y;65N=#PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EL97-T
M;VYE<R!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4&AA<V4@24E)($-L:6YI8V%L(%1R:6%L(&]F(&$@;&EC96YS
M960@<')O9'5C="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-
M:6QE<W1O;F5S('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D)I;VQO9VEC86P@3&EC96YS92!!<'!L:6-A=&EO
M;B!F:6QI;F<@=VET:"!5+E,N($9$02!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F(&UI;&5S
M=&]N92!P87EM96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y-:6QE<W1O;F5S('!A>6UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I<G-T($-O;6UE<F-I86P@
M4V%L92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O
M;F5S('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%F=&5R($9I<G-T($YE="!386QE<R!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y
M(&]F(&UI;&5S=&]N92!P87EM96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F5S('!A>6UE;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-3`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8CDQ-68X,#=?8C,Q
M-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V(Y,35F.#`W7V(S,31?-#,X-%]A83!D7V$Y,3DT.&9F9&,P
M.2]7;W)K<VAE971S+U-H965T,S,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,645-/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC
M:65S("A$971A:6QS(%1E>'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0W/CD@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,SXQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`R,"P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,C<L(#(P,30\
M8G(^36%N=69A8W1U<FEN9R!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CY-86YU
M9F%C='5R:6YG($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/D5I;G-T96EN(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,30\8G(^06)B=FEE=R!":6]T:&5R87!E=71I8W,@0V]R<"!;365M
M8F5R73QB<CY0<F]D=6-T($1E=F5L;W!M96YT(&%N9"!0871E;G0@3&EC96YS
M92!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CY!8F)V:65W($)I;W1H97)A<&5U
M=&EC<R!#;W)P(%M-96UB97)=/&)R/D%F=&5R($9I<G-T($YE="!386QE<R!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$T/&)R/D%B8G9I97<@0FEO=&AE<F%P975T:6-S($-O<G`@6TUE
M;6)E<ET\8G(^4&AA<V4@22!#;&EN:6-A;"!4<FEA;"!O9B!A(&QI8V5N<V5D
M('!R;V1U8W0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CY!8F)O='0@0FEO=&AE<F%P975T:6-S
M($-O<G`@6TUE;6)E<ET\8G(^069T97(@1FER<W0@3F5T(%-A;&5S(%M-96UB
M97)=/&)R/E!R;V1U8W0@1&5V96QO<&UE;G0@86YD(%!A=&5N="!,:6-E;G-E
M($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/D%B8F]T="!":6]T:&5R87!E=71I
M8W,@0V]R<"!;365M8F5R73QB<CY0:&%S92!)($-L:6YI8V%L(%1R:6%L(&]F
M(&$@;&EC96YS960@<')O9'5C="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/D]A:R!2:61G92!.
M871I;VYA;"!,86)O<F%T;W)Y(%M-96UB97)=/&)R/C(P,3,@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M-#QB<CY/86L@4FED9V4@3F%T:6]N86P@3&%B;W)A=&]R>2!;365M8F5R73QB
M<CXR,#$T(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA>2`Q-BP@,C`Q,SQB<CY!<'1I=B!3;VQU=&EO;G,@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`R,BP@,C`Q
M,CQB<CY!<'1I=B!3;VQU=&EO;G,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^075G+B`P-BP@,C`Q,CQB<CY!<'1I=B!3;VQU
M=&EO;G,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`P-SQB<CY!<'1I=B!3;VQU=&EO;G,@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M-#QB<CY!<'1I=B!3;VQU=&EO;G,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY!<'1I=B!3;VQU
M=&EO;G,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`Q-2P@,C`Q,CQB<CY&<F5D($AU=&-H:6YS;VX@0V%N8V5R(%)E
M<V5A<F-H($-E;G1E<B!;365M8F5R73QB<CYL:6-E;G-E(&%N9"!S<&]N<V]R
M960@<F5S96%R8V@@86=R965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^1G)E9"!(=71C
M:&EN<V]N($-A;F-E<B!297-E87)C:"!#96YT97(@6TUE;6)E<ET\8G(^;&EC
M96YS92!A;F0@<W!O;G-O<F5D(')E<V5A<F-H(&%G<F5E;65N="!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$S/&)R/D9R960@2'5T8VAI;G-O;B!#86YC97(@4F5S96%R8V@@0V5N=&5R
M(%M-96UB97)=/&)R/FQI8V5N<V4@86YD('-P;VYS;W)E9"!R97-E87)C:"!A
M9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CY&<F5D($AU=&-H:6YS;VX@0V%N8V5R
M(%)E<V5A<F-H($-E;G1E<B!;365M8F5R73QB<CY#;&EN:6-A;"!4<FEA;"!!
M9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY&<F5D($AU=&-H:6YS;VX@0V%N8V5R
M(%)E<V5A<F-H($-E;G1E<B!;365M8F5R73QB<CY#;&EN:6-A;"!4<FEA;"!!
M9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5L+B`Q.2P@,C`Q,CQB<CY&<F5D($AU=&-H:6YS;VX@0V%N8V5R
M(%)E<V5A<F-H($-E;G1E<B!;365M8F5R73QB<CY#;&EN:6-A;"!4<FEA;"!!
M9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5N+B`Q-2P@,C`Q,CQB<CY&<F5D($AU=&-H:6YS;VX@0V%N8V5R
M(%)E<V5A<F-H($-E;G1E<B!;365M8F5R73QB<CY-87AI;75M(%M-96UB97)=
M/&)R/FQI8V5N<V4@86YD('-P;VYS;W)E9"!R97-E87)C:"!A9W)E96UE;G0@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N
M+B`Q-2P@,C`Q,CQB<CY&<F5D($AU=&-H:6YS;VX@0V%N8V5R(%)E<V5A<F-H
M($-E;G1E<B!;365M8F5R73QB<CY-:6YI;75M(%M-96UB97)=/&)R/FQI8V5N
M<V4@86YD('-P;VYS;W)E9"!R97-E87)C:"!A9W)E96UE;G0@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^075G+B`R."P@,C`Q
M,CQB<CY5;FEV97)S:71Y(&]F(%1E>&%S($TN1"X@06YD97)S;VX@0V%N8V5R
M($-E;G1E<B!;365M8F5R73QB<CY#;&EN:6-A;"!4<FEA;"!!9W)E96UE;G0@
M6TUE;6)E<ET\8G(^<&%T:65N=',\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CY5;FEV97)S:71Y(&]F(%1E>&%S
M($TN1"X@06YD97)S;VX@0V%N8V5R($-E;G1E<B!;365M8F5R73QB<CY#;&EN
M:6-A;"!4<FEA;"!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5L+B`S,2P@,C`Q,SQB<CY5;FEV97)S:71Y
M(&]F(%1E>&%S($TN1"X@06YD97)S;VX@0V%N8V5R($-E;G1E<B!;365M8F5R
M73QB<CY#;&EN:6-A;"!4<FEA;"!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`R-BP@,C`Q,CQB<CY*
M;VAN<R!(;W!K:6YS(%5N:79E<G-I='D@6TUE;6)E<ET\8G(^0VQI;FEC86P@
M5')I86P@06=R965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^2F]H;G,@2&]P:VEN<R!5
M;FEV97)S:71Y(%M-96UB97)=/&)R/D-L:6YI8V%L(%1R:6%L($%G<F5E;65N
M="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$T/&)R/E5N:79E<G-I='D@;V8@4&5N;G-Y;'9A;FEA(%M-
M96UB97)=/&)R/D-L:6YI8V%L(%1R:6%L($%G<F5E;65N="!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S
M/&)R/E5N:79E<G-I='D@;V8@4&5N;G-Y;'9A;FEA(%M-96UB97)=/&)R/D-L
M:6YI8V%L(%1R:6%L($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y.;W8N(#(Q+"`R,#$R/&)R/E5N:79E<G-I
M='D@;V8@4&5N;G-Y;'9A;FEA(%M-96UB97)=/&)R/D-L:6YI8V%L(%1R:6%L
M($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N
M8VEE<R`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@<V%L97,@:6X@;6EL97-T;VYE<R!P87EM96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6-E;G-E(&9E92!P87EM
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O
M;F5S('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW+#<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-3`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5S8W)I<'1I;VX@;V8@
M<F]Y86QT>2!P87EM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG0V]M<&%N>2!S:&%L;"!P87D@=&\@06)B5FEE($)I;W1H
M97)A<&5U=&EC<R!#;W)P(&]N(&$@8V]U;G1R>2UB>2UC;W5N=')Y(&)A<VES
M(&$@<F]Y86QT>2!O9B`Q,B4@;V8@;F5T('-A;&5S(&]F(&%L;"!L:6-E;G-E
M9"!P<F]D=6-T<R!U;G1I;"!T:&4@;&%T97(@;V8Z("@Q*2`Q,BXU('EE87)S
M(&%F=&5R('1H92!F:7)S="!C;VUM97)C:6%L('-A;&4L(&]R("@R*2!W:&5N
M('1H92!P871E;G1S(&5X<&ER92X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U)O>6%L='D@<&%Y
M;65N=',@;V8@,B4@;V8@;F5T('-A;&5S('=I;&P@8F4@9'5E('1O($9(0U)#
M+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y2;WEA;'1Y(&]F(&YE="!S86QE<R!P97)C96YT
M86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1FER<W0@
M8V]M;65R8VEA;"!S86QE('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)S$R('EE87)S(#8@;6]N=&AS/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@;V8@<F%D:6]A8W1I=F4@
M;6%T97)I86P@=7-E9"!F;W(@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O:F5C="!E
M<W1I;6%T960@8V]S="!F;W(@8VQI;FEC86P@=')I86QS(&]F(&1R=6<@06,M
M,C(U+4AU33$Y-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,RPS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O=VX@
M<&%Y;65N="!O9B!P<F]J96-T(&5S=&EM871E9"!C;W-T('!E<F-E;G1A9V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3(N-3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O=VX@<&%Y;65N="!F
M;W(@<')O:F5C=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PY,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,Y+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,SDL,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0VQI;FEC86P@=')I86P@8V]S="!F;W(@87!P<F]V86P@
M;V8@9F]O9"!A;F0@9')U9R!A9&UI;FES=')A=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(S+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,RPR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U;F0@9F]R($9R960@
M2'5T8VAI;G-O;B!#86YC97(@4F5S96%R8V@@0V5N=&5R(&QA8B`H(%!E<B!Y
M96%R(&9O<B!T:&4@9FER<W0@='=O('EE87)S("D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&=6YD(&9O<B!&<F5D($AU=&-H:6YS;VX@0V%N
M8V5R(%)E<V5A<F-H($-E;G1E<B!L86(@*"!T:&5R96%F=&5R("D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@4&%T:65N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO=6YT('!A:60@=&\@96%C
M:"!P871I96YT(&%F=&5R($-O;7!L971I;F<@8VQI;FEC86P@=')I86P\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S$L,S8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T+#,X,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X+#4P,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,Q+#<W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W1A<G0M=7`@9F5E(&9O<B!C;&EN:6-A
M;"!T<FEA;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PW-#D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,RPY-#8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R+#@T-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W1A<G0M=7`@9'5E(&-O<W0@<&%I9"!D871E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#Y$96,@,S$L#0H)"3(P,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VX@+2!R969U;F1A
M8FQE(&EN<W1I='5T:6]N86P@9F5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU-C(L-SDP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-"PU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!;FYU86P@<&AA<FUA8WD@9F5E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#`R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!P<F]C97-S:6YG(&9E93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!E>'!E;G-E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,38L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!F965S('!A
M:60\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(')E
M8V]R9&5D(&9E97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M-S<S+#0S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<W."PR,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX+#(S-BPS-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,W,RPR,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@<')O:F5C="!E<W1I;6%T960@=&\@8V]S=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#,L,SDQ/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P
M;65N="!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V5C=7)I='D@9&5P;W-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`S-"PW,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`S-"PW,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?
M83DQ.30X9F9D8S`Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(Y
M,35F.#`W7V(S,31?-#,X-%]A83!D7V$Y,3DT.&9F9&,P.2]7;W)K<VAE971S
M+U-H965T,S0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$514T%'/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D5Q=6ET>2`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA
M<GD@;V8@<W1O8VL@;W!T:6]N(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!5;FET<RP@
M0F5G:6YN:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDL-C<S+#(Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^27-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT,#8L.3(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(L,3$W+#,P-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9O<F9E:71E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,CDL,38W*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(%5N:71S
M+"!%;F1I;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-RPY,S,L-S0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-RPW,S,L-S0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C
M:7-E(%!R:6-E+"!"96=I;FYI;F<@8F%L86YC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+C`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C
M:7-E(%!R:6-E+"!)<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@."XX,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92P@
M97AE<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4L(&9O<F9E:71E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+C<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H
M=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4L($5N9&EN9R!"86QA;F-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-#<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D
M($%V97)A9V4@17AE<F-I<V4@4')I8V4L($5X97)C:7-A8FQE/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N,C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A
M9V4@4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT@*&EN('EE87)S*2P@3W5T
M<W1A;F1I;F<L($)E9VEN;FEN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG-"!Y96%R<R`Q,"!M;VYT:',@,C$@9&%Y<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I
M9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@5&5R;2`H:6X@
M>65A<G,I+"!)<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<W('EE87)S(#4@;6]N=&AS(#$V(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@
M4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT@*&EN('EE87)S*2P@3W5T<W1A
M;F1I;F<L($5N9&EN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG-"!Y96%R<R`Q(&UO;G1H(#(T(&1A>7,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V
M97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT@*&EN('EE87)S*2P@
M17AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<T
M('EE87)S(#0@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06=G<F5G871E($EN=')I;G-I8R!686QU92P@0F5G
M:6YN:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-#<L,SDV+#,P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06=G<F5G871E($EN=')I;G-I8R!686QU92P@16YD
M:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R
M+#8T,2PW-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64L($5X97)C:7-A
M8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,BPV-#$L-S<R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&]C:R!/<'1I;VYS(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@<W1O8VL@;W!T:6]N
M(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYU;6)E<B!O9B!5;FET<RP@0F5G:6YN:6YG(&)A;&%N8V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3@U+#,X-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S
M=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,R,RPQ,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S$P
M+#0P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYU;6)E<B!O9B!5;FET<RP@16YD:6YG($)A;&%N8V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.3DX+#`X-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V%B
M;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8T,RPR,#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E
M:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4L($)E9VEN;FEN9R!B86QA
M;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N,C,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E
M:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4L($ES<W5E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X+C@Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R
M86=E($5X97)C:7-E(%!R:6-E+"!E>&5R8VES960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XY-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R
M8VES92!0<FEC92P@16YD:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-2XY.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES
M92!0<FEC92P@17AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2XP-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N
M=')A8W1U86P@5&5R;2`H:6X@>65A<G,I+"!/=71S=&%N9&EN9RP@0F5G:6YN
M:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<X
M('EE87)S(#0@;6]N=&AS(#(@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA
M:6YI;F<@0V]N=')A8W1U86P@5&5R;2`H:6X@>65A<G,I+"!)<W-U960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"!Y96%R<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT
M960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@5&5R;2`H:6X@>65A
M<G,I+"!/=71S=&%N9&EN9RP@16YD:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<X('EE87)S(#<@;6]N=&AS(#8@9&%Y<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@5&5R;2`H
M:6X@>65A<G,I+"!%>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)S8@>65A<G,@,R!M;VYT:',@-R!D87ES/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@
M26YT<FEN<VEC(%9A;'5E+"!"96=I;FYI;F<@8F%L86YC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-2PY,#@L-CDV/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@26YT
M<FEN<VEC(%9A;'5E+"!%>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@
M5F%L=64L($5N9&EN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU+#<S,2PR.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64L
M($5X97)C:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#,L-S,T+#8Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(Y,35F.#`W7V(S,31?-#,X
M-%]A83!D7V$Y,3DT.&9F9&,P.2]7;W)K<VAE971S+U-H965T,S4N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$512TM-/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D5Q=6ET>2`H
M1&5T86EL<R!497AT=6%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,R!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0S/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/CD@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;"X@,#<L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`R-"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#`Y+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D9E8BX@,C@L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`R-RP@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D%P<BX@,C@L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/E-E<"X@,S`L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CY$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIU;"X@,3`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CY%;7!L;WEE97,L(&-O;G-U;'1A
M;G1S(&%N9"!B;V%R9"!M96UB97)S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^16UP;&]Y965S
M+"!C;VYS=6QT86YT<R!A;F0@8F]A<F0@;65M8F5R<R!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R
M/D5M<&QO>65E<RP@8V]N<W5L=&%N=',@86YD(&)O87)D(&UE;6)E<G,@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q-#QB<CY%;7!L;WEE97,L(&-O;G-U;'1A;G1S(&%N9"!B;V%R9"!M
M96UB97)S(%M-96UB97)=/&)R/DUI;FEM=6T@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CY%;7!L
M;WEE97,L(&-O;G-U;'1A;G1S(&%N9"!B;V%R9"!M96UB97)S(%M-96UB97)=
M/&)R/DUA>&EM=6T@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CY);G9E<W1O<B!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#$P+"`R,#$T
M/&)R/E!L86-E;65N="!A9V5N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/E!L86-E;65N="!A
M9V5N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*86XN(#,Q+"`R,#$T/&)R/E!R:79A=&4@4&QA8V5M96YT(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,S$L(#(P
M,30\8G(^5V%R<F%N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/E=A<G)A;G0@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CY787)R86YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIA;BX@,S$L(#(P,30\8G(^0V]M;6]N(%-T;V-K(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,30\8G(^0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,S$L(#(P,30\8G(^0V]M;6]N(%-T
M;V-K(%M-96UB97)=/&)R/E!L86-E;65N="!A9V5N="!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$T/&)R
M/D-O;6UO;B!3=&]C:R!;365M8F5R73QB<CY,86ED;&%W(&%N9"!#;R!;365M
M8F5R73QB<CY0;&%C96UE;G0@86=E;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`Q,"P@,C`Q-#QB<CY0=6)L:6,@
M3V9F97)I;F<@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CY0=6)L:6,@3V9F97)I;F<@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q-#QB<CY3=&]C:R!/<'1I;VX@4&QA;B!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/E-T;V-K
M($]P=&EO;B!0;&%N(%M-96UB97)=/&)R/DUI;FEM=6T@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB
M<CY3=&]C:R!/<'1I;VX@4&QA;B!;365M8F5R73QB<CY-87AI;75M(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D5Q=6ET>2`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@=V%R<F%N=',@
M9&5T97)M:6YE9"!U=&EL:7II;F<@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N
M('!R:6-I;F<@;6]D96P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M97)C:7-E('!R:6-E(&]F('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U
M+C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q,2XV-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&%S
M<W5M<'1I;VYS+"!R:7-K(&9R964@:6YT97)E<W0@<F%T93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XP-R4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U
M<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C(W)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ
M73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$N-C0E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@87-S=6UP=&EO;G,L
M(&5X<&5C=&5D('9O;&%T:6QI='D@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-S0N,#`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S)=/"]S=7`^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S)=/"]S=7`^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#@N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#8N-38E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.#<N-S8E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&%S<W5M<'1I
M;VYS+"!E>'!E8W1E9"!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG,R!Y96%R<R`R(&UO;G1H<R`Q,B!D87ES/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<V(&UO;G1H<SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U
M('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG-B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&%S<W5M<'1I;VYS+"!E
M>'!E8W1E9"!D:79I9&5N9"!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S-=/"]S=7`^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P
M/ELS73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&%S<W5M
M<'1I;VYS+"!E>'!E8W1E9"!D:7-C;W5N="!R871E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$N.#0E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BXP-R4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E
M9"!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VLL('-H87)E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3,W+#DU,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV."PY-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C@L.3<V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU
M;6)E<B!O9B!S=&]C:R!O<'1I;VX@9W)A;G1E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S$R+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S(S+#$P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB
M97(@;V8@<VAA<F5S(&]F(')E<W1R:6-T960@<W1O8VLL(&=R86YT960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV,#(L.3`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3@P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYU;6)E<B!O9B!A9&1I=&EO;F%L('-T;V-K(&]P=&EO;B!G<F%N=&5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U-RPQ,C,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB
M97(@;V8@<W1O8VL@;W!T:6]N(&-A;F-E;&QE9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97-C<FEP=&EO;B!R97-T<FEC
M=&5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)T]F('1H92!T;W1A;"!S:&%R97,@
M;V8@<F5S=')I8W1E9"!S=&]C:R!G<F%N=&5D+"`R,"PP,#`@<VAA<F5S('9E
M<W0@,R!M;VYT:',@9G)O;2!T:&4@9W)A;G0@9&%T92P@,S`L,C0P('-H87)E
M<R!V97-T(#$@>65A<B!F<F]M('1H92!G<F%N="!D871E+"`R,#(L-C8W('-H
M87)E<R!H879E(&$@=F5S=&EN9R!P97)I;V0@;V8@-"!Y96%R<R!A;F0@,S4P
M+#`P,"!S:&%R97,@=F5S="!A="!T:&4@9&%T92!O9B!G<F%N="X@5&AE(')E
M;6%I;FEN9R!R97-T<FEC=&5D('-H87)E<R!G<F%N=&5D(&%R92!P97)F;W)M
M86YC92!B87-E9"!A;F0@=7!O;B!T:&4@86-H:65V96UE;G0@;V8@8V5R=&%I
M;B!M:6QE<W1O;F5S+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E
M9"!C;VUP96YS871I;VX@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<Q,"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@
M=F5S=&EN9R!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG-"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F('-T;V-K(&]P=&EO;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-C`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C
M:R!O<'1I;VX@97AE<F-I<V4@<')I8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+CDV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`U+C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,2XY-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O
M;2!T:&4@97AE<F-I<V4@;V8@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPX-S,L-34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-S4L,34S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E
M<B!O9B!O<'1I;VX@97AE<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,S$P+#0P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AP96YS92!R96QA=&5D('1O(&-O;6UO
M;B!S=&]C:R!G<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<S-"PW.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.34L.3<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C(S+#DY-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(X-"PS-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY."PR,C0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]G
M;FEZ960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3`L.34S+#@U-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#DU,RPX-38\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!P<F]C
M965D<R!F<F]M('1H92!P=6)L:6,@;V9F97)I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV+#8S-BPW,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPV,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L-#4Q+#(U,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')I8V4@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<N-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-RXU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E9"P@<VAA<F5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,2PU,S@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U,2PX,3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DX-"PU,C0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L.#(W+#$R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-C<P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!C;VUM;VX@
M<W1O8VL@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,RPS,C4L.#8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$Q-BPY,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$S+#<P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPU,C4L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;F1E
M<G=R:71I;F<@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3,L-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@W-BPW-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N9&5R=W)I=&EN9R!A9W)E96UE
M;G0@9&5S8W)I<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)U1H92!A9W)E96UE;G0@96YT97)E9"!I;B!O;B!$96-E;6)E<B`Y+"`R
M,#$S(&AA9"!S:6UI;&%R('1E<FUS(&%S('1H92`R,#$R(&%G<F5E;65N="P@
M:6YC;'5D:6YG(&$@8V%S:"!F964@97%U86P@=&\@,3`E(&]F('1H92!G<F]S
M<R!P<F]C965D<R!R86ES960L(&$@;F]N+6%C8V]U;G1A8FQE(&5X<&5N<V4@
M<F5I;6)U<G-E;65N="!E<75A;"!T;R`R)2!O9B!T:&4@9W)O<W,@<')O8V5E
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M;'D@9F5E(&]F("0R-2PP,#`N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B=);G9E<W1O<G,@86=R965D('1O('!U<F-H
M87-E("AI*2!A;B!A9V=R96=A=&4@;V8@-34T+#,Q,"!S:&%R97,@*"!T:&4@
M(E-H87)E<R(I(&]F(&-O;6UO;B!S=&]C:R!A="`D-BXP,"!P97(@<VAA<F4@
M86YD("AI:2D@9FEV92UY96%R('=A<G)A;G1S('1O('!U<F-H87-E(&%N(&%G
M9W)E9V%T92!O9B`Q,S@L-3<W('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@870@
M86X@97AE<F-I<V4@<')I8V4@;V8@)#DN,#`@<&5R('-H87)E+B!4:&4@0V]M
M<&%N>2!R96-E:79E9"`D,RPS,C4L.#8P(&EN(&=R;W-S('!R;V-E961S(&9R
M;VT@=&AE('-A;&4@;V8@<V5C=7)I=&EE<RX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)U5N9&5R('1H92!T97)M<R!O9B!T:&4@
M=6YD97)W<FET:6YG(&%G<F5E;65N="!E;G1E<F5D(&EN=&\@=VET:"!#86YA
M8V-O<F0@1V5N=6ET>2!);F,N(&%S(')E<')E<V5N=&%T:79E("AT:&4@(E)E
M<')E<V5N=&%T:79E(BD@;V8@=&AE('-E=F5R86P@=6YD97)W<FET97)S("AC
M;VQL96-T:79E;'DL('1H92`B56YD97)W<FET97)S(BDL('1H92!#;VUP86YY
M(&%L<V\@9W)A;G1E9"!T:&4@56YD97)W<FET97)S(&$@,S`M9&%Y(&]P=&EO
M;B!T;R!P=7)C:&%S92!U<"!T;R!A;B!A9&1I=&EO;F%L(#(U,"PP,#`@<VAA
M<F5S(&]F(&-O;6UO;B!S=&]C:R!T;R!C;W9E<B!O=F5R+6%L;&]T;65N=',L
M(&EF(&%N>2P@870@=&AE(&]F9F5R:6YG('!R:6-E+CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@
M9G)O;2!I<W-U86YC92!O9B!W87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,RPS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0;&%C96UE;G0@86=E;G0@8V%S
M:"!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y-2PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!L86-E;65N="!A9V5N="!A='1O<FYE>2!F965S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L
M=64@861J=7-T;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!G<F%N=&5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3,W+#DU,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!E
M>&5R8VES960@8GD@=V%R<F%N="!H;VQD97)S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,RPS,S(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPQ,3<L,S`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5G:7-T<F%T:6]N
M('-T871E;65N="!D97-C<FEP=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B=4:&ES(%)E9VES=')A=&EO;B!3=&%T96UE;G0@8V]N=&%I
M;F5D('1W;R!P<F]S<&5C='5S97,Z("AI*2!A(&)A<V4@<')O<W!E8W1U<R!W
M:&EC:"!C;W9E<G,@=&AE(&]F9F5R:6YG+"!I<W-U86YC92!A;F0@<V%L92!B
M>2!T:&4@0V]M<&%N>2!O9B!U<"!T;R`D,C`P+#`P,"PP,#`@;V8@:71S(&-O
M;6UO;B!S=&]C:RP@<')E9F5R<F5D('-T;V-K+"!W87)R86YT<R!A;F0O;W(@
M=6YI=',[(&%N9"`H:6DI(&$@<V%L97,@86=R965M96YT('!R;W-P96-T=7,@
M8V]V97)I;F<@=&AE(&]F9F5R:6YG+"!I<W-U86YC92!A;F0@<V%L92!B>2!U
M<R!O9B!U<"!T;R!A(&UA>&EM=6T@86=G<F5G871E(&]F9F5R:6YG('!R:6-E
M(&]F("0W-2PP,#`L,#`P(&]F(&ET<R!C;VUM;VX@<W1O8VL@=&AA="!M87D@
M8F4@:7-S=65D(&%N9"!S;VQD('5N9&5R(&$@<V%L97,@86=R965M96YT("AT
M:&4@(E-A;&5S($%G<F5E;65N="(I('=I=&@@34Q6("9A;7`[($-O+B!,3$,@
M*")-3%8B*2!D871E9"!-87)C:"`R-"P@,C`Q-"X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU;2!O9F9E
M<FEN9R!P<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U
M+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06=G<F5G871E(&]F9F5R:6YG(&%M;W5N="!O9B!S96-U
M<FET:65S('-O;&0@=&\@:6YV97-T;W)S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)U1H92!#;VUP86YY('=I;&P@<&%Y($U,5B!I;B!C87-H
M+"!U<&]N('1H92!S86QE(&]F(&-O;6UO;B!S=&]C:R!P=7)S=6%N="!T;R!T
M:&4@4V%L97,@06=R965M96YT+"!A;B!A;6]U;G0@97%U86P@=&\@,RXP)2!O
M9B!T:&4@9W)O<W,@<')O8V5E9',@9G)O;2!T:&4@<V%L92!O9B!C;VUM;VX@
M<W1O8VLN($]N($%P<FEL(#(X+"`R,#$T+"!T:&4@0V]M<&%N>2!I<W-U960@
M-3`P('-H87)E<R!A;F0@<F5C96EV960@;F5T('!R;V-E961S(&]F("0V+#`P
M,"!U;F1E<B!T:&4@4V%L97,@06=R965M96YT('=I=&@@34Q6+CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)T%G9W)E9V%T92!O9F9E<FEN9R!A
M;6]U;G0@;V8@<V5C=7)I=&EE<R!S;VQD('1O(&EN=F5S=&]R<R!W87,@:6YC
M<F5A<V5D(&9R;VT@)#8L,#`P+#`P,"!T;R`D-BPV,S8L-S(P(&EN(&]R9&5R
M('1O(&-O=F5R(&]V97(M86QL;W1M96YT<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE
M<B!O9F9E<FEN9R!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^075D:71O<B!F965S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#<R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1D(&-O;'-P
M86X],T0S-SX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1&EN;F5R1F]O=&YO=&4^#0H@("`@("`@(#QT9"!V86QI9VX],T1T;W`^6S%=
M/"]T9#X-"B`@("`@("`@/'1D(&-O;'-P86X],T0S-B!V86QI9VX],T1T;W`^
M5&AE(')I<VLM9G)E92!I;G1E<F5S="!R871E('=A<R!D971E<FUI;F5D(&)Y
M(&UA;F%G96UE;G0@=7-I;F<@=&AE(%1R96%S=7)Y($)I;&P@87,@;V8@=&AE
M(')E<W!E8W1I=F4@;65A<W5R96UE;G0@9&%T92X\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO=&4^#0H@("`@("`@
M(#QT9"!V86QI9VX],T1T;W`^6S)=/"]T9#X-"B`@("`@("`@/'1D(&-O;'-P
M86X],T0S-B!V86QI9VX],T1T;W`^0F5C875S92!T:&4@0V]M<&%N>2!D;V5S
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M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T
M;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;,UT\+W1D/@T*("`@
M("`@("`\=&0@8V]L<W!A;CTS1#,V('9A;&EG;CTS1'1O<#Y-86YA9V5M96YT
M(&1E=&5R;6EN960@=&AE(&1I=FED96YD('EI96QD('1O(&)E(#`E(&)A<V5D
M('5P;VX@:71S(&5X<&5C=&%T:6]N('1H870@:70@=VEL;"!N;W0@<&%Y(&1I
M=FED96YD<R!F;W(@=&AE(&9O<F5S965A8FQE(&9U='5R92X\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?8CDQ-68X,#=?8C,Q-%\T,S@T7V%A,&1?83DQ
M.30X9F9D8S`Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(Y,35F
M.#`W7V(S,31?-#,X-%]A83!D7V$Y,3DT.&9F9&,P.2]7;W)K<VAE971S+U-H
M965T,S8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5424%#/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-U8G-E<75E;G0@179E;G1S("A$971A:6QS*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L
M+B`P-RP@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!
M<'(N(#(X+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D]C="X@,S$L(#(P,30\8G(^5V%R<F%N=',@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`S,2P@,C`Q-#QB<CY3=6)S
M97%U96YT($5V96YT(%M-96UB97)=/&)R/E=A<G)A;G1S(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U
M8G-E<75E;G0@179E;G1S("A497AT=6%L*3PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E
M9"P@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,2PU
M,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS.#8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!C;VYV97)S:6]N(&)A<VES
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG0V]M;6]N('-T
M;V-K(&9O<B!T:&4@8V]N=F5R<VEO;B!O9B!A<'!R;WAI;6%T96QY(#0X-2PP
M,#`@=V%R<F%N=',@86YD(&%P<')O>&EM871E;'D@)#$X+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8CDQ-68X,#=?8C,Q
M-%\T,S@T7V%A,&1?83DQ.30X9F9D8S`Y#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V(Y,35F.#`W7V(S,31?-#,X-%]A83!D7V$Y,3DT.&9F9&,P
M.2]7;W)K<VAE971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B
M=7)N.G-C:&5M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\
M;SI-86EN1FEL92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#`V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970Q,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$U
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-BYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C`N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Q+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970R,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,C,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(T+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970R-2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,C8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#(W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R."YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,CDN:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#,P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970S,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S(N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,S+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970S-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,S4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,V+FAT;6PB
M+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%]B.3$U9C@P-U]B,S$T7S0S
8.#1?86$P9%]A.3$Y-#AF9F1C,#DM+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract', window );"><strong>Schedule of derivative warrant instruments activity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeWarrantsUnits', window );">Beginning balance, Units</a></td>
        <td class="nump">1,968,623<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_TransferFromLiabilityClassificationToEquityClassification', window );">Transfer From Liability Classification To Equity Classification</a></td>
        <td class="num">(306,900)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeWarrantsUnits', window );">Balance, Units</a></td>
        <td class="nump">1,661,723<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Beginning balance, Fair Value</a></td>
        <td class="nump">$ 6,707,255<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification', window );">Transfer from liability classification to equity classification, Fair Value</a></td>
        <td class="num">(2,143,793)<span></span></td>
        <td class="num">(600,880)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ChangeInFairValueOfDerivativeWarrants', window );">Change in fair value</a></td>
        <td class="nump">3,653,473<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Balance, Fair Value</a></td>
        <td class="nump">$ 8,216,935<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ChangeInFairValueOfDerivativeWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in fair value of derivative warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ChangeInFairValueOfDerivativeWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DerivativeWarrantsUnits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative warrants units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DerivativeWarrantsUnits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of Transfer from liability classification to equity classification.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_TransferFromLiabilityClassificationToEquityClassification">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Transfer from liability classification to equity classification.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_TransferFromLiabilityClassificationToEquityClassification</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeFairValueOfDerivativeNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENHAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note Payable (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Premium Finance Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Premium Finance Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Premium Finance Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 28, 2013

</div>
          <div>Premium Finance Agreement [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NotePayableAndConvertibleNotesTextualAbstract', window );"><strong>Note Payable and Convertible Notes (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 157,825<span></span></td>
        <td class="nump">$ 157,825<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Down payment pursuant to the agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,995<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent', window );">Amount required to pay in monthly installment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,995<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on note payable</a></td>
        <td class="nump">$ 157,825<span></span></td>
        <td class="nump">$ 140,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NotePayableAndConvertibleNotesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_NotePayableAndConvertibleNotesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the required periodic payments applied to principal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentPeriodicPaymentPrincipal</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.6-04.12(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 4<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 13, 16<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5AAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract', window );"><strong>Summary of fair values of derivative warrants on basis of valuation model</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MarketValueOfCommonStockOnMeasurementDate', window );">Market value of common stock on measurement date (1)</a></td>
        <td class="nump">$ 6.70<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">$ 5.89<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Adjusted exercise price</a></td>
        <td class="nump">$ 2.48<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 2.48<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (2)</a></td>
        <td class="nump">1.07%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="nump">1.27%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Warrant lives in years</a></td>
        <td class="text">3 years 2 months 12 days<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">6 months<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (3)</a></td>
        <td class="nump">74.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="nump">73.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (4)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsProbabilityOfDefault', window );">Probability of stock offering in any period over 5 years (5)</a></td>
        <td class="nump">25.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
        <td class="nump">25.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RangeOfPercentageOfExistingSharesOffered', window );">Range of percentage of existing shares offered (6)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
        <td class="nump">35.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueAssumptionOfferingPrice', window );">Offering price range (7)</a></td>
        <td class="nump">$ 7.50<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
        <td class="nump">$ 9<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">The market value of common stock at the above measurement dates is based on the Company's trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for September 30, 2014.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[3]</td>
              <td style="vertical-align: top;" valign="top">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[4]</td>
              <td style="vertical-align: top;" valign="top">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[5]</td>
              <td style="vertical-align: top;" valign="top">Management determines the probability of future stock offering at each evaluation date.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[6]</td>
              <td style="vertical-align: top;" valign="top">Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at September 30, 2014 and December 31, 2013, respectively.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[7]</td>
              <td style="vertical-align: top;" valign="top">Represents the estimated offering price range in future offerings as determined by management.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueAssumptionOfferingPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value assumption offering price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueAssumptionOfferingPrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MarketValueOfCommonStockOnMeasurementDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Market value of common stock on measurement date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_MarketValueOfCommonStockOnMeasurementDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RangeOfPercentageOfExistingSharesOffered">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Range of percentage of existing shares offered.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RangeOfPercentageOfExistingSharesOffered</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreed upon price for the exchange of the underlying asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsProbabilityOfDefault">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of likelihood a loan will not be repaid and instead default, used as an input to measure fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bbb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueInputsProbabilityOfDefault</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeTextualAbstract', window );"><strong>Derivatives (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RangeOfPercentageOfExistingSharesOffered', window );">Range of percentage of existing shares offered</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">35.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeTextualAbstract', window );"><strong>Derivatives (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
        <td class="nump">$ 2,143,793<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NumberOfSharesWarrantExercise', window );">Number of warrant exercised</a></td>
        <td class="nump">2,117,304<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeNumberOfWarrants', window );">Derivative warrants</a></td>
        <td class="nump">306,900<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at September 30, 2014 and December 31, 2013, respectively.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DerivativeNumberOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative number of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DerivativeNumberOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DerivativeTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DerivativeTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NumberOfSharesWarrantExercise">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares warrant exercise.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_NumberOfSharesWarrantExercise</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RangeOfPercentageOfExistingSharesOffered">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Range of percentage of existing shares offered.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RangeOfPercentageOfExistingSharesOffered</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAdjustmentOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Note 3 &#8211; Property and Equipment</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Property and equipment consisted of the following at September 30, 2014 and December 31, 2013:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">September&#160;30,</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December&#160;31,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Lives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 1003px;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Office equipment</td><td>&#160;</td><td style="text-align: center;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">3-5 years</font></td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">166,354</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">15,480</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: right; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(25,343</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(1,560</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Property and equipment, net</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="text-align: right; padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">141,011</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">13,920</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal;
 word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Depreciation expense for the three months ended September 30, 2014 and 2013 was $14,326 and $0, respectively. Depreciation expense for the nine months ended September 30, 2014 and 2013 was $23,783 and $0, respectively. The Company wrote off certain undepreciated property and equipment during the nine months ended September 30, 2013 and recorded a loss of $4,122 on the disposition.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001213900-14-007643-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-14-007643-xbrl.zip
M4$L#!!0````(`+I]7T6:UW!C9[T``%4H"``1`!P`871N;2TR,#$T,#DS,"YX
M;6Q55`D``_#F4U3PYE-4=7@+``$$)0X```0Y`0``[%U;<]LXEGZ?JOX/&C^O
M+-XOGB13CFUUW&U;'MOIZ:[=+1=#0C(J%*GFQ;%ZJO:W+T"*$BF1-"D"%"4A
ME4ILD"#.Y3L'MX.##_]\F]J]5^#YT'4^GO"GW$D/.*9K06?R\>3KT["OG?3^
M^>FGOWWX>[_?^QDXP#,"8/5"'[W0N_JK__OGAYND?D\]11\XY7K_S7,#D1\(
M'"_U>.%,E,Y$KG=^^[^]?C_YU&?#1Y]!=:(/"*=\_`P]??OFV?`,_]M#M#G^
MF1$XTX\G+T$P.QL,##.`#@RGLQ?#FQHF"`-H&K9_:KK3J#U.%[F3G_ZVJ&I#
MY_NRZH\?/T[Q9T]=;X+>Y<0!?OP-$7+2ZRVKX#<LN*R4KJ`,XH>9US>:^"%&
M[_.ZK@^BIYG7?9CW,OHX/_C]]N;1?`%3HP\=/S`<$]&5(0N6L+*JLJH#?5<2
M>+6L5OQ&NI+C.DXXS:]C!=X@F,_``+W41V\!#YJ9NN]7W*QD@9D'3(RJ0D+U
M@>&9GFN#P1CIOP_>9K;A&('KS8?H]_3'/#`N_(HR0$\SY(*@I,FH/?3*!CB"
M7'#(,3@RKYMNZ`3>//N^#\S3B?LZ6#S$J!7['-\7^4S5T/.0(1;573R-(+]9
MV0(POQYZ4%`%O)DO^77P$UQ)V*P$G5?@!_G5XF<%W#D&-/W\>M$C7(W?K.9#
M,[\2>E!4)9AY!770DX)*H=^?&,9L66]L^-\B/2\>%,AP\;1O!$%Q5?30@]_"
M`/AK5;%]^+GUHB<%;;[9)>;]^\V:^PD#KP3QZ"GV.-A%8[]UYD?>Z`&,>Y$?
M.UL88;FW&\P\=P:\`"*25_XU_@!FY..)#Z<S>UGV$IDL]O']Q'^?OOG626^0
M=!47KA.`MZ#W")#O1SW&HA>)^PES\1`B[[%X\?DB]`-W^LSQSY?`?$:LJ4\<
M]QS_?1H]BWGE#\#&+NC>\(+YDV<XOA$UYG^>IY^<OT'_^7P6P-='UPZC%V[!
M]!OP3E84`2>`P7SU.[1PR1@"KQ<)-"N_!(T7U[^>?.)0-R!JFBAP'P;KE5<?
M],%DBDJ3`@LUB1PB-&$0T]*S('H>=^@+U)U59^_D$];%61Z3'P:Y[6%"!AND
M#?*E@:`!72O%3(`:OD04H"*LD7[D9U)?3#U?"MA:JR#RZ0:3ITG)JLE!!C.5
M0"1PS[?&_!G[B0R(>/WYE]!9*Z\!HD?;-9Q?01`@XIS)->J]88"<PFA\@7MQ
M[P'X`)G;2RSAY_.)!P"6;%3W!II(O^`2O`+;G47%CG7A3E'7:D+#AG\9N-5E
MG0-%:"T)ED#W70IC>TAK8$'!5GJ@;T2X1Y.1,ZUL1+B"TN=U\D9T[C^/QL^"
MBFS(P[8B9&PHM[R&#2')N1X2=!8)L?HOD,R`EVL^%ZC?P9.&)USWT*VDJHRH
M&$B9I&G803P)"F)0HWY$[`OJJO;J*0E0\W+2`61!G5M>`]1##UA?PL!\0>2Z
M3M:7E8!ZX8N0`WJ<H0^[Z"M)K37!/S\8S@3$!F2\P6DX/5#H5Y4DS;ZA@CZ:
M-+^43:+2DT])44:W;1@;ZD%D9FPEQH9\(3.V`S6VM&Z9L>W(V)A1=<ZH.@[X
MU4H10SQ#_&X1OS:)CS!?8R5LTTC(3N*C!2\[QT;RRNG;R%%-XG=J%;N>Q*N9
ME2G2GE_-1S6G/)^'D^U1S?8(J'I&%?VMY1DUY!RI[1%P6@&(U!P0/8;??&A!
MPYL_&C88C1\#U_P>8>;>-LS8^"9[X\H*N5E`)(^GUB"BU86(2AXBBQ5P+0<)
M>`4\K[R&F_GJP"CV)IB/QD_@S?!O+]'H!94DO03K06,<UA+407:C6E](V0/Y
M"13#-\-WF_C>]/A:W>E2UB0(>WSE^1',<BPBK[R&1?SBOCC^%W?V'5GP2NG,
M`,KD<A!X7_?G>E]0:/ISAEZ&7IK>6J_KK;.`)SV%XY]'9I`#>"&GG*T#=&0=
M@.=J@@A5$`1J73[_?.>^YF`HKWS+0?`]<!Q_;K\:#C28VRR7S$$XSK5NG^?[
M0@KQ9#=^T6PM#HS>G,5MEM^`B6%?1=3'GFYQ,*?;4+,`/%NC/'%B&?K;4*5`
M<T8NR$R7%'6YV14A;:;VWBIT10*5V>?PCZMH.]O(V<Y>'GQ@@YD.#F8XONY@
MAL[!A[@OR,5*`8;:P<#67E:DUF'6$1(+;&>![02'#C1`O9H++XX\B=E(#R6G
MG'4?G>@^1'SDIT[W$57@*2RH+#PCET3.93&45][=[D/$(54B1][2EMW'(FY`
M7.\^-LO9KAG;-2/<D8@X2H)F1R(FNP59?'-23CD[.]LB\-G9V9*.5.]S8JV.
M%%60J"TJR_DVE%O.UG&:^D,]LXI#;5>5Z;(M2ZXW),ZJGY0EB[?QFESN6(_;
MU'VG!L2;4E7K2S4]AMZ55&DLP'35#'>YJD+0?CN"-/TVO::^]_9;;YVY,U)E
M!^]H&CX[>'=<%L)ZN$[T</N*M,<`-8NYO[`-WT^?8OJWX2$U[(F;+&1CE=HA
MPP\#11DHGF"`SX!=.Q9\A59HV!$@KJ8SVYT#X%]"#YB!Z_G12H_CAS:>7._)
M1E`N;PN74HU#AITR[)PC3BV(M\U>P2,P0P_B#*)7;Z8=6L`:>N[TPIW.PB!:
M%AR-KPS/06[;OP?>XXOA@<_S_`_LGTNB*`CFU#H&S-$,5V*X7.(R+9"C@N5R
MUSQW@;CSBPR;R^@T=LW7\SJO;ROJF^6=DM(&^NKE.EY4H)"F=0O!LCP&[3BH
MKD!DF<DW%R&YY=FUM:\.#.Y#SWPQ?+`GBVF%ZU4EO+2P28DCQRFDM4V<@%!=
MQ=WWKD)-TQ$HI`#90K#,=J@ZU"Z@8OW(U1HH\LJSH+CWP!2&TR%T\-KEOL.B
ME)N6G"J%TUC9XS@;89Y[YE%KSY8H'5&I*U5V]J)S>RC;>XH=IR[88RM@Z_/[
MMS[?TB&_/>N9-COO-@[YD>UH6.+;CD>E[/ALQEZ"FN4J8;E*N@=@-G$^"BW_
M,#SK:3X#F6%MM)*_5QNM:3966Z.%_!R5CH<&]'XS[!!\GB]__()$C@<$\QM\
MF"P>6R7/KIU9&/C1`WX_U%^-PQ4N2EAER*B&#.%XD"$P9-1!AG@\R!"/$!F7
MJ*%7`P<D?9[?&4'H@?V+%\SGH<50OW:TF[JI*U[OE+*Y:;B<<A:BTL*:IE1W
M33.JP%.(H5ME/LR%B*#FE&=GAK>&$X[11#[$VQG[/C$L8Z8M7-1)B1A7H+;3
M+A9XCMQR=KR%3O<0Z9AJYT]"QS@-B>M$OQ^,GC=X8KK.U_6AC1K(0F/O1BL'
M`4F\&C@:GV-//4F=5C>@91L_HKULAEV"V,T5=W)4?4/HS%H(S^78B*S5LWG;
M3>!H!*5L@PNVM<>0P<;W+8WOCQ4?;%QU4*.<HX4QFT>P>02S,'(6=A]MO8&E
M5`_&'/(9.U*D#,&WG-TD;;.\4R'RFX*M=Y(\JD#CAJI$L-+SK>'E"#:GO.."
M%3/YORL(5NP+%!*&)X+5"Q%[/MLOP693&500K$3S1N_EU25K<LTI[Y1<UQ?U
ME+Y`(3F+DDFLM-:M=EU$!'HAA4I>H+I2+1FL7-^/#F9\LN2EHT,2.F!8OUJ)
MP:$-.&RZ3YJYK>0DH7U6N9RZ6=YQ#ZKVN7K1/Z@"M>@?'!^8)]>\\D[)=1U]
M:B9TCOR%396EQ%P+C9Y&K77WT`8>Z-RML='/+)(1=M1D<J5:K_]NX\:2]Z7*
M\KGO5S[W/49:=AO]W$:2":YP[P)@QX]-%NZ>YS%Q5"#0R^>.^^;$:T_"NB%5
M=D-R-VY(/@X$L:M1V=6HS(+:&$@?<RX;`F/N[<UCQ_G_CL,*V`5Z>Y6JK%,7
MZ.VQA1Q8W-OA1(-U!!];9L)[`F^&?WN)S!.5),Z!#28V$^.]*R@VHC@$>V"9
M(8\L,^11(IYMR71B2V9?D<9.O#)0;(""I?#?<0K_/<8.NV+WD*_89<!D5^QV
M\(K=?88ERR?.0+$."I8REL&!Y0]EH-ANYLXRSQP]..X]%[44S.]M(PKLN?HS
MA%&0S^?Y<JQQ:^!M9.#-T\_W`S`5V%M!IX1/!B)2,:7?OKE!\!FZP0OPC!E`
MDP/3OW"]V6+CY<9U)D_`FR9W,F-SAD&LL0OTJ8GKS4?C:^0%DC>L>$,<_SB$
MGA]D-A-&XT4L@H608(7FGL"V?A1KN5B;[-HD-&VIF61SOY9^F+FU'3ZXK=W=
M@1^77C@YGV$]&?LS#>UDD"$94RM2"3.J?3&J!V`".`M&XP<P"5'CZ#6D3<]]
M-6R\[/;U<6@9S,QV;&;5E<0,K^.#Q_,QPE4T.+D#`0Y.]'/#@!9#E.Q)B'OT
M72=((E[W8Y'E<(>919JD$K94&P_,$1!R!"/C^P.T)N`N&MX8]HWQS?4B%[PP
MW/N(Y.C=IQ_NTXL;^H9C(?4\O4`O`.!01ZGO"::Q':P$NVBQ3+P,[SO'^]`-
M&=[IX3TK7H9W`AO8SP\X/W$\T8(.G(;3_<`NP8WMZO:2B"JUB)V6&0,D84`:
M;PR0=0&9EAD#9.F(8#\]'_-"A)2^3]Z%63KYP/EKYQ7X:/"Z'P@H")!?IBK,
M,,/@T#0*8QAZ#HRBX]"T`[[AG_;D)$6M((QB-AF$R"VCOT+P@U(0QB-`_%C'
M&H51*MC=KX_7U!`SN;TP.;SJRBRNPQ9764',X+IN<.B+MCO!>DSV^`X^]*G[
M1O:^4IAA==VPXN#095Y)O'G/[&E']E2H"V9&73>CH@@89D7[$(S$C*@31L1.
MDW3<M-AQDFX:'`N8;<^26%QJLVL+<W;E]N`FDO4;V+)"(G4#6WTAM9#.^ZC2
M<.XT@7?;"3D["VJ6@?NHU%W#A_WBOCC^%W?V'9&[2IG+_%:97)BOH@G>];$W
MF,)P.H0.[CKV!'4E0]H2;HY+RRP-W,'K>&A`[S?##L'G^?+'+TCD>.PWO\'3
MNG@8G3R[=F9AX$</^/U0?S4.4U%AQ:PR9%1#AG`\R!`8,NH@0SP>9(A'B`R6
M(_20M<NNRCX\G3:Y5F%?#Y%1O6ZA^G+'#HZR'3P,]^E86W=A2/MP7<LP')E!
M+@PWRKN\^\9S5(1T$?J!.\6[^/E2RBMGHSP:F]9(P?4VK3$B^'2#9#:MMT$$
MWNT!?X:(YZM7],]RS7"M?.&O#P$_!1RO`)3+.@F'?>S(_7N_W_OJP*#W"*+]
MH5ZOWT_*?_K;]?_Q_S/\[?X+>`.7LJ)J?SR`/^&GZY?OX/7J._3>?JBZ*4F2
M*<NR^?2?ET_#LR^2=*9\X:_/_G'-:U^N_\%_&)Y)_!?EHZII5SHJ^;AH(*8D
MQ$UC>_'QS3-([HOR*3!\I(M/"QE$#Q/JDV?)[_@;.5_\^GBY\3GHNY+`JV?H
M6?VO/2,Y/D<WY"R_&XTUP*?4RW?A%$1YC+9L>J,^+KP$CCN%3MYGJPHH\XE!
MEOIRSF=ABN%LL_A133GB*IMJCD9IT:.ZGT.FBRRLZ(N+I^]]%(/]RHYFLQD[
M^&`!>'85&?`#F$`_P*[@SIB"WL*"'L!X^_B]DT_GJ"D'AM/>/=+?U#"C(#/#
M]O^K=^V8IQ\&1<UCFE?/<%")9]AHY`O>?@5S0K2EG7UA6PDAYTAT%A;?T#8F
MA`@8(T&`N.W,YY,V+T+/PT701R+[`QC>5>SX"#7?[_,"\JLQ`45M);1<NF8X
M771<A-I'7OU?<>/ICZ\W&&<Y(\OY:A:1;3_3UCHA*]$,48E/D)0L$6OMY),1
M4TJ2D'^)>62DVLF:Y!#:P$N"H0F1\#@U;/35W@.8N1[R&Y,>OL7-<.9I^\PT
MO.8F5O>K1)V8/PH#/.NQ\*?R2-QBQM?#'C7ZR*(_[UG`A(AP_^/)]=WPY).(
MW(HL<VK&IY00AEE87A!C^"]XWH[^PXDH7@T;^_;SX`(-T>;HW6C+H(P3'HV5
M34RQL#X&WRA/<8+'$2DVD"9DA=<41?\PJ$4945:XYU_""#GBNE(VRM]A1>9$
M0=LM*PNP;["R45[*BJCK'*>(NV1E"22Q`&!5M2*+HJ@HG=!*!==4Q@K/JS*G
MJ'(#7NX],#.@=?4VBR+@'6N$0_+/?1\$_J)C;D,I`J^)6LKH*Y!%D`M2^E!4
M7N?$K;EH7>JR*B,$I>#3G#1BT!8D09!5K0)MA8F4[D`K4N1%'8_CJY!#@FQB
M$I9XCN?KT[VXLW9^B89*/J0EX3<?GCG0_G@2>"$X&6Q)`"E9B9(JINQZC8)-
M0VG'>!4YX_OCINL10\Y<91U-9X52:DS3#5%O=&_,C6\V=H>H!&G7NH'&-VA'
MUR"WZ/Q$5=,SOJ\Z>12X(J8(5>0%/`4@RU8JK+U=+6D\KQ4K*9<LDFR04HN@
M:H+.;\_'G1N`Y.46I<^C'EA(B3^'C`94-A!N2?>PVG38C5]15$X5THZEC"`2
MA)/"J";PBBYN0?ANY*R*@BRD!UXDB23FCCE!4*3TV*$RE;N6X19DM2*US$Q\
MF1YA$72"E^Z`8](37XGCV9(8.EX033W'`,'+BI;^:"ZND"."CB12*Z"MK3$)
MDJRD5V762-B6/&*C$5U)&WT9>>>6!>-+9.X-:%T[%\8,!H;=2D<JZ:+(2^G1
M7SXQ#>DEUG]J:.2MRUPM>A]`8$`'6%>&YR!WX:.!83@-H]'@)1CC,(@V1-U7
M%)G/CEK>)XP<&Z0TT-=D5=44C=^6C<@&7ES;`IZ/US^"_/TETM+G95F7TT#?
MI&-[*HDY#5'EM?0:;3F1J1X;]8:[$>S&$LE[1)%B@-ZR2AT.LMTOFER.O,<`
M(S_R\O?`BW8$J2@B%<Z3XD@X^<2=<IDUQRH4DN5I:]VTQ%.\37L>!B^N!_\"
M%GG]%&P?RUS\IXB5=<+(L+"=.EIBX=KW0YH:J#QVKDI.,VG6)*=BC$.K(JH<
M=T%)3JFQ]!;.2=#RHRARRV_`Q+#C*(_XE-LBX&T1E;R-[ZI`/3EF2?<N8L3-
M[M@AW+&09&=G?8K`;7CD$K((4$^T.R%(/>V>9)URO``A26H)X3%%#8DF*VY=
MX75)SU\XJ4QT*[U2?7$7Q=UM'3C8KN`+R(_R-S^`5^"$H"AN05Q$8X;V=H%H
M9:$`%9K/!H.VWGR6>Z(KF_6Y)]I\DG<1S4-32547P4Y4D)#=NU`U0132*STE
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MD7,)_2CF&[TP&L<QSGS;F-F"&J)>KB_QZ2W)<G*(BI'H_+6Q&(E2,YKAU`30
MF2P<5'[,&-&>%@T1-%U):7*#AOH$$@6:S'.JG`Y*(4`@49^F<I*DIP_1$)=@
M4Z<K*YRJRV)="J\=TYT";!WT8=@OQN&*C&VH).OTBL'8C$JB@.P7(Y*D+)M2
M60++?#*O\702^.VM+O*"G@IU6FN^+F5DYQ@RIQ&CC&+W6E\PE(Z!I/KY91FM
MO8HLAC1=E+3TZ/(=DIK33Q9IO,+S0JOT$W6&NJ)JFKI#^3=UDZ(BXY.G6W)P
MYSINUJNVYSTUC9-2_K.0E.WI)8QT4>$DJO12139U^1)'<C6*0=#N0%02.)U/
M4YDFH!YEA&?<J"O199X(960'G&@@IW*"1$%FC0>9NJ`@C2H52$M.!R1A5)\-
M'YIXJ1S:85`0`=,,>H4!>7WNE$N1_`YE39EHAM(R)M(K1)29:`;H4B;X'6F"
M)!-IMUN#B7\#.'E!9>>OR$U/P%V(MYQ&XZA:*AJ(LJEL1BQ%J[8*AP;7J;GX
M=L128K>!4>6S*T@<KZ8G]9UBMX'YY;.K2;JB<T)'V6U@J/GL*K+$B8I&DMW$
MMH&%TQBB816]_:5UU8EJ"J?Y=!"AM.'H0!;0[#;M&=\G-;TYA'ZV`?X![R].
M<<K(OW:^A=>`)GJ[:$5$82:B-,)X(CMR+E[PW0[7SO)VJM%X-:]M88"=+'54
M)HDT_<0F6+4X6*W5F1Y`V+\$\?_7SB)UW>7BA$UN"KL6YCT\+_'IJ+/M"&V%
MU88:E&11YB6ZG*[E+:.CP-(E80(4-;:4;"ZW]VDJYZ!*?JTV=J<TF2LWE"J$
MML)JTRU-$?7=LM`JJ]G\7/35*4J2G#[Y59-`NKPUU9^N\ND5C@:\W8$`9[J]
M]UQ\UX+U>?X5#=^NG>5>(CX1^=J6!4JZI.KIQ-75J:/&4U-?J8N(?TUIRA-2
M9)06Z<D]-_\,H0<*<XW2UY/&I8-+JU-&C9_&$1Z<IDI-.2K0Z[6#!HJM6U)6
M1=5)H\90\W"'K(ZV8^D!#?]BW8[&Z4R+]#7"2^N!]_F4$**VL45DDU96H1:I
MP@3`\H>>.\5G3/$AAM$X=0JR[:'R=@0E%Z+)^:MQG+I97CXIT=:2:;Q#%&F1
M-D:"),HB)]?D()I"I]^\>@.>"7WTYF@6G>I`;G1Q=YD_=#ULRVV,"155U),9
M?DWR*++5]-2!+G`XJ]2V7+WC4X?003INN0<312%657WBJ+'4/)!4T>4*P]MW
M>,J_H"*^ZV=])M#&^I(B:`KW[F4@^?11Y*NAMA2!5T7NW4MTWF<K">+#^0M;
MB/=6,G/>5=,-2"(<TXBC!YZ,-SR(H"21_V_O39O;MI(%T.^IRG_`RW7NE:M`
MA@#W9"95LFS/>,:R]"PY\^:3"R0.18Q!@,$BF?/K7W>?!0<DP$TD14J8RB04
M"9RE3Y_>EYU.OY/=$VG6C,B4WSAB$5)I:5&97?A.''LC;TCF_=N0EZ/+?[M_
M#.HT&KU>0W"372SYT/M_K"?&:C6[2DC8%0!4D'9TYP3"@7.!:="^YSK"N7,-
M=Q)HBL.3:`07<'RJ443"]ULO'OHAMHC$+&KO+J`I0"7EUA[@&-<A]GUE\2V`
MY8V_,PGQ]__UD]]<[_Y_[Y+?\./4B).9S_[ZTPA&_-6P&M/DER",`(;&_R7>
M!+AIP!X,@),3_)]IT#>F$0.I'/UF3)SHS@M^-1K3[[\9N)R:X\-6?C7^`Y*W
M-YK]!DOVP^A7XW]XX2#Q4$+0ASE^-8(P8.);+\`.OV(PGR5`UVKQU$'FB<_A
MBGXS'L+(S;ZE1Q_&7L+H.Y8]AYNIQ4G$DN$X^[;VP`;?/%@`S@>_AM]8[<%S
MDS$?ZB<)$WS[$6`IG%P-/L`/J'D9EO&_SF3ZV__T;,OZS7C+XF'DD7!GA"/C
M31I[`8MCPPE<XR:=`*QG^+V&*T:&+(;$%ISAEX&<ZQ=<BOICNO,SKXXW?[QT
MG%:G<1#@[^S"U=MM+WB^AZ+N'/7<SMTM[?YI%T>=XO*FN<99,F9J"+OQFVB2
MJ;Z!2QU&^@-R/.V)UX8'5]P8>$`0AN,`3N\.:^G20/C?B9=@Z$T2`F>C0@5X
MV0<@F7Y+QE&8WHT-='<Z4U1[X(0-WQLQ^`H>2!C&MADN*(T.9M?AGN\,]"HZ
M_G3L&%/T(`Q]9GB321J$?)B9<79^_>'VM3'UG00QAL@/_6A$W/-`W\3>Q/.=
MR%"+AOGKAMP?'$YXQ^BE!R\9TZ0/X]#W@8(]!#!$G`YBS_6`I)G&)7.S]SA<
M+\\_O#:-,WB?`><<)30Y]_,B)`#'?6R=#/"8&4Z\&L(@(7@.CV#R?6<0\MQW
M@XU@A[@T7"/LY@Y@$<`]2E+2L'$JD*R=@>_%!&9C&H6`/?`/<.(AFR;X$<%%
M(!G#2N)TBAU382:X9H@UH-Y8O]C&4-2M,!(L7,%AFCVP\',"0)F$]/G&#YV@
M]D^ZFM2(E0J*&+RBB'&F;?WRYI\7%[E]IUB$!"8SZ">8;18#CX"_/WQZ:YQ/
ML:\\"2AU`+L!4H)MJA,$<*3!<(RG;4Q2/_%J0S[C,(RF"#]FQ++TBUBU%QC.
M,(4?)C/`4Y#'?99^8Q//`92Z_`@8)3IDUXW%"Z;N8?>WV`@'_^&G:QH2QR-1
MKX,@YV85.TR\/7!,<#!N.F2(HAXWJW(PC3!T#,'&'R`T]&`8.&#?^R\L-0Q"
M$,,".I/$&X0NWB,XC6^P+4*+N;O"Z#Y&,5YL?BN<*8P]C1"_X+$9')<KEX26
M`..>`=^>PNT&\I8@CM%UEG>V;MR.F4!0?PX/8D*O(@@A?0#&#Q.-'<#C`6,!
M7ZV$,7Z/VRXY$(0B=C6/X57?`W#BBIRD>#)"<$4.'CS?Y[,"$>?;1S3B$C11
M(-<;P56E[<ZFC#8A3N,!+S3<$2^A,RH&/CP+JX*18'_UDV*CE6!S;"?RO`6;
MJP!TAB'5/C+LGBDH./(I(8@81++A<GL!$"3'2+)*3`NR"Z_G^^[[D*+D=#9B
M&M,T0M]`@F2-TT]]$H<[5EW85N-GO.WXH\=KI1*CTTIX,MXK(.8Q11[+D;@R
M*4MG[]<?\DL#IL/$FHGXR+F1X.#81)V_>Q.@SB`K]/NK%C@DWP<<%^C;)I)]
MXY[:T+S"RM#&%"!-4<NF'$8``40?E.*`30&OE+_E0<I/!G%5#B(Z%0@A`HC>
MT)DP>@H5_0A$%5S1_*/Y61/^O!^B<&<:S('#P<&TMV!50^8AC6_4F\TF_RE>
M0`"Y3N,SR@0Y.4(_(QU`!/'\E.HTW,7%.<`YQ`;FEAAK#,<(N7^#CN9!>#B(
MH:8@`*"\A"_GEO$`DI>:%Z4GG"*_'UHJ7C(Y.OPI!S=1AI1\S,>#TB<KVGA=
MHX?JT^W"D=/"'*ZCP\)P"0Y'$ZQX!D?M?&,A?/P%3HCWPI$QRB"9@@@$[PS@
M?LU!UN1\%#`?`8%3`+K$R(RY8"$O9,0GS$P$"-"1M$3!(E!2)=DH!9$.-(33
MXK;/F[97#/<(#V5-&B\9(UY-^#O0[Z=C(,43G(:>4GF_2MF!:PTD22D#L!8'
M:,G`"Z<Y_JA&T`P#(&5C@R<I<"=H!B!S<W6WCP>-JKM]A(<"PO0E61CL!DG2
MS=Q=SBG$NO%JN>QJ&E(H00M80.)=F+US(6PI:((IDBA@3>?3R/.S;RRK8'&Y
M2=QPX@T]T*Y'``%.HM#GA/3J$[MW7`=7D/OZ+?.=!Z1B*!\LK)>&N0"E(8V-
M/P`1THA)P5S?2N'V*_0^&O1^D33GQQ^._5C@AM^P:2)T^+:\W&1*'<+F2(WE
M=DCC`G@[]T/3M;UZ"$")&'M3XY(AZ.\*Z0I7_4GE6J%ECX!HH*5`T8,\C0&M
M%>G"O-:(<[-HSMH.,P+]8/ZH>$EGCM%OUKL_+_@"0)]'&E3XTA"=&&3]9]^]
M."E4N/EBS.(!N*K(IP2M:EY0(XG)]X5)@)1:KG:%);L(PJ1\M$P;11TLIW?#
M>$5,9:5Z>0Y[Q]:M\'[3['<;IM7L:F,6`ZU<2\9U66;3MLU&N[VXMM+UO!SJ
M<>RTHSJ48SP4Z6S&<@1TH?1((*-F?`F<U/70M$.1>][$4,%!\`V"C3^YPC-]
M2W8>H0$B\4_5N)X8=ZA"DIAN]XE5"!)1.NG4#3`50',G33&]EMN.%WE19E,"
M\12&G?KP[ATO,8XNV2$Z1_F[2!F_!+0PDC@YL0)N`LPG9]K]4K^I&W\[/[_.
M,1,D4W)#V1Z\#%"<910L$B>.4EP8W^8=MCGFIK]1P:IN,I,T/J],>-3&/HX+
M3>;O\NY6FA9.>\J&9"I_C_XRJU'[?SE7$Q[$'L[_62W'N*G]?W4*Y(G0+.#/
MB.V"4A\2AP'H^JG+=-NIMGENT@O#A)]>Q(0E'CB2`B>!$!$%;APKQ`/N@]P&
M@49I%'@Q>HDC-D*7/*W3<9%`\"?.R/9!:3RX?G'!(@0VN;.U9U\+WP*)'@)S
MT*HAXJ'@'CIWC#M]`S9D<0P20W8AR-9IC!PORA8H(<:EA#AS$(@-3BG@-T9<
MQRN*-FMY*>4K*`'@.<@9/4!O(&7D.+]G91.,4@##C#D1@3;>#KCQ.$Q]%WVA
M$7,(Q>&=_Z0!]]\H')<#KQXP[SQ0B\5U&@S(LYNYDYI"SR0$X\B%+FM&P1<!
M[R$NSZA(FG&"(%4V9@.6*^_"/]>:EBSR7"!5^X3;1@.Q091B*)SP>+4J+?.(
MN%\EDASAH4B1Y#KCU23H:Q'+ZX@;JPF,9%:E5$%DLA-52<9AS.9H4N[IXH`Q
M'F<&Y#76XF")J`Z5/UJ?16L^I$DWS/<FL`,D^2>&J<\942OJ<82'(JG'%WY;
MWP&D)B0Q`_O/5!>5V)#7=]8@*US1<&38>T+RTCJT!A_"4\&`DMVJ)4*.CC69
M$^7YB?.-84"HV#^2%R>.TXF(**`(.H<<]T(H%*&@SH33(PQ'X>63\%5?JQ(C
M0A9<8=I+UJ*VG(@6SQ/Q-JC\(2;[:[AIQ/V,3/?^DQ!,L;M<9..B[)"$3Q[+
M)WT)2+#5_D^-<#[K2UI1SB,\%$DY/[-A/N]M!56\$$Y\(&*@*_'[J2YW)L-$
M:E@9%4_DD#Z"=HU$2[P[U4AR=6V/"$.J:WN$AR*O+15\0/Y)'[0\\76DFLR-
MPD-_8K*,C;V[,0@BO@>#N9FB0M)+&'EP5K#V":8IJ>!83.6A4/ED3$&+/J8M
MP14?8(X#K(MEZZH;-^EP;`P<'ZV@9+OZ\0<CC5.2?GBD++X-H[Y_^^$"<UU2
MM!:B+H1OGR>:,[+)PR!:!($B`TUFD"QT9^':T./D\K*!7.K"G)>!$WRKB-`1
MX7M%A([P4#*;#2]7QIT2JH[:"@ITZ6!';TP\(OE?O8;6;!`;`#8\3GH8QHE(
MJ1(UBBES#4..`?R8.U7S/;JSY,RZ!PH@Y7\7"`L;I3Y0CWN=4J%9%VC)>_0,
M4+HECSK^3H%#AU@`T,88M1^YDG]A!*;4NVCZA'PD0$M!P7)-H6V)=:@<Q^$P
MG:3\LZOW8.5#3$*,IU<A5I*2<V<4TGTYSAT*<DBVL<F'%TL_B2"'//036$3=
MP+)<7L05MHF#!JV`?%FDO+E>!K[AV*%(#-BG]GYU=X_G[E8$]0@/11+4#Q.\
M9]([^#$,[FH?*3E&5+;6*6O^(.GUR\PB%+%[CSW$<+5A#)_&$&2&G-;9/`]`
M@1B1KGONAXM$F"6W8GD1D!I,0!K2%RZ/\")K$I$F)XK(P\\U0#C]&7DDN5\0
M,T8PEQ*]GPGFZGJ!-TDGP@$'8I]F\QF%:02"YI^I$V$FKY#>N)ORPPCSA!DF
M.XFXL<R=S$ED1G='*1'V%)8:R]P6DO=&?@CP`""$@I)G3DH$#"=?*"R*/&[U
MRYSH*#;,,Z\H\QW6.T$^X-$RO=P9QBCT\@F\.',-<Z\V3Z0ATQM09?U0I'.5
M(LIXXR^RP8GLU2%JV<D#*MH$.W0L\P7EI^2IM/.KKNCQ$5W]BAX?X:%(>JSW
MA5A5C0-43E=[?%Z8U.\HO[5"%3;B,6,)"*7J`4ZCM314.`PW\PR`8!7@L7YC
M4CK-SSJ@6%28Y,\T1#HG'IU&WI!QD1,>RGVI`DDPE@.#2)Q[Q_-YNN%(6Q8^
MILB=*VIVB)'XK#@>?1FZS">?JPSXA"_EZ.$`3N">9]GSEUTG<82$BU0='_Y/
MZMYQM0"5A,JN?X2WI")=1W@HDG01.?E#R@1Z&">\ET[6,15F%`EE%Y>-Z-;S
MO$%..;@@^)"%@HE<;E)S,=A.*+<FBH#8$(4$*U'>#@1"Z6:<\:P"5$:!F@&)
MT(L!2$E'DBRJ=N)-'3(JGNN$=>R!RAD-QS,J=\-C*62)'!%5KLF0P31-A&/T
MCH@G;@N-H/`.=V^@\Q86+.BHH)44S4GQ=7Q!0J)&[*+$1R%F4[4CS8DJ_*$@
MA,X/GP8:0>2KXN)AX<ZP(!-.Z:,X^VMU\X[GYAV0'&;_%S"MRL2L/J"/F(EL
M6$`!Z>+KU0V_!#S4%V[Y+BZ[4H^S0`9\(>%TB11+49((*Y\,R>\AWI@P!_T>
M)/E@>,4!!)X*F:K;_OP.B-]VN^BVBZ]XA32XJ\'"I:=(45*X)-'@\5.8<9?Q
M:ADLSFTM&@T`<89Y-+KK@4R4H,X3_?@#V<_XWS+T?H)>!!6:FE\&*8&BDF$A
MG<EPT`NRSWEZ918,FI&O53,@!"3A4Q!`1=$1)?"\%:#<#&S&F;!=\9A9%)2P
MF!]LXC[$A!2^*)-'Y5&;$".>8@\"TQA&S/7@<2_^!G\!.M1?&Y2=DPEY7'N-
M2$`5(7ADA"1'":6A1%%(Y1=YDHJNFPYF]#,3:3&JOAZ0ZX/X-RH24-'HYW=`
MG+@VBR6R!:6(UV\4YB?E-M#,4UD(:Y$\II+``B&,_5^,X?NY*%EG$*:))$[Y
MV-D"[5,HOFF,*U2F+T7:YI=Q$-M5%;=?6:F._U#(ND$F#+HQ>,EC`Z4!+'D\
M+@M$%[I1@3G=T9,V*2DPJ&7?\/@,8.$^T1OT^WD+CK/,PN(0)5DWV(QJ/>BY
MK><W%T;/;NBYN`A+;\XH=YDI>GRG6<\%57#0%G8Y>M?4`NW+(O71A9F%W?)-
M>A'1.SB%6>8:T$Q1'"BP8Z*RG-@!N/0,)N$-U:"EJ:G<5E68406KC&,]US4;
M5!3`%/0T10E4S+]LKBSY0;H'3!&3,M.3&S(C'\RAC50&-FZ;@\>F/MP>[H%=
M@20$M8JD'R])YU6<MY]>[*C7L!5=WZV@-B!;=XV*OD]C@+K\)+?N_9?5N%E*
MSK?=>1A8.D;,C8UGZ.^IX[KB;P6Q2(+K'HOY8'$_P<D&89*$D^QD$[?@&,27
M]+,<2,Q2XP/`"=3;TZ3P$(O>UIDI+_"NH,8'K(FK,8!K^VW^-P$"/N7<;S3!
MKP;E,"&`0H1/\->?;-U0N*==G3),[`HF"S!I5C#18'*+9:!VNJ=?DF@/%&H5
M&.>VM?U(U41;CO2(<\_"=G0Y[]=G#[+G-]$F2`#:S?#;782M.21Q^Y_AD+'1
M2,</.8@@<:U&!X4Q29A\-B+QV;)1@.9UE8L2CTHIG!0;E2"\FE1KK^3L![B6
M30?IVO.C1.AAX,/4#K*$:NL[VOJK1^VX9]I6Q^PWV]7.=[GS1Q(D4K.+R-%R
M`K1@==J8'A>(A1N=\\;W:N.9JAULN8..V6UT3;M=CN\O=B?:;?V%#$+RK\HX
M-V^<^_&'RN-RA,>R^Q0SZDMN4&/R36H%I+&(D,TRB[*XC0E+QJ$J="K*'/'J
MJ#1;@K/5C2_4\C$9>[%XP\2H8M$YT_F^S*VAI1TH)T:6#16K(.&B%D*\!JM<
MR'S.VM+21Y@P&[',\\13'BCC+'`H4Q9'C%3))=]Y$/YB:D4X(,^P2//"3+NY
M+"Z^-\SP&HH^JJ+[4LZIHI+YBH#%2XMF'@\'O6KD7^%P2J=8CW/,^YWRMHJ3
M,$+%^!LV':.8'8SH43&+BY.HO6#ET)E([*,>6D7SFI@'IQ+=J`>FZ#8)L,2,
MXS@IVHBIKS<K;57F4')BX2GR(IEI6!60.3*24_&!(SP47]5]TIK6OLV:U@+1
MB5>GAGPN:7E+M0HRJA;$/&$$J"\6?7*QDD#)BQ'S)H,42%_F$;_CW?5RF71S
M[0Q$QSKLGBO<O67->/G**OIP1*A8T8<C/!1)'ZAW7.T-\>1K'FR[D;R8E:)<
MS%#G#4QXRY,IEQX>G$@UQZ1[S^M-#F::R/4&756UF^$XI"K!_,U<QNE"WI0F
M-D9,5)J+LZ(J*A293X]R8DRTYBY`"8?7=*&($A9K]2AEW0)1$AXDO,G4#V>,
MZ84)]#;;&,F(Z7)%#6%I;HHBHCXG-2X&824"()^BX:8H`9!?G)*#:838P$;H
MHI6L+E'BTO/=<HA>BH.10U.SU*R(0AB-F"CKHJ8!L3T)(XH;SW[GLF\="ZO>
M>V$:DWRHEIC;!6<-&*H#HJ3*MR&9ET=F\F(U5.AS;@(%+![)E$<7AEUR1P7'
M5,=&"521#*3,`0O8R$,YD\HT@&`J^8I8*[(2@*7K>K1:/#W'<VO4KY#:GU:\
MXXC(5,4[CO!0).]XYT08H!T;9Q_#.'YM7`,5O>`MFWA+TDUJ%#K^D$I=X9H2
M7JH*.UW+%E`T7D&'%0S#M#NY,$RU+%P/+40+M,QW\N8OZPU4Z@8VS1ERL=+S
M4VI+4[H@7EPP,UG,X!W@!$B;U$M94V=>(#5K:24;:@MA]X&AB11)%+`C[+8:
MI.0,P%HOJC56KIN6WC1<J[$CR6)9P.8T3)#`\M(\N$?TH/,I3,'L9*I265OR
MX@;95!>6UP5B02Z_BK/BR31-5,!F(70Y6,G8X?NJ-XK(IA2-UE0>.LSIU>0&
M*K*]&87(4]8JGO(@\91%_@V)1\\[8$S%5F1K;#9,8B61\0L^4>CO?,DQ=FN!
MK#Q$9=]!>%O%X72L4CI*+UUQMG*2P2>V:?<:IM5;*VKHR$(Q=@:"?K]G-O8#
M@GW%9!0R]26WYU]"W#D`N2&H+",V/_ZP-;G9VH>_%^*'$_?-5LLR^ZWR\/-%
MV!P+8UAY4L_HG+IFO]DTNZWNGL]I?]QHK2O?D@O<+-B]=5@,:I6>F!NF(,L?
M%('66XQEF5W;-BV[\P@$V@3,U1%M?$0-N..6V6N6IT?MXHCV'[BU*XW=[M>[
M"+GG:M/+G="@X-`&ZJ`J&\M1G%CFX4>EE+HWBXBLZR@,X/.0+7KS"L[T0V!<
M.C-*=^#^HZR(I#;F#5H!R?_T)D2GC!?'*18L+WKBRY2<>CABK=$WC<^\$1RO
MP',!.XJ<H>PX<P$G'$X8-DDXA^6ZJK$>A8^)D881P__<AE-O:'0:G36'Y$GC
M<3K%4"O1$E0TI9,>(3)&"E>>FEK.T\[F^9P];@K#)O=&QEC6R849HUD-FVYC
MVGOA)'>IQ\W6R1BDE+NQK$#R0;S-9]4:)+NJ5Q=VA%8>*WY&3@:K_/[(WZGF
M@LW<I(-$[J?6+-Z2PA#[-^S(FD0\SJ)V.YORWAF`4:[^G8(X![$X'T1C-5VS
MU:BU&J9Q11%IYUG@W5L9%$81*/FI2S`#MA^GDPG%F?%-1BQKKX@@4ZB!SE->
M!DK6?\F<?[$Z&*KG#F_P(U"52F&@*2"4AY[0NQ`MSU2@F9RZ,>]I)M8DZIB*
M<OAZX1GI=N8MEQSI9.1F=>G;3*3O5K91HB]];BN?<QUCP\.%Q7#COE-Z8R@R
MA^(1T;8OW:IZU^U<=^S,F8HAED"+J?".,\(2_2HIP6I34D)'OP#S7<Q5/04"
MR'Q[1]WA`VL5'>+0D2T"#&70):V<M\.\^2()B2QHL;(KI2*-]8IS'2/GJIRZ
MQW<H0&+_D09L7V(`Z!.YZ$-X"@C<.Z1ZWFIJQGL=R;!E3W!4*BRCA_[%-*B@
MKR09<+;01\J%;(@-9GPL26A<#P-)\O6G2T:4<>*\(.!<Q5?\D2;\4K^I&W\[
M/[]>SK-5ZV\ADVCR!Z]^5KH$8!=GUFO931,I,2.3>2T):P0KCQIP"B\K)YA:
MOUZJ_X,A\J;6+47(2>AZY2[IG+<8%X>E+L_LUX;O#)C/([T*NP''64?U\J.!
MH9JO$?18!XG1@_$P\J9:]^6"=ZD4I:I6N<!.`5E8<`</NGPW9RUM"EGAQXM`
M.,)>,V5#!"%UTJ&BY:68Q4LGR=:HU.$+(^['CBO]WL5;6,!RQX]#+.0$5W.6
M!>;KPAO'7[N+8AN6O*2M?8$?J3DKKY+IS8<89+B"0RJ?/+KO,1G!Q?)'0:!7
MQ\PU\5+4F2B`[\\6L)?6+>XDMLV^BYSIV.A9C1K^TZZAB,"A&R<B-)#Z`I5"
MU`V1:L$:)XPEDL>+`"T$=-$<K3/GM1">,"\B\D0)05%05(Q\]L>'=Z\Q%`PO
MC7;60P<O^H2$W5RG(X[M,`[&F&6Q"SZ[`S!EB!*G(Y#./=&4>XH!(`DB`?S!
M;P:386X*:9,YD8=C*Q<D7;I=V?IR%_`.PQ-)('/#89K%30^%O(QB'+DD[N0U
MQ!P-17QPW?JF)KQ-ITS2T4^6=]14^*,5QXJ'@"+R<OXAH?U!0EL2<A3_8S;D
MH2%874UJ`_S@3%0<A.R65SNN[JD_NJDW&<CB*X5XR%2""TGM:)5=W!J&"V)Y
MV+E3RL)+U?U2Z2HZBL42Q^QVK=66RIJ!?W4E5JOJ9(.0M[+RO827H<!C@;\1
M&OR+K)G5%B+[UB)ZRQ3)4'GAG%B@%_`?@6QA!QA7Q-=J$:UY.5W"GL?-TO/(
M\(58#N*'5I(XX3*$K)Y0A>0<CWSWHH7N'W\XUF/9M]AMFW2197!V#9[#Z#W]
MNU*ZE`JZ!,+%C,=O+\B\O*L*Q?&+$I0B0CX?Y3Z5B04YL0O#)I6]BX=ZRT!Z
M(3``X2)AEM@I=AQ-B'$CRQ^./4;=#HD`*BD:NSRK,'QA=L@'G&Y!@%488@%-
M53R21-G\\ZO(=+N,$G-Y(IDGQ9N:3"Q[;9-)1:J/@B:L"%MYR33\"$]+4O#S
M]`[@LS<:#F3BFJO[*G8ZF^!&7>&:\;<01P$1&_1#0=;%0(*NQIE](A.#R_.P
M8=(IVK%%]K\7Z$1'$\4CQH7M`8:*8UPYN9(346;=X>U6YXL&9YUQ4(_Q`JK;
M"P_?A3S6G#;!94X:1C:S'H5A`JHBD]H])B_5C?>8U^20;)X7EDUM<RK!?95N
M$3'1)E8HH61Z%XUSN6G;\8#<[V7'@J'`/>*6"M7?VY7FHF+3"QT"8M1VKH$<
MZ\)<JZ4.`.JGOAZ#)'#20(]D9NV*F9T@>:QXUC$>BG20D;GFSQ1IX[O[#5-_
M<\1M,M^2'$5S(+:89QKA[534D]M3%$$3XO_*.VT\,$7A>,ND;.DTML8/\M[7
M9=3@%]>[Q\]_^26-:W>.,_WU*KIS`E%E)&>L.@]<G0M?C10/SEAP5ML?GK[)
M*NMG//X:QAN"YG0+1__&!U7L]Q]_^(N<^S-G<==.E,QNL\Z8VK#J-6(A\,=G
M-OKK3Q?\\]?^Y;NO#>OK/YS@*Y+,VT;C*__G]NIKL_'UADWSW__T>\GE,^90
MJ_3.E=RX_%U:A=`K9LMC["=D_7:NAXP`FT%P,W3`K73__OC#HR&PB\VMHI$[
M6&9YRL6.#@8_4`.+RYM_7ESP(KR>VL:>#V$=-.0D_92/:_F&CGANR;+VM030
MP8"P-4SC;RQ`/X)QGO@HEP^-OP&[F1H?O8F'%,(-`V[)]GW)>(3_($NP]9#7
MC$/,C0T?T$N&C,9S/0H^.@>Z$GCIQ/A[Z+N48_PQ`8'[#`4):F@<@-SM+B[C
M0^9YD8LAY]4EFX3$'F_\T`F,?Y*X04H<JF:1<4'I9L89W:G7]2,`=5'>Z-,M
MYNF7<!48[]D@2@$]#(NJMC;L?!D..D+R,F$76#C^(5;BR(=#H.*$F?,L0H%"
MB!_&^5W$LC8U'$=J&8Y@BV\O2;D0)1!&U5TZN_GGA]>FYIO1PN$XNT3T0[3*
M9<2+U653YW+CM<//VU2SA:)&BZHG=ZLIRTBC4_CR=1K%J=9Z2`V4!Z'/5^4:
MPO%-2J:/T7:D?4;HOI8A'[!O/4!M&'F\!^;42;@<B:!$RP:5(@GU>7(2+<48
M)FPX#D!]N)MQG9<\WW$Z11L#4(N`J^ZY6E1#'R@$3JA[NZE@%0>[&Z5W:,5V
M2=B-"\'"SX6`X9I(@/XC%BOWGUDF3&HMCCTS_RNL`VD`6C<U84<Q6;TAEX5K
MG$9,_0W0NXN<B2B"F/FK-30I`Q%MQ9U#8S5PG*3N3`VOGPG5*!"-/;&D@=I4
M+#S;HEJ-++%(+F&*NWE`LPM%-%"DQ2",`C97*^PHB.1QL^-*KGK^P)PSM84#
MF%;>YXGS3=`*U9MOXOD@H*#14?KJ?CVJ0]@[5JVH>[%B;S)_LM'X>7<5*M:J
M0"%6OU8-"O&LRN#*98&)K#&>F*EG>UY*U-`3GN>'VC2]<_[]E346"I<W7S%!
M%K#;^4)%GMHVP%X)@M4P6J?)RIJC;;:154FU\\"5R?V]G\N2^S$,;P3""I`<
MC!$-C$]PI=ZB'''.8QA)\-4ETD]OSW49%#TQ$;O#4E$AB-S.%%U;CI]M>20]
M04IHG/+DE25((:_OSQM@;/;.&MTM2E[NS[VL55+HMAMFH]%XS`+VB0::5WK9
M5=8.WG[-:S[S4(TA\Z9"+%XXR\SE1=[*]V_/#7FHV9;6.-VMB,]:X%O9X<`R
M5Y_?XPXM2Y<]&$-^UE+>]AO2`FF+M==X3+7,G%FF<E,O8_()1+/:8%83'T4+
M8P<FFSD^:+1P0>R?\=]8)"UV?-']'(:;Q__80`<#C\U'Q0V3V7ZEJ&>K(6+4
MU;7B<?!#96^@D4VDK'A+5?UZJ3&#-N9%I?753NVXGAW^70CU6;8Y<%,&N"!Q
M<L&@PQUIJC*_:(H<((F]\^[A`W_7P2\&@#=H5ZI)8X`69EYHN+@2X8Q6GR(%
MK/Q%0%D7_O:Q5BLW;O#RJS,TVA@8S_^*4TTT'?'7SP;PI=W0O[5YO/P0?\@]
MWE3;]F+]+GJ!LO<(HZ^<1H0O3#"7@O&H_1$3>3[*J",5HOJSPYPCW=#36W2S
M1H`MWH=KJ467!PGH1E"RU@)*P\]9MWN>:I'E"^LC8HMV>D.&XX@X'"+9>!-P
M*(JW7W*S2\VS/%/B\7/#M7K5L]HFJ+G&U$\IT03MA.P>3;B*(Q4;9R4)F3IQ
M%@;`37X\BR>KHUIN9^9;"!_(ER-RAF2I4DG_]+UA%6IXFK;&V5EF6U20_/&'
M-6'YEI=8S>+\BND'P<GJ]8G$$)P6][R.E;*B&J=@IKO"\AG()^PNT8JEWI]`
MS\I2EO*$7(!S](,+BGD_X+SO`MT`6)8!0_6,Z[$#&&S]8HOQ>+'@`::9>ESO
MBIPIB928'>9BO/IPE@"#AT=XYM(HXG$3W$\A\C@_PLK3_Z839U`[']IVN_1R
MRAU3D"4R]5=-R[1Z;:6\X0WD&7,\+S&F,$F@GLSE,4`Y>!3.\V5*9?+9,-63
M14OD;O*!.!A#%"6U=$I7$]YXU>V;';LII8GJ)NYR0^\%#P%B!]">P(1C3,Q%
M=^!B=UU"ND7V*KO(<(/`=]GLX)7=$4*;:[R"$<0]`)D54U01R9;+<>*R\#+=
M_';)U09X`QZYV%=6OPN<L</79UL]L]-H[6*5A1?AG*=7%J]RH8UH?LECBCJ&
M&RH3ACDPAIAF*MUS!9R-^)8Y=TMCU5F"_(J<Q4JN#E('CO?*[O9,NV]QR/2(
M*.0!4]W!(XG=NO8=7C4*)"$$%&WC8%%<IWP<^\*O*Q5$L99XP;/*N3,^+T\X
MQM^9XR?C(<;_9_%(QALG^$:]N^#*3M7Q.WC\2B,@K5MV=J`$PBML;2C20*BL
MAF.X7@3W.8RR"E:T1)-79&(XO2L#K,J70@2(.9-"JK=VX,C\1C`L12;<.[(C
M#J@-,25MK[G7NE&TD@_!7+$GZH>)=;E$J:;B%9$)'!,8T>SAB&(<C.+1D+:&
M@"`_2TC>1=0>(0J'C+DQ3SY1E0G*U\NM)PZ:76JB7R=1?$FQ<ZW8LHGMQ\\K
M#33Y&5#VLH0I!X$D:BI(?4QQ4A'/,0>Q4KES'K("_"Z+X8(2?^7E*@2\5;,*
M-#VEP')1:L["_\IB77([S17_*CJQDGX=(GS=08TP4M:H-"!T"?TU8"OM==H,
M^97!#'3(J9"4HZ$7JRC[-]GN]>8<<0J"!ZUB;2#G84H+<B9<^]4">(QX.&9N
MZLMLVAG'<WU9:D$B[ZDCY3"Q9,P%0%4IC(7/<`WX.$;[9W(1#SV1,H?KDDM0
M,\IEN+*]('47@2D&C"+''-\7N0:`E6S"LW/G@XW*E)1MUJ[CPVHZ-M<B46M#
M)@.JLCP*Q[WW8O2QZ<7L]+=Y>UEA^4$70P+7TP&NH\Z#/T%_@#`N=2F[C==Y
MC<!`0AB5AD@:X)E'E5GT92`EQ4)_O,\N-AR.[E@$!&7(<[NIEM(`:WF@#5E7
M;Y'O\/2]+/[?.!-?8?-;G(9W)7HGZNN]%HR15,6($AP3<J9PN[27E%"BDJ.A
M*#5Q)=!\7D+,G3N`R1U5M<RQ#7D/M?6+PDQG'@'*E%=$/R?`)7$^(A&>3&A.
M3CM>.'M>;VG`*+7RGLUWC1/%31R)/XB9D1%[$\]WHFPX'="%`$$[`,7JD<L7
MG:,("GA#LN`B.KN`LR*I4`D)`Q`26*3`E5NCOJ2I)B$XW`S+-(*4V64%S<U+
M686"5"&:O]=OCLB;5,F;674"<J*I<R$/'MQ]-$NHX>.\-,?#/`->38>CZB(.
MFYRJ\GJ1LE8/AH+F69DQH)1CZKK$I;38F.!V!TRXW1_/=^F&+R%03K%\B;RO
M@(9?A`%%(R`OPYR?6#MIX1W"YTQ#*+,9.Y6TGFA,=HRF)A&()PMW@!70BH4$
MR[3;EMFPVAN*"T?D.=TD>/^Y6FN5=:2_VK<3<`92KE6MT)J:I9*Y%N&$S\I?
M\JWH;K5?Z&IE!E.\ZP\A43P@:;&YL"VZ1?]P`IZ9("LR&7FNG.T60Q(6AL"2
M=I+N\VHM@G)S-ZSN8I6QW=NH,N;NE91<6[JGD_21O@F)O&YHR;9"^EH4#9OP
M6>)($8F2E0/<1\I[,EA$L])FO"HS%+J@1]1\CU?"(YT6=#11[I+S6\'OX`0I
M6.N3(YP;[_0BQNO(C8<G"B=N`%R/R`FO5%-+!<H+W+H'A@<&8300'-*//Q@Z
M99H3J+Z`DF)<RUMUGI$"(HL2(^%&`WGQ.,%"$0X%CS,<5J-_'^0O.O'+EJO/
MFQ6/4B_ID21R.:A9X+55HC:@7+O=,IM60U[8^4606)5;P<*=!G'B5:>./EW5
MJ%*)YR,0^FLD\A52G?G%6,V>V>YVRZB'*%\NU63L?<VO33\W?;Z@AM+&7S7-
M)MRO7D<KS0=G,4<H5328.&[M;E?F^!W?QGDVK%W&>?57.'\6S0?S"$O%68T+
M_NL\WFYS<7GM!8>P<7[!"[,O#I!;`MX+9'>JK.^V\Q0/HL^U!XJS`>WAH32Y
MLUB?(%EF3R-(QA-3I*[9;]O[HTAPQ-M3)"WL:1'S"D_!-`:(_-*?R4.@YF5%
MN;XY357HT>H"`=Q>=<Q.LV-V[8;N!;C-V7-"I;^*,*7<#LB^2VJ]1!X4Z$%P
MCAC52*3=OR(7-UG(<Y.2@!X1"$+NJ#7P7S6L])MH-8\JFGT,&WJ;M>)>)[)@
MA8-(TZC0<I2/B6C46YB[YY.1>\G]X?I0+/620I+0Z9G];F=3#0EI4)X(+!B3
MVSP`_8CL(!6^SOF8J0-43\='9;83#J<%8YGB<M+FS`V]"T:$8DOJT4#NF.I9
M4/B\KXE#Q:H:W*UTX'O#C./PH%[D<?`SB!6@]5EV4[%PNM$8<B/:1N`K<[QP
MD;18S7I7T1;N5L,LE(RYS3]OUSO9\V1,`'HGPA.Y7PL8V`,2)"QE[\5D[%'X
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MJHPLU!#9?I8=+D(1A&P\H`Q/N"!)BK3U6!NN1^OUO<.3W[:NRTH0;-Y9G4]9
MW%N]I&#-1Q#JXSWMZ30A@LRO`D@>(,V=;FF3>[BB'XE?5(^FT6@JMKP:K/*M
MSI;O;%+[IGB4ECT_C%;(Y>"K>4(X6+N!0WLGJVEO`8?=S/R4<'CDW<P5YRHG
M7]E"KK`_(LOTE+T*5ON4T9LUX618%-%7K7<M)-D"#L65P,J?U\M'=3IFLUW.
M!X]]^6VSU6OL:O7[XE<+RS"6<-./+(Y_Q>""=)**.KYH3!]ZO)'I_D6.E2O<
M<#Q^7#L<<!<+W/5J]B&?;0_K?:WFS&Z;S5:YD+C1*;VN#F>WAV.9[<X&M'"3
MLSF@M+"PK)9<5+'!TT1?X=JHU-HIS=EVM!*2^'2+V^U*-L;P5BE^8[,[GVTN
M'>QK#2"SFPW+JH[ER(ZE:?;MQ]"^U9#52&!6$17_JMPAE=MQ`[?CCS^<^K&\
MU?01E3TUVJH<$\6QO+):9M/N%)9;JAM+9]NHG!*?S&Z:W5ZS9+)<=;$HY*&V
M*N(;PXK$8G@YW"+_J[M12&93U&0:(H7#P"<?8Z4PW+EE6K;JJNUZ\33D6>EE
M`6U9W,TF`31ZX,U;-JAB;)X1]?3U&)M6+L:&OKKF=;D(A0X66;-#*EMQON,[
MD^=\*+EDQ]X:Y7J!5TRPA1_/EM6SH44QZNP1JEC4[IH]NZUJ%:@R5\@B0K*?
M1X;O.:I).I!I&G>*!6B`>ZW9XTQ4JW3#AT!OC@7SF_U^&Q-`9+*49)\9.B(+
ME3W-M3Q/OAUM!)F%"XM,'-^?R&QUC24":]\F>R&W"PFSNK%-F<(P3;"K.B46
M#QR?8#G7C*S\"$F8$#4BQ2J*2@TN8]0E##?/DR/OWL$!L0=?E%(&#O#TOS,7
M,X[.51>UBG$_&SJ39]SM'./.\&%UR^'C/+B*;Q_CF3SG0]&5.JQ(FY5_Y]DL
M4KW+4M7F7A"I;$A.\3DJAH%9#Z*ZV!05Q6%"]7R8['XR2I-4M)%'QK$TRVT^
M_Y5R7F-CP+!\-M6>DDO37M-XS5RV;"PS7>@+M=:A*!M&M>>(1;O4-%ZOX%4T
MSUPJ[H!R2*D.Q[T3>;RR+X+!XT7R'2PP-DV5$#)RO`B>]%.>5*CG'8^\[\RM
M`5K6Z).6@&R$/`^;3FM$1\7S<M^?W[PQSF\NC-MPZ@U!CZD;/2M/(EL-KL>K
MX[S#__#2,T5EKN01K2Z;9Y:FJ*FY)(Y@,^::Z_F\>G@!QE`Y%9Z^&/'<)5Z9
MC5?PFD]^SB&!>NR>R1+G`MMRB'2&I=2RS)VA5N:*Y%.LE<XGHC.D%J[:^Z_Q
M0`7FXU`#!K_R<1*LWIXZV+A:UIQY37G;8L%9?N99[KP_A@_PRS4^DTLVE^A#
M[5I4";WE4)"IV$@$1*VA+%T,6R'ALSS&F,[)R]U[GKX/9(T.7J&"=D[Y"Z&7
M%Z1\J2G#WK>JS5B0DGB):UQ:I0<!Z>)`KOCFM=R'!AN%94`PV7Q%`/VY-4"6
MVX,&L5-B3W:_WD4OP#-E3X>5&2J1K13\F3)%Q-!5HK:Z05ZF@VUHYVWQ9EA.
M+-)Q2IO>5H?]Y'=M5PDV+=NN=[.0WRK'9M,@P=,,H\>R1U6FA0Z1]Z@"_($J
MP$XWMNMPS150W#;N8OL`H:U#/?8:I'M,6]E?7)K*,>E9]9XEF=,;;B4V%RW*
MI3M2W*#>;FV1:2!>>WRR@=VK6[TE^0:6V>_TL%W5X9:T)4B:]4ZS?/[R<"0%
MB6[=[BZ!1,?L-KJFW6X_<B45X:H(U[&DWU#]E1$6JT'C9.9$'/I.'&=FP"2D
M2):%'X[E(,Z:C8[9;VR:\;$8:OY4Z[=-J]4TN_T-8NCW$9!=D9#3W\I3QN1K
MXOF%Z@B16?H/H+^\I,R.V@80F8/PCS]4B5$'.*&FV6DWS59W1ZE1E>18D?W#
MD_W2G`BE]2Z:M=>F(T>9NG(@(K)F#HO9Z5AF=XD"7B47/<G!]$S;`JVC66X/
MJ/*+GJ\WZ.C<X<\\6FOCH&!0J:VNV6RTM`Z?Z&M533=-ZOY)$13"?,`?6'3P
MBAK`^9`E'DBEU3%7S<:E+L^'FS`'PV]=F;.#T5%AFC7_I'84L@>[-*_P2&,D
M%J*;$88UUS!2R9EZ,%$5J'$\F%F1BR,\E/Q]57%;!7>;WU(0DH>BKDK*>ZB(
M0$ALSN$%X02;FN%8W"`*OS$_"Q#3:JG&<<H;]5)O%N8`=9$Y!/&8L82N^WS;
ML0IGUL69/-RJV(QCB<W80D&H2H^^[("8JM#FJ17:?"FVM&>TE0-&PI2$.UPZ
MT3<0>Y3>E(M_1U&*ZT>\2`+V\#FSRDN`[35J9HT0D17!,IUZM]P'_5+B9-KU
M7O^1BS@H13LGB0N[W.32)'9+$S8N86G76[TCH6=/NO9#1\1\]N)OQ@B+U7B4
MM1\G1D14R3Z::!&KWNAN.-G/Q[-V^[%K/U@Y5GKF7R+'P\?<:@QGR(K\'@$X
M]VI#:=;MXRUIO-F+/_YP,*@UZOLL!'UH<OCN.R83`W.\#WTGX<&!9\VC(87=
M34M4'PTAW"0FY`C(H,(#U\,4Y<`U9A[S7>.L=32XL$$XU!%1IKWLX-!4XCH*
M!S)T&).=N6XGFU)2WOM,M>/%WM&"1!IG[:-!'WL#/_YQD9)'KWP?6M5G"O\$
M9(!C1R.:P_]BW[V8VJ^JA/@1E<8ZZQP-(IP^'=DD)&4?"%%`/_"3:F?/RQ!$
MA"%GW1T?_,;::K?>WEFKB$.OO=S0LCW'V%.8T0Z=D,_8;UUEHA_`V[D%R.:)
M7Q).EQYC[B[*L$(![76I^Q;+%-N6B)^?M^`\E^]@;U@N3?PKM>-=@<!J-HNL
MUHH.'0UD,&YELLQC(JKU.`.0HQ=\)UB9*:O$5597#.ZYF['A/],PR9Z_NKTP
MN,>&5SM92&CF54?YPY_^??/.N/SG+3VY&(-7$*16,9PC9C@5ZZE8SUY93RX4
M_JE8CUVQGG+6$WGQMUJ!]^LA7Q]S,`-2&X!*3YR'!TPB0[B-B"'-C#>>[V-5
M*Q%VJ=6DG&=9%9,X+291L8:*-3Q7UM"L6$/QX&_8T$ECEJN`[(:,5_8=.T#6
M'9?]F2*GD,K%V`-]!3A!$F:,@]H7\!\0:]6SF6^1%^#7?(TCAUH=(/\!9N1-
M*$*_C/UH0ZLA/%5U=>I$1*'H8^`Q53`W=B;([UP`>S03B3AWQ2UU#LF:7F+Y
M^Q]_V(X+59ROXGSK<[X-K60_'809+.&'1\,'I+>_XI#S@U]F_"C71X#-!TP`
M/QPPH_&S,--1J7!DBXP"+$2Y+2I\G@`00(M"%HM==.0XL>IR!_]E,6.\3#M5
M>E^78QW+U2NY:@<00A]YR0Z\PNWP?:/HD).@P4>AG1P-S9'!,Q4U7H<:Q[*5
M@QZI)!IDS`4LR<1=EB7\;F*J.I9+55'7BKI6$NZ&-+53T=25-%5:8D3;(K+P
M+X;[Q<OB_;R`D]@YRDL2+Y>/T0[3;/\L70CR?:TW(TR]?F/'%2T8C_K^5H2\
M(N25F+PU2>]6)+UX\,_8MCYFLK=A9F`/BR)UL90O%Y?ES[&QQ"V\N?5<[X"[
M?7M;O4TNMNOS$ODV]KJ%MUDP/%QCW'DC/AW&R)EX_NS7=8_.^R_C1Z[.<N;/
MV^NIYV*0S'W[P#!4./NRS%SLP_'5QG,/A]%T[`3QKX:3)F$1UA8;J0M]"G`S
ML+F5&*K`.KW"J%QBBE[IRB^]0X\`8O%2%HZJ$*8;';]:_``_4-??3JZEI8;>
M)/;D$)SNUD#=LF+/Q7/%4X$&("I&A:SHN%#W&6#I1O7,*F2KD&T7)/$C""=!
MS!NC?@9!QHE`HSR7+5DK"E@A944!#X)L1X-'ZRA<O(CEZ6/<?/]ZJE1'IK4D
MA#DRTAA)TLA[5-\S/YR*)N625,I2IE[D@DX;4=04[ZR>M9B6<WFQ$0X`PJ0I
MPE03YQLSTNDH0D!.G9F01[&P*@\"ACV!:@EXP5<3SAP_F:DGZP9(M@YO/S[T
M4]YFFR*S8*(A3'*'861.Q-9JC?O,+E9%Q8^0BN\JW*O=Z9:?X7.-]5IF#3T1
M'"F,HNYM8'V5[RR8"'/AST</#=7-`LY0()[\)N+#YKZ3E4N?!Z5PEMHW"XHU
M+MK)E7QR*ALO<KT4NI%/]E3/!X,_/'CBC1>"R!,Y4Y8"M8I!]HFF^8NM;S$W
MN=6N-_%_=J-C=3O=CH3+V?Q;N2+"]`C2?Q;Y,P.6`9>E<!5SOHRY[$VR"Y8P
M,5U>S,F*CG$=A6XZ3(RWNG`(LMHUB%_P4>K92K7FXB('5N$JZ\:9VLQ[$$/X
M7AA(DNKK;T'X$*!X"),G#`2^MRR&:V%\=`;Q:Q0`[4:CB?)ES(8I]>T@Z?">
M\?H7,37(,-"IB^U(8;F)-PC=&0@_+$!+_G]2+J'24AT?9"N#3;R$G-&8=Q!Z
M<0B$BX$`^@6#,-EWF(=B?83'64G'9D[\G3@N_*8$[!%C4I3%%U\U39`[\?^/
MS!ZH!-E*D*W,$94Y8N\8]^,/^S!($/',S`.9"4`9"+*&25VSVR:2:<C(=F<X
M]H`52:(ZUV)%#8TL"GVVD4.E"=4D<64JJ"CL45#8RE2PUZ8T\LE]]>^]5!2E
M5+\[S58CUX(*[W1;5;N1[:;<?X^.9K=?:&J2Q;BXTJ0,_(&7>+PIH7$]=D#)
M^6!<`-6DQ.K;"#NA`5-6*I"+216H/JZT@70VMY'1.UNWJF@M]"71ZSYRH6/E
M(.WR%1SL*BS'K#-[]0EN>81/=,E6G<W1W+"2`VFN<2"G=2*6V6X<TYEL>D5:
MK]$$Y8=W!'!ET9I.`>`\Q6OD^3P%(1D;7^HW=>/]V_/C@?ZIWXCV:^.]%\4)
M53/$/CMP"K'C[[C-SLO%[\YKPQF!_,B598+T*ZLAC9%H3PU80A`_FN8E^P1Y
M956M=/[*JEI95>%,OE`<TQ*/3CQV?)]J;"3A,J<6EKUU@'^E01+-:H-937S$
M4AX>2G8RM`D$.<NFS$5%<TFX@UGFQ3L,LTH\G]:#[:<C>/!7;($((\A&0@N$
M?8Z%FG!<AM(!*,N=_'945,2354$J_#Q2_*PH8H5Q%<9MY66:L(2*)W&RF#F9
M*'K`LLE!1!66(DPVEV4"L^=T+C!U/'=9X$4="/R"&XM<_M)[!?/\(_5GAMVB
MI'.[7E1;^W9<X`U3CB]N&[#F+0-8_C!B0S3PN@9]+HGHQ2I2P%[JQGQP,%:1
MDD8(5QDA[/F)<+P@5,O"-P<,F`H%/7#N6`Z?V`N&'*8Y,,C1"@(B*@IQ7!3B
MF3BB*]=<%<7[Y%&\I5G^1P^??)CGZ4L,@T)&O$@:JO#=4S_I2S8)28ZY\4,G
M,/Y)M!;%O@L'1)/(N"`7NW%V>?//BXO7N5SZF&&;`I_$(\R`PH*;LD+$YO6"
MG@M]W-8R?#)[??YW8E.*5Y&X8]W<!L=9$:4BHE2)9$>P%5K\\!$B646@CG5S
MM/@KYYOQV7/OF/&)XBHPVL(!5=:A=B!G5Y\_?<Q+7K?YW'(MH#L)C6D:#<E4
M12D[CN@AA8X2%/-X,?44_2EH02LSBYDB"0@>@+5CI,V4(CY$[4HYH\$"MQ`O
MW\/8O(JD;C!$HUR6"(]3D@G1F4ZC\#L54O-GQJM&O8GV/I_JNFO["4?%6Z*5
M(I`*5_(V)7$6*X[-^;#@.I!A3VU&#92;%M;34NLI64,E[E;B[LF2GXJ;O,#C
MK(A2)>X>Z59H\<5B146@GL'1GH,H>7\3^I0Z'F-8#[;IH0__82"&:8WJX*U[
M;\BR!CYQDKHSF>#H1NF=<3ZLV7:[]O?TTNJWC3,L=#MQ!K7SUUS(]<J;>DO/
M,:7M"^?N4#IW$Q3KXE)_-*5BJA5[>JL]D!V'89S,2[56O:^D2%YBZL_4BRB\
M'>.6?C9<3.[7G.2)FB8;6TZ($Y2N+3=0EC-J-_OD<T<AG,1N7C"@2ZLI=;Y?
M!<9Y>@>7R.APW[1I7`V3$"O%V[:9Q0Q<.C/#ZIB:T.]DI0]@1@<^N4)!X0=.
M9XJX+E0>>=;KPSP('S38.`L@M^NV!'G=.*>`LESU^Q]_$&K!PE&I]S)_OH@3
MH!U0:Q,C6]T<1@_@W3BO^&"8F4)F)T+#.<;8"2U(?Y0'+<2B"3"WKHNY<>K2
M.`9$B;C20RH]Y&3Y0L7F7^!Q5D2ITD..="MS6,P>H9&<RI;7IDK3D]O9"VA\
M<(71M`&H-&TIJNN"Y5P!,[W<;3P%L37$'S/Q,E^X[#W^^/<TP9#@&,1B$1VB
M2HC+,)'W?[_X?/&:O`RIYXM0XFG$[KTPY1T7PN`N1'UD3M,2#H<W%SWC3&5\
MR`IEKXM]##@7">C#-`)Y.@'9'3N5^PQEYB+M3FA5^:D7)'``$#6-Q4)JF":&
MZ\=.Z#SE%9468^K=DS+"!_`9;\I.]74P!Y8K%/?H%RC19?1`8U(O[B+8+(GZ
MBS7;<'$(&%6PC>N/7#>8.#%"'N,/C8$3?)-*`6\N0S`J707IJ=1NGE[A*J?P
MJ<!PO(G-"!`.=**FIA3!*Z!.UMOR"Q-&``V%@!`&VC`N+U!'\=>D[M*B\'>`
M4N&RLM0C[)$3JUYF2S!TSL>$*Q^EXDPYCOC.@*/7*TL$GD]A$LP44H8%'@^?
M/(0R@0@&>&6+IS%RFU%*4>&:96D0&?/]X$0N+4&&S_/Y>9^V(6S"XW8">FZ^
MN+,1/G`EDR]=V"_N`","6EKA"LY+XNPM=61R>C=EV>!T.W5\5:6C"!IH7RD^
M)'QO+J5*-\J8!;L:&?/Y745+6BOB_52(\HM.Y3R5K;T$P4#XP/%Z!C"B,8$1
MQEC^'BUR)0TA%[WW*IUFQ$1VYKS?WLI9.%]UVY1,GVLD:2K&18P-DT`E'5]V
M]ZN4]2IE_:GI7/[K*BNFRHK9<U:,+&]768..8"N\W'B5%_-"K-=7(C/9ZJ]A
M2YDW*,S93I;JX#F]%2MJO&I:9K/3(<V4&GY/G<0C5RYV#B=SAS)R+%HS\GG,
M/+R2BPZU=$JEUTDO[)O=5A^6SUV@S661DT46D\QK2[(@"((^MTI(G<X+[D-O
MB+7DT?/I\)IAP"?KQGNA<"\11+,E2(DT#_VBH%&KH\HA2WBQ(`(^MTECW>?'
ME[;P0$BN<RJ[??ZTJ'*,OL#CK,A2,5FJA.$CV`HMOM@V7)&H9W"T6=2?W7NT
M_(L"Z9?``]H5>[S4VRW[#F+L9?UMW3A'?X_F4>2.Q!4Q@%G0'WFP8,1A&&!M
MN!)YU8OGQ4511M,4S3JICZ9+P9A!&-2,B*'[1K38A,F2-!-WN0#=PDJ<I<N<
M6R#,/W#0H8G.L8@YM$Z[)255#/:+PO1N7"Z+;]1OB>3C5\VFV6]UZD:6`,7M
MN1'C>5CD*A*:!:ZI(!91#-0RF[TF>J)XD2)<H[&A2;G$DNRHN,KE]N1*@*\$
M^!,FIQ5W?(''69&E2H`_VJW0XL>5`/]<210(\)D09G<>+</_(QP'L?'W</H-
MY&%-FB^5@$7XW2_S*559'!27V&6[4<S;"KQT8MAVNSQ>;=50J8H>`TDR";&%
M$\KB(,A[\3@+/E,M][`"01K%J4.94BB.?@CN47B_DX48/@&8WV*>V;OO;,)K
M()Q]^/063JO7Z+XVQLR?'W432W\/M`B+@M&$*(X*2;BAD=_3HNL2JD1:9/*W
M;;/7ZIJX1R<(4LRD&CN`7L-9]HC9L-L$%'P($[8(`0"40Q;'*.[+)]M<=9HS
M[2]X'GC&GK80T"'>LT&4.I'4(VZY0H+_RJJHBD@Z=\.P%1[+MR*DI&+0E=YP
M`INK](8C/<X??Z@TATIS>.&:@U=I#D=-I!ZG.7P*[X7B8#U:<4@6C/_7+`CB
MF7_O!)Y3J0^/4A\LL]M]M/H@P;"&#B&";$A#R$*`''<"HP.".E03#2."%I6#
M5;MRAL,H%:M5P3PPK9,8;]E0"/H<'9M9Y3C*5>%ZQ3^<0*H5K8.X)_@B*PVC
MTC!.F-I7S/L%'F=%EBK]XFBW0HO_3Z5?/%<2=:6):MTBZ6M.O8!QTI$S3+A`
M-Z==_"T,W0<0_K"[%AN.`^Q6/0,AO+A8]MG_BO)O=N,W\:;ZQOKM=5T-1R)Q
MB#H+X]VY1($!>L"XS*WH&DL'4UFOL^'?+J]?RS:5(DS'0=$S'/I<4LX2^.$5
M;RKS(&5%9@]M\T8Z!>$=AYZ2$M2<UUM@U`\AUKA[`X(\Q4/)**A\V34O!A4A
MJZ5<F!F`T4Y:L).>.][NV&:WW^!)XN6A1W50Z"(O=+UA9KV7*@59\?/=Y(;`
M9AS8I\I7CPM+LVEX$;$)O$#OEFUSH>Z;MFEYIL=?E.W%9K,>3>[J<75WJWJ[
M55FL51;K$4#HN4G7WW:7Q7HJ^ZX*F^T487_\X0FT!BQM9A<:;.=4AHO/5_.*
MPODP,:Z"(>D']=Q?6]:?%A)XUDD%?^65PU3QL7G)?8?5I!OUWC*YOKRARH8Q
M-7.P.BHANJHY=*3;6U_JK(R2E5'R%+9"BR^FW^N)3:>RT1<O)^4"IXO=PW/2
M1EG)5'SEW(=A$N,=)A$R+X`A?)_=D3?YDKG>$#DP?/XWB\?>O:,'2NBV2OEZ
MWEAY/D1V*NJ.SF4#J@G)$@<R2F9W$QW+5-^-A:@&DCAX\("^.R&=<&EC_EL^
M#S!S/XR8\,H[L0?B@@CZ2"E\6(_2X)T@L+"JRD.,.>`&/EI90=T'X`PI*S3F
M\L&087R!8XP9["*<AAX#Y@!XR":\_"G9&Z:^@T;)/`2FPD3I^+X2^.:JAL+$
ML)HP@E7$X_"![*]B<ZZ3.(;6+(_#@`MM(^\[]>4`\4>:)C4Y[I75:YK-OB73
M3+'SQHPL+;`AM42J\0EGIPRH<+BZ*79.G.O;JH\'&5CC=!"S/U/>[6-9%95R
M^E75V:OJ[!VGA%@A6X5LNY+#!_CA(T/5_%SRRIC0;:`0K\+""@L/@(5SM.^E
MXM_1H%9Q.<9Y=^#S\`=FQ5W6">_&N(=<6#<:.\/1"`5>.B<,T<4LQO?>"`VM
M]RQ(F9GA-T9`_SN,OIG&IW]SP3G?&`[+_'L!&0/#@-K(R3#?NB&MOBTM[E<V
MDH.'12.Z;*Z6WG^N<#]8X']^1W'QEEJ=];9T%;"%H(2X8&M4/*4CS:HYFRVH
M+*3B8*`#:6DK%V/H:\`G?&!KB9$&B><O!$S/3\=#/T)I_=6KW;B@`H'^*;LX
M\`50X4DO4<N+46/)`R$##F(7J$.^;`^X7'D&W<4GAKP$O_QP*!O\-;M]V`IH
MAJ#(&3=P81@JNZX78P^*3__`?>KIGZB14H_%L$"K[\QGT<8IM0./V3"-4&U5
ML!A1#9QNLRDU;?;=BWFM(18XY87+__)+&M?N'&?Z*TPR\1+"C//`O8`GX6T6
M##T6O_7BH1_&:<1N@=J\@<U^^_W''_XBW[Q)X(MQZ&.5I'=_IK"N3V'""EZB
M-N;PQV<V^NM/%_SSU_[ENZ\-Z^L_G.`K'L5MH_&5_W-[];79^`HPR7__T^_/
MF=L<L6CS7)T`4MY!I#6ZAK1@6=9O!L?F%RW^5`A9">"5`/X2!7`EHO57BJQ.
M$&+5/OCR3H8ES'D:/)`W088<RA^E%(5#DMR,X@>*0"A+&%>C$<,8`#.CQIW?
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M^"23<-]]!WA3*SMJWD=S^%K9FW9)(F=%_8^+^C\+XO^BO1XGAG#/`^-T<4.D
M7#4U:Y9.9?-5`W@72+VYHY($<F4/,&XA,:XE6SO/>#&))Y(E8(J_Z'WI49F$
M,(J-,QQ6BW7X('_1I9!LL?J\Y%/_E=:EWN*"@)MCLV?>:V*<=_#3G9/09MKM
MEMFT&I)ESJ_BAK[."4+S7-5)C%>=NF@E2L,0HS_S8+:1=\]JU%ZTD._/+\;"
M.G#=;AG_AIFH$`$VVXQ9%FOPJI^;/F_.$M$26+[9;`*'ZW4:&12]8%Y4H2:O
M)$.(T\ZX:[VB6"="L>QNO0TP.WV*56'<B6#<L^&1'_(%9/+J^#Q7#!Q?:KT\
MQ1=(\CW2\DQ#6J+3Y6F[KAORMMZ";L\%?6F)O"+RK(B"%[-8C;%1G<P+KNKE
MPPD7/$1%5@4^L]2JBYK`-OMM52.(.YJ2!"/Y9NJ%5ZV&:M4%,/*B3#$$[I?Z
MY%@!#H6-HM7N>'G27K=IMMO=.O![J:2JW>2/+`Y]%YB\9?8R)K\F!Y>=V*UF
MU^RW;5!//=Z_NH"KDWRS/G/.3CIB\AVR,(BN\A2E**<2C<@59W:%M$!*?#`4
M0Q*U<'BZ.3TQ<@"B]XZ?*J%-S8K+:M0[64]P)S9<QKV46/T*U'#OOS([Y`T<
M_;?:S7`<8J_ND->NPNWA`Y/09?[<"Z/0]WG<I`,KY,6N@$!%7OP--L%X=@R<
M0V)$N,Z:8=4[K9]-LJY0]:W[T'<2'C%:,WH]_2?70^,"',[,PXI9-:/QL\F]
MP62%P!1\-(?XWHA+=QQV6Y2!PG#-IJT=,,M.BKF5C6!;=O3C#Y4(5(E`E0AT
MQ!AWA=$W&--OMXH"-T:>S\,CQLP?`:>^$Q7_B)T"0>=B3X#]/2?&3:VYH%-_
MUE^YD:_D=&P>)8]LB8U&O&,\#LGC2:QNYCWP8J-X.&('#K$S]$V`_$"MY].8
M`:*0(8`Z,6D_B$F'5.Z%=IQ9O26K)59#FO%<K@1F-DQ1MW]EBX92*-D@DT[R
M@IZ)N0XP+'IUQ!>ZV/<+\'^2,W[+C`@.S:A'LVB+IN5*UK9BP6F<K1/KZ8"P
MEDYR%@AIU%'"2[>];#,\(&CBS*C3JXB;P0E1Z.(U-!<7/X\.Q@T]H(Q%AH8)
MQFLN65U^_(-_C?\'H->-CQ\OC+/<,.H9]:I+T4)Y7"XH>8DU+O%E$#51H#5Y
MH1K=!I+;LVYYPH?FEF\6^6::]5)OTX+!19^,(M]$%%6OZ#(*H+<;2KC-Z0X+
MHC.OIYF5-YV'O83V2Q1PJB",*@BC$G=>G+BCD/!:V3C.[W0^9%F%^"E4RKRU
M"'E(&`2,Z^$J_;,D[J*`DN-7\PM9RW?0Z9G];J?,Q+&A?6)S8X)]',8$/:YP
M_V:%BD15)*JR`508]PPQ3C'%=.![PRPD,!//%$[65'I.:15]KHW,:3[42,`V
MVSSL*E.$IGQ*I8VB8]SL=+D6NCI4+J]M`VMJ8&<U1[(OS<:?<(_-D$E53LT,
MBF^]K?L#@%O%7&UZ0&<XK,KU8@H,C(MR:H+B9VGD7K=C=ML`*=6X@(=UJOV*
M*$,)(*Z!%_A1B#^EK@=_9CZ5+J\)L-R!8EEFJVV9=KM1KQM?E#+(HRD%:',;
M*.DO[?AQJ-PDN9?0A.(`/M1<4*X%F]>E%V&$"/3V$;"<N2/.VQI";NR@>KQP
M#?V0Y]&`T#6"D68F'JAN!>%G6S'IHR>9SX-B5CSZ9!#N>6#<E4@EM7)<5R/!
MF;]2^-?SE+.(+N<ILM7NFI;=E!19<6CE"@#.,\<IT24OP^YYAJ10.`5;*5X"
M,:5,AR0].B\MF*IF4([9*UI/`0GHK#=[MKYH\\<?L)P/5NRA7,L"(62^G4^S
MWE7*+/'8N=]MS7..K)7'J+N,BKV+;1>S?UD(L83A5ZSJA"A'CMR?+`UYT5RK
M*GKR1$KE.5+4>][!`NDASP!&SH%$^IXLH,&+]@14S1$J2EAQX><MOV\6DSB7
M&2RM+FPR]<,9==H<A@$:?50$\2!T(M>8T"BQ8?7FK2OH-8D\\G^(8(-'-<N4
M*^HT;+/?Z"Z9B%9'!3U]GX(75B[LBO,)'G6\9&"Q!ER>/B8&0!M-N1VEQM#3
MY-\R<4]V*_^"15Z>XL=MV&2GHS8Y=J@>*;5\1<.3BM]MB>!=W'&SO;@H8;*2
M(;TTA:RL*KL=Z;ODKTI04\E4%N'%I6`?C&CB$3@JA`6[+;%[%8M>T'6I(G<5
MN3N4])?A64G9V>>*<4>L5SSWV"(1=,$-395B42D6E6+Q8CGM'%-]IJ3OO8J9
MPAJ(1IQ.)ABA!N*?,+=C9->]5C%E37G_UPJ!GQJ!E^<\]>O=EY/S5#6JW&&C
MRD&8).$D0YVU.Q6)66I\``"GEG:W79\C`34^8$V0DP'&C<[_)D^0IIS[3:!Z
M'/J>BP`*$3[!7W^R:6F?4B)L0!&Q8DF\I]WM##8__G!0Z/R++C"P@'-`$^>.
M&>^D$_<:(VJ.'5I/"ZO/RFZ#M7=EY/`MBR;&F1=P<]#K"H0:",]5&/L'`)@7
MQ-[0^`-C]7:ZS[7:R@DR:`Q@@W=1F`:NW//_#(>,C98UR>U9;>FENTH34+`"
MEX+\YXMP-TNW)4'8V;S;+KV3$Q%\-EK_Z%4S5WM^F`C1FX]CF?U>VVSV6@=:
MS([!\.IQNV_6[?5.[O$;;V^Q\?9NSM]:`H%>O;GZZ'>SCAU#8(VC7[;QMMEO
M],Q.O[.7W3^2,)$^4D26))'$):#&:]G*GO*!<HT6=K,%G]CH=$OI2M-NFE:C
ML;L9GV@GO7JO?_*;L#!B_N1W4=O53/N3&XHOJ+%$N)%R^.+5W;T$2*#9B_RW
M]<'N;35G3:MAMC;!^F6GM"_I?M=7I%%?PM$VVO%!59-=K.;Q1..XP''D^]ZW
MB"/7TI(KR2E@BX;LM8^EM<&A;$R<6J6DR0VQ&](CY.@]KT5#'=OL]WMF8XE2
M6`33[7?VF!/:];5IU_N]%[CM7KU3SBF?[[;;9K=IF?82GKF+O>]>W#Q.^7P?
M4U9;J;:RQZT<7(IYEQ6&K:28O4HQG5;3M!O[I>S[Y&KE!LXR(T^]\1(EMD[=
M[I[LMC<^Y"9(+"VS8^U76M/(XB\4DR'_>JXA054(Y5'&`SU7=%L+MW[\X4AB
MT)Y-NL).<J%4=A8EY6#YW+FD+.GZ$I&9^1)_:S6.H,I^^;)^V'`PN,/54^[2
MJS:<"=4FMJQZORWJVF&Q'RJMU!`I2C20S&"B0CN.T>)M#G@^D][_1WW"5"6Y
M=IX%I=4E=.?J!K[J::43J'8P-9)T_&'JT^-IO*Q08"U7*+!N_(%H,\#?TUBT
MH5SK3=$9$C#FS'J=56>(9!>F>J_ULU$S['JC^[-Q9K_.Z@3*`H`=#C/3.&N^
M+BPP",_T.O5VYV>$>Z];[W9$0<&SUFOCORP*%VL/5IE83\\X7P9IJ]AIA7$G
MQ$R7U0^TNVW3:C<IC4$O-219$GXOG+L;E@ZLJ'%U-RIJ7&'<,\2X<]]7!%+K
MVA%F3G.J+#!@]&D21@FLP>4Z`2\D!W1T*MJRY&L>B&JH:0!$.[P+Z#WLFL>"
MF#=HD2W40?9?I/ND#KP"<MUO-\U>NY.K2)'K"U[&.6@CB]4R<#41OB$2X.0J
MJ&)JLV5V^WUZ\U6_;?:[EJEMT)]M7!=CBT589@<4P7Z?O_O*[K7,YL(Z*OIP
M[/3A69"'%\V0JD(-!T<W7Q1J^)?H*$&(-E`H5^%?A7\'P;\YNO=2,?"X\>V9
MBN3E)1M$GYVJ9D.%P4^/P5A,F^/`!J)B5:BA*M3P0@HU5&4:3@5659F&TR_3
ML+L@][FM;C]2-=&6(U7E.1Y;GJ-O=KI-T^Z71WL^Y_(<5GU)^/:+*,_16E9\
MX#F7YVAUS6:_8S8;Y:'=)U:?XV\\?'!C6KRGJ/E6HV/V[?)4QU-)">K5>];)
M;Z);;VV0M7^DFSC9ZAQZ7M;Q7-`SV[0LH()+<GJ*IUS4<)YH!YO5HGCN6'WZ
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M!^_TS'ZWL\W8,-`4I$7>'=RYPW][`?:1#S#G%!ZEFD`XW#^<(,6$!$IO'?HA
MUNFI\E&/^U[:7<UP?LKW\D4GI)X2QE6<`#F!X\>A8@?)0X@$-4[]A`AW(06W
M&PVSL7&%FDU+OW4Z6*2!3U)2!(ZJ-\!8:I7(?`#C&'`%%B4.<`>`(C*D`&O:
MP3@3EO"2#_E*;[C^]VP094P#)_Q'&C!1Z('!NZ\:6CDXJGL`.K?\HJI]<$HW
MO^(U%<95O.8PO$8%^V5DFLBIY`2N,9C1<#)U>!SZ+A/$77$I4?@'FWJVS+;=
MTIA/CLD@75Y6@<VR.F:_V:D(]'%?EXI`5QA7$>C'$NC'U"!S/1<6D8@R8`9^
M112V-G#B^2II$>/UD$%RUPAYO/-*9)LN@"A^OV?:MBA4UEA/3/_++VE<NW.<
MZ:\W.*-@2._^3+UD]BE,V%LO1J-2&K%;0*$W/CSS^X\__$6]E`YB]F<*:/7N
M'OX5JX=0M4*D^\Q&?_WI@G_^VK]\][5A??V'$WQ%&-PV&E_Y/[=77YN-KP"E
M_/<__9XC&5F%`F,..^;)`[\0M22<`K:K/Z6?J(,H*+X3<<G*<Y39X),5_H@!
M?D`0&3U#:8+6;T8&$H/#9(XN#O('\.,/)7N451C6VBIM<ZV;KU_\IUV!N#%7
MPR3$F[&HKLL*B%,0:[Y[$T![?V8T>YTYC3PG%,D*+(!^]X#(>&/@D?P0K5Z;
MAE!WAU3NW".OK!X^4B^\*&4XKU^,-U@PG<4Q[&7@!71UX^O0]X:S?=R,BIE6
MS'1GU;8^.0F0>[PV$HEU^J;1,$77SH')!%XZ,:[A4D[@D%(*+H+Q/P3#NG&&
M%U(.83=^FS.?V19B@?Z`'$][XC4OOS3P@.`.QP'@^]V,&",2"J0`7B*XHLN`
MWX53)"V#B#G?0#((TSMRED3.5%9IHGX!*#3`?:=B$R[H9\!M8]'I`#TPC@^H
M:4P=#)7RF>%-)BF("33,S#@[O_YP^QJ]-`EB*J_3BC\J#HW?Q!Z<@`,D22X:
MYJ\;<G]P#.$=HY?(8HB3/@`+!@(4/@0H!0"I\5S/B6:F<<G<[#T.U\OS#Z]-
MXPS>9T!C1@E-/F)1Q"&!M7(D_S><>#6$`R_Q:.E496<01@X5DF4CV&$B^E#`
M;NX`%@'<A215G3%8C,$37LQ]4D!)L=(WDN9@"*(/?D1P$4C&L)(XG4YA2*RX
M"J+2-??$_6(;0\!EQ!PC@?OA<YAF#RS\G`!0)B%]OO%#)ZC]DR@/U0YQ8.;(
MN*`R',:9MO7+FW]>7.3VG<)5CK`]!OT$L\UB;PCWT_CPZ:UQ/IT"U28"7@>P
M(YNR376"`(XT&([QM(U)ZB=>C1?^@)U'TY#Z5L13@%%(1T(K]0+#&:;PPV0&
M>`JBI\_2;VSB.8!2EQ\!HV`N1B+EX@7+69S#P7_XZ2+7Y#@.')$YT7!,D!,7
M`5V()MX>M&M'H9L.&:(H]><PAAQ,(R0>5"N8'B`T]&"8%)MF_)>$V1#$P(#.
M)/$&H8OW"$[C&_I5$2WF[@JC^QC%>+'YK2#^.HT0O^"Q&1R7*Y>$738,X-8S
M8PJW&\AG@CA&UUG>66XAX0CJS^$!"0&%$$+Z@+&,H@'*@#'A.)4PQN^IE'+Q
M@?#6,`B[`0",W=.*`.L*)R,$5^3@P?-]/BMP'+Y]1*,!;T*"%,CU1G!5:;NS
MJ9!D^&D\X(6&.^+Q^ES%P(=G854P$NSO)9IX3C-8YJ0%A,J^<ZS(]4Q%TJL@
M*P)D]TS!>W45D9@M=9@"5N(8=$H.CY"9ESIOR+OZ[OL0SO:.Z0*`B?[>.$6#
M/(S".5_.;3S\,_5P%JO1^%GZ4$O*\S.RG,`FAJ#=4DU0C3F5R<>Z8';](;\T
M#\O1\S4KY1;G1E:QJ-KV^ZL6J&O+)C)LX1I^U:@WK,P-;<[YND%H1?D;!`R0
M<N1O>9#RD\$[(@<1UB0A_@&[&CH3)M5S0'[?QQ7-/YJ?->'/\\`FTV`.'`X.
MIKV5>4$:]6:S*4T#\P@@UVE\1FDN)P'J9[1@3LA/J4[#75R<@^T;^`;FEAAK
MHH+J\%`:-X8OY^,)0&96\Z+<BU/D]T-+Q>LD1X<_Y>`F2O]2`L&<C-QD11LO
M[2B7/W):F#.D+FW84P[F=#B:H/$%CMKYQK`YQ2]P0B#')4"V_BNZ38#P0TW6
M!C.LJIN#K,DE(,!\!`0UHH,-H1C%14)Y(2,^(9^>Q#@`Z`@TH6"(4F+$4,<@
MJ38%81QTNY<H)U6,JQ*5*HQ[]ABW)G>6(@T2U82"QS+*ZE`X@I`1Z*D0Q`$G
MX6XM;F``@@S,1"G@L#\LV3KPPFE.LE$C:,8X&:8FE-P$36\3,G14=Z2Z(Q55
MKC#N^6$<*+"79(^UN=L_[^W/F0]U4_]R?=$TI"*`_H*`5*HP>^="6)[18%TD
MQ<.:SJ>1YV??6%;!XG*3N.'$&WH^^_$''KU,["4179D_L7O'=61`@OKZ+?.=
M!QG0O+!B&N8"BWO'QA]PZ&G$I#JL;Z80`-7MK6YOQ2\JC'M^&`>T.0L5L]N2
M+)/+$`/#R.C'_6W&!9;P&*%KDLCMU4/`HGCL38U+%E&>21%'X(92,E"ML$F.
M@-RC7571\3QWF,`D\/N\C0WG9M&<5YDG-#)_5+RD,\?H-^O=GQ=\WJ]-XAV%
M+PT9A<:AZ_F[%R>%YDF^&+-X`&Y8XU.*J&Q=.2(MQ?>%`95,@-Q(%9;L`@,(
M2T?+;'=HL<I9*6&\U0VO"]CX.>P]<<C>V#3[W89I-;O:F,5`*[<IXKHLLVG;
M9J/=7ES;6@VXLQ"I\NBG7(R4$WOQU>A<&?#X(_S?^X@D=+U[%>FR>[+=U.C9
M&N3FT11Z*4ELV_5N'_]G-[N-3J-S8"\I43,Z7T2B:XQ+"!*.A#7C2^"D+A9^
MQ7XE`,>)\5X9;3\$N#;^Y(JHHUNR!`M+`Q*\5(WKB7'1NH&U4BFH);,,QRBC
MDNU!)%'P@!VXPDP/%9A&;.IP[](B_<VLSB!,P[!3']Z]8T"$'8S?@=^1D-.[
M2`VP21(&`N/,_(("!06"FW/^?*G?U(V_G9]?YP@H7DVYH6P/7@8H3B8+%HD3
M1RDNC&_S+O4=X1P8%:SJ)G-:X?/*R'^!X55Q7.A4>Y</I:%I1=PQ$N?W&`MA
M-6K_+Z?D(CJDA_-_5LLQ;FK_'P9%X>(!H/Z,6,T,M`ZBJ@!=/W69[EW1-L^-
M_F&8\-.+F/#5`156X"00(J+`G6.%>"";8V^.0*,T"KP8(X`B-L)P*UHG;TG&
MGS@C&QOOQ0WK%T&U$0*;0I6T9U\+[R.Q6X$Y:#T38:Q`@9P[Q@-Z`C8$`@M<
M,KL0Y`WAZ9YJ@1)BG#-F'0KE!D5S<,1UO*+HU9*74KZ"7`_/0<X(E!%>=RDH
MZIZ533!*`0R8NBHS5[<!;CP.4]_%.)>(.:XH@?"?-)BK@2`'7CU@WKVH%HOK
M%*'Z"UUG",$X<F$X$J/`N@!-F=GM+N+@3A"DR@MEP'+E7?CG6M.2SXX+86J?
M<-MH()6^RWWB+<Z0!7?3N/!:_%7GR!<*@`#?B@\_$SY\G3$HDNBT,UZ'QZZ^
M59)"EUX%CH&<K23C,&9S%S'W='$$+`^<!9H2`[1)[Z&:*'!T0Q6FH<^218+H
M+)WYW@0%4N:6W)EE-T"_*5]B=C5Z!R<^(=99W8T3O1M?."YF)PD4/9-&;Q0;
MS8FP:UP:+CORQSFNQ^O=)'P(MXY11+N5-(5H%&MB!(IH$^<;P_AML7_*A8GC
M="+"2"C@U:%H#<'G1>2V,^&W#6.0XIB)>X=QQ1CC2D(D?\,5%HID+5K"243Q
M/!A6$J1BD>P[)L7!'VZ6>:>%?)!<0Z'VG`MSZ61(\@0/O96F;"1':O\E9"%_
MW75"`,0UC*YIML]LZ`,HN%$&@'>N!+NW+!Y&WE0HX16I.$E2,7^\J\C`A7!X
M3Q%#!$(J;,Y84J2&E5D;=/_I(V@(>$O%NU.-!I7@Z:;8F!/^G'A\'KCX'\S_
MO'=\O)"5%/A,T!?/E0@G?=!.>!UVEID!>;A(3%KN&,`"',CW8#`WD[^(;861
M=^=ASL($T\E4*&PN3QOSL#"]#%!]@+DHL"Z6K:MNW*2@"P\<'RT:7`]-XY28
M'H^*Q7=AS/=O/UQ@1E**>C\*>/CN>5*6=5VD:F6FA4)C+*X,[:4N\)=8Z+"4
MF31P@F]EDN0ZURG/23#>)IE=PWX3>!/?HNR=Z@H^DRLH3YB;U^3QKKI_E\YP
M#""(^&M,O8;W0=4+`%EK&,:)2/P"3C'DF7QH((.3C1P$7PU!"3A+9ME[N`%2
M[''A8K%1Z@.L[_5[*DJ/O4<;%R6%\@C;[^2N/\0"@#+$*/3)E?P+8]:DN$G3
M)V3M`TH"<J5K"B%3K$-E8@Z'Z23EG]7:R'9(0TQ"C!U7@0V2CG&S*J_*P-^]
M0W:.1`MK[7BQM/@)<L"#Y8!`UHW/(/Q[HC(H=C-/6$!669)972\#WW#LD!\-
M]JF]7\;;UZ,/.DWY,,&%X$-7T5LO!NKE^%>CCV%P]Q$#YL\)DA5]>2;T)3MM
MO$%XRC4Z9H.?<X[0%!2EN,ST0M"T//80`Z9C[SX:0]PZ\D9D\V`%0D8W^9X;
M6",1Z\-U62^"FX>Y)T/ZPN7N:M(IZ:8Z442N&RX6PUV9D:F9&WPQ60`3(-&L
MG6""K1=XDW0B+*L@!6B:WRA,(Y`Z_DR="--O!3/G]N</(TSN99CG(IS@F9^`
M4XR,#(U2HG,I+#66:0W$_D<^G`\"(12$+;,^(V#X;4;9(<J*L]`O<Y*$V#!/
MNJ%T=2SUB&31HV5ZN3.,40+B$WAQ9O/G[@J>0T$*.%;+T`Y%6LW)/4YJ,M?$
M1<KI$%6/Y`&UCV2A0*0V)<]_G5]U"7G:AM3HI.HM7/![<BE4!.FY$"3M3%?6
MD``1W-4>GQ<N="3E:"L4`R,>,RQU^EX]P(F4EH('.W8S`QEPT0`CC+XQ*:WD
M9^5%EV"2/],0+[IXE%=Q)1$$JZOJ7RH7&7JIT#WFW#N>SU.M1MJR\#%UWUU1
M:4*,Q&?%\>C+T&4^&=9E^`9\*4</!X![]SPWG+_L.HDC)!XD:_CP?U+WCHN)
M*#2N,&^5WSW]AB*$_\"=7(V4B?1#`$>?3C+5IBIO4X76'6-HG2IO0W3B#\GM
M],@3A<FK:%5&:I`KNVQ$UYFGU'"2P$6<A\Q[+1)429_!^`"AQ9@HW`#?Y"(#
MX046BU!F]!D/_D.M`\@4W'T]PUGR<$F+J/B&-^7UZ,YUBCGV0+>(AN,955_A
MGC!9L44$?VG243!-$V'XOR.JB-M"6P^6G"9K)CHG8,&"0`HB2`$H%!+`%R1D
M1<0CR@D2`B05W]&<!,+>#^+5_/!IH%$ZOJJ%BM;9SK`^$$[IHZ#V:Q6Q6Y&5
M*D9\SQAWO#58LO]S1'NF)5D^8GJE80'O(I*MEZ'\$O"X,J#/NR#32F7/7*SX
M0L(Y"BF[HK81%N(8DFE>O#%A#IKF21A%Q^]+S-^I;DI%IROL>['8Q^FT742G
MQ5>\2!Y0V6"!7%-L'5DO)+GG,3F8C)+)QS*FE%ON-.H-*@3S:'37`STD00-"
M1+98_I>,SYW@)E4H7WX19$\1I2P+^4-VO;P@^YSG,V;!H!G;634#[E\R++5_
MM+DXH@:BMP*0FP'-.!-V4!YCB*H)5G.$3=R'&+7.%V7R.*\9\;9XBJT73&,8
M,=>#Q[WX&_P%"%9_S2&>J57<$!212BB"NLB@33XHBE6/HI#J;_)(=MW,,YC1
MSTS$SJL"B\!F@Q=92Z&B;A5OK;#OQ6(?9XK-8AUHP8!$)%_:X)7S4+/19^&L
M11J0RO$)A/KS?S$&JN<B9IU!F":2K>3C:`LL=<)(F,:X0F7_5TQI?ADOD<`+
ME(T3`-N1W;'E_15.]DXMH>C/<4_/_PH=V7TY"MOPCS_L'>?(64$>"2+JR(=B
M`U4-+*@_+LN;$`:S`K>WHZ>-4EIB4,N^X7%UH!_XQ!(Q0,5;B/#('"8.,;MU
M@V2IPH*>77M^<V'T[(:>#8RGY<WYV"XSZQ_?:=912!5%M86;C=XUM;R0LL02
MC+7)@N;Y)KV(6#*<[2QSX6N>)0X4V#$)`IP?`[CT=#(1MJ-!2[-=YIKTY=/;
M8)5QK&?;9H.*(KV"Y:>HWHKYE\V5Y>I(-[XI8@EG>BY.YK.#.;21RL#&76WP
M6-9;?!62$-0JJ>,HJ>@+DCHR=.,]$4I[5:W$,P%HJ]WIEFMLBYI=&3H5'.^`
M?/4UZJ$RC0%(\I,&N1IWSLCYBN&\*L+*P`HU8NZ__M3@?T\=UQ5_*Y!%$E[W
M6#,(ZW8*Y.8=T3+42=R"<Q!?TL]R(#&+:JEF:3TL5[^MWR_>+T5!C0]8$[1D
M`'3JV_QO\@1IRKG?!*I3CB$"*$3X!'_]R=;=97O:U2G#Q*Y@L@"39@43#2:W
M6&UJIWOZ)8GV0*%6@7%N6]N/5$VTY4B/./<L3E47;']]]B![?A-M@@2@S@V_
MW478Z4H2M_\9#AD;C73\D(,($M=K4#2^)$RBSVO=LI6L7)@A6DKA).7LR-CV
M-6BU_DY.J<#5;#Q*RYX?)D*)FX]3.]`B7OCVVUMLOUT^\ZO5N[:6[+IGVE;'
M[#?;CUE#M?M]$"BR#!21I^4$:<'LMC%]+A`3-SKKC2_8QC-5.]AR!QVSV^B:
M=KL<X5_L3K3;^@M9B.1?,N$O_^)"`M1:J4VYQ.I@&$[8K?.]RE5\)KF*_$0-
M.-+5R8IZ290T%ADR6<YL%D4V8<DX5+5911DO7M"59DMPMKKQA3H0)V,O%F^8
MF%4D&CD[WY?Y0;1\0N7UR/)\8Y4D5-07C9>-E0N9S\9>6MH+*R-$+'-5\5Q&
MRJ4.'"J)@"-&JJ28[SR(&`CJC#N@:`>1P(PYY'/YR7QOF+L\%&V]14NYG!=&
MI:D7`8M70\U<)`ZZX<@AP^&43K&$Z)BWW^9=?B=AA(KE-^RD2!&$&%^H(M\7
M)U%[P6*G,Y&R3HT!B^8U,<-;I7!32V;1_!A@B:4EXJ1H(Z:^WJQT6YD'RHF%
M:\F+9`[]DGI1961,)W6?15/I\\!]F[64?L?SRG>>]%E1O0,7-=,ZAFO'"U<L
M7IT(^;FDWSB58,GN<!#S]$B@-5C1S,4"*24O1LR;#%*XZ)G#^(XWR,PEA,_5
MV!=-)[%UN?"&EG5"YRLKN0UK8'J^6NX$?Z'[]9F7B"&H52+!,[D<U$&O]H;(
M[S6/\MY(-,BJ:BZ6V>`M)7@3"EX8$KMLJ.:NA/2\=.9@IG'7-VC5K]T,QR&5
M\^5OYJH&+*3(:A)"Q$0-P3@KE*1BX/GT*!+$=-'N`F1FO$X311NP6"NM*8NO
MB(+EP,PG4S^<,:975Z%&LYS'(<+=8V9T44-CFILB3*CS1(USO*%VOU0=D_SB
ME,A#(\1&ZB>R%;(N/.#2\_U+B%B(@Y%#4[/?K!),&(V8*-6DI@$)+0DC2EC(
M?N=B3AUKQ-Y[81J3**"6F-L%IXL8Q@%2@TK0(_&&!Y;R`E14LW1N`@4L'N62
M1Q>&79Y'!<=4QS+^5&,/!(H!"]C(0Y&":LV`#"*)JE@KTE&`I>MZM%H\/<=S
M:]2UD=KWEE9-7HL2ZL3SG1-A_&U\S2*Z9OLCFL\U0.7(HE&.(J9O_S$JOB@C
M(?'7./L8QO%K`_"8&F5@.PMJ%+1)54W''U)Y.IP]X>7EL!.[;+I#XQ7T]\`0
M/+N3"\%3R\+UT$*T(+M\IWG^LO;SZ[J!+0.&7&;R_)2:HI0NB!?$S+3/&;P#
ME!YICWHI:SK.2]MF381DPW<AR?%311($[`9[R@8IV4&Q()5J1I3K7Z0WM=<*
M@4FR5Q:L-PT3)*"\?ACN$9V)?`I3,#.9`Z?/D)^ZJ($[5?3EQ<M8D$O;XZQV
M,DT3%:Q7"%T.5M);0:V4G3E$>K5H;:5*BL"<7DUNX"7&YYTL^<N;(JO`ML,$
MMA49EO-)4,\U<D<YN;,U-ALF,;+(^`6?*'0TO>1@I[5`5AXKL.]HJ*T"(BRK
MO^!-S5V`*\[53C4$P#;M7L.T>NN%<!R=,WP3,"SSBMMFO]\S&VN`X9B\XH4L
M=,DU^I>0N@Y`=P@J>Z$Z6_M0][::OMEJ66:_51X.O`B98^$/+^F<NF:_V32[
MK>Z>SVE_3&FM"]^2"]PL^+BU`09M?$*MTO-QPQ0D^$?0]SVO16,2EF5V;=NT
M[,Y&0-U^:]41;7Q$#;CCEMEKKI^NLLT1/39P9H495[?X?F(/6BO**`S@(\]"
MC/?=^+FR@1R9#>19F(`_,]1)C0RIC3Q6K^JW\"$P+IT9A9USYU16C%@;\P9-
MD.3<>A.BQ\>+XQ1;.A0]\65*'D,<L=;HF\9GWC"/UY7"*Q0Y0]F@Z0).*9PP
M[*IR#LMU50-""D,2(PTCAO^Y#:?>T.@T.FL.R;.5XW2*(3NB,:AHWB?=360)
M%7Y"-;6<IYW-\SE[W!165>[JC+%8F0LS1K,:]IO&?.O"2>Y2C]O,DS%()W=C
M69WE@WB;SZKU!G95SS1LAJS<8?R,G`Q6^?V1,U7-!9NY20>)W$^M6;PEA2'V
M;]AY-(EX!$/M=C;ES78`HUS].P5Q#F)Q/HBP:KIFJU%K-4SCBB*;SK,`KK<R
MN(A\<_FI2S`#MA^GDPG%*_%-1BQK0XD@4ZB!GEE>W$S6QLD\B[$Z&.IX`6_P
M(U`5KV&@*2"4AV[6NQ#-WE3!GSS&,6^%)]8DZF&+AB%Z41[IT^8=RASIP>0V
M?>DX3:1C6'8=HR]];JB?\TMC8\B%Q7#/@E-Z8RCFA>+:T+$@?;9ZP^E<8^C,
M4XNA>D!/J2B1,\(F)BH8W&I3,'A'OP#S#;Q5(C\!9+X-INYM@K6*QH+H)1>!
M:C)XCU;.VX;>?)&$1%926-F]4Y'&NN;RJEP3%5L^ENH!%<95&+<SC`/F^(\T
M8/L2X$`#S$5DPE/`FMXAO_)6\R'>UDX&+GM"%J):-'HX9$R#"LY(,AUGZ'WD
M.2A`L,&,CR59A.MA?%&^`T7)B#)2G!<HG:L<CC_2A%_J-W7C;^?GU\NE+=6Z
M74B3FN3(:_J5+@$8_9GU6K;/11[*R-512\(:P<JCCKO".<]9G=:1FDH&89BT
MJ74"$Q(NJKP\DB$79("+P\*[9_9KPW<&S.<!@(7]KF,A:2P]&ABJ^1I!CZ63
M&#V8=906@NOBNU0:5U7/71"$`%E8<`</NGPW9RUM"ED4R(M`K,4^:F5#!"%U
MB:.V):68Q:LMR5[(U,P18^['CBO#)8JWL(#ECA^'6/L)+N$L"\W7Q6Z.OW87
M!6XLP4M;^P(_4C=F7K77FX],R7`%AU2A'!CU@>D(+E9,"@*]6F^N7Z-B/40!
M?'^V@+VT;G$GL3'\7>1,QT;/:M3PGW8-A3L.W3@1$:/4\ZX4HFZ(]`G6.&$L
MD=*9B-M#0!?-T3IS7@NQ%S,C@*+RPIBBP+$8^>R/#^]>8X0@7AKMK(<.7O0)
MJ2FY+GX<VV$<##W,0EY\=@=@RA`E3D>@5WFB[?P4XX821`+X@]\,)J,?%=(F
M<\(JQU:N`KATN[+UY2[@'4:MDBCMAL,TBR4?"DT'!7!R(=W):XA9&HKXX+KU
M34UX/V*9IJ.?+&\>K/!'JZ<5#P%%Y.7\0T+[@X2V).2HN,5LR".*L"";U./X
MP9FH\@FI.Z\P7F&DE.^;>INA+.Q6"/9,I;B0OH5V],6M810IEJN>.Z4LZEC=
M+Y6PHJ-8+'',;M=:;:EF&_A75V*U*F@V"'F;1M]+>"$'/!;X&Z'!O\@:-6ZA
M;&VM7+5,D0Z55ZN(!7H!_Q'(%C9W<T78M1;HG->P).QY.#4]CPQ?*E16`P%.
MHH,L.U`%<%4R:Z4E51CW##%NWUJ2;1IZ^D$-GD/GD?Y=*1M)!1L!67#&LS`6
M5!3>!H^R<42149'GDL]5F<KTH)R4C,'1RK#,$S9D.HR0[X#/D.Y!T@_V`D](
MSD();3CV&#5>)GZEE)X84%8ET^CVO2W8I(HQ+N!\2I(AA2/__"IFVB[CEUSJ
M2^89YJ8F2<M>;I+\\0=-Q:IX:T7I]DWI5L2Z54RW0L5#,]WS]`[VN#>V"R3^
MFAO45%)+-L&-(KXUXV\AC@)*[!`T<D[VQ4""%<:9!3!3-,MK'<"D4_3QB0H;
MZ+;+&(:F[$:,J[,#S.'!A!^*N$E$>PZ',G(6*GEG/0S14N`%5$P;'KX+>1(0
M;8)K=31,Q),=X83")`@3)NUGF#5:-]YC0JE#VF]>'36US:DB$JNT]X@S<F7F
M(;<DNE5E5ZG(\8!5[V7'0AB`^\MM@62X)8N=-,@6&S?I$!"CMG.;YL0.3')=
MZAS%8UE3N"%PTD"/%$3::_M&R\20+)9JTP`I/;B*C$A_IEBNX/X0$555)8+#
M5B)0QVOP\]T@O31WWS6ZPXOGH((!]`=SWB-$6$50N!%/W7&AQ*Q$<^.!J4M/
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M5B/0)F"NCFCC(UI=F6Z3(SJT56A7NKG=KW<I8OLEV(H&!5BXJKI/02C?SNU`
MQ58FT8+FVHF2V2T>HL/3JV\1H2H;TO.P(=E694,JMR'M2[Z[]'P6)[#I0R@X
MA[2GR/YN3V8Q.;JHJ+V;>[IVLUS1Q^(C(\_'Y`NLC!,8GX`BO(W2.^.<5VZA
MK".]H=&GM^?J+^NWUY@=$[$[[*L41C/,\8W">Y#5U79',CL'1N,M*J>\V.(J
M\T3_P&[T!2AI-I5NNV$")SA5BXIVWO9KWN*6)SH/F3=->"//A2/,LH\H<>S]
MVW-#GF6VF96'NJV,_TCO*>@W*XYL^V/*2\S+Y*_U)"1=NKJ.L.!1,KOVG2`Y
M#]QW?Z8>E27:ASQ5N8"?U`5<M:)ZRK2,[06E!:%F?Y&C&RRBW%/U1`N2<5K:
M>JP-U[,?P>ZT)>B/H,OO2RLX38CLW`/[#`"R6R_^OF14N<5&H[EEM[-MWMES
MA[2#K^8)X;"L1=H&X^RF8=N1MHK;\VH.XZ++%G*%A2MY-5)23/8J6.U31F_6
MVKQ$[J*(_O1QP^7FBC*%M],QF^UR/GCLRV^;K=X^E/7]VE26.=4_LACK40R'
MZ23EY6M<-HW8T.,59O<O<NPB/*/`WWE<"ZSB1[99S9G=-INM<B%QHU-Z71W.
M;@_',MN=#6CA)F=S0&FA/!A!&CEY]4HI2)C`Q<N=`KL-(-G5:"4D\>D6=Q)Q
M-IM(!WL+KVE99L/:36Q-=2R[.Y:FV;<?0_M60[;0DY-Y;U9[8(JC8;(Z"Q^H
MPQRYN2NO3>6U*?':M&R[WJT2M%Z:^?Y+X.TM:^$T(8)YKP8EONYT8[NV`>S3
M7+)]G,,^IGPV6]E[:)75Z%GUGB69TQO'QZK*YAHE*A8LR/5V:POSM7CM\19L
MNU>W%J*7<O$T_4[/[-AK[V0'1O7M0-*L=Y;$NZT,`[/L;MWN+H'$ZKH,ZZVD
M(EP5X3H6G\ZM;!!-(7^R3-P,.P#&L6K33173>5.S_`_'<A!GS4;'[&\<\[=H
MOWRJ]=NFU6J:W?X&AME]6/DJ$G+Z6WE*0Z\FGE_P3N]>8(Q0S+_?N9A?N0LV
M*-I5^=J>X'R:9J?=-%O='7G;*KFQ(OJ')_JE9G:E\VY0%_8DO"$'(B)KND7,
M3@=3]A]#0RI_U1[6L+J^ZMY<5OA7Y0MZ,E]04;[7<A\@^@V=))ADE1[U-V1%
MHZN`*CQ>C?Z0_;DO0Y?Y>TNJKS+I%Q$K?_:5Z^]87'];<*`J7>IE^UNKY*!3
M2PYZ*<K:,]K*`1VM)=ZT2R?ZQA)N7\1Z!L-P,@D#&`6%)>QRRPMI4T=&:K1X
M9I6'+>_5*;N&!W*%+[93[ZZL1/'LW;#M>J__R$4<E**=D\3%7(-]9]$0.PA/
M(V^X:`M_U`7=..W&KK=Z1T+/GG3MAW:X?O;B;\8H8HRW3&8QMI5&JF0?C3/2
MJC<VJ"Y*K_Q\/&NW'[OVPY;E$<J_X6-R/WK+LL3$(P#G7@TMS;I]O&F81PJS
M1GV?J:N')H;OOD_9$%GC?>@["8\\.6L>#2'L;II4>S1D<!.7XQ$0084'KG?O
MN2QPC9G'?-<X:QT-+IQ^@ZR=[>#05.(Z"@<R+@T4/*'9C48,FR(ARW2"F3&%
MOT+7"&$=AB"1QEG[:-#'WK29U]&0DD>O?!\ZU6>*+0)D@&-'$YK#_V+?O3A!
MI(BQB'',D03(REGG:!#A].G()A[/?2!$`?W`3U>2()!V#4H58LA9=\<'O[&N
MVJVW=U;<XM!K+S>S;,\QCKSH_`MW;=,I5[[.1_DZMP#9//%+PNG28\S=11FU
M(J"]+G7?8IEBVQ+Q\_,6G.?R'>P-RZ6!?Z5VO"L06,UFD<U:T:&C@<SMF"'9
M+/>7.`F5?78&($<O>$YBPXN!'V/-9UY&^L<?#.PB`>(WQ[>>;75_BPVXZ6[&
MB/],PT2]85S=7AC<8Q-33>F%?#FJ#"(>_O3OFW?&Y3]OZ<G%*,/ZLE.N6,[1
ML9R*^53,9Z_,)Q=K^53,QZZ83SGSB;SX6ZW`^_7@Q(;+X)N)%P"S&,R`U`:@
MU!/O26/D)L@0;B-B23/CC>?[AH,*OFAG$*,!T2M@6A63."TF4;&&BC4\5];0
MK%A#\>!OV-!)8T:T7&@4AAOB8&%BC!T@ZX[+_DR14TCE8NS%U+,F"3/&87B@
M5?`?$&O5LYEWT:0I-&_CR!G"T\1_@!EY$ZK66L9^M*'5$!Z9F5&+FCH142CZ
M&'C<FX^OQ<X$^9T+8(]XY<.(W7EA\,2L:1LNM"$U?"8\J.)[%=];G^]M:"7[
MZ2"L8`DW/!HN(+W]%7^<'_PRXT::EH2\92Y@`KCA@!F-GX69COJ](5-D%&`A
M:KF,G02^!""`#H4,=NK,U#C<*H<CPW]9S!@1GU&:@$ZU+K\ZEJM7<M4.(((^
M\I(=>(7;X?M&T2$G08./0C<Y&IHC@V<J:KP.-8Z)9D[SD4J<;,X'+`'UI:ZH
M[%ZF^6YDJ#J62U51UXJZ5A+NAC2U<UPT]<<?C@<V&E65EIB8RZIDX5\,^(N7
M1?QY`2>R<[279%XN(:,=IMG^6;H0Y/MI$B?PDR#4BTYG>F_!:VUJ+@A_5I'R
MBI0_9U)>"<HYHMX]+J)^/)#YC%W/8JR$0R0V,["'1;&Z6"F2"\SRY]A8XA;>
MW'K^EU]V5(-'E?.Y]'S85!BP:V=&%7_4%Y<L&8=N5;JG<@Y4SH%C=@ZLKI$C
MG]Q7D5!%,O;5&T2_XH<L-R-IXDZW596<.;:</56VHUTJJ\FH;``_"Y2#WPN\
MQ",MSS&NQT[,C`_&A0_?HG_]-O+@WZ";.88/(D*`WHQI%+KIL+Q1X%,7;UE1
MMZ3;;IB-)27JCZQTR7)$.[-7G^:6Q_E$=V[5\1S-A2LYD.8:!W):)V*9[<8Q
MG<FF5Z3UVGCCP:MW!/"/',K&^73JR[8:(\_G5JED;'RIW]2-]V_/CP?ZIWXC
MVJ^-]UX4)Y3B@J67X!1BQ]]QY:67B]^=UX8S`G&2APL0I%]9M"'\/^KS`4L(
MXD=3SV:?(%\P-&QF'2CN+7J#9NDW&,R!=!T("!&.&[1J7TWQ8WR.1F<OF>W!
MUO#U_,&)W-O9E)U_]^*O[R93/YPQILU^269P;I-PO?L"4,EO=ZBKMCO=2E%]
M8<5</Z7D;P%YI6JC.0^;?S$D<""_G0.28"6,=[+0X'5AH<$*5AJL/K.)`R(Q
M2&%()2-GF*0H';-H8IS):FSE]4)?(@C/[^XB=H>Q^!\`8%X0>\/C:^*ZVF#1
ML]K22'"5.7VWZ>#9V<+8T-E-A=8%>TN^<6>O;39[Y47,=KN8'8-AM<%EZ>Z;
M]34ZENYFX^TM-M[>S?DOU$76(-"K-U<?_6[6L6,(K''TRS;>-ON-GMGI=_:R
M^WTI69)(XA+0GV;9Z%"C!S_$<<K<X]&AFG;3M':G0SW93GK+*DF?RB:L1OT9
M',4)%"<LOJ#+&O9).7SQZNY>`GQ)?17/FE;#;&V"]<M.:5_2_:ZO2*.^A*-M
MM..#JB:[6,WCB<9Q@>/(][UO$6>A_5U.`3M0.\G=MP7<7H[>\UKT:JYFO]\S
M&TN4PB*8;K^SG;:3?.2U:=?[Y6TCGN^V>_5..:=\OMMNF]VF9=I+>.8N]KZ?
M6K;')Y_O8\IJ*]56CC?D;7,I1JA[Z.6LI)B]2C&=5M.T&_NE[/OD:AM7XK;J
MC9<HL766=7,Z]FUO?,A-D%A:9L?:K[2VNK#4?/H'A3B,G(GGSWY=-Z'!^R_C
MT1TJ0H+N=2[-X]Z)/"=(YKY](`]M]F5)^,://QB^%[#:>.[Q,)J.G2#^U7#2
M),P#!U3,*"F+&RG,1@$Z%3ZHL0H"1E;$>91$ARQFX.3+/"JF,Y];\@@P%J]D
MX;`*8;H1`A1AWV+N2E$/]6UCG8XQ<BK++'LS^^1@5AN%4(DTLRILJ@J;JL*F
MCBT4J`J;JL*F7E+8U.Z,3G-;W7ZD:J(M1ZK"Y1X;+M<W.]VF:?=7)^@]QW`Y
MJ[[$G/(BPN5:Z[25?X[A<JVNV>QWS.:2IM\G%B_W-]2QCB=@KM7HF'U[9QWK
MGVP?O7K/.OE-=.NM#:)HCG03)QLMMR(L[HG`>6:;E@54<(F-O7C*H^DJNUEL
MV'/'ZM/?P:%\ET*/77)9WX?1B'E%W'0WZO@>5.\#>C`W7$R.YO1-J[.^=TO,
MM"X=.L[`Q4Z]N[YS:^F.GU',9K7OQ^Q[_Q),%:UZV+7HPKK9;S;-;NMT@P"V
MOSA6_45NNU6WVB]QV[;9:5EFMVOO=?-5^;P3TRBJK;R,K3R!&/-2PU5__.$I
M!)GNB0LR6X2L+C%Y'_MN'R._-,J-Y,>^[8T/^?!BRRG'K*X?L9J+Q#O&@%5Q
M=K)DO.([IQNQ"HL?%"#A0"%><0'V"@./#`.SHUD:6;NO`.0L\/>CQUO!82?H
MHICB\_CKU>AKT_KZE@TQ>KB9CRHN^/XG(PT\/LB7F[<_&2X;>@"=&$-??^]T
M&UV[W<[V5;B20RWUJ^JR\6:F/O[=8Y$3#<>SC^R>^100K7[[$$S3)*8?+!$>
M/;?;[['W:^#YP(NBE/WTRRGLQ'XV.VD6[^30&%@4:E_6*&794GNVU>DWCV6I
M1WY9#K23`UR6`^UDG<NR.0:>!XGG>GZ*C]RP81K1$^^^#_W49>Y[D"N0:Z6\
MR_/5Z)T387QV?,TBXFOGDS`-DC6R6YHEL"GD0[QMWMS>+*MKVY;=R3:WD[4?
M)S"^/G(I;V;%`Q3D"ZT`>[_5LOHMNX+Z8Z&>JVV]`NBVW6M8O=8S`/I&++7X
MWC?Z3:O7M%X$,([GWG?[S6:WU:V@?M![W^_W&GN]]^_^3$'3Y*T"/@3W+$ZP
MB<#50\"B>.Q-KU4CW"42C]V3:H"=`VWA]Q_9G>._@VTD,P('*KN!ETX6`#)-
M(Z:#PX:K7V\T,EBLO?2=[[==P"IPOT7?;[W?UD^_-^K]9G?;'5-W","&B3`N
M8'U7-"A\"&`WL>>"D(E(\CZ,^+`?,$L-ACP?PI^Q1ZUCBF!PD<9).,'-'N;0
M`0A]T>OB<;O1T>`Z"J<L2F;7/A#`\\#%EZ8(S'>R?>B7F(U2_R/<LV)A?V.:
M4CKEFYEJ?G'I#,<>G.9,_UWF<=^.(\9XTF.&$AMMY`0@\#X%BD69[('[WON.
MG^(\`)+0B$'_"1X-"4(I(HM(0,?8'O8S(M'38'V.]#<1[9O-IL#[@D5NNP$X
ML#W1KFTWH%UJ_MC!*>\BZ_WPZ?U/OS?[71BONTA[^#+5!N2V7*1%1[H7JVG;
M#;2:K5RQVM9GYN.EN7;@3F7M0T67H=T0!'V*6S3\.T,R@+^9Z;]PRL@F(3:3
MN_%#)_@G^1U`L+EP@B&++BC!FH/BZ\<PN,,,\>LT&F)#.MR@EW`J<P%CWH71
M[&KT(6'J"9<F^,0>WD;IG=8X;0W[2K>-;A@!U:4`>ZE@_<R&S)LF5Z//["Z%
MR>$Q`'$4WCL^2JM?;MZ[SAJ`MK:`-"]+<36ZAM.D]N#+R>)Y>E=(UQ>_WP"^
M7P+@-A'('P"<6_;=B2_?`FN";\*@`,CG=\#@<`_TKNRB2$T4U4^+M%=L;^'.
MVRT!KGE`*`AQ=>#:\=PON"@UQX?@W\!;;Q_"VW&8Q@[P4I\X[C+&V`#A98:`
MLG(`M/I?_Y$&<]]O`,`\8GX(@)<G:<*N1AQ\GUG,T%9:"$#1#/$M6DM#$@4`
M]A>J39_W7[KFY9!=1$,="3<$WN9`OWU@_GVQ'O*B@&XWMH$ZA]X64!][4<(J
M9`>X;X7M$GX*\E</P`KH[;7NR6WX/DQ7GD"C62P\-5H%WY_L"?2LMJ5.8&LX
MJI.X=#P`8H`[><]8#*N3^Y&](RNDUW%^-;P>"]JF$.U2?TV'Q!Y$NZ7@.!PH
M-O;-'!H4MM7K-%H'@\?[?R^!1U'<Q3ZD_JT$TB(Z9O7:3W2IGD9?6HY)G4/2
MF'VJC\=%NZU>_[D`]M`WU.[V[+[UHD"W')7Z7:O1V1P>U[XSY,=Q!_^Z8=$]
M8'F,;^T&#C?I(/9<SXEF-PX%DZ+ACK:=GWG5%FOMGWYOZ7I5^<+5WH2[..:-
M`F]#W10D3(@K3"S%^RSZ_B:!0\7E7/A.'.O[U&835P!]!U>C<US<G49>0%7Q
MG0>B*>+!K8%78E3M]/I=B2-K`.?1@#P<MISJAF^]!/?Y(7"]>\]-'1X]QUVE
MX>*]+XXO:7;[;7N+76K?R>)#5.,52--51`CM4@R?=,;O)03UZQ01'8>?<Z/V
MZ^JN;[K0I][AHZA>,4`PD.VQT,A,(K?A.P>9`9E7E[E\NJ!"1P56YJ+OCUA:
M:&KR?`D4'@$E,BCXBU`J_'X#*+V/F/OW-$$/NS*_2T:^'R@U.YV]0:G0,W$:
M'HL2J\NBJ7%GL.I(HC('JZ+O-X#5/\)Q$/\]G'X#C,K@MF,LZK4;UOX@8WW]
M%-X70*;H^RVQZ)H%03SS[YW`<W9]P[K=_<&F66:8*_K^V&]8L]7L-?<'JDVX
M^1&3;*NS3S*T+RCMB0P5Y,3P8![L</-E"KKA^S#*#?A2V%6SV6])SEX.C4<"
M[(1YEFWW6MU]P^>D.9=.:/8%H<Q+8,_SK\7OCUC;Z/8[=O-@L-JMI^7@#*S?
M;?4WAM7;E%V$,?&RM]@[Y#D%2OV.9U>S[%K3RL-E;M,*)F]9/(R\*4^@H/"U
M>PPTCX$<Y(P-`%1I)ET*L%ZQ-MOH%@!L0T.'WMI+/6`X^(01T<J9:YPYKPW'
M&#KQV!@Q9K`_L8=.$AI6XV=LV92,F7$7A7%L3*-PR)@;&Y&#=;,-+Z`?<84&
M-Y(8W%1W-1K1E3>-LP&.'81!S1D.41RB+F+L.Y8U8+`$;S)(HY@O2TUL/WY>
M)X!]#5_/S0"COK(:#1-(JS$*(\/'H%FYFAC&':81W$=C,*,)IGF(U?.%&[;%
MA;WA40F%:O0+OM\4C]2E,>B6\4,`N*N^*WW>=L48.ZX1>Q//=R(#'IS$AA-G
MI^7(84P$MI]B29ZM<,_</58ARCP(:RX^/Q667(,;@>7+F#[E!+/_BW.HMVMT
MD&9E;8PWL^P&/Q4YN5V\%0;<(P\@YK+8NPO0CP6L)LRHR]8@10QSX!^>M5>$
M&=DH0_Y>S-\C4SSBW13HN'P8>6*,U;#7H!^$"_D9\BL3N45&.H7OF&S8)F9Z
MD^V9(SF_+7$Z'/-5U(NP9?F)[QQ+]DDL_O541XZH*([F$2"^!AP(W:N1-/9G
M+S[9O?N7EX"`:'0,V'(R5E`<>0$*K7X8(]**+PFM<]"1:"T]N:7[VQ8$^_8[
M_MZ6N5P;;$!D.L+@H>\-/9[Q"K+N4QWBBAS&1CO;7=G2Y\['&W+1_;V'H0<H
MVKKW7AS">IY8[%P9-)P[R)7;V.FV]TCX]K7M'!$[=UU*5G7\C(QI5(S6\Z3R
M@9+QN""`J3P>"`=`FYS$./->&UZ.!>!:XW2"^9<@.L#?$Q;=L0@$O"PQUS0&
M*9`X%N/13@8`,$H^!G(?PD@@:&:JHW$FOAH[G,MS/[-,:'MM/``II7E0.)@!
MQTFBT$V'P#V`TWA)B>QO%GUI/(0IB!-"U`&)M$R$=533S:&>BZRD`FW]L=!=
M/`*42<M%KFA,"6EP1"#O@@TXHX1Q,5N!1$PH4`GK^O$KX1(.#5`N&H3WS,P=
M002+]I"O.L12@B&QDT@)\FHX'="%`/%\'U0```;^2A4Z$13PAE0#,L8_DG@O
MAZ>->RIKW1@XP3?8G@12;F7Z0H"<`L\/^$RPXX3.(1;U]/@7802G+N0^0'.X
M"D;7Y*R2!7?.G=R$0-U""6V=FU<4"2%#0M[,_@[2)VQ`\:NGI\_%`2YVVVI8
M[<7PA_*=Y,IT1(D7)T#-T"Q#P7#AS/&3V=]2ASKBL3C+#3SBZ+_?*8M"W%^E
MMNK7!H`'Z#YU9HAYES?_O+A`E1C4611?HUEM,*N)CX#+L8?7*^*@P'O*]=$`
ML#.&,R.9#H?S>=2KBX03Z!)`"$;P?)H8MX)MM'\USJS70&"X5&2,HG`BY,$H
M3DCVXR&R-+*)]^7,!LHW9N+6PC`(>E"8X=;7M>(AFYQ<KM^]K+C`W+<IPI.S
M.)XP_(D]T$_+^;)=S)?M;L'W>>L>]A27F%EN"BW$]':[U;2T^AGK[6/'.]]3
MV./JO5N])]][_^M[-EC<.QJ+I]%F99_:C:?:3&<YN1+)3VN=XH?KJ[4S]CM=
M'A/SI`?8+DZC`"ZU\/VJ`^Q8[6;OB;?3+-Z.U2CX?C>GV+.[%GJOGF3;FRON
MNZ,_5K_7:MNM)R>^5\.DD/@N?I_5QGPS^^10#9J-JZ0U>YW'7MK"\M!:=/N;
M6?:(R#\X?W`B5]8]BI,H)0Y^A9K2+>A%HJSTWW@D<\"7<`">M1'D9-CUH>&0
M@WTF7?,0X-5QS(4"S"X%FV4QW9U</;2RU3]RAX6'OCMD6!VS?AK[6T8@G_X,
MB\24W8@OR_;6K;?WO[="YEW"U/>V;@$J@>17T6>TC>32"3(KMO@UMIX`*?>0
M2K&`PUO!XB2!N?_,LU.&^B;1KL6)6^\F4S^<,1:_]2(V3,(H)J`&<>HGN`P!
MW<\(?F[]\0)O4E`5;1D8VW6]FT`%1BI#^7UC,%I6O=/9(1RO1?P&5@GCE^;\
MWO%\M,IB>`5\D]6_?5++4U%XL-T&/2!7FG+MO>P%!B4$$%GD(@'<G5>LV;0:
MCP($6:C)4/N`7P9W;[UX6%KF><^&FH*Z%MU.MRW=?D7+W'P/^[=4%&2"@^ZE
M)V"5[:3H%*D.;S!D'V!XS_&OTX'O#56@S1'B9*?3['3M$IQ<NIO=@>#@B&I9
MK;9EMY]VUT^#VE1LI?'8G6MHEW,::MZH)V!"O[_W[ED-O43%<7@8;*5\T^A:
M;O;,=K=;%F;E)/B&BG>;(I>FH%K4P]%#S5^L%ZI&96#9)13W2#)^/]<`)<,$
M>:`:0"#.V"R%&&(L@2@J$`/H*1(P8FB)XMZZ5QT,0J9`9'@4_@*B8P+5H;#:
MB/R.6*7Y'MU]\*^:X_LA=[L]&6Q;,@5]SE53\#T/!)%N4@H*0"_IY<<_<'\8
M[6ORT$D*Z8-U+6":[M.G*`YRD9YG?MB",,%FO31H6'E(BR:K&U>!<0[([!MV
MCW<=SOMY171A&PY+7`R,5%`1KNC"53/A;:"S!:(CW<=SB^<A*`",[>]):2ES
M6<%\5&P0V=RQ7J(Y_7[=_/<:E=6SY3SUZG,*R^_7[3VL_F^$<[M)(5K.K-NM
M7F.-]=."=K/T776\LT"Z:K>V6?OY<)A.4@KF>,NF</D\LO?#9Y^1X3_`XI=1
M(LJ"E0Y\F`/2=9I=K?S0T-C5F=OM9JNY7W!\"A,J[TU!^4MSC(NEK*+O\U+6
M=<0F7CKAP9H;*?M6N]NS-0.2OM8M]K!1(N*Q[F$3D]4C]K"T:>,@R5R`,B)7
MN`FO0;H;>M.2A-!M?*"[.XA^/]>M<9U=Y/:=LML0%!B0W*,8RQ>!Q#$&B17^
MNL#D-[ICGT*>";>[8@7[VO]FN]$BJJ4G7YH8OU!ZT,YY0UG41[_3RW*62U;S
MF-5N1[M+(XTZ5G?MU9+("@H2JL^RA^B,M'-O)!IGW(;<!Y__=O_-`6DWM6:C
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MC^`KQ2RK]J=R5UP.T3M%PXW;PS[^"'V05%$I.@1_U$6Q+I*[;G.]+>67N</-
MG2IA65%MH+=2DMHS7'?((W6DZ1/2K&#^1[>Y=>_X&H&,A?)0K]/NO`"0E`0E
M%H.DV]TK2-XB*V*!NS^JF3=N:RIZ(V_I?M0JGRGYT\-]UH7/SF#Z:-)7>O+V
M#D]^;W+*H8[F0S!-D_@Z"@?"JHN&MY$#TM\AI1B+&IWKOK,U%KB+_>R)P5KM
M+??#^S+C-<>RN5F)HW>`+1A'RC,>*;2.%><>/LI$MG1/I%DW9<&+=1>YTUUM
M9RY;00]Z6E'N@KLDXQ@/;95LZ&OL9XU65BUQ)WO9H_'8MF1FV-K;6:1T[G]2
M7O]FUS77-LQ>+NIOV6IV^X4*6<&B%[JL\ZL@?I:6VB?96HECT+:L;K,QWQ.]
M<-D%KEGY_),>6LG.<A[/\B6K77T,@SLT$NC-K'C5ETO/QZ#6@*(\UB@R*2+5
MY_KTM`N^WW_-;-%/$J3*FRD,',(H\JVU0Q!JP"JLAIX+L0&L=@;??=9'.A\,
MPB1YXU$9-6?*TL0;QA=A-!4P+5_[F]D%#'471L#XD1[*)UPNIN/']UB@*%>-
M^VHDCL6]YO6.UJGWWG[>\+_WV,.>#N"&P7[<Z@2>[@1NQU[T^`.PVL^<!NWG
M!&!$/[Q#R$MF,)WZ(J!G':A7>+\-U#G55U7IT(!3H?B^@'V.-4$)XI]80IDG
M%:SW2M`KF>;Q!S`?'DQ0RS=^OZ:BE9)L;](=Z#&@E:KN9UA+D++/(#[=!50%
M5CU^R9)QZ.8?^&^)L><4!?<R@K+70Q,ZEF8+WOP$LK+A_#S5M2PK`O]LKT`S
MI[$6@*.D)PVO_BJ>OPWU31T<@/M7^G\7^\5<54JU+:K22\FL`V:X*<.<T_=_
MO_A\45@M>AGP3@#<>\?7WPNK*,.T?WC,F)O6P'DWJ:UL/;ZXLET732=DE?5'
MU%?>$CO$0U<C27@S#\-S-[L5NP9MZ:$I!\S6P#OIR[0"<-8F@"O0UI84!#UI
ML/U^;=G_QCC5Y1O/!`DA&,']=5POQ)7?LTND&V7-(_<)GBOGVV?/O6.?'-Z5
MX*,S"",G`3%.@(>OGIZ]?0AOQV$:.X$+0$$;5,+82I,'UD=IYD2'90!X=F!Z
M'Z9K@ZFU!9BB\#]LF+R+$P^[G[C8;'(I7>^6=(3H/*ZSYCGPI/N;T$_I@74V
M:]NYW1;L8_M-JL++<^U#[8+O3WB3E\YLT:%N=0J^/]5-VNWB^VQW5^9'7SI!
M.H)M4D'L]7US2*V:N]_/7EG<QB=F[>'$-H_UVM%QV>L?U]OP(5"::]&33RG?
M+3_%>9FLR64R&6^TP<Z*H/$^C,1+:_4]:W2+8WCT[_>&P!A%TNQG)UZXC4=L
M\F@XI-77$7M7V\S'*.ZV:?L^#S)G'4>,AF?.I]@9SO&Q`UX8HKCU-DKOSMT)
M/!HG47E%`%'4NTB9/04E=[TJNHN$,N>AV1:@U8FL.)'R\M"+)5'MG9[(^Q3T
MLIP=B*JLJK52ITA04$%%^3?6<WR&![&&BU*JZIL!:VT@DZ\#WX`77QR$[4T@
MK$,J"_4,`Q@;WL3Z3UB7R$M2KG2OZKMK%3!HT0?L,8S[2P"*=Q13+/HM^^[$
MEV_/<1L*NDN@FKO1&V%JJZW`N!0BCX?;P74L[+/6L;O]S?9W/7:BB3.<K<8"
M(8;/84&GX/L-L.`?X3B(_QY.O\&URC!BMX=N-Y0\K^U60>`<AG%Y4:YPR&+L
MU_V,@9'A?_&^YRH91BE%2HSP=X$Z&Q<CVZ0JWI8$Y)H%03SS[YW`<W9,,?(]
MP38`B0[)C^R./WAP_?=)H*2VFR]BI8S_'P*!<\L*0I:T/2KZ?KDXV)L+5RA:
MR",6^HAB>^<^`#9Y!]<]8=Y:48Z]9K-OK;\5)6N`?+ONKIH"&XOJO&]6<$OW
M4:RYHD,O_K$'TK>WW=W6/?)$)[RK-(D3)\!6SSQ99&>%23=.%BVMI-AK-WMZ
M%\E=;_DDX+F;/*%^I]NT^XWG",R-Z.>ND-/N]WN-YXF<F\!S-\C9[3>;W5;W
M1("9[R%:7E]]T[3SQQ4[6ITIB$U@=D@`"L#P%%`^;$FIU71A3EYYJ5#>G130
MM)M6!=%=D=I6H].W>X>#YK(>V!HVJ/J>.PI%VQGZU0#Y6FMW]2[<T3'`8S?(
M4U-Y]#N"QB.1[WT8C9B'NUG>VOS(>$1[MRRB``HG`>1=X63?ZNQ0=-PS-,4]
M0)OZD6HVG5;3;G1V!]"%'9\$.'>DV'1WK-CL%9B:UO0OAEUYF7M^SR+GCNVC
MR/D6&+NLA'BS;C?WHD`N`\4)0W_SFD'E[9_KNZ07IPGZ_9+JY3W,^SN4YY\_
M]'>*^'LR6NT,]/%&ZMO&X#^`7K8,_CWJ5_($P#CI,]CA!8`#L$[_`.3()WL/
M&O7^)@QXI_`X]9/8X6VHCN$8RJ0OEY7T)FK5"3U-U?:E(I55[S^/(RHP))T4
M->/-TIX*''LR$IV>>@?*]0ZC#-8$Q0E#?Z?JW2X]9=N"?K!ZRL'&&N5G-G&`
M?P9W".D(8\4='RM(V8=N;-3[=^M2;T'U!%M^%A!?"^U_OV[]VVI<VM;3`YQ"
MR&G@VAIWJK948V3SG*1LYD,C-[4?>Y*=GCB(U\3F[K_;EU;G[5'`^*!7Z,!!
M.DBFNY=Y0!]VOZ</Z_4)]*7=>F)([XHWE(L\9=-;AV^LV+SL[I`=;K'E9P'Q
MM=&[=63`WHW#Y@/,X@6Q-Z2F*4_J(9]/V.LW>IV-[)+;[OJD0/OHECFM;K/?
M:3;VX_\[,L#NW?HQC[/=IF6_#)S=KVEC'F?M3LOJ=NT3`^R"#?<V3!Q_#1CO
MML7EFG#&K,7.CK,`UH'`,X3X8E/1K7N%%A7>J0[I5#N_5J=YZ-B#^5:4O^QR
M[W^P&$7WP%5M[$/\2A/OS^_N(G8'*'B\0DNSVVQUK!UBX-90>59'<X1"SZ,.
MIJQ_J-;].*;R]R?3@KYA]61GS77W=3J`*`EA*`:$C>K@QH!8*Y?J,R!8Y.'K
MG$GB3CZQY&JD^=77`%*S!$B'R$*F^B-S3/JQ6SXT_)XR=ZR!>H7=SYD<=@&_
MS-+\")IX[KK4N<?Q\T&<2P709G&A%:M1\'VY`/KA^FKM9.)VU\(TD;UN>2?L
M%P3@X#)TO9%H8:BU&,$J_[OS2SP*77^_&E%;E`1E58,#'1NR1`KUC!C/R;CC
MGC73L!LF4`#YZ#T\9S0-T!^2<6R,HG!"P]'3A@L';AK-AFFW\B]8U+VE^'&[
M89N=3E<^/W;NF>'0:W`[C"G'25AA2W:`"5RCV5Y<E)/0T#@H/DY3U(U;^"J2
MIN7<+OFK8IL&_(%SC<)H@K4(#3)@TUSI-.2=9)SAV&/WA`,XP9!%"0QK3%2K
MLOH.!)8UL&@GWH=WV`Z''MYE@NB&CO:=[V(G%YG^]0?'/S[LP7U<K7G@[&@?
MNW1<<9E:DE`E/AT85LOKP!5:]?:P9QVN5/F+N?%[(';KUP?8K87GFC0PIFPR
MZ]3,['6;[;8FJ:S<Q^XVO3^I8EG/A@-N]/#HSTO;=-M6N[GE3L]]/QQB:<EB
M`H2Z41`7JWGYFGRK-9CE!??:_:Z6LK3>LG:TD4U5L14WK-4\F9T\WJL".VX\
MT69W5]`26]8V6]U^_RB.[9$[L3IVL]]OG<A6=H*!_9YM/VK#BO2RZ-X;LN+W
M/H7!/;<P(MF.R0^@_XXM"#Z%R;]9LJ(E\>;6UA6->_OM9J^MN>7WMITUS#HD
M*GUB#_1+L2XL!0*[."[$[BY^O]S"W[3;(`2N-+_DE[;;O?2_OF>#Q</$:OK3
M:(/#[*QCA]O'1CK++^YBS>9'B6B(MG:;VA\\Z;$=5B9M=N<UE</M>(>$><&S
MO/R<K4Z_V=EBSV0,I!88#Y&7Z"T3-'/)6@VXY@@,7-9%`O,[VI`<.8,!_V<1
MT&\OP";(\#AMU.BC)<MJ&F/'-6)OXOE.9"1D]'-B,A_!KW8VC`GO#_T4PW"P
MD;(3CXT18P;[,W5\[+UL-:AI,C>6847"J9#=C<A!2=V$MX(PJ#E#\DR@"PM;
M'!/WC9@W&:11+-8KA[27CTC&K@?.66-\?BH:9VI60GQ9M(K^/VP$C:=MT+$A
M.!SX9X*K*=Q&-LJ0O\?MC!Z=-[9MQD^XC[J!408P!*X>QL"7AWZ([0KD6`3I
M<#1BB"4F[_,L=5V`,1/M";P`A\:M1.&]YS)ELQMY@1-0TVC'O??B,)H9,>>(
ML9Q1=L26/:GAW*35,^M!+1_"0T^G-=]#KFEX`+^8#5/$31AP!'M+(H>.FMIF
M?ZG?U`W9`=5X]QV@'-PQ>L[A<_@SP@;8[2N[C99.V;=Z%=+OYG9LPGY__T#"
M0HB669S'S:'.F?>:T$)Z5W%+[7;+;%K*>'M&D/R)>T!^>KV`($YBO.K4&PTT
MS_)W"%///!AZY-VS&IF6"Q%W?F:KV3/;W6X9*L),\`83RC`@#28YXAGT<]-S
MH[(\^@@(`*S"-5XU39`V3!`W\"[,73%E^<8FY3AFAA^'.=J],/'?:2G<GT"D
M3ES/5%MA(>6$0WKPDK%QX01(P"+7^!L+4B^9&1^"81TI9L2F<$3P!@42&&>$
M(Y]S7W)<(:`RC"'WLWD98./9,/1]1MU^_1FG$3]]T1[XZ;69N\/`E4+E#L`?
M](?A8C8;-=>9&2&'L8YFZ13_1&13_B7#SGLHYE$MP8Y6]]CB'OY5<T`M22@E
M&]C""$:"]0IWAB1R'!LWP94BHP^R4'1O7(W^)>_+\1DC<ZUCU]M%UMPH%X5V
M`6RUM`?+-J+`RHY=LNM0X3(>M\HGL@LW^]ONZSP!KA"PV?'NK=4HVYJ^]IPY
MX$^D4EFLB/L?V,.$E;1#RC98I@(N?+]9E'+I<K9?\Z:,8D-C^](5TT'(.ZV,
MTF]FXJN_ASZVB]NUH:PP;J/7;#9M@1HK5W3@M6]A&2N)KE#5H3?<YV=VIYIF
MJL6L*UVVOEXZ4<%M*/@>=2\O-O3I##4?30+2/++K!Y+Q8PS72F,6_\H%3_+B
M:S\8#V-O..:<-\ZQ5Y-K'^CY1^&2I+3!+"<?``OGC/X5X#3R=N+O\*U'7#1C
M[B;,R&#82,92F)ET"H/_`F(^GDO\6R;'.C1CK,E*VJ)IN2@"K+'@-,[6";H$
MCX7+"<&Z.$'";;>];#,P*4@B$Q!\!DSJ:C0A8`27MPH6SZ6U&_I6B2<@KI',
M=_GQ#^-_G<GT-_P_0+=N?/QX89S]!-_#(QB^X1J7V%+)L%ND4[>DU+,*ZQ1Z
MBAC`*['9\FHEVZ#DZA+"O#NP9"Q%B]')\Q4`*Q*6Y^,QP.6(=FZ)<[)EKBO>
M<2R_:\^+CKE%ZAO0#%87:/6.\+$W3NRMDEBNADFAQ++X?6;,>'</_U).W;GO
M12#K>EFY%_H-)?O"F!!<;``OLH/]CK]3WWI_9K1Z=,MSA&CND5=6S\S!K1PV
M`$&`X?]3JQGOPS`)0B`L-XP:$AJU&H+7]X)OOX[$;Q_A#^,[?97`YO_Z$T"2
M`>5P?Q+?1J$/WXZ39/KK+[\\/#S4OP\BOQY&=[_`039_P9]_P0=_4D/[X3`W
M(GEUPD@..([PT/[G`V#15TM^Z3L#YL.CSN"K^.&7A:6>1_EQ@0S)U^'CBG6*
M)W[!1JXU.:)\'0T`N<GE/.%??Y)`_&K_9(`NS**__F35&]KR-MANLVR[S:?<
M;G-?VVV5;;?UE-MM%6ZW_?CM=LJVVWG*[7;VM=UNV7:[3[G=;N%V>X_?;K]L
MN_VGW&Y_7]NU&J6DN?&DM+E1N&/+VL&6[=(MVT^Z97M_6R[E2-:3LB2KF"=9
MK1ULN5VZY?:3;KF]ORV7<B;K25F35<R;K.X.MMPKW7+O2;?<V]^62SF4]:0L
MRBKF47;C\5NV2_4'^TD5"+M$@RC;LAPNM[J(Q6$:#=G<%G4!?7T-35OPQ(>A
M@CO0](+:EQL>0#%QHF\L,>XIT[C`\TH9-H/P'IYD3@QZ+UF2T!P4&Z"-\WP<
MD8F3A2!(OSHW9_V9ADGVU-7M!1J28%;N@U>A&DU+Q&J@$BP>_O3OFW?&Y3]O
MZ<D;-DW$HPUE@LJ!\7%P;>\0KI$7?ZN-,#K!(_=JG!@16OH>G-AP&;IER4(Z
MF,$)!`[/<C#26-H3;R."]LQXX_D^.EZ%2Q4&FG+GZ<)Y[!86O1W!X@T;.FG,
M<B9;-P3D@>=%4IF+82FP/(DT8P_C%F9H*U60(@,H_\$;8@R+>/8^])W$\[U$
MN)*SOPV\KF%$`,=DFPE9,,O@K0VMAO"4@WCJ1!3)0Q\#_-X+1-C`!`_83>,$
M%HQX&[$[+PQV>Q:6M:/#N,RVKN$@I>=ASB*#]<\\YE.LR(`9C9_%_:9<.SP!
M1IG7W.!/%F@O,1X00_$TI\Y,C1,K\Q?\E\6,$?Q&*5K.=@R<UAZ!P[T1TR@<
M.`..58`0?!>"1"K+/0"#.<.QP9"4<@CM_E9:W=UO5EZ.F)\H41D*?(*M3ADL
M)DC@4;H*[+O'TS]5^,1(QMS1WN=`0IC!\8AGARX$G65%KQ!^B_2=WEM@$*9&
M!OW9;B%L-W8$8144PW$H(T%SOAX.:PQ^XV@E?Z8`Q3).4;3G_#<?X0_Z%E?M
M_8K_AC__?U!+`P04````"`"Z?5]%AK_CCM$&```D8```%0`<`&%T;FTM,C`Q
M-#`Y,S!?8V%L+GAM;%54"0`#\.935/#F4U1U>`L``00E#@``!#D!``#M7%]3
MVS@0?[^9^PZ9]#F80.^N,.4Z(8%.9FB3@7)W;QUA;Q)-;<F59$CNTY\D'$AB
M6[:38,L<+Z6876E7O_TC[5K^^&D>^*U[8!Q3<M;N'ARV6T!<ZF$R/6O??KOL
M?&BW/OWYZR\??4Q^W"$.+<E`^%E[)D1XZC@/#P\'\SOF'U`V=8X.#X^=)6'[
MD?)TSO$:]</QDK;K_//EZL:=08`ZF'"!B/O,I89)X^N>G)PX^J^2E.-3KOFO
MJ(N$5B%7KE8FA?JMLR3KJ$>=[E'GN'LPYUY;K0&C/ES#I*6G/Q6+$,[:'`>A
MK\36SV8,)F=M)$@@^;OO#T^.#Q7WNSXEG/K80P*\<^0K36]F`(+?$A1Y6#YM
MM]3HM]?#)Q60*S#!41#.$`N0"Y'`+O+Y@4L#1]$Z!09UE-B2RXU\O3Y74L@U
M\6$N@'AJ^L>G:N"]2J!MA[IKD_H*+<K6%RV>4T,R0?Q.XQ+QSA2AT%&+Z8`O
M^/*)7M[.83>&YUW\^'N/<SE]/V(,B%A.X*,[\/6TWS/HG(K%[",^ZQ%/_;CX
M&>%[Y$LQ>$_T$6,+Z7M_(3\"@_@%^3?A[[%U#1%SEY/(_ZYAGW2/F,+A41#H
MT3H2X&#)/V$T,"YQ/"_=2A'*/&`R/LGP%'$I)`V5`,AOMQX`3V="_JE=-89C
M!B'"WL4\!,)!*C$2,V!%#;`0M_WX%5(C1N\H%SUG(U3]/Z-7;MBJ/E[M$E;K
MM=\LPTTW4<L"#`V!B<58FJ:0KJ4"9!A(<;^".;*8V"R&Q"QXX2!2(4(WX$8,
MB\4`0LJQ"90$I<4X)&2-E_[X+7[GV,,51G?8QP)#@5B91EQY7'==&LD-UQ@M
MT)VO\K=\PB+P2FE2:I1:#3];K41^**.3C=EC0X%K\)6?C!';"M,,]F:"F:&,
MC1GF*Q6P%#L?M%3JAF"4*GOAS%,A)`-@\IPJ\#V4"I)FMH:`9%8B1NO]VSXA
M;]\HJ/MC1GVY7%SM<L7"M'5,(:ZAUC$!B;*GA<FK3J52UVKAV0N>4M!(RFYC
M?N_3(*"D$!Y)TH:`D13<QAS=\V00T5*,$?:&I(]"+)1(V9NK+(Z&X)(IOXWY
M^AH$P@2\"\0()E,N-X-1$.D=X``FV#6>VXLP-P2T(JJ\9?#R)WUY-"R5S_-9
MJ_:0_90M+-B]&J'8](>F'.3WLUEL&CIIE#OUD?;3O+\1\E]5D^:CR2@$IJ?8
M6Q<_;_0*V_EYHE3L!+$(9!IW&DU-LA3:ZO<<'*2GJ-;V`.[!I[J/$<MCW&X8
M^6KUY$P(DAL-HQ(VQMC/0*1ROJKR>H%T$BZ8KG+D(Y;+V0S,<M6P\>`U@)"!
MB_5"&"MOJV3-P&-=9AN/59_E8>**<CXB`\QUHU"*-)H\MA:[)H_)86P&0'E:
MY)^D.K4?I6S-\4,BQ06UND6R_"IUU4ZPCVU)[::>7.Y-8T\1/3^+O]EWHI='
MZ/J:YV\O##Q5V_J0"&#`"^QB$Y2UVGGNLF]:>T+\XK9>2QMR)14]/3._(E:`
MMUF0%5"H`2^AVA:O0!3*Q!MTM>7@';<-M1E[VC)G9N!54AM/TB^1Y*Q&QB"\
M9?5*=<GBTJ</+U*N3!F\IFIEBB35!TXEQ)C1>RS5.U_<<O"&Y,F'>U*U>UT2
M-T?5PH-4[N0[9(8:G;DD*`E/7]?&QNA[(YT%SI'4K$\#%87R:F-9#`V'*DLM
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M,4'$W='=4@>I_FW3,#:@T63U&JWQ1=,L%AM=R0!5\N73+,6L[.)+35T`CU_*
MI1AR'JFK+=)GGN^]F0)D/F_#P2R@X7XKNAEEHE4Y+N;`7,Q!M>AU?UZ&Y[\1
M8S)0\TO*E,99%:/2PS04ONV4;<!79NS*:^G?SAL#P]3;W,0;PDBY86IH-=;0
M2ZW+Y[:!-*5-65A9&WN8]9R.7B'BJ<K:V`&M9X/^"A%/57:GO+K]6TC+(RQ:
M.;T.U!5TGV_QVI%IM!=^S\@T]:OY(F2%2JQ]=R"_K;]-Z6A_4]0:*8K`G?*I
MLSVI;NMY.5W>S\S\*EH>8^.`SE-HIY=/G[Z6+W_Y#U!+`P04````"`"Z?5]%
M\`$=0B\U``"#5P,`%0`<`&%T;FTM,C`Q-#`Y,S!?9&5F+GAM;%54"0`#\.93
M5/#F4U1U>`L``00E#@``!#D!``#M?5MSX[:6[ONI.O\AY7GN.))L=Y*:/E/R
M+?&,;;EL=_;93RB8A&3N4*1"D'9K__H!>)%("3>2@`!V_)*X;0!<:WVX?FMA
MX3__Z]LR_.$-)3B(HR]'HQ]_.OH!15[L!]'BR]'7Y^M//Q_]\%__[__^G_\,
M@^C/%XC1#Z1"A+\<O:;IZM?CX_?W]Q^_O23ACW&R.![_]-/DN"IX5)3\]1L.
M&J7?)U79T?'_O[M]\E[1$GX*(IS"R-O6HLVPZHU^^>67X_ROI"@.?L5Y_=O8
M@VFN@E2N'[@EZ+\^5<4^T5]]&HT_348_?L/^1BY2QD\WGZDW<'I<_/'H!VHO
MF'A)'*)'-/^A_/'KX\U^O2!*C_U@>5R6.89A2#Y%A?@U7:_0ER,<+%<AJG[W
MFJ`Y5\=*`"KZ*17Z/VAKQSVD(3^CB':-3SZ:PRQ,-<JVW[8F2>,E#"(S@A9-
M]Y(S;^+3$BU?4*)3R$:[?21\)<(D7O:"/FT4UR@GJ_4^TD9Q.M4Z9,H&<YDJ
M@62-PS1:DA9&)S_],ODI;^4BCG`<!CY,D7\.0SJS/;TBE.*O$<S\@/SVZ(==
M':&7!E&0+5>O,%E"#V5IX,$0_^C%R^-<5X5&>XI]]5<6I.MG^!(BW$'`1O6>
MHEPB["7!BD[J\?PEPT&$,(:1C[/E$B;K>(Z#113,B011"CTOSB(BW&)%[.,%
M"/LHA4'810<]WW5!^9$M[4<:U9_-STLIII'_5$@QFS]MI9ANI'@HI;@LI'A&
MW](,AOV,T/_S/4WQB$(ZW!]@0@96`B-,I2?SP&7G#BYKT:S`W5%1;+BG^`])
M3!:H=$WZ/)W-5F2-2KO;6M1:3T'OXQ0]P#6=:[O+QVBD]]!-@C>R%7_;#(1N
MT]!^*]H%ZS-!\-KJO6U8+H.4]A(ZZ9+UGDXLY#RVG58Z;1NDC6H5VZM_H5P2
MTLZV5F];R]ZGNYF;]74*T[VC,IOI*=I3]H+17QD!Y.J-HM+=8KR6<@')H9#4
MIC/\+9&F(2?1`T4^W4(7OZ6-:=U%YWQ'[#4^&E*&(4Z8IXK\1#&'^"4_5F3X
MTP+"U3&UVC$*4US])K?CIY]&):7P'^6OP5-*9*$]G&B*;LB/N/I*"%]0F'\;
M\`N#GXY^.+8E<K[95Q$W+PA&I:A;=*=)4VARL*N:*\]XK4B3>1(O50Q6?C*6
M21LG/DJ^')$:&2:2Q/FND([%'XJ#XZ]T1B(=\BK,ZY%!A!;TAZ/-W\,8(__+
M49IDR").%R'$F.Q<T]C[<_HM4.IANW7`V`AZ`L)!@.8&(0F2+"7XH!X:G[IT
MEPWBB@',?F$P,8((CTP3P,$R,QL9MA;?$23@LN)*S4+39&2-8;-5AXO1P6<U
MLO]&>/I`FD1)@OQ<WKL&I<J:U_BUP(D9L%AD[SY0[!'!F=?$2K@SC`I!SSMA
MQ*P%3H>%$5>)$J.1,R!==`*)60N<#0LDKA(E2&-G0+KL!!*S%O@\+)"X2I0@
M39P!Z:H32,Q:X.=A@<15H@3II!=(^S0$_4TUB)_?8T7#*]0"O[AN>$4E2L.?
MFC0\*82ZF)Y7#XQ^&I3UA7J4`)P9!.`ZSI(.]N=5`R,S!(TA\PO5**W_V8'%
M88HQ2O'T!:<)]%+!>M`L"$9F"!=%--H09PS!'=KF%M)=9*2;1*DR##OEP<@0
MV:*&!L/"(BA8PKMS.+R`^'4:^?1_U$7Q!D/*_T_3"Y@DZR!:_`'#3,0J*]4'
M(ZNG>CX.'.Y%62=W<"23[PH&_M6W%8HP(M+/TE>4-#07H*A0&XRLGOK;8JBJ
MD:MSH^J<"$96S_EM8=F7W:'C?14C\A#2<*):H,@]$@\>?C4PLGK"5UZJI#HX
M-$Z>D)<EN3-]%>-`A,Q.23"R>I)7!H,EMD/#I-!#.D&!D=7C>\M=6BZM0RS6
M;0!?@I`8#>7QCO1$]1J'1#Q<1)(H[)U5FP!CJR?]-H>;5BHY-&1J<JN???B5
MP-@J.=`*!2F0+-W<V5>74<6XC,TD^I+?)!GR]S40S8CJK8"Q5:I!`@QG"FVI
MGK/PUB*;N^#*K`[&5MD*'8#R]7)H6T@CJ"N!Y<@Q2H.Q59:B$U`\-1Q:^[8A
MVJVF3%$U,+;*171"2JJ/FYM/.5`L=:QR$IW@X6BAQ66J'10U-,#8*O>@=Y>8
M*^/0:E.[##'=N<HA8LOYM<#8*CFA`2V9<@ZM29W.TR*C6*4Z-&`GT<VAM:GI
M99:YIQBEP<0RW2&T-->;P53#G8,4'?QQI(3);E$PL<IF=`*$J8-#R]/4]X/B
MXP\P\&^B"[@*4A@*4.'4`!/+D0\=P!&IXM`B]$@OV47(OX))1%9*3`[=V3++
M3]J7Q-:>T+4AKPPF5GF'3L@I:N70<K2O9JL=!)A8Y1PZ@<31PLVC$G-#U,-I
M`B:N4`\:#E5\#65@'C<O!1N])MS(97/HX4V$0N<0(W*>6=)0$E@`GD!RM*%'
MG?/UML@#7--?3=]AXM^J7"#NW;B5"\?>*_*S$,WF4ODQ3P'I765=W[!RS5D+
MK)RY5Z=A!GZCNE"&?$5RB[I1SHF;TSI!Y&R!=W5VYZ387>>M4I%/`Y7NX1))
M[P6;^)SUR]Y[\')F"T.Z?W0FK09UY9JZU5[EX.7VJ^4JC-<(Y7OD62Z&]!XA
MMX[=B^VF9@)V#Q$:P9W)8^N2/5_?PS1+9#L)=@5#U^%=VU+PE7>(]]P*J32?
MLXJ;NCBOO+CS#2T#IJF$BP.M!RJNK))ZX'%PN?L'I)-$*EWB&N7L9C#@=7TV
M$GN"NS-"9/-W;27%4X\H7#%B-)7@.1'LSQYLBKQQNRD0;!(J:K:1K8"'I$OU
MI,T^</^_AD&2.U++:QM1/73X#D%,IEE_%CW2FS$)$9<4N(^CI/HG@2W`*I2K
MUN_88%]U*"!C7[5]PP;[JAUA]KRAU48#)V(WMCA?;W[\/4`)P>MU?8O>4"@Y
M5ZDUX`)UJQ5V2<^2&L.=[<M&T-($^3ES7WKISK]5.]996'6D)$BK:ONW!]R5
M,^"!D7?PL+@1]B9:92G.=1Y)CXZ"6G;YT=9#48(K6S\'QV]-T'$G^,8NY`0U
M"%]-/X=X3I:DDT[X35Q(%VH0OYI^6F(_>5G@JA>)&/O!:;H1K+8US/>"@FL'
M.IJUR\X9/HKI,I!#PYIY25")*:]?E;)"UNE"0T:B[R@J65('1[R-#LV\38D4
M?A!FU+9EXAF:0_:;%V;$$M<$7TJ'9FG.AL[F563V`TIRPE2%=-/U";O1CCVU
M4`]YU/$A&\R;3IAE9+TN&PV<>>MIAO,UNP%90*6YK[K`\>GO9>S>;-B,[APV
MV7(JA0+(JEKG``V#V*;GN!JC:11^5QA!1_N!@\RA8B"E.[&3*J.-C8^[H8_=
M8GWL9@#N#,.>$@Z=^'O.&],E/4::VZL5[=LE!\V?*[09R=$XH/YOI_>E1_L)
M(R(9=#;?CF`PHBJ/)M#5]"&)`=W0,.A?319Q@@;`R/MQ$;^1.2(HU@_RP^ZR
M07X%;M$"AE=$D73-.:@S2MD\6.M$JMD'.(KJWF>I(E-(P3W5[!:Q=GCEF&W?
MMKO2#L:PMH^%'2VL];C&69^FY<9!_#Q5LY2=`QBK!S+6@'U1W3EG<=]5.%\K
MW%Q7J&WS\IFY>;VE`1PZSW$EIO)*^2Z%VM:OIREBTA+0IH(#&,#Z\+2]5AT.
M6`?9R#OHO9(I*UG799;28H):=D-N%,<7&T.)5NX,RNLL(9:E-R\C_SKX1G_"
M\N`W;B6[M]MZ0296RJ%U<?/*2_UE4<GVAUO'T,/`CFQZA&H[E+]R_XU8`9:,
M!V5-/3"LO),1&IJ-#4<-=Z;&_J"XLAW1A8Z#FXY:]F#ILK57UKV7H4?"E/#[
MPNL8+6;(]\+;(0O*UOH12T]+N\_-,\SDT'ZF2$IZA]+7V+^)WA#.'SZ8O9/M
M,WX-5@]D(T'^#1>BD$_E-BP]>&T(1?94T<X8!J>0VIQU@W%&]VHWT45,5BWR
MR=P#?!TGA;0W48K(AIOH3?Z)<UAX<T:_5BT]H'V0#J#+/`Y-#C5M'F`R2_*M
MC)]??:AB!M16?%YM2X]Q'W1"4#6#0R<B[E'^"J?!DHK_%:-Y%MX&;\)K/:W:
ML?0"^$'[0GN#:'DB@'?7C_8]&A[T2A,0/=+IB3?M,XI:>A+\<',Y3V<M#P3(
M%^WB\PKK<%'0TJ/@5I;6FL8E&*<FP*B@IT^OJ.(BJF/I)?'#0215OD3KS(6X
MPMICL.OG!$:8UB`[M4L[F<,XXMPJW$N45;5[WY!GY_-UXR_*UPI;M&?C]J`*
M&!R^O*N*3D3]:>_Y.]I*?"SJC;AU-:\EU.R>TTYY=TC^NG12DG^_L/5+<^WL
M+L?.Q5MOO3%RQ0]C"JQ#Q#K>H66<!#!\"F,8_0]*4T1S3ES`R$/)!:)$DC@*
M4K6^W0MJ[*'`V&>V4<>=D70;1XMGE"P?LH1LDS':OC-\OKX@BB]BN@^GFX2J
MA"]9]#JVZ%:B?RTK8`]+.,2W\K7@Z""=D#NV:#TXLP>>;3N(U!!#F$$.WC]<
M6=7=Z2B'V`?<H_?+)%M,5ZLP\*#P_KFPO-W@SAYCD;$9$.EHT+WZB#P4K%*Z
M?BWHR[Y$:B)"$K_!D%ZT_?IT[4,Q..HMV`WLU`M7.ZT=6IPY^Y3+#%&YG^/Z
MWR^R)*&/-_`#<#2T:BAZM,-FO1W/U5-E+5V".ZBWG[X+0H33.$*X?(J#/XX%
ME8Q%A_9"2=76S/$KT]:A5(82CK]U5H`/JO^#ZO^@^C^H_@^J_X/J_Z#Z/ZC^
M#ZK_>Z/Z>:%RC<_?1#@-TBPEDWHAR2/"B%C@50Q-JT;L)JE3QJ>U3B:/;_+.
MH@5'S9^QFY5.XTALK;7)ARP>R3Z71K;=P7_#"/&OPO,+VR5)E7'ARFXR=/@6
M!GX(WZ=1_L@HC-9B^W**V^4UE2TLD-YD+/!_PR7"^`*N@A2&OR5QMA(;F5?>
M'9Y0:&61^":C?'_+X(),7P&!=XIQ[`5$7'X6!ED5A_@^H;5E*L@B=0_)+VE-
MN6#HUK%-3D"LK$,NE-Z7^@U=,=:0:6'$18>CASO'_OZHN'+NUP;/]Y=KP<K%
M:\D0X`#"%-Z=X=(MY;R=B\^=`-@7W*$EY.9A)K7\IHREZ\6=K-X4VN3)>+I(
M4#Y+<O90^X5,7<VUL6GB:'<0@W-75U8Q8_=KI;L=CHE$=JR);)"%[6Q(VQN4
M/A8]A-/A@A2AH1//E.#;B"`^!(OJV+R,S.J3#$-+Q3?8CV\#C_08=$G?]8WS
M^_\%M[0DLR&1)OAW'L:HB$.GQFQ>158$J+M>)ET,-)<+&8Q!M'A"R1L1$:L.
M%UE%,+;"'+4:,THZF%Q*KZ(%7!23J)K9N17`V$KZN3;F%LMNDMZO[:KN8-3.
MXBIUP=A>LCA%XRNK8=(%\)68I@JK5C2_H`H8VTN_IFAUF?1:'`&::.GL!0=^
M`)/U$Z2G$B5:FE<'C,WP`U9I::&R6J8O34ANQ://\,WF]4AI&2$JKPS&AE@(
M==I:B`0'/36]W.'ES*-H^Q1I',Y#'#4?0NB5:ZET+6.5!6.KX3**PX*QM'&5
M,7I)C3V/*R8(5JP.QLY$RJB%X;=6SB$"?#:?DX-7@FDH"IDP\D.P8&)C%0=C
M>^Q,&ZNS9S*N1@;'T7U&59K-'\C7R.#ELN:[Y<#8'LW2W=)\54PR*\7KLP\P
M\+]&Y"N;W?]-]$\$D^?W^/DUSC",_*L0O2$^^=NN&3"QQ[KT1*B+ID;='*KR
M/+^C\(W[.&S+9L#$'H]S*`!KFIID?=3E>0V2%&D8@U5#8&*/#SH8B'5=39)&
MLW?D%U(IS0O/\76<">'LW""8V".<>L+:3V>3\:IW1/44132D_AHAFL.U"JPO
M+V%S=R?RFF!B+S]_3\`4E=,2UZITM*U<)%0:M0-NO0:8V,N,WQ,)B5(E`I]-
M(%"&+F'Z]@+RG^-ZRI(RIHP'A4)5,+&7H;XG)JK:E>#\;#BW^=4WZL3%Z"$A
M7:/%TQ*=V@$3>XGJ>\+62=42PU\.N45LNQ,$DR%2$'*5-@=D(\;W_:!HK9#A
M,D.**,@J@LE@>0HUW2I<C#`7C=SZ%W%4"'0=)S1K5A#!X@_DWR]D/T(W*&2X
M!K'/0ZMC<^!DL$Q&'XTK9(U0&K7O7T)ZD[4F@W34*54&)X.E+]3UJS`RPEK<
M$:LML^4]>B_>U;H.Z"$@B!;W"/FHF*0Y?4IY2.K\!C@9+->AW0Q5QS#"@^R(
MB1XAV3[YY^OR$B^7PQ=7`R>#Y314-*L0,4)=D$ZP"-Y05*S4L_GL)0P6>??@
MGI`%5<#)8,D*F585"D9HBNT&]CF^@I0?R3T\\BU\HS@X&2Q!(=*HLKP1>H*<
MV)+TZ^H:(=(!&@'H/./S:X"3P9(1$J4J"(R0$.6WR2GA(L9Y'Z![%XGY=TJ#
MD\$2"@*%*K,;X0T:._SB0;!<^CG*-PE*1Z']:N!DL"R"BF8;9ZT1+U'>5H-5
M>J1OMW&=0)SRX&2PU(%0I<KX1AB#XLLXSX7]UI*H5JD+3@?+!2BK5P%DY.#?
M&)Z%+#38&<_F3>\&6<`J!X?2'*;6%#@=+"G05=L*32,404.HRA52$^Y\O1%.
M"45Q$^!TL`?\MEI6J!DYOQ<\P6Q>3=!;B;CN5&X-<#K84[M$J0H"(P=V\FV/
M8`T7-.8Y?PLV+=@<Q-TG"*J`T\$>V&5:52B8B2O(>T#@%0>FDG0C,OMO`8Z3
MM6P!4JP.3@=[H&^C8864D0-^8_[<>J:V,VAM`LV70:7E1J4A<#I8.J";KA6.
MID,5JNWG^?KW./2#:+&9?Q7B$_B5P>E@.01U_2J,C%`*M4%?'1;.U]NKNM<!
MGU90J`I.!TLMJ&JW"24VO7.XSL)P?1F$&5&JS.]9A+3\1;1YCA7.O-U:`Z>#
MI29Z*%S!:B;#-OQ&/8`;OT5&_O-`OHS2JV_T-@Y_%R*O"<X&2UHH*E=!8X2R
MJ(9])<2C8'O!*@O.!DLZ<-6I#&[XND1.4N&,+'NWJ)ZX0,6EQJX)S@;+(2@J
M5T'3CSK0=*<R?=VFIY]&?BWG4#E^&4BJ5P9G0R0?6NI7X6F$A]@F'A(P#XU"
MX&RP7,.^'I5MC;`+3RA-B]?"RHL2>0B>W-RR>N!LL'R"DFH5*/V(!#T3V#1)
M`YQ._3<:UI/??8G7,$S7OV4TY"I%"&\?;17EIVG5#C@;(N707=4*\'Z,@ZZ<
M^&1W65SFN,SH:RO%%JAP)-^C]_Q/X@3Y*@V`LR&R%!UTK+#MQU1HPI;*=TX?
M4JZG.)A26J4XP9^OMT7*"6KZ#A._".ZC[^XD6=YM\Z7[^15&I5/UM^(.4,0-
M=CVT".!LB"R+%2MM;@R[T$.W27"*ZTC\&UNR*N!LB!R-DE858BYDC;E$+^FV
MOW%"KOB%P><A4C,2?2I\^K$Q6M_@*,GS6?(8+%[31F32UNU;_A6/!!!V:@]\
M'B(#U%_EJB.XD(OP(8D]A'Q,GV<O9I?I&PQ"Z@:C(3/D-T_((YN9-!!N[]HT
M`SX/D6OJK&F%MJ&$K:3Q=_JU:'$98(]28;P#-*LL^#Q$JDBL3F5P%Y*VUGL+
MW?[3P]\--3,,'[*7,/!F\WG^>J7BV!*V`3X/D8/JIF8%LA,/QFUW98W8@IH=
MU':JO-K@\Q"IK;8*5I`:S=3!C.^MB<6;/%7K@\]#)*G:JUB!Q26GCK?ZWY)/
M-2U"?],P"9$0D?E\PQ$TC$+5B()LN2)'G27T4);2"SSX1R]>'N?&(5/'"A&E
M:7HD<M3-?067*"7+,CXZ_(2?B_(0POP!B8T\MU5Z4/%,+ZD,JG/1(:>W39IN
MKGQY9F[1'*?8!#!S((!AN#]DVAF=,[6UT(N?+I3*[:>_>G&4DG%P57@"OAQA
MM"B=NN7?PQ@C_\L1.5>BP_<"KH+GZV?R;4DB>H7:P,RIH&-&>CF>W%V,BJ+N
MI#'G*TJ^+,UCKE`;&#IA*&>C5X2D)9Y-!?]6>+J2E]X\L`Z^RUJDH]Y(*WV<
MDED>6'T=5'%,L7'CZN/.$+S.$F+3+$%$M^O@&_V)_\"[O!*P^JAH+[#$2CF4
MY3Z_ARO9PVS*`*=>)^VZ4VFHXQH4TN%2*P5LO5O*M*3`V%MQW9FK.EC;E>6_
MK=D=7,S+.&ZI_1OE@)48!DY/9MM]3UYW.GR94TQN\GHY8"5HH)W)=^5U:$KG
M+E'WJ-JK\U\&:M\(&%F)'M!!*+54<@@8?\5HGH6WP5Q$$"K4!B,KT0(=D6D)
M[XZ:[DR77(E_2V+<B?'+*X*1E1B`PX"YU="A\3GUO&R9Y0ZB2[1*D!<4F531
M*D2Y]2/Z_D22EN]<<Y430*[K$V!D)2A!:^?0:@LMKRB97\H[+MY@Y"8;I64N
MJ/23O:-T2'?I?9RB![BF](`E+^F6O7A.H)^_[U[%3!'C%=')Q1^F&*,4JSA/
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MK1JQZUC4>!COIKI),!EI(R\S]!Q7=XODZ9W56[#D<>QF=`9P+375O=9CY/VX
MB-^(^F\(IW2EGY0_4UPGM36^^"VXR?]')X=*KJMOJR#9O`W'0%2QIB4OHPXD
MVVCHT):Z>5O^FJRG148WP::-5\625U$'>$JJ.>0':LKY-8*%,POY@EO(RG4M
M.0#-X<C34>85ZL7,U=V+94Y_J@.7HN.4M^2>T[:V"?7:9+FQ/Z)RE4IE!8.G
M7@R,[-T+UC1.]M0I$7'A\GYS#%=)7\O$2@])$'G!BOF47KL&P,C>E6$CLYU0
MT1)?%^[MYUO<XCY)@NG[]F3[^QJ'1#Y\D24)RCWY]W'D%?\0`=VN)3"RE^9.
M%^(=-"ZAY][O/V0,Q"7IHV]D32![Y3(&8G3H((BM"+<*X0V,TC8"%[9BR$(2
M=DK:"#;@V(PWA^W)._`KV^TN-3D02L"`@,-JUZ5VR//0^C*-[;O1#4,*;+T5
M=]#6=L:ST]+LW\W5):N1GCL]F6WW/7G=Z?#=KBY9O3VL9O)=>4VZ!9ZRY1(F
MZ]G\&@;)'S#,T&R^77<V"1NC<X@#/)O3$CEU<!?[2.K[T=*XJ2`!-<24]DQZ
ME34)]QU,_D1I*5W-S3&+[A#$65($)@F>9%=NP(['6B\23#]L"_W=F2LWEIAB
M3(Z!>=Q$(SFK8/Z4UK7C0C<)=2O5'7(>L>1]#/"?UPE"-^1LEB"</K)'=]LF
M[+CJ;8'.LX!#+BAV7UTA+T6^)..XK*I-?[Z5$;ZCNA:_E'F4_XA#HGH8I.L.
M8YS=B$W_OT7D&49PR#4FDOPR>`M\%/D]>D"]"9LA!!;QWS.!0VZXC=PWT2I+
M\4,2O\"7O*]2\S28%A'P_-HVPPT.A;E$>RU>.<X1+.<`9O/Z$[-7WP),\[87
M3R/EB;T1ZWV@5O5M!BJ8/(&UTE_F8^L#)&,"J7*R\XY42O5LAC&8!$Y)[Q(P
M)_)H[SM%2W^P/==H[=&JWPB8MS%6N@RNUH!=!RI#LO/U[\A?D/Z1A\G3!?HU
M6)VO;R("$7I*R>*<YQ&BTI$_GJ]9C=&3F[IOUK00=MV^,O!EGN!#6&?@3N:M
M?N?K>YCG^A1[G-D5W'(_'P)W6=_;M8X[W.I6QGNXE.>49A6W[OCFVUF&2U.)
M[PP55QSD>N!QT&U>[BBE/MQ&.;MN<U[79R.Q)[@[(Z1=/)0#M^Y=6)`:!G'(
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M=GW&3E!%#9-)1-$R3@(8/H4QC/X'I6D>E79!<_TE%XC>^9`D%E6L;_GVJ2H:
M;=1QB$3@KZ[GZPNB^2*FD8UTWU65\"6[BXXMNO`B;N>M1@^=!]$7.#I(5[Z.
M+5I_CK<'GFT[B-00[FQZ'.H?KFR?W.DH!\G(3K]X'20XO2"%*=OS3)>\V?PV
M\(C%R#*9Q'[FR7*UMVK%KD.TQ[AE[!'::VYP_Y8+\X2\./)[HZG>C%TOK`$X
MVZENTEF;B_/\&B3]\51NQ?([R0;P;*>Z2>\2.=B%\8**47Y_NEJ%01&+)\90
M7M/R2\AZ<5-4UZ0WJIC4B1;4^T4.@3#DA[J)*UA^UE@O,F(MM5P/YW%#<W+B
MSC]_CU+Z72SAA#CE+3\DK!<.H9):KFOS'.7H_3+)%LH3&*^\Y7=^]:(A5-+H
M;6KDH6"5SN:/:$'?ER9R$R&2^`V&UT3GKT_7/A3CH]Z"I8NY9A!KJ;;)B]1W
M`1F]:1RA,D.V+"R25]Y2YO!>[EZY0B:WV7R1-R+A4B8>&"V:L)GG6VAB!B1M
MU9(<;NV%JGCU4!6_"%5)VUYC%[PI57YINA,4<RN(05&NVRX"I;V0O)@2I7J'
MC"AI93%&;U;1Y2.:9"C1),J0REW<'[$DAW/$?,22?,22?,22?/>Q).3S<9IV
M,;ZHVD`B1Q2T,'F>F<$_'P-_@>YAT>8M?(F3_&PK-KZLGMT<Y,K65U'#),L_
M)6V]/<5AED^5DO[.*.O<*]><3LX1W2@IGR#_]RSU7H,(QU$1BO6(,"(ZOJI$
MJ*G6=^XY;#8$;=0Q2<WG;K8;L@&_"1I^MNLXF9(-PQ*^W$17]!FP<#WULA3=
MK5$8!_XMROY$RT#"3&IIW*Z36AE0;;J:I/Z_1L$;2G">+O09?8/X[I)(3'Y3
M=4&5D=BJ$<L^:67XVBMETBGPW_%KA'^/5W^2V6$KF1@641W+'F9E%*0ZF&3Q
M;V'@A_`])R/$IMXO:=E1K&Q@CN2RI*6ZYIP'%$5X';[!2+9TB&M9=@1WFE4X
M6I2F_\7(-`*7".,+N`I2&/Z6Q)GD",<K;]G3JSY]B.3?'-N,[&[C9$G6B-<`
MS:^^(;*^$]S+UU0EVUI91<L^6_4-K9(B%0AN1]@?^K:%(;?O(;CX/BI_W+9@
M!#N8<C$;OVZQ[X?680IW/`,N=1%7G`PN]96#.":T!3(.\B+%J&TDXP$N31SZ
M!LQHD'<F.,AUT-VA1;OE>^AFB*B#!#PTE'#HR;[V:63'AHBH+B^D<U/7[`KL
MSB:DB\%=V2RTM_QWD[IW;)<=W.G.;-/O2^Q.M^^6O7=LER14L_J>Q$9O):(D
MB'DLQDX),#9#^IE<,%DJF'1J%Y_B'O3VRH"Q(3)/NORQ+,.U74U8D]OW]L:S
MO91UL^(A3J;/[_'S:YS1@'DR5NB]V10AR<4N41TPMA(QQ.Z$#!-+93?8<9O?
MOHZSUK9NU@%C>]=*VMN:(;O))6NZ2%`>KR]:M1J%P-@,N6)\X=K7PNBEW.IK
MXAEXIQ@8&^(_U%:P?1.)[%@3V62\;%=#.K&:=;3H03+<%.33)7I#8;S*98S\
M!YCF%Q*+W`*57!**KVU#8&+O"016[V7M,3KI9'`8M(.$)Z.]QPH4[2X0W.A%
MU_*SD?^TBB,<)\BOPD5;6ES>`IA8H2NZH*"HC,F8\09SKHB%J`Z8V'MU0-'Z
M4O&-GKE#Z!4+UB+_C]H*(*H$)O9>'%"=[:7RF]PJUNZ/W<$(+DI)E"RO4A=,
M[#T8KPB`LAHFP[>?T`HF^=48.O&A-`W;(*%6&TSL'?P5L6BAB,D@;=(/LCGI
M$AG-+:R(@:@.F-BC`10M+Q7?9'SV(_F4\@K++`PF5L(NVEB8+[?)&.VIE\XB
MCR9NDUPRV"L()E;B(=J8E"VSR;CK:4B^DEX%$4Y1("$&667!B?/'3Z[81L.L
M1<2:VHN4ZBV`$WMG44.94A@*NA3.@]Y0E*%'Y,6+PMR;3$5W*'V-_6:!?S-?
MNNS>&#BQ=^IM"5H3]IXJN^/E?T;>:Y3/TT\H>2,G?'P18^'KB9P:X,3>$5H+
ME"*]'!JQ=\0:*8KH_4@94KM%P8F],[<6B)@*F>29RF1MF]C,:\3-_,4H"D[L
M';%[V5NHD$F>Z<"I!4_L';O[X]-649-DU6ZBQ$OV.\K<LN#$WC&\/Q)<C4SR
M4I<(>TF0-SB;/\9K&*;K\OO/<?T&(0\'Y0;`B;T3?']PVJEI-.MP\?'9O+JQ
ML7U!G<NH\*N`$WLD0']49(J9Y+08.=F+B!P>"MP*X-0>9]`?`[%:)JFOC=LP
M\NN^=/J*<T'R\QE&245PZB2!H#HJE-0SR:)5FPDR54(_B*GSY0W=0?J6'PQY
MJ`@K@=.!'O$553/*O3TD\;^0EUYAFLR(+%3TU",(N-DK"TX'>B@7:Z0GHP%O
M8Q6_1YNS#TL$^;+=H@EP.M`S>2=%*^",'-9KPES'22F-`D3;PN!TR`=VODJ5
MV8V<V1N!*11SFGVM>A0B3J[CF$8PYP]]^$M2E"J1UN)XA7$Z+=H#IT,^S??2
MNL+7R-G^.HO\YDGI*TW2MO%94>GH3O+Y/?XGV;UP-]'MF@&G0V8$NBA;@6B$
M+9`)E*<3H*(0B;HB6&\#G`Z9,VBM:86=$=[@/J/*DO65#'BJ%`^?W7+@=,@,
M`5.;RLY&>('I,LZB]`$&!/LKZ+V67^8&$;"+@[,A<P(BI2KC&Z$$GE(RS+ZN
MKA$B<V-C,>2&UG%K@+,ADP`2O2H4C!S_RV]?9KE_C78#$9//+@W.AGS@%^BT
M<30:O=!$A,8!^9!PC\PN#<Z&?-H7Z%19WM3]_'F<+*E3^3R.,NHSH_<%]S9L
M950`EWYIUPPX&_*YOXNR%8AF'/4Y<1UX9-;,WRA\0_[Y>ALT3C;;2P%PLJK@
M;,B\@*J"%4"FLC:41-!L?IV%X?HR"#-*$A6)8Y_2V/OSZB^BS7-,-8ZC_#<"
MS#JT!LZ&S!#TT+E"U@@_\`](_1/IU3?J1L)T&KB/4S+HRUON6_<K#TSE!L#9
MD#F!=FI6D)F/'7AZA0G"TS<8$&"",$C7Y^M22-+32JF5@@B46@)G0V8&.NI;
MH6GH3DR>1*HXNLWFLXQR\63H(]+75C1RB\L8R&N"LR%S"(KZ5>@8817NX^@1
MS;/(IR/^)L)ID&9%ZX)@0F$E\'G(#(-<M0H.(SS#0_$`[EH4R;DM`CX/F4G8
M5:0RK)G[-T12GTK[D,0>PI@(*[`QNS3X/&3J0*#3)F;6S`RSW4:0,Q>-"0TB
M6"Q1F\,8?Z91J`P^#YE84%>Q@LF%./];!#$BRU10\""4A1HQ0!05!Y\'RC%(
ME:J`,O,@8=4G'E&$WF&H<(015`&?A\P=R!2K@###&521)=,%$6-!T"]V<MR%
MFU,>?![TN5^D565_,^\45E^^)O-E2/=J,`R;S!X^7Q,-5S#BAIFW:@1\'O()
MO[VJ%7Q&3OG;P*P=MK83?"J-@,]#/MNW5[6"K]^Q7L]^8>IY298_'C"G>\_R
M0(4OLB1!>9XR<O#RBG\(MA$M6@&?!TH-=-6U0KL?3:!K=[@HI!5N"<LRX.>!
M$@9L32H<^O$#NN[/LR+V2W9)@(VP'OAYH*R#NG85AOVH"#T8UD2\B<JSNP`Z
M5G'P\T")"ZE2FUNC#@#%[E8JF$EJ@I\'RF^TT:]"T@5RXPF1A35(UY=H%>-`
MM"'9*0E^'CBEP=*G0H;+9AQOE;TEC3;5I[]IZ$]D09&_S=32L`"]P10%V7)5
M<,,H2VEX&?[1BY?'N26N_LIR\5(8A/CHT/V">M3.Z1M:=)M-5HLBX]SV`MSY
M>ENDW*]/WV'BWU89>D1=J7?CH-I''=(DWBORLQ"5[D:1_)BG0)X`76097=\`
M9C8NY!B]/R;UPLH9K3H-PT_Z0Q7WTU\],J60P7M5I%;\<H31HJ3NR[^',6G[
MRU%*CBV'[XB%,N0KDM??&N6`F7V1TK,`1D#D'"5W=78GP5-WG;=*1?Y#"*-[
MN$32]U5-?`X8VITIOU^W!R]GMC"D^T=GTFI0VT]`.-&K''SF[VJY"N,U0GG<
MXBP70_KX'+<.L').,#T3L'N(T`CN3!Z7*`G>($V@<+Z^AVF6R'82[`K`C#_5
MM2T%7WF'DA%NA52:SUG%@2'?K/+BSC>T#)BF$BX.M!ZHN+)*ZH''P>6NC`^6
M+G&-<L"*?US6]=E([`GNS@CIS!D4JRN>92E.8>0'T>(Q#FF"!OI'$]R3\(/`
MBKO](,2+,7LYM'IJ5+*X+7^8#EA\"UCQ_IOO'\;[X]9\W\]\^!N=Z/%-5`39
M_I;$0F^<@:^!D940AZ%V1YX%79H<Z6'V!N,,^9?YTS>%K,6=J]I)%U<WKH3+
M;^O&P,A*#(:U#M7-0%IRK[LQA1$3S5%`SQ>;<6%P"F-\#8RLQ)`,=0KC65!+
M>GHWNN3VYL,ANB3C:V!D)2YFJ%V29T$MF?==Z9+;V^NFCQQ[WP(CMTE]Y[HC
MRWY:WB1PHS/6#/H/%"Q>4^1/WU`"%ZC:I3PD[(P]!Y8`C*S<`1MJQVUC52T/
M-MAVCC-/9::ZM#XIP,C*O3IGN[5FRVIY`\.1KEUI9[UWMQ($C*RZ6P;7P=L;
M5\LK(X[T<<:)U%8O;RD*&`W3D62KGW<QKY976]S8=]<.%I;VW8H2@-&'D\J0
M5?4\>Z.Q/[_(]7YI?=YX1!1H\GMZVX?>[*'I%5&R',OZ]F&E`>._G_?+@H6-
M/CN42_Q)P8J?A,<+M+L2\51B]&`K<H#QW\+19L^V1M]<.OQ0Y":SM"`*&/\M
M7'96S:OG[2HW-AK\#1;/!J*4;Q:D`>._GT/0@H7UO.?EQF&Q9O,;HFH0X<#[
M`X;9@=PRS6^"\8<'49L=]3Q8YD8OW6,NG^.4IG`[4(=5^3P8?S@139A4S]MM
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M\#U_7X0+%J>DY?0(7890$QJ17NX,MJ?L!0=^`)/U$]RL&C+JC5?'5&:``W!O
M0I4<VAK6Q*,$\&Q>ZXMRKXFTLK%+\.KLG!`)#GIJ>CDTZHRCZ,I"9@S.0ZQ?
M&^YJNA`Q=MRRMF_<JPT+QK+%5<:=(?0<I%2[F\@/W@*?/E<F.;*QRINZ*GZ`
M(QM7'9>.U;M"_B-(7Q]16&05>PU6S_%5E-+@.-F<U[(E8U>EU8]L7'P4\510
MT.'!>$"@75GIS"-^B"6OBAC`ET&"/%(+%Z]#8O)=FN]'O`BJU;9\P;O+4&.L
MD2UT=6>@WD1O").VY?1RHZ#E:\W]$1.HY9!/[)$2#))]S*:,J>NZYO<N314<
M2N&8"R9W@6U+&;M!JKS/:-I28.^:P.Y,1UT,[LIZW][R#D:EW!';+;.E%()&
M.<OW3G>[,]OT^Q*[T^WOX#<UJ]?+6;XQJ6CU/8FU+*^\S6I^LZJ\4H6K]\JY
MFU-F:<OW\A2O!LD4<&@3\[>XO&R%UY-U`@Z;>BB#N#._7J*7]"8BELER;QT[
M/Q2_,!A;B?#K!B]'?(<FA'***X,19\DCS1W2R,&W^2,N_XI%F6(ZM0?&5D(&
MNV':74.'XG6N89#DD\,4XVQ9S"6/`?[S.D'TRC9*R$'\$::BN5RU"3"Q0BAU
M`[>54@YYGEER5Y?S_X@I%Q,20W1`E-T(F%BAG/1A*E#+(1>-2'+)PBFK"B96
M\LGI1W"CC$-4E4C>2\J2HLCO,1;K38")E31I^G'<4TK+<QN<LZE8$.S%6<1;
M_EK5!Q,K9$P[=-IKI.6Y"`XTU=:I>"'P.7[($N^5G'YJ=S5XJ"A4!1,K/$T'
M0%25&=*S!LX_[3JQ0C?9H0YX^KOT>H#HJ="=RT*Y:O<HG<UK3R:(ND_?ML%D
M2#R3%FWU9.(7Y7?NT9^GOA\4TC1[-F^U,/4],!D`067>`GHRV+NQ,-E_L'<R
M((+,E/YZLLM;[E$T.<Q=[`?SP,NK7"+L)4&NR#3R>5GG#_%9<#(@GLZX(;Z+
M7/#;5X+5)BT=WP`G`Z(&]6K]7>12S_]#L[EN-HG2AP$T?0:<#(B2U*ZX<RG.
M>SQ&4.0'KA;O#;5D\H4)WB?!R8#X4:-&&%3R\>_TD=>3`=#!%DTCS0Q^P"[Z
MD,0>0CZ^)F:L96C<:"7:3$GK@I,!T-#MM*FP<X*(%K%=;<%LWQ@X&1*-W$V]
M"FX7:.)IF#>.?/:41=U8$1:M`FH-@),!$;XM5-J$)3D`Y28G+DK>R*K`%OX^
MSB\*H6(OC?.0Q_K?+V*<WL?I/U'ZB+QX$07_%@YP8]\$)P-@@@]CA:J/N<`&
MU]<S.O'!R$,W%!T8/F0O8>#-YG-$9T+%%5[8!C@9$'/;3JL*4R?XV&TVA7P[
M21:QO`>+UG5.%7`Z)!Y4I$0%D`L<9BULX0$FLR3/)>SGQU,%K!1J@],!\8ZJ
M^E0(.L$HBC:*]^@]_U-GC_NF`7`Z)!907:4*2B?X/;;8>?_K@62S/C@=$O.F
MK%&%HY&XQ*\1:?P]"2@Y7$7=\>(76&7!Z0`()K'TE7V-!!?6OSI=)"CGL6HN
M0!5;L^J!TP'P.>J:5!BXP.6P]J3;"S8MM^C;BN!T0!R-@BH59/WX&*54:Q<0
MOUXCY@(A*`U.!\">R.3?W/@Q;^5I2NI%:*UNZ7H-<#H`ZD%%A\KB+A`'A6+;
M2'G_7QE.EXBY1$OK@-,!$0-B+2J,G"`"NOKE"Q6WEW7Q+'U%R?,KC)CQTB9B
M(EJ*`,Z&1%0<TBA5A^Q'?$@NJ&S\(>?K\E>_QR'Y+G>VEE8$9P.@,%JH4L'0
MC[W@P/"(%@$5DK:X>9A*82LOJP?.!L`_J&M28="/=N!@4":4J5AA7K`%MRPX
M&P!%():^LJ\3435;,KC6#1J9A=7X<%YM<#8`>J&M/A6"+@2=Y&M;Z9L5G6T;
MY<#9`,@'ON25_1TA&^8(X_SSG(,7KR@X&Q:AL"]\!0270CC>:G9+6FWJ2G_3
M4)9(@R)_ZWEOJ$O'7Q1DRQ79\RW)`3!+`X^(_J,7+X]SM6EJ>O171E:TJS>Z
MZ[M$*0Q"?&3A!8Z:&+=5$C#1/,JI`JK=NCWQ\]2?ZJ)O,H4:Z-8P#/<[LXH)
M.9,]1W)^VBLJF9_^ZL512GKJ59COGKX<8;0H3_3EW\.8;&^_')'3![*/WWHE
MRT#+J0%<2$?+P4@-T9HB[N0R8P@I?R&$5P?83E<K,+DR1EM5OEN47,EQJQ,N
M![/?[D@KS<?*+`^L)L,5C@\EC+9:N#.<+E'^>'3PAL[7]Y#>TY6L2>P*P(7G
MR%HM27P]'$KHN!62/BLDG>=8Q8'M9\;XAI8!TU3"Q3'3`Q57%AX]\#BXY'1[
M<=[J,V*\KL]&8D]P=T9(_F((=?TDZ;K^A.?YNOX7V?L;RHT`%]X6:[7ZM-/-
MH5RS=?&D,]]^86#[M;!VAI>#MU7+S='7"2-7UB938#FX6G5]+FID]8$O]DA@
M`\$07,>0X24@VZ&<2SY=]G*%I!H867V=2YU*55;&H</.H>XDC.S%!*@@PJ$2
MU'5S9R&JW8RYH)<-$SKMGT,LW/;Q*^5/OP\..8D^L@'(\-,=T^_0M"'D'_\+
M4$L#!!0````(`+I]7T72\%%`#W<``(13!P`5`!P`871N;2TR,#$T,#DS,%]L
M86(N>&UL550)``/PYE-4\.935'5X"P`!!"4.```$.0$``.V]>W/DQI$O^O^-
MN-^APN?$\2B"(VDTEKWRGMT3S9?$-6?(0W+LZU!L.$"@FL0*#;0!-&?:G_[6
M`Z]NH`KU`)!)K2-LB2(K$_@5*A^5E97YO__/ETU"7FA>Q%GZ;[]Y]_6WOR$T
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MR1)O>$OS.(LN4K=7/:)>])WORR`O/=ZZ0[_0>S]D99`XO7&'<J%W_4C=YK:A
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M^:$T!7E8OQ[[<01:->*;,&/>TK9\>[!(UWFV\1.?ZKTRKRGZQEAG5#`%Q(*&
M7S]E+]]$-/Z&JQ'^@]`G;[]]5WEA_X/]ZF_RN7?T*>:/2\N/P88.*)`?WUU]
M__V[/US]Q[OO_H/-PG?O?WSW_=_4]`OHC:OW?_K#'][_\*?K][^[9C/ZN^^O
MWO]!\T:]=58MK78<X0.75@W+H%A"1BQ7R*%HV$W#$A)QQL0R#Y(K9N6__(GN
MQVRJAG!I&ZK#H%@^U4`B1A(V%-1"S@%@<2LQNI(&K8*::MXUOV)6*.*6Z#()
MGFS4_Q$AI-X_QG"\5)J_$SX`C:+W>VU0S3ZX:D95^B'5O.OZ;)?G_$EQ$0;)
M7VF07Z31.=M]FJAS-2V$1M<@.5XQU5`BQQ(^F#G2$>'#P17[3#A`]/O8ZE*J
M>"7AO-)0;S<>&%L;)7](!ZGCCQ`H]X[\[V@TO,]+@^KWH?4RJMX/B)99STT8
MW%2U*P@A]+H*@W*5R(%X%/K4`$`TN78E*=7X,-4R:[ZU'9?L-X6+.N^QP*#9
M^[B4"ZGK%XC!Z#3^E&!06`+%JC,V"L?T2\J*E%*5M"A5P@`QI)T8PC*VJ"J-
M"R(CBP$!M1O*%39J._J42T0W+^.$YF?,6CUE^5!L<R28>T0.'^T_QJ,($XIA
MI!Z'QEQ,B`%!I']P;1D&^@]I%XGS9YM-EMZ76?C+_7/`OOK-KN3)4SQGRR+H
MK^4">`*@1Z>*I@LJ(LA.B"0D'4IP&[(D.,B3`X.U.7:,H&/A)E_KH'@4"'?%
MVZ<@V$HAHTE9U+\YEK;JUW^[+YED<Z-WL[Z,TR`-8V;YLB(>25X9U#=V/*$L
ME"7RXR5[&B0\C9.M4DK+`C"#90YP#1G)UJ0A)#6E!BV8D7-9R%K+9\403%P?
M@L=D-*ZFHEK:^"G?7KW^?A9#8-/"IGOMQ0V6?KT,&B@%"=@*/TN"HKA9"SNY
M^A(;A],,&*$Q/0,8>R=N?`A7QV(0T\!L&%);,Q4:/+9$M0;M#$B/R](RU7V!
M\VP3Q+UL497^&**$LAZ#*,86F!R(PXY,"0#,HJC7DM:J#)`M;EEH'M-B=<M8
MTCRGD7B7#W3S2'-KVZ)C!6Y=M#A[OHL839K1];J3!,@LC0NRU3$V?.9F?&&:
M&1P-'QAA.S44MF'?5<<";`NCQ:58@J=HQ&M&3&@LE,'2TV^`-/0P8G0VG<U2
ML,)ALU0X%4OP#(U8S8#M[3L,`N:^HJSMUC`?&($[][=;"A:P=DN%2[$(S]$(
MV(R8D-DM[=(SL%O#]#!B=#&=W5*PPF&W5#@52_`"C5@M@`VIU=(N30NK-<S'
M7-P4-04JD_CP.7.Q1$8L0.H(C.)2NGJ,!(W83(CK[7=C`N,-QKY,@#6:3@8#
M2;.4C:=TPX^/2%%_OY)]OVV#M!#?+\M)UJ'4C?V:B`ABO([9;S['Y7.<RC\\
M9TE$\^*WA/Y]QW-)XO71&["'=-^'S4BR)T%)RF?VMZTXUL[6XK_BHMC1?.A)
M)=ULLSS(]YVG<*8;21\7`D<<4<&'::>2S?P16W`_PT*QJ,LCC-!/IOC8(.KC
M/1@R@_(?3+&JU2$G0J,09\'X]CVX:IP4EXF2%%_56$T.C?ZGHIS,8[122%J?
MT8S35,KSDLF!K]NHY@'I-VJ0*34EIT&C**=$]O9WX/IQ"C@&:G'-/Z&I5AP:
M_$^E.*GW.*9@1MU')0.P;+/K.*57[$?W-+,.!_"HU!`J3=(B'T;$.!R>XPPX
MX,-.RI5FETS6DB\M*ZNBH&5A6M%2105U`-)[^UY1'S$`2TE*R]<&-P_Z1:(]
MMS@B@5G65?D7URLO"B;0AD"%;7@1G9"ZO`_26RVF<&H8<OP?T=D"[9(S,@?#
M'!;/*PZ*YU4:\7]=,,_V)4C8VQ2K\BS(\SUSRO\<)#OC2RJ&S,"RCPVQ]M8B
M(Q!U<\4/'=(3OHVHJ8D@1V%QO(&&_`?:DDZ.:MLK=@^$C'_!1_H4IRG_A&S#
M)M]L)L!M1P)`N)3]7@D4+BG=1A'I\]2-."VM:-E>>1O$T<67+4T+RM[OIGRF
M^8$1L/58C%A"^R]FN(\7<$5%*C*QE@4A.?)S4#DW?EBI)"L$V$R`#2LO*`#;
M(?@O0`N7R(0?Z-[";L>\I`QJMF7JE0<L2T[O+)K&C`B&]XN7G9XV4[[VX:X&
MC>W52JP!W.5M:<:\EW)_RZ98='E@9G[+(VL?J8,1U?&"MYY:I'U3(H>?$$$@
MFWW4)">$$2&SET[H!"S:PDJI*'81A.%NLTMX%R02T6U.PU@<>BVK'>8'C-`-
M&!='0_NO8;1\_C,S,G&Y/Z=;7C+$U/3WR."N"QR_?_\46H[@TL*'3"\HG39F
M2[TT8.[_X'H9R?<_I(%Q;MTBY?#&L7E[LP,5!'%OI6,(X<?ZO"^<`VNT,JW#
M\(M+WG4</,9)7/+;WJG,GZ@262Y$@HGM&:TY/RA[9('X>,UU2!N7EEF`&8^X
M["V7#[RKU>G5]=7#U<4]67T\)_<_K>XN?KJY/K^XN_\MN?B_GZX>_HIB;S[A
M)[P_2-VJ/NB;<[J.P[C\"HU1MQ53K;4W9@:HC#P/T76<H-T%+4K->EWD3%VK
M<*:#52-)6B)4;I(3F`X1OD2!<=DR<E,T;!;?-(1AMDO+XC;8\XQ:ILK8;_(=
MC?KO:!POMV$)%DVWPMW;DU34I"(75K!B0(:T#0J+/Q'F;0=S4&&NC[O0V'J'
M=:V/D5OP`Y;A.RK"IK=!KA=>_>;+B">T%V"(?$Q\3TA%22I2G"?2OFAU@DO>
MDKR:@RUCB*=I@LLB-XL5F#!<6I0_9B6MW\C2[`Z20IG781S'*U.,:H40DZTT
M!U"+%1K3IUE#6A,W1+?T^C^G>?P2E/$+-?(_M1I#SPO:=(T@[;5Y:H:C\"]G
M@J;9R8(;().E:61XM(S@HT4.06IP<V.TSC#(C?O;'Z9*S1GRL<^7L@`P$.9!
M8S@=MX:XI-@CR`MO%`]Q:`089\A6N>J!5[OY`G`+8BY_T2G;;.)R(ZX"I-%9
MEI9Q^D33<'C]#U]1T+$`N]2DQ=4+F;>CY8VF[G@4ELT/3ZC#`W>W97SMZ6^T
M:.B7+[=@D:HP<IT>-$EAY*Z^Q=FV:`'8G&579]B(S(T'F&@F,'XE)6S@:/,,
M\!T7FJ<8N,X1P,6W3I$8J_O$@Z10AG88Q\!EKFXYIQ/R[MMO3[Z5_Z_;HG[]
M[3M^:D!6N_(YR^-_T.B$?#MK)UC[="9;M$4?;2'1_D\.=\O@!@=P,R2-;ST!
M_\]O:W@OG.1?R??M!'0!IUE:%8**Y/T^1*UQ#215ZYX,T4&X]U5'7I6*T>K=
M/CVT"S*`:,C[;9LNBU$GY$HL,D3NASD0I1(Y&=8B[]Z=O/O^>S;N7R#5R;3@
MN4(YU"C?]75J.PGLSS^<_/[=#R>_^^%[H5B^^]W)][___N1WO_M#/7A8ZYP0
M]K<M#7E0.<%W=JN29R/OIT>\>'I%%(DFPT%R&\3157H6;.,RZ"T>92:*BAPL
M]4F)IY<YT(PD?"BY2DDU&(65=P+"[Z2_C5,2S@3$X;:Q,0SQ$=3O#I=LI9<0
M?6*5@G9I*;^C91"G-+H(<EX]IEBU%U"K#::M%V+"$=HO,4)]O`QK(E)3D3<=
M.J+*^P<UW4Y`5P>7D"<.GOP@0:7TB?-'!0K<83`71B,7PH`=?.35U)\8H@2[
MECR$PBAJMRK+/'[<E2(A\2'C(90YCN,=+BU;0OIM42D\FH8]SQO$+3)"(,\E
MBX/XL*R&C<`CLD!@=_7,&XMKJ3LC1*=-Z;K3@/TAG+[^H%OA.K.7'WYEN!O\
M2@6KO\3?)\-VF]@CPT/!#]H+-4!L=HL8E<OI@$KJM.0(&[R6G@<G_FO$GG)E
MX:*.,H,]Z6/NV4TN:MY'(@AW2W-Q_N5V^*?FAN,\4(-V](B0GP7>Y$12RS`^
M8?3RN!"%?S@!UBJ\W<2UT5A]NU5K<1"F9`4KE_(0NCU[MO4-QKA!>P:C:$?E
ML3JF;XE0^0@>^"H9[!TBH;.39BO6M*:LCA4&690GMFYV\9`##EMXA,I4WF8Z
MN/:W=\9X#N4K'L2#Q,X-K3P+VW9`CD&&.ME34QBT`W88+=HA7E,1`\LQFQC?
MQ^QK7O%5#D5OG4V_U:'Z`,X0\Q,93P/=Y0682>:[A35B!7EQ9!RG/N6,[URS
MQ7:N]B<S7AC'=JP@GLFDB'@/&*ENT'@I%M(W>F5FC`^@9O'=A&M90?LK>IQZ
MC8)[[^V$[-7LN@W6IVWZ)?A^N_<N=IMM)3D"JSVR+1V2*YCL\&F`F&RNH4VR
M!9*C[.PX)?1+^,Q&4[ZSJ;J,%[(^/#_M8K\,L\TV2*<_QQ.UYWEMD2509TE4
M?T2,3H=U7$1%"Z[H/"(B>E[HW`O]_GI8#\X9"9G4P[`!]PHB!R;+U,W)@(P9
M7*5,-].FP;MM\7XE.927H<;33VNLQA3D9DUNV(92]%Q"UX3=')$<29JA&B1@
M!FMDO6D-EHIV\73F(*'%'7VAZ8XZ]&WKD4.;I3Z>GJSP$:BLS?@[5W]$9T<4
MJ\>L.,(1[=(KO]*2Z5/5Z+2PM1<:!E`60X?I>$U=*"I_@Q@&FQ=OQC8UD$$*
MB-BN"0.CH*9>_E)=0=D\\`[>YTQ$DTPT`*Q>R]9(C#"#-AEC6/O*6(X7J:\=
MBKI--J(S76=H.0VS/*(165-DQM+K:T4M1=.P-*?QYG''9ECXS^A,K)$D&EZF
MTW%:6L/\2%.F[!+>CR':Q&G,%1T/?ZEUS*#"'64#98K'\1VOU(I"MB0YH)E-
ML[B8:C]@P0$-&KMMN!JUUGN,Q_(EV=ONR[8F^Y`6VD(?(>G7(9^QS;1?/77C
M]ZY]673V9V@5&59+[Q`N;EV".+W.BN(F/8\+>;*2I3=KV6;TG;%Q&>$"9EO&
MT/4T,",@;SC)5X2MM0X5]X!F:M1K?QIIC8L/YH"B0T#*)NTP!A,O*K-2%C"H
MX'P!(]VA=P7T+,!#7;;NP``#:)]@"),Z4@05[/*&("_<JKKT^>MHY\O#YB^?
M]>)UZ)P<I8`8>3I]:C`!E\=*7/581[&[I.#QZP,<:K'F`U#8>+,7_TA+DG`S
MR)=E+1=9BJ$3C!F`:X.7AX^]]X7`+.K>H5N^?6":';Y&I4M<R_H;,(2VX":8
M>Z)?/M.<5,D!;ZKQN`K6N<.**UB5F418%]]XF1K9S7%NRV<0L4TK+30'78I$
MD",RN(RAX_?OY]7($:A"RA:OK0B3@6R!_5\;,'5I<*&/I"P=TL"U&.ULKYO?
M.20O&3"$MI$FF-5M.4](-_!WDY+NGQ@QHI-J%Z!U1*E*V&=(UT%<7ZK+UH09
M51(U/'#M_5WPRH^9U%%<%>S(J"WKW!IS%O3?)'Z?'-R!,M9AE@UI5=S0[&-,
M72D-`[B6Z&I,_9(([5CP;8H_&EJ2X:T)@HB%#9`J$&D$!<PG&Y6=D2;P*NK%
M=0`MM6%(_0[SD!C:_SK&,B0AM9@++PN12V7R[@E``-7[I6L)3N:9<.<C$=<)
M!_=*!B76+(1S0+FTIJG;`M2U)$Z#(@YY>F.<[$KSZ^6C;*`\CW%\O:3^NK%'
M4__EA`@JF:PLZ1!D>M@C:\Y.>+64L+K,S$G)6_+8((R&$8+9=,,5JK7L8SR6
MEKJ_T/CIF3UXQ?1\\$0_[C:/-+]9BW?K7/\<%T:M3G)]"K3'X#P[QPN^9D0J
M3D2R:BNN=6]/@TOYPG,25'/2500'5ZZQ:(59UKB%@79\Q/)==:J+L#?KLZ!X
MODRRS];W\?0\X#KM:)$I;W+SB]R<@`@*;!>YG5%EAJ@`VX^,K\211B0:!@![
M<?X2MWGV$D<T.MU_*FATE38I#RO>>50V+W!--'!X`K2-=IJ5(8=4+.6:#3G=
MDS><$[E*OR)MDE++;4XI]HH3^,]&1Z@O>7[0$/Q>/@-TI&$"V*O[G\CE]<U?
M[LGEW<T'<G-[<;=ZN/KX(UF=/5S]^>KAZN(>81J'LU8P#0K8LE^^-?!_[8I2
MW/A\R.XHG\PXH0?1C(?,7W,JFJ[.\6RXIL2SS&2_$7#S&-YUL'D0Z45@^9]?
MBU[&,J-E)FY\RQE-ZT@+^RW_.>23N2MD>;SV="N`T^N_TFD#\WGGU(8C/:1G
M>/#B>]<J*$>CLVS#C]R<;MRJN$#[RDITO3T>'_CVD8\DW:&HG#YS-+RD784F
M[`Q%>T]7OPK-*C(-LX"\M\Y^3BC_@=^JWV1Y&?]#)5V#FLV,%Y3O9(A4=V_\
MA#2$LG!$AQ2%69X`([KL69L5JK5_1HS,Y2\HTXV0JF]_>/^MD"G^&W$;]28]
M$RES5^EE$.>B`O_-NLT5,\[3L&`(9;EL,`^F6-ZD1!*R#0/AI%5/C9MU)X$6
M1]J$-U;`]-DH"W?<]1M4Z`@`?XTB9=8'L$B0?O/$B`T3AM%X-=9Z2^O@F',#
M*%F<4^9QG5/Y[\[.YBS8QF60.%0Q-N8(6-C8'/5`96!!Q!M,RY^^XDNZC>M4
M+'`%=;P@RT5;'`421#$)X?1UTOQQQ&*\T+ZIJ;]BFJGZUG&*)UIB+[-CE:!-
MV2'23K*4B>NAH05CZ/B'S1Q8JRK)`?!P?S;HB(1XJI5H$4DQYPHOTK<YW09Q
M=%[U?ZRO8*>1N/DA7]?=^3#CCL<1,9P-$TEGF\>*6WW96AAK>:%FIIIKTQAK
MQTFHT=9E?@1<>>DFW#%&:5DY+4AN;T/#1N3!V"@!2V_&B#6\&KR73;[VYU34
M:[.^N&3"$9\O,X#:T(FI*4E-BBBCR0EG`RB28UZ!JZ):LXX^2H\=O%0V;M-U
MN\6=,"(RR!6/,S*"WGJ[T6'S:J(CMM"C#O17$3/0K&S7N,$02WA97H5AMDO+
MXC;8!X\)]P#8;_(=<]O:U_6WNF9/P6>)#6?'4.9K;J1B)\^&)<.N&D!MM!VG
MI,&^[6`/*NRS55*=-M"R)'2$CHV-JG!T=HP>@4YIWM&$;W1O@URA+0VMSPA;
M/"[0&'[#0,RQ/CPA%2=2L4(:B;&%;Z0`R%N25^BWC%.OE34B+\EH^5NZ27J>
M>&]HV?I&-IRA_2&K63"ZB364YX_(V_$&/)1>/D<IZ66N6%F`/,BAQU7]98(E
M7-U3,5J^X(Z;O>Z:^/X8%FU]E;[0PN]6F`MGL(IX+K/0]]2JT7,J:*<*>5.@
M.[X/.X063WC*?5GK:]+9LUU:H)D36%T_6H5_W\4Y92_+]$RYOV6?LV2[PHNZ
M/Y&M^V7#&=K]LIJ%WOEG1<PO7E;DI*8_(8+#B=B'7$"UY9H1.WO3YX#OJ;(U
MV3:@MYQ48`9KVC4_YBYD/59P1\5>RHT<%0NV>!V5Z1V4U^"8F&XCVXOCB_@K
M]D=GWI`/]EAQ`W+&/=:\3MD0S(L'(BIU?+J_."=7']G__GQQ?U2F`T-)XTF6
M;[V%-%FPK\#CG-C3Q**)+^,T2,,Y2S!IGP#M<3K-BJ7&;IAA*/4Q_VP<;SF'
MX+^*$DR6L(]*,%U>?5Q]/'NE)9@,M()/"$W'?FF]>$>WE?M\L_Z8E;0^CS'U
M1]7T4-ZG!M'QHFV'\EV4&%P?32+P*2V`-)O_+"4I&UH?/*)(\9X!!YC#-"8N
M6O=(2;QXN"W/0DJC@ANHJZ+8,6U$;]9GHHJO*+EB'64;9PCMZIA@[M\ID#2R
MV6I-):JGRHK'@A"1!^,"\CY(9."LKN+,QYV(XEGLE]EZ37/NO819L?Q-F<G!
MWM&0QB\\Y:(B1N>2&,NF66QLE)MW79/N(RZ^T#R,"_:(FZTX"%^ET5^"/`^8
MSKO,<NX,C3D6;CR7=C8<D2L5C-@JU#QXB9.*"V%L2,V',$9BIP7HG$P-7&A6
M7O*#UN"YTJG`\W#VYXK7XH5/<,`F:_;->7"P5P=E<1_(1]H'_2(GAG@#1_,%
MC."])ZM9F"!`A,K1\`8O@OO;&OSCGJP;R*\IB<KC:YM\8W#7RU[4)XX"+:[<
M^'LQ'<O_Q0])7]A6@*?D,H\_BXY3=DTC0G8\H:)$EL@'H[S<3HL?.AQ.B.1!
M!E+@$<24/&%7??\&+OD)'8?BC-(3XM7'L[N+U?T%/Z`40>W5QW/YP\7__73U
MY]7UQ<<'#*>4$WS)MA+=T,<#B[&Y*"5MW,V*X>)UJW?;;2(ZU01)W:GF*F5>
M_T9L3%Q/(XW90GN6YOA[@:L.9=O.B'2(L99TF@AS%!=ADA6[O(K?\2E8\RF(
M6U[XSMPL%[Q9S6Q#GLO?)&0FFA;E;1`;]T$]I(&[`WCPYOVT<?EGPO^.PNR/
MO+#0#Z)`$`^HQ-5@-#9O:*&,7*CK$`!<D,TV]"'XPH^P!E?VV$WC0W)H&]3'
M,W"AE?>V$4-`UKSG^Q\O?X&FY`3H[(-B<9E>,#^@A=A/<]OSD>%G/[:);VDT
ML-T_;^RW[34E_^=`[KL]9TB9<75"*JZ=I$N^1Q_,0&M98^OJ.<,4*=Q&[C6F
M6?I6S%E\,&=#$4H\-Z6FDK/1;:/70[R/5COET1_R("W6-.?')'5MC/U9$A1%
MO(Y#X>4^9'QW>_Q;4^,\X0-!6TY,-&?'$G38@*+F+,]M&][DD`V_BB79'_T!
M0<;(G'/5S$YUB-EMYR!//I-FQLI,7%AB/X7S3I%[GXLY5U33_:&9LZ/Y.9P5
MY70AZI(Q]Z)RFZ"33@L9-"[OY$I^O/_&)$];VJV^R9^"M&K$=):E19;$45`U
M:;IEB[L6ZYMU99B#I.G_;5T"8**'03G84\U5OQ58$>:Q2,O@^NIT5\0I+62R
MROUNLPGR/?_]??R4BH7"U'Y5XH<[D;?L-<*9+WZX^-ISS5:7[PDYX"QFK,N;
M3UO#G;3L-7,%YGA/*HE:[WN:)[TJ3=790J111Y!:.:K%Z(%^*4\3AT3MY=\/
M.K8'\$6\E,&-0AETXA5"Y8[I6?Y"1+P1KK,O!-]C&E.&QHN$UCU&D=G%7V[Y
MBW1-`<.]\*QYW(RGL%JZG^-\X"[6C2+L7[=HRWON29<(FR.X%#C`FVMFZW/D
M!ML($RQ2UVH,9U?)BC6TEV,W#Q8KN7M,@M6EF`L\.@OOL-J-C+,-7X"[JL/%
MG&P-JP$C*,MJ@G'@*E%;\ZLAP&96?9!55>N,`8*95N,EJK6MXUS0B-X$UM6.
M-[1YM9P)NQ7]&DSL1!.@+T`);E]=%KSI-6QSQDN+^3E]+-U3D5344+94B:9W
M`X+7%ZD;\Z#JPV4,8;7)\K(*JO"(5<0(17H/CXJ@L/_&4/A`LYPL,#.OEQ.M
M;5>0PDJZL^U6LH$VTVI\H\L-J^$UA]359^@LZ\C*,S*B*A[+2U&=S725,D'>
MR1/'-/J)1D\3Y?=Z/0+.\OK,2U]"VYPQ9)O:N8"2#COA*5<,K=.6`4VDMVB,
MV%%W_J]`37A89)]GP9MMKYF:3J#P.@$S31"^$/<44F/H37@\:/%[1=EF$Y?U
M*YYEXLR;IJ'?)2([IF`WABRQ]ZX'M?2R8D>7`S;78EZPN)T'IT6NO\%CQ1&E
M4#N[!+;<H9T`Z]EP7_I8S?R\4X#.U+NM?R/C;LEZ:<F7ERIL[?4Q%91![KW]
M\3*L[KPA,ZW^KPUF&8?7B];T'9$L7M6(UQ9^SI*(YH5\%1Z>G,"L63"&MF@V
M<]"[L-VA_6U]B51$>%^#(?-!+L>C,U;6"]JL;I$QU^7+DCT6].\[9D$O7EQN
MT:GIH<R6!E&_7$(]E,BQ&(W"V!?2F@<E,?0Z<S<,:D;@AD"#T6#IS:GEW5M-
M>('"I]['EJ%A&3H5EZ7%JK[3Q#9"CW$J$D0*<4=F;ZK`=1R@5+@6U?&B:ZYU
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M%YP]EYR1N35DMGA;DLTVB'/^)C?Y>5QLLR)(;M;76?ITS7M^KXJ">EM=MV=`
M&V''F>EU06G8D"PG-2.^/^2LW@I>1#+#(^I+3\S`9*`SW3Z28M:(Q>4!<#>T
M#+3"R'TW$)D?N2-GL'`[@_%([*2PT-C@\=5F>/417&XZ->2;4&#G$I4RST"K
MD@R90EM24^R:_B$'Y;X[M'@$$&H&T-E)JY5N9!C-.((U]'.T@VIZN/Z52D3J
MWGYX)'`Z3(@LX-@J&VEXJ2!>ON1L0=DL\$#5.7VA22;VOA=?MC0MJ)OM,V()
M;?G,</=/(B25"(QTZ$A%N*C(^169G13^658@M'<6:]NPL.PX/X!KM_SQXGBH
M*GPK/H9SYH\A.\#[\X9X!ZZ3-I2D+I,L:)$;2G?(]\]!3M^>!H4H"+T'\TK]
MEIJ!.37EM?C5V"!/X_2IN*6Y^!:>X=I1=M!6=1QO[X)<14$8"1$T>*1Q+JAO
MKK.B^$H@YE>[F3H2'-#93\/5:V0[QW@M+9D?Z>=.YFZ>I>S'D'9VK8X&U)XO
ME"5UF('>I0WZ^:"7T`$33+[P7!-P1T-ZU$_I@`\:8^NZW+56UYHI]'7,2:Z[
M&#*%-L6FV$=O-[X2>SP97G1FV&H5.]WLQ"&M33"Y;M\;T^(##7CE@.B&N?7A
M+L^9HA'W;JSMLB-S*./L.A?J8XH3TF%%:EY$[(4K;D3>^OKY0121QV:NIYJ2
M3D_$@I9DG>7E<].!F\_-IIZ;@/VUT]8\)0')F[EZY,]!8]^]9$=KY-TX+V[I
MPV<:[1)ZLUXQ;R2*DQT_6[[G;R?>^.)+F.PB&O'NX#Q8L*O[,Q[O2]S=@AG>
M`-R'F&-6>_)8/41<L.T\AK3/(?6#"!<#TGF4N,W3"R$LH<(\/)6E9S7HSFK1
MSBH]F-7P<%9I/:M;-JL%ROC$?$)OYD5-_W@XM:EJFB<$R=K;LN<+5D?)?@:4
MHG:S)KHNJCC=JBDFH/6H@K84>5Y-19DU/VXY:S0^D^OBUY>BLF6*YOZ'L^=C
MPA':DS%";=FZ$5R>IT?<D>1M]PX(?7U-[MQLN@$[.!L]6.3?PS:/\8.WR:.(
M=;98T3D#7FYG`RV:YC6@/P=YSM56W&T;(NTS1B-LMKH-C>\(,W,9#LIT(R3S
MVQ_>?RODDO^FF_C:/NHO<L*+F[2J#<1'")__0Q;19-25'E1TDST.R@1/-U^:
M'.Q#<:\9DYNTBFFROS?,B>".0`\L/%T=X]Z&-8MAI5'P<.=C703LI9FZ#7_2
MY/,49:&0T&"HZ`?0NGJI<_LM)^=K-"[2Q(I*ZS]-]2QOQ?PA3FA19BFM\]V:
M7WR@Y7,6V<4SG%@N[3:YX3Y>],WX)E.0M+^2/!"HS!F`=]3BI@&\E<P6UW2S
M?MAM_6%;G!O!`T1G^0N:QB-TX0>WL1-18)&FVTUD77'%^23S:4[W[9@*S8I9
M(PG!_:C*^\'0<9TIYU"WK9*9U(\BD_H@D;S[`/*X/QA8/82(IU3*$X>3^>N9
M/O``U.12;'GVY/O4I;6>?#1[RNI+/%1(<S!*<$0$%9@Z?O?C)2]7*A]`?N9#
M<$26O-\:+#@TN%:T$:!#BL4MNK,LMN^=1CSV_#'8T/-L$\1#-3#U^FB6=P"W
M\_/,K*)I6F5QY#!D%GN9B>CJ!,4TP%O>&:7-S`C/\0*+7U';;)-L3ZEHWG4C
M*HI^H)M'FIO:9@T#L)Z.&DP]D:_&$C&8R-'D9SD>P_5/&S`'&/C"F@^(4]-*
M1RB%$@9<$\LQL='WLU12PU4-.]W+'CP*O]RPS_TA%VBW08E.76+KA&]#JVY$
M<.ZPTVQ;F"X%"[C5IW5X1RJ0+>RHCA0TT_I5W77&!X)Z5Q;3:J#3!@F77E#5
M:9/2@]'*U1$QM/(ZQG*\EJJ_`_DJ7J^^(K._O,\FRW#FU6Z)_SE1TS3WQUT<
M!6G8"_)/M7JJ?KV@'I:-5%H8N4-*=,$@U>;P.D[I54DWQM'1*9X$ENLWQ2P-
MU[W1'S>,G#9P]D3PQ[%U>H7S!)=3.)GDZ;,-_1^#[<BYLQ\M5E6JJ%O:XI1/
MA';$)IDUE^/1DX.@5'%":NZOY8+CE//5INED,K[5WC5"Y3S.C;X02V)T#L#]
MMNETS20GX@:/`RMX(1L(K-)(?\>>#?B8I?GAE7M%`I"^2H#_`\$+8TPP9YI\
M\HI35<BJK9#!+T-U^4%E];SFN8$ODC&5O)D5SO!^&IA>.MTW/_X4TYS7OMU?
M\\JW+F<$IERAO3UC]+I:.PT!4"(0/$)P_\-N%=NU.]"S!)/7KF;NOZ#=\8HE
M4W!_P!"[;DD?&K:.Q>NL=:"<(,S8X>VYS;HWL]E&','D_"K=[LI"*)QW;D==
M6E9H+/`@3MTJE@0G1)"0=SA/E^S@C4'!8V?5J]+.N`[PP2!IW]FEQ6E9@%O+
M05SFDO4=KKPR.UAC$.#MF7K5F5FO`7H,$O1^.EOU'K.M>N\@4>]?CZU2PQN#
M@M)6O9_(5KV'EC2/.)-URL'$#P6WAQ/-G4[>Y2-$E'2P$O--JHNE5J69L:4E
M8)K`S',"X>W^E!(\>VS:)8M!4;2C.MV\60^\Q:ILRXH<E9M>/19E'H2EJ4,Q
MS;-`ZRCYSY3J9/EF/2Q5J[(;#;H9*!=?,\?AN<P\3=GZ-=6*GU$,#+RE21X$
M=R6A\\*F;I&"&/Y2PB$6]:V$1@?T*@2"N!<.`!(5``0W*@96E.&5BB[EZ^VM
MX%>L9IJG0P<,)I_-Y?HIX-O/S[,T%Z[^#U.&Q>^E3_?##*R*NLSY"F`E8F:=
MU]X]*H5\8ZH^@WA"X`K;S"]]^C(Y,SX?AR9S+Z`SS@_:A3!`;"@7(Y>008\>
M%D,)[L68KF`COV24V=+RZ5)3!D<9F9$*)75MDI]H$F$J&&/XVNB.OZVKJ(`6
M3O$TH;H3-P=EX?)<G&;,:09-W4#K?2_@>=NO>>Z0FEQWZ?4PS0X/?66Z;K7A
M/>(7"@O4#WNE`8!FKF82RQ,BGX#`3YEKIAZR,IB^1PE`[$.)\#8K*6,=),F>
MQ$6Q$W?!18]6/!VI)]49<P8SJB=Y)S&<TR+,XZU\R.FN8-JZX)D5S0'H??R4
MQNLXY)WEPI`_E+W&;9;$(7M=J[.1Z9X'FLPPS8SUSP(;KCRIH>8K,H(ZR0X=
MWJ1E3FKNJ,KU__>=+??.4/-/%[.OC]WI*CHU&CK3%;33M:VXHW&'IU9<X^D@
M4SS,S?TM:/CU4_;R341CZ?FR'XX=7O:KOUW3IR"Y8(\M]R:G68,D2SN?P^_=
M3\]F(X@<@N&(:+*W7MS)T:R305=E:/R\JU@^R.X$I$\'Y1X,(.C5[:X6!*:C
M"__7!K,$JC6CU>@](F\GFE?F2>/=QNRX8)`$I/U>[[U[V_=J`(Z+<UC>V;X=
MGO%+@]L(S7I6MZP[&K]TH$_9_OQTKVG9Y-:@O<L2^BC"#'<O#%-1G8A6"Z78
M!#24)Y!]H%"!!0_V6ZQJHSB^"3\TDLO?R*[RBQ$KJ/"Z&4ZGQ8NIM,OR,,$"
MQ18K5QL&-N&SM%1^",+G.*7YOOL^;K?@M:R@[:<>9Z\C<3WZ<('BO`'O`XV.
M0@.WC08KU,@FZO@L?B-^EZ>QZ&F31I?Q%_Y385F\1<,![*ZZ#E7OWG0]6*S#
M>CB.S><$@-9C@.#N<H^N/?W%;#7YTE)TEFTV5=ED-XLUP`#:3@UA.EYI<DQ5
M>1UA;QU;#*BLZ60?`-QP*L7#R%SVJ8'S#ZY-*\!,^RR08.UT,S77:?HUDC(O
M_YPNAQ#U,O/EGGWP-;BS-(>^4L?4IWH0=(889>Y@D#@5O9GXR:\Y:ZPWBS,I
MI>I!*,OC+#F%F6(*L_$I?%,]Z2LTSM]\8CQ[YM318Q=O,__W75SN/]#R.8NN
MTA=:E-RHWGQ.V3[H.=[>4K;VF9%],NYE8\$0K`V]!>9>GHB@)9*8M-0GI*$G
M+0,4\1P?N.T?18.O!F*<LHTRX\3\&,:=%]IZW),PVVR#%$^!'^NUK>\-;\S-
MVR'I[$*OJFL$5^E9EA9Q1'/A\%YFN7R?J^I#K/AW*.(A9UBK-'T?!>IR>,^3
M-L11LV123@Z8$L:55(J@YDLZC/$X%/-.4'/%)4Z9['<G:,TFB,H).M04,TV0
M>SHZTAD"V0O.IR5,?2G/YZ!)[K@HRG@3E#3Z5-#U+KF.7\QK%5HR19?PH<!N
MF1/1<"&2#1%\4/A3OLA;:#L)+1F"AB_O0[>HW3)`!CGZ5RT6%RXOOH3/O.'S
M'5<;5B[1(#UL=>%!1(-=P\7%8S&,B'%X?!$K$#D-*5L-8EM!@_"9K&ZOY$W:
MYRQAMD`44:S3H$-I<F4#7F%8#R@(K9X9(?([K&:C!D"$#43F&VC$S:`*\0#Q
ME-LGR=_H[&R`"N04;.CMM4[F_>`%\WE/PKU>6PKJ\+UX@',AQS='<ERC7.SJ
M@Y<^B;?(U1(<<7=]7/K4VD3/"-0*CV#LN7GU<!D_`!;8R6`-2`)*`SLE+&06
MUT38QDVOE@M<+?,[FO`=P6W`-@P/>9`602CJXIWN#_ZB*,LQN*-Q9`ZULW:=
M"UW!\6H\$02DR^N$N]B'?P8JL?&J)@-L>^XE*=IMNAOGI36%V;NYW(BTX0R=
M,&LU"\>R<+3`\=V$G!T=>):J_2HV2E^U8`LIMW;W'H<HH6SS((J1%8CI_N*$
M[P]F`=4K26O>!LB\M[T?Z";+XR"Y3[(@_1,MV18L3I_.`@8J/Z/\A,KNBH8E
M4]#ML`7VWFV\BI0(6M(0$TE-)#FF2Q[>B.__=':&ZR(E<DCN._\I%F8A%N8O
MS<(,Y<(,!3FR<("M$AH/#1AS7-J)N,[2IP>:;V[9:GH."LH#%W$I2SR<,>W^
ME/&$2YX67H^(;#H?.;.'<D?<YZ,7_ZI&\Q1J/IXT!!@JTLV(-S/$"^;N>*YY
MK4_DRAN/W"O>TJW%D/-CH,,![O/3J^K(.+WEK!J!("VS$Z)3$Y@J_LTT,>7X
MQ`SH$VPU!2>2*J.(A.LSO+=F'^GG\WSWM-INDS@,S%L=C1"#I`1HL!PO4S:4
M\+&D,QA'>0G<2.S3!BRA1!Q*T`Y&DCXP)B;J+`(EI;?HWO'DKVW)SR&>=@DG
MV[.GY-E+D/"N`9_N+Z/`(:YBPQ8TLF*%OQ^\$\3<0+?DI*8GG`'Y1.X)XX$P
M'C$)]$P'_>O[K\GE^0ICX&(J\'D+/JC!K[O@D04P[.5]/(1AP1/)">:U::4/
M<SX83DD4"/5G#ATB/$4W%D>'XH1%MT*-SUL&F2"1N_,=Y1KA(>O^_6R7YTR'
MVQ9UF.11T,$$OWDR7OHGA'&41OG-0_;58=H-VU!+SMCJ-,PS29WB"YLXH469
M,:6P#?;<C^"7(>3,E%GSXY;S16/%)Y0PGS0'H^=,L#MIF7^H/U9Q*S^6471A
MA`-(B&$,E5ZL6PI2D4!?1[#%TT%0RQV"&(/K5Q'JH54E#28D00<C$5)''O3D
M_O<'#TX]K]*BC,M=26_6\@#TCA:4(7]VB$!8<H:]<V@Y"SV3=I3:T7#@D8DJ
MSZ-F@C`0X0W_3U<80PS3?-4V+R)NOBIS7:HDB;QB@BS*X"36!C<8K=@ND''F
MJ[[ZZGKR9X)X.-//G&-:VZO0C"#S)S+*1#$Z2.T)NG2TB6>]OZ)3OPLHCS'O
M<.H'^F\8F9CQW?V'X!]!2BW;C.@XP!Y2*5#UMB35.%(-1.CKF4(YS[\FR\'Q
M.$>R_30;.1"9PZ:5&X,3H$%R;VF^#N(H"3ZOTNA,ECNT<*24M"`.D1I)+_=)
MCA2FN1J+R#%!BL/>S7`#4E7=1&+N1\1#;;95A-X"^Q_!AA;%6;"-RR#Y,<]V
M6P<+K&8":H0UV(Z7C!Q*JK%$#$9HBWT175^CO)-B#RNL8#WQP<@L\YA(C1MG
M)0=O<?]Q%SRQ3Q0S1;(JBBR,@]*TR]@X/8B=UB,Z7C[U:&$;VO&([+4CGO\5
M;+;_VD4$*NJ3?J:@&8_$BAL(D=J2ZXB7SOFXNKUQ:Y+6(83.Q^AB.%Y&[&^8
MKLF:O/+M[C&)0W*S7LL8%MI.8KVU8Y2;T%)YF[+54TXI5T(F=QB'*$#,U?%;
M'W__YN\8+A;B>&-[8V/\RD@,RN!25IN0P^'3"9+=M<!A6M`-7Q^)9K%BNI"'
MY^W=-W$6KX]LPZ80@/%]VC&A?VU>-B0.@^2!']$TW"WV9WH&,!5[]9AZ5\^K
MX42,)YTECV:+AAZ10Y5?1TBE@!0@LZ<F8J0I`*RC]C\AB4.:%O2<OM`D$W7^
M95!W0W.V%TSB?XB/-B[[:G7F^`10R^TZ*[W0O^1#.HSJ\XQ#5@@4RV*S<8)C
M.MQ=BZE71W0T'6%O.F`UVN2R;>K0N+&?H"5!6NP2WOCQGN8O[!T*)]]GG`M0
MRX)Q=/V"VS4-J8D0:*Q7C<VE]8$7N*(&A\X],A4W79.$,1;^31/2I^!)ACD\
MG"$-%]AV"1ITO5X)S5@,<C(Y)JRV=G0!&G014++P%H_.S;X/06HL*7UM8,8(
MQ'(:8CQ>6]T;Y"T=2OLY`<)-BS"`UPZ+041B2VW$4&U.C;AXJXQ/:5S6E<1\
M;*J6#ZA5U2,\7F)\=%NO;@'UX%A9V0Z5[+Z=Y3,FM;B[")-\(&1^@H%8C7L*
M.B:+MQO:/19Q%`?Y_C[@#4]$ZR.;2L$:!F!M@S28>M<X`]D)1_8C0W`.[P2B
M&7M"3`#!M>P96VWZMCQ*ZL6EIGW^QV##?NS6WG`JN&O"$3K]R@CUB(!A.HF?
M#M<)X83\/P\J6F$M=VN^?(T2O0S8>?NSMTD05IZRW99WF!!DBZO`T$L+K(<1
M,0[1#M8:0#`O`/L-JAL")/M/G0RH]YN#5)/6?NKVUWJ@7\I=D-B6B[/C"5R3
MUA2Y<0&X@E3$V&J\S0?X347]%1KCZ+*L3:JOFC%<VH.]6:_CD.8%OV)(V5L-
M:5"5%S],"[7;4R`Y7HOUL-^2[D`46SU<""*ZCM.8L_YQ%T>\#L3$.$YY@*<(
M$G[?/N!)&2G7?#D3$W`S:R(=VBWJ(*%_!X<=-]HWZUO&C]EPNS[R?6)0\SF`
MI=<D0`SA-8#J05BBL^8OG[4O3VC*GIG,T!/>V:0[X4`46K9Z_VTU"%DH6274
MXSY%C]+_6L@FVZ7E;1!'G]*(YDU0^BK]*PWRA\_9PW.V*X(TNDCH"QUU%-QX
MPMS1LD;>N^D@.!#.@@@>G=.EJY1P-H3Q(34C(CG![^8G@[[ET'<">GLJ':>$
MK;-W"/;\L^/<\T]<LD]<UI^8"DY(P@:.PJVYDV;)<#GU]/"9)B\]?U5_(<B6
M-^RM-^N9\%97DA,>WV6R*="HK>\0^3JSX^VKKU)P0N8O.2H!@YM]EHP75&?/
M<5[2J?VMEBMNCZN#WE^)5;Q>D=<U#E^CP-Z_)K_+'>F`ZJIXO3;?ZUC4)_"^
M&I;>"NOF,XWD8XT<OH?LDBTOA>)2*WB/IX#Z9#ZSTXOQ,EZD6O06FTGRD)&:
M*Y98V9334LU(QF?G6`V(?GY\J\F[`O&UB\AWFWQI!'(B+#:A?%;6%5=D'IVW
M6AGW[=P?X=^?((C3DJ;\`.62TF*51G4Y[:H_BUDA(Q,V,%T$3/#UJKNW1(13
M$4;6EOB_G:O?D'V)?U]P:T:%P`>;!(>X-UT7TV^:0B'QL,S%3%,H?YS'Q`EL
M]4U*_C@K)TG'!M0+TN(;2W%K[@9?SB$VSJ$F1TPRZZVY$@RB"I8`A<R=&)>P
M<7]!P\-;`_PER/.`Z9*KHMC1Z"&KKX#PF@M9*M)GC3P"(SX@+H$9PN,U5E,1
M2<;W,LT]($DIDZSAO0)/?+'$QQSR;8TOE/@*F41>/`<Y"K=A^@^Y>F*N]U-0
M4G(O0(H.3YV/B\2;L)!1M3MAPF2".BH-LXLOO&1+06]SIJQN@_PFOR]YTN&?
M@V1';VDN9MS*R[!G#NI[.,Q%OY9'NQ9)S80(+CQ]E=SD1#(B@A.YY>W+."\L
MX9;IYD`H(T+K.=B*.=CRGENSX'7W9.:&S#Y[QE#+S_XB/GLS#<A\'U=M,.X1
M67.>[7C,ZQ0,V6&7W9D6O.=CCV/HR`:!9S,-$"3>RIBDV!\B32"]4222QX-$
M/N-\1T?%6'/H/\X--A_'`&UO734T]4D/HX(6^=D@5B<6$8,(K0T`,")S$XR%
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M,YRW2ZP^XASJ39-'-.73_*L&'+X&O0OB@D:G^ZJKN)4?.<H+MJ;`*-+>[?#C
MQ4Z))"*G>U*1X7$;W?`=*$%*<HGO<<^3#F;!YW&??Q:`R!Q$0WDTN/\_PLA;
M<S!E]!2_T%1&]F[6-X])_"2^JEG.LI8>Q&73(SI>7/7H.C[/-I8=`GA/RA%-
M%:9F^ZEL1C3V#LZ4<)#X'082I'8C=,03GJX_9!<!SW`6143L3N54/)#<C3]&
MICMJ?\@('UQ7N<%C]*WAB(/J,B,T$%GZ8C0)UJ78*&ZV"16=BL*DV\X1D0]@
MC9=!?:02-=^/T,Y7).5S4)+GH!"N`$/.TRZ?Z1%X9/[!B&3:7&0_9."M,^[+
M("\_;2\I9:KIH&6FD3N@(P?Q!K1X>H6>^6#R:<OO)H@XRV&/5WAOP![-V]V6
M)_`+L0'6!_/"0>(-C,N/VAG0T$XEU^<[>I850G'P4+.5*Z!B`>H)*'$I99MG
MX/"QTB<X'ZA%Z0W#,:_7&`N'4)^7%!VQP./1V'T6_OH\HR;DGT58^6B.S^+N
ML$P!!YD+HE<(XQZ(@G[:3"!Y@4044UY3$4.US_@9X@&?V3.(;"2#I[I.4Q.)
M4R!XG\0/%M=@$E99P^*G#>U_/>[)ZJ?K4\+&/M+G(%ES$O8;!.[++,B1^#&&
M8FB863/`P+]2C>!]<%'ACLVUG4^C9@);9T:-K5<K1*ZFHWM,8C0>=P`I'H]J
M+]:`CFX<Y7PT,I=@3*(,:K"H.$PD[<4=#6G\XG.EVHP1B(-@B'%X@16DID-\
MJ]H385XC5-VK1N`4S`T1B7]@(X]J)\&(R[1;"OFLX#&AQ<WZL`;$99;792"L
MG`@G_J#^A=N,C&Q/.GQ$0X>CPB\\GEHSP^.93#\3S*_/.S/!NQ(<55;AP<MB
MKIEP]VF@IP*9-^2A-<8=)1?FT^K!NG)%Y^&G^^;A]F&6,7[P(9=1Q"/ZK:EY
MTE5TI_M6T<'[5]/A9;+ZN<;;E>''?2O#"+RM90$C\;T<Y-@P3C/"S+\RGLAW
MO5G7.\3VB58.EXX-;&4\';Y>P34QF&N6)MC1T3)X7"074$R:FH!'1[(0>3L3
MHD+FN(P+F4%Q/#6/*91`R#_9$^\DG25Q&,O/=TF'8K<#O7%U]##=GK6(!A93
M-5H<ZG3&\[P3>"?"&0T_T>BBF>-$VJ$/](1PD#@`!A*D:1*M(9[(P,>AS&&I
M+L4$R2IZB8LLWSN%5XQY(C#])LB'C4L<-EEG#3&IJ1$&3MSQ?LC2\CG9-WE<
MZP9N4,-%&!V9X/L:`$;I2AB+LZE?,<YPVEA'6\"FW=AT]C4BTF(?\3#C"A_W
M,$0_$OWHU$!JV1R$/V2<%]Y_F1H\\P."%GP;&S@(#<AX)@)W!Q`]$N_(6?0-
M@R1&+*<L^EL?BIWN?\J2*$Z?FMV8E1]ER!%+>5\M:FU-W^;PFVFGBK836<'C
M0KF"K?Y"GFD2#8@AGM/QV;ZS+.+;@&1S\%Q]YS8L@\R5LI)GJUJ]&G93[N?J
M0_K3_8<@90N-?_C+V#`CUX@/5.S&`*%VS]8DWC!]TU(23@KO#;GAZ^[1FI04
M)F:;%MYZ#GA.X1V?[S<"$(E+8R&&VL#/*)-)@[N7NR39G\?)KJ316;"-RR"1
MQ<7_O@N2ATR?N:?=E#H]`CH\Y#8O^NBQ8$4J7J1B5K<VX.QX,B!D#N"R,\+K
MQXD9B:H9":L9J:K^BQEA[A%2KPC+E"!SG?QTBE%0RH7_!&TCO_`:4DWMAQW[
MQRWC3,N++UN:%H-Q\J&V>.-L@-I&&N#K=R041-UZ+#OQ+TE):E)XS\H+7J>B
MR4[\:ROAT;G@N324G!$?$L?*7`1U+25'>4RV#ZL?<F=;QV68`;1+-(1)Z:JW
M&N$.5?460QPW6YH'HBY+0GG08E-ML5I)R7%5];7]/H=`\/D02@$R/[8ZH)ZT
M/M/M+B]V05I>\[7AV@=)S0:X(Y(&WTC!IIJ."$*<?9+LT=7UF[8U.JD2<'9/
MFAX>$N-O+G\FW964/,SU1`51P%L'Q:/`N"O>/@7!]ANN/[ZA25G4OQ$:Y>VW
M[]Z^?R=T2O7KO]V4SS2ONUJOTNB<OM`DV_)WJ1P24\_!AB.4*V&%NF>3.5';
ME)XW/^_0U7L-%*Z&%\[;NG):T]J=%WC>A6R3B\9,VR]?K=VV8#?!66U:[!+N
MVYGFL!Y1@)CGX[<>Z)I3_1U'7JK%^\XEN/9FU.*ED6V-!Q>UVA`>#O>O5T;+
M,A'V\S;8\W^)]CQ:*=/4.AIE!EO#;!QKK\Y40T(JFJK%%Z#$OGZ`'@7"O!!N
M*X2R/U>-<$W1Y8.:2J5!^;`Q3DM[S:N\C(MR%;WP,NL%<Q3NLGV0E/L?=[Q5
M0\F^!8_]QR5_U]&XO"/3I=T`5^R];9^@)S4#X4=7+$C+XX1TN("Z$U/AKC%&
M;7H@N.WV6L^#YMV-X]+R*\[DKHIB1Z/S7<Z4B(S9R<IC'^EG\2?CBR>V7*%W
MO\;H^P4K^2FPI"22M.HB=5+5&SP1W:DD`P254KT1'Z00QH)!#16%QS0MP")+
MYH,7T76<BESH'W=QQ-4"[%<L9H(9%V&2%;N<+@ZS*ODI`:+Q!=UTKE&XQI#E
MXM:%/_\T*&C$^RNP;;K8(JQR4<:/&[S3?3ND\FA7GX,\DMU[KM*BS,76HA#Q
MJ(?G(*UJ7_TH;E5?I69]%9=_'RB?=,$9'Q2ZMX^<,>D^G'2>SG-%N^/J3:IX
MA9.ZX5CG+8B,-9?L/4CU(B=$O@J)T[DZ-VKM*[9Y;PKL/`E_$K:/Y2N8#["]
MQ=+:4+LM6>QE%K<Y0<*OZ(LK'KR2*GL-`<1Z#Z/D`[YK42/LZ60VE,?'Q."3
MJBHP&R^5,*9]"5I,7IL1<U02QI;!*(9@P#NM(V)EYJ:JF"RM),[I8]FJ,),.
M"3I**&=O$$7_5O)CV?&H3N;I?V#O,9F_?-QY^7+@Y<$,NGH5:4WO`-G2Z_\L
M"8JBN?!XD]_%3\_E00'RMG15]=?BG:T%=7P(M'EUG9M>K(7SX8:JOGB<Y42,
M/CDNTY]UJF36@S`%#:>:D8O#8OZ:"G?@YLY+0(QLH=L3EE84MWD64AH5EVS:
MI/5>O01QPHLW\"*[[#?W--SE<1F/7[MQXPEE7"V1]_TY24[X@B.US]JP>+O.
M\K<%_VW+!8%1]@3]8YXQE;<]@,Z[BA85_$*)%<R&NRQPK76W8NB=\/,IC6C^
MF7-+G\[C(N1IM59)/L,,0!-[%)B.%UMW&*G'(;":SABBN3"X)^CXP$"6A*.3
ME/'$FT%J2&/,3W3XF=H5/TD,DMO=8Q*'-^LUY:<_+I9XA"$&,SR&66^#:VI2
MD1-)3VH&R,RO+=B/M!RPO%N),9L+H\O9@`_*(P^CJ4$2I\KOB,*U,!)78[]"
MSPTPXGY0\4TT+@S"(:-C$6U4LX0.%)CA'@E?'Q4-[-`B<&7\D*Z>GG+Z)!LN
MRZ79N>S:;@5$L@V_]Q:G+[1@:Q190A$L=O!(B(5TVYX!*/EY;XOJP,E@:[3.
M8\<<)4MF(!>2++`JC\I5O0^[Z@G^*M,42%55'G79R+-OP):%BN2FE*V,JB]1
M&7-:W#,*GVFTX_J.>6];FI>\WFU:KE*112%N4S[PP)"U>V3,%]Q',I^!GJ-4
MD8HJ1A7Q"1'DXJI$PX#\+%C\)RZW80+@F2-P>)_!<MV;.0ZF3!>O'+!>QR%M
M7N(#W3S2?,RS&"&&"K>HL/1*`(AQW:4HARXNA%.@H*,HP&((VK6EC1<,4RXM
M&Z*/^>I+;'V%J$,(;<.Z&'IWV?C?R,_\K[CLC^M+@]N.WHHQ,@XM%<@*M]/Y
M!R10FO[PO15+Y#S;!'&*0ZG[O#"8_AY8'5JMW1V_]$JN*C(JU[)6;(^(H77V
M,195P4THMV76EP?7X8,KR4B/'U(N+@%QJI6`01$_(H+2Y\?OWELT\N^X''7?
MEP;3ZX,K1:O9#RD`4@>&M\S7<4JO2KJQ=M!-.$);`2/4`UD#NI`+)R6"%I?1
M6!@KN(TQ7]%&AL>`'1J9_4C+T_T#>_SJL2CS(!PM>.O"$3#AQQRUU7KF)3G8
M/T[WA'-A^]^*#PY3Z(7[?K?9!/E>5(RO^`CL360+C>&T7]1C63&F[-"([Z>"
MKG?)=;RV/O<Q8HG6Z![@MI1<24LX\>NPNEJP#9H7F$QX_T4VA67M\$,CFR*_
MT-N<5ES0F=`:G:7P"3(<Z;%VN([/=W`;>A6*UB'GWV4;Y##WY9Q$P,>$2Q:+
M5[0,P]UFEP0EC<[I-J=A++)VV,\)%24RTFBUR?(R_H?XO?+M;6W[=,^%=@`F
MG,%>6F7+FG1Y\SS:BKL0DB[_D^,DBI-#_8;*GYAQ[JYI4?R1=&<PZCQANEGX
M0<Y"*M)?(YRS$!C.`K@S-K4V,O+8)GNH?P.OBO5!D@_]4NZ"Q#3V8<X'II&R
M$4*5PW84L*L(L80VI@?XIJ+\"MP!LEV>F@;#!DS@$E<?\H`W1V_O++/7E!6_
MY!]614'+PC.+U>HAT.Z-Z]SH\ELK@DXQ`+'P9?'#^H^2'?)LUXGF))MD3L#-
MMY<<66;%VCQA`L-,-_%N<QFG_!YBT[7+[.3<A`.0,=:CZELI,9Y4!&V?O?E.
MV>VODKB"6E>@L/6?,UIZ.G.K(Y^@.W4:R`*:EW%NF4NE80!:D$.!J9^65`\C
M?!R<#$R)9,W&(:MDH5MBXY4L!JFQ^Y>],_VQT+S'`\!*=WO,R62^I2;C`R18
M/LNDV#J7FDF!*R;M*T'ZZM#.W+T-Z,>LI+?!GKNI[%%G6<J631FS_^)_*,:#
M/VJ]:<D9U.3:SD*O&@P;1BH&8F5W6!#!`T&P"!0^:"AILD5J:O7MV$[0VK6Y
M?UU?R3[?T8>L+ES3EK8TVBO:L`-J"FN!5]&41Q9<:,HP,'I>EJ&I6G73%HF%
M#^I.@;?JM"1;]52%"H2\EL]YMGMZ5A:'!=A#SX67DHA]9E[_I?[,G:*X2/;;
M]K*L:W=KS,MM2U+0\.NG[.4;64^';TC>5S]S+?6^LQ61O_W;E?@77PWUDR^^
M;.-<'G@%I7%0VY@=E%MACO=X_;8D;9GJEHAP*A2>@SO"!A9M844#L,!<`\O%
MJO4'3'G!]F2X#$*ZVBC*V1I4X^_2X^C/<(!HM$L#'TWD<`29=Q9(NI[VEJUJ
M9MFR?$]2[I$'\^!Q"2Q8(+K-XS2,MVRK-/S^2/I/]"7&H@M%AQA6[C^E@4PM
MH9%M/6L+AM!GR":81U5$APQ3_6L?C*NF1F*6QT]QRF1.-/&<KS:VSZGW*_B*
M$R3CN:"4678'WU#L;E2?$?R@WE@)&1W*CW/SCK`<).")3GLW:Q[+,8JGJ(E!
MHB<:+`,*HAE:=?_DD1$^&CXJXHIC*W$PK9?.@<,^W#$-$"3QBS%)44<KE)1+
MNT@B2%N%;VV]H4-::,?G",E0W+ZH`_>(?!FCU][*OY^0;%<699!&0,7H+9:#
MA4T[((3=(TA9C,.J+6VS/W.+%*BYX8@;:-"..I<U;=UH6[1+E>3HH@HV.+//
M*1<W$9/<[G+N798\C,Y;7C3Y:N#FQVWU6NS:E:P6ET\>Q)>W+?/B)A<!_N<L
MB=A_G>WRG(I[(1_9U,G_L-[1V[*'-G/V\]%;XO)<J.;!^T)VN2"RC?Y8JUU_
MSN_IYE3T0V#"S7NZ;+*T?$[VH@5LD"104CWMXK392%KRAK7+5RE;1;0H[X*2
MWI<\X,`45,AW'D^C^U(7CCCL\PCJ41M=TQ/.X(1(%J3E@3!<;@GY]N@8(*X1
MYT!G;-XKS]I2:]G-=1NC\0>4!VGJ/"13EJ!9<L:XS2]NM(<],QV^.>?$>8/M
M7>C@?9BU)UNSAYY`T2)+Z[<3XO&4/T-^_LI';CY$ATS%,XV"TD9\8*Z%&2'L
M+<1J?RK(B%+CP(>M_>#M!+RM2NH01+-GQ8<DR&TAA)JK<09,_-7%8<S"4FUH
MU*<-7UBOQ6H&>NOR**2'3;_,A?M#%0JHVBA6P79TZF?VSVZ''YN/8R_\!HZ.
M!5-O]76^DRF2-^NCQQ:7F9?[X\88Q!]RG(-^B+-*M>4-WHZT6D$8*SQ*;?XY
MX)5[ZSG8UG.PSC"I-HR3@,3]\M$*:G_,B>M<P:2;]E![NG#2`%.,`:4A[.8A
MI0[U:PDJV0#N!UHZ^0^O)K`T-6)LCI>E4#N'E_H<IR@"&%(:%9<,Y_'-5;/(
MDI8!5-D_'::!$Q0QG/#Q_<O,\.Z0)9Z/E(=C*TRR:4'WA`B!:^/Z@;@PDH*F
M,?-:BMUCEC-)$`=ZN[3@-1383Z'ZA@R6.Y\F(J>M:*BFGB*`5!V<\4[`(IB=
M5'=7KM*_/,?A\]$S^>52&MD&D]R>`1U8<IR9@6A#Q4EVWZYX5>X+N4J)8-?3
M1$1R1.3?S#$E0F'54U+%8^*4?!93TI5N>=H]SY1X!:)PS`DV'\E/L1@%JIP>
M`)O5\R$H>>F?/;\4?$Z+,(^W0TO.+*U"R0Q'+H\:ZV@:3TTJ[L/S>O0--<($
M'G.<9\>BNZEQEC3?@'LK3DO6(F]'Q<G;BQ'-+6I'Z2J]WST6].\[OH%:KRG3
M#4_%S;I3+>,FY[6A7X*$#M?,46LUOP>!^C.><W2\E`4[TGCJS(EI.9*&)7=X
M#BKRW.2DPQ>/:S/+[#2;,F:[BW9VLF9VF)T/N_5LV#:'SC@[[EX.QNE!YO!,
MH8/&O1ZOI_B?U[%'O+#5\T+K,B?2J?I+7!Y[6V;!)#N&,.=S=IC[KDU-WM;[
MD0P(Y[!`^,G\*M$4>`_J<\F=B2C))0KD9#/<M;`_;/0#V'S%"MSGP:](WMS3
M:A?__5>\+D&,HO3:=(OYL]%B1A*!<]%;FI-$&V[>.K=76NI'_@_N0E\&<?[G
M(-D9WV(VYP?JJ9HA'B^L1@2=V$(23DD$*1Z?TQMG)8/D2?R3UU@C:X[S91:<
M[M[CO$"1^8$6\CKN[IDPF\"KZV[2ZZHJ=U3T+'O(3FE*UW$8!XE4;@7[_)>4
M;^7-ZJ/XL`?R^#SF8R2TU50E(A4_7I:VY4A:EJ3B">\/3C@;':1ABW0MQX/5
MI?IOMP1<',>I)R1N)Z3^[B2O)J0J/O"H6RT]M>\^*V9UO6:>%%GERVDJL#C9
MOF9$YW([\X8][^GL!]I7N\WCD+XS]=H=&(-7;+"8@]&SH`[Y25<Y"@XHO/DI
M8'>`;8>`P5=FL%W7#L7]=%PG=G,;__F6YO>\C+R#+SO``X'#.H1LS"5IM\?\
M\@`19-B\,!-<O0/6=IO(D^%EPP!T[I3Q%^OX3$/`T$3;C`3-U-KW&7BK@HLO
M)4TC&M4'TG4]0H,S#/7&WYPI:'3-`OOQ&JQ)V_2,MF@H>!KMO(@W1XC%T>2A
MKL%T7KL49&2Q-UNY'@_`&7.<P#UI$F)NUL>/531/&=*]HUR`7)1Q='V3U]!P
M#=/7/A#-4J:'QN2*]F1NJ&$*B)\R$S8TKHJAT.F<E3$6$!&(=OM4:2H:M1Z5
MS))U"D"8\<40?S"<@4$_NZ5MP@]L`7>#$HBN'DX`^GC;)/NWBOJO89CSX_VF
MRES83`?[5=;D9XE&;&B<`5=),`Y9&#%%)_=B]U0E*PQ)OS(9V(8K9.ZY%7I'
MR9=L@.[FS(-\*&?K<=\]:%!T4P#-4+=?ZJ.IZA8LO?W]MBMT+Y^H?6:Q"MGO
MF2/AU*/9]1&@\0GG>=&U;>]G879DNB`U-Y3MFZ>?$";-42^3KQ-<9.:_XH8H
MI`$Y#<C"''ZJ8SSHX<A_AO1RD3=K&/A0T"))&J^1F.2'SY,M/$&B-#R(,BN#
M9`X(#YQQF]4\TSUC69#IO@SR<@X0I_0I3E->-^4Q2'@ED;DRSR6.B]0J6<88
MQ;SO/D76O($@-$MIQ\>BB7=I-:Q-SKLD]-;Y#XQ9L:8Y+V]Q'0>/<<),RED2
M%$6\CD/QC1XR?HGI^+=6GK#'4T"=89_9Z6FXBI<L>]-P(X>$/!E1,CSZ`QZ'
M^-<\*>[^\2RS(@KP),VLA(>S4F;B/F;O#\C<96\5,^XQNS]B^2!AK<B;O(JN
MF_^16K2('^<$%PPT0*DVWB>=A*@3PD8CB?,A!V7KW7H!&_!U9[SD9>?P^@$;
MAP,8=S75'B.QUE$VWH[EV3.;5'J5#CZA=F*MG$A#CJ`.HRGJWA&`H.-E/#JI
MH(.!4T2)79Y@XQ3G=<DI80T'.;'E;5G)ZK@W9L8.SO-Z4+2>'E&Y#XMUG1Y1
MV@^*SLT=9?&S&+/X*<IL+X[`XCX,=9DV`@RWTJ_CE%Z5=&-L:+4LX-.*AG#I
M%A,?1\1`'`>*LR!!D.:C7&^&&3U]>O_S_=UF$^3[F[76"MVDIT$1%S=K/D*X
M"A^RB$VI^KB_']2=Z$D@!V53S5+OD%?RY2[LJ$-+;E(B^/._-T\@XA&`&0'+
M3Q;S%5O/L5"XCH1-S:.8+?;WEV:V-OP9X%9S>LE3'XE,\QAO/?,AR'^A9?7\
M;NFW]`,-BETN&@DH[@^H/7(+KJ#[71OTO29H@K95#8>%*ID":#F`7#68%76S
M.SRLL,@$N8-:5-IY\^XK1)OC):$CVR5;2_KX3MF<Y=)[B$:IKHIBMQ'7*XJ+
M+S0/XX**&^&F^V<#1E`[:A.,QVNXX\UTJ$Y(30=3%F$R>*OHOW8%3[FF-1ZP
M:@BNJ\E@@S[.!8.XW<7%+Y<YI5?5W8\["R?"GB_TYMYB!DQEDI,33D]J!N1N
M#C]"6]%K+M`"W)J#:^X&Y5B<I/G@D3??S>`-T76<QOSM?MS%$3_\6WKQ2I<H
MZ"[>W.S[@@=_;#67443(F"D&/7WQ94M#7@>+YAL_KZC+!Y=3=(#0W">29.1A
MH+O&O%IW*FC\UWRKDLG1B/TZ+8SZTDT2OU!1[W]/@QEJ@1LITJDPG66I".'L
M@H3A6L]P@AP789+Q7=@":%1F@-8R--2AQC^MAA'588`%0#8*8>A[(=M3]'6Z
MPY:BPP23I?ISEK!/SG,DI]I3J#ACW%4H9\':KK4<7L/&PAAW@^^E&8E^6^$#
MCKQY_UHV%79K5V=/.O!?S;Y"K[^<=Q8*MI@T]GG\$D<TC13ZVMJN'?+#N-<X
M0FRMFVMZ`,T\-=8&4U1CVL<TP5'\8GI8Y,WO@+3Q+&M4IX,;X%`:V%-O>/K%
M!\S`M.U5NMV5O*?;8W5OB*<1K(-=8ESLPXHE&H]8BUNC;B7=">E0RL0>08O3
M4;3"V@66K>OCZ:J_'P^>!.F>;*NBG.SUR/<RG$+>?-]37'C<J/%E;N<_:?AY
MY]3<\?SQFW6WQ?3%E[@HV?S+*D"BVV+;K5KE"5DR`\G`L\#:.R,1]PUX3_N#
M#O<U>5TJJV(`W<C&&RCORG[0HYW60&7Y.RFCP$7!EH5*WOQ^^>0@0+Q(RCC8
MZB=U$J,Q)V^=.N"(U3UK5?D\ZE2H<6:@68D&6(WVDTTC;43-3EP!-E!$0@_;
M<7"Y>_,'3+F%KI_M>(O5.FL"*[(T0E-!',\>'.4$=_&H4Z?LQR!.K[.B.-W_
M1*,G]FZB;13?!S['V]/]51IF&WK/EHM(=KS.9&&&T_T0,YX#X'A[;_XW@K\8
MN,"L:^XH=9Y^0OCSR1O^!E^1TSVI7H)TW^*$_T&^"&G>A-2O(OXZR%WF=>&\
MX8CT"SRJOL"C]@L\NGP!!%<UE](^AK=`9W\=5'K^VO_.J9XK=`3-&+V+I+Z"
M*ZL+HP8/H=FM=LL;KUJ6$U9T?:!?>*:4U<56#35P5=<^&LVJJP:CNDKJ!J4@
M;ZKA((%FJQ4R%OE0D\*=NXO++UP6;]:V%8H,F4';KC&LNK!(0\$#=+-5(YHB
MY\D"6W,9\;,"$+CY,5J>EKDO0YR\C<W'W>:1YC=K&;BL^-;7JHP,S@@'$*,S
MANIX5<GQ_!RF.GZI<Z]K&NAS&$=`K8@T=P.G/VFQ/WIP1U.=+!R#0G+$8"1,
M:NNJ)Y_0KZP?Y%313\<&]`!!BT_C:K;"C\@^>B%2F47`8P)7*.FQ(L-6AF]<
MJL;/!#0\EO:KK[/TB5]]N&5+XSDH**]O$`NOPRJ$/\H&*NX^CN]X,7**M^)*
M64U#6B)4$6U';*4E-K!8L>':U`9XQWAX6]G5X^-+3#^?QEGY3/-@2W=E'!9G
M6;[]0+EL6]G:<6:@%M<`:Z]6A20A1S2$$Y&?)1F.&.KK0NANF=T@_IE#?#R"
M&#(B9.;95!S'C?0H)V_5<<L5TF6<%^49&QR'0?*0QT%RL[Z.0YJRK=MMGD6[
ML%0JDOZ.Q)8ER&[=&G<O^5=8+L&!U"R(X,&]^IH+J=B`J9G9D%\=HV;N<D"2
M&O=V;MSV$8")@*_%)P]K\*4:/)((@9N(JT,&EORF45'WE.&.''646E5;\P;U
M?>QG8G@)2Q:8U=;\<W"%78'-/P6%7`9]589"D4THM*;NEBWC:53;PW.<NVHV
MA;:W8`GG?=G@'E[`@@-F-38;\BOTZFM6Z$A5EK\T&OE>YOR\%13;>2;9$W].
M]8#5=IM4+?$<W"T3=J`>EA'>7B.PAJC6/*1#AM"'F@/E.DYXUO#GN'PFG[Z^
M_YI<GJ\P.D^^V"M%0X*6#)E[9"ZSXQZ1`2__"V=B*YEM-OS0.4CN@X1:^#L:
M:A#71H>FEU@DHT?-8,)'(W)6$&.Q=S_LP80MF(*-1N)2C(J+VGM0D_H?0:U+
MF@O^'VG)&1<N1T]*)K!'3FILO5,*/K2*"K/!0@@*A!X`7D@>ATJVF&0D-V68
MN'AC2_(8DRB#TR,5!SP)'M>:.T"6Y_'7BU[\L3SHO];<>QE)]KB&N^<S-4AU
MUH<&),+4C]ZJ=4S_N)[N`L^'F(EWF:7T-MASUIK[.YK&-4HFL+VCU-AZG8/J
MH:0:"WB99Q)`G99OFP;;5I+ALE=C*]"@R9&*@[=TJ$6P>691/=1HTVG%#V0;
M:H=X2%L3I4EJ.=12!K]5]</;053)UO)YS+-\0V%QM_4W#-MON.DA1K*]=1!5
M]8;7AIFWDFF9%ZLTXET'XO2)IF%,"U4>LZ;3^B@S4)-L@+7?AJ$A(0'//N@2
M0>4T_PH0NF^8)X`8=HF0;:!-Y7'<,1GE-$4&=U:6-@G<?<TYR@/$$1E'-I#I
MRRAP96N_6ESV7H<S,#29V0ZB,>9(C#'P5@`WP2]W<?1$/XH/%21L(68YI]X[
MQ-''F8$Z#P98>T4)@U^(H"$U$6FI$,;77P]$=_?!$6,N,*8UQJ2A0N8^F$KD
MN/LPRLG??=B6\<M]ENQ$A3`;GV&0$,91&,;0,S9\&&G&8?((D`%P,/TV"(IZ
M'!8;KY$!C6$?HO)/:<EI]-.N#)_CM,C2,]Y&)+^C!67@GL\H[TOJ8-7-F<+6
M5#;'WDN[X)7*6UHBB4E-320Y0G/_BC%[5&'V!/W<@@XEZ+P&'0IR9`Z!K5`;
MU&4VY3C-18.K51I=Q0>)PY=9O@K+>!,\7J47243S9+\*=R7]L*=)%D?7=/<+
MW<2![?T#_R?!74N88)94-R9YQ.PJ/D[<9]Q)Q9Y<I:1Z`!%/(-4C2/T,1/[.
MS+/U3?^*`Y*9<KSZ,/?"ZEV+6+/I"JKIBE-"J^D*Q'1MJNE*JF<@\>(F550C
M]RB\'^.MEC^E,1.[0C1%>J!?@N+#.7LG]IO:&C@[BY:<03U&VUDXEH*6GE_^
M$AS(!W).:B:U3X76?9QP`K)F`KX^_WKQ&7!W)J>=@K*=@J">@LK'1.E:.NF!
M<?_2CJVW-ON/[#DM?LJVOS!WMGVTA>^H9P#B$HY@.EZ&8CBIQI/.HL3CMJ%'
M9.]>.4%ZKB#M&@(D+I")&*D]&RVU?R)=$$=)\%F<@CMX)4/DH*['()Y>)I4<
M5.5T(/0?K%#\KV"S_==9<;A[`=:?(\PVVR#%=G2DEI)QFSU`.^DVXY:F:;%/
M7H+4*JPSQ@+$.(_BTN\4NB2(#+0/JFPI5/9&VA/6MD."Q%";B97:5(_0^Y]"
M9?F&^?C/,5U??*'ACA?[O5FOX]#M^&F<&^RYDP':WCF$H"&"B#14I")#:.E?
M$TB/DR4'E&N),A0H:8,RDV3('`1CR30X0QIEY7]X)%K8K[[$H[<T>\-ACG&Z
M[]L+F8L_DI_YG^'O&BKF5Q.X;L=.]%W/LTT0]^137X#M@!"V).(A!M77E@/P
MM(Q3SK]!D;HNE?<:>/B</3QGNX)MIMB6@U>6*BE5EW;J+UX]`Q#Y'\%TO$;8
M<%*/YQ%S4E/,9QHM._%8`F)?^;WRW6%4G,DR4RL]+?7$(G#)/J96!-3RK&<$
MJB9',(Z*1$T!)!*3`>-?'U0T7%>/J770<O'W&&1UP7/Z0I-L*^YHI]%M4(I:
M!K(^V%-.14MBFY0A>ZXP?J4#^IY#4M7E[#`1@4S)IJVL5S/"%,&9$G]TA'\K
M\3?5]6I&2$(]S@M?X\E;L_0_O3&544UH&TX@-3%ST]6WH'BY'^;8@@G@=<4<
M:)"%;,S$W'HB)I/I-+K?9FF1Y32J4XA=;+$-.YC")C9XE8N,69R&O,VUAU<+
M$^--.GB+!F^39H]`<\SX@76`D;@5]L*KJ75BSLM_'Y`$H6"X>A+_</<G1CC!
MQA9'4/9\VWH\$00(U,FKQN;1(,497/`D_XG3!S$2.X,(LI:-MW*XI]L@%Q^-
MZR):EDGU,'MOQ)05B"=BC+-7TZ\AE(Y(0XI`8_Q:8-K['7/B1.)NV$FFVM4P
MY.-?U#1(=^L@+'=YG#[Y>!EZ1K#%3?48>Y4*N\,-!`FX)JC!!S2H"ZKCXKW(
M[KB62%RLDX(2Q!BI4!RO'SD.I:'!!\'>B%ABP+8?U<J"VAX,D_E7M0G+FS3D
M#6A<BF`-4,-VD1A`TZNL$I:D'H3NJ'4R`,!]%52KRJ"A0H_4?XTGC$UY$:=%
M26.;O)MA0IC*3<,8>FM##"/U.#39-8:O/_K>0&6/-`M(4_9HB&K."LC7FD8?
M3B5<KQ=M]^%4&_9:TP]CI%;P-5S3CU\3U%EJ(]M@?:7UD7O2ZE4C^7JZ-B>Z
M2LST2[EC7JBZ\4E?>=JP`S&M5GCM!.]-Q>`KP!8I,(!Q&&[[I:PVYQ:\EN[]
M=4=?:+JC=S3,GM)8]`VM6R]\H.5S%AT.^`>-3#T$GR=`N0Q>L](/(H@QI,/E
MI&W.0B2C$W(TC/%"X5),.A4?ZR9^O-!5O[<)&L/K+Q5:2^S!?FF]\$##YU1L
MI>]I_A*'M#C+BM*X#Z"2'*KWGQI/+[F^&4GJH42,1='>SPE'$+)Q!5E3"FY;
M#=>7MF.?BG9I&?D0Q&E)4UZJ224<6BW3IX>V>P.(^B=<S1`8L?`%L$I3YG"1
M30<'D&!8+@X+`],C]D\IDY;Z9EWEL5W2H899`YGY0W0PUT,&$?1RC:J^E#?K
MYK+'97]U++_Q,GO[^I79@E;Y5@"G;L[OCN383;/V-?='!H@F;R-['I1V?>N&
M&:!J'UMA&F\=RP>B,#YN,*HU3J(Y8+A'5KUP(`NAZL3%OM^MH/86X7-:A'F\
MY=_E9GV7[8.DW%</>,CN:,(>$MT&>;DW,J\6W$",K@W:XR76H>7FN*)NQ/\A
M(Q4#(CC`V^BIP&9KDE=@\1CQ^<"1,B-Y]26WG`,2LV\MJ6IGP)R5?[Z<Y'ZS
M_DC+>QYRNZ4Y+ZH</-EY"EH^H`Z#'F$O"ELM-J9!>!12$)"6`H\#X0:+B5/:
M!%>W\\%R=R@FQ87,P3`0MG$_0\?$O\A@G!<E/W]B/.,@X?QEA2(C]T)##>).
MZ-#TZNKQL:0=+$2?R.'POH(]DK!%PJ6""\4<2.P]@ZF@(#'[HQ*C-O-JT@G2
MX*N[HFG4+4F1YVQV15:OG7$?YP9KX@W0]H];ZUO$:710OZ5#ALC:.R"L(M?-
M=>GU+HWB]`F3K??];@=U9UHR;&;?5!@-C/\H*__0/?O^O)\2VWD$49SQEE,O
M]`/;<O".2F9!?#T'F'#^"*I>8+\:+T()+06I2>!=`F=$?$O=0;2I2,BN8#MJ
MWF4L5X@8`N=A:M!(G`@CF=,<'FC)IZ@3]U\T+"\*WDJMI!$_([3R'X89P%:#
M&,8T4.",#R/-.'&(C<<OL(1!&Q@A&RB$_;#+8,$%)<IW3V05OOWNN^_?_K3[
M\.Z'[Q'Y#%Z(D3D&.L$R*/PP1.U_X)!]3IO#R*%':`.$`V%1&WXPAPY6B'O!
M:D9-.FD`PQH#,(0X"^`Z%L];>0SK%L#@XM2(VS^*;H09O^O;HJWQ"]0Y_?LN
MSBL_*NK,%!)'PT&Z-<<4%LRFU$N765X]S<H+47``=4-4J+1:AC=.KH;B\42L
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M^Y`W?)-*]NSW@K)\IF0M)JAD$\1_79#>95M`+VVB23K.)B,[L5#:8LI\+MIY
MX*R0^7>.NL.@&9TEX]FUX&K-UBI_%'NB64**%4.8'!4[S&[*3C`1:Y=K.W@7
M;PK0UMJ-*;2<!F(FEM=C\\S!J/*2<(5.9]H+B0/G(N::+!H;;OX5OFJV9UE:
MQ.PYJDVIIF29@@5L/3L5KEY62;.V#D:B*6MGCR.<%8>[@^/[29"Y*7K),2C7
M-TP_1=]4WFV86X[3+-T5M\$^>$QHS]6I+H^;9<#8\H3JK&N)?.!DI.9`!`M2
M\1C<;E5\X-V/:8$_"N#;"OC0]J&8";A#_@S,)T?B>#B*NK9_LQ5#;V7U%Y'E
M6%Y\X2G#!7_6QZQDG*LVPNV](2N/Q((KJ)-B@_YXW5:TI$-,)'65Y$\Z]'A"
M05-`IAW(J80L4^A)-"-D=\=G,<S(/"1KX1YWFLQ93GM3^?XY8&MF]1+$[/WB
M)"[WI_OJ)>C-NGHKL_PA![;P=Y=-\8]<8I9L2)</.=W7.DPD)U>\X)VJR?'S
MW"(ILNRG0LY$T)V)QWTMYB(QY_-,,^%Y^7FBJ3"?`"3.EKL^,+P8;<;36Z]]
MS-([RN_.<.UYE19E7.[X"P3)<%$CM7X?X03J6HVA[)5H9*NR)2`'%!`ED*9%
M]I;D+;;X`-M`\2]`5\D%G`X:,H_(2/;&O2`]&_\($E-$FR#<&Q<YZXZ'B?P<
MO'%OBU_]%4DI,^V[5I<<M_4K0XBG\_Q""=S(DAR->G0&^Q^HL)F-^.S>YADO
M.QJG3[9V5<4"]D!%A:NW@NN!I!V)RX(Z0-FV4'`93&\LR"RD7GP,3E6&Z2?P
MFMLPPV66/]!\$Z>!=-R;R*B1M33D!&)'35'VW;!NX)$'RCND?%??$,/;7T^,
MU19>9)1U,++M:C`;1GN#/<V'U(%$8NBMY%+M`IBQ6;K"]C4-"GKQ91O+LV%>
M@?&=J2>AYP%=:5N!K%<4EP\C[;AYBI[:IV98PKC?L7T:1](>HW;%:I82J#YE
MQ`UAW=%N-_I12.`UQ77B9%17?)#!="E8;#[IYR#1GWH.]-C3T<.T7-0B4J?[
M5,,A3RY]P1RWSB5YA0GR:-(75#=TG].G(.=UEQID"+T"`Y'2=)_4$$_72&#U
M],2GLJ2K3;:SK%^F9@);@T2-3=-GH!E,Y&@4EM`5CY"%&D\@1O.>3SPN'20)
M'S)]PQ"/VB.3`$0601B3,(-")"H.TTG_)7.4DJMV5;0Y5<7I_BS;;(/4K`*Z
M)4?8UB.&J#7*0G`@'1;=K+R"YQ)4;.#]!E_4-[N2D8@2A]WR)&LQ`QV%TLW(
M+/@1>CC3#'AT/@&:`B3>B)/4&[16,6(WG<XZ3@XUU%D&FMJ,,P[?QG`6-#JL
MGW&\E`YSO(,R%7:9`'649XY%>R&`C]61LA%\"^_*B.W2(==5&.8[&MWFV9J?
M'E4Y%<79+L_YW;LT^LBF4_['F'_FQ!*J0:@=[EX(1U*3+CD_\\71-'0:;/3+
MEC<RZT$"ZR'JL%2U?45M^"U_$O(DW\;^^*,AA#_S:#'T#SJ>@"3&^95KN5A3
MT<DZ[O5B0!#O/UHTAD'^FFKI1=ZI@'Z55OD+ID9FF!;*FBB0]./*;;G[.*WS
MA5#8#$,$#Z)X9K]D:)F)<E1H;(5N:6F-PB#ATH(QW"5`)R,C[>U'V$%;BG&\
MQMT_9A0K]V-S3WS=+AGA4`]N<,MCN&"-[-$8KZ6%45Q3.0T*7A)WPUUBL:/N
MM.PXW;=#JLW>ZG.01S?B"*WH!/7NLH37H>-_-+5S<ST=RE+.-IN]'!3.Y>TC
M9T.ZC^KV!^+QE^ZX.G(A'GA"JD>R'SIQV9_Y8TGUW/]<5LD`S^ANLPGR?>>F
M6D%$JXJXC)'L?"'FHBBS\!>2R6P!]7R`N4+SZB^M,S73HU^Q!?BXVSQ2X_*?
M,[X`M,LWQYPN9`).B'PBJLC%/^>S/Y\R=?V^#/(2[9S*/W`[\BF-2S8QI_0I
M3E/N:3P&"3\KF&E:+M+H]4S*A?2]3H=G!'S[,YN!,-HP3?_TUV9@?Q3.*-LB
MBI7]8YZ9QQ%G>?1KW5P-S^.<9D`^441MQ#/Y;[*E8S>`<]EJNH-MQ!,GIK!]
MJZ$FHE+Y/\XT!1%=Q^P)[,U^W,41-R>X)N*J*'9]V*]V]ZA1S;-N'8>>N[A9
MXR(MO^?Y+F?F5;Z,K'LC_EB];%WU9B@JJ'<\')X`OO-SF94Y;5#]G(X90G1V
M,,ET_:6.U]7EIA8W+?-CO)@-FI')F!]@:R(K+V&^CQG%19ADQ2ZGH(C[RY;+
M=)R^4.8MY5Q<`Q(&Q7-""SXF?.:B/]UD_"`G(Q57(AQWR[.N;/B-K[.%,]O9
MVK-_;5O7RRQ?T[ADDM8X*TMM70<?_5JWKL/S.*?;T'DBE.,`.)/5J%_)'M5P
M]72WZ.O.YX^$<JI*I<`88\!I4<0P0OZF2?(KVLMJ=/6L>]FAY[XV.]=6D=#9
MN5FC[(.O`+X;GF5>Y]TN-T^<T>Y!GH4:SNF@LIO+%DRQ%UED6CI[-C8<XYYE
M/DVVR''=T/-?GS5H^QFH,F)F,>$##WZM.YZA.5P@3,J?!Y4!`S:/G3&_&F]6
M*8.S^K+]I[XVW=5)E_@+C9^>F3E>L74;/-$Z"G6;#_>96RJ'1/]:K]WC-9__
MQ?+7ZO<@U8NT#5[$J_RJG.-_3C^FO$++3S`R4_^ML@^GGKK_/CF*)F9OZ<Q%
M[3NA<S$*J^P52S?#S5N<\I70;JDFG7<7^U:X)T8N;>5F.'F:=?KO:%&R/_$9
M"K/-ALV[/([@-VBSXUP?LH5PS!#.VJA9>VWYB-.K5K_]\(3O\^K,6)-9YVC)
M_!R:B=\._;YYZJ\QJWT;2+I$9N)P?XQ1O3UC<J!_.B3T[!V<W=$#GP!?<0T8
M-3S-!F[:5WMU!G`@<P/%9L[ZO5[MCL[^"\QJ]@:3!I$9/JP?8M3DK54YB:]W
MM^*H0.;=LMB^%#JU;7Y&B>F$S_BUT.]4)IO_Q?(=4"EHI),_?D("FT6!0S@7
MS10S>R<0_?PXCNO1^MCGCFZ"F!]?GF5IF0=AN0L2WMOR.RO/>NE7`W6N%_\.
M<&D!S5N1SFN)SKUX#@+`/X?%K)$W;`NSIT%>?'4T]:-I!+`>.8SN&7?*%WXO
M[U8Y4B0-+-1;[>D'/=X^J%[9U.,&>CG0ACT`WV)8DY_J-?EIK<E/Q\^_Z5!H
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M&WQR5T]/N2C7=#P;**Y98YX>^*O42VOQ*=(VG9_^VLQQ[]*`Z$H\:IF7R/\:
M>2<4>]7Y9W[A:OWSFQOP=$S;&;\,XIR\\#\>M.N,*-\CQ2F;WUT9)_$_N)KE
M4<G3)`A_>7L?/C.T11T!Y?>A^(!-%M$$WT9T^5G5F2R\-=H7U+9+IK7J7^BU
MV;0_BZ2!51I=?-E27L3@(>._ZNRNF\4'LP7U>,'7ND7U^29SFD#Y7N*$J'XS
M4F;BUT?!6Z7">@TWRA;\.N.*_5=5^M%;V<RZ47%_N\65?OA,HUU";];B0OGI
M_BP)BN*!OZ+U_D/'"GS;H,794W75:.YYRHOV3*\)"O*SH/E/?#[2^(<T<VTT
M?)9>G+=Y_,)$Y)9Y]D+J/E";0LLJ:BA;KD1SO/JJ@:0927Z68T%6G=7<&NA6
M!>G2:ZNMM276N7)I:85.P01:V:FP:>J-22T'N<Y<)MI"KPUS6'K5/;`'W*P[
MCL3J2VS<Z%E!#*7/5%B.5QD?QPUI=YO`'?^/6?HVZ/SN@?U8!*',QOR9,\.C
M[[3?3:ONABF77G?=T@C,+653WYGY[L2[Z4%K]M`:TGX^>ONM;NF4\>5\GO%,
M`GR*U7%A&*E<6]Z+*^.XY'[N51K%+W&T"Q(K93Q,#*:,%5AZRIB/X]JX'8E.
MU^H^BU[7#E*"+ZN_Q.7S'4UDPYOG>/N07:1E7.ZE3K#5M=;LH76M_7ST_=1V
M,`\3RN%XE:KC"C!2JK:\O>]976RV2;:GM#B/<QHR*J[+S]BS=DG)3^3,-N56
MK$!N,QGC['76J0E)0TD8*>G0*C=6"P:M)P)YPF^<-+BXX_.8\6M4&T$Y(U+[
MNSL3?-&H^:+BKFM+B^0JBYUPJF^?&/)9VI1>57W2W78EQ]30AK"'YGC=U0.`
MU,7,+P]NEH=7DY'5/2)=6@Y$#+Z*R%_'*;TJZ?AMY!%BJ)V*"LOQ>I+'+<T!
MS,]\+!&#\6Q5M-]%NU49IO1WUOZ^8Z[?`_W";RH4J\="W%HP59Q:%J"E892X
M>J9;#"3U2+:WK<9BT*5.4-Y40[]"5-+$%D,I1R*KQJ$7EO&:&0IZ;R'FF8\B
M&V!5%+M-TS)7)!*<QT68[=+R+BA'\Z8LF8'LNBRP#B:("EK2(6[SB6IRPNGA
MJS3X(I6IL$%+S!LD5%"C&FH^!U3[G1?45X79A-G*JWH;9LQI\30A[J?(REKG
MHCN\3%L525#%T=&J2(3Z2,N;=:?*MG4RD?\#H;=[4\S9<-</R91(KLT-`LGX
MA/1.]:OD2\:>N].=!R!PB>:<+-F=F6,N!!O^4]Y.CNBM=E*7+4/CFDPN<F9I
M7]Y/FZ:@ET?2Y2J*1$N?(#EL2&;D)LWW<+C27//,Y6!:.#$LF4D&2F8V%;C:
MA]:](Z_J^U'0<?,%Y[/56D$['T6WVY-"8P'X>8LOLX&2&=V<B\>]5/75N&VU
MS$0=K*:"96=:G_*Z1:F\;(PDJC^W)ARI0C7'DU_-9:9;MNH^9%&\CD-!<DZ+
M,(\%NE4:J<I`SG-]S>A=P-W<>6=ZAEM(_,&D^^03TGFV..F;I[(CP!U<MTGN
M3L>QQXS/45Y`U.>]%6KR(J^F5M_%EVV<B\%F[O<,#WQUW4@&YFP&O=<^92ZO
M>M&>(9:3AJ+.VMPKW^#D<;JGO1J?3OR#7\!LXAIN=4$G>_:K]=F&9W(&724C
M`]630((`*"?PI9J0[>"$O%Y73".A\[I>0P]^-:[6P6WS>JO=G"$-Z;A9&DJI
MG__J'+'Q&5V@*D:G*E1[&HJEW,4RLWI8_*D;_7S]7INAU,[::TWY\.6O^&<A
MI5%QR29;'"X=54@:VCYJ39`!0VCORP1SOR:`I"%\55;GNC=-;H2B<-?<^[F9
M4?*J;K1NP-NVH$+G]1BO82-79IS;XI>'$\&<1L->%D]020OC*EZFW*!\!V.T
MO1O!-2%1^@05,0);[HRR^@O)^94S6;4KS#8;!DY::<!T"J_E9F!T#5DM+9[U
MW9U[FK_$(1U^N8]9*IOZ"2^@$/4&NW\_RXKR8U;^E99W-,R>TO@?]J9WQA>!
M-MESSK'J]AFI'J94)R>D>:+<2K`MQ(&ZX0]D8TJRIR5IGXDHCK+DO'Y*\^;/
MA]%@.JR6P1V+V27;R"&9[RV09+&*K<]'^EG\Q?A:E2$SL!"((5:;#-.JGB0C
MEP,6/B&?%.?A5N/`A8D'.PC#!1IL5JT^:F#$R3N1\U,:T?QS'O.8ZNHIIR(@
MT3G3-O4K#)F!7DPSP-JW0RT):6BZ*2@H]O&3P`L:>-&,\-POLLV"#]DU-U-Q
M'+_P-LH),GK(M1?OM7*S_DO5*\#4DH]Q@2L8.H).;]-J$AXZJXE09'QXXHH[
MN#XK<`$61C59D2,%4K4LO,US4WEU]<3^<184SY?4_(*6E@6H*5;BZBVGIJZN
M&$GX4,+'XK&[#E@"@27D6-9S8'$WLOY@D%E4O02-VU$%_<22O2H974KW"NGN
M7SO0D8/<8M+B&9/J>CB(9$^&10I"4&,!D>PYP2"Y<3,N.>H[,QK:Q8\"1$6*
M]A9Y]%^[HN2O9AW*5S,"#\5K,`Z7'^FFT9!V/*8PN`6F;C$()1;XT/782C0+
M/2NY>-O*VI]NCM5/]]6O?LH2MLTU,YD&7$`LIPFZ7JOWNL5>0\2O[5:_)14=
MO"'U@D8;:(_[>O-(GF>"9F]79\.&Q,P:"YW:VHZS\%8-=_0IYK6<^&>[9U_/
M*WX]S@QTTVR`M5^-N24A#0W.^+4OO**!AS-^/0L^9+MM4W$<WW>/<O)6'1^"
M+_%FM[E9KZDX7\OC<#0Q3D,(XCLH,!ROHVH8J<<1,1#>/[!\_:Q^_>TLKV_O
M`WB]/Q([KQ,#M6D?I%IZ"WU3/M.\2N6SKO1P1`R]53[&<KR&Q-_KI%0<T6^[
M5V\6/U5@`-\'#RXGH[WO(27`R>J:%H4HY6(20%;3`9Z>'B,8.%=LAL"'B2U>
M?+6+8EYJ?2@<#'GT.;ADQ@X[#XD6SPG</1;T[SMFHB]>V#_<.M\.\H#6_@ID
MO82_9A@1X_!VN-5\*;-+PD,,H-<;>YY-VS$E.5B>J1+/Z$+C8[$U'QOY//KT
M2@4M@B7FUFI,PPB;<NMB-%QX6+N'C7X^)V77<@%>CG9-O!7$2+2=LAE.WZC"
M-P";#0,696W1A'R8$E@RKC6=?6PTQO6B37YLM-"UIM]/?[E=PW;\<9QR=QU]
M/5T?H"/.1=6D1-,0:*`*[1@/F,K6H\C&%E91=P<":PXT#RJX1D&SX$$2RC:4
M)$U)Y1$&B_>2$U?=Q%6P,WYI,^?!E].@&-R#:G6@CA.TX=&B[+6:D[?_[F5#
MB'8\$02HXN(NN*I&%V&+ZW$(%[A-'5^91E95PT:L2@F;&=M?_IW]S/[%;]:S
M/_S_4$L#!!0````(`+I]7T4J>P=#/$4``.3&!``5`!P`871N;2TR,#$T,#DS
M,%]P<F4N>&UL550)``/PYE-4\.935'5X"P`!!"4.```$.0$``.U]6W/C.)+N
M^XDX_Z&C]KF[6O*ENB=V=D.^]7C793ELU\R9)P0M03*F*5+-BUV:7W\`7B12
MPI4$E03;+]TN&P#QY9>X)1*9__G?WU?^#V\XBDD8_/73Z*>?/_V`@UDX)\'R
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MY-*+7V_\\+T3')S&6\*XPO$L(FLFF^GB(HU)@..8#L"G=+7RHLUT\426`5G0
M_M%Q.9N%*1V8P?*!=FY&<-QDD+?[8$NXC]CW<I5.-L^1%\2LOU38#8`(FVK9
MQ8<HI-J:;-@L^$=*UHSZ!MWC-M.R:_=A@A^\C??"BAKWJ%J[M=9&Y(T.Z+>&
M*KBKW7H66*U(DHU.*F@Z;)FRTJU&L[$A:ZUE1YD.))L&?2HJMOS\4_H2XS]2
MBNSZC<%KT)&#)NS-?.%V(O*V$U$HGXCLS(!M/@P*_YF-XN.#+S[;T2+0&)2B
M04L+@E>9R1MW5=*8O3FYA7;LMV%O?O;V9M3&G52W:66N;MR_6G6;L\3+;KC&
MY7"-=\/5VP[7=3%<YSCQB-]ZFFC\W3Z`'T&A'\$>#:[R7CSC[TG:Z&!J]?,=
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M=D>[4>L@G6]Q,&>76OEO60.6;GBS^_AP5ON<SV[`PT@U?[/?(%GCDY<XB6CW
MRH9\AC=K'FG713]_^N&S=B<+D63BCO'LIV7X]GF.R6?6;_9#!N#'GT?%3?Q_
MT%^A_-./>$G8%X/DWEMA3H]%1=&HZ&"5P4E4[ZP7S<HFZ8\U^@Y]!XH2G]?9
M%?"/LU?B;YE?1.&J@02+OH1J*&$TQ]%?/]$Z:4P[&6:F`+9E.`8)EQ1*Y/FW
M5->__R_>2%G8*XO&#M/`P5+P,#HV$1.*8\ZPW/C>4D!`K0PZ<5+P!Q@*@8^/
M+?#+-&(P;TA,9^U_8B^BVZPKNG`)9"\JCDZ=I$$&IV#DY-B,E&B>:;,"%JI%
MT)F3DM^'4$C[%$K:VS.&1/FY9=&YT_(_P%(0<09%Q&XLWM#?Q`HJ]DJC+TZ3
MP4%3T'$.2T>N)?J$5,JC7P9`R1Z>@I0O,-O4&^+CZ)(.UV48R3>IM9+H5R>)
M$"`I*/@%Z*00KE9A\)2$L]^?Z+D7Q],T85[?S-E<?FR05$2CGQUF2(FL8.Q7
M`6.?]TT0^X*P;);0\.-NI$@++W[)"$CC'Y>>M\ZU"?M)7/YF7ZV*7Z.MT^]T
M<4,"VB%")YXP)@I;ADGUYN8,"["><Q]2-8"L()1APU2<]?$@QB*T;%!\"TR/
M(;EU6]+_K/-^;N4#(_'2]^)XNLC&^>0[X6T'E'6@C"5B<A0D\@"XS6<5T56X
M\D@@(?*P,)3518L9/IE\$&ZS^$2WI3B>/)1]S<!]Q:L7',G&I;@6E!E'3I)@
M=,IA6&+V#4<OX?;N!X;@BT8$<VM!68N:$RR$(391N\?P92.&N;6@[%'-&1;"
M$-O$W6/XJA'#W%I01J[F#`MAB&WL[C%\W8AA;BTHFUESAH4PQ';]XS`L\!LH
M9I[G]U"3-8U:4`8V$]8T88@O`7K!&BV$F_`FJ@=F>6M,G12)^,Z@#^S=A&G4
M@#Q1-30"-A29<B<%(KY9<&I!+(_G=R3`M_1'+3/1MC`:N68@JG?=ULD$R*HP
MB6.<Q!H6YWI!-.J+4:C.!I\Z3M\'83'(<15^+=H<[I5'(V`[$(<=&8V\[@^"
M31;[A46%H/]C3R#>/!^S.!')I1=%&Q(L_^[YJ>Q*1:L^&@$;A<0D"DRYVJ@&
MH01TL[#VR/SZ^QH',:;`I\DKCFI"DZB`1FTT`K89F2J`+J9AF`AUF=[##VPE
M,N7TL/>VS'])Y4',\<=N_JSWP?=RUXKR;>\]E@]:<34T`K8.:2_.2A3#&)]/
M>)9&V?/$-?,/D)K\:B71"-ABI,TDK^.VAB?H*4<YG:(QL&G(<"N<]=>661UR
MYKPCW@OQ2<+N>(/<3O(:^A17G#\&UCC;Z#:!QGWQ-=(YN1JA&L8,6X&L?[(5
M5T)C8/N2$85*+>"A&\3!IXCP$Q<!1ZBHZ&^BE/;]`+QL'M=O!8V!35@*5@43
MOR'`(>I&)411$Z7@5D=C8"N8#6T0(QO&TL`"$I58U;1S2J,QL/6K$<LB(,-P
MF=G%)3*:Z675T!C8QM6(9B6B83C0&+',DP2PK:L1MP(<MAQF>G)VTR,2C8%M
M6G9WY!D<6^MK4HD]<_3[)UFH<_&MD[@6&@.;O"P0K8(WC#6XD<5%(L\38#N:
M!>(5Z(:Q%M==DU07S)S2Z`3<FB:E27BER`4RB,-RY6VNTF-@KR@Z`??%:L`F
M%\4P#KR3^9SD_7[PR/PVN/36)&$@Q+8.?@UT`NZOU8!9&9AA++R/+'IH@.?7
M7A30C44\F<W259I9<:[P@LRD-XSJRN@$V*K5B'9-7,-8@@\E9+3E0B?`%JU&
M#`MP#.PXS-UZMKC"1"?],6M9.#B+,7:F!_V+.U+/O?@1A,3^J89*>!IE79UG
MV\,''&4Q:[0/.J(&W`Y:HH]Q$*>B.MP\:-$D35[#B/Q[-[J5NK!?L3?132SH
M``_;,(Y1/)RW<9P:$Y]7ZDU`%&ND[W`-XUC%PRB/VJ99$SIFBGWJ]\`-XU!5
M,0DU6/XU:D.'5FFG!YH`K6W#@2^U:I$*M19]22WHD"O6F.<!@PX%T!'GRK5>
M4`,Z^(IEKG>@;`4-Z-7(UEO@I:%+@1T3+/.]AZS#<`.0=I6MT.+I8KK&4?8]
MN,"NMP'M)=YV2L.,(J@!$K[5\W'\B-]PD&+YH[6]DM"V$(D,!1;HP_X/PLY1
MC(!@6;R7U0GM(*P#;=TP9E6*9!BVC$?*!)4B>Q-_1=77#[-'E@5>Z66AI!ZT
M14/*F^B24(%G$,/Y-QQ0R?CLF<=\1==$)A7F(:SF6U$3VI#1@'$-1,,8XE>8
M]I;N_5C?I1[PNV+0]H@&=.YW?QB6Q]\\$MR%<3P-KDB\+O;NTT7^7G<D&Z_2
MBM!6AR;#50FHM:V1E^06?L=ELM."MC`TX)6+80B>&UM@^;:3Z:X.E;O2T.:#
MYMOE.H8AQ&*Y#X.PCJX,(*0^#RGK0@=_-29:"]$PKGYN@P135C1.1'LEP>/"
M:I'$YY<'I>WYIQ>+Z^Y-9&4[L?V=W$2EK`L>3;8%XWK@AG$>$HJIR1P.'F^V
M!>ER4(-8MG&BM?NJE0,/1FN^'A]T?P@;Z-)?O_0AN/!B,F/V.>*GB?3^55$3
M/$2M,<$Z@&Q=MD->POX#D^4K!32A*X2WQ/<I"VX^7628*]>/^IK0K$'PJ+;&
M"M("9V>7]WVYQ66Q?F_\\+T7V3FWG3%SB#^H!G&=2Y<9UH^'*'PCE*6+S;<8
MSV^#[;%_0AEZR]]B:)R*C1N#OA16T2%<FQO@M'3;!#F7-]M[0>^F&[&ELRNS
M%U@/DM3)_%]IG,>O>`X?\2P,9L3'-:3/H;U)HHO/05].VU2QKN0SA/@SY489
MSR_#%3O6JBY`^16@;[:[HIBO4&(9#,+_H7I)3'_V<49F,)^LPB@A_S:Y(A=5
MA[XZ/ZZ^Z$ID&);#@=[&'U=EM"_RFUL>6]XU"'+0L8Y/@\M7+UCBV^#&(U'V
MQ&6ZV!G*>?M<[;K0E_?'40,C<0S#I8/*+\)T3;W"^?\K$BM"T.BY=6LV`NTW
M<-SIQ$PN0WB#)D&LG7Y/NXT>^"88T&NL(H=@!['//43\D*>]NBHP<--?&>F+
M3H/@/A!&S.LJCS;R0;A,'.+?2^ACIC;[E<&=)CI1$2[*(1A5)-*JAF)JM0!Q
M&@+WLNAX&1)!'J;*Z"0=,5(=G0;[X-5A2K^N'FGC'\`-A!)]/6M)&SVJM]0'
MKY$C*1`'^#`,>/IW+U9NKL']2"Q?9YK`'HC[(`_R;?"&8UL.#Y+&P',K6_5X
M4`$=Q@Q#9]#"\C69_9&2"`L3V4I41;\1\%3-#<GF:XXA[D&<K_4%:&5N`<\`
M;55A#'%;.T[U;TTJ`OS869,DC8'GG;:Z)JF`6MO$`!Z8'O&ZF%:GBVKJ/XE:
MB*J`)[1N2"-?)Z0H![&V4#G-,)['-U20+%H;"QA.A\TNL)=L#Z*J"Y[YVJHR
MZ,&%M<<)_!*J7;_^CJ,9B3&+798%+J.;IG]X442W3_%-&#%YB5P4#)L!3X1M
MA?[&R(>P,NA+T,H6`CQ#MM4)PQ"WK=?PD%M/AI=E+:3_8P>Q-\]GB^<#CD@X
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M/7.33?BL!I7BL2<N43\TYB1558CI1M2GG;[IS!0&K4`/<AT21%?G1B"',_1*
MA[2:(]_Q;_7Y3G$:XTY9%R;!MJ!39B//I!GHH:?%@]!3P0CF<`8?<](IG9>.
M'CCF)3&R;_`K0(RN>D]T!I*@!O28$8N4/U`D,(8S)JJQ1\""J=\&E(LTW_L'
M\[_A^;*Y8;!%JS"CR[B[>D.P>;/PX[05@Z+!W$X@PQGQS">1)"5^>GIF)UX<
M0%BN)%TQNPPP:0=BE&MU4&=<FS4$/9*->1%<>AB#'LYHS6WMQQZ8^5<U1EZ]
M($B.8.9<_1KZE/`X[PW;YIN-*NTVH`?4H;@%SB`F@(8S6)[2EQC_D=+6K]_8
M;''T..U[W]=R2N)7`1E*>WW1&CJB.M!#1298D0>5!,H`KS;#[=6FM[W:#.57
MFQ]7G#V[XBP9I%ND%]JSS(B>D;21H!57@AZT'5\;RH$/(+@-R\\23Q=[`W>3
M_U=G.M=K`#K+0M=JHBV$(<37J@E07U-DU:!3)'2L'RKH0WC;]XT]8;R.$[*B
M<I&]WZL7A,YVT#'SAV"M/;P"Y/HA(F&4/RY[Q+.:6]\N%G-EXRB]0S5K"CK;
M0<?ZTD0<0P@Q+7B_J+^XZ-2'3GO0]2JC*X,A)&X4.B7HZXQN$]!I$CJ?<O3%
MT%GJQB-JSNUJ[9$H>T@1Y0E!/'^ZN`M94,LW/,]C,.MK49/FH!,F=*Q1345B
MZYD)I'95W"/T=4A<"3H;0L>:(@=>Z,,O+NM#Y:G,5D(5AP*EZ4VK/GC:@X[5
M1%\(A<K\ZK+*;)]W&BQ"@BK@R0ZZ7FEDN+>V-I>5X9'*B(J<;>RO\!OVPVQK
M5J0`4<X>&K7!,QUTK"*Z(BBUQ?47U)4LFL6CB<LP-CI*Z[4`GMZ@<YNMOAA*
MW7':@'OM10$)EBQH5):455]C%#7!\QATK"DZ\$L-<=KL>X_?*U=<41C0'V>X
ML@735QG3IL`3&W2L0XWD42I5:\LO[)*U[T9CJDM:]<%3&W2L0/I"*+7&OOG7
M+=>D9_:LZ\,QJ2^.2=LS?B6UT%?L,>?3^93NP&9I%%'V,E<+G5FA47L#=V=J
M+)-!A`Q[FKWB>>KCZ6)")X(Y\5-F>"PR)U))7'^?^2F=C%@H&[;[3TM9[V_P
MM!8EZQ\;N`]5-P+KS-^J+R$X8%:Q@07BV.F>5,QFXUZO*>@5IWE(CB9(A_-R
MI+PU]RH7YC!C\<\3G:.54T=O1EP7D3@&.L@JU\,P8^LCXD!MHN=VW&Q5E#<!
M/38[B21@`A[XH*4.M+J#4":IF0;%\P=6(B/L:SC'OG+'9*EEZ&.1596Q*),.
M`T(#!J#P]I[SPRP+#H2A$(SDKX2**PD#7&8^W?[B*TY>P[G>J#5K!7I2;QE4
MHB'BX>S"\G@`,"/-I;@2VV4^,T/1:9IY#.R<""9L`E_FYK"+S:Y,H5&3=R_*
MU4AK']7R&]!C4CLNA4W`EH:D#V.^SK'0KTR^$]G[NEHYZ-V15?[X*G*`UVV:
MF\MI)XA@SBP$]]X*7X4KC\C>WW7Q.>C7O`<:(9A;.H+NMOY=K]9^N,$XBPB4
MIR3]BE<O.)(MOJ(ZT*][NZ)8X`@F$\,@KE!WY]&+S;V7L'VS?#'B5X!^Q'N$
M54D,W-;!'&A^V`'36E]XQ:'?X8JY47%9Q^#V1%]8E)23>ZT<]%M8$15\X@ZZ
M[C9CRLE*-%?=D0#?)G@EFZG;-P[]JO4(L[H=(=D*]P*EA@HY5[8_<6'^WC3P
MGVC:./2363LZTLP<HB>=088F?-GY_\:E_V^\\__UMOZ_Z\+_=XX3C_@?#L"]
M<P#.XP/0[LJ]5&F!^S"(ZDZK"ONIM6]`VT^/Y2AL0TYN;[JVHKC8;'_\&\$1
M>U.ZN6,O2A5'8+T&H`VU5AE7*)52$`/1F$)LV9@[1*P\.ANU`VUSU2=7H1RZ
M8`>B([?!.DWB3$`CY5%<4@O:TFK,GT(-^`@'843E81PWXKZH!6U.[9#["L)A
M9+CG@3QI1'Y1"]J8VB'Y%82V3"8](;_%)DO'EF?U.]`FWV/N3&W)"WJN$GC_
M;=/1<^!-DIW?Z=Y34(G5P4:ST'9CZ^S7E<R6B`:Q]]G=WU0$H75]6"D/9>&U
MQ:3JEG$/ZG`\2:T8;$<?%MN>6&SM/=G6=GNU\:&!VV[M"\MM4TM+*5QL^`VH
MO'"[^RJTJ=B^@O$5N6,1#E&KM5RR5%6A3<D=\VZB;$-R[-7TY>V3^ZX.*7PZ
M._*^A8R^V,Q?#]@TW)S!`QC0-I5>[$9TK'^V/@%M679DGU&3UX>24HE,5NSD
MWIV&YNU#VZ5MJDTGBKD3TP`=_J;;@)^3;<#/J3S@YU5N/V*ND"D%_V%%:FM%
M$MPRM&-)9`NRU?1`K3\VQ=.'<TZ,9S\MP[?/<TSR,49_V!]:]%?H#B\]_YKB
M2#8"BPRG%)0%Q29)=?H%((5,=DM*W@FA(6*_")3!02"T0\GN=]:"6`5SYZ18
M`H6G/$XIJ%,Z3S*<2>FPLX.XR13&XKO8:`1IT*@-=73O;I(R!._X0UEQL$;Z
M9:615J,V]/E<DT9#':CCZ\-6I+D*?/6H"`,<;:H`E08\22WH,Z\F:WS*%;@&
ML2K<I/0,GKTH#^8WY#O[*59[=PHK0;M&M>);#FL8EK+MT>R2Y6JGRR)[@*E8
M^X5U0/V:.EWQI9`=?PY=A:1<U@\+@^=NE7+#IU.`PNW%FH6)+%Y0*V?L@[+@
MB58%E`CXXW8?BKY.S(BRBS*;S8.E3^UNTK8NGD*Q6N<^M.P-WU)X^36"RC?>
MZD?`<JY:5PG[QFN.I`9QHL@CI>91AF^#-QQGD8RG[_0@%;^2]0..9DP1EC+_
M6>TVP%*U=J0!_.7/3!S]#,E?6<)OXSAE,_EM=I]$:&\SUF["*`=Z&R28LDE%
M1O\9$_8WT6S5KE6P)*U'T1Y;`AK&P;<BB`<OFD;9*6*>/7TI_0_T]L^BVF`)
M6X\Z%>D*8ACO7X7FI.LX(2N&_%N,%ZE_QS+^-#&.\]I!(R"CZ5$5R5PD/=V5
M9SK/G)Q>6;RT1T:6:+7B%$4C((OI\98@$>J"3[!DX.J-2MYSC;U'7A"-'+:'
M&F\G*I@+)NTGZ&[#8ZEP<[;?T:145@>-@>R>QV-7";\@^MQYQTQ1!M`KF!B+
M?[KTM!>;VE^TG],:M`?M-]EEHEH!7+?O,_3`*NXJ]1OISZM40Y;Y2F,&?#B:
MHKS!/"P,_5[4C"HUW?`//D7)^_`JC)@_N!]ZP?_BA"[[=%-RZ04S'%UB9FZ2
MNXWJUH=^]LDG@[/!,@'D]A"]"X/E,XY6#VE$]Y0QWN4TO-A<4F$M0[9I9?<K
M98FY8F9OV"+T@U++TWP+*3CNGBI&+L"M7!D:M@CMQMI"!4QU2BF'GBTX]_C]
M*DJ7D_6:GGL]:?@`:7EHM]46C'!6'1G*?EX6/N(9)NN$S9G+U&?5-K3W4?CF
M^>P5Z;>GF[DG9U:_!6B75;M<F^$>QM6>8&&]DWA4Z58%S\URE$-B#:[CWJT"
MB%<I9OK_'%;_?IE&C(3F5C:=5L']975(-U(7;=1]75QVO=YF18^+Q$;B]412
M"=R9MBU1W(5$!7@H01H4=P%`X1<^K@0^K@0^K@0^K@0^K@0^K@0^K@0^K@3`
M@T**W-]J_;X-XH0D:4*GL!S"(Y4^E=RKG%6C1J`M^MK4&J."-L<T'K-6E,#R
M9Z#-]!9G`&/<T-[7HI,W;8MYJWWU_NT%6!Q80EP8VC"O3:JP]SWU8K[SR-SW
MWB=!EI[9"S9R<@3%H6WIVO1(^M]3M^3_\58XCB^]-4D\_[<H3-=RAD3EH2W:
MVA3)`-AR.+;,T6^IMZ0B(%2M)G$<S@A%*HZFHJK2*\.QE"H5"%MNPT,*G0)M
M,K9L:Y`#==SUI'7$%&B[DI0</J$"&&Y;B5J&3`$V$@DH$?#'[;[;]#7+*`$5
M(J`1;8===WSNO'V8*OG:E@%[D-^(JWJWP?PF1)%YEQ'.)GW!%N6P$-@+=LM[
M$@&RWA(DW%+PBL&^#C^4JDSTE1[W[!KBDA9A;@#/S/"V[:_\J":K`_N,FR=P
M#B]*`/WTU[DC,QS$^(IE6`^S$`&YV6:%(Y9LH$A-H$EBH\9@'W9KLML<64^O
M'5B4FM1GSYB?</1&T<6Z`U55$?8IM^YHU4+14TO_=;#TEOE"H<>9L`(:`QE*
M3+B2]]Z6R=_6XE?94'WU`C.>=.JB,62(24W*M('T]#[@6T"2\DF`)G>2*F@,
M&:A1DS)5_V'#D%@R,J<O,9D3+]H\>>P@I&5D%M5!8V#3AVTCLQ0HV#1KB?D=
M))9N=+JH.G*KC,[JRF@,_1!62IZ`<#U8/3M</OC>K%A.E',RKRP:0]MA],3.
MF:*%<`81VK;+AV9C8,^68[\T&W_I[=9*)`#-"-J:U=&X1\XR0HHX8]P$WR"&
M_72QH,?O*&:N0IC"91@D0YU7'(TA+4@FC/&'LQ!3/TV&]RE;>*:+!]I1*ASA
M]<=^.70":1AJ3I,8C"W;GE6?\3S1\X-'YM\"VKWM6>XV^"?VHN?W\/DU3&,O
MF%_[^`V+;T;,FD$GD):DEN0VP=I3VZ`VE.=W[+\)4RL;-H-.((U2QV*_@K6G
MCL;Z4%Y)E&`+H[]L")U`VKB.I@%5M#W=8$_?\3P'I#69/8<W82K5A<8-HA/(
M_"$M=:(=ZEX&;?[JD2#!+(T\OL&8!3@N'[<4D0>$6SEU370"F>VC)=>:\*`]
MK;4L8N5])@.B9Q>KUD`GD'DV6M*H@%70]Z5G]!5.B3'+((/GSV$U5%7A8RKB
M4:,J.H'T:&I)J"Z^@ME?>L9LI9O7WYFC2(P?(JJ2#_HI<AJU@TX@_:5:<MX(
M;*$`O_9JN17M*DWWW.C$3?.6&M36?M*S@3N9STG>D;S[5RG6I%!5$9TZ;`/3
M0U>2VC>/MUJ2C\LPR+'<A!&+#TD"+_\#_?<+W?FQK2"=84@X%U'=L#ETZK"=
MK`WF4BWZ9C"K=/W*8\_^*]U7CG>MRNC48>.8/L*2X+[9Q+Z2@*S2U3U^SS,Q
MWA!VT"/!\A[C.<Z7)8$N:T\&-K^!3AVVI%D71*E5?;.R[2'$CQ[=J,XO-D7$
M`^&=F+P:.G788J:#K:2S;\$%J/(MR1L.\HW-=#%]\<DR$[[0B"*I@DX=-H:I
M<)44]LT,MCMI/(?7'C/=93>UZM-6K3@Z==@`)L-4TM8W\Q<]TD?)M_4-QE3Q
M:H^H1,R):Z!3AXU="E@E?WTS<A7=IF?!RS#.=(_M$Q7<[95&IPX;K"202L[Z
M99>JG>+R_),9;-H?MAW3.O`>5D.G#ENI=+!M'3YZ-@"G63=JMM)'EF=4>)TK
M*(_.'#9-24&5S/7-(I5W.LZRBKP97OWHU$5G#MN:M`&6[/;-L%2;4W(8S*L[
MGB[J]Y1TM2^O*K6F7KVFT)G#1J>F>$M5Z)L)JH:GO-2LX+K8;'%IJ8"\"73F
ML`')%&=)>=_L0[D):[HHEZ0=&*%3AK`&.G/8*J2`5?+7-X,0[?:,27K)WFIE
MB=YSJ=/CF81`415TYK!!2(6KI+!O!J%<\\@L/U$7EF@*=_Y&XC#:J!9=S>KH
MS&&#D0G&DN:^&9!J*\;NBGJW9E26C&S7H+7$ZC2$SAPV-S5#6RI!WZQ0E4-!
M>4ZXV/PM].<D6&Y7'`W_*G%E=.:PC4H?84EP:Y-5=Y-Y>22\V.QBB]P0L>%*
MHRHZ<]AXI8MO^V:E?]1N]Q<WJ>]OKHB?4GD4T<ES5\`_J"">0PW#2+/6T+G#
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M2VT!LVG9RJ!$CP'Y2\FKE*4RS+>;N3?+/7[/_B1/IZ33`#IWTP[6`&6I&&"V
M,$N*P:!=T,WIO!I@:L)L?KF%Z&*S*U+,JI-W+YKGWMPL(V:49L,EV^D\OWI!
MX9SQ6_XZ-Q`^CCAV%]"YFW8\$#EMXY<XKMZ[>)KY0V'Q:VI5%?3%32N@%JZ2
M;J!H97;(OL(OR4[+!>ZJXL+HBYNF/P6BDMK6UCY(:HOL4,5EU#1Z),O7I.;1
MN7,=*?X:CR3L-VH/?7'3OM@>=*E#KD;X?HC"&<;S^(:*-)\')V\>\=E--G,3
MI+]YPC.ZX4N(=!-LT@SZXJ8)LS'64D=:VS.MOF?('I6^LVX&RRL2SYAI5F0;
MX95%7]RT/\H!E5PYG;"AJJ'L8,;.]+<!!>OY#^F+3V;3!45"H6N.:&D;Z(N;
M9LUF0$O]<#UO]&[+6_-HJHA0[R`@JHV^N&DM-858ZD-KFZG5N;W<JW"??U3P
MB.9[W?KHBYM63W.0)<]=6#L_5X5W1_NY+U#VNYI$*4!,5["M8&HR95((2+I:
MTS/LRIOA-&%/8N.?9N$J[P*=\=:8RHQ%X?PC)=F5VQ5.Z!XF_G3\E2KKRH/O
M9;D!M_V1)#30KHM^!IA8MRDKA-W+LE3(9E?-)A#0H=Q(_H+9U0"BV^G!A?@N
M-L_TVXHL6AJU$=#)NPF5P@V8#LB!Z@&#J$REI5$;`1VJ#5DT5($Z/K=5(,]7
MLH6FS$#/+8^`L^=I,B5P^1$A&D1*GILTHL?&-,)4+#?D._LI5I(LKH2`<^.U
M8EH."SJYLQV^LT@)B@5\6P9!I\]KO4S7H-AB$&@JSK`HQV:E%`+.A%<3OH2?
M76_=7BL+?WTE1;5R"#IY79T!/DT'/7:<J#QRI9JH:CD$Y&YB1M1^CQV?\X3S
M_IU&JE!U930"<@(YPD&T#A(ZA5G'ZG"/RR-;"Q/<02-HU%=K59U<0\W@XQS$
M<4:(^5N,%ZE_1Q8R(Z9&;30"-ET9LFJH&GM`AZT3OT5AW&C]R"JB45^-5U8T
M88<1-O.II><5LUFZ2K.;MRM,NSTC>9A[O/9Q1EO`$L!%"?EW]GNA5&0O+RQ]
M`HWZ:BTST2NKTFB]>?DUU\``+UF'^C8/4;DVW*Z@45_M;5;FH!*AK0RL29AX
M?A\NL:L@BTOLXO[_3WR7+0HCP)'9GK.$R"-$HZJ#]]$FT`:Q@:LN(-(G`+MB
M4!?,)MSP)\-]%(-@\#>/!'=T/SD-KDB\#F-2A"*+8RQW[)=7A+H^;L^R&E?K
M7;=XSW/L5>\^3/"#MV%V+""/+?:6AGE,^V',KO?42QN_`JQOUG/DL1AN.S]]
MJGGYT[_\#[GRZ#MJ&;0'O4J*Z>`/K\8@H>XU1$%YRA`S@AO;PT+]\:PRE#QG
MCW,`K*_L"%VA>,5`%ZT#D<K$#N_#)#P2X!5=<(K<8]O^"N_SU)6@/)1$`N?N
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M"<AA/`VI!YRZH5O://2UPDS.JP+F&V6%>BUTMM;\_D18^Q9XN4<.GDM"ZVC7
M!?-CZE`'1#"M.:C8C*=1\Z\J,O,Q]$([M:`\F).1O?5<"FT;&]/IV3L31R$H
MR;"M%D,CR'`WMD;H`:*"3Z>#8=6GG3*92!$%]B$BP8RL&2+-Z5G4`!I!AL+I
M9HZ68BUTHW4@+%#=8">1_%5Z%$^C[)3R&OH46'R91DSJ5)KW83#+_R%3$K.6
MT`@R'+@U;6D`NE`;H'A974PIMP'M"SW9/-(SS%.2F56WF<6TIQ59(V@$;"`T
M]1DQA`9]YC.[&M_.@L(CG4%M-`:V\NE2:XJIIW;<8B7+PG\*T`@)55=%8T><
MNXP`V3J1=903KPVE^DV@,;`WF!FUAL"@SVVB'-5I;AV<+O8`Q3>A*==-VD)C
MX'>)1J0W1FCKE'><]7>:)G'B!=G%4Y,5^*`^&@._$K2Q!O-1V3JC66=V%W)Y
M__0A9E-<!XV!7=`,&50@L75$ZC#A=+'E\PLS_FWPCU<R>]U#DZ>+DBR^39I#
M8V"?,].%N#'(0@T<SZ]6/PM^]1+F0[!A]WWR.-1&]=$8V+^MW0E9AJK0`K!D
M:H+)((MI4,YDM\%3^A+C/U*V$!71\F.687)[]3^-V,.N-\_'$K^(-FUF0;Y=
MT``[2+<FDYZIQ17M_1L5_1LN[_CS">T?)-F?Z81J8-(&&CMB&FN&K*09*&"(
M@.0#1XXL2QZ;O&X\$OW=\U/AQ:A&573BDDE,%U#)9-\,8O6%J+R)+]R#G\,+
M'.`%F1'/S_4SIGV^P6RY$E+<O$5TXI+YK"7.4B&`'!VZV-Q5IK`=YBQ[FNQ=
MNG8;Z,01$UPS9*5"],X(M^>Z5<QJDGRA.M70B5.F-0TP)7]],Z-=%P$'RD-&
MZ;2CNQW3K8].7#*C&:$JJ>V;':V6F6H?D<#C6*\B.G')HJ8'IV01S*YF;\W=
M+2"%ON+Y;GK*S4NJ)5>G"73BB*VM$;!2'P9@8)-BSI:HXJ392BMJ#:$3!TUN
MAO!*#0$SOMEZY+TN+@)S5UT-WU91%73BB)E-"\C62<7Z&>S8<:%VEJ48+"Y4
MV8/=B&(/!?^&YTMV*4D1O&6/!PV#1S5NU4K$Q-TCR`/;7;5#>3<VJ@>@S5J#
MCQC5B@/.?JVY'/KY)/30KOLM(.)[#D%QT$"+S2G1LG-O`5HB<)T=UYX2+TIL
MD9C%#Z%=8-?R=\1[(3X%>NE[<4P6=+9E_7P.V3W,_F]%-#=N$#2LE55%:"6"
MGKH%6QKLD"_ZCC+8;00;KXWVZP`JW/@.XM;T5Q6=/.BXNC)4`"VKNF`&UY9/
M<0?K0*7;UI<$&VU#Q=RR/W/8DD9K[^66.0U$@4)>69JQVX`[#I0Q0G0J0T7U
MLJ\*VG"A?97=6%`@'Q<"+"B_V/-TYFXUX*TYHP]S#D#`\%UW5:'`]TH.RF0C
MP>AXG%RC!,[@SB<'TA=8O*L]'@!!1FF:@9U*:K*7T+/KK=L$-4O3#.PGLL<`
MGZ:#'O<H,-VQLS4#NX+H\;7?8VCKH>T=R)U&!%I.:>@(W=K+EJ#OT#2*[@73
MU<J+-M.%],`Z#2Z\F,33!2N12?YK.,?*.+%6&H>.^"W@DW<;:`MN/R\'OWK1
M[S@I<%4?]01?L<=VWIG[N,193[L!V&._+18Y&F(D@4$LU%LA3N(X7640XNOO
M.)J1&&<^XY)50%D7*MYXEWIB!!YZ4>E.1QY)_/M-A'$UYI*AJO":``M&#J4R
M0B%`QS7J<GI9XQE[NH2CE?'LLJL*&[(<9';9`P\=+ZE[%?E[Z%.IL2NZ!O,+
MOQ'8".>`:L,1`W0TINX5Z(J\D3D.YBW4I]H$;(QT0.4Y$,(PKD>WD&^#=9JP
M0`DOA4L`D^S"2WW9)9-&;=B`ZL=2&`7^G@:'RLQ]60RS;>2<Z^\D3E@&FNR%
M1A8C0QQ72+<^;"SV+H_+1A+H:;`ISJQ7QD81G7^UZL$&:N^2=2WD'<:4@G>2
M*`)7?[A*@+I*5+K[FT>"NS".+S9%K[/H&&P#\TK6%YO;@)*9AX1FQ>_"W*7O
M8L-KC)W(];TPNN[$P!T\CB$^MV^^=_`N-O=95!>%(PF_0G^\2HY!N4KM]B4S
M%!6Y]U98F5V95QS:GT5,C8K*.@:WB2SV94JOB5HY:"\7$15\X@ZZ[C9C9IY]
MX*%.X.?@FC`<S^UL[C4(G<6^*GP)/[O>NCTZFWD-0F>PKS/`I^F@QXX3U<A=
M$#JUO191^SUV?,Z3KB%W1JZ#L@:@,]7W8:G4EQ2TKX#R`;MFWGIA!?`<]?I<
M<`RF<EC]="8\WN4(I!>'G)E6-Q[V#$^0<7>/>K<.Z9AAH@F-D-E:]_NA#?-_
MI7DP\NE"\L!<JQZL3T4[WD5P8!/-"Z;T^Y3M0:>+?*(J^ENZK(KF<6DE6.\&
MX\E;C:67.>$K!K8"@"JF@[@&K"^",6,*(+;\U\"C*K*G!B2;2&(ORY/,-A0X
MF!&P*(N5'DWV>V1RNVS4#L1]\ET8+)E'[4,:S5Z]&.\ZK+H$5M2$OKDUECQ_
ML=-`Z;;MJ4BD\>!%R2:+#L1&*]W)76RJ?U'9^+4;@;Z(U>!38!DV@C@<G5#>
MIQX6AKY--:-*33?\_:I@:S1Y>7DC^/V"A,DKCKQUMK+&EV&T%IJ2M>I!WZGR
MA<_9(.D`Z:>!B?8OC(CG/_FA%_PO3I+,@?"2Y9J-+C%[#26G4+<^]*6K-I4F
M@(9@3!`O1!>;2RJR9<C\5YE=M2PQ5RS"#5N$OI5MO"*WP.OX+908N0"W<A%O
MV"+T97$+%3#5*:4<>K8W>&#=NR%1G%S2PNS`_<RFU^GBCLQP0'O^$(7S=";V
MMFK0"O25=`OV."N2.?9^;C4R'$]X%M)C<%M5T&\&^@J[`UTP`P\=_$"F#<^O
M)&JO#-JM@-]?=Z`,9N![ZJ)`#TY^N&0(BJY/UFN_B/@L5P!U3;"K[6Y(UP0,
M'91`],PO6\:H`-AM#SUD>;[8<U->`>R>NAM:Y3BA(P2([#X+>G+->GZ/$];E
M6&'O$90'NWONADLI3.@7^Z);:?Q^%:5+[7E75![L+KH;*J4P^_J@'L\P62?3
MQ2->ICZKMJ']C\(WSV?I%KX]W<P].;GZ+8!=9'=#MR%PZ+?T75MQ[C0<B35J
M@[W![]"T5P?7TVWU5T+7GB0,\$.>$U/E^"LJCT:]M:_5>>#9\V68^FDH$:/=
M@HD+-"(F#9I`(\@PHE)Z.'2:`NN.85CGI%G5D62>.R<E,/$P'/!1$F5L$G]1
MY'6D5<]QGR-MC,/Q+AFPQY$VFVH'E`]_HP]_HS[<*7[X&QW/W\@B9V&2-*%,
M5LT9MR(-'#V]J)MZOS^2^1+?>WEW:+MAE)E&Y,RIZD'[^VA3IP.DIP:`">W&
MVU/HI]DZH!AIG++0?C7ZPTO0^;Y>@]'O_BU-*/H@#H/<N?"12IA*YU7'ZU*W
M/K0CC#9_)H!Z>AF6W<;?TMWU+:E=Q]^$$0O/M_)>;H-KGW;=WTQF:8*_;K`?
MDOD=3G_'*Z*PR%MI'-H51EL;K*'MZ67;MX#0%N,L0O,S_N[%7Z\H6/J;4O5U
MY@"C1L`]7[2Y-X?5TVNX_PE?@_AOX?IW.J7M0,DYE=4!]V/1IE")`OK>3&1W
M]\C<]]XS`XF<I\.2X.XHVNP(^MYAI&A;4^4##H)XX[]Y@6JYE-<"=S=I-!D*
M<!2\_=HSWO['6^$XOO36)/'\WZ(P59SS1>7!_4GT9ST9@NW9OF<TT1W5BBZI
MKP0OKK]CNI>B^C9=+,A,>0)1503W#-$_>VA!*1D<WEN=8[_S`LW(T/PBI`W<
MCW=>EMYY]=<11:T$IFJEED3?3/S6W($=?;\E\%F1XNRG"Q+(J[V1HT^U!+0W
M0`]]!001C7T,F6JVA5]$#8"M^Q\HQP?C$.IC:&-43?P2BBK]==LYI5D4]3&T
M66J/`SY3AWT>1%;W9O'4Q]#6*3W*#OH,O7B)MC(X(J'H++M7`HTA(VF:+T:\
M[MNZ\K86`"+KGO!$>%`&C2%C8^X)4RCN2E][=@I[?@^?7\.4.8E3+6+/PQ.,
M%:_Y9'70&-)><R!M#B/*WH-&`->BZ29,C6FJUT%C(--(0YHXO8<-IR4R:BPC
MG"62D*T@M4)H#/F@IN$B<HC`EIN-->M2V4/Y4K)7#(V!C`H"J<I$7^EQS]:4
MPE)QA=^P'ZXS0,'\P4NR!WAY%(H2A,(B9-H0.H$T#_"HX6T)&J'J&<=F1(IP
M0:81T61+TO6>'F'*'@?SIW48Q"'M1ND<:4B7N@5T`OE.R9!"33@]]<ZNF84U
MB93502>0*3PTJ5,"Z*G+]H/OS?*E?)G]1V^YDU5")Y#&!MVE38F@I^[8E0=P
M7[W`6Q8@M&C3J8M.(,T4FNQI`^FIH_03IK+(!4NG>IPDO@F->K71":1]0Y-(
M`RBVW*%M[2NIXJ4+JH,IBZ.MR9RL#CJ!-'1H\J4$8,L%VA9+CTR0NIL0;F%T
M`FGVT.1%W/.>^C]/9LDTF+&0CXJG`P<%T4DO+!]R/OB]MN73;-<0Z-/N)=<D
MB!-,%(9:7EETZH`E0]AQ:P[,5CF1&#OO)+'+M.NB4TA[1D-3KC:PGF[Z9+#U
M$ACKMX!.>QJ5I<Z4&<L\C(/PIWC$;SA(\2.>A<N`9*>:,NC75YR\AO-Z@7]S
M\R(W;PR=0MI7#`FOJTQ+T(/0GF<\>PVRK<83CM[(#,>782Q-F"NH@4[[ZB6B
MK0<R9-!&<%ON<B1(<,">#*MHWB^*3B%-.U;XY4+JJ1F\"->X]8N^P<+`>YRB
MZ+2OSXF49$DA]=0,?N38I*>0MI[VY)I"[:DM?3](ZY67"(<HKRPZ[:M'C!Z-
M0DP]/4%=X7@6D:POT\5CN/'\9%-T_3FLOHL5D:C=`#J%-#*U9]8,:$\CC13]
MGB[*YV4/.)HQ+I;"42JI@L[Z^B!'CU(5M)X&'^$D@,F=*D44"BN@L[X:K?0(
ME`/KJ9U^ZWX2S*MN8%'$'E/(=D/*BNBLIR8JW?&H!;"G84S*C1M='+PY"=E5
M^AO^ZK&DP*QO@E.*K!(Z<]:(I`FNK[%.'J+P7WB67,<L@AQ=U]G!6.*G>E`6
MG3EK]I%CLA;:Q/8V-GP/ML=C7N_5^QR#)M"9LU:?1E!+UOMF#JK@N`FC`H@&
MO[O"Z,QMDY`85,E9WZQ"-:=.IFLL4F>9."N,;L*0/?G),JG-5[0HP\\ZKN7E
M:M`>.G/;7M0*=ZD<?;,>W:3!O'Z8_L8">FX]$A@PMN5_?@__27>*PO..63/H
MS&V;4Q.XI0;TS1ZEPI(%R&$H*)BF]%?;0&=N6Z6,L9;$]\TR=9\R!R*Z':$$
M,'F(R-TOA\[=MD%Q\90D]<WR-%F%:9`\>(3JW+4W>RTZ+?1MXQ='YVY;G62P
M2N;Z9G1Z2NC<\&U]@S%=#6I[!Q%YXAKHW&TSDP)926'?#$Q%MZ_2[)Z>J9_L
M<HU?&IV[;5*2H-JZ+/2,MNU23/'&A/91>ISAET;G;MN3)*A*VOH5RN$!1XLP
M6C&GF(LP2-G-.W.C/=A7%RY10MN@63/HW&V[4A.X)?]]LRWE]TAD1E>)+-7W
M&YY?;'8OX^B!:B5A7545G;MM=]*%6++;-RO4SL`Y7=RDOK^Y(G[*C)]Y3/:G
M))S]?OT'%<1SR(05!MEO)(0W:`V=NVV!:H&Z5(N^V9_^X;&[QN3Z.[M/CMG<
M=1\F=*8J8A;M/$!$FJ#=`#IWV^9D!K3DNV_6III/S],K%5P\>?,(997X)-E<
M;`I\5,,+P%IN4%HMH7.W+4\-$9>JT#?[4Q%7-#_;3Q?3E%V-T?D*4QU?,V];
MH45*71-]<=M&I8FPI+9O5JO[,'C$BS28LVGJ-H@3DJ1YQR3^X])*Z(O;%BPU
MN)++OMFQ'NA$L_)F&YGG_ZX(^N*VI6H?2LE*WTQ3$PIRSH`^1.$,QS'%*2&(
M7QI]<=LT)4&U?:#1,]JJ6S9Z+&?/#TC@Y2OZ]KPNGB`U*J,O;ANN]$&6'#O^
M%NX.>S&FJSK)373,NCKB:("L./KBK!5+":MDN6_6JJTN/N(`OWN^QE%54@5]
M<=LZI8)6LM@[JU3IDS=94@1+JG7YEENXTQ&41U\<MRS)<)7D]<UVM.WT#5TA
M?+:I]GR_;O".+S94.&LO$+ZF,FH$?7';AF0.MN2^;W:DG3/MW@U((^YU&D%?
MW+8>F8,MN6]M.&IV46AG>S69S:(T2^>U8$>$XL0=7Z81DSF5)3V9S_)_2'9=
M!JV@7YPU/35%6RH*F!G*UDY\F0.5;K^+,N@79PU2?"PEB6#V)UMAB'@OV@JK
MJ818:3WTB[-6+7U\I0(`1?:S0W\%VVU0V(4DK/.*HU^<-8LI86UC6`QQD.L0
MKJB)?G'6>F:"L%0#(!<P.TKPA.D>A"2;*[P.8R+;O>V51+\X;R[C(2I)M9KG
M]'-51'>T*_MB8[^KR8UBP,%\%]VO)CGV(CD@Z6J=7[/@-&&>P/%/LW"5?_OZ
MCS2#E7C$CS\=6:/RCTL"6/(+HI\!E'_VBN>ICPM'@`N6\9B=W>AJ7FCS]@D_
M/=7MRA2GP,F[%\VS.*6R86/K&P@X'^TA78)191.PVPEM<RST*XI4T;5R"&B7
MW`E_@J/Q/EZW:6XNIYT@@OF#[P7WW@H+D[]U^3D$G)'W0",$<TM'T-W6O^O5
MV@\W&&>.JM.L[\J$S,(Z"&COWC7%?(62BF$0,8&O<$3>/!;"YF)S[R5II%J,
M^!40T&[_B*N2&+BM>,%`\\,.F-;ZPBN.@&[6U=RHN*QC<'NB+QR2E9-[K1P"
MNE174<$G[J#K;C.FG*Q$<]6=)+F'O<81T$W\$6=U.T*R%5C<-37,MT3Q-$WB
MQ`OF)%@^ACX+U,/^V(5J2C^(@)P'[.J293U52FP0VUB+XLE#EQQ'>?-OH1&0
M-T/WRM6Y,E<D:$F1UYE;=!:2P5%E_HUMD>+;('?P_BT*I;=U'7P-C8"-T:XI
MM$B&MDZ6<[P@>;:CWU(R9UYI`%K-;"BW<9SB^566%30'F[^QK!A8XO*%I70#
M8=P8&D$;SH^MD\U$!)TCIQ]3*)7N`A-F2-B.R@ZG4,[7T`C8Y.[:%"J2H:TT
M0J!>&"UELWOS<PQMYGP-C?I^;=`S;1;)L'5^I%]S;0ZR]R=S1_49^+0&?=?A
MF"[S)6@K<U1^7+L.7-7E:JR9KG7YX%MH!'QQXYHN\R4(G1:K'YI<X>(?F"Q?
MZ?HRH8B\)2Y/&`\1/ZK@D7N`1L!W7JYIO8E<;647<\`,)[QSXEIUNAH3]GJ!
M1M#W?7T;%Y9E"YVZK2?CHA0,^-`PZ@@:N7J]"#4ZS,5K*PE>KXTU*K%Q+%E0
M`\2P*VC\<9'9O8"MI1?L]2@9S&%C_'$7VIE<K25N')`5"6@X:/8`C?]LU[!'
ME*NUC);@*\.+6F`OQO/'(V;.Q?3W[$$P>Z7(HKCC:#56#8OC]@:-_XQ7OP`R
M[FLRT0SLCQH$_"BU2^#]K:1(&ASU!^D'&O]);HGAI&LM1:K5O$3'GP"$8>\!
MNH+&?Y(+95`!@Z>&[<?N2+R=%(E/%B@9H#=H_&>\L@:0L;64NN"'"3MDW5(9
MD2`FL[][?GHDPU+]FVC\<6]M49+6TA$[<%5M>E/S'"8L=O&1-%[G\VC\<3G=
MC5#!DSOW8PST;*K_N&RV*$EKR:]=OR?X.X[9_B^8LZ"T,_KC<\A^5=DC;I,3
M'&T0-.X3.OFX;CZBI*VE(C\X$(`&P"P"@G[$P=2)@\F>#5YL+GTOC@TB6^[7
M<C!6)0^"V[%G7(\^R6.$3^-'/,F/>)(?\20_XDG^.>))@II;*7^9U+)IN9BD
M%>N+L$Z/8DKJKS52-(X'BJQ"4BX;AX6A@T1*J>&SR0?A]O3]D,5;Q'3*FF72
M4,[=_`K0<2/YU/!I%"-PF\IF`3^![>@FQ!UTW/49-%RMPB"#KB3MH"QT>$,3
MXKB==SQ*YB..DX@PLYD>@=SRX+'^3%@4([`550>(RMN'J9*^;1GP:'8FE-5[
MW3I<3`_.%.R(-5U43F2*\P2W/'STMR:'"3$4QZ?2ZODZ3W7J[7[S3'^*F0T_
M#&+E*#5L"3RLFIA2@>VR`3ZH3:W`N_?.(W/?>\\2L0GY%)0$#QS61/YU)F7(
MW#Y^/*4O,9D3+]H\>=N9367M$=6!#ZO5R-PCA>/X+JD"B1DWIXN*OJNO#925
MX8-/2<D3$*X'JV=3\-;R,5G*+#["LO`1D_3$SIEYA7`&$??^F21,,+?!G+R1
M.<MKJM@<\\K#Q_UIM#D60K%UZ@&:=@^`_8,DKX_8S\.!OI+U<W@=),R!134'
M&[8$'N%&3*FF"FC@Z]G,7-X(QE<DPC-:*\X3%L>IG[#84O*Y6J\V>%B6)CQQ
MIG(#M`.X2[T-WG!,VU8;JFH%P>.-M"=;`LQQ^_\C.SDJENAM&?A0&4V6Y7KW
M;47YA>1+;>C?E0*/W5`7OX2B2G_=MD)\)0%9I2LE2[5RX*$&]CG@,W789\>Y
M\K[K<54M!_X^7I.K@SX[OEA5KYWN-/)-<LO#/]=NLHB)H=@*]6WM_)"YLA=O
M&&+)<P)):?!WQ6)Q\TX!8@P#V/5_O.3M3MU4ZB.P^![Y':[+VGN%7Y+;@(HT
MS:['^+&EQ(7!7KTVTPP!`%O+/B21Q8Q<^-]-HT<6.*06<'#[Q[CX:RP+%-.H
M/;#WG<W4H3E&6]X<D!ISXY$HF\LF<9RN\JGOD<2_WT28/2;%E,'DT4MDBX]N
M$^@$R,353"^,8-FZ,NY#QD\>\/+E\=]#9A#TJ20;*`6_$70"9"^SIQ828+8N
MM?JN&(I-@ZHJ.@$RP-E7@BT<6T;4.8EG?ABG$>XG]5?LP@`'\Q8S0K4)=`)D
MX[.O"@>P;)DAVLT&`IN$'$D\"]-`M!4PJH].@`R#9@2;8[*50\MR7.)R\YHG
ME7X.'])H]DI/O97''B)*-:JB$R!+80,V=>'\21(^F6>W[]`$Q?D:.@$R<,)8
MG$02&$1V)5E6^[WW2IE,[G$R7532[,@TKVW;Z,0MRZ85O,#IB&0AQ5N,H<E\
M3G(8]=$D6N"Z^AXZ<<(DVKT,K*7Z<?EVAY,NK,.5E/,U=.J42;8K"5A+M-.'
M(WEC(;&H-U_#.5F065;E"L>SB&22F`1S49J%8WP6G3IE(>Y<%-8RW8!/GDT"
MX=-S-HFRPGI3IHUOH%.GC-%V<5O+,N/HN3?[#XNLNMU3*Y-H6/H,.G7*_&T=
MNK4L+TY.=+4PO^6&96MY[#*1B^B3Z-0I&WRG8OAS)%09:/+W4R>N&@"%8RV;
M2A\NJ!^B<(;Q/+ZA/%1B=6[%(MM"*NNB4R<N.LSP#"6)B,PD:JH)YHVA4[<N
M*IH!M):-HP]3Q<3/&L=S_IS+[GB#6+:0Z36`3IVZ6C``U5U:B2-JP3:P,X[>
MZ(K(1WT?9@]:<7YZB3,_\.K?+\,XN0^3?^+D$<_"94#^+9U>.OLF.G7BSN$X
M<BC5T^E[A^H:SN9K-E7>LIG3\Q_2%Y_,I@N*A$[@FOL::1OHS*D[`C-<I3HX
M[:M=B::3;>#ILIV-&ME>1E`%G;EE:9?!*+D%RP=O/<CP@Q=-HRSN^3PS1&@0
MK5$;G3EEV]9%5-+O=+14Z9;\'K]G?VKL!+-M`)VY96?6!U5J07MOZQX<3@2X
M,]UOH0SU^NC,+1NO-J92%8`,M@+/IF\![=5[1-C51^DY+/)*XI5%9TZ8,N7]
M+ZEI;6WLC)K),L*9J;5R)Z]#$Z\>.G/"8JB/I:3/<6LA[^BP>^-I>);:541G
M3ED!-<"4?+>V^%E^T5`/#GKIQ:\WF+L@2DJC,R<L<RH$VX>GO:9HDM!Z`=[H
MTU2M@<Z<,&SIH"CI:FV6@IU!<YGL'D?-_Y7&"4,MLWN*ZJ!SIPQ/<APEP6X;
MFIKZ]^2RV077B*?)*XZ>7[V`^\:E"^\JPRZ@<[<,8<<42ZG+0.ZGBN>,V\O)
MBTWQJ[^%/NVP<(%15D3G3AC(#,"4#()Y=`HX?,1+PO"QSFSS.VJ<N%3UT+D3
M]BU]+"6!K<U:E@DLHB:6=RPBKR]A673NA/%)WO^2G-:&)F#GF=WE2D7]:KD:
M]&Z81+71N1.F*U-$)?U@[_WMT)]M!`K/#IGQHU8.G3MAVA+WO23/?5/6`L=Q
MUG/!X5I4%)V[9JXZ['[)8A<&JL]5L=S1+NV+BOVN)BL*!@?SG?-/35ILX@A(
MNEK3[?G*F^$T(3.*_*=9N,J[P-(:X3]2VOKU&]N@7^'$(W[\"2`[6+4;DMBT
MJBKH9X#%K-Z7+&"P?M>W\86A\UN)Q"E8L00HW(XZOH^*?D\C2QVG!H).R""@
M1X_,"HC!\:E.1R>J@X`3-DA8TJ9UAV10Q"K3!'#+(^#,#E)^M"C=X1A$2.B(
MO%$.WO#%YMYCH104<R^_`H+.#FHT]8HQ.)X38@>,I6%4SKJ\X@@X(828&Q67
M=0QN3[6%C5<YQ=;*(>`\$2(J^,0=='T0&3^S3&KL2B:BI]Y*_NF+3?4OJAQC
MVHT@Z-2@1O.N&2Y;8=>!AG`5DG(F/BR,@)-]FG&EYGN'RNV9N6G>QQ%PDD\^
M%WS>.%T?P%9W;ZZZT\B9):J"1OVR'9F9&NHP;*4T,!Z/HM"0>V:QPG:LRIVE
MJ(9&_3(.U3G@W$;JX!G"H#S2@Y@1I,.`#I>"D:N/;@#*4'D*=LD>!$?L&NC"
MBZ6;97$E-()T/FA.N@*1+1N%[EW89]9)%E*)_N/_`U!+`P04````"`"Z?5]%
MJ-W:.K,5```>[@``$0`<`&%T;FTM,C`Q-#`Y,S`N>'-D550)``/PYE-4\.93
M5'5X"P`!!"4.```$.0$``.T]VW+;.++O4S7_H/+3G`='<3(S9Y.:9$N^9;QK
M1RI;.;/G:0LB(0DG%*`A2-G:KS_=X$4`"=XL)0;'?DEDHKN![@8:W;@T?OO[
MPRH8;&@HF>`?CDY>O3X:4.X)G_'%AZ,OT\OCOQT-_O[QQQ]^D]Z2KL@@(N&"
M1I_)BLHU\>B'HV44K=\/A\2+&&?Q:KTDX0H*XHAY))"O/+$:OGE]\O/K=V^1
M=$!7E$>7(ER=TSF)@^C#T9\Q"=B<4?]H\.,/T!HNWY.(KSI2_O&'@<+-T>[O
M[U_=OWTEP@5`O3X9_NOF^DZQ<#3(@=\'C'\U,!YF89#AO!UB\8Q(JJ,@A!_E
M2#K"+\.DT``/:NC_ZQHJ*!)G-0B,RXAPSVQ0B8F4[9-W[]X-5>E./.\Y79"(
M^I5UO!N&(J##%$RO)Y;'"T+6.>:<R)G"2@N4,HY?GQR_/;&@'9,HJD:%PI#-
MXHA*'=43,8_"K2EK2;U7"[$9IH58Z]MRK5X<AM"/JW#3THHF^Y39\:"@`H4^
M>$L[#I94(#&^H3*RHR5E%=QQPCQIQU-%B'921I/,LR-!004**"C:KJFTJDZ5
M5/`FHW5841F45-06TGEEQ_QU"*6FEM8A]1HZ,PD]U9_G8$6.Z<,Z()Q$(MQ>
MPM^&1`7G\<I.R(_"(;(Z!*!C@*(A\PS<9D0-"6TIX5Q$)`*3^_$WLEXS/A?X
M&8?J>VSN%)`&^./+[54K.ZAX/!=>C-9UQ/T+'K%H>P5T`13K.1HP$%,M1-X"
MG\ZA(M4Z,)R#XT&&IO\DW!\D-`8:D=^&10H9T5A2?\P_JM^@-PDT%`9:P!0K
M!;%A[`BV@P?!>'%07<'0$/4!9'\FN!0!\[$[GI(`;?3=DM)(?N$D]IDRI:B!
M%G!V/;P!X=^!R&BJ")W0(*4T2$@-?LJ)_=>+0BH%/2$P!T1+JC#;:L=$LJOJ
M[>-4-?C)(/ZB.I17+D<YGH_7-%3-J!M430AVE?U<I[(=R8&8#W9$7\99C;+.
MB%Q>!N*^K:XL\'95_=)>54ASH(B^J`K]`RJ]D*VQPO'\-):,4RG!%;B+5RL2
M;L?S.[;@$(EY!#P$3_G7$`5.0+@>0\=<>1#[T;"K]%=T+)CT`B'CD.(?NUI0
MCUD]RNE(:\+O6EV#766#K+9GJ^A;&I!DKHJVTY!PB1@P3!(55I;:E?/?1>6D
M^`-%8*!3>+8"GX0"9H5HBW[UGS%;HP5*A&TML0OZ;T5!9[B)KYUA/ULA?Q81
MG9`MF04TD:W^P2[2=T61(LH@Q7FV@CR'6'0#]6UV1GWWP2K(D]=E"YVC/%LY
MGHG5BD7*VX#A#7X(SCZ4[R;+.@"[G$^*<M9(*#-@$'FVDD=C&&T3(:>_[?)\
M4Y1G`OUL!7<7SR3],P:N+C;8IQ(1EK[:A?FV*,P=WB!!?+9RU1Q6D;O%)'>+
M1;U;7.EB[T/+KL.?OXVK/?@I^_427CU.;U-T20[2`U)*=OW_\JWTG]3Z?+5?
M%57I>FV`L6NL%!Q7QU\O6LA")J*%6[H&:LKMTB]%O_:@[$7R6D!@FK+B9[N<
M2\&OAO@B7"T*((5`0A=V,YA=^*4PN3;J>%%'$D3HDC>^6(7\IA1")S@OTC2\
MG=G.VY&9MR-WO@?)78]UZGGX-"(LL#E.CR9EUU\I-#^4YW2>5/O2`?;2VLD!
M>\!)11<HK28<N`L,3EXZP>,VEE(!3NE#%&>;^0>E:.\0I1610W>(M/KGVRVJ
M0J9SW>PW`=F55UH*J0NLGKV1;I"Q,?):PMK54EJA:*&6EW%B"VR-,5('8%=$
M:>&A*O1]]F/#MLEK&Q<MX.RJ:+T*\3(>RIO%QC"P?+>+O+0@H6\=O_1Y?;WG
MW`S!2M_M`BXM.A@K/B_R+<GQI$K`%>'*V[I-^Y>8PRKC0@!156R7MV6%P"+O
M9V^::U8I#4O2`LZNAU*8WK"<^>QMC2EI3Y=.NB(2Z>.B/;A=/Z6HN9U^7D9.
MLF)L#!+SDUW>I4`W6WE^]AW?D)YA^ZTE=O&6`M:">%_Z;?%\D=&#JPKMPBX%
MI:4S2'^9;HW_X.7C6SH?J%N\[_$NX8<CR59K/`*;?%NJ.Y-X8?HXNPS];V#I
MU<,JR$"0<LV=8J6BHA32BC,2Z37*^EO&0$1%I6"TAUGCCX8'X`<$WI4?4T=.
M<1.065=N`(4&SC$"_;HK(X6A<%AVAME56OBUNV`+!<")"*,!+R4MJ+M@G^0[
MN!:>(E.#@G\=9WC'^.GXY,WQVY-7#])/&M:A_IRCCO5G>-WJMR<O:%ESAH!5
M_M*BLMI\`15UJOJLB$,:1#+[<KPCU9;KFGOV=6VQH*6_CW<DNK;!ELJ@32-T
MO.R/?9IARXK0JATZ8O[7'DHIY4QHTXH<2?W:H_9R"H4VU>^PDI_'.P)=&U!,
MQ]"F^@P'?^Q3=3$Y0ZNZ,R3UJUOM3?E'VABC(`P-++1([]`(GORZ3PM:FD*M
M]FC?FNO35;1MC4[E8D>D6^-J$Y^TZ149#O[H-AH;DFBT$4,1:P_%V--_=&N$
MX)\?TX[Z9"N/GS,5+:M.T@1-JBWU^4)&,QF%JEMB%(>>X;_;@2?NI<IT]!Z^
M,;ZXBN@*0Y^C`4FA/AQ%88S.IX("=X\)?ZKP_#A,$YIP%@2X&9/!2H@$H=(8
M2S^%(EYGE3`@?S08?AR4^+L#PE2>3>_%!/Q;"O.6?Q<)[^L-7<UHJ''6!)CP
ME"21>>^+%6'\R9D"EYVV9*L:U$'&+D4<MN.K&M(EMCY!Y6-^MB1\0:_X)6'A
M_Y`@IN-YZ9ZFXJT=N#[(5@)F)A)N;1S.22`;6$S*9DG>D@]''LB210?A?!(*
MCU)?7H9B=?%`0X])BED[U.$.,")_D#`D/)*7(L14#IH0.F-^.WGX='8@<6BZ
M5*=<H-\B?]>,S%@`UO0L(%*J8V-(="J2=4;SJR:CPY#KF>!V@R#K`F-^2B23
MXSE"J);<")\&ZM0UKLR>!F`7[&)[-#'#O$39]T>*[0`"NF$!1*B@O0G9JFV6
M_,,-C990994PNB*ZQGA^UC/K]3`MW%"":\?^*-JIFM]2#%O!%U'ZM?@V>U-R
MR.W9[V3L=)>!(?'Z#D'M.TO'C]XO`3/TXAF]JI33*-W8*/D7Q0*7W(G]U'$-
MX-AT>3`%:Q3_.D,@V=&SA4"'I>N0Q'"37G#E15])&2.U*X[)MYB?)D0#9ROQ
M(:YX1$.8)D8>_"E9P2_9EU`ZV&"DX0"&!C[A]+(DT+R+!T]YX[=(6)\R;*6Z
M1GWJL14)GJ[]FBJ2QMK5E)49O5%]Z]3T9(_D,"Y?)E4?NTXU$_5@#O$#,XD(
M&0GN`D'X/VD$_1X&^QEZRN$9Q6%0FH3:H[@T/7VF]^=AO!BMUT$:8Y08JP9Q
MB1'P\R@8^O'\EBYP2U.$6VAQ*#8DP##KR]VE3TJL=4%RB]G=C8X\!)!I4&#P
M5PO7AV#2'$Y7/,&GF*$21]8ME92$WK*\YM0-SR7M-EN2QPKEX)1=$MNMD!2=
MNAOR'P)]N3S8[>4NL7!-F!^0>Y6=;+4F?%MBHA+")3;^@3LG\HRL640"A5/B
MHQK$)48^Q60!?S$0]TA*X3&PIK+$2RV42^R,%B%5?X\>F.Z6%;Y__^#?9U`[
M/GE2$_QG;3Q7,K2U/BMQ2>1G`>-X_'**9C=O::D+U8.YQ-`U@QA/TG.ZH8%8
MI]N+Z,SCJC\)V'^2[<5*3A^)[Y((,#B.`UPHN*/A!OB1-8IMAG6)M0N^`%NF
MM%+)4@V,2ZQH-Y-O"&_DJAVX2PQ^X2R:Q.",$4FK^:J%<HF=24"\5.@V/NS%
M+C%0F4ZN<G6R-89#ZXZ?8Y3\>#X!DC1/69HL%)2*]'8S""\6-'RZU;71"I=W
M)^!`?^$^#?/!<,7_%V*:Z;V8+D6,5Z@N`IB<#`^C*V8OMOM;<S6]I\&&/D8>
M&>9?3!Y+%D;T<3UDA]L+F8SOJ9_PUJKG3P6>\2G(9@\:O9#1#4'3QI'N):6X
MNY2MDF2[]/H*3`O@/BS+F=-QYMLB2Y5SM@G4!R:S8R:X+T;]J<C\*&WO0N.V
M%?2>>QS?:KLI.[0U"4%#X(^,0_5TCZ\.44QHJ+9H[+M1+5&-;4+U[<DV=ZJ,
M=0M[WA.3-/)]M3L+/J1BY#RFU:PVP^[-<ZZ];S94C8U^"+H3GBY%.*7ABG&2
M%,#?,S"V6/E$-:_JJ$`7"NV<\^\SI+6VGA-<MM?::U-^2WACEQS@GO+H'&>K
M>/69WB='$BX9SJ4@\\^4^C09K17*JU/^8<E^L_%R0!-18)7>$K#A_NDVW58P
M]W_K(?O`+FAIP<"[3&S<>#Z>!6RA]*<[++50_;#\^<0U%1<$O4H5BUNGM@)$
M#ZP\>!9A]&4-'B2>)-?7S/6=WQJ@_O`(T_"9D$I/:)G+_)4`W#'2QE2:G.[)
MCKRCX:R:=&V0+DVNR7T&P]^]Q=-,>JQ;">(>(U*=?MDT!S;MP%V*;(QNE;1;
M974?S\V0%`Q$%I56=<JVV"[IUV`@"TLU1DZW.2-5;#=AN<1NXG:-Y[N;1UGK
M];6(&B#'F,%#M&0!+;Q3YY"3Q!DPG9G<5$,9H?;3GLA-I,Z\9#).O6J(-/T-
MDR+<6@9?:XQ>N&/&F-I%VKM1I0TJ95.JQF,[7)<ZLC8Y9//%Z?9W$?C0JGSP
MV9>4ZN!=FF:TOII-CJ?;W>[Q)3-\G5;0O>C5NO6YC(-@>\Z".*)^>IPK61;\
M,P:O6]@]BL<2<,BRW9`'7#'((\48_IE`(RFF>,`3+N:J?S-P'Q;$LRZ<,7)K
M6BQ[<1\8TX-BL#XR!EMS3?4C$Q41=!5P'YC>G4TRG8O"]SZP<D>C*/F0;J.I
M)5PK=\V@?6!8K4C>APP;C0D8L4<:IWYLQ7U@+//*K5&FYA)9-MZ:45SRCVRO
M#U0?%6H%[=`QH4E(5RQ>I4O&U<?3&N!<.M]ENFKENQ768I<8T!Y;2-X_WV#>
M1O@+"VJ.J77$<Z@76F**\YA.A;KH"OW-NE+0!<FE:`3<$E!+<GXZ6^U`#9F>
M2P6(6Y;1:A,FT"J/K;-]ZF8C4D+HP>I_ZI.H^;N"+9WQ-M!]"2E5Z-"1_RY8
MO9##>5H'Q(<F;Y@[J5D@CT,W=HY2"LX-?PB:<?#A<E!;`V!!Z8,)T))I%2?;
MBIQ;9;`^[,GKJT"IK08/0RGJBO^Q9-ZRP%=RLJYB':D3A?T6D@YY&`W`I,QT
M><5W^?/'\[FZ@RLQ/LT]DK%*Q;$A0>%<Z7YD^F$:2^F_$FW^P:*BFLW=O"YH
M+CET5RJ1-7Y(6_X)_\'-_CR_E<9G*^B>*'H6X<WS4&4OS98OTLLR4W%*.9TS
MW!1*U"?5OA>)8N.$ZCY$>C!)F.SE&K8<U6V$-&QA]Y.YA[U_^!!1<.+\&]0$
MB[99D%(SOMNCN.7F&-M[128*1WY:P+H4P-UY2^K'@2UEXZXG2LS:MH'VV[+[
M/9*`0TL/Y6D';V+63TPIQ)YST"&]DT,D/CU0MM.GGHUK4_S:EI':P?=B1L[3
MY3TF&VM=]L[]Z#DTW&](^)5&*2NZH\W3K*3*"S&M>@></>?H0YH$=9Y1K2_D
MH=?%`Y,JQ8$:HBKB,,*T]BCNQ&5YSQQ!M+!*I]XDE%+'.FTIBBM!'5+?;IC5
M9<VLA'%HR&77S9,NE!J-['B?Y5IZ!9Q+<\Q.\%FC+1-+'9!+S(QFLPVC]Z=,
M1$L:DK5ZB%">B;"<#:H9U*5]M`EN"5VR4$;&[0+,1:URV_B34/BQ9]GL[(CH
M'--WU!/<?PS773"=8QLO[3^*ZPZ(+C$-XS`0"VQSVMBZ]*!M@%UB+AE_><*I
M.Q+0$D\U,"ZQ,II'$%9A6S_3"!M9SDU7#>(2(\5W#2P^236(0R[)M>`+O+>D
MGT-*7M*NR]+:":L/9[BT!\1'A:?BBZ\5-(-^9_6V?(I@-A-1U-*UJ8=T:1R.
MR==;YB_H9Y+<-;@F,Q&JM,@EOII!76)L!%'9YDX$"L=B):W%+C%P">'Q[W'D
M+2$6%-Q,QEN1D+P]BDN,*K_I"FS!%3,<ITL1XGKOBLRN^$7@TS#8CKPXHC=;
M&@CF7]/X*UVQ<HKO`]%S241?.%,[5M%V/(<`G<B;\Q&>?,FU7-$A.N*YQ/(_
MQ)++W\7Z*_3E'1OEK,*U8"XQI.=QKDWR[&+C]8XTH9S+;;`AW#+XF@!=8@H,
M`KC[9TM&\8XHF`)H^G@^AYC&8EJ;85UB+=D2+21]UC]^?Q^K1<;GI(&E=,_F
M9Y?$K*6R&^TR_94SS=:"N<M0EI:O@:$BF$L,I6LN9O+I"8G@1[9X47-3H3.N
M2ZPW\M<G)KA_MP9'78"'FWFTS8RU07*)6?-R=TW'K(=SB:4[NB8).=1&?A&O
MFK>V""XQ>4-XC$^]QSB/5K-6#^820WB-M^[Q@HIREUB`4&_,/5RH+@<-EC*G
MFAY`DZ(+W`.FK#SYVHM=8J!FB<_VO&4[<(<6?>N6,"NWV+L@.<1K?F4ZG50+
M66ELI7U8L"YN+A0/ZEB+=<8<RK=V*[8DB+9I4Z="?V2@,LE5+4Z[_O=]6$U;
M.IYGVUF[0T7&4U\U4,9AG*=-(F+99TS"V_J]R`S&Z(%/?J`Y=ZJYKP=)>#1E
M4;RGU@*V#W8CV[&#$41\)@@>2*8W!!_/,U)2-L#U@M50_!_UH@N):^:8JD?(
M0GX"2W$?&#L7]SR?N&QL6"U,)RR'+([6;G4C5#7<SI=>W@=%&ML[J`+<XLE>
M<Q7AI1"X/*6>LO57`(IM+AQ5?SR)O07T[:\,7<;<-Z=V,\^[2K<'<\WT7N##
M'/H4U!7S+R`-=7`F?:"D@RA,M![((6^Y\>2[[7G%`H!+7B$8V[D(5RB;4\%C
MF68K*?72-'NDN9O0#?.;J?2`US7,,\XDN0''LOSTM4F4VN"XI'E+`NG1AK`@
MO69TNBWE>ZW//MV([!+SGP6_I7.P2$@G>ZM9G<8QX_(&N#Y,[A/0SHIXV\*"
M@_ZU#VR,X+>/?ZNK^E*6LM-5`?2!.=U@%-]-L24K:0GOTHC+FW5+.;TG@=V6
MUD*YQ$X>P8P6T.0%^#3EU"J5('WHDGGK,35,@*:/!($YI4O;FR<=\7HEBJ++
MTU84[?#Z(`HUU1^?$HFA^@H3\"9;C+OEI].M!I.=.+\GH9^^A:!R:U#_#\H6
M2_A_M`&W>$%O*6ZTP(C&]7QD$S,8FP]>?/^JW5HD5+S-FMF?57"OI71J*0%9
ME/[WKMTM!5RLUH'84BK/64B]2(3I_A,FP,4[A.7GOELBN+3EF&032#?2I&7[
MK0K`H:TVRZUBB=G"/>AT>3H;<Y^J/8I#*Y)JP+4PB%7V</<RPJ<DNQ,O;:%\
MNRJ,_O+$]VWUG,^Y!VIW4)M!G?)2C0-.9T0N:]^9W0'TP1<IG-Z*P,!RNJUE
MT`3J`Y/9!?5L/<4_W::?\($/&LKR0E0=K$NC[I8N\FT`]?!M]:AK!G5IU*5O
M5E0EO;`7NZ2970[$BPV>LZD^C-,(^:1NP5!Z2_`N/_[XP_\#4$L!`AX#%```
M``@`NGU?19K7<&-GO0``52@(`!$`&````````0```*2!`````&%T;FTM,C`Q
M-#`Y,S`N>&UL550%``/PYE-4=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
MNGU?18:_XX[1!@``)&```!4`&````````0```*2!LKT``&%T;FTM,C`Q-#`Y
M,S!?8V%L+GAM;%54!0`#\.935'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`+I]7T7P`1U"+S4``(-7`P`5`!@```````$```"D@=+$``!A=&YM+3(P,30P
M.3,P7V1E9BYX;6Q55`4``_#F4U1U>`L``00E#@``!#D!``!02P$"'@,4````
M"`"Z?5]%TO!10`]W``"$4P<`%0`8```````!````I(%0^@``871N;2TR,#$T
M,#DS,%]L86(N>&UL550%``/PYE-4=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`NGU?12I[!T,\10``Y,8$`!4`&````````0```*2!KG$!`&%T;FTM,C`Q
M-#`Y,S!?<')E+GAM;%54!0`#\.935'5X"P`!!"4.```$.0$``%!+`0(>`Q0`
M```(`+I]7T6HW=HZLQ4``![N```1`!@```````$```"D@3FW`0!A=&YM+3(P
M,30P.3,P+GAS9%54!0`#\.935'5X"P`!!"4.```$.0$``%!+!08`````!@`&
+`!H"```WS0$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESWAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details) (Abbview Biotherapeutics Corp [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Phase I Clinical Trial of a licensed product [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">$ 750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Phase II Clinical Trial of a licensed product [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Phase III Clinical Trial of a licensed product [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Biological License Application filing with U.S. FDA [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">First Commercial Sale [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">After First Net Sales [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">$ 1,500,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongTermPurchaseCommitmentMilestonesPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Long term purchase commitment milestones payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_LongTermPurchaseCommitmentMilestonesPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MilestonePaymentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_MilestonePaymentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPYAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 11,750,675<span></span></td>
        <td class="nump">$ 5,533,366<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">671,903<span></span></td>
        <td class="nump">218,389<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump">12,422,578<span></span></td>
        <td class="nump">5,751,755<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
        <td class="nump">141,011<span></span></td>
        <td class="nump">13,920<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
        <td class="nump">34,733<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump">12,598,322<span></span></td>
        <td class="nump">5,765,675<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">1,731,207<span></span></td>
        <td class="nump">378,955<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable and accrued expenses - related party</a></td>
        <td class="nump">278,291<span></span></td>
        <td class="nump">81,185<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">157,825<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="nump">8,216,935<span></span></td>
        <td class="nump">6,707,255<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump">10,226,433<span></span></td>
        <td class="nump">7,325,220<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
        <td class="nump">10,226,433<span></span></td>
        <td class="nump">7,325,220<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity (Deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; 50,000,000 authorized, none issued and outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized; 29,619,495 and 24,565,447 shares issued and outstanding, respectively</a></td>
        <td class="nump">29,620<span></span></td>
        <td class="nump">24,565<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">88,120,950<span></span></td>
        <td class="nump">64,933,145<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(85,778,681)<span></span></td>
        <td class="num">(66,517,255)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity (Deficit)</a></td>
        <td class="nump">2,371,889<span></span></td>
        <td class="num">(1,559,545)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity (Deficit)</a></td>
        <td class="nump">$ 12,598,322<span></span></td>
        <td class="nump">$ 5,765,675<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph k<br><br><br><br> -Subparagraph 1<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13495-108611<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34720828&amp;loc=SL20225862-175312<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8,17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SecurityDeposit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
        <td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Note 1 &#8211; Description of Business and Summary of Significant Accounting Policies</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Nature of Business &#8211;</b>&#160;Actinium Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Actinium&#8221;) is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;Actinium&#8221;) initiated collaborative efforts with large institutions to establish the proof of concept of APIT and has supported one Phase 1/2 clinical trial and one Phase 1 clinical trial at Memorial Sloan-Kettering Cancer Center (&#8220;MSKCC&#8221;) under an MSKCC Physician IND Application. In 2012, Actinium launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. &#160;Actinium&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that Actinium&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;API&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&#160;&#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API was considered the acquirer for accounting and financial reporting purposes.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">As a result of the Share Exchange, the Company was then considered a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On March 20, 2013, the Company&#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&#160;&#160;On April&#160;11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space:
 normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &#8220;Merger&#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company was cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company&#8217;s common stock.&#160;&#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Basis of Presentation - Unaudited Interim Financial Information &#8211;</b>&#160;The accompanying unaudited interim consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary&#160;for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2013 and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2013, as filed with the SEC on February 28, 2014.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Principles of Consolidation &#8211;</b>&#160;The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Use of Estimates in Financial Statement Presentation &#8211;</b>&#160;The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Reclassification &#8211;</b>&#160;Certain prior period amounts have been reclassified to conform to current period presentation.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Cash and Cash Equivalents &#8211;</b>&#160;The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are
 usually in excess of FDIC insured limits. At September 30, 2014 and December 31, 2013, all of the Company&#8217;s cash was deposited in one bank.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Property and Equipment &#8211;</b>&#160;Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three to seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Impairment of Long-Lived Assets &#8211;&#160;</b>Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Derivatives &#8211;</b>&#160;All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Fair Value of Financial Instruments &#8211;</b>&#160;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.55in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.55in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.55in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or
 indirectly. These might include quoted prices for similar assets or liabilities&#160;in&#160;active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.55in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.55in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of September 30, 2014 and December 31, 2013. As required by ASC 820 &#8220;<i>Fair Value Measurements and Disclosures&#8221;</i>, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 802px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level 1</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level 2</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level 3</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>Derivative liabilities:</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 406px; padding-left: 0.125in;">At September 30, 2014</td><td style="width: 8px;">&#160;</td><td style="width: 8px; text-align: left;">&#160;</td><td style="width: 72px; text-align: right;">-</td><td style="width: 8px; text-align: left;">&#160;</td><td style="width: 8px;">&#160;</td><td style="width: 8px; text-align: left;">&#160;</td><td style="width: 72px; text-align: right;">-</td><td style="width: 8px; text-align: left;">&#160;</td><td style="width: 8px;">&#160;</td><td style="width: 8px; text-align: left;">$</td><td style="width: 72px; text-align: right;">8,216,935</td><td style="width: 8px; text-align: left;">&#160;</td><td style="width: 8px;">&#160;</td><td style="width: 8px; text-align: left;">$</td><td style="width: 72px; text-align: right;">8,216,935</td><td style="width: 8px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-left: 0.125in;">At December 31, 2013</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6,707,255</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6,707,255</td><td style="text-align: left;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font:
 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Income Taxes &#8211;</b>&#160;The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Research and Development Costs &#8211;</b>&#160;Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Share-Based Payments &#8211;</b>&#160;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Earnings (Loss) Per Common Share &#8211;</b>&#160;The Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221; (&#8220;ASC 260&#8221;). Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options and warrants have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 802px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September&#160;30,<br />2013</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September&#160;30,<br />2014</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 610px; text-align: justify;">Options</td><td style="width: 8px;">&#160;</td><td style="width: 8px; text-align: left;">&#160;</td><td style="width: 72px; text-align: right;">2,280,184</td><td style="width: 8px; text-align: left;">&#160;</td><td style="width: 8px;">&#160;</td><td style="width: 8px; text-align: left;">&#160;</td><td style="width: 72px; text-align: right;">2,998,084</td><td style="width: 8px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 1.5pt;">Warrants</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black;
 border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">9,441,942</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">7,933,747</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-bottom: 4pt;">Total</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">11,722,126</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">10,931,831</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;<b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Recent Accounting Pronouncements &#8211;&#160;</b>In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers. Amendments in this Update create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition&#8212;Construction-Type and Production-Type Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs&#8212;Contracts with Customers. In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The amendments in this Update are effective for the Company for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the effects of ASU 2014-09 on the consolidated financial statements<b>.</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-10, Development Stage Entities. The amendments in this Update remove the definition of a development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows, and shareholder&#8217;s equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.&#160; Finally, the amendments also remove paragraph 810-10-15-16, which states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity (VIE) if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities it is currently engaged in and (2) the entity&#8217;s governing documents and contractual arrangements allow additional equity investments. Under the amendments, all entities within the scope of the Variable Interest Entities Subsections of Subtopic 810-10, Consolidation&#8212;Overall, would be required to evaluate whether the total equity investment at risk is sufficient using the guidance provided in paragraphs 810-10-25-45 through 25-47, which requires both qualitative and quantitative evaluations. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein, and early adoption is required. The Company evaluated and adopted ASU 2014 10&#160;at June 30, 2014.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal;
 font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-12, Compensation- Stock Compensation. The amendments in this update apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target can be achieved after the requisite service period.&#160;The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, and early adoption is permitted. The Company is currently evaluating the effects of ASU 2014-12 on the consolidated financial statements.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-15, Presentation of Financial Statements- Going Concern. The Update provides U.S. GAAP guidance on management&#8217;s responsibility in evaluating whether there is substantial doubt about a company&#8217;s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company&#8217;s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently evaluating the effects of ASU 2014-15 on the consolidated financial statements.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Subsequent Events &#8211;</b>&#160;The Company&#8217;s management reviewed all material events through the date of the consolidated financial statements were issued for subsequent event disclosure consideration.</font></p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQKKM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="3">3 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="3">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="3">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 07, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 24, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 09, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 27, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 28, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jul. 10, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Employees, consultants and board members [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Employees, consultants and board members [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Employees, consultants and board members [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Employees, consultants and board members [Member]

</div>
          <div>Minimum [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Employees, consultants and board members [Member]

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Investor [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 10, 2014

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Private Placement [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Common Stock [Member]

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Common Stock [Member]

</div>
          <div>Laidlaw and Co [Member]

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 10, 2014

</div>
          <div>Public Offering [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Public Offering [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Stock Option Plan [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Stock Option Plan [Member]

</div>
          <div>Minimum [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Stock Option Plan [Member]

</div>
          <div>Maximum [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Fair value of warrants determined utilizing the Black-Scholes option pricing model</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 200,000<span></span></td>
        <td class="nump">$ 200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5.55<span></span></td>
        <td class="nump">$ 11.66<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair value assumptions, risk free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.07%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.27%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.64%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">74.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">73.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">88.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">86.56%<span></span></td>
        <td class="nump">87.76%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair value assumptions, expected term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years 2 months 12 days<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 months<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair value assumptions, expected dividend rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueAssumptionsExpectedDiscountRate', window );">Fair value assumptions, expected discount rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.84%<span></span></td>
        <td class="nump">2.07%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantsIssuedToPurchaseCommonStock', window );">Warrants issued to purchase common stock, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">137,952<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">68,976<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">68,976<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">312,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,323,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Number of shares of restricted stock, granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">602,907<span></span></td>
        <td class="nump">180,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod', window );">Number of additional stock option granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">157,123<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of stock option cancelled</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms', window );">Description restricted stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Of the total shares of restricted stock granted, 20,000 shares vest 3 months from the grant date, 30,240 shares vest 1 year from the grant date, 202,667 shares have a vesting period of 4 years and 350,000 shares vest at the date of grant. The remaining restricted shares granted are performance based and upon the achievement of certain milestones.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock option exercise prices</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.96<span></span></td>
        <td class="nump">$ 5.55<span></span></td>
        <td class="nump">$ 11.95<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,873,557<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">275,153<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of option exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(310,400)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Expense related to common stock granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">734,799<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">95,971<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,623,994<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">284,371<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">98,224<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,953,856<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,953,856<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from the public offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,636,720<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,600,000<span></span></td>
        <td class="nump">11,451,250<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 7.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 9.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 7.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, shares</a></td>
        <td class="nump">61,538<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">551,810<span></span></td>
        <td class="nump">1,984,524<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,827,123<span></span></td>
        <td class="nump">1,670,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from common stock issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,325,860<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">116,936<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13,700,000<span></span></td>
        <td class="nump">12,525,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_UnderwritingDiscount', window );">Underwriting discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13,700,000<span></span></td>
        <td class="nump">876,750<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_UnderwritingAgreementDescription', window );">Underwriting agreement description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The agreement entered in on December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued or issuable. Subsequent to the closing of the 2013 offering, the placement agent continued to provide certain financial advisory services to the Company until three months after the Company had up-listed its securities for trading on a U.S. National Exchange for a monthly fee of $25,000.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Investors agreed to purchase (i) an aggregate of 554,310 shares ( the "Shares") of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 138,577 shares of common stock at an exercise price of $9.00 per share. The Company received $3,325,860 in gross proceeds from the sale of securities.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Under the terms of the underwriting agreement entered into with Canaccord Genuity Inc. as representative (the "Representative") of the several underwriters (collectively, the "Underwriters"), the Company also granted the Underwriters a 30-day option to purchase up to an additional 250,000 shares of common stock to cover over-allotments, if any, at the offering price.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PlacementAgentCashFees', window );">Placement agent cash fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">395,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PlacementAgentAttorneyFees', window );">Placement agent attorney fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">40,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Fair value adjustment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Warrants granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">137,952<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantsExercisedByWarrantHolders', window );">Warrants exercised by warrant holders</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">83,332<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,117,304<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RegistrationStatementDescription', window );">Registration statement description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to $200,000,000 of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the "Sales Agreement") with MLV &amp; Co. LLC ("MLV") dated March 24, 2014.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaximumOfferingPrice', window );">Maximum offering price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Aggregate offering amount of securities sold to investors</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. On April 28, 2014, the Company issued 500 shares and received net proceeds of $6,000 under the Sales Agreement with MLV.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other offering expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">125,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Auditor fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 72,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr>
        <td colspan="37"></td>
      </tr>
      <tr>
        <td colspan="37">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[3]</td>
              <td style="vertical-align: top;" valign="top">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EquityTextualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_EquityTextualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueAssumptionsExpectedDiscountRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair Value Assumptions Expected Discount Rate</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueAssumptionsExpectedDiscountRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MaximumOfferingPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum offering price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_MaximumOfferingPrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PlacementAgentAttorneyFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent attorney fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PlacementAgentAttorneyFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PlacementAgentCashFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent cash fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PlacementAgentCashFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RegistrationStatementDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Registration statement description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RegistrationStatementDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award options additional grants in period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_UnderwritingAgreementDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Underwriting agreement description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_UnderwritingAgreementDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_UnderwritingDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Underwriting discount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_UnderwritingDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantsExercisedByWarrantHolders">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants exercised by warrant holders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_WarrantsExercisedByWarrantHolders</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantsIssuedToPurchaseCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Issued To Purchase Aggregate Shares Of Common Stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_WarrantsIssuedToPurchaseCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityFairValueAdjustment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents a sum total of expenses not separately reflected on the income statement for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 7<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4,6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceInitialPublicOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section 45<br><br> -Paragraph 3<br><br> -Subparagraph (k)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfessionalFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 23<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569655-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4582445-111684<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockDescriptionOfTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of significant modifications (such as a change in expiration dating, vesting rights, or exercise prices) to an equity-based compensation plan, including the terms of the modifications.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2BAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details 1)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
        <td class="nump">10,931,831<span></span></td>
        <td class="nump">11,722,126<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
        <td class="nump">2,998,084<span></span></td>
        <td class="nump">2,280,184<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
        <td class="nump">7,933,747<span></span></td>
        <td class="nump">9,441,942<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 07, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 28, 2014</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2014

</div>
          <div>Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2014

</div>
          <div>Subsequent Event [Member]

</div>
          <div>Warrants [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, Shares</a></td>
        <td class="nump">61,538<span></span></td>
        <td class="nump">500<span></span></td>
        <td class="nump">386,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Common stock, conversion basis</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Common stock for the conversion of approximately 485,000 warrants and approximately $18,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SubsequentEventsTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_SubsequentEventsTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionBasis">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describe the conversion features of common stock if such stock is convertible. That is, shares of common stock into which another convertible security was converted, or shares of common stock into which another class of common stock was converted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockConversionBasis</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Details) (Memorial Sloan Kettering Cancer Center [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">New Drug Application [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract', window );"><strong>Summary of milestone payments related to related party</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RelatedPartyMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">$ 750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Receipt of Regulatory Approval From U.S. FDA [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract', window );"><strong>Summary of milestone payments related to related party</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RelatedPartyMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">$ 1,750,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RelatedPartyMilestonesPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Related party milestones payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RelatedPartyMilestonesPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
        <td class="text"><p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0;"><font style="font: 10pt times new roman, times, serif;"><b>Note 2 &#8211; Related Party Transactions</b></font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify;"><font style="font: 10pt times new roman, times, serif;"><b><i>MSKCC:</i></b></font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"></p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;">In 2010, General Atlantic Group Limited donated all of the equity shares of its wholly owned subsidiary, Actinium Holdings Ltd. (formerly named General Atlantic Investments Limited) to Memorial Sloan Kettering Cancer Center (MSKCC).</p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;">&#160;</p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"></p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;">On February 11, 2002, the Company entered into a License, Development and Commercialization Agreement with Sloan-Kettering Institute of Cancer Research (SKI),&#160;an entity related to MSKCC (&#8220;License Agreement&#8221;).&#160;&#160;The agreement was amended in August 2006.&#160;&#160;Pursuant to the agreement, the Company licensed certain intellectual property from SKI, including critical patents with respect to the Company&#8217;s core technology, and also supports ongoing research and clinical development of related drug candidates.&#160;&#160;MSKCC agreed, subject to certain conditions, to utilize the funds paid for certain clinical and preclinical programs and activities related to the Company&#8217;s drug development and clinical study programs, including the payment of certain costs and expenses that would otherwise have been borne by the Company.</p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">The Company is obligated to make the following milestone payments:</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p>
<table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1.5pt solid;">Milestones</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom: black 1.5pt solid;" colspan="2">Payments</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 88%; text-align: left;">(1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval&#160;for each licensed product</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 9%; text-align: right;">750,000</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">(2) upon the receipt of regulatory approval from the U.S. FDA for each&#160;licensed product</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,750,000</td>
<td style="text-align: left;">&#160;</td>
</tr>
</table>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.5in;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">Certain amounts due under the License Agreement were deferred and then forgiven under a forbearance-related arrangement.&#160;&#160;On June 19, 2011, the Company nonetheless agreed to pay SKI (a) $50,000 in 2011, (b) $200,000 in 2012 and (c) $250,000 in 2013 under this agreement, in respect of the $50,000 annual maintenance fees and research payments.&#160;</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"></p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;">On September 4, 2013, the Company entered into a letter agreement with SKI to set forth the amount that the Company owes SKI for the period from 2011 to 2014 under the License Agreement.&#160;&#160;The total amount that the Company owes SKI for the period from 2011 to 2014 is $815,100 plus all relevant licensed intellectual property related pass through costs to be determined.&#160;&#160;The amount owed does not include amounts the Company may owe for patent expenses under the
 License Agreement.&#160;&#160;During 2014, the annual maintenance fee is $189,000 plus pass through costs.</p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;">On March 27, 2012, the Company entered into an additional clinical trial agreement with MSKCC Cancer Center with respect to conducting a Phase 1/2 trial of combination therapy of low dose cytarabine and fractionated dose of Lintuzumab-Ac225.&#160;&#160;The Company will pay $31,185 for each patient that has completed the clinical trial.&#160;&#160;Upon execution of the agreement, the Company paid a start-up fee of $79,623 in 2012.</p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;">For the three months ended September 30, 2014 and 2013, the Company incurred approximately $26,000 and $0, respectively, for maintenance fees and research conducted by MSKCC For the nine months ended September 30, 2014 and 2013, the Company incurred $197,106 and $218,604, respectively, for maintenance fees and research conducted by MSKCC.&#160;&#160;As of September 30, 2014 and December 31, 2013, the Company has a payable to MSKCC covering the annual maintenance costs, clinical trials expense and patent costs totaling $278,291 and $81,185, respectively.</p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify;"><font style="font: 10pt times new roman, times, serif;"><b><i>Placement Agent:</i></b></font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">On August 7, 2012, the Company entered into an engagement agreement with a Healthcare Investment Bank as its placement agent for the 2012 Common Stock Offering whereby a director of the Company, is the Head of its Healthcare Investment Banking team.&#160;&#160;&#160;Pursuant to the agreement, the placement agent was engaged as the exclusive agent for the 2012 Common Stock Offering. &#160;&#160;In consideration for its services, the placement agent received (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.&#160;&#160;The placement agent or its designees also received warrants to purchase shares of the Company&#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.&#160;&#160;The placement agent also received the same fee and expense schedule for any cash exercise of warrants within 6 months of the final closing of the 2012 Common Stock Offering and a 5% solicitation fee for any warrants exercised as a result of being called for redemption by the Company.&#160;&#160;Upon the final closing of the 2012 Common Stock Offering of the units, the placement agent was engaged by the Company to provide certain financial advisory services to the Company for a period of at least 6 months for a monthly fee of $25,000.&#160;&#160;The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company&#8217;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.&#160;&#160;For a period ending one year after the expiration of all lock-up agreements entered into in connection with the Share Exchange, any change in the size of the Company board of directors must be approved by the placement agent.&#160;&#160;The placement agent also was engaged by the Company as placement agent for its Stock Offering and Convertible Notes financing in 2011 and, as a part of the fee for that engagement, designees of the placement agent also hold warrants to purchase 1,251,015 shares of the Company&#8217;s Common Stock.</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;">&#160;</p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;">On December 9, 2013, the Company entered into another engagement agreement with its placement agent for the 2013 Common Stock Offering, (&#8220;the Offering&#8221;). The Offering was completed in two tranches, December 9, 2013 and January 10, 2014. The agreement entered in on December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company&#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued or issuable. Subsequent to the closing of the 2013 offering, the placement agent continued to provide certain financial advisory services to the Company until three months after the Company had up-listed its securities for trading on a U.S. National Exchange for a monthly fee of $25,000.&#160;</p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.5in;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;">On December 27, 2013,&#160;the Company completed the first sale of
 the Offering pursuant to a Unit Purchase Agreement, with certain accredited investors (the &#8220;Investors&#8221;)&#160;pursuant to which the Investors agreed to purchase (i) an aggregate of 554,310 shares (the &#8220;Shares&#8221;) of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 138,577 shares of common stock at an exercise price of $9.00 per share. The Company received $3,325,860&#160;in gross proceeds from the sale of securities.</p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;">On January 10, 2014,&#160; the Company conducted the final closing (the &#8220;Final Closing&#8221;) of the Offering pursuant to a Unit Purchase Agreement, dated as of January 10, 2014 (the &#8220;Purchase Agreement&#8221;) and Subscription Agreement, dated as of January 10, 2014 (the &#8220;Subscription Agreement&#8221;), with certain accredited investors (the &#8220;Investors&#8221;)&#160;&#160;pursuant to which the Investors at the Final Closing agreed to purchase (i) an aggregate of 551,810 shares ( the &#8220;Shares&#8221;) of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 137,952 shares of common stock at an exercise price of $9.00 per share. The Company received $3,310,860&#160;in gross proceeds from the sale of securities under the Purchase Agreement at the Final Closing, bringing the total gross proceeds received by the Company in the Offering to $6,636,720. &#160;The aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments.</p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">During the nine months ended September 30, 2014, the placement agent received a cash fee of approximately $0.4 million from the sale of securities and was issued warrants to purchase 68,976 shares of the Company&#8217;s Common Stock at $9.00 per share for a period of 5 years.</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;"><font style="font: 10pt times new roman, times, serif;">On May 28, 2014, the Company and the placement agent agreed to terminate the December 9, 2013 engagement agreement.</font></p>
<p style="font: 10pt times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;">&#160;</p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.55in;">On July 10, 2014 the Company completed a public offering that totaled 1,827,123 common shares, representing gross proceeds of approximately $13.7 million and a net amount of approximately $12.6 million after deducting the underwriting discount and the other offering expenses. The Placement Agent acted as sole book-running manager for the offering, the Placement Agent acted as lead manager and MLV &amp; Co. acted as co-manager. The offering was made pursuant to a shelf registration statement previously filed with and declared effective by the U.S. Securities and Exchange Commission.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6NAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">50,000,000<span></span></td>
        <td class="nump">50,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">200,000,000<span></span></td>
        <td class="nump">200,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">29,619,495<span></span></td>
        <td class="nump">24,565,447<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
        <td class="nump">29,619,495<span></span></td>
        <td class="nump">24,565,447<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">September&#160;30,</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December&#160;31,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Lives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 1003px;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Office equipment</td><td>&#160;</td><td style="text-align: center;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">3-5 years</font></td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">166,354</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">15,480</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: right; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(25,343</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(1,560</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Property and equipment, net</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="text-align: right; padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">141,011</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">13,920</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Oct. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Actinium Pharmaceuticals, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001388320<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30,005,507<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivatives [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of derivative warrant instruments activity</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Units</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Fair Value</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1081.81px;">Balance, December 31, 2013</td><td style="width: 14.54px;">&#160;</td><td style="width: 14.54px; text-align: left;">&#160;</td><td style="width: 128.18px; text-align: right;">1,968,623</td><td style="width: 14.54px; text-align: left;">&#160;</td><td style="width: 14.54px;">&#160;</td><td style="width: 13.63px; text-align: left;">$</td><td style="width: 127.27px; text-align: right;">6,707,255</td><td style="width: 13.63px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Transfer from liability classification to equity classification</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(306,900</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(2,143,793</td><td style="text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">3,653,473</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">Balance, September 30, 2014</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,661,723</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">8,216,935</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock', window );">Summary of fair values of derivative warrants on basis of valuation model</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">September&#160;30,</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December&#160;31,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1081.81px; text-align: left;">Market value of common stock on measurement date (1)</td><td style="width: 14.54px;">&#160;</td><td style="width: 14.54px; text-align: left;">$</td><td style="width: 128.18px; text-align: right;">6.70</td><td style="width: 14.54px; text-align: left;">&#160;</td><td style="width: 14.54px;">&#160;</td><td style="width: 13.63px; text-align: left;">$</td><td style="width: 127.27px; text-align: right;">5.89</td><td style="width: 13.63px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Adjusted exercise price</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">2.48</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">2.48</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Risk free interest rate (2)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.07</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.27</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Warrant lives in years</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">3.2 years</font></td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">0.5 years</font></td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected volatility (3)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">74</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">73</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected dividend yield (4)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Probability of stock offering in any period over 5 years (5)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">25</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">25</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Range of percentage of existing shares offered (6)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">35</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Offering price range (7)</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">7.50</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">9</td><td style="text-align: left;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="width: 42.72px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(1)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The market value of common stock at the above measurement dates is based on the
 Company&#8217;s trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for September 30, 2014.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="width: 42.72px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(2)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="width: 42.72px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(3)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="padding: 0px; width: 42.72px; text-indent: 0px;"></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(4)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="padding: 0px; text-indent: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;">&#160;</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="padding: 0px; width: 42.72px; text-indent: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(5)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Management determines the probability of future stock offering at each evaluation date.</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="padding: 0px; text-indent: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;">&#160;</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="padding: 0px; width: 42.72px; text-indent: 0px;"></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(6)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify;
 text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at September 30, 2014 and December 31, 2013, respectively.</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="padding: 0px; text-indent: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;">&#160;</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="padding: 0px; width: 42.72px; text-indent: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(7)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Represents the estimated offering price range in future offerings as determined by management.</font></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative warrants on basis of valuation model.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41678-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 25<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41620-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579245-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5580258-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579240-113959<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41641-113959<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41638-113959<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624171-113959<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624163-113959<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJCAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements Of Operations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of reimbursements</a></td>
        <td class="nump">3,773,438<span></span></td>
        <td class="nump">778,232<span></span></td>
        <td class="nump">8,236,343<span></span></td>
        <td class="nump">2,373,200<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">3,257,147<span></span></td>
        <td class="nump">830,730<span></span></td>
        <td class="nump">7,347,827<span></span></td>
        <td class="nump">2,730,233<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump">14,326<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">23,783<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposition of equipment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">4,122<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">7,044,911<span></span></td>
        <td class="nump">1,608,962<span></span></td>
        <td class="nump">15,607,953<span></span></td>
        <td class="nump">5,107,555<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(7,044,911)<span></span></td>
        <td class="num">(1,608,962)<span></span></td>
        <td class="num">(15,607,953)<span></span></td>
        <td class="num">(5,107,555)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(1,299)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(2,508)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on change in fair value of derivative liabilities</a></td>
        <td class="nump">967,887<span></span></td>
        <td class="nump">189,348<span></span></td>
        <td class="num">(3,653,473)<span></span></td>
        <td class="nump">216,112<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
        <td class="nump">967,887<span></span></td>
        <td class="nump">188,049<span></span></td>
        <td class="num">(3,653,473)<span></span></td>
        <td class="nump">213,604<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (6,077,024)<span></span></td>
        <td class="num">$ (1,420,913)<span></span></td>
        <td class="num">$ (19,261,426)<span></span></td>
        <td class="num">$ (4,893,951)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted</a></td>
        <td class="num">$ (0.21)<span></span></td>
        <td class="num">$ (0.06)<span></span></td>
        <td class="num">$ (0.73)<span></span></td>
        <td class="num">$ (0.22)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - basic and diluted</a></td>
        <td class="nump">28,496,902<span></span></td>
        <td class="nump">23,601,895<span></span></td>
        <td class="nump">26,540,368<span></span></td>
        <td class="nump">22,401,711<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5618551-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -Subparagraph (a),(c),(d),(e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeGainLossOnDerivativeNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Note 7 &#8211; Equity</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On December 9, 2013, the Company entered into another engagement agreement with its placement agent for the 2013 Common Stock Offering, &#8216;the Offering&#8221;) The Offering was completed in two tranches, on December 9, 2013 and January 10, 2014. The agreement entered&#160;on December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company&#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued or issuable. Subsequent to the closing of the 2013 offering, the placement agent continued to provide certain financial advisory services to the Company until three months after the Company had up-listed its securities for trading on a U.S. National Exchange for a monthly fee of $25,000.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On December 27, 2013,&#160;the Company completed the first sale of the Offering pursuant to a Unit Purchase Agreement, with certain accredited investors (the &#8220;Investors&#8221;)&#160;pursuant to which: the Investors agreed to purchase (i) an aggregate of 554,310 shares (the &#8220;Shares&#8221;) of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 138,577 shares of common stock at an exercise price of $9.00 per share. The Company received $3,325,860&#160;in gross proceeds from the sale of securities.&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 27.5pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">In January 2014, the Company completed the final tranche of a private placement of the Company&#8217;s common stock and warrants and received approximately $3.3 million total gross proceeds from accredited investors (&#8220;2014 Closing&#8221;). The Company paid its placement agent total cash fees of approximately $395,000 and paid attorney fees of $40,000 for their services resulting in net proceeds of $2,873,557. In the 2014 Closing, the Company sold 551,810 shares of common stock at $6.00 per share and granted 137,952 units of five-year warrants with an exercise price of $9.00 per share. The warrants are exercisable for a period of five years from the date of issuance. The transaction date fair value of the warrants of $0.6 million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rate - 1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5 years. During the nine months ended September 30, 2014, 83,332 warrants were exercised.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;
 -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 27.5pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On March 24, 2014, the Company filed a shelf registration statement on Form S-3 (the &#8220;Registration Statement&#8221;) which was effective on April 17, 2014. This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to $200,000,000 of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the &#8220; Sales Agreement &#8221; ) with MLV &amp; Co. LLC ( &#8220; MLV &#8221; ) dated March 24, 2014. The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. On April 28, 2014, the Company issued 500 shares and received net proceeds of $6,000 under the Sales Agreement with MLV.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Placement Agent &#8211;&#160;</b>During January 2014, in connection with the Common Stock Offering, the Company issued the Placement Agent warrants to purchase an aggregate of 68,976 shares of common stock with an exercise price of $9.00 per share. The transaction date fair value of the warrants of $0.2 million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rate &#8211; 1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5 years.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Public Offering</b>&#160;- On June 30, 2014, the Company received gross proceeds of $12,525,000 from the public offering of 1,670,000 shares of the Company&#8217;s common stock, $0.001 par value per share at a price to the public of $7.50 per share less underwriting discounts. The Company paid an underwriting discount of $876,750, paid the other offering expenses of $125,000, and paid attorney and auditor fees of $72,000 resulting in net proceeds of $11,451,250.. Under the terms of the underwriting agreement, the Company also granted the underwriters a 30-day option to purchase up to an additional 250,000 shares of common stock to cover over-allotments, if any, at the offering price.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On July 10, 2014, the underwriter exercised their over-allotment option to purchase an additional 157,123 shares from the Company for $7.50 per share. Including the exercise of the over-allotment option of $1.2 million, in gross proceeds, Actinium&#8217;s offering totaled 1,827,123 shares,
 representing gross proceeds of approximately $13.7 million and approximately $12.6 million net after deducting the underwriting discount and the other offering expenses.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;">&#160;<font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Approval of the Equity Incentive Plan</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">During the nine months ended September 30, 2013, the Company granted employees, consultants and board members 180,000 shares of restricted stock. During the nine months ended September 30, 2014, the Company granted 602,907 shares of restricted stock and cancelled 50,000 shares of restricted stock. Of the total shares of restricted stock granted, 20,000 shares vest 3 months from the grant date, 30,240 shares vest 1 year from the grant date, 202,667 shares have a vesting period of 4 years and 350,000 shares vest at the date of grant. The remaining restricted shares granted are performance based and upon the achievement of certain milestones.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"></font>&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Stock Option Plan</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.55in; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Following is a summary of option activities for the nine months ended September 30, 2014:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 29.7pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of Units</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align:
 center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Remaining Contractual Term (in years)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px;">Outstanding, December 31, 2013</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">1,985,384</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">3.23</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">8.34</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">5,908,696</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-left: 0.125in;">Issued</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,323,100</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8.89</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">10.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-left: 0.125in; padding-bottom: 1.5pt;">Exercised</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(310,400</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.96</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt;">Outstanding, September 30, 2014</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">2,998,084</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.98</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8.60</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5,731,296</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt;">Exercisable, September 30, 2014</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">643,206</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">1.04</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6.27</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">3,734,610</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal;
 widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">During the nine months ended September 30, 2014, the Company granted employees and its board members 1,323,100 options to purchase the Company&#8217;s common stock with exercise prices ranging from $5.55 to $11.95 and a term of 10 years with vesting over a 4-year period.&#160;&#160;The options have an aggregated fair value of $8.6 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.84% - 2.07% (2) expected life of 6 years, (3) expected volatility of 86.56% to 87.76%, and (4) zero expected dividends.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">During the nine months ended September 30, 2014, the Company received gross proceeds of $275,153 for exercise of options for 310,400 shares of the Company&#8217;s common stock.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at September 30, 2014 was $10,953,856. During the three months ended September 30, 2014 and 2013, the Company recorded option expense of $734,799 and $95,971, respectively. During the nine months ended September 30, 2014 and 2013, the Company recorded option expense of $1,623,994 and $284,371, respectively.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Warrants</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Following is a summary of warrant activities for the nine months ended September 30, 2014:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new
 roman',;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of Units</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Remaining Contractual Term (in years)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px;">Outstanding, December 31, 2013</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">9,673,290</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1.06</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">4.89</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">47,396,307</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-left: 0.125in;">Granted</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">406,928</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8.81</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">7.46</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-left: 0.125in;">Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(2,117,304</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.96</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt; padding-left: 0.125in;">Forfeited</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">(29,167</td><td style="padding-bottom: 1.5pt; text-align: left;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6.70</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">Outstanding, September 30, 2014</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">7,933,747</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.47</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">4.15</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">42,641,772</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">Exercisable, September 30, 2014</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align:
 left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">7,733,747</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">1.28</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">4.01</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">42,641,772</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">During the nine months ended September 30, 2014, the Company granted warrants to purchase 137,952 shares of the Company&#8217;s common stock to investors and warrants to purchase 68,976 shares of the Company&#8217;s common stock to its placement agent in connection with the January 2014 closing.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 27.5pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">During the nine months ended September 30, 2014, the Company also granted two consultants warrants to purchase 200,000 shares of the Company&#8217;s common stock with exercise prices ranging from $5.55 to $11.66 per share and a term of 10 years. These warrants vest when certain milestones are met. The fair value of the February 2014 and June 2014 were $0.6 million and $1.2 million, respectively.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 27.5pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">During the nine months ended September 30, 2014, 2,117,304 warrants were exercised by the warrant holders. The Company issued 1,984,524 shares of common stock and received gross proceeds of $116,936.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 27.5pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">During the three months ended September 30, 2014 and 2013, the Company did not record any stock-based compensation related to the warrants. During the nine months ended September 30, 2014 and 2013, the Company recorded stock-based compensation related to the warrants of $98,224 and $0, respectively.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Note 6 &#8211; Commitments and Contingencies</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>License and Research Agreements</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="width: 48px;">&#160;</td><td style="width: 47px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-top: 0px; padding-right: 0px; padding-bottom: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">a.</font></td><td style="width: 1472px; text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">AbbView Biotherapeutics Corp&#160;<font style="line-height: 15.3333320617676px;">(<font style="color: black;">formerly Abbott Biotherapeutics Corp)</font>&#160;&#8211;&#160;</font>The Company entered into a Product Development and Patent License Agreement with AbbVie Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt;
 line-height: normal; font-family: 'times new roman', times, serif;">The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Milestones</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Payments</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left;">(1) when Company initiates a Phase I Clinical Trial of a licensed product</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">750,000</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">(2) when Company initiates a Phase II Clinical Trial of a licensed product</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">750,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">(3) when Company initiates a Phase III Clinical Trial of a licensed product</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,500,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">(4) Biological License Application filing with U.S. FDA</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,750,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">(5) First commercial sale</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,500,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">(6) after the first $10,000,000 in net sales</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,500,000</td><td style="text-align: left;">&#160;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;">Under the agreement, the Company shall pay to AbbVie Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">The Company met its first milestone in 2012 and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012.&#160;&#160;The milestone payment for the Phase 1 Clinical Trial was recorded as research and development expense. The Company has not initiated a Phase 2 Clinical Trial and no payment has been made to Abbott Biotherapeutics Corp. since the July 24, 2012 payment.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt;
 line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="width: 48px;">&#160;</td><td style="width: 47px; text-align: left; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">b.&#160;&#160;</font></td><td style="width: 1472px; text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Memorial Sloan Kettering Cancer Center (MSKCC) &#8211; see related party disclosure.</font></td></tr><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td>&#160;</td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td>&#160;</td><td style="text-align: left; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">c.&#160;&#160;</font></td><td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Oak Ridge National Laboratory (ORNL) &#8211; The Company is contracted to purchase radioactive material to be used for research and development, with a renewal option at the contract end.&#160;&#160;For 2013, the Company was obligated and paid approximately $0.3 million to purchase of radioactive material with ORNL.&#160;&#160;During 2014, the Company signed a contract with ORNL to purchase $0.4 million of radioactive material.</font></td></tr><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td>&#160;</td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td>&#160;</td><td style="text-align: left; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">d.&#160;&#160;</font></td><td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">AptivSolutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab-A) used in the Company&#8217;s Phase 1 and Phase 2 clinical trials.&#160;&#160;The total project is estimated to cost approximately $1.9 million and requires a 12.5% down payment of the total estimated project cost.&#160;&#160;The down payment totaling $239,000 was paid in 2007 and 2012.&#160;&#160;On August 6, 2012, October 22, 2012 and May 16, 2013, the agreement was amended to provide for additional services.&#160;&#160;The total project is now estimated at approximately $2.2 million. As of September 30,
 2014, approximately $1.2 million has been expensed to date. &#160;AptivSolutions bills the Company when services are rendered and the Company records the related expense to research and development costs.</font></td></tr><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td>&#160;</td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td>&#160;</td><td style="text-align: left; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;e.&#160;&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (FHCRC) to build upon previous and ongoing clinical trials, with BC8 (licensed antibody).&#160;&#160;FHCRC has currently completed Phase 1 and Phase 2 of the clinical trial and the Company intends to start preparation for a pivotal trial leading to an FDA approval.&#160;&#160;The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC.&#160;&#160;The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA.&#160;&#160;Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter.&#160;&#160;Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year.&#160;&#160;A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug.&#160;&#160;Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.</font></p><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">During the nine months ended September 30, 2014 and 2013, the Company recorded fees of approximately $0.1 million and $75,000, respectively, related to this agreement.</font></p></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font>&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="width: 48px;">&#160;</td><td style="width: 47px; text-align: center; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">f.&#160;&#160;</font></td><td style="width: 1472px; text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC.&#160;&#160;The Company will pay $31,366 for each patient that has completed the clinical trial. The Company paid a start-up fee of $19,749 in
 2013.&#160;&#160;During the clinical trial additional fees apply and will be invoiced when applicable. For the nine months ended September&#160;30, 2014, the Company paid approximately $16,000 for patient enrollment.</font></td></tr><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td>&#160;</td><td style="text-align: center; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td>&#160;</td><td style="text-align: center; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">g.&#160;&#160;</font></td><td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center.&#160;&#160;The total estimated cost of conducting the clinical trial is approximately $500,000, which includes a non- refundable institutional fee of $14,500.&#160;&#160;The estimated cost is based on treating 24 patients through 2013.&#160;&#160;Upon execution of the agreement, the Company paid $33,946. During 2013, there was one patient treated and the Company paid $34,383 in July 2013. During the nine months ended September 30, 2014, the Company recorded an expense of approximately $0.1 million.</font></td></tr><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td>&#160;</td><td style="text-align: center; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td>&#160;</td><td style="text-align: center; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">h.&#160;&#160;</font></td><td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University.&#160;&#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&#160;&#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&#160;&#160;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable. The Company paid the start-up fee in February 2013. There were no payments made during the nine months ended September 30, 2014 for this agreement.</font></td></tr><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td>&#160;</td><td style="text-align: center; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height:
 normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td>&#160;</td><td style="text-align: center; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">i.&#160;&#160;</font></td><td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania.&#160;&#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&#160;&#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&#160;&#160;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable.&#160;&#160;The Company accrued the $16,000 fee at December 31, 2013 and paid the fee in January 2014. During the nine months ended September 30, 2014, the Company recorded an expense of approximately $16,000.</font></td></tr><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td>&#160;</td><td style="text-align: center; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td>&#160;</td><td style="text-align: center; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">j.&#160;&#160;</font></td><td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On January 27, 2014, the Company entered into a manufacturing agreement with Goodwin Biotechnology Inc.&#160;&#160;(&#8220;Goodwin&#8221;). Goodwin will oversee the current Good Manufacturing Practices (cGMP) production of a monoclonal antibody anticipated to be used in an upcoming phase 3 clinical trial of Iomab-B. Total cost of the agreement is $3.3 million. The Company paid a non-refundable payment of $562,790 upon execution of the agreement. Periodic payments will be made upon reaching certain milestones. As of September 30, 2014, the remaining cost of the agreement is approximately $2.3 million. Goodwin bills the Company when services are rendered and the Company records the related expense to research and development costs.</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="width: 48px;">&#160;</td><td style="width: 47px; text-align: center; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">k.&#160;&#160;</font></td><td style="width: 1472px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal;
 font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On June 20, 2014, the Company entered into a CRO agreement with Act Oncology. Act Oncology provides project management services for the study of Iomab-B used for the intended Phase 3 clinical trial.&#160;&#160;The total project is estimated to cost approximately $0.8 million. The Company paid approximately $0.3 million during the nine months ended September 30, 2014. Act Oncology bills the Company when services are rendered and the Company records the related expense to research and development costs.</font></p><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p></td></tr><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td>&#160;</td><td style="text-align: center; text-indent: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">l.&#160;&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;"><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;">On September 30, 2014, the Company entered into a research agreement with the Albert Einstein College of Medicine of Yeshiva University (&#8220;Einstein&#8221;). According to the agreement, Einstein will use certain materials provided by the Company to complete a research project. The research project will explore the feasibility of using Actinium 225 to prepare patients with blood borne cancers to receive a hematopoietic stem cell transplant. Einstein will periodically provide the Company with reports showing project data or research. The total fixed price of the project is $183,391 which is payable to Einstein in three payments. A payment of approximately $92,000 was made subsequent to September&#160;30, 2014.&#160;&#160;</p></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Lease Agreements</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue,&#160;New York, NY. The agreement was terminated on May 31, 2013. On June 4, 2013 and amended on October&#160;4, 2013, the Company entered into two rental agreements for office space at 546 Fifth Avenue,&#160;New York, NY. One of the agreements was terminated on July 6, 2014. The Company plans to maintain office space at 546 Fifth Avenue, New York, NY at least until December 31, 2014. The Company paid a one month refundable deposit on the space that it maintains in New York, NY. &#160;On April 22, 2014, the Company entered into a sublease agreement for office space located at 379 Thornall Street, Edison, NJ. This agreement expires on September 30, 2016. The Company issued a security deposit of $34,733 to the existing tenant.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELVAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Machinery and equipment [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Furniture and fixtures [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 28, 2012

</div>
          <div>Actinium [Member]

</div>
          <div>pures</div>
        </th>
        <th class="th">
          <div>Sep. 25, 2013

</div>
          <div>Actinium [Member]

</div>
          <div>pures</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership interest acquired by company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100.00%<span></span></td>
        <td class="nump">93.70%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition', window );">Common Stock issuable in consideration for equity interest acquisition</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">99.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Three years<span></span></td>
        <td class="text">Three to seven years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SharesExchangeRatio', window );">Shares received by each API shareholder of Actinium common stock for each API share exchanged</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.333<span></span></td>
        <td class="nump">0.333<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommonStockShares', window );">Common stock shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,970,137<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ExchangedInCommonStockShares', window );">Common stock shares exchanged</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,322,055<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common Stock issuable in consideration for equity interest acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommonStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_CommonStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ExchangedInCommonStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock shares exchanged.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ExchangedInCommonStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharesExchangeRatio">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares exchange ratio.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_SharesExchangeRatio</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:decimalItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityMethodInvestmentOwnershipPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6539997&amp;loc=d3e1205-110223<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentsMilestoneMethodTableTextBlock', window );">Summary of milestone payment</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Milestones</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Payments</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1252.72px; text-align: left;">(1) when Company initiates a Phase I Clinical Trial of a licensed product</td><td style="width: 14.54px;">&#160;</td><td style="width: 14.54px; text-align: left;">$</td><td style="width: 127.27px; text-align: right;">750,000</td><td style="width: 13.63px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">(2) when Company initiates a Phase II Clinical Trial of a licensed product</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">750,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">(3) when Company initiates a Phase III Clinical Trial of a licensed product</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,500,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">(4) Biological License Application filing with U.S. FDA</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,750,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">(5) First commercial sale</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,500,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">(6) after the first $10,000,000 in net sales</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,500,000</td><td style="text-align: left;">&#160;</td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MilestonePaymentsMilestoneMethodTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payments milestone method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_MilestonePaymentsMilestoneMethodTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Summary of set forth liabilities measured at fair value on a recurring basis</a></td>
        <td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 802px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level 1</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level 2</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level 3</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>Derivative liabilities:</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 406px; padding-left: 0.125in;">At September 30, 2014</td><td style="width: 8px;">&#160;</td><td style="width: 8px; text-align: left;">&#160;</td><td style="width: 72px; text-align: right;">-</td><td style="width: 8px; text-align: left;">&#160;</td><td style="width: 8px;">&#160;</td><td style="width: 8px; text-align: left;">&#160;</td><td style="width: 72px; text-align: right;">-</td><td style="width: 8px; text-align: left;">&#160;</td><td style="width: 8px;">&#160;</td><td style="width: 8px; text-align: left;">$</td><td style="width: 72px; text-align: right;">8,216,935</td><td style="width: 8px; text-align: left;">&#160;</td><td style="width: 8px;">&#160;</td><td style="width: 8px; text-align: left;">$</td><td style="width: 72px; text-align: right;">8,216,935</td><td style="width: 8px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-left: 0.125in;">At December 31, 2013</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6,707,255</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6,707,255</td><td style="text-align: left;"></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of earnings per share</a></td>
        <td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 802px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September&#160;30,<br />2013</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September&#160;30,<br />2014</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 610px; text-align: justify;">Options</td><td style="width: 8px;">&#160;</td><td style="width: 8px; text-align: left;">&#160;</td><td style="width: 72px; text-align: right;">2,280,184</td><td style="width: 8px; text-align: left;">&#160;</td><td style="width: 8px;">&#160;</td><td style="width: 8px; text-align: left;">&#160;</td><td style="width: 72px; text-align: right;">2,998,084</td><td style="width: 8px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 1.5pt;">Warrants</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">9,441,942</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">7,933,747</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-bottom: 4pt;">Total</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">11,722,126</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">10,931,831</td><td style="text-align: left; padding-bottom: 4pt;"></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;<b>&#160;</b></font></p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><p style="font: 10pt times new roman, times, serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify;"><b>Note 8 &#8211; Subsequent Events&#160;</b></p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.5in;"></p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0; text-align: justify; text-indent: 0.5in;">During October 2014, the Company issued approximately 386,000 shares of common stock for the conversion of approximately 485,000 warrants and approximately $18,000.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Nature of Business</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Nature of Business &#8211;</b>&#160;Actinium Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Actinium&#8221;) is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;Actinium&#8221;) initiated collaborative efforts with large institutions to establish the proof of concept of APIT and has supported one Phase 1/2 clinical trial and one Phase 1 clinical trial at Memorial Sloan-Kettering Cancer Center (&#8220;MSKCC&#8221;) under an MSKCC Physician IND Application. In 2012, Actinium launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. &#160;Actinium&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that Actinium&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;API&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&#160;&#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API was considered the acquirer for accounting and financial reporting purposes.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">As a result of the Share Exchange, the Company was then considered a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On March 20, 2013, the Company&#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&#160;&#160;On April&#160;11, 2013, the Company changed its domicile
 from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &#8220;Merger&#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company was cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company&#8217;s common stock.&#160;&#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation - Unaudited Interim Financial Information</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Basis of Presentation - Unaudited Interim Financial Information &#8211;</b>&#160;The accompanying unaudited interim consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary&#160;for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2013 and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2013, as filed with the SEC on February 28, 2014.</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Principles of Consolidation &#8211;</b>&#160;The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in Financial Statement Presentation</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Use of Estimates in Financial Statement Presentation &#8211;</b>&#160;The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Reclassification &#8211;</b>&#160;Certain prior period amounts have been reclassified to conform to current period presentation.</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Cash and Cash Equivalents &#8211;</b>&#160;The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At September 30, 2014 and December 31, 2013, all of the Company&#8217;s cash was deposited in one bank.</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Property and Equipment &#8211;</b>&#160;Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three to seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Impairment of Long-Lived Assets &#8211;&#160;</b>Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Derivatives &#8211;</b>&#160;All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Fair Value of Financial Instruments &#8211;</b>&#160;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.55in; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.55in; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.55in; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities&#160;in&#160;active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.55in; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.55in; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch:
 normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of September 30, 2014 and December 31, 2013. As required by ASC 820 &#8220;<i>Fair Value Measurements and Disclosures&#8221;</i>, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level 1</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level 2</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level 3</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>Derivative liabilities:</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 803px; padding-left: 0.125in;">At September 30, 2014</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">-</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">-</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">8,216,935</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">8,216,935</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-left: 0.125in;">At December 31, 2013</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6,707,255</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6,707,255</td><td style="text-align: left;">&#160;</td></tr></table><div>&#160;</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Income Taxes &#8211;</b>&#160;The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Research and Development Costs &#8211;</b>&#160;Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-Based Payments</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Share-Based Payments &#8211;</b>&#160;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Common Share</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Earnings (Loss) Per Common Share &#8211;</b>&#160;The Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221; (&#8220;ASC 260&#8221;). Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options and warrants have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September&#160;30,<br />2013</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September&#160;30,<br />2014</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-align: justify;">Options</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">2,280,184</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">2,998,084</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 1.5pt;">Warrants</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">9,441,942</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">7,933,747</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-bottom: 4pt;">Total</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">11,722,126</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">10,931,831</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr></table><div>&#160;</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Recent Accounting Pronouncements &#8211;&#160;</b>In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers. Amendments in this Update create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition&#8212;Construction-Type and Production-Type Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs&#8212;Contracts with Customers. In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The amendments in this Update are effective for the Company for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the effects of ASU 2014-09 on the consolidated financial statements<b>.</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-10, Development Stage Entities. The amendments in this Update remove the definition of a development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows, and shareholder&#8217;s equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.&#160; Finally, the amendments also remove paragraph 810-10-15-16, which states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity (VIE) if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities it is currently engaged in and (2) the entity&#8217;s governing documents and contractual arrangements allow additional equity investments. Under the amendments, all entities within the scope of the Variable Interest Entities Subsections of Subtopic 810-10, Consolidation&#8212;Overall, would be required to evaluate whether the total equity investment at risk is sufficient using the guidance provided in paragraphs 810-10-25-45 through 25-47, which requires both qualitative and quantitative evaluations. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein, and early adoption is required. The Company evaluated and adopted ASU 2014-10 at June 30, 2014.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-12, Compensation- Stock Compensation. The amendments in this update apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target can be achieved after the requisite service period. The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, and early adoption is permitted. The Company is currently evaluating the effects of ASU 2014-12 on the consolidated financial
 statements.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-15, Presentation of Financial Statements- Going Concern. The Update provides U.S. GAAP guidance on management&#8217;s responsibility in evaluating whether there is substantial doubt about a company&#8217;s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company&#8217;s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently evaluating the effects of ASU 2014-15 on the consolidated financial statements.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.7999992370606px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Subsequent Events &#8211;</b>&#160;The Company&#8217;s management reviewed all material events through the date of the consolidated financial statements were issued for subsequent event disclosure consideration.</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -Subparagraph (a)-(d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationRelatedCostsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConsolidationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41620-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579245-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579240-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41638-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph n<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41675-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 60<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390181&amp;loc=d3e202-110218<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PriorPeriodReclassificationAdjustmentDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting subsequent events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of activities related to related party</a></td>
        <td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 821px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Milestones</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Payments</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 723px; text-align: left;">(1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval&#160;for each licensed product</td><td style="width: 9px;">&#160;</td><td style="width: 8px; text-align: left;">$</td><td style="width: 73px; text-align: right;">750,000</td><td style="width: 8px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">(2) upon the receipt of regulatory approval from the U.S. FDA for each&#160;licensed product</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,750,000</td><td style="text-align: left;">&#160;</td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQSAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Summary of stock option activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Beginning balance</a></td>
        <td class="nump">9,673,290<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issued</a></td>
        <td class="nump">406,928<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="num">(2,117,304)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
        <td class="num">(29,167)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Ending Balance</a></td>
        <td class="nump">7,933,747<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
        <td class="nump">7,733,747<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
        <td class="nump">$ 1.06<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Issued</a></td>
        <td class="nump">$ 8.81<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, exercised</a></td>
        <td class="nump">$ 0.96<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, forfeited</a></td>
        <td class="nump">$ 6.70<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 1.47<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
        <td class="nump">$ 1.28<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Outstanding, Beginning balance</a></td>
        <td class="text">4 years 10 months 21 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years), Issued</a></td>
        <td class="text">7 years 5 months 16 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term (in years), Outstanding, Ending balance</a></td>
        <td class="text">4 years 1 month 24 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Exercisable</a></td>
        <td class="text">4 years 4 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
        <td class="nump">$ 47,396,307<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
        <td class="nump">42,641,772<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable</a></td>
        <td class="nump">42,641,772<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Summary of stock option activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Beginning balance</a></td>
        <td class="nump">1,985,384<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issued</a></td>
        <td class="nump">1,323,100<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="num">(310,400)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Ending Balance</a></td>
        <td class="nump">2,998,084<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
        <td class="nump">643,206<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
        <td class="nump">$ 3.23<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Issued</a></td>
        <td class="nump">$ 8.89<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, exercised</a></td>
        <td class="nump">$ 0.96<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 5.98<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
        <td class="nump">$ 1.04<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Outstanding, Beginning balance</a></td>
        <td class="text">8 years 4 months 2 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years), Issued</a></td>
        <td class="text">10 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term (in years), Outstanding, Ending balance</a></td>
        <td class="text">8 years 7 months 6 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Exercisable</a></td>
        <td class="text">6 years 3 months 7 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
        <td class="nump">5,908,696<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
        <td class="nump">5,731,296<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable</a></td>
        <td class="nump">$ 3,734,610<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently granted or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDKAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract', window );"><strong>Summary of liabilities measured at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="nump">$ 8,216,935<span></span></td>
        <td class="nump">$ 6,707,255<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract', window );"><strong>Summary of liabilities measured at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract', window );"><strong>Summary of liabilities measured at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract', window );"><strong>Summary of liabilities measured at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="nump">$ 8,216,935<span></span></td>
        <td class="nump">$ 6,707,255<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34720828&amp;loc=SL20225862-175312<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36459792&amp;loc=SL20226008-175313<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUNAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Minimum [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of property and equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Lives</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Office equipment</a></td>
        <td class="nump">$ 166,354<span></span></td>
        <td class="nump">$ 15,480<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
        <td class="num">(25,343)<span></span></td>
        <td class="num">(1,560)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
        <td class="nump">$ 141,011<span></span></td>
        <td class="nump">$ 13,920<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3GAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (19,261,426)<span></span></td>
        <td class="num">$ (4,893,951)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">5,221,673<span></span></td>
        <td class="nump">284,371<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
        <td class="nump">23,783<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposition of equipment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">4,122<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_GainOnChangeInFairValueOfDerivatives', window );">Loss (gain) on change in fair value of derivative</a></td>
        <td class="nump">3,653,473<span></span></td>
        <td class="num">(216,112)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="num">(453,514)<span></span></td>
        <td class="nump">114,143<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Security deposit</a></td>
        <td class="num">(34,733)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">1,352,252<span></span></td>
        <td class="num">(585,043)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable and accrued expenses - related party</a></td>
        <td class="nump">197,106<span></span></td>
        <td class="nump">344,501<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
        <td class="num">(9,301,386)<span></span></td>
        <td class="num">(4,947,969)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(150,874)<span></span></td>
        <td class="num">(8,030)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
        <td class="num">(150,874)<span></span></td>
        <td class="num">(8,030)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on note payable</a></td>
        <td class="num">(157,825)<span></span></td>
        <td class="num">(140,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sales of common stock, net of offering costs</a></td>
        <td class="nump">15,435,305<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash', window );">Proceeds from the exercise of options and warrants</a></td>
        <td class="nump">392,089<span></span></td>
        <td class="nump">3,467,393<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
        <td class="nump">15,669,569<span></span></td>
        <td class="nump">3,327,393<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash</a></td>
        <td class="nump">6,217,309<span></span></td>
        <td class="num">(1,628,606)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump">5,533,366<span></span></td>
        <td class="nump">5,618,669<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">11,750,675<span></span></td>
        <td class="nump">3,990,063<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">561<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification', window );">Transfer warrant derivatives from liability to equity classification</a></td>
        <td class="nump">$ 2,143,793<span></span></td>
        <td class="nump">$ 600,880<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of Transfer from liability classification to equity classification.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_GainOnChangeInFairValueOfDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain on change in fair value of the derivatives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_GainOnChangeInFairValueOfDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from the exercise of options and warrants for cash.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in security deposits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInSecurityDeposits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivatives [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivatives</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Note 5 &#8211; Derivatives</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&#8217;s common stock at prices below such warrants&#8217; respective exercise prices and these provisions could result in modification of the warrants&#8217; exercise price based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option as defined under FASB ASC Topic No. 815 &#8211; 40. The warrants granted in connection with the issuance of the 2012 Common Stock Offering, and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a &#8220;Lower Price&#8221;) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;Activities for derivative warrant instruments during the nine months ended September 30, 2014 were as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Units</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Fair Value</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1081.81px;">Balance, December 31, 2013</td><td style="width: 14.54px;">&#160;</td><td style="width: 14.54px; text-align: left;">&#160;</td><td style="width: 128.18px; text-align: right;">1,968,623</td><td style="width: 14.54px; text-align: left;">&#160;</td><td style="width: 14.54px;">&#160;</td><td style="width: 13.63px; text-align: left;">$</td><td style="width: 127.27px; text-align: right;">6,707,255</td><td style="width: 13.63px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Transfer from liability classification to equity classification</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(306,900</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(2,143,793</td><td style="text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom:
 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">3,653,473</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">Balance, September 30, 2014</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,661,723</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">8,216,935</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">During the nine months ended September 30, 2014, 2,117,304 warrants were exercised, of which 306,900 were derivative warrants. The fair value of these warrants totaling $2,143,793 were measured on the various exercise dates and reclassified to additional paid-in capital.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at each balance sheet date.&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">September&#160;30,</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December&#160;31,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1081.81px; text-align: left;">Market value of common stock on measurement date (1)</td><td style="width: 14.54px;">&#160;</td><td style="width: 14.54px; text-align: left;">$</td><td style="width: 128.18px; text-align: right;">6.70</td><td style="width: 14.54px; text-align: left;">&#160;</td><td style="width: 14.54px;">&#160;</td><td style="width: 13.63px; text-align: left;">$</td><td style="width: 127.27px; text-align: right;">5.89</td><td style="width: 13.63px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Adjusted exercise price</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">2.48</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">2.48</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Risk free interest rate (2)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.07</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.27</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Warrant lives in years</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">3.2 years</font></td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align:
 right;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">0.5 years</font></td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected volatility (3)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">74</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">73</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected dividend yield (4)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Probability of stock offering in any period over 5 years (5)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">25</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">25</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Range of percentage of existing shares offered (6)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">35</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Offering price range (7)</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">7.50</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">9</td><td style="text-align: left;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="width: 42.72px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(1)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The market value of common stock at the above measurement dates is based on the Company&#8217;s trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for September 30, 2014.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="width: 42.72px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(2)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="width: 42.72px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(3)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif;
 font-stretch: normal;">&#160;</font><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="padding: 0px; width: 42.72px; text-indent: 0px;"></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(4)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="padding: 0px; text-indent: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;">&#160;</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="padding: 0px; width: 42.72px; text-indent: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(5)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Management determines the probability of future stock offering at each evaluation date.</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="padding: 0px; text-indent: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;">&#160;</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="padding: 0px; width: 42.72px; text-indent: 0px;"></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(6)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at September 30, 2014 and December 31, 2013, respectively.</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="padding: 0px; text-indent: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;">&#160;</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="padding: 0px; width: 42.72px; text-indent: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 42.72px; text-align: left; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(7)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1337.27px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Represents the estimated offering price range in future offerings as determined by management.</font></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80748-113994<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5618551-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5708775-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 25<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4E<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624181-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4H<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624258-113959<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624163-113959<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5708773-113959<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80784-113994<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4D<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624177-113959<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41620-113959<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579245-113959<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5580258-113959<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579240-113959<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41641-113959<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41638-113959<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PropertyAndEquipmentTextualAbstract', window );"><strong>Property and Equipment (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump">$ 14,326<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 23,783<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposition of equipment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 4,122<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PropertyAndEquipmentTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PropertyAndEquipmentTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>133</ContextCount>
  <ElementCount>218</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/NotePayable</Role>
      <ShortName>Note Payable</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Derivatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Derivatives</Role>
      <ShortName>Derivatives</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Derivatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativesTables</Role>
      <ShortName>Derivatives (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Descriptionofbusinessandsummaryofsignificantaccountingpoliciesdetails1</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Related Party Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual</Role>
      <ShortName>Related Party Transactions (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual</Role>
      <ShortName>Property and Equipment (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/NotePayableDetails</Role>
      <ShortName>Note Payable (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativesDetails</Role>
      <ShortName>Derivatives (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Derivatives (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativesDetails1</Role>
      <ShortName>Derivatives (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Derivatives (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual</Role>
      <ShortName>Derivatives (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityDetailsTextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>036 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element atnm_CommonStockExercisePriceParOrStatedValuePerShare had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">Element atnm_FairValueAssumptionOfferingPrice had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">Element atnm_LongTermPurchaseCommitmentMilestonesPayment had a mix of decimals attribute values: -6 0.</Log>
    <Log type="Info">Element us-gaap_CommonStockParOrStatedValuePerShare had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">Element us-gaap_DevelopmentInProcess had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_EquityMethodInvestmentOwnershipPercentage had a mix of decimals attribute values: 2 4.</Log>
    <Log type="Info">Element us-gaap_FairValueAssumptionsExpectedVolatilityRate had a mix of decimals attribute values: 2 4.</Log>
    <Log type="Info">Element us-gaap_ResearchAndDevelopmentInProcess had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">'Monetary' elements on report '035 - Disclosure - Equity (Details Textual)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - Consolidated Balance Sheets (Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jun. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - Consolidated Statements of Operations (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>atnm-20140930.xml</File>
    <File>atnm-20140930.xsd</File>
    <File>atnm-20140930_cal.xml</File>
    <File>atnm-20140930_def.xml</File>
    <File>atnm-20140930_lab.xml</File>
    <File>atnm-20140930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of option activities</a></td>
        <td class="text"><div>&#160;</div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of Units</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Remaining Contractual Term (in years)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px;">Outstanding, December 31, 2013</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">9,673,290</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1.06</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">4.89</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">47,396,307</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-left: 0.125in;">Granted</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">406,928</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8.81</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">7.46</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-left: 0.125in;">Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(2,117,304</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.96</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt; padding-left: 0.125in;">Forfeited</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">(29,167</td><td style="padding-bottom: 1.5pt; text-align: left;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6.70</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">Outstanding, September 30, 2014</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">7,933,747</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.47</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">4.15</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">42,641,772</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">Exercisable, September 30, 2014</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td
 style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">7,733,747</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">1.28</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">4.01</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">42,641,772</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"></p><div>&#160;</div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of option activities</a></td>
        <td class="text"><div>&#160;</div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of Units</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Remaining Contractual Term (in years)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px;">Outstanding, December 31, 2013</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">1,985,384</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">3.23</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">8.34</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">5,908,696</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-left: 0.125in;">Issued</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,323,100</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8.89</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">10.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-left: 0.125in; padding-bottom: 1.5pt;">Exercised</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(310,400</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.96</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt;">Outstanding, September 30, 2014</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">2,998,084</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.98</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8.60</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5,731,296</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt;">Exercisable, September 30, 2014</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">643,206</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">1.04</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6.27</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">3,734,610</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal;
 line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
